{"566f6c7d0f2d912ddbc28ce04ca1475aef4cace9": [["INTRODUCTIONThe common thread among herpes simplex virus (HSV), West Nile virus (WNV), enteroviruses like Poliovirus (PV), Coxsackievirus (CV), Influenza virus (IAV), Measles virus (MV), and especially human respiratory viruses like Coronaviruses (CoV) is that their primary site of infection is not the human Central Nervous System (CNS), yet they are all \"Neuropathogenic\" and exhibit fatal neurological abnormalities in humans.", [["CNS", "ANATOMY", 334, 337], ["neurological", "ANATOMY", 393, 405], ["herpes simplex virus (HSV)", "DISEASE", 36, 62], ["enteroviruses like Poliovirus (PV), Coxsackievirus (CV), Influenza virus (IAV)", "DISEASE", 87, 165], ["Measles virus (MV)", "DISEASE", 167, 185], ["respiratory viruses", "DISEASE", 208, 227], ["infection", "DISEASE", 283, 292], ["neurological abnormalities", "DISEASE", 393, 419], ["herpes simplex virus", "ORGANISM", 36, 56], ["HSV", "ORGANISM", 58, 61], ["West Nile virus", "ORGANISM", 64, 79], ["WNV", "ORGANISM", 81, 84], ["enteroviruses like", "ORGANISM", 87, 105], ["Poliovirus (PV)", "ORGANISM", 106, 121], ["Coxsackievirus (CV)", "ORGANISM", 123, 142], ["Influenza virus", "ORGANISM", 144, 159], ["IAV", "ORGANISM", 161, 164], ["Measles virus", "ORGANISM", 167, 180], ["human", "ORGANISM", 202, 207], ["respiratory viruses", "ORGANISM", 208, 227], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 233, 246], ["CoV", "ORGANISM", 248, 251], ["human", "ORGANISM", 304, 309], ["Nervous", "ANATOMICAL_SYSTEM", 318, 325], ["CNS", "ANATOMICAL_SYSTEM", 334, 337], ["humans", "ORGANISM", 423, 429], ["herpes simplex virus", "SPECIES", 36, 56], ["West Nile virus", "SPECIES", 64, 79], ["Influenza virus", "SPECIES", 144, 159], ["Measles virus", "SPECIES", 167, 180], ["human", "SPECIES", 202, 207], ["human", "SPECIES", 304, 309], ["humans", "SPECIES", 423, 429], ["herpes simplex virus", "SPECIES", 36, 56], ["HSV", "SPECIES", 58, 61], ["West Nile virus", "SPECIES", 64, 79], ["WNV", "SPECIES", 81, 84], ["PV", "SPECIES", 118, 120], ["CV", "SPECIES", 139, 141], ["Influenza virus", "SPECIES", 144, 159], ["IAV", "SPECIES", 161, 164], ["Measles virus", "SPECIES", 167, 180], ["MV", "SPECIES", 182, 184], ["human respiratory viruses", "SPECIES", 202, 227], ["CoV", "SPECIES", 248, 251], ["human", "SPECIES", 304, 309], ["humans", "SPECIES", 423, 429], ["common thread among herpes simplex virus", "PROBLEM", 16, 56], ["HSV", "PROBLEM", 58, 61], ["West Nile virus (WNV", "PROBLEM", 64, 84], ["enteroviruses", "PROBLEM", 87, 100], ["Poliovirus", "PROBLEM", 106, 116], ["Coxsackievirus", "PROBLEM", 123, 137], ["Influenza virus (IAV)", "PROBLEM", 144, 165], ["Measles virus", "PROBLEM", 167, 180], ["human respiratory viruses", "PROBLEM", 202, 227], ["Coronaviruses", "PROBLEM", 233, 246], ["infection", "PROBLEM", 283, 292], ["fatal neurological abnormalities in humans", "PROBLEM", 387, 429], ["respiratory viruses", "OBSERVATION", 208, 227], ["Coronaviruses", "OBSERVATION", 233, 246], ["infection", "OBSERVATION", 283, 292], ["fatal", "OBSERVATION_MODIFIER", 387, 392]]], ["These viruses infect millions worldwide and cause a spectrum of neurological and psychiatric illnesses (1) (2) (3) .", [["neurological", "ANATOMY", 64, 76], ["neurological and psychiatric illnesses", "DISEASE", 64, 102], ["neurological and psychiatric illnesses", "PROBLEM", 64, 102]]], ["If we look further into other chronic viral infections -such as Human Immunodeficiency Virus (HIV), John Cunningham Virus (JCV), Herpes Simplex Virus (HSV), Human Herpesvirus 6 (HHV-6), and Human T-lymphotropic virus (HTLV-1) -we realize that peripheral viral infections and the occurrence of neurological sequelae is quite a correlated phenomenon (4) (5) (6) .", [["neurological", "ANATOMY", 293, 305], ["viral infections", "DISEASE", 38, 54], ["Human Immunodeficiency Virus (HIV), John Cunningham Virus (JCV)", "DISEASE", 64, 127], ["Herpes Simplex Virus (HSV)", "DISEASE", 129, 155], ["Human T-lymphotropic virus", "DISEASE", 190, 216], ["peripheral viral infections", "DISEASE", 243, 270], ["neurological sequelae", "DISEASE", 293, 314], ["Human Immunodeficiency Virus", "ORGANISM", 64, 92], ["John Cunningham Virus", "ORGANISM", 100, 121], ["JCV", "ORGANISM", 123, 126], ["Herpes Simplex Virus", "ORGANISM", 129, 149], ["HSV", "ORGANISM", 151, 154], ["Human Herpesvirus 6", "ORGANISM", 157, 176], ["HHV-6", "ORGANISM", 178, 183], ["Human T-lymphotropic virus", "ORGANISM", 190, 216], ["HTLV-1", "ORGANISM", 218, 224], ["Human Immunodeficiency Virus", "SPECIES", 64, 92], ["HIV", "SPECIES", 94, 97], ["Herpes Simplex Virus", "SPECIES", 129, 149], ["Human", "SPECIES", 157, 162], ["Herpesvirus", "SPECIES", 163, 174], ["HHV-6", "SPECIES", 178, 183], ["Human", "SPECIES", 190, 195], ["T-lymphotropic virus", "SPECIES", 196, 216], ["HTLV-1", "SPECIES", 218, 224], ["Human Immunodeficiency Virus", "SPECIES", 64, 92], ["HIV", "SPECIES", 94, 97], ["John Cunningham Virus", "SPECIES", 100, 121], ["JCV", "SPECIES", 123, 126], ["Herpes Simplex Virus", "SPECIES", 129, 149], ["HSV", "SPECIES", 151, 154], ["Human Herpesvirus 6 (HHV-6", "SPECIES", 157, 183], ["Human T-lymphotropic virus", "SPECIES", 190, 216], ["HTLV-1", "SPECIES", 218, 224], ["other chronic viral infections", "PROBLEM", 24, 54], ["Human Immunodeficiency Virus", "PROBLEM", 64, 92], ["John Cunningham Virus (JCV", "TEST", 100, 126], ["Herpes Simplex Virus (HSV", "PROBLEM", 129, 154], ["Human Herpesvirus", "TEST", 157, 174], ["HHV", "TEST", 178, 181], ["Human T-lymphotropic virus (HTLV", "TREATMENT", 190, 222], ["peripheral viral infections", "PROBLEM", 243, 270], ["neurological sequelae", "PROBLEM", 293, 314], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["infections", "OBSERVATION", 44, 54], ["peripheral", "ANATOMY", 243, 253], ["viral infections", "OBSERVATION", 254, 270], ["neurological sequelae", "OBSERVATION", 293, 314]]], ["Since neurological anomalies are fatal or potentially lifequality killers, it ultimately restricts the host survival and procreation activities.", [["neurological", "ANATOMY", 6, 18], ["neurological anomalies", "DISEASE", 6, 28], ["neurological anomalies", "PROBLEM", 6, 28], ["anomalies", "OBSERVATION", 19, 28]]], ["By this definition, invading the host nervous system seems a less promising evolutionary path (7) .", [["nervous system", "ANATOMY", 38, 52], ["nervous system", "ANATOMICAL_SYSTEM", 38, 52], ["host nervous", "ANATOMY", 33, 45]]], ["This makes the scenario of peripheral/respiratory viral invasion to CNS even more complicated.INTRODUCTIONThe Central Nervous System (CNS) is strictly guarded by the blood-brain barrier (BBB) and effective immune surveillance.", [["CNS", "ANATOMY", 68, 71], ["CNS", "ANATOMY", 134, 137], ["blood-brain barrier", "ANATOMY", 166, 185], ["BBB", "ANATOMY", 187, 190], ["CNS", "ANATOMICAL_SYSTEM", 68, 71], ["Nervous", "ANATOMICAL_SYSTEM", 118, 125], ["CNS", "ANATOMICAL_SYSTEM", 134, 137], ["blood-", "MULTI-TISSUE_STRUCTURE", 166, 172], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 172, 185], ["BBB", "MULTI-TISSUE_STRUCTURE", 187, 190], ["peripheral/respiratory viral invasion", "PROBLEM", 27, 64], ["the blood", "TEST", 162, 171], ["effective immune surveillance", "TREATMENT", 196, 225], ["peripheral", "ANATOMY_MODIFIER", 27, 37], ["respiratory", "ANATOMY", 38, 49], ["viral invasion", "OBSERVATION", 50, 64], ["Central", "ANATOMY_MODIFIER", 110, 117], ["Nervous System", "ANATOMY", 118, 132], ["brain", "ANATOMY", 172, 177]]], ["An intriguing question emerges over how these non-neurotropic viruses (most of them respiratory viruses) cause their respective primary pathology in the distal part of the host body, ultimately disrupting the sanctity of CNS.", [["body", "ANATOMY", 177, 181], ["CNS", "ANATOMY", 221, 224], ["respiratory viruses", "DISEASE", 84, 103], ["non-neurotropic viruses", "ORGANISM", 46, 69], ["body", "ORGANISM_SUBDIVISION", 177, 181], ["CNS", "ANATOMICAL_SYSTEM", 221, 224], ["these non-neurotropic viruses", "PROBLEM", 40, 69], ["them respiratory viruses", "PROBLEM", 79, 103], ["their respective primary pathology", "PROBLEM", 111, 145], ["primary", "OBSERVATION_MODIFIER", 128, 135], ["pathology", "OBSERVATION", 136, 145], ["distal", "ANATOMY_MODIFIER", 153, 159], ["host body", "ANATOMY_MODIFIER", 172, 181], ["CNS", "ANATOMY", 221, 224]]], ["Is there a common pathway for all these viruses to enter CNS and cause neurological disorders or do they all use a unique route for causing their neuropathology?INTRODUCTIONIn the usual course of infection, viruses usually cross the infected tissue and travel back to the bloodstream and lymph nodes and, through a hematogenous route, they can gain access to the CNS.", [["CNS", "ANATOMY", 57, 60], ["neurological", "ANATOMY", 71, 83], ["tissue", "ANATOMY", 242, 248], ["bloodstream", "ANATOMY", 272, 283], ["lymph nodes", "ANATOMY", 288, 299], ["CNS", "ANATOMY", 363, 366], ["neurological disorders", "DISEASE", 71, 93], ["neuropathology", "DISEASE", 146, 160], ["infection", "DISEASE", 196, 205], ["CNS", "ANATOMICAL_SYSTEM", 57, 60], ["tissue", "TISSUE", 242, 248], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 288, 299], ["CNS", "ANATOMICAL_SYSTEM", 363, 366], ["all these viruses", "PROBLEM", 30, 47], ["neurological disorders", "PROBLEM", 71, 93], ["their neuropathology", "PROBLEM", 140, 160], ["infection", "PROBLEM", 196, 205], ["viruses", "PROBLEM", 207, 214], ["the infected tissue", "PROBLEM", 229, 248], ["a hematogenous route", "TREATMENT", 313, 333], ["viruses", "OBSERVATION", 40, 47], ["infection", "OBSERVATION", 196, 205], ["infected tissue", "OBSERVATION", 233, 248], ["bloodstream", "ANATOMY", 272, 283], ["lymph nodes", "OBSERVATION", 288, 299], ["CNS", "ANATOMY", 363, 366]]], ["Clinical observations show that any virus that is exposed to epithelial and endothelial linings usually breach the CNS because almost all human mucosal epithelial linings are heavily embedded with peripheral sensory nerves.", [["epithelial", "ANATOMY", 61, 71], ["endothelial linings", "ANATOMY", 76, 95], ["CNS", "ANATOMY", 115, 118], ["mucosal epithelial linings", "ANATOMY", 144, 170], ["peripheral sensory nerves", "ANATOMY", 197, 222], ["epithelial", "CELL", 61, 71], ["endothelial linings", "TISSUE", 76, 95], ["CNS", "ANATOMICAL_SYSTEM", 115, 118], ["human", "ORGANISM", 138, 143], ["mucosal epithelial linings", "TISSUE", 144, 170], ["peripheral sensory nerves", "MULTI-TISSUE_STRUCTURE", 197, 222], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["Clinical observations", "TEST", 0, 21], ["any virus", "PROBLEM", 32, 41], ["epithelial and endothelial linings", "PROBLEM", 61, 95], ["virus", "OBSERVATION", 36, 41], ["epithelial", "ANATOMY_MODIFIER", 61, 71], ["endothelial", "ANATOMY", 76, 87], ["mucosal", "ANATOMY", 144, 151], ["epithelial linings", "OBSERVATION", 152, 170], ["peripheral", "ANATOMY_MODIFIER", 197, 207], ["sensory nerves", "ANATOMY", 208, 222]]], ["However, in the case of non-neurotropic viral infections, it all seems opportunistic, because these viruses first exhibit their primary disease symptoms, followed by a secondary set of pathologies which include the neurological aberrations.INTRODUCTIONBacked up by over 100 years of extensive research and abundant literature, we can dig deeper into various viral strategies to disrupt CNS and make a wider comparison to find some commonly exploited pathways.", [["neurological", "ANATOMY", 215, 227], ["CNS", "ANATOMY", 386, 389], ["viral infections", "DISEASE", 40, 56], ["primary disease symptoms", "DISEASE", 128, 152], ["neurological aberrations", "DISEASE", 215, 239], ["CNS", "ANATOMICAL_SYSTEM", 386, 389], ["non-neurotropic viral infections", "PROBLEM", 24, 56], ["opportunistic", "PROBLEM", 71, 84], ["these viruses", "PROBLEM", 94, 107], ["their primary disease symptoms", "PROBLEM", 122, 152], ["pathologies", "PROBLEM", 185, 196], ["the neurological aberrations", "PROBLEM", 211, 239], ["viral infections", "OBSERVATION", 40, 56], ["neurological aberrations", "OBSERVATION", 215, 239]]], ["In the following discussion, we will try to explore this issue on whether their entry into the CNS is opportunistic and accidental or whether these peripheral viruses are equipped to run such a multifaceted pathogenesis.IS IT EASIER FOR RESPIRATORY VIRUSES TO ENTER THE CNS?Major routes for entering the CNS are broadly categorized into two options.", [["CNS", "ANATOMY", 95, 98], ["CNS", "ANATOMY", 304, 307], ["CNS", "ANATOMICAL_SYSTEM", 95, 98], ["CNS", "ANATOMICAL_SYSTEM", 304, 307], ["these peripheral viruses", "PROBLEM", 142, 166], ["a multifaceted pathogenesis", "PROBLEM", 192, 219], ["peripheral", "ANATOMY", 148, 158], ["viruses", "OBSERVATION", 159, 166], ["multifaceted", "OBSERVATION_MODIFIER", 194, 206], ["pathogenesis", "OBSERVATION", 207, 219], ["VIRUSES", "OBSERVATION", 249, 256], ["CNS", "ANATOMY", 270, 273], ["CNS", "ANATOMY", 304, 307]]], ["First, the hematogenous route, which means entry of peripheral infected blood cells like monocytes/macrophages as a \"Trojan Horse\" via crossing the BBB (schematic presentation as Figure 1 ).", [["blood cells", "ANATOMY", 72, 83], ["monocytes", "ANATOMY", 89, 98], ["macrophages", "ANATOMY", 99, 110], ["BBB", "ANATOMY", 148, 151], ["peripheral infected blood cells", "CELL", 52, 83], ["monocytes", "CELL", 89, 98], ["macrophages", "CELL", 99, 110], ["BBB", "MULTI-TISSUE_STRUCTURE", 148, 151], ["peripheral infected blood cells", "CELL_TYPE", 52, 83], ["monocytes", "CELL_TYPE", 89, 98], ["macrophages", "CELL_TYPE", 99, 110], ["peripheral infected blood cells", "PROBLEM", 52, 83], ["macrophages", "PROBLEM", 99, 110], ["hematogenous", "OBSERVATION", 11, 23], ["peripheral", "ANATOMY_MODIFIER", 52, 62], ["infected blood cells", "OBSERVATION", 63, 83], ["macrophages", "OBSERVATION", 99, 110], ["BBB", "ANATOMY", 148, 151]]], ["This route might also include infection of brain microvascular endothelial cells or the para-cellular passage via disrupting tight junctions and increasing brain endothelial permeability (8) (9) (10) (11) .", [["brain microvascular endothelial cells", "ANATOMY", 43, 80], ["para-cellular", "ANATOMY", 88, 101], ["tight junctions", "ANATOMY", 125, 140], ["brain endothelial", "ANATOMY", 156, 173], ["infection", "DISEASE", 30, 39], ["brain microvascular endothelial cells", "CELL", 43, 80], ["tight junctions", "CELLULAR_COMPONENT", 125, 140], ["brain endothelial", "TISSUE", 156, 173], ["brain microvascular endothelial cells", "CELL_TYPE", 43, 80], ["infection of brain microvascular endothelial cells", "PROBLEM", 30, 80], ["the para-cellular passage", "PROBLEM", 84, 109], ["increasing brain endothelial permeability", "PROBLEM", 145, 186], ["might also include", "UNCERTAINTY", 11, 29], ["infection", "OBSERVATION", 30, 39], ["brain", "ANATOMY", 43, 48], ["microvascular endothelial cells", "OBSERVATION", 49, 80], ["para-cellular passage", "OBSERVATION", 88, 109], ["tight junctions", "OBSERVATION", 125, 140], ["increasing", "OBSERVATION_MODIFIER", 145, 155], ["brain endothelial", "ANATOMY", 156, 173], ["permeability", "OBSERVATION_MODIFIER", 174, 186]]], ["Another major route of entry is the neuronal or axonal route, involving various peripheral nerves endings such as olfactory sensory neurons and intestinal nerve endings.", [["neuronal", "ANATOMY", 36, 44], ["axonal", "ANATOMY", 48, 54], ["peripheral nerves endings", "ANATOMY", 80, 105], ["olfactory sensory neurons", "ANATOMY", 114, 139], ["intestinal nerve endings", "ANATOMY", 144, 168], ["neuronal", "CELL", 36, 44], ["axonal route", "CELLULAR_COMPONENT", 48, 60], ["peripheral nerves endings", "TISSUE", 80, 105], ["olfactory sensory neurons", "CELL", 114, 139], ["intestinal nerve endings", "MULTI-TISSUE_STRUCTURE", 144, 168], ["olfactory sensory neurons", "CELL_TYPE", 114, 139], ["entry", "OBSERVATION", 23, 28], ["peripheral", "ANATOMY_MODIFIER", 80, 90], ["nerves", "ANATOMY", 91, 97], ["intestinal nerve", "ANATOMY", 144, 160]]], ["It is called the axonal transport route because pathogens cross one neuron after another via synaptic nerve endings (8, 12, 13) .", [["axonal", "ANATOMY", 17, 23], ["neuron", "ANATOMY", 68, 74], ["synaptic nerve endings", "ANATOMY", 93, 115], ["nerve endings", "MULTI-TISSUE_STRUCTURE", 102, 115], ["nerve", "ANATOMY", 102, 107]]], ["Viruses are known to exploit the motor proteins, such as dynein and kinesin, for the retrograde and anterograde movement during neuronal transport (8, 9) .", [["neuronal", "ANATOMY", 128, 136], ["dynein", "GENE_OR_GENE_PRODUCT", 57, 63], ["kinesin", "GENE_OR_GENE_PRODUCT", 68, 75], ["neuronal", "CELL", 128, 136], ["motor proteins", "PROTEIN", 33, 47], ["dynein", "PROTEIN", 57, 63], ["kinesin", "PROTEIN", 68, 75], ["Viruses", "PROBLEM", 0, 7], ["neuronal transport", "TEST", 128, 146], ["anterograde movement", "OBSERVATION", 100, 120]]], ["Viruses can adapt both these routes to enter the CNS and these have been reviewed elsewhere in detail (12, 14, 15) .", [["CNS", "ANATOMY", 49, 52], ["CNS", "ANATOMICAL_SYSTEM", 49, 52], ["Viruses", "PROBLEM", 0, 7], ["CNS", "ANATOMY", 49, 52]]], ["A list of viruses has been provided as Table 1 , showing their respective route of entry to the CNS.IS IT EASIER FOR RESPIRATORY VIRUSES TO ENTER THE CNS?Olfactory receptor neurons display some key anatomical and functional features normally absent elsewhere.", [["CNS", "ANATOMY", 96, 99], ["Olfactory receptor neurons", "ANATOMY", 154, 180], ["CNS", "ANATOMICAL_SYSTEM", 96, 99], ["Olfactory receptor neurons", "CELL", 154, 180], ["Olfactory receptor neurons", "CELL_TYPE", 154, 180], ["viruses", "TREATMENT", 10, 17], ["viruses", "OBSERVATION", 10, 17], ["CNS", "ANATOMY", 96, 99], ["VIRUSES", "OBSERVATION", 129, 136], ["CNS", "ANATOMY", 150, 153]]], ["Olfactory receptor neurons are found predominantly in the upper respiratory tract, an area commonly known as the nasal cavity and nasal septum.", [["Olfactory receptor neurons", "ANATOMY", 0, 26], ["upper respiratory tract", "ANATOMY", 58, 81], ["area", "ANATOMY", 86, 90], ["nasal cavity", "ANATOMY", 113, 125], ["nasal septum", "ANATOMY", 130, 142], ["Olfactory receptor neurons", "CELL", 0, 26], ["upper respiratory", "ORGANISM_SUBDIVISION", 58, 75], ["tract", "ORGANISM_SUBDIVISION", 76, 81], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 113, 125], ["nasal septum", "MULTI-TISSUE_STRUCTURE", 130, 142], ["Olfactory receptor neurons", "CELL_TYPE", 0, 26], ["receptor neurons", "OBSERVATION", 10, 26], ["predominantly", "OBSERVATION_MODIFIER", 37, 50], ["upper", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81], ["nasal cavity", "ANATOMY", 113, 125], ["nasal septum", "ANATOMY", 130, 142]]], ["When any odor gets dissolved in the mucosal lining of the nasal cavity, the apical part or dendrites of olfactory nerves sense it and transmit this signal to the basal part of olfactory nerves' bodies for further transmission toward the brain (16) .", [["mucosal lining", "ANATOMY", 36, 50], ["nasal cavity", "ANATOMY", 58, 70], ["apical part", "ANATOMY", 76, 87], ["dendrites", "ANATOMY", 91, 100], ["olfactory nerves", "ANATOMY", 104, 120], ["basal part", "ANATOMY", 162, 172], ["olfactory nerves' bodies", "ANATOMY", 176, 200], ["brain", "ANATOMY", 237, 242], ["mucosal lining", "TISSUE", 36, 50], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 58, 70], ["apical part", "CELLULAR_COMPONENT", 76, 87], ["dendrites", "CELLULAR_COMPONENT", 91, 100], ["olfactory nerves", "MULTI-TISSUE_STRUCTURE", 104, 120], ["olfactory nerves", "MULTI-TISSUE_STRUCTURE", 176, 192], ["' bodies", "CELLULAR_COMPONENT", 192, 200], ["brain", "ORGAN", 237, 242], ["any odor", "PROBLEM", 5, 13], ["dissolved", "OBSERVATION_MODIFIER", 19, 28], ["mucosal", "ANATOMY_MODIFIER", 36, 43], ["lining", "ANATOMY_MODIFIER", 44, 50], ["nasal cavity", "ANATOMY", 58, 70], ["apical", "ANATOMY_MODIFIER", 76, 82], ["dendrites", "OBSERVATION_MODIFIER", 91, 100], ["olfactory nerves", "ANATOMY", 104, 120], ["basal", "ANATOMY_MODIFIER", 162, 167], ["olfactory nerves", "ANATOMY", 176, 192], ["brain", "ANATOMY", 237, 242]]], ["Olfactory receptor neuronal endings are directly exposed to the extrinsic stimuli and are capable of interacting enormously with all the environmental macromolecules.", [["Olfactory receptor neuronal endings", "ANATOMY", 0, 35], ["the extrinsic stimuli", "TEST", 60, 81], ["neuronal endings", "OBSERVATION", 19, 35], ["extrinsic stimuli", "OBSERVATION", 64, 81]]], ["This interaction is responsible for our far-fetched ability to sense almost one trillion kinds of smells present in the universe (17) .", [["smells", "OBSERVATION", 98, 104]]], ["These olfactory nerve endings work in a chemoreceptor function.", [["olfactory nerve endings", "ANATOMY", 6, 29], ["olfactory nerve endings", "MULTI-TISSUE_STRUCTURE", 6, 29], ["a chemoreceptor function", "TEST", 38, 62], ["olfactory nerve", "ANATOMY", 6, 21], ["chemoreceptor function", "OBSERVATION", 40, 62]]], ["This means that any macromolecules can be physically incorporated inside olfactory nerve cells and travel in a transsynaptic fashion to the CNS.", [["olfactory nerve cells", "ANATOMY", 73, 94], ["CNS", "ANATOMY", 140, 143], ["olfactory nerve cells", "CELL", 73, 94], ["CNS", "ANATOMICAL_SYSTEM", 140, 143], ["olfactory nerve cells", "CELL_TYPE", 73, 94], ["any macromolecules", "PROBLEM", 16, 34], ["nerve cells", "OBSERVATION", 83, 94], ["CNS", "ANATOMY", 140, 143]]], ["This makes the olfactory nerve cells an extremely useful tool for respiratory viruses to reach the CNS without even bothering about the BBB barrier (18) .", [["olfactory nerve cells", "ANATOMY", 15, 36], ["CNS", "ANATOMY", 99, 102], ["BBB", "ANATOMY", 136, 139], ["olfactory nerve cells", "CELL", 15, 36], ["CNS", "ANATOMICAL_SYSTEM", 99, 102], ["BBB barrier", "TISSUE", 136, 147], ["olfactory nerve cells", "CELL_TYPE", 15, 36], ["respiratory viruses", "PROBLEM", 66, 85], ["olfactory nerve", "ANATOMY", 15, 30], ["CNS", "ANATOMY", 99, 102]]], ["Respiratory viruses, such as Influenza and Coronaviruses, are reported to preferably take this olfactory route for entering the CNS over other routes.IS IT EASIER FOR RESPIRATORY VIRUSES TO ENTER THE CNS?In the case of the current pandemic caused by SARS-CoV-2, the patients have been widely reported to exhibit the symptoms of anosmia/dysgeusia (i.e., smell and taste-related alterations) (19) .", [["olfactory", "ANATOMY", 95, 104], ["CNS", "ANATOMY", 128, 131], ["Respiratory viruses", "DISEASE", 0, 19], ["Influenza and Coronaviruses", "DISEASE", 29, 56], ["anosmia", "DISEASE", 328, 335], ["dysgeusia", "DISEASE", 336, 345], ["CNS", "ANATOMICAL_SYSTEM", 128, 131], ["SARS-CoV-2", "ORGANISM", 250, 260], ["patients", "ORGANISM", 266, 274], ["Influenza", "SPECIES", 29, 38], ["patients", "SPECIES", 266, 274], ["SARS-CoV", "SPECIES", 250, 258], ["Respiratory viruses", "PROBLEM", 0, 19], ["Influenza", "PROBLEM", 29, 38], ["Coronaviruses", "PROBLEM", 43, 56], ["the symptoms", "PROBLEM", 312, 324], ["anosmia", "PROBLEM", 328, 335], ["dysgeusia", "PROBLEM", 336, 345], ["smell", "PROBLEM", 353, 358], ["viruses", "OBSERVATION", 12, 19], ["VIRUSES", "OBSERVATION", 179, 186], ["CNS", "ANATOMY", 200, 203], ["dysgeusia", "OBSERVATION", 336, 345]]], ["The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) has also accepted anosmia and dysgeusia as the heralding sign for COVID-19 (20) .", [["anosmia", "DISEASE", 89, 96], ["dysgeusia", "DISEASE", 101, 110], ["COVID-19", "CHEMICAL", 137, 145], ["Head and Neck Surgery", "TREATMENT", 39, 60], ["anosmia", "PROBLEM", 89, 96], ["dysgeusia", "PROBLEM", 101, 110], ["the heralding sign", "TEST", 114, 132], ["COVID", "TEST", 137, 142], ["Head", "ANATOMY", 39, 43], ["Neck", "ANATOMY", 48, 52]]], ["The exact route taken by SARS-CoV-2 to enter the CNS has not yet been experimentally established.", [["CNS", "ANATOMY", 49, 52], ["SARS-CoV-2", "ORGANISM", 25, 35], ["CNS", "ANATOMICAL_SYSTEM", 49, 52], ["CNS", "ANATOMY", 49, 52]]], ["However, since this virus echoes almost a 79% similarity with previous SARS-CoV, we can expect some similarity in mode of entry to the CNS too.", [["CNS", "ANATOMY", 135, 138], ["SARS", "DISEASE", 71, 75], ["SARS-CoV", "ORGANISM", 71, 79], ["CNS", "ANATOMICAL_SYSTEM", 135, 138], ["SARS-CoV", "SPECIES", 71, 79], ["this virus echoes", "TEST", 15, 32], ["previous SARS-CoV", "PROBLEM", 62, 79], ["CNS", "ANATOMY", 135, 138]]], ["The presence of SARS-CoV (the cause of the 2009 and 2013 SARS epidemics) in the CNS has been well established, both in human patients and experimental animals.", [["CNS", "ANATOMY", 80, 83], ["SARS-CoV", "DISEASE", 16, 24], ["SARS", "DISEASE", 57, 61], ["SARS-CoV", "ORGANISM", 16, 24], ["CNS", "ANATOMICAL_SYSTEM", 80, 83], ["human", "ORGANISM", 119, 124], ["patients", "ORGANISM", 125, 133], ["human", "SPECIES", 119, 124], ["patients", "SPECIES", 125, 133], ["SARS-CoV", "SPECIES", 16, 24], ["human", "SPECIES", 119, 124], ["SARS-CoV", "PROBLEM", 16, 24], ["SARS", "OBSERVATION", 16, 20], ["CNS", "ANATOMY", 80, 83]]], ["In the case of SARS-CoV, the brainstem region was reported to be heavily infected (21) .", [["brainstem region", "ANATOMY", 29, 45], ["SARS", "DISEASE", 15, 19], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 15, 23], ["brainstem", "ORGAN", 29, 38], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["heavily infected", "PROBLEM", 65, 81], ["SARS", "OBSERVATION", 15, 19], ["brainstem", "ANATOMY", 29, 38], ["heavily", "OBSERVATION_MODIFIER", 65, 72], ["infected", "OBSERVATION", 73, 81]]], ["SARS-CoV is also reported to spread through mechanoreceptors and chemoreceptors present in the lower respiratory tract to the medullary cardiorespiratory center of the brain via a synaptic route (22) .", [["mechanoreceptors", "ANATOMY", 44, 60], ["lower respiratory tract", "ANATOMY", 95, 118], ["medullary cardiorespiratory center", "ANATOMY", 126, 160], ["brain", "ANATOMY", 168, 173], ["synaptic", "ANATOMY", 180, 188], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["lower", "ORGANISM_SUBDIVISION", 95, 100], ["respiratory tract", "ORGANISM_SUBDIVISION", 101, 118], ["medullary cardiorespiratory center", "MULTI-TISSUE_STRUCTURE", 126, 160], ["brain", "ORGAN", 168, 173], ["SARS-CoV", "SPECIES", 0, 8], ["lower", "ANATOMY_MODIFIER", 95, 100], ["respiratory tract", "ANATOMY", 101, 118], ["medullary", "ANATOMY", 126, 135], ["cardiorespiratory", "ANATOMY_MODIFIER", 136, 153], ["center", "ANATOMY_MODIFIER", 154, 160], ["brain", "ANATOMY", 168, 173]]], ["This explains the widespread display of vascular and cardiac anomalies in severe patients of SARS-CoV epidemics.", [["vascular", "ANATOMY", 40, 48], ["cardiac", "ANATOMY", 53, 60], ["vascular and cardiac anomalies", "DISEASE", 40, 70], ["SARS-CoV epidemics", "DISEASE", 93, 111], ["vascular", "MULTI-TISSUE_STRUCTURE", 40, 48], ["cardiac", "ORGAN", 53, 60], ["patients", "ORGANISM", 81, 89], ["SARS-CoV", "ORGANISM", 93, 101], ["patients", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 93, 101], ["vascular and cardiac anomalies", "PROBLEM", 40, 70], ["SARS", "PROBLEM", 93, 97], ["CoV epidemics", "PROBLEM", 98, 111], ["vascular", "ANATOMY", 40, 48], ["cardiac", "ANATOMY", 53, 60], ["anomalies", "OBSERVATION", 61, 70], ["severe", "OBSERVATION_MODIFIER", 74, 80]]], ["In the current SARS-CoV-2 pandemic too, patients are displaying intense vascular and cardiac anomalies which are becoming the main reason for death, however the exact cellular and molecular mechanisms still need to be experimentally validated (22) .RESPIRATORY VIRUSES TAKE THE HEMATOGENOUS ROUTE TOODijkman et al. reported that human coronaviruses (HCoV) cause far fewer cytopathic effects on primary human respiratory epithelial cells (23) .", [["vascular", "ANATOMY", 72, 80], ["cardiac", "ANATOMY", 85, 92], ["cellular", "ANATOMY", 167, 175], ["respiratory epithelial cells", "ANATOMY", 408, 436], ["SARS-CoV-2 pandemic", "DISEASE", 15, 34], ["vascular and cardiac anomalies", "DISEASE", 72, 102], ["death", "DISEASE", 142, 147], ["SARS-CoV-2", "ORGANISM", 15, 25], ["patients", "ORGANISM", 40, 48], ["vascular", "MULTI-TISSUE_STRUCTURE", 72, 80], ["cardiac", "ORGAN", 85, 92], ["cellular", "CELL", 167, 175], ["human", "ORGANISM", 329, 334], ["coronaviruses", "ORGANISM", 335, 348], ["HCoV", "ORGANISM", 350, 354], ["human", "ORGANISM", 402, 407], ["respiratory epithelial cells", "CELL", 408, 436], ["primary human respiratory epithelial cells", "CELL_TYPE", 394, 436], ["patients", "SPECIES", 40, 48], ["human", "SPECIES", 329, 334], ["human", "SPECIES", 402, 407], ["human coronaviruses", "SPECIES", 329, 348], ["HCoV", "SPECIES", 350, 354], ["human", "SPECIES", 402, 407], ["intense vascular and cardiac anomalies", "PROBLEM", 64, 102], ["death", "PROBLEM", 142, 147], ["RESPIRATORY VIRUSES", "PROBLEM", 249, 268], ["human coronaviruses (HCoV)", "PROBLEM", 329, 355], ["fewer cytopathic effects", "PROBLEM", 366, 390], ["primary human respiratory epithelial cells", "PROBLEM", 394, 436], ["intense", "OBSERVATION_MODIFIER", 64, 71], ["vascular", "ANATOMY", 72, 80], ["cardiac", "ANATOMY", 85, 92], ["anomalies", "OBSERVATION", 93, 102], ["VIRUSES", "OBSERVATION", 261, 268], ["cytopathic", "OBSERVATION_MODIFIER", 372, 382], ["respiratory epithelial cells", "OBSERVATION", 408, 436]]], ["They also showed that all HCoV strains were budding preferentially from the apical side of epithelial cells, but many viruses were also getting released from the basolateral side (23) .", [["apical side", "ANATOMY", 76, 87], ["epithelial cells", "ANATOMY", 91, 107], ["basolateral", "ANATOMY", 162, 173], ["HCoV", "GENE_OR_GENE_PRODUCT", 26, 30], ["epithelial cells", "CELL", 91, 107], ["epithelial cells", "CELL_TYPE", 91, 107], ["HCoV", "SPECIES", 26, 30], ["all HCoV strains", "PROBLEM", 22, 38], ["epithelial cells", "PROBLEM", 91, 107], ["many viruses", "PROBLEM", 113, 125], ["apical", "ANATOMY_MODIFIER", 76, 82], ["epithelial cells", "ANATOMY", 91, 107], ["many", "OBSERVATION_MODIFIER", 113, 117], ["viruses", "OBSERVATION", 118, 125], ["basolateral", "ANATOMY_MODIFIER", 162, 173]]], ["This way they can pass through the epithelial barrier and enter the bloodstream and lymph nodes (Figure 1 ).", [["epithelial barrier", "ANATOMY", 35, 53], ["bloodstream", "ANATOMY", 68, 79], ["lymph nodes", "ANATOMY", 84, 95], ["epithelial barrier", "TISSUE", 35, 53], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 84, 95], ["the epithelial barrier", "TREATMENT", 31, 53], ["epithelial", "ANATOMY_MODIFIER", 35, 45], ["bloodstream", "ANATOMY", 68, 79], ["lymph nodes", "OBSERVATION", 84, 95]]], ["This explains how they can infect leukocytes and travel via the hematogenous route to other distant organs like the CNS, kidney, and intestines, etc (1).", [["leukocytes", "ANATOMY", 34, 44], ["organs", "ANATOMY", 100, 106], ["CNS", "ANATOMY", 116, 119], ["kidney", "ANATOMY", 121, 127], ["intestines", "ANATOMY", 133, 143], ["leukocytes", "CELL", 34, 44], ["organs", "ORGAN", 100, 106], ["CNS", "ANATOMICAL_SYSTEM", 116, 119], ["kidney", "ORGAN", 121, 127], ["intestines", "ORGAN", 133, 143], ["leukocytes", "CELL_TYPE", 34, 44], ["leukocytes", "PROBLEM", 34, 44], ["the hematogenous route", "TREATMENT", 60, 82], ["CNS", "ANATOMY", 116, 119], ["kidney", "ANATOMY", 121, 127], ["intestines", "ANATOMY", 133, 143]]], ["This route has been shown to be taken by various other viruses like Measles virus (24) , Nipah virus (25) , and Influenza B virus (26, 27) .", [["Measles virus", "DISEASE", 68, 81], ["Nipah virus", "DISEASE", 89, 100], ["Influenza B", "DISEASE", 112, 123], ["Measles virus", "ORGANISM", 68, 81], ["Nipah virus", "ORGANISM", 89, 100], ["Influenza B virus", "ORGANISM", 112, 129], ["Measles virus", "SPECIES", 68, 81], ["Nipah virus", "SPECIES", 89, 100], ["Influenza B virus", "SPECIES", 112, 129], ["Measles virus", "SPECIES", 68, 81], ["Nipah virus", "SPECIES", 89, 100], ["Influenza B virus", "SPECIES", 112, 129], ["Measles virus", "PROBLEM", 68, 81], ["Nipah virus", "PROBLEM", 89, 100], ["Influenza B virus", "PROBLEM", 112, 129]]], ["Still, for SARS-CoV-2 infection, the preferred route FIGURE 1 | Major entry routes taken by viruses to reach the CNS.", [["CNS", "ANATOMY", 113, 116], ["SARS-CoV-2 infection", "DISEASE", 11, 31], ["SARS-CoV-2", "ORGANISM", 11, 21], ["CNS", "ANATOMICAL_SYSTEM", 113, 116], ["SARS-CoV-2", "SPECIES", 11, 21], ["SARS", "PROBLEM", 11, 15], ["CoV", "PROBLEM", 16, 19], ["2 infection", "PROBLEM", 20, 31], ["infection", "OBSERVATION", 22, 31], ["CNS", "ANATOMY", 113, 116]]], ["The schematic is describing two major transmission routes taken by viruses to reach the CNS: hematogenous transmission route and olfactory neuronal transport route.", [["CNS", "ANATOMY", 88, 91], ["olfactory neuronal", "ANATOMY", 129, 147], ["CNS", "ANATOMICAL_SYSTEM", 88, 91], ["neuronal", "CELL", 139, 147], ["hematogenous transmission route", "TREATMENT", 93, 124], ["CNS", "ANATOMY", 88, 91], ["hematogenous", "OBSERVATION", 93, 105]]], ["Respiratory viruses may infect the lower respiratory tract and lung epithelia, which are in close contact with fine blood capillaries for oxygen transport.", [["lower respiratory tract", "ANATOMY", 35, 58], ["lung epithelia", "ANATOMY", 63, 77], ["blood capillaries", "ANATOMY", 116, 133], ["oxygen", "CHEMICAL", 138, 144], ["oxygen", "CHEMICAL", 138, 144], ["Respiratory viruses", "ORGANISM", 0, 19], ["lower", "ORGANISM_SUBDIVISION", 35, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 41, 58], ["lung epithelia", "TISSUE", 63, 77], ["blood capillaries", "MULTI-TISSUE_STRUCTURE", 116, 133], ["oxygen", "SIMPLE_CHEMICAL", 138, 144], ["Respiratory viruses", "PROBLEM", 0, 19], ["the lower respiratory tract", "PROBLEM", 31, 58], ["lung epithelia", "PROBLEM", 63, 77], ["oxygen transport", "TREATMENT", 138, 154], ["viruses", "OBSERVATION", 12, 19], ["lower", "ANATOMY_MODIFIER", 35, 40], ["respiratory tract", "ANATOMY", 41, 58], ["lung", "ANATOMY", 63, 67], ["epithelia", "ANATOMY_MODIFIER", 68, 77]]], ["Viruses travel toward the basolateral side of lung epithelia, enter the bloodstream, and eventually infect monocytes/macrophages in blood capillaries.", [["basolateral side", "ANATOMY", 26, 42], ["lung epithelia", "ANATOMY", 46, 60], ["bloodstream", "ANATOMY", 72, 83], ["monocytes", "ANATOMY", 107, 116], ["macrophages", "ANATOMY", 117, 128], ["blood capillaries", "ANATOMY", 132, 149], ["lung epithelia", "TISSUE", 46, 60], ["monocytes", "CELL", 107, 116], ["macrophages", "CELL", 117, 128], ["blood capillaries", "MULTI-TISSUE_STRUCTURE", 132, 149], ["monocytes", "CELL_TYPE", 107, 116], ["macrophages", "CELL_TYPE", 117, 128], ["Viruses", "PROBLEM", 0, 7], ["lung epithelia", "PROBLEM", 46, 60], ["macrophages in blood capillaries", "PROBLEM", 117, 149], ["basolateral", "ANATOMY_MODIFIER", 26, 37], ["lung", "ANATOMY", 46, 50], ["epithelia", "ANATOMY_MODIFIER", 51, 60], ["bloodstream", "ANATOMY", 72, 83], ["infect monocytes", "OBSERVATION", 100, 116], ["macrophages", "OBSERVATION", 117, 128], ["blood capillaries", "OBSERVATION", 132, 149]]], ["As a \"Trojan Horse\" route, these infected monocytes can travel to the CNS.", [["monocytes", "ANATOMY", 42, 51], ["CNS", "ANATOMY", 70, 73], ["monocytes", "CELL", 42, 51], ["CNS", "ANATOMICAL_SYSTEM", 70, 73], ["infected monocytes", "CELL_TYPE", 33, 51], ["these infected monocytes", "PROBLEM", 27, 51], ["infected", "OBSERVATION", 33, 41], ["CNS", "ANATOMY", 70, 73]]], ["In the olfactory neuronal transmission route, viruses travel from one neuron to another via synaptic endings by using cell motor proteins to ultimately reach the CNS.", [["olfactory neuronal", "ANATOMY", 7, 25], ["neuron", "ANATOMY", 70, 76], ["synaptic endings", "ANATOMY", 92, 108], ["cell", "ANATOMY", 118, 122], ["CNS", "ANATOMY", 162, 165], ["olfactory neuronal", "CELL", 7, 25], ["synaptic endings", "CELLULAR_COMPONENT", 92, 108], ["cell", "CELL", 118, 122], ["CNS", "ANATOMICAL_SYSTEM", 162, 165], ["cell motor proteins", "PROTEIN", 118, 137], ["cell motor proteins", "TREATMENT", 118, 137], ["CNS", "ANATOMY", 162, 165]]], ["For the sake of gaining perspective, if we go back to the history of the 1918 \"Spanish Flu, \" contemporary doctors and researchers observed an intriguing association of encephalitis lethargica (a debilitating nervous disorder in the form of sleep disorder, lethargy, and Parkinson-like symptoms) in flu patients after the recovery.", [["nervous", "ANATOMY", 209, 216], ["encephalitis", "DISEASE", 169, 181], ["lethargica", "DISEASE", 182, 192], ["nervous disorder", "DISEASE", 209, 225], ["sleep disorder", "DISEASE", 241, 255], ["lethargy", "DISEASE", 257, 265], ["Parkinson-like symptoms", "DISEASE", 271, 294], ["flu", "DISEASE", 299, 302], ["nervous", "ANATOMICAL_SYSTEM", 209, 216], ["patients", "ORGANISM", 303, 311], ["patients", "SPECIES", 303, 311], ["encephalitis lethargica", "PROBLEM", 169, 192], ["a debilitating nervous disorder", "PROBLEM", 194, 225], ["sleep disorder", "PROBLEM", 241, 255], ["lethargy", "PROBLEM", 257, 265], ["Parkinson-like symptoms", "PROBLEM", 271, 294], ["encephalitis", "OBSERVATION", 169, 181]]], ["These neurological perturbations could reduce the quality of a patient's life for decades (3, 28) .", [["neurological", "ANATOMY", 6, 18], ["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["These neurological perturbations", "PROBLEM", 0, 32]]], ["Following that, many episodes of the Influenza epidemic and their association with subsequent neurological disorders started convincing researchers that non-neurotropic/peripheral viruses, especially respiratory viruses, can affect the human brain with long-lasting neurological disorders (2) .", [["neurological", "ANATOMY", 94, 106], ["brain", "ANATOMY", 242, 247], ["neurological", "ANATOMY", 266, 278], ["Influenza", "DISEASE", 37, 46], ["neurological disorders", "DISEASE", 94, 116], ["peripheral viruses", "DISEASE", 169, 187], ["respiratory viruses", "DISEASE", 200, 219], ["neurological disorders", "DISEASE", 266, 288], ["peripheral viruses", "ORGANISM", 169, 187], ["human", "ORGANISM", 236, 241], ["brain", "ORGAN", 242, 247], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["the Influenza epidemic", "PROBLEM", 33, 55], ["subsequent neurological disorders", "PROBLEM", 83, 116], ["non-neurotropic/peripheral viruses", "PROBLEM", 153, 187], ["respiratory viruses", "PROBLEM", 200, 219], ["long-lasting neurological disorders", "PROBLEM", 253, 288], ["Influenza", "OBSERVATION", 37, 46], ["peripheral", "ANATOMY", 169, 179], ["viruses", "OBSERVATION", 180, 187], ["respiratory viruses", "OBSERVATION", 200, 219], ["brain", "ANATOMY", 242, 247]]], ["Those viral infections, where upon a strong immune response causes the brain to be cleared from viral particle through apoptosis and clearance of infected neurons, presented more challenging scenarios.", [["brain", "ANATOMY", 71, 76], ["neurons", "ANATOMY", 155, 162], ["viral infections", "DISEASE", 6, 22], ["brain", "ORGAN", 71, 76], ["neurons", "CELL", 155, 162], ["infected neurons", "CELL_TYPE", 146, 162], ["Those viral infections", "PROBLEM", 0, 22], ["viral particle through apoptosis", "PROBLEM", 96, 128], ["infected neurons", "PROBLEM", 146, 162], ["viral", "OBSERVATION_MODIFIER", 6, 11], ["infections", "OBSERVATION", 12, 22], ["brain", "ANATOMY", 71, 76], ["viral particle", "OBSERVATION", 96, 110], ["infected neurons", "OBSERVATION", 146, 162]]], ["For example, in Vesicular Stomatitis Virus (VSV) infection, which infects the brain serotonergic system, immune clearance results in a permanent loss of serotonin neurons, resulting in neurochemical and behavioral alterations (29) .", [["brain", "ANATOMY", 78, 83], ["neurons", "ANATOMY", 163, 170], ["Vesicular Stomatitis Virus (VSV) infection", "DISEASE", 16, 58], ["serotonin", "CHEMICAL", 153, 162], ["serotonin", "CHEMICAL", 153, 162], ["Vesicular Stomatitis Virus", "ORGANISM", 16, 42], ["VSV", "ORGANISM", 44, 47], ["brain", "ORGAN", 78, 83], ["serotonergic system", "ANATOMICAL_SYSTEM", 84, 103], ["serotonin neurons", "CELL", 153, 170], ["serotonin neurons", "CELL_TYPE", 153, 170], ["Vesicular Stomatitis Virus", "SPECIES", 16, 42], ["VSV", "SPECIES", 44, 47], ["Vesicular Stomatitis Virus (VSV) infection", "PROBLEM", 16, 58], ["immune clearance", "TEST", 105, 121], ["a permanent loss of serotonin neurons", "PROBLEM", 133, 170], ["neurochemical and behavioral alterations", "PROBLEM", 185, 225], ["Vesicular Stomatitis Virus", "OBSERVATION", 16, 42], ["infection", "OBSERVATION", 49, 58], ["brain serotonergic", "ANATOMY", 78, 96], ["serotonin neurons", "OBSERVATION", 153, 170]]], ["Lifelong neurological and psychiatric changes are brought upon by initial viral infection, however, no diagnosis could prove their association with a particular viral infection since the virus has long been eliminated long from the host.RESPIRATORY VIRUSES TAKE THE HEMATOGENOUS ROUTE TOOPost-Polio syndrome presents a perfect example of how some viruses could remain latent in the brain and cause neurological dysfunction much later in life.", [["neurological", "ANATOMY", 9, 21], ["brain", "ANATOMY", 382, 387], ["neurological", "ANATOMY", 398, 410], ["neurological and psychiatric", "DISEASE", 9, 37], ["viral infection", "DISEASE", 74, 89], ["viral infection", "DISEASE", 161, 176], ["Polio syndrome", "DISEASE", 293, 307], ["neurological dysfunction", "DISEASE", 398, 422], ["brain", "ORGAN", 382, 387], ["Lifelong neurological and psychiatric changes", "PROBLEM", 0, 45], ["initial viral infection", "PROBLEM", 66, 89], ["a particular viral infection", "PROBLEM", 148, 176], ["the virus", "PROBLEM", 183, 192], ["RESPIRATORY VIRUSES", "PROBLEM", 237, 256], ["Polio syndrome", "PROBLEM", 293, 307], ["some viruses", "PROBLEM", 342, 354], ["neurological dysfunction", "PROBLEM", 398, 422], ["infection", "OBSERVATION", 80, 89], ["infection", "OBSERVATION", 167, 176], ["VIRUSES", "OBSERVATION", 249, 256], ["HEMATOGENOUS", "OBSERVATION_MODIFIER", 266, 278], ["Polio syndrome", "OBSERVATION", 293, 307], ["viruses", "OBSERVATION", 347, 354], ["latent", "OBSERVATION", 368, 374], ["brain", "ANATOMY", 382, 387], ["dysfunction", "OBSERVATION", 411, 422]]], ["Many cases have been reported where symptoms of poliomyelitis, such as weakness of affected limbs, came back after decades, sometimes even after 30-40 years (30, 31) .", [["limbs", "ANATOMY", 92, 97], ["poliomyelitis", "DISEASE", 48, 61], ["weakness of affected limbs", "DISEASE", 71, 97], ["limbs", "ORGANISM_SUBDIVISION", 92, 97], ["symptoms", "PROBLEM", 36, 44], ["poliomyelitis", "PROBLEM", 48, 61], ["weakness of affected limbs", "PROBLEM", 71, 97], ["poliomyelitis", "OBSERVATION", 48, 61], ["limbs", "ANATOMY", 92, 97]]], ["Similarly, Chicken pox, caused by a double-strand DNA, enveloped herpes virus, remains latent inside neurons for decades (32, 33) .", [["neurons", "ANATOMY", 101, 108], ["herpes virus", "DISEASE", 65, 77], ["Chicken pox", "ORGANISM", 11, 22], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["enveloped herpes virus", "ORGANISM", 55, 77], ["neurons", "CELL", 101, 108], ["double-strand DNA", "DNA", 36, 53], ["Chicken", "SPECIES", 11, 18], ["herpes virus", "SPECIES", 65, 77], ["Chicken pox", "SPECIES", 11, 22], ["herpes virus", "SPECIES", 65, 77], ["Chicken pox", "PROBLEM", 11, 22], ["a double-strand DNA", "PROBLEM", 34, 53], ["enveloped herpes virus", "PROBLEM", 55, 77], ["herpes virus", "OBSERVATION", 65, 77]]], ["It manifests as shingles when the active virus is produced from its latent genome and starts showing symptoms of itching and pain.", [["shingles", "DISEASE", 16, 24], ["itching", "DISEASE", 113, 120], ["pain", "DISEASE", 125, 129], ["shingles", "PROBLEM", 16, 24], ["the active virus", "PROBLEM", 30, 46], ["symptoms", "PROBLEM", 101, 109], ["itching", "PROBLEM", 113, 120], ["pain", "PROBLEM", 125, 129], ["shingles", "OBSERVATION", 16, 24], ["active", "OBSERVATION_MODIFIER", 34, 40], ["virus", "OBSERVATION", 41, 46], ["itching", "OBSERVATION", 113, 120]]], ["It can produce a replication-competent virus which can travel down the axonal network and again infect the CNS neurons (33) .", [["axonal network", "ANATOMY", 71, 85], ["CNS neurons", "ANATOMY", 107, 118], ["axonal network", "MULTI-TISSUE_STRUCTURE", 71, 85], ["CNS neurons", "CELL", 107, 118], ["CNS neurons", "CELL_TYPE", 107, 118], ["a replication-competent virus", "PROBLEM", 15, 44], ["replication", "OBSERVATION", 17, 28], ["virus", "OBSERVATION", 39, 44]]], ["In such a situation, we are faced with a challenge that diagnostic assays can detect the virus only in the blood or CSF, giving us a false diagnosis of patient being virus-free, while parenchymal tissues might still harbor the virus.CURRENT PANDEMIC OF COVID-19/SARS-CoV-2Information on the general characteristics of SARS-CoV-2 virus, ACE2 receptor utilization, their transmission, and pathology is extensively available in the current flood of literature (34) (35) (36) (37) (38) .", [["blood", "ANATOMY", 107, 112], ["parenchymal tissues", "ANATOMY", 184, 203], ["SARS", "DISEASE", 318, 322], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["CSF", "ORGANISM_SUBSTANCE", 116, 119], ["patient", "ORGANISM", 152, 159], ["parenchymal tissues", "TISSUE", 184, 203], ["SARS-CoV", "ORGANISM", 262, 270], ["SARS-CoV-2 virus", "ORGANISM", 318, 334], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 336, 349], ["ACE2 receptor", "PROTEIN", 336, 349], ["patient", "SPECIES", 152, 159], ["CoV-2 virus", "SPECIES", 323, 334], ["SARS-CoV-2 virus", "SPECIES", 318, 334], ["diagnostic assays", "TEST", 56, 73], ["the virus", "PROBLEM", 85, 94], ["virus", "PROBLEM", 166, 171], ["parenchymal tissues", "PROBLEM", 184, 203], ["the virus", "PROBLEM", 223, 232], ["COVID", "TEST", 253, 258], ["SARS", "TEST", 318, 322], ["CoV", "TEST", 323, 326], ["ACE2 receptor utilization", "TREATMENT", 336, 361], ["pathology", "TEST", 387, 396], ["virus", "OBSERVATION", 227, 232]]], ["Therefore, we will mainly focus on their neuropathological aspects and other unique features.CURRENT PANDEMIC OF COVID-19/SARS-CoV-2The initial evidences for SARS-CoV-2-related CNS damage emerged when a SARS-CoV-2 infected patient was diagnosed with acute necrotizing hemorrhagic encephalopathy along with other usual symptoms of COVID-19.", [["CNS", "ANATOMY", 177, 180], ["SARS", "DISEASE", 158, 162], ["CNS damage", "DISEASE", 177, 187], ["SARS-CoV-2 infected", "DISEASE", 203, 222], ["necrotizing hemorrhagic encephalopathy", "DISEASE", 256, 294], ["SARS-CoV-2", "ORGANISM", 158, 168], ["CNS", "ANATOMICAL_SYSTEM", 177, 180], ["SARS-CoV-2", "ORGANISM", 203, 213], ["patient", "ORGANISM", 223, 230], ["patient", "SPECIES", 223, 230], ["SARS-CoV", "SPECIES", 158, 166], ["COVID", "TEST", 113, 118], ["CoV", "TEST", 127, 130], ["SARS", "PROBLEM", 158, 162], ["CoV", "TEST", 163, 166], ["CNS damage", "PROBLEM", 177, 187], ["a SARS", "PROBLEM", 201, 207], ["acute necrotizing hemorrhagic encephalopathy", "PROBLEM", 250, 294], ["other usual symptoms", "PROBLEM", 306, 326], ["COVID", "TEST", 330, 335], ["CNS", "ANATOMY", 177, 180], ["damage", "OBSERVATION", 181, 187], ["acute", "OBSERVATION_MODIFIER", 250, 255], ["necrotizing", "OBSERVATION_MODIFIER", 256, 267], ["hemorrhagic", "OBSERVATION_MODIFIER", 268, 279], ["encephalopathy", "OBSERVATION", 280, 294]]], ["Brain MRI images showed hemorrhagic rims in various cerebral segments such as bilateral thalami, medial temporal lobes, and sub-insular regions (39) .", [["Brain", "ANATOMY", 0, 5], ["cerebral segments", "ANATOMY", 52, 69], ["bilateral thalami", "ANATOMY", 78, 95], ["medial temporal lobes", "ANATOMY", 97, 118], ["sub-insular regions", "ANATOMY", 124, 143], ["hemorrhagic", "DISEASE", 24, 35], ["cerebral segments", "MULTI-TISSUE_STRUCTURE", 52, 69], ["thalami", "CANCER", 88, 95], ["medial temporal lobes", "CANCER", 97, 118], ["Brain MRI images", "TEST", 0, 16], ["hemorrhagic rims in various cerebral segments such as bilateral thalami, medial temporal lobes, and sub-insular regions", "PROBLEM", 24, 143], ["hemorrhagic rims", "OBSERVATION", 24, 40], ["various", "ANATOMY_MODIFIER", 44, 51], ["cerebral", "ANATOMY_MODIFIER", 52, 60], ["segments", "ANATOMY_MODIFIER", 61, 69], ["bilateral", "ANATOMY_MODIFIER", 78, 87], ["thalami", "ANATOMY", 88, 95], ["medial temporal lobes", "ANATOMY", 97, 118], ["sub", "OBSERVATION_MODIFIER", 124, 127], ["insular", "ANATOMY_MODIFIER", 128, 135], ["regions", "ANATOMY_MODIFIER", 136, 143]]], ["However, the direct presence of SARS-CoV-2 viral particles within the brain and CSF still needed experimental validation which could further confirm their neurotropism (39) .", [["brain", "ANATOMY", 70, 75], ["SARS", "DISEASE", 32, 36], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 32, 42], ["brain", "ORGAN", 70, 75], ["CSF", "GENE_OR_GENE_PRODUCT", 80, 83], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["2 viral particles within the brain", "PROBLEM", 41, 75], ["experimental validation", "TEST", 97, 120], ["SARS", "OBSERVATION", 32, 36], ["brain", "ANATOMY", 70, 75], ["CSF", "ANATOMY", 80, 83]]], ["A strong association of SARS-CoV-2 with neurological disorders has been extensively discussed in the current literature.", [["neurological", "ANATOMY", 40, 52], ["SARS", "DISEASE", 24, 28], ["neurological disorders", "DISEASE", 40, 62], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28], ["neurological disorders", "PROBLEM", 40, 62], ["strong", "OBSERVATION_MODIFIER", 2, 8]]], ["The latest updates on neuropathologies during COVID-19/SARS-CoV-2 can be explored in detail in the following references (40) (41) (42) .", [["neuropathologies", "TEST", 22, 38], ["COVID", "TEST", 46, 51], ["CoV", "TEST", 60, 63]]], ["Since this pandemic is still going on and most of the patients' data collected so far are only from the acute respiratory illness phase, there is a lack of any documentation on the long-term impact of SARS-CoV-2 on the human CNS.", [["CNS", "ANATOMY", 225, 228], ["respiratory illness", "DISEASE", 110, 129], ["SARS", "DISEASE", 201, 205], ["patients", "ORGANISM", 54, 62], ["SARS-CoV-2", "ORGANISM", 201, 211], ["human", "ORGANISM", 219, 224], ["CNS", "ANATOMICAL_SYSTEM", 225, 228], ["patients", "SPECIES", 54, 62], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 219, 224], ["the acute respiratory illness phase", "PROBLEM", 100, 135], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory illness", "OBSERVATION", 110, 129]]], ["The majority of data regarding neurological damage during SARS-CoV-2 infection are still without laboratory validation; so, we will have to look on how the previous episode of coronaviruses have influenced the CNS.NEUROINVASIVENESS OF CORONAVIRUSESThe presence of Coronavirus RNA (six previously known coronaviruses) have been reported in human brain autopsy samples which clearly established that, being primarily a respiratory virus, it is naturally neuroinvasive in human hosts and can successfully replicate within the brain (43) .", [["neurological", "ANATOMY", 31, 43], ["CNS", "ANATOMY", 210, 213], ["brain autopsy samples", "ANATOMY", 345, 366], ["brain", "ANATOMY", 523, 528], ["neurological damage", "DISEASE", 31, 50], ["SARS-CoV-2 infection", "DISEASE", 58, 78], ["SARS-CoV-2", "ORGANISM", 58, 68], ["coronaviruses", "ORGANISM", 176, 189], ["CNS", "ANATOMICAL_SYSTEM", 210, 213], ["coronaviruses", "ORGANISM", 302, 315], ["human", "ORGANISM", 339, 344], ["brain autopsy samples", "CANCER", 345, 366], ["human", "ORGANISM", 469, 474], ["brain", "ORGAN", 523, 528], ["Coronavirus RNA", "RNA", 264, 279], ["human", "SPECIES", 339, 344], ["human", "SPECIES", 469, 474], ["SARS-CoV", "SPECIES", 58, 66], ["human", "SPECIES", 339, 344], ["human", "SPECIES", 469, 474], ["neurological damage", "PROBLEM", 31, 50], ["SARS", "PROBLEM", 58, 62], ["CoV-2 infection", "PROBLEM", 63, 78], ["coronaviruses", "PROBLEM", 176, 189], ["Coronavirus RNA", "PROBLEM", 264, 279], ["coronaviruses", "PROBLEM", 302, 315], ["a respiratory virus", "PROBLEM", 415, 434], ["infection", "OBSERVATION", 69, 78], ["coronaviruses", "OBSERVATION", 176, 189], ["Coronavirus RNA", "OBSERVATION", 264, 279], ["respiratory virus", "OBSERVATION", 417, 434], ["brain", "ANATOMY", 523, 528]]], ["Further, it was established by many laboratories that a persistent infection of coronavirus happens in human CNS cells, such as oligodendrocytes and neuroglial cell lines (44) (45) (46) .", [["CNS cells", "ANATOMY", 109, 118], ["oligodendrocytes", "ANATOMY", 128, 144], ["neuroglial cell lines", "ANATOMY", 149, 170], ["infection", "DISEASE", 67, 76], ["coronavirus", "DISEASE", 80, 91], ["coronavirus", "ORGANISM", 80, 91], ["human", "ORGANISM", 103, 108], ["CNS cells", "CELL", 109, 118], ["oligodendrocytes", "CELL", 128, 144], ["neuroglial cell lines", "CELL", 149, 170], ["human CNS cells", "CELL_TYPE", 103, 118], ["oligodendrocytes", "CELL_TYPE", 128, 144], ["neuroglial cell lines", "CELL_LINE", 149, 170], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108], ["a persistent infection of coronavirus", "PROBLEM", 54, 91], ["human CNS cells", "PROBLEM", 103, 118], ["neuroglial cell lines", "TEST", 149, 170], ["persistent", "OBSERVATION_MODIFIER", 56, 66], ["infection", "OBSERVATION", 67, 76], ["coronavirus", "OBSERVATION", 80, 91], ["neuroglial cell lines", "OBSERVATION", 149, 170]]], ["In a mouse model, HCoV-OC43 RNA were detected for much longer after the mice survived the acute encephalitis episodes due to coronavirus.", [["encephalitis", "DISEASE", 96, 108], ["coronavirus", "DISEASE", 125, 136], ["mouse", "ORGANISM", 5, 10], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 18, 27], ["mice", "ORGANISM", 72, 76], ["coronavirus", "ORGANISM", 125, 136], ["HCoV-OC43 RNA", "RNA", 18, 31], ["mouse", "SPECIES", 5, 10], ["mice", "SPECIES", 72, 76], ["mouse", "SPECIES", 5, 10], ["HCoV", "SPECIES", 18, 22], ["mice", "SPECIES", 72, 76], ["OC43 RNA", "PROBLEM", 23, 31], ["the acute encephalitis episodes", "PROBLEM", 86, 117], ["coronavirus", "PROBLEM", 125, 136], ["OC43 RNA", "OBSERVATION", 23, 31], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["encephalitis", "OBSERVATION", 96, 108], ["coronavirus", "OBSERVATION", 125, 136]]], ["HCoV-OC43 infection in a mice model was suggestive of a loss of hippocampal neurons (47) .", [["hippocampal neurons", "ANATOMY", 64, 83], ["HCoV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 10, 19], ["loss of hippocampal neurons", "DISEASE", 56, 83], ["HCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 25, 29], ["hippocampal neurons", "CELL", 64, 83], ["hippocampal neurons", "CELL_TYPE", 64, 83], ["mice", "SPECIES", 25, 29], ["HCoV", "SPECIES", 0, 4], ["mice", "SPECIES", 25, 29], ["HCoV", "TEST", 0, 4], ["OC43 infection", "PROBLEM", 5, 19], ["a loss of hippocampal neurons", "PROBLEM", 54, 83], ["OC43 infection", "OBSERVATION", 5, 19], ["suggestive of", "UNCERTAINTY", 40, 53], ["loss", "OBSERVATION", 56, 60], ["hippocampal neurons", "OBSERVATION", 64, 83]]], ["These reports suggest that coronavirus is not just a flu virus with harmless disease outcomes but is also able to maintain a persistent infection in CNS.", [["CNS", "ANATOMY", 149, 152], ["coronavirus", "DISEASE", 27, 38], ["infection", "DISEASE", 136, 145], ["coronavirus", "ORGANISM", 27, 38], ["CNS", "ANATOMICAL_SYSTEM", 149, 152], ["flu virus", "SPECIES", 53, 62], ["coronavirus", "PROBLEM", 27, 38], ["a flu virus", "PROBLEM", 51, 62], ["harmless disease outcomes", "PROBLEM", 68, 93], ["a persistent infection in CNS", "PROBLEM", 123, 152], ["coronavirus", "OBSERVATION", 27, 38], ["persistent", "OBSERVATION_MODIFIER", 125, 135], ["infection", "OBSERVATION", 136, 145]]], ["Coronavirus infection might actually be a factor or co-factor for long-term neurological abnormalities to be revealed later in life, which we might not easily link with previous episodes of coronavirus infection.NEUROINVASIVENESS OF CORONAVIRUSESOther strains of coronavirus, such as HCoV-229E, also infects human primary monocytes and activates them (48) .", [["neurological", "ANATOMY", 76, 88], ["primary monocytes", "ANATOMY", 314, 331], ["Coronavirus infection", "DISEASE", 0, 21], ["neurological abnormalities", "DISEASE", 76, 102], ["coronavirus infection", "DISEASE", 190, 211], ["coronavirus", "DISEASE", 263, 274], ["HCoV-229E", "CHEMICAL", 284, 293], ["coronavirus", "ORGANISM", 190, 201], ["coronavirus", "ORGANISM", 263, 274], ["HCoV-229E", "ORGANISM", 284, 293], ["human", "ORGANISM", 308, 313], ["monocytes", "CELL", 322, 331], ["human primary monocytes", "CELL_TYPE", 308, 331], ["coronavirus", "SPECIES", 263, 274], ["human", "SPECIES", 308, 313], ["HCoV-229E", "SPECIES", 284, 293], ["human", "SPECIES", 308, 313], ["Coronavirus infection", "PROBLEM", 0, 21], ["long-term neurological abnormalities", "PROBLEM", 66, 102], ["coronavirus infection", "PROBLEM", 190, 211], ["coronavirus", "PROBLEM", 263, 274], ["infection", "OBSERVATION", 12, 21], ["coronavirus", "OBSERVATION_MODIFIER", 190, 201], ["infection", "OBSERVATION", 202, 211], ["coronavirus", "OBSERVATION", 263, 274], ["primary monocytes", "OBSERVATION", 314, 331]]], ["These HCoV-229E-infected monocytes would turn into macrophages after the activation and can enter the CNS, particularly in immune-compromised patients.", [["monocytes", "ANATOMY", 25, 34], ["macrophages", "ANATOMY", 51, 62], ["CNS", "ANATOMY", 102, 105], ["HCoV-229E", "CHEMICAL", 6, 15], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 6, 15], ["monocytes", "CELL", 25, 34], ["macrophages", "CELL", 51, 62], ["CNS", "ANATOMICAL_SYSTEM", 102, 105], ["patients", "ORGANISM", 142, 150], ["HCoV-229E-infected monocytes", "CELL_LINE", 6, 34], ["macrophages", "CELL_TYPE", 51, 62], ["patients", "SPECIES", 142, 150], ["These HCoV", "TEST", 0, 10], ["infected monocytes", "PROBLEM", 16, 34], ["infected monocytes", "OBSERVATION", 16, 34], ["CNS", "ANATOMY", 102, 105]]], ["In mice models, it was observed that HCoV-229E could invade the CNS by taking advantage of an immune-suppressed environment (49) .", [["CNS", "ANATOMY", 64, 67], ["HCoV-229E", "CHEMICAL", 37, 46], ["mice", "ORGANISM", 3, 7], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 37, 46], ["CNS", "ANATOMICAL_SYSTEM", 64, 67], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["HCoV-229E", "SPECIES", 37, 46], ["HCoV", "TEST", 37, 41], ["CNS", "ANATOMY", 64, 67]]], ["SARS-CoV-1, the causal factor of the previous SARS epidemic, was reported to infect monocytes to activate them into macrophages and dendritic cells (50, 51) .", [["monocytes", "ANATOMY", 84, 93], ["macrophages", "ANATOMY", 116, 127], ["dendritic cells", "ANATOMY", 132, 147], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 46, 50], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["monocytes", "CELL", 84, 93], ["macrophages", "CELL", 116, 127], ["dendritic cells", "CELL", 132, 147], ["monocytes", "CELL_TYPE", 84, 93], ["macrophages", "CELL_TYPE", 116, 127], ["dendritic cells", "CELL_TYPE", 132, 147], ["SARS-CoV-1", "SPECIES", 0, 10], ["the previous SARS epidemic", "PROBLEM", 33, 59], ["macrophages", "ANATOMY", 116, 127], ["dendritic cells", "OBSERVATION", 132, 147]]], ["These reports suggest that coronaviruses have developed a mechanism to take the hematogenous route for entering the CNS and these peripheral monocyte-macrophage populations can serve as a reservoir to maintain their replication within the CNS.", [["CNS", "ANATOMY", 116, 119], ["peripheral monocyte-macrophage populations", "ANATOMY", 130, 172], ["CNS", "ANATOMY", 239, 242], ["coronaviruses", "ORGANISM", 27, 40], ["CNS", "ANATOMICAL_SYSTEM", 116, 119], ["peripheral monocyte-macrophage populations", "CELL", 130, 172], ["CNS", "ANATOMICAL_SYSTEM", 239, 242], ["peripheral monocyte", "CELL_TYPE", 130, 149], ["macrophage populations", "CELL_TYPE", 150, 172], ["coronaviruses", "PROBLEM", 27, 40], ["the hematogenous route", "TREATMENT", 76, 98], ["these peripheral monocyte-macrophage populations", "TREATMENT", 124, 172], ["a reservoir", "TREATMENT", 186, 197], ["coronaviruses", "OBSERVATION", 27, 40], ["CNS", "ANATOMY", 116, 119], ["peripheral monocyte", "ANATOMY", 130, 149]]], ["There are also reports of coronavirus infection in brain endothelial cells shown in cell culture models (52) .", [["brain endothelial cells", "ANATOMY", 51, 74], ["cell culture", "ANATOMY", 84, 96], ["coronavirus infection", "DISEASE", 26, 47], ["coronavirus", "ORGANISM", 26, 37], ["brain endothelial cells", "CELL", 51, 74], ["cell", "CELL", 84, 88], ["brain endothelial cells", "CELL_TYPE", 51, 74], ["coronavirus infection in brain endothelial cells", "PROBLEM", 26, 74], ["cell culture models", "TEST", 84, 103], ["coronavirus", "OBSERVATION_MODIFIER", 26, 37], ["infection", "OBSERVATION", 38, 47], ["brain", "ANATOMY", 51, 56], ["endothelial cells", "OBSERVATION", 57, 74]]], ["SARS-CoV-1 was reported to infect human brain endothelial cells (53) .NEUROINVASIVENESS OF CORONAVIRUSESThere are a few examples where the hematogenous route for entering the CNS is exemplified, however, coronaviruses are equally known to take the neuronal transmission route.NEUROINVASIVENESS OF CORONAVIRUSESIn the neuronal transmission route, the virus typically infects the neurons located peripherally and actively transports itself using the cellular actin-myosin machinery of neurons to enter the CNS (54).", [["brain endothelial cells", "ANATOMY", 40, 63], ["CNS", "ANATOMY", 175, 178], ["neuronal", "ANATOMY", 248, 256], ["neuronal", "ANATOMY", 317, 325], ["neurons", "ANATOMY", 378, 385], ["peripherally", "ANATOMY", 394, 406], ["cellular", "ANATOMY", 448, 456], ["neurons", "ANATOMY", 483, 490], ["CNS", "ANATOMY", 504, 507], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 34, 39], ["brain endothelial cells", "CELL", 40, 63], ["CNS", "ANATOMICAL_SYSTEM", 175, 178], ["coronaviruses", "ORGANISM", 204, 217], ["neuronal", "CELL", 248, 256], ["neuronal", "CELL", 317, 325], ["neurons", "CELL", 378, 385], ["cellular", "CELL", 448, 456], ["-myosin", "GENE_OR_GENE_PRODUCT", 462, 469], ["neurons", "CELL", 483, 490], ["CNS", "ANATOMICAL_SYSTEM", 504, 507], ["human brain endothelial cells", "CELL_TYPE", 34, 63], ["actin", "PROTEIN", 457, 462], ["human", "SPECIES", 34, 39], ["SARS-CoV-1", "SPECIES", 0, 10], ["human", "SPECIES", 34, 39], ["SARS-CoV", "TEST", 0, 8], ["coronaviruses", "PROBLEM", 204, 217], ["the virus", "PROBLEM", 346, 355], ["brain endothelial", "ANATOMY", 40, 57], ["hematogenous", "OBSERVATION", 139, 151], ["CNS", "ANATOMY", 175, 178], ["CNS", "ANATOMY", 504, 507]]], ["This route was confirmed in animal studies too, where coronaviruses such as HCoV-OC43 and SARS-CoV-1 were given to mice via intranasal injections.", [["coronaviruses", "ORGANISM", 54, 67], ["HCoV-OC43", "ORGANISM", 76, 85], ["SARS-CoV-1", "ORGANISM", 90, 100], ["mice", "ORGANISM", 115, 119], ["SARS-CoV", "SPECIES", 90, 98], ["mice", "SPECIES", 115, 119], ["HCoV", "SPECIES", 76, 80], ["SARS-CoV-1", "SPECIES", 90, 100], ["mice", "SPECIES", 115, 119], ["animal studies", "TEST", 28, 42], ["coronaviruses", "PROBLEM", 54, 67], ["HCoV", "TEST", 76, 80], ["OC43", "PROBLEM", 81, 85], ["SARS", "PROBLEM", 90, 94], ["CoV", "TEST", 95, 98], ["intranasal injections", "TREATMENT", 124, 145]]], ["First, viruses were found in the respiratory tract and later were detected in the CNS of susceptible mice, confirming the olfactory route being taken to reach the CNS (55) (56) (57) (58) .", [["respiratory tract", "ANATOMY", 33, 50], ["CNS", "ANATOMY", 82, 85], ["olfactory", "ANATOMY", 122, 131], ["respiratory tract", "ORGAN", 33, 50], ["CNS", "ANATOMICAL_SYSTEM", 82, 85], ["mice", "ORGANISM", 101, 105], ["olfactory route", "MULTI-TISSUE_STRUCTURE", 122, 137], ["mice", "SPECIES", 101, 105], ["mice", "SPECIES", 101, 105], ["viruses", "PROBLEM", 7, 14], ["viruses", "OBSERVATION", 7, 14], ["respiratory tract", "ANATOMY", 33, 50], ["CNS", "ANATOMY", 163, 166]]], ["Similarly, murine coronavirus (Mu-CoV) also takes the olfactory nerve route to enter the CNS (59) .", [["olfactory nerve", "ANATOMY", 54, 69], ["CNS", "ANATOMY", 89, 92], ["murine coronavirus", "ORGANISM", 11, 29], ["Mu-CoV", "ORGANISM", 31, 37], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 54, 69], ["CNS", "ANATOMICAL_SYSTEM", 89, 92], ["murine", "SPECIES", 11, 17], ["murine coronavirus", "SPECIES", 11, 29], ["Mu-CoV", "SPECIES", 31, 37], ["murine coronavirus", "TEST", 11, 29], ["coronavirus", "OBSERVATION_MODIFIER", 18, 29], ["olfactory nerve", "ANATOMY", 54, 69], ["CNS", "ANATOMY", 89, 92]]], ["The HCoV-OC43 strain is experimentally shown to travel further from the olfactory bulb to other neural regions such as the cortex, hippocampus, and even the brainstem and spinal cord (39) .", [["olfactory bulb", "ANATOMY", 72, 86], ["neural regions", "ANATOMY", 96, 110], ["cortex", "ANATOMY", 123, 129], ["hippocampus", "ANATOMY", 131, 142], ["brainstem", "ANATOMY", 157, 166], ["spinal cord", "ANATOMY", 171, 182], ["HCoV", "GENE_OR_GENE_PRODUCT", 4, 8], ["olfactory bulb", "MULTI-TISSUE_STRUCTURE", 72, 86], ["cortex", "CANCER", 123, 129], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 131, 142], ["brainstem", "ORGAN", 157, 166], ["spinal cord", "ORGAN", 171, 182], ["HCoV-OC43 strain", "DNA", 4, 20], ["HCoV-OC43 strain", "SPECIES", 4, 20], ["The HCoV", "TEST", 0, 8], ["OC43 strain", "PROBLEM", 9, 20], ["OC43 strain", "OBSERVATION", 9, 20], ["olfactory", "ANATOMY_MODIFIER", 72, 81], ["bulb", "ANATOMY_MODIFIER", 82, 86], ["neural", "ANATOMY_MODIFIER", 96, 102], ["regions", "ANATOMY_MODIFIER", 103, 110], ["cortex", "ANATOMY_MODIFIER", 123, 129], ["hippocampus", "ANATOMY", 131, 142], ["brainstem", "ANATOMY", 157, 166], ["spinal cord", "ANATOMY", 171, 182]]], ["This olfactory route being used by other viruses, such as influenza virus, Borna disease virus, and herpes simplex virus, has been extensively reviewed by Mori and colleagues (18) .CORONAVIRUS-MEDIATED NEUROPATHOGENESISSpeculations about viral etiology behind common neurological diseases such as Parkinson's disease (PD), ADEM (Acute disseminated encephalomyelitis), and multiple sclerosis (MS) has gained much strength in recent times.", [["olfactory", "ANATOMY", 5, 14], ["neurological", "ANATOMY", 267, 279], ["influenza virus", "DISEASE", 58, 73], ["Borna disease", "DISEASE", 75, 88], ["herpes simplex virus", "DISEASE", 100, 120], ["neurological diseases", "DISEASE", 267, 288], ["Parkinson's disease", "DISEASE", 297, 316], ["PD", "DISEASE", 318, 320], ["ADEM", "DISEASE", 323, 327], ["Acute disseminated encephalomyelitis", "DISEASE", 329, 365], ["multiple sclerosis", "DISEASE", 372, 390], ["MS", "DISEASE", 392, 394], ["olfactory route", "MULTI-TISSUE_STRUCTURE", 5, 20], ["influenza virus", "ORGANISM", 58, 73], ["Borna disease virus", "ORGANISM", 75, 94], ["herpes simplex virus", "ORGANISM", 100, 120], ["influenza virus", "SPECIES", 58, 73], ["Borna disease virus", "SPECIES", 75, 94], ["herpes simplex virus", "SPECIES", 100, 120], ["influenza virus", "SPECIES", 58, 73], ["Borna disease virus", "SPECIES", 75, 94], ["herpes simplex virus", "SPECIES", 100, 120], ["This olfactory route", "TREATMENT", 0, 20], ["other viruses", "PROBLEM", 35, 48], ["influenza virus", "PROBLEM", 58, 73], ["Borna disease virus", "PROBLEM", 75, 94], ["herpes simplex virus", "PROBLEM", 100, 120], ["common neurological diseases", "PROBLEM", 260, 288], ["Parkinson's disease", "PROBLEM", 297, 316], ["PD)", "PROBLEM", 318, 321], ["ADEM", "PROBLEM", 323, 327], ["Acute disseminated encephalomyelitis)", "PROBLEM", 329, 366], ["multiple sclerosis (MS)", "PROBLEM", 372, 395], ["viruses", "OBSERVATION", 41, 48], ["Borna disease", "OBSERVATION", 75, 88], ["Acute", "OBSERVATION_MODIFIER", 329, 334], ["disseminated", "OBSERVATION_MODIFIER", 335, 347], ["encephalomyelitis", "OBSERVATION", 348, 365], ["multiple", "OBSERVATION_MODIFIER", 372, 380], ["sclerosis", "OBSERVATION", 381, 390]]], ["Particularly with various coronaviruses, such as HCoV-229E and HCoV-OC43, being detected within Parkinson's disease (PD), ADEM (Acute disseminated encephalomyelitis), and multiple sclerosis (MS) patient's brains, it is now discussed as a link between these neurodegenerative diseases and viral infections (43, 60) .", [["brains", "ANATOMY", 205, 211], ["Parkinson's disease", "DISEASE", 96, 115], ["PD", "DISEASE", 117, 119], ["ADEM", "DISEASE", 122, 126], ["Acute disseminated encephalomyelitis", "DISEASE", 128, 164], ["multiple sclerosis", "DISEASE", 171, 189], ["MS", "DISEASE", 191, 193], ["neurodegenerative diseases", "DISEASE", 257, 283], ["viral infections", "DISEASE", 288, 304], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 49, 58], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 63, 72], ["patient", "ORGANISM", 195, 202], ["brains", "ORGAN", 205, 211], ["patient", "SPECIES", 195, 202], ["HCoV-229E", "SPECIES", 49, 58], ["various coronaviruses", "PROBLEM", 18, 39], ["HCoV", "TEST", 49, 53], ["HCoV", "TEST", 63, 67], ["OC43", "PROBLEM", 68, 72], ["Parkinson's disease", "PROBLEM", 96, 115], ["ADEM", "PROBLEM", 122, 126], ["Acute disseminated encephalomyelitis)", "PROBLEM", 128, 165], ["multiple sclerosis (MS) patient's brains", "PROBLEM", 171, 211], ["these neurodegenerative diseases", "PROBLEM", 251, 283], ["viral infections", "PROBLEM", 288, 304], ["Acute", "OBSERVATION_MODIFIER", 128, 133], ["disseminated", "OBSERVATION_MODIFIER", 134, 146], ["encephalomyelitis", "OBSERVATION", 147, 164], ["multiple", "OBSERVATION_MODIFIER", 171, 179], ["sclerosis", "OBSERVATION", 180, 189], ["brains", "ANATOMY", 205, 211], ["neurodegenerative", "OBSERVATION_MODIFIER", 257, 274], ["diseases", "OBSERVATION", 275, 283], ["viral", "OBSERVATION_MODIFIER", 288, 293], ["infections", "OBSERVATION", 294, 304]]], ["Even murine coronaviruses, known for demyelination in mice, have been found to contribute to oxidative tissue injury in human MS disease (61) .", [["tissue", "ANATOMY", 103, 109], ["demyelination", "DISEASE", 37, 50], ["tissue injury", "DISEASE", 103, 116], ["MS disease", "DISEASE", 126, 136], ["murine coronaviruses", "ORGANISM", 5, 25], ["mice", "ORGANISM", 54, 58], ["tissue", "TISSUE", 103, 109], ["human", "ORGANISM", 120, 125], ["murine", "SPECIES", 5, 11], ["mice", "SPECIES", 54, 58], ["human", "SPECIES", 120, 125], ["mice", "SPECIES", 54, 58], ["human", "SPECIES", 120, 125], ["murine coronaviruses", "PROBLEM", 5, 25], ["demyelination", "PROBLEM", 37, 50], ["oxidative tissue injury in human MS disease", "PROBLEM", 93, 136], ["coronaviruses", "OBSERVATION", 12, 25], ["oxidative tissue", "OBSERVATION_MODIFIER", 93, 109], ["injury", "OBSERVATION", 110, 116]]], ["This provided a very interesting, although worrisome, correlation that long-term infections with coronaviruses in human CNS may contribute toward MSlike lesions.CORONAVIRUS-MEDIATED NEUROPATHOGENESISDuring coronavirus replication and proliferation in lung epithelial cells, the alveolar gas exchange phenomenon is severely hampered because of damaged lung epithelial cells (62) .", [["CNS", "ANATOMY", 120, 123], ["MSlike lesions", "ANATOMY", 146, 160], ["lung epithelial cells", "ANATOMY", 251, 272], ["alveolar gas", "ANATOMY", 278, 290], ["lung epithelial cells", "ANATOMY", 351, 372], ["infections", "DISEASE", 81, 91], ["coronaviruses", "DISEASE", 97, 110], ["coronaviruses", "ORGANISM", 97, 110], ["human", "ORGANISM", 114, 119], ["CNS", "ANATOMICAL_SYSTEM", 120, 123], ["MSlike lesions", "CANCER", 146, 160], ["coronavirus", "ORGANISM", 206, 217], ["lung epithelial cells", "CELL", 251, 272], ["alveolar", "MULTI-TISSUE_STRUCTURE", 278, 286], ["lung epithelial cells", "CELL", 351, 372], ["lung epithelial cells", "CELL_TYPE", 251, 272], ["damaged lung epithelial cells", "CELL_TYPE", 343, 372], ["human", "SPECIES", 114, 119], ["coronavirus", "SPECIES", 206, 217], ["human", "SPECIES", 114, 119], ["long-term infections", "PROBLEM", 71, 91], ["coronaviruses in human CNS", "PROBLEM", 97, 123], ["MSlike lesions", "PROBLEM", 146, 160], ["CORONAVIRUS", "PROBLEM", 161, 172], ["NEUROPATHOGENESISDuring coronavirus replication", "TREATMENT", 182, 229], ["proliferation in lung epithelial cells", "PROBLEM", 234, 272], ["the alveolar gas exchange phenomenon", "PROBLEM", 274, 310], ["damaged lung epithelial cells", "PROBLEM", 343, 372], ["lesions", "OBSERVATION", 153, 160], ["coronavirus replication", "OBSERVATION", 206, 229], ["proliferation", "OBSERVATION_MODIFIER", 234, 247], ["lung", "ANATOMY", 251, 255], ["epithelial cells", "OBSERVATION", 256, 272], ["alveolar", "ANATOMY_MODIFIER", 278, 286], ["gas exchange", "OBSERVATION", 287, 299], ["lung", "ANATOMY", 351, 355], ["epithelial cells", "OBSERVATION", 356, 372]]], ["Afterward, the lack of oxygen in the entire body, including the CNS, may cause hypoxia disorders.", [["body", "ANATOMY", 44, 48], ["CNS", "ANATOMY", 64, 67], ["oxygen", "CHEMICAL", 23, 29], ["hypoxia disorders", "DISEASE", 79, 96], ["oxygen", "CHEMICAL", 23, 29], ["oxygen", "SIMPLE_CHEMICAL", 23, 29], ["body", "ORGANISM_SUBDIVISION", 44, 48], ["CNS", "ANATOMICAL_SYSTEM", 64, 67], ["hypoxia disorders", "PROBLEM", 79, 96], ["oxygen", "OBSERVATION_MODIFIER", 23, 29], ["CNS", "ANATOMY", 64, 67], ["may cause", "UNCERTAINTY", 69, 78], ["hypoxia", "OBSERVATION", 79, 86]]], ["It might activate anaerobic metabolic pathways and mitochondrial pathways within the brain (63, 64) .", [["mitochondrial", "ANATOMY", 51, 64], ["brain", "ANATOMY", 85, 90], ["mitochondrial", "CELLULAR_COMPONENT", 51, 64], ["brain", "ORGAN", 85, 90], ["anaerobic metabolic pathways", "OBSERVATION", 18, 46], ["mitochondrial pathways", "OBSERVATION", 51, 73], ["brain", "ANATOMY", 85, 90]]], ["The resultant acidosis in the brain can cause multiple dysfunctions like cerebral vasodilation, brain swellings, interstitial edema, headaches, and congestion, etc (65, 66) .", [["brain", "ANATOMY", 30, 35], ["cerebral", "ANATOMY", 73, 81], ["brain", "ANATOMY", 96, 101], ["interstitial edema", "ANATOMY", 113, 131], ["acidosis", "DISEASE", 14, 22], ["cerebral vasodilation", "DISEASE", 73, 94], ["brain swellings", "DISEASE", 96, 111], ["interstitial edema", "DISEASE", 113, 131], ["headaches", "DISEASE", 133, 142], ["congestion", "DISEASE", 148, 158], ["brain", "ORGAN", 30, 35], ["cerebral", "ORGAN", 73, 81], ["brain", "ORGAN", 96, 101], ["interstitial edema", "PATHOLOGICAL_FORMATION", 113, 131], ["The resultant acidosis in the brain", "PROBLEM", 0, 35], ["multiple dysfunctions", "PROBLEM", 46, 67], ["cerebral vasodilation", "PROBLEM", 73, 94], ["brain swellings", "PROBLEM", 96, 111], ["interstitial edema", "PROBLEM", 113, 131], ["headaches", "PROBLEM", 133, 142], ["congestion", "PROBLEM", 148, 158], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["acidosis", "OBSERVATION", 14, 22], ["brain", "ANATOMY", 30, 35], ["multiple", "OBSERVATION_MODIFIER", 46, 54], ["dysfunctions", "OBSERVATION", 55, 67], ["cerebral vasodilation", "OBSERVATION", 73, 94], ["brain", "ANATOMY", 96, 101], ["swellings", "OBSERVATION", 102, 111], ["interstitial", "ANATOMY_MODIFIER", 113, 125], ["edema", "OBSERVATION", 126, 131], ["headaches", "OBSERVATION", 133, 142], ["congestion", "OBSERVATION", 148, 158]]], ["In severe cases it can lead to degraded brain functions, drowsiness, bulbar conjunctival edema, and eventually coma (67) .", [["brain", "ANATOMY", 40, 45], ["bulbar conjunctival", "ANATOMY", 69, 88], ["conjunctival edema", "DISEASE", 76, 94], ["coma", "DISEASE", 111, 115], ["brain", "ORGAN", 40, 45], ["drowsiness", "PROBLEM", 57, 67], ["bulbar conjunctival edema", "PROBLEM", 69, 94], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["bulbar", "ANATOMY_MODIFIER", 69, 75], ["conjunctival", "ANATOMY", 76, 88], ["edema", "OBSERVATION", 89, 94]]], ["Since patient's reports from China and Italy have consistently shown that critical SARS-CoV-2 patients often develop severe hypoxia, subsequent cerebral damage is likely to happen.CORONAVIRUS-MEDIATED NEUROPATHOGENESISThis could be true for persistent infections of other coronaviruses within the CNS, however, more experimental evidence is needed to establish such a correlation for all the recent coronaviruses, such as SARS-CoV-1, MERS-CoV, and SARS-CoV-2.WHY THE BRAIN IS \"THE MOST SUSCEPTIBLE\" FOR CYTOKINE STORM?Cytokines were once given the analogy of rain.", [["cerebral", "ANATOMY", 144, 152], ["CNS", "ANATOMY", 297, 300], ["hypoxia", "DISEASE", 124, 131], ["cerebral damage", "DISEASE", 144, 159], ["infections", "DISEASE", 252, 262], ["patient", "ORGANISM", 6, 13], ["SARS-CoV-2", "ORGANISM", 83, 93], ["patients", "ORGANISM", 94, 102], ["cerebral", "ORGAN", 144, 152], ["coronaviruses", "ORGANISM", 272, 285], ["CNS", "ANATOMICAL_SYSTEM", 297, 300], ["coronaviruses", "ORGANISM", 399, 412], ["SARS-CoV-1", "ORGANISM", 422, 432], ["MERS-CoV", "ORGANISM", 434, 442], ["SARS-CoV-2", "ORGANISM", 448, 458], ["Cytokines", "PROTEIN", 518, 527], ["patient", "SPECIES", 6, 13], ["patients", "SPECIES", 94, 102], ["SARS-CoV-1", "SPECIES", 422, 432], ["MERS-CoV", "SPECIES", 434, 442], ["SARS-CoV", "SPECIES", 448, 456], ["critical SARS", "PROBLEM", 74, 87], ["severe hypoxia", "PROBLEM", 117, 131], ["subsequent cerebral damage", "PROBLEM", 133, 159], ["persistent infections of other coronaviruses", "PROBLEM", 241, 285], ["all the recent coronaviruses", "PROBLEM", 384, 412], ["SARS", "TEST", 422, 426], ["CoV", "TEST", 427, 430], ["MERS", "TEST", 434, 438], ["CoV", "TEST", 439, 442], ["Cytokines", "TREATMENT", 518, 527], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["hypoxia", "OBSERVATION", 124, 131], ["cerebral", "ANATOMY", 144, 152], ["damage", "OBSERVATION", 153, 159], ["persistent", "OBSERVATION_MODIFIER", 241, 251], ["infections", "OBSERVATION", 252, 262], ["coronaviruses", "OBSERVATION", 272, 285], ["CNS", "ANATOMY", 297, 300], ["coronaviruses", "OBSERVATION", 399, 412], ["BRAIN", "ANATOMY", 467, 472]]], ["As moderate and timely rain is needed to sustain life on earth, similarly a baseline amount of cytokines are actually needed for multiple cellular and physiological processes during the life of an organism (68, 69) .", [["cellular", "ANATOMY", 138, 146], ["earth", "ORGANISM_SUBDIVISION", 57, 62], ["cellular", "CELL", 138, 146], ["cytokines", "PROTEIN", 95, 104], ["cytokines", "PROBLEM", 95, 104], ["multiple cellular and physiological processes", "PROBLEM", 129, 174], ["moderate", "OBSERVATION_MODIFIER", 3, 11], ["cytokines", "OBSERVATION", 95, 104]]], ["Cytokine storm is a condition where the regulators of inflammatory immune responses, and thereby the production of cytokines, becomes out of proportion and out of place.WHY THE BRAIN IS \"THE MOST SUSCEPTIBLE\" FOR CYTOKINE STORM?This results in the production of an uncontrolled amount of inflammatory molecules.", [["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cytokine", "PROTEIN", 0, 8], ["cytokines", "PROTEIN", 115, 124], ["inflammatory molecules", "PROTEIN", 288, 310], ["Cytokine storm", "PROBLEM", 0, 14], ["cytokines", "PROBLEM", 115, 124], ["inflammatory molecules", "PROBLEM", 288, 310], ["inflammatory", "OBSERVATION_MODIFIER", 54, 66], ["BRAIN", "ANATOMY", 177, 182], ["uncontrolled", "OBSERVATION_MODIFIER", 265, 277], ["amount", "OBSERVATION_MODIFIER", 278, 284], ["inflammatory molecules", "OBSERVATION", 288, 310]]], ["Cytokine storm happens in multiple bacterial and viral infections and septic conditions, however, the term \"Cytokine storm\" only gained its popularity after being discussed in the context of Influenza disease in 2005 (70) .WHY THE BRAIN IS \"THE MOST SUSCEPTIBLE\" FOR CYTOKINE STORM?This overreacting innate immune response creates the situation of \"Cytokine Storm\" which typically means that proinflammatory and anti-inflammatory cytokine levels are high in the serum of patients.", [["serum", "ANATOMY", 462, 467], ["bacterial and viral infections", "DISEASE", 35, 65], ["septic", "DISEASE", 70, 76], ["Influenza disease", "DISEASE", 191, 208], ["Cytokine", "GENE_OR_GENE_PRODUCT", 108, 116], ["Cytokine", "GENE_OR_GENE_PRODUCT", 349, 357], ["serum", "ORGANISM_SUBSTANCE", 462, 467], ["patients", "ORGANISM", 471, 479], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine", "PROTEIN", 108, 116], ["Cytokine", "PROTEIN", 349, 357], ["cytokine", "PROTEIN", 430, 438], ["patients", "SPECIES", 471, 479], ["Cytokine storm", "PROBLEM", 0, 14], ["multiple bacterial and viral infections", "PROBLEM", 26, 65], ["septic conditions", "PROBLEM", 70, 87], ["Influenza disease", "PROBLEM", 191, 208], ["proinflammatory and anti-inflammatory cytokine levels", "TEST", 392, 445], ["multiple", "OBSERVATION_MODIFIER", 26, 34], ["bacterial", "OBSERVATION_MODIFIER", 35, 44], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["infections", "OBSERVATION", 55, 65], ["septic conditions", "OBSERVATION", 70, 87], ["Influenza", "OBSERVATION", 191, 200], ["BRAIN", "ANATOMY", 231, 236], ["immune response", "OBSERVATION", 307, 322], ["proinflammatory", "OBSERVATION_MODIFIER", 392, 407], ["anti-inflammatory", "OBSERVATION_MODIFIER", 412, 429]]], ["These cytokine flares are usually destructive for all vital organs such as the heart, kidneys, and lungs (Figure 2 ).", [["organs", "ANATOMY", 60, 66], ["heart", "ANATOMY", 79, 84], ["kidneys", "ANATOMY", 86, 93], ["lungs", "ANATOMY", 99, 104], ["organs", "ORGAN", 60, 66], ["heart", "ORGAN", 79, 84], ["kidneys", "ORGAN", 86, 93], ["lungs", "ORGAN", 99, 104], ["cytokine", "PROTEIN", 6, 14], ["These cytokine flares", "PROBLEM", 0, 21], ["all vital organs such as the heart, kidneys, and lungs", "PROBLEM", 50, 104], ["cytokine flares", "OBSERVATION", 6, 21], ["destructive", "OBSERVATION_MODIFIER", 34, 45], ["heart", "ANATOMY", 79, 84], ["kidneys", "ANATOMY", 86, 93], ["lungs", "ANATOMY", 99, 104]]], ["If such a scenario happens in the brain, this becomes extremely devastating and further paves the way for meningitis, encephalitis, meningoencephalitis, and overall neurodegenerative conditions (68, 71) .", [["brain", "ANATOMY", 34, 39], ["meningitis", "DISEASE", 106, 116], ["encephalitis", "DISEASE", 118, 130], ["meningoencephalitis", "DISEASE", 132, 151], ["brain", "ORGAN", 34, 39], ["a scenario happens in the brain", "PROBLEM", 8, 39], ["extremely devastating", "PROBLEM", 54, 75], ["meningitis", "PROBLEM", 106, 116], ["encephalitis", "PROBLEM", 118, 130], ["meningoencephalitis", "PROBLEM", 132, 151], ["overall neurodegenerative conditions", "PROBLEM", 157, 193], ["brain", "ANATOMY", 34, 39], ["devastating", "OBSERVATION", 64, 75], ["meningitis", "OBSERVATION", 106, 116], ["encephalitis", "OBSERVATION", 118, 130], ["meningoencephalitis", "OBSERVATION", 132, 151], ["neurodegenerative", "OBSERVATION_MODIFIER", 165, 182]]], ["Earlier, many viral infections of HIV-1, Dengue, and other flaviviruses have been reported to cause a cytokine storm phenomenon in the peripheral body which can reach the CNS via either disrupting the BBB or sometime even via trans-cellular crossing of the BBB (11, 72) .", [["peripheral body", "ANATOMY", 135, 150], ["CNS", "ANATOMY", 171, 174], ["BBB", "ANATOMY", 201, 204], ["cellular", "ANATOMY", 232, 240], ["viral infections", "DISEASE", 14, 30], ["HIV-1", "DISEASE", 34, 39], ["Dengue", "DISEASE", 41, 47], ["flaviviruses", "DISEASE", 59, 71], ["HIV-1", "ORGANISM", 34, 39], ["Dengue", "ORGANISM", 41, 47], ["peripheral body", "MULTI-TISSUE_STRUCTURE", 135, 150], ["CNS", "ANATOMICAL_SYSTEM", 171, 174], ["BBB", "MULTI-TISSUE_STRUCTURE", 201, 204], ["cellular", "CELL", 232, 240], ["BBB", "MULTI-TISSUE_STRUCTURE", 257, 260], ["cytokine", "PROTEIN", 102, 110], ["HIV-1", "SPECIES", 34, 39], ["HIV-1", "SPECIES", 34, 39], ["many viral infections of HIV", "PROBLEM", 9, 37], ["Dengue", "PROBLEM", 41, 47], ["other flaviviruses", "PROBLEM", 53, 71], ["a cytokine storm phenomenon in the peripheral body", "PROBLEM", 100, 150], ["many", "OBSERVATION_MODIFIER", 9, 13], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 20, 30], ["flaviviruses", "OBSERVATION", 59, 71], ["cytokine storm", "OBSERVATION", 102, 116], ["peripheral body", "ANATOMY_MODIFIER", 135, 150], ["BBB", "ANATOMY", 257, 260]]], ["The role of exosomes and other extracellular vesicles in Dengue viral hemorrhagic fever has also been discussed to highlight the importance of exosomal secretion in cytokine storm phenomenon (59) .", [["exosomes", "ANATOMY", 12, 20], ["extracellular vesicles", "ANATOMY", 31, 53], ["exosomal", "ANATOMY", 143, 151], ["Dengue viral hemorrhagic fever", "DISEASE", 57, 87], ["exosomes", "CELL", 12, 20], ["extracellular vesicles", "CELLULAR_COMPONENT", 31, 53], ["Dengue viral", "ORGANISM", 57, 69], ["exosomes", "CELL_TYPE", 12, 20], ["cytokine", "PROTEIN", 165, 173], ["Dengue viral hemorrhagic fever", "SPECIES", 57, 87], ["other extracellular vesicles", "PROBLEM", 25, 53], ["Dengue viral hemorrhagic fever", "PROBLEM", 57, 87], ["exosomal secretion in cytokine storm phenomenon", "PROBLEM", 143, 190], ["exosomes", "OBSERVATION", 12, 20], ["extracellular vesicles", "ANATOMY", 31, 53], ["hemorrhagic", "OBSERVATION_MODIFIER", 70, 81], ["fever", "OBSERVATION", 82, 87]]], ["Even viral proteins such as HIV-1 Tat, Nef, and Dengue NS1 circulate in the bloodstream and trigger the generation and transportation of cytokines to multiple organs, including the CNS (73) (74) (75) (76) (77) .", [["bloodstream", "ANATOMY", 76, 87], ["organs", "ANATOMY", 159, 165], ["CNS", "ANATOMY", 181, 184], ["HIV-1", "ORGANISM", 28, 33], ["Tat", "GENE_OR_GENE_PRODUCT", 34, 37], ["Nef", "GENE_OR_GENE_PRODUCT", 39, 42], ["Dengue NS1", "ORGANISM", 48, 58], ["organs", "ORGAN", 159, 165], ["CNS", "ANATOMICAL_SYSTEM", 181, 184], ["viral proteins", "PROTEIN", 5, 19], ["HIV-1 Tat", "PROTEIN", 28, 37], ["Nef", "PROTEIN", 39, 42], ["Dengue NS1", "PROTEIN", 48, 58], ["cytokines", "PROTEIN", 137, 146], ["HIV-1", "SPECIES", 28, 33], ["HIV-1", "SPECIES", 28, 33], ["Dengue NS1", "SPECIES", 48, 58], ["viral proteins", "TEST", 5, 19], ["HIV", "TEST", 28, 31], ["Nef", "TEST", 39, 42], ["Dengue NS1 circulate in the bloodstream", "PROBLEM", 48, 87], ["the CNS", "TEST", 177, 184], ["viral proteins", "OBSERVATION", 5, 19], ["bloodstream", "ANATOMY", 76, 87]]], ["Ultimately, all these influxes of peripheral inflammatory molecules inside the CNS activate the brain resident macrophages, i.e., microglia, which becomes hyper-activated and starts producing its own set of inflammatory molecules and causes neuroinflammation.", [["CNS", "ANATOMY", 79, 82], ["brain", "ANATOMY", 96, 101], ["macrophages", "ANATOMY", 111, 122], ["microglia", "ANATOMY", 130, 139], ["neuroinflammation", "DISEASE", 241, 258], ["CNS", "ANATOMICAL_SYSTEM", 79, 82], ["brain resident", "CELL", 96, 110], ["macrophages", "CELL", 111, 122], ["microglia", "CELL", 130, 139], ["peripheral inflammatory molecules", "PROTEIN", 34, 67], ["brain resident macrophages", "CELL_TYPE", 96, 122], ["microglia", "CELL_TYPE", 130, 139], ["inflammatory molecules", "PROTEIN", 207, 229], ["peripheral inflammatory molecules", "PROBLEM", 34, 67], ["microglia", "PROBLEM", 130, 139], ["hyper-activated", "PROBLEM", 155, 170], ["inflammatory molecules", "PROBLEM", 207, 229], ["neuroinflammation", "PROBLEM", 241, 258], ["peripheral", "ANATOMY_MODIFIER", 34, 44], ["inflammatory molecules", "OBSERVATION", 45, 67], ["CNS", "ANATOMY", 79, 82], ["brain", "ANATOMY", 96, 101], ["macrophages", "OBSERVATION", 111, 122], ["inflammatory molecules", "OBSERVATION", 207, 229], ["neuroinflammation", "OBSERVATION", 241, 258]]], ["This whole process of making microglia ready to act is known as \"microglial priming.\"\"MICROGLIAL PRIMING\" MIGHT EXPLAIN A LOTIt is noteworthy that most of the chronic neurodegenerative diseases have an association with unresolved inflammation, also termed as neuroinflammation.", [["microglia", "ANATOMY", 29, 38], ["microglial", "ANATOMY", 65, 75], ["neurodegenerative diseases", "DISEASE", 167, 193], ["inflammation", "DISEASE", 230, 242], ["neuroinflammation", "DISEASE", 259, 276], ["microglia", "CELL", 29, 38], ["microglial", "CELL", 65, 75], ["microglia", "CELL_TYPE", 29, 38], ["the chronic neurodegenerative diseases", "PROBLEM", 155, 193], ["unresolved inflammation", "PROBLEM", 219, 242], ["neuroinflammation", "PROBLEM", 259, 276], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["neurodegenerative", "OBSERVATION_MODIFIER", 167, 184], ["diseases", "OBSERVATION", 185, 193], ["unresolved", "OBSERVATION_MODIFIER", 219, 229], ["inflammation", "OBSERVATION", 230, 242], ["neuroinflammation", "OBSERVATION", 259, 276]]], ["These diseases are mainly Alzheimer's disease (AD), Multiple sclerosis (MS), Parkinson's Disease (PD), Huntington's Disease (HD), ischemia, and strokes, (67, 68) .", [["Alzheimer's disease", "DISEASE", 26, 45], ["AD", "DISEASE", 47, 49], ["Multiple sclerosis", "DISEASE", 52, 70], ["MS", "DISEASE", 72, 74], ["Parkinson's Disease", "DISEASE", 77, 96], ["PD", "DISEASE", 98, 100], ["Huntington's Disease", "DISEASE", 103, 123], ["HD", "DISEASE", 125, 127], ["ischemia", "DISEASE", 130, 138], ["strokes", "DISEASE", 144, 151], ["These diseases", "PROBLEM", 0, 14], ["Alzheimer's disease", "PROBLEM", 26, 45], ["Multiple sclerosis (MS)", "PROBLEM", 52, 75], ["Parkinson's Disease", "PROBLEM", 77, 96], ["PD)", "PROBLEM", 98, 101], ["Huntington's Disease", "PROBLEM", 103, 123], ["HD)", "TREATMENT", 125, 128], ["ischemia", "PROBLEM", 130, 138], ["strokes", "PROBLEM", 144, 151], ["diseases", "OBSERVATION", 6, 14], ["Multiple", "OBSERVATION_MODIFIER", 52, 60], ["sclerosis", "OBSERVATION", 61, 70], ["ischemia", "OBSERVATION", 130, 138], ["strokes", "OBSERVATION", 144, 151]]], ["Many researchers have explained the phenomenon of \"Microglial Priming, \" where microglia undergo multiplication followed by activation and stay in this \"primed\" condition for a very long time (78) .", [["Microglial", "ANATOMY", 51, 61], ["microglia", "ANATOMY", 79, 88], ["Microglial", "CELL", 51, 61], ["microglia", "CELL", 79, 88], ["microglia", "CELL_TYPE", 79, 88]]], ["This \"priming\" makes the microglia extremely susceptible toward a secondary inflammatory stimulus.", [["microglia", "ANATOMY", 25, 34], ["microglia", "CELL", 25, 34], ["microglia", "CELL_TYPE", 25, 34], ["the microglia", "PROBLEM", 21, 34], ["a secondary inflammatory stimulus", "PROBLEM", 64, 97], ["secondary", "OBSERVATION_MODIFIER", 66, 75], ["inflammatory stimulus", "OBSERVATION", 76, 97]]], ["Even a small molecular trigger can induce an exaggerated inflammatory response from the primed microglia (78, 79) .", [["microglia", "ANATOMY", 95, 104], ["microglia", "CELL", 95, 104], ["primed microglia", "CELL_TYPE", 88, 104], ["a small molecular trigger", "PROBLEM", 5, 30], ["an exaggerated inflammatory response", "PROBLEM", 42, 78], ["small", "OBSERVATION_MODIFIER", 7, 12], ["exaggerated", "OBSERVATION_MODIFIER", 45, 56], ["inflammatory response", "OBSERVATION", 57, 78]]], ["It was experimentally validated that TNFa and the activation of microglia has a positive feedback loop relation (79) .", [["microglia", "ANATOMY", 64, 73], ["TNFa", "GENE_OR_GENE_PRODUCT", 37, 41], ["microglia", "CELL", 64, 73], ["TNFa", "PROTEIN", 37, 41], ["microglia", "CELL_TYPE", 64, 73], ["TNFa", "PROBLEM", 37, 41]]], ["This explains why the brain is so susceptible to peripheral cytokine storm created by any route, be it bacterial, viral, or any other aging-related inflammatory abnormalities like rheumatoid arthritis.", [["brain", "ANATOMY", 22, 27], ["rheumatoid arthritis", "DISEASE", 180, 200], ["brain", "ORGAN", 22, 27], ["cytokine", "PROTEIN", 60, 68], ["peripheral cytokine storm", "TREATMENT", 49, 74], ["bacterial", "PROBLEM", 103, 112], ["viral", "PROBLEM", 114, 119], ["inflammatory abnormalities", "PROBLEM", 148, 174], ["rheumatoid arthritis", "PROBLEM", 180, 200], ["brain", "ANATOMY", 22, 27], ["cytokine storm", "OBSERVATION", 60, 74], ["bacterial", "OBSERVATION", 103, 112], ["viral", "OBSERVATION", 114, 119], ["inflammatory", "OBSERVATION_MODIFIER", 148, 160], ["rheumatoid arthritis", "OBSERVATION", 180, 200]]], ["Cytokines produced by a 'primed microglia' pose a much higher threat in disrupting the homeostasis of the CNS than systemic inflammatory molecules added from peripheral monocytes (68, 69) .\"MICROGLIAL PRIMING\" MIGHT EXPLAIN A LOTThe secondary stimulus which activates microglia can begin in the CNS by many means, such as any neuroviral infections or FIGURE 2 | Multiple Organ Failure because of \"Cytokine Storm.\"", [["microglia", "ANATOMY", 32, 41], ["CNS", "ANATOMY", 106, 109], ["peripheral monocytes", "ANATOMY", 158, 178], ["microglia", "ANATOMY", 268, 277], ["CNS", "ANATOMY", 295, 298], ["infections", "DISEASE", 337, 347], ["Cytokines", "GENE_OR_GENE_PRODUCT", 0, 9], ["microglia", "CELL", 32, 41], ["CNS", "ANATOMICAL_SYSTEM", 106, 109], ["peripheral monocytes", "CELL", 158, 178], ["microglia", "CELL", 268, 277], ["CNS", "ANATOMICAL_SYSTEM", 295, 298], ["Cytokine", "GENE_OR_GENE_PRODUCT", 397, 405], ["Cytokines", "PROTEIN", 0, 9], ["systemic inflammatory molecules", "PROTEIN", 115, 146], ["peripheral monocytes", "CELL_TYPE", 158, 178], ["microglia", "CELL_TYPE", 268, 277], ["Cytokine", "PROTEIN", 397, 405], ["systemic inflammatory molecules", "PROBLEM", 115, 146], ["peripheral monocytes", "TEST", 158, 178], ["The secondary stimulus", "PROBLEM", 229, 251], ["any neuroviral infections", "PROBLEM", 322, 347], ["Multiple Organ Failure", "PROBLEM", 362, 384], ["CNS", "ANATOMY", 106, 109], ["inflammatory", "OBSERVATION", 124, 136], ["peripheral", "ANATOMY_MODIFIER", 158, 168], ["monocytes", "ANATOMY", 169, 178], ["secondary stimulus", "OBSERVATION", 233, 251], ["infections", "OBSERVATION", 337, 347], ["Organ", "ANATOMY", 371, 376], ["Failure", "OBSERVATION", 377, 384]]], ["The cartoon representation of how \"Cytokine Storm\" generated during respiratory viral infections can damage not only its primary infection site (i.e., lungs) but also disrupt the homeostasis at the kidneys, heart, intestine, cerebral parenchyma, and blood vessels because of the ubiquitous presence of ACE2 receptors.", [["site", "ANATOMY", 139, 143], ["lungs", "ANATOMY", 151, 156], ["kidneys", "ANATOMY", 198, 205], ["heart", "ANATOMY", 207, 212], ["intestine", "ANATOMY", 214, 223], ["cerebral parenchyma", "ANATOMY", 225, 244], ["blood vessels", "ANATOMY", 250, 263], ["respiratory viral infections", "DISEASE", 68, 96], ["infection", "DISEASE", 129, 138], ["Cytokine", "GENE_OR_GENE_PRODUCT", 35, 43], ["lungs", "ORGAN", 151, 156], ["kidneys", "ORGAN", 198, 205], ["heart", "ORGAN", 207, 212], ["intestine", "ORGAN", 214, 223], ["cerebral parenchyma", "MULTI-TISSUE_STRUCTURE", 225, 244], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 250, 263], ["ACE2", "GENE_OR_GENE_PRODUCT", 302, 306], ["Cytokine", "PROTEIN", 35, 43], ["ACE2 receptors", "PROTEIN", 302, 316], ["respiratory viral infections", "PROBLEM", 68, 96], ["its primary infection site", "PROBLEM", 117, 143], ["the homeostasis at the kidneys, heart, intestine, cerebral parenchyma, and blood vessels", "PROBLEM", 175, 263], ["ACE2 receptors", "PROBLEM", 302, 316], ["infection", "OBSERVATION", 129, 138], ["lungs", "ANATOMY", 151, 156], ["homeostasis", "OBSERVATION", 179, 190], ["kidneys", "ANATOMY", 198, 205], ["heart", "ANATOMY", 207, 212], ["intestine", "ANATOMY", 214, 223], ["cerebral parenchyma", "ANATOMY", 225, 244], ["blood vessels", "ANATOMY", 250, 263]]], ["In severe cases, this leads to Multiple Organ Failure and the eventual death of patients.\"MICROGLIAL PRIMING\" MIGHT EXPLAIN A LOTbacterial invasion.", [["Organ", "ANATOMY", 40, 45], ["death", "DISEASE", 71, 76], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["Multiple Organ Failure", "PROBLEM", 31, 53], ["A LOTbacterial invasion", "PROBLEM", 124, 147], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["cases", "OBSERVATION", 10, 15], ["Multiple", "OBSERVATION_MODIFIER", 31, 39], ["Organ", "ANATOMY", 40, 45], ["Failure", "OBSERVATION", 46, 53], ["LOTbacterial", "OBSERVATION_MODIFIER", 126, 138], ["invasion", "OBSERVATION", 139, 147]]], ["However, it has been observed that conditions which contribute to systemic inflammation such as diabetes, ischemic conditions, and arthritis, are a major cause of priming microglia, and this can be particularly seen in elderly populations (80) (81) (82) .", [["microglia", "ANATOMY", 171, 180], ["inflammation", "DISEASE", 75, 87], ["diabetes", "DISEASE", 96, 104], ["ischemic conditions", "DISEASE", 106, 125], ["arthritis", "DISEASE", 131, 140], ["microglia", "CELL", 171, 180], ["microglia", "CELL_TYPE", 171, 180], ["systemic inflammation", "PROBLEM", 66, 87], ["diabetes", "PROBLEM", 96, 104], ["ischemic conditions", "PROBLEM", 106, 125], ["arthritis", "PROBLEM", 131, 140], ["priming microglia", "PROBLEM", 163, 180], ["systemic", "OBSERVATION_MODIFIER", 66, 74], ["inflammation", "OBSERVATION", 75, 87], ["diabetes", "OBSERVATION", 96, 104], ["ischemic", "OBSERVATION_MODIFIER", 106, 114], ["arthritis", "OBSERVATION", 131, 140]]], ["This puts the elderly population at a much higher risk of experiencing neurological and cognitive disabilities if exposed to respiratory and/or other peripheral viral infections.\"MICROGLIAL PRIMING\" MIGHT EXPLAIN A LOTOther than microglia, astrocytes and neurons can also produce multiple cytokines upon exposure to external stimuli (69, 78) .", [["respiratory", "ANATOMY", 125, 136], ["microglia", "ANATOMY", 229, 238], ["astrocytes", "ANATOMY", 240, 250], ["neurons", "ANATOMY", 255, 262], ["neurological and cognitive disabilities", "DISEASE", 71, 110], ["peripheral viral infections", "DISEASE", 150, 177], ["microglia", "CELL", 229, 238], ["astrocytes", "CELL", 240, 250], ["neurons", "CELL", 255, 262], ["LOTOther", "CELL_LINE", 215, 223], ["microglia", "CELL_TYPE", 229, 238], ["astrocytes", "CELL_TYPE", 240, 250], ["neurons", "CELL_TYPE", 255, 262], ["cytokines", "PROTEIN", 289, 298], ["neurological and cognitive disabilities", "PROBLEM", 71, 110], ["other peripheral viral infections", "PROBLEM", 144, 177], ["A LOTOther than microglia, astrocytes and neurons", "PROBLEM", 213, 262], ["multiple cytokines", "PROBLEM", 280, 298], ["external stimuli", "TEST", 316, 332], ["peripheral", "ANATOMY", 150, 160], ["viral infections", "OBSERVATION", 161, 177], ["multiple", "OBSERVATION_MODIFIER", 280, 288], ["cytokines", "OBSERVATION", 289, 298]]], ["Such alterations in cerebral homeostasis mainly happens at synapses (78, (83) (84) (85) .", [["cerebral", "ANATOMY", 20, 28], ["synapses", "ANATOMY", 59, 67], ["cerebral", "ORGAN", 20, 28], ["Such alterations in cerebral homeostasis", "PROBLEM", 0, 40], ["cerebral homeostasis", "ANATOMY", 20, 40]]], ["Synaptic anomalies are responsible for deficient learning and memory and disruption of normal behavior (83) (84) (85) .", [["Synaptic", "ANATOMY", 0, 8], ["Synaptic anomalies", "DISEASE", 0, 18], ["Synaptic anomalies", "PROBLEM", 0, 18], ["deficient learning", "PROBLEM", 39, 57]]], ["This bridging of systemic inflammation with the CNS anomalies is a challenging interaction, however, at the same time it gives us a hopeful window to treat neurodegenerative conditions just by controlling systemic inflammation.\"MICROGLIAL PRIMING\" MIGHT EXPLAIN A LOTWe will now briefly list the neurological anomalies caused by the following viral invaders.SARS-CoVSARS-CoV-1 was the reason for the 2003, 2009, and 2012 SARS epidemics, which started in Asia and spread worldwide.", [["CNS", "ANATOMY", 48, 51], ["neurological", "ANATOMY", 296, 308], ["inflammation", "DISEASE", 26, 38], ["CNS anomalies", "DISEASE", 48, 61], ["inflammation", "DISEASE", 214, 226], ["neurological anomalies", "DISEASE", 296, 318], ["SARS epidemics", "DISEASE", 421, 435], ["CNS", "ANATOMICAL_SYSTEM", 48, 51], ["systemic inflammation", "PROBLEM", 17, 38], ["the CNS anomalies", "PROBLEM", 44, 61], ["neurodegenerative conditions", "PROBLEM", 156, 184], ["systemic inflammation", "PROBLEM", 205, 226], ["the neurological anomalies", "PROBLEM", 292, 318], ["systemic", "OBSERVATION_MODIFIER", 17, 25], ["inflammation", "OBSERVATION", 26, 38], ["CNS", "ANATOMY", 48, 51], ["anomalies", "OBSERVATION", 52, 61], ["systemic", "OBSERVATION_MODIFIER", 205, 213], ["inflammation", "OBSERVATION", 214, 226]]], ["This virus causes the characteristic respiratory illness, which includes high fever, dry cough, and difficult breathing, and severe cases manifested by respiratory failure and death (86) .", [["respiratory", "ANATOMY", 37, 48], ["respiratory", "ANATOMY", 152, 163], ["respiratory illness", "DISEASE", 37, 56], ["fever", "DISEASE", 78, 83], ["dry cough", "DISEASE", 85, 94], ["respiratory failure", "DISEASE", 152, 171], ["death", "DISEASE", 176, 181], ["This virus", "PROBLEM", 0, 10], ["the characteristic respiratory illness", "PROBLEM", 18, 56], ["high fever", "PROBLEM", 73, 83], ["dry cough", "PROBLEM", 85, 94], ["difficult breathing", "PROBLEM", 100, 119], ["severe cases", "PROBLEM", 125, 137], ["respiratory failure", "PROBLEM", 152, 171], ["death", "PROBLEM", 176, 181], ["characteristic", "OBSERVATION_MODIFIER", 22, 36], ["respiratory illness", "OBSERVATION", 37, 56], ["high", "OBSERVATION_MODIFIER", 73, 77], ["fever", "OBSERVATION", 78, 83], ["dry", "OBSERVATION_MODIFIER", 85, 88], ["cough", "OBSERVATION", 89, 94], ["severe", "OBSERVATION_MODIFIER", 125, 131], ["respiratory failure", "OBSERVATION", 152, 171]]], ["This SARS coronavirus emerged from the bat reservoir (87) .", [["SARS coronavirus", "DISEASE", 5, 21], ["SARS coronavirus", "ORGANISM", 5, 21], ["SARS coronavirus", "SPECIES", 5, 21], ["This SARS coronavirus", "PROBLEM", 0, 21]]], ["It infected palm civets as an intermediate host and then jumped to human hosts (87) .", [["palm", "ORGANISM_SUBDIVISION", 12, 16], ["human", "ORGANISM", 67, 72], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72]]], ["A total of 8096 infections happened across 26 countries, with a high mortality rate of \u223c10%, causing a total of 774 deaths (88) .SARS-CoVAs it occurred 17 years ago, research communities have had enough time to investigate the immediate and long-term impacts of SARS-CoV on the human CNS.", [["CNS", "ANATOMY", 284, 287], ["infections", "DISEASE", 16, 26], ["deaths", "DISEASE", 116, 122], ["SARS", "DISEASE", 129, 133], ["SARS", "DISEASE", 262, 266], ["SARS-CoV", "ORGANISM", 262, 270], ["human", "ORGANISM", 278, 283], ["CNS", "ANATOMICAL_SYSTEM", 284, 287], ["human", "SPECIES", 278, 283], ["SARS-CoV", "SPECIES", 262, 270], ["human", "SPECIES", 278, 283], ["8096 infections", "PROBLEM", 11, 26], ["total", "OBSERVATION_MODIFIER", 2, 7], ["infections", "OBSERVATION", 16, 26]]], ["SARS-CoV was found to trigger many neurological abnormalities such as encephalitis, aortic ischemic stroke, and polyneuropathy (86) .", [["neurological", "ANATOMY", 35, 47], ["aortic", "ANATOMY", 84, 90], ["SARS", "DISEASE", 0, 4], ["neurological abnormalities", "DISEASE", 35, 61], ["encephalitis", "DISEASE", 70, 82], ["aortic ischemic stroke", "DISEASE", 84, 106], ["polyneuropathy", "DISEASE", 112, 126], ["SARS-CoV", "ORGANISM", 0, 8], ["aortic", "MULTI-TISSUE_STRUCTURE", 84, 90], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "PROBLEM", 0, 8], ["many neurological abnormalities", "PROBLEM", 30, 61], ["encephalitis", "PROBLEM", 70, 82], ["aortic ischemic stroke", "PROBLEM", 84, 106], ["polyneuropathy", "PROBLEM", 112, 126], ["encephalitis", "OBSERVATION", 70, 82], ["aortic", "ANATOMY", 84, 90], ["ischemic", "OBSERVATION_MODIFIER", 91, 99], ["stroke", "OBSERVATION", 100, 106], ["polyneuropathy", "OBSERVATION", 112, 126]]], ["Interestingly, most SARS-CoV cases displayed signs of cerebral edema and meningeal vasodilation in autopsy studies.", [["cerebral", "ANATOMY", 54, 62], ["meningeal", "ANATOMY", 73, 82], ["SARS", "DISEASE", 20, 24], ["cerebral edema", "DISEASE", 54, 68], ["SARS-CoV", "ORGANISM", 20, 28], ["cerebral edema", "PATHOLOGICAL_FORMATION", 54, 68], ["meningeal", "MULTI-TISSUE_STRUCTURE", 73, 82], ["SARS-CoV", "SPECIES", 20, 28], ["CoV cases", "TEST", 25, 34], ["cerebral edema", "PROBLEM", 54, 68], ["meningeal vasodilation", "PROBLEM", 73, 95], ["autopsy studies", "TEST", 99, 114], ["cerebral", "ANATOMY", 54, 62], ["edema", "OBSERVATION", 63, 68], ["meningeal", "ANATOMY", 73, 82], ["vasodilation", "OBSERVATION", 83, 95]]], ["Within the brain, the presence of SARS-CoV viral particles and their RNA sequences were identified concomitantly with ischemic changes of neurons, demyelinating abnormalities, along with evidence of monocyte and lymphocyte infiltrations in the brain (89) .", [["brain", "ANATOMY", 11, 16], ["neurons", "ANATOMY", 138, 145], ["monocyte", "ANATOMY", 199, 207], ["lymphocyte", "ANATOMY", 212, 222], ["brain", "ANATOMY", 244, 249], ["SARS", "DISEASE", 34, 38], ["demyelinating abnormalities", "DISEASE", 147, 174], ["brain", "ORGAN", 11, 16], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["neurons", "CELL", 138, 145], ["monocyte", "CELL", 199, 207], ["lymphocyte", "CELL", 212, 222], ["brain", "ORGAN", 244, 249], ["SARS-CoV viral particles", "RNA", 34, 58], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV viral particles", "PROBLEM", 34, 58], ["their RNA sequences", "TEST", 63, 82], ["ischemic changes of neurons", "PROBLEM", 118, 145], ["demyelinating abnormalities", "PROBLEM", 147, 174], ["monocyte and lymphocyte infiltrations in the brain", "PROBLEM", 199, 249], ["brain", "ANATOMY", 11, 16], ["SARS", "OBSERVATION", 34, 38], ["ischemic", "OBSERVATION", 118, 126], ["neurons", "ANATOMY", 138, 145], ["demyelinating", "OBSERVATION_MODIFIER", 147, 160], ["monocyte", "OBSERVATION_MODIFIER", 199, 207], ["lymphocyte infiltrations", "OBSERVATION", 212, 236], ["brain", "ANATOMY", 244, 249]]], ["Table 2 has been provided with a comparative percentage of patients displaying neurological disorders.MERS-CoVMERS-CoV is a relatively recent member of the coronavirus family, identified in 2015 in the Arabian Peninsula.", [["neurological", "ANATOMY", 79, 91], ["neurological disorders", "DISEASE", 79, 101], ["patients", "ORGANISM", 59, 67], ["MERS-CoVMERS-CoV", "GENE_OR_GENE_PRODUCT", 102, 118], ["coronavirus", "ORGANISM", 156, 167], ["patients", "SPECIES", 59, 67], ["coronavirus", "SPECIES", 156, 167], ["MERS-CoVMERS-CoV", "SPECIES", 102, 118], ["neurological disorders", "PROBLEM", 79, 101], ["Arabian", "ANATOMY_MODIFIER", 202, 209], ["Peninsula", "ANATOMY_MODIFIER", 210, 219]]], ["It originated from bats and used camels as an intermediate host for many years before jumping to human hosts (90) .", [["human", "ORGANISM", 97, 102], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102]]], ["It has similar clinical outcomes to SARS-CoV, with typical pneumonia-like symptoms such as high fever, cough, and dyspnea, which often leads to acute respiratory distress syndrome (ARDS), collectively termed Middle East Respiratory Syndrome (MERS) (90) .", [["respiratory", "ANATOMY", 150, 161], ["SARS-CoV", "DISEASE", 36, 44], ["pneumonia", "DISEASE", 59, 68], ["fever", "DISEASE", 96, 101], ["cough", "DISEASE", 103, 108], ["dyspnea", "DISEASE", 114, 121], ["acute respiratory distress syndrome", "DISEASE", 144, 179], ["ARDS", "DISEASE", 181, 185], ["Middle East Respiratory Syndrome", "DISEASE", 208, 240], ["MERS", "DISEASE", 242, 246], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["SARS-CoV", "SPECIES", 36, 44], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 208, 247], ["SARS", "PROBLEM", 36, 40], ["typical pneumonia", "PROBLEM", 51, 68], ["like symptoms", "PROBLEM", 69, 82], ["high fever", "PROBLEM", 91, 101], ["cough", "PROBLEM", 103, 108], ["dyspnea", "PROBLEM", 114, 121], ["acute respiratory distress syndrome", "PROBLEM", 144, 179], ["ARDS", "PROBLEM", 181, 185], ["Middle East Respiratory Syndrome", "PROBLEM", 208, 240], ["pneumonia", "OBSERVATION", 59, 68], ["high", "OBSERVATION_MODIFIER", 91, 95], ["fever", "OBSERVATION", 96, 101], ["cough", "OBSERVATION", 103, 108], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory distress", "OBSERVATION", 150, 170], ["Middle", "ANATOMY_MODIFIER", 208, 214], ["Respiratory Syndrome", "OBSERVATION", 220, 240]]], ["Severe conditions also included septic shock because of cytokine storm resulting in multiple organ failure and eventual death (91) .", [["organ", "ANATOMY", 93, 98], ["septic shock", "DISEASE", 32, 44], ["multiple organ failure", "DISEASE", 84, 106], ["death", "DISEASE", 120, 125], ["organ", "ORGAN", 93, 98], ["cytokine", "PROTEIN", 56, 64], ["Severe conditions", "PROBLEM", 0, 17], ["septic shock", "PROBLEM", 32, 44], ["cytokine storm", "PROBLEM", 56, 70], ["multiple organ failure", "PROBLEM", 84, 106], ["eventual death", "PROBLEM", 111, 125], ["septic shock", "OBSERVATION", 32, 44], ["cytokine storm", "OBSERVATION", 56, 70], ["multiple", "OBSERVATION_MODIFIER", 84, 92], ["organ", "ANATOMY", 93, 98], ["failure", "OBSERVATION", 99, 106]]], ["This virus is considered a potential neuroinvasive virus, based on clinical and experimental evidences.", [["This virus", "PROBLEM", 0, 10], ["a potential neuroinvasive virus", "PROBLEM", 25, 56], ["neuroinvasive", "OBSERVATION_MODIFIER", 37, 50], ["virus", "OBSERVATION", 51, 56]]], ["Studies reported that almost 25.7% patients of MERS developed insanity and around 9% patients were getting seizure attacks after the MERS-CoV infection (92) (93) (94) .", [["MERS", "DISEASE", 47, 51], ["insanity", "DISEASE", 62, 70], ["seizure", "DISEASE", 107, 114], ["infection", "DISEASE", 142, 151], ["patients", "ORGANISM", 35, 43], ["patients", "ORGANISM", 85, 93], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 133, 141], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 85, 93], ["MERS-CoV", "SPECIES", 133, 141], ["Studies", "TEST", 0, 7], ["MERS", "PROBLEM", 47, 51], ["insanity", "PROBLEM", 62, 70], ["seizure attacks", "PROBLEM", 107, 122], ["the MERS", "PROBLEM", 129, 137], ["CoV infection", "PROBLEM", 138, 151]]], ["Another study also confirmed these trends andSARS-CoV-2/COVID-19The latest addition of novel coronavirus, first observed in 2019 in Wuhan city of China, has been named SARS-CoV-2 based on its genome sequence analysis (95, 96) .", [["coronavirus", "ORGANISM", 93, 104], ["SARS-CoV-2", "ORGANISM", 168, 178], ["SARS-CoV", "SPECIES", 168, 176], ["Another study", "TEST", 0, 13], ["these trends andSARS-CoV", "TEST", 29, 53], ["COVID", "TEST", 56, 61], ["novel coronavirus", "PROBLEM", 87, 104], ["its genome sequence analysis", "TEST", 188, 216]]], ["This novel coronavirus shares a 79.5% sequence similarity with earlier SARS-CoV and an almost 50% similarity with MERS-CoV.", [["coronavirus", "ORGANISM", 11, 22], ["SARS-CoV", "ORGANISM", 71, 79], ["MERS-CoV", "ORGANISM", 114, 122], ["MERS-CoV", "DNA", 114, 122], ["SARS-CoV", "SPECIES", 71, 79], ["MERS-CoV", "SPECIES", 114, 122], ["earlier SARS", "TEST", 63, 75]]], ["SARS-CoV-2 causes symptoms typical of pneumonic respiratory illnesses, such as varying degrees of fever, cough, and pneumonia, with an extensive risk of multiple organ failure with a \u223c4% mortality rate observed so far (96) .", [["respiratory", "ANATOMY", 48, 59], ["organ", "ANATOMY", 162, 167], ["SARS", "DISEASE", 0, 4], ["respiratory illnesses", "DISEASE", 48, 69], ["fever", "DISEASE", 98, 103], ["cough", "DISEASE", 105, 110], ["pneumonia", "DISEASE", 116, 125], ["organ failure", "DISEASE", 162, 175], ["SARS-CoV-2", "ORGANISM", 0, 10], ["organ", "ORGAN", 162, 167], ["SARS-CoV", "SPECIES", 0, 8], ["symptoms", "PROBLEM", 18, 26], ["pneumonic respiratory illnesses", "PROBLEM", 38, 69], ["fever", "PROBLEM", 98, 103], ["cough", "PROBLEM", 105, 110], ["pneumonia", "PROBLEM", 116, 125], ["multiple organ failure", "PROBLEM", 153, 175], ["mortality rate", "TEST", 187, 201], ["pneumonic", "OBSERVATION_MODIFIER", 38, 47], ["respiratory illnesses", "OBSERVATION", 48, 69], ["fever", "OBSERVATION", 98, 103], ["cough", "OBSERVATION", 105, 110], ["pneumonia", "OBSERVATION", 116, 125], ["extensive", "OBSERVATION_MODIFIER", 135, 144], ["multiple", "OBSERVATION_MODIFIER", 153, 161], ["organ", "ANATOMY", 162, 167], ["failure", "OBSERVATION", 168, 175]]], ["ACE2 is an established receptor for many human coronaviruses and influenza virus (97, 98) .", [["influenza virus", "DISEASE", 65, 80], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 41, 46], ["coronaviruses", "ORGANISM", 47, 60], ["influenza virus", "ORGANISM", 65, 80], ["ACE2", "PROTEIN", 0, 4], ["human", "SPECIES", 41, 46], ["influenza virus", "SPECIES", 65, 80], ["human coronaviruses", "SPECIES", 41, 60], ["many human coronaviruses", "PROBLEM", 36, 60], ["influenza virus", "PROBLEM", 65, 80]]], ["Inside the CNS, binding of SARS-CoV-2 with this receptor may cause elevated blood pressure and cerebral hemorrhage.", [["CNS", "ANATOMY", 11, 14], ["blood", "ANATOMY", 76, 81], ["cerebral", "ANATOMY", 95, 103], ["SARS", "DISEASE", 27, 31], ["elevated blood pressure", "DISEASE", 67, 90], ["cerebral hemorrhage", "DISEASE", 95, 114], ["CNS", "ANATOMICAL_SYSTEM", 11, 14], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["cerebral", "ORGAN", 95, 103], ["SARS", "PROBLEM", 27, 31], ["this receptor", "TREATMENT", 43, 56], ["elevated blood pressure", "PROBLEM", 67, 90], ["cerebral hemorrhage", "PROBLEM", 95, 114], ["CNS", "ANATOMY", 11, 14], ["pressure", "OBSERVATION_MODIFIER", 82, 90], ["cerebral", "ANATOMY", 95, 103], ["hemorrhage", "OBSERVATION", 104, 114]]], ["ACE2 is also expressed in the capillary endothelia of the CNS; SARS-CoV-2 could bind and break the blood-brain barrier to enter the CNS (99).", [["capillary endothelia", "ANATOMY", 30, 50], ["CNS", "ANATOMY", 58, 61], ["blood", "ANATOMY", 99, 104], ["brain", "ANATOMY", 105, 110], ["CNS", "ANATOMY", 132, 135], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["capillary endothelia", "TISSUE", 30, 50], ["CNS", "ANATOMICAL_SYSTEM", 58, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 63, 73], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 105, 118], ["CNS", "ANATOMICAL_SYSTEM", 132, 135], ["ACE2", "PROTEIN", 0, 4], ["ACE2", "TREATMENT", 0, 4], ["the blood", "TEST", 95, 104], ["capillary endothelia", "ANATOMY", 30, 50], ["CNS", "ANATOMY", 58, 61], ["brain", "ANATOMY", 105, 110], ["CNS", "ANATOMY", 132, 135]]], ["Since SARS-CoV-2 shares almost an \u223c80% genome sequence similarity with previous SARS coronavirus, we can expect a lot of similarities in various protein structures and their mode of pathogenesis as well.NEUROLOGICAL ANOMALIES CAUSED BY SARS-CoV-2Since the pandemic is still going on, long-term secondary effects of SARS-CoV-2 infection on patient's health is yet to be observed by clinicians.", [["SARS coronavirus", "DISEASE", 80, 96], ["SARS", "DISEASE", 315, 319], ["infection", "DISEASE", 326, 335], ["SARS-CoV-2", "ORGANISM", 6, 16], ["SARS coronavirus", "ORGANISM", 80, 96], ["BY SARS-CoV-2Since", "ORGANISM", 233, 251], ["SARS-CoV-2", "ORGANISM", 315, 325], ["patient", "ORGANISM", 339, 346], ["patient", "SPECIES", 339, 346], ["SARS-CoV", "SPECIES", 6, 14], ["SARS coronavirus", "SPECIES", 80, 96], ["previous SARS coronavirus", "PROBLEM", 71, 96], ["pathogenesis", "PROBLEM", 182, 194], ["NEUROLOGICAL ANOMALIES", "PROBLEM", 203, 225], ["the pandemic", "PROBLEM", 252, 264], ["SARS", "PROBLEM", 315, 319], ["CoV-2 infection", "PROBLEM", 320, 335], ["ANOMALIES", "OBSERVATION", 216, 225], ["infection", "OBSERVATION", 326, 335]]], ["Neurological abnormalities are still recorded at patient levels, and their molecular mechanisms and animal model studies and cellular data are yet to be performed and validated.", [["Neurological", "ANATOMY", 0, 12], ["cellular", "ANATOMY", 125, 133], ["Neurological abnormalities", "DISEASE", 0, 26], ["patient", "ORGANISM", 49, 56], ["cellular", "CELL", 125, 133], ["patient", "SPECIES", 49, 56], ["Neurological abnormalities", "PROBLEM", 0, 26], ["animal model studies", "TEST", 100, 120], ["cellular data", "TEST", 125, 138]]], ["Clinical reports have shown that SARS-CoV-2 infected patients display the symptoms of intracranial infection like headache, loss of consciousness, epileptic seizures, etc. A majority of patients reported loss of smell and taste, a condition known as anosmia and dysgeusia (100) (101) (102) .", [["intracranial", "ANATOMY", 86, 98], ["SARS-CoV-2 infected", "DISEASE", 33, 52], ["intracranial infection", "DISEASE", 86, 108], ["headache", "DISEASE", 114, 122], ["loss of consciousness", "DISEASE", 124, 145], ["epileptic seizures", "DISEASE", 147, 165], ["loss of smell and taste", "DISEASE", 204, 227], ["anosmia", "DISEASE", 250, 257], ["dysgeusia", "DISEASE", 262, 271], ["SARS-CoV-2", "ORGANISM", 33, 43], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 186, 194], ["smell", "ORGANISM_SUBDIVISION", 212, 217], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 186, 194], ["SARS", "PROBLEM", 33, 37], ["CoV", "TEST", 38, 41], ["the symptoms", "PROBLEM", 70, 82], ["intracranial infection", "PROBLEM", 86, 108], ["headache", "PROBLEM", 114, 122], ["loss of consciousness", "PROBLEM", 124, 145], ["epileptic seizures", "PROBLEM", 147, 165], ["loss of smell and taste", "PROBLEM", 204, 227], ["anosmia", "PROBLEM", 250, 257], ["dysgeusia", "PROBLEM", 262, 271], ["intracranial", "ANATOMY", 86, 98], ["infection", "OBSERVATION", 99, 108]]], ["Interestingly, the asymptomatic patients who did not display clear respiratory illnesses were also experiencing these neurological symptoms (103) (104) (105) .", [["respiratory", "ANATOMY", 67, 78], ["neurological", "ANATOMY", 118, 130], ["respiratory illnesses", "DISEASE", 67, 88], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["clear respiratory illnesses", "PROBLEM", 61, 88], ["these neurological symptoms", "PROBLEM", 112, 139], ["respiratory illnesses", "OBSERVATION", 67, 88]]], ["Many Chinese hospitals have constantly reported that novel SARS-CoV-2 infection has attacked the CNS of patients and these patients have displayed symptoms of viral encephalitis (105) .", [["CNS", "ANATOMY", 97, 100], ["SARS", "DISEASE", 59, 63], ["infection", "DISEASE", 70, 79], ["viral encephalitis", "DISEASE", 159, 177], ["SARS-CoV-2", "ORGANISM", 59, 69], ["CNS", "ANATOMICAL_SYSTEM", 97, 100], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 123, 131], ["SARS-CoV", "SPECIES", 59, 67], ["novel SARS-CoV-2 infection", "PROBLEM", 53, 79], ["symptoms", "PROBLEM", 147, 155], ["viral encephalitis", "PROBLEM", 159, 177], ["viral encephalitis", "OBSERVATION", 159, 177]]], ["Genome sequencing data from the cerebrospinal fluid of SARS-CoV-2 infected patients have also detected the viral sequences, which added support to the idea that SARS-CoV-2 can invade the CNS and could likely be the cause of the neurological anomalies associated with the disease (103-105) .", [["cerebrospinal fluid", "ANATOMY", 32, 51], ["CNS", "ANATOMY", 187, 190], ["neurological", "ANATOMY", 228, 240], ["SARS", "DISEASE", 161, 165], ["neurological anomalies", "DISEASE", 228, 250], ["cerebrospinal fluid", "MULTI-TISSUE_STRUCTURE", 32, 51], ["SARS-CoV-2", "ORGANISM", 55, 65], ["patients", "ORGANISM", 75, 83], ["SARS-CoV-2", "ORGANISM", 161, 171], ["CNS", "ANATOMICAL_SYSTEM", 187, 190], ["viral sequences", "DNA", 107, 122], ["CoV-2", "SPECIES", 60, 65], ["patients", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 161, 169], ["Genome sequencing data", "TEST", 0, 22], ["the cerebrospinal fluid", "TEST", 28, 51], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["the viral sequences", "TEST", 103, 122], ["the neurological anomalies", "PROBLEM", 224, 250], ["the disease", "PROBLEM", 267, 278], ["CNS", "ANATOMY", 187, 190], ["could likely be", "UNCERTAINTY", 195, 210], ["neurological", "OBSERVATION_MODIFIER", 228, 240], ["anomalies", "OBSERVATION", 241, 250]]], ["However, a direct cause-and-effect relationship between SARS-CoV-2 and neurological abnormalities is yet to be established experimentally.", [["neurological", "ANATOMY", 71, 83], ["SARS", "DISEASE", 56, 60], ["neurological abnormalities", "DISEASE", 71, 97], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 56, 66], ["a direct cause", "PROBLEM", 9, 23], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["neurological abnormalities", "PROBLEM", 71, 97]]], ["It is plausible that many opportunistic pathogens might permeabilize the blood-brain barrier and cause secondary intracranial infections.", [["blood", "ANATOMY", 73, 78], ["brain", "ANATOMY", 79, 84], ["intracranial", "ANATOMY", 113, 125], ["intracranial infections", "DISEASE", 113, 136], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 79, 92], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 125], ["many opportunistic pathogens", "PROBLEM", 21, 49], ["the blood-brain barrier", "TREATMENT", 69, 92], ["secondary intracranial infections", "PROBLEM", 103, 136], ["opportunistic", "OBSERVATION_MODIFIER", 26, 39], ["pathogens", "OBSERVATION", 40, 49], ["brain", "ANATOMY", 79, 84], ["secondary", "OBSERVATION_MODIFIER", 103, 112], ["intracranial", "OBSERVATION_MODIFIER", 113, 125], ["infections", "OBSERVATION", 126, 136]]], ["This might be the cause of the above reported symptoms of headache, vomiting, limb convolutions, and consciousness disorders apparent in severe COVID-19 patients.", [["limb", "ANATOMY", 78, 82], ["headache", "DISEASE", 58, 66], ["vomiting", "DISEASE", 68, 76], ["limb convolutions", "DISEASE", 78, 95], ["consciousness disorders", "DISEASE", 101, 124], ["COVID", "DISEASE", 144, 149], ["limb", "ORGANISM_SUBDIVISION", 78, 82], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["the above reported symptoms", "PROBLEM", 27, 54], ["headache", "PROBLEM", 58, 66], ["vomiting", "PROBLEM", 68, 76], ["limb convolutions", "PROBLEM", 78, 95], ["consciousness disorders", "PROBLEM", 101, 124], ["limb", "ANATOMY", 78, 82]]], ["COVID-19 is primarily a lung infection and causes a massive peripheral \"cytokine storm, \" which partially explains why this infection would also cause acute cerebrovascular disease (106, 107) .", [["lung", "ANATOMY", 24, 28], ["cerebrovascular", "ANATOMY", 157, 172], ["COVID-19", "CHEMICAL", 0, 8], ["lung infection", "DISEASE", 24, 38], ["infection", "DISEASE", 124, 133], ["acute cerebrovascular disease", "DISEASE", 151, 180], ["lung", "ORGAN", 24, 28], ["cytokine", "PROTEIN", 72, 80], ["COVID", "TEST", 0, 5], ["a lung infection", "PROBLEM", 22, 38], ["a massive peripheral \"cytokine storm", "PROBLEM", 50, 86], ["this infection", "PROBLEM", 119, 133], ["acute cerebrovascular disease", "PROBLEM", 151, 180], ["lung", "ANATOMY", 24, 28], ["infection", "OBSERVATION", 29, 38], ["massive", "OBSERVATION_MODIFIER", 52, 59], ["peripheral", "ANATOMY_MODIFIER", 60, 70], ["\"", "OBSERVATION", 71, 72], ["cytokine storm", "OBSERVATION", 72, 86], ["infection", "OBSERVATION", 124, 133], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["cerebrovascular disease", "OBSERVATION", 157, 180]]], ["Other patient reports also suggest that severe SARS-CoV-2 infections is often associated with elevated blood levels of D-dimers and significant platelet reductions, again giving some explanation as to why the patients are at a higher risk of cerebrovascular events in their body.NEUROLOGICAL ANOMALIES CAUSED BY SARS-CoV-2Human coronaviruses share a strong similarity with neuroinvasive animal coronaviruses, such as PHEV (porcine hemagglutinating encephalitis virus) (108), FCoV (feline coronavirus) (109), and JHM virus (110) , regarding structure and mode of replication.", [["blood", "ANATOMY", 103, 108], ["platelet", "ANATOMY", 144, 152], ["cerebrovascular", "ANATOMY", 242, 257], ["body", "ANATOMY", 274, 278], ["SARS", "DISEASE", 47, 51], ["infections", "DISEASE", 58, 68], ["platelet reductions", "DISEASE", 144, 163], ["neuroinvasive animal coronaviruses", "DISEASE", 373, 407], ["porcine hemagglutinating encephalitis", "DISEASE", 423, 460], ["feline coronavirus)", "DISEASE", 481, 500], ["patient", "ORGANISM", 6, 13], ["SARS-CoV-2", "ORGANISM", 47, 57], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["D-dimers", "SIMPLE_CHEMICAL", 119, 127], ["platelet", "CELL", 144, 152], ["patients", "ORGANISM", 209, 217], ["cerebrovascular", "ANATOMICAL_SYSTEM", 242, 257], ["body", "ORGANISM_SUBDIVISION", 274, 278], ["SARS-CoV-2Human coronaviruses", "ORGANISM", 312, 341], ["animal coronaviruses", "ORGANISM", 387, 407], ["PHEV", "ORGANISM", 417, 421], ["porcine hemagglutinating encephalitis virus", "ORGANISM", 423, 466], ["FCoV (", "ORGANISM", 475, 481], ["feline coronavirus", "ORGANISM", 481, 499], ["JHM virus", "ORGANISM", 512, 521], ["patient", "SPECIES", 6, 13], ["patients", "SPECIES", 209, 217], ["porcine hemagglutinating encephalitis virus", "SPECIES", 423, 466], ["feline coronavirus", "SPECIES", 481, 499], ["CoV-2Human coronaviruses", "SPECIES", 317, 341], ["PHEV", "SPECIES", 417, 421], ["porcine hemagglutinating encephalitis virus", "SPECIES", 423, 466], ["FCoV", "SPECIES", 475, 479], ["feline coronavirus", "SPECIES", 481, 499], ["JHM virus", "SPECIES", 512, 521], ["severe SARS", "PROBLEM", 40, 51], ["CoV-2 infections", "PROBLEM", 52, 68], ["elevated blood levels of D-dimers", "PROBLEM", 94, 127], ["significant platelet reductions", "PROBLEM", 132, 163], ["cerebrovascular events in their body", "PROBLEM", 242, 278], ["NEUROLOGICAL ANOMALIES", "PROBLEM", 279, 301], ["neuroinvasive animal coronaviruses", "PROBLEM", 373, 407], ["PHEV (porcine hemagglutinating encephalitis virus", "PROBLEM", 417, 466], ["FCoV (feline coronavirus", "PROBLEM", 475, 499], ["JHM virus", "PROBLEM", 512, 521], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["SARS", "OBSERVATION", 47, 51], ["significant", "OBSERVATION_MODIFIER", 132, 143], ["platelet reductions", "OBSERVATION", 144, 163], ["cerebrovascular", "ANATOMY", 242, 257], ["body", "ANATOMY", 274, 278], ["ANOMALIES", "OBSERVATION", 292, 301]]], ["All these animal coronaviruses can invade the CNS and cause multiple neuropathologies.", [["CNS", "ANATOMY", 46, 49], ["coronaviruses", "ORGANISM", 17, 30], ["CNS", "ANATOMICAL_SYSTEM", 46, 49], ["multiple neuropathologies", "PROBLEM", 60, 85], ["coronaviruses", "OBSERVATION", 17, 30], ["CNS", "ANATOMY", 46, 49], ["multiple", "OBSERVATION_MODIFIER", 60, 68], ["neuropathologies", "OBSERVATION", 69, 85]]], ["Out of eight reported human coronaviruses, four of them, [HCoV-229E, HCoV-OC43 (21, 108), SARS-CoV (21, 36) , and MERS-CoV (21, 36) ] have been reported to be neuroinvasive and neurotropic in humans.", [["human", "ORGANISM", 22, 27], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 58, 67], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 69, 78], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 90, 98], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 114, 122], ["humans", "ORGANISM", 192, 198], ["human", "SPECIES", 22, 27], ["humans", "SPECIES", 192, 198], ["human coronaviruses", "SPECIES", 22, 41], ["SARS-CoV", "SPECIES", 90, 98], ["MERS-CoV", "SPECIES", 114, 122], ["humans", "SPECIES", 192, 198], ["HCoV", "TEST", 58, 62], ["HCoV", "TEST", 69, 73], ["OC43", "TEST", 74, 78], ["SARS-CoV", "TEST", 90, 98], ["MERS", "TEST", 114, 118], ["CoV", "TEST", 119, 122], ["neuroinvasive", "OBSERVATION", 159, 172]]], ["This suggests that we would observe a heavy burden of neurological abnormalities in SARS-CoV-2 patients in the future.", [["neurological", "ANATOMY", 54, 66], ["neurological abnormalities", "DISEASE", 54, 80], ["SARS", "DISEASE", 84, 88], ["SARS-CoV-2", "ORGANISM", 84, 94], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["neurological abnormalities", "PROBLEM", 54, 80], ["heavy", "OBSERVATION_MODIFIER", 38, 43]]], ["The SARS-CoV-2 pandemic is also more worrisome since it has already infected a very large amount of the human population globally (\u223c19,000,000), and is still ongoing.POSSIBLE INTERVENTIONS AND DEFENSE STRATEGIES AGAINST SARS-CoV-2 AND COVID-19As the COVID-19 pandemic has crippled socio-economic activities and human interactions globally, the world needs urgent measures to contain and suppress the viral transmission as well as get an effective vaccine as a long-term goal.", [["SARS-CoV-2 pandemic", "DISEASE", 4, 23], ["SARS-CoV-2", "ORGANISM", 4, 14], ["human", "ORGANISM", 104, 109], ["SARS-CoV-2", "ORGANISM", 220, 230], ["COVID-19As", "ORGANISM", 235, 245], ["COVID-19", "ORGANISM", 250, 258], ["human", "ORGANISM", 311, 316], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 311, 316], ["SARS-CoV", "SPECIES", 4, 12], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 311, 316], ["The SARS", "TEST", 0, 8], ["pandemic", "PROBLEM", 15, 23], ["SARS", "TEST", 220, 224], ["CoV", "TEST", 225, 228], ["COVID", "TEST", 235, 240], ["urgent measures", "TREATMENT", 356, 371], ["an effective vaccine", "TREATMENT", 434, 454], ["a long-term goal", "TREATMENT", 458, 474], ["more worrisome", "OBSERVATION_MODIFIER", 32, 46], ["infected", "OBSERVATION", 68, 76], ["very", "OBSERVATION_MODIFIER", 79, 83], ["large", "OBSERVATION_MODIFIER", 84, 89], ["amount", "OBSERVATION_MODIFIER", 90, 96]]], ["Based on available clinical and epidemiological data so far, the World Health Organization (WHO) has already issued many guidelines which has helped in designing the prevention strategies to suppress the general viral transmission and mortality rate due to SARS-CoV-2.", [["SARS", "DISEASE", 257, 261], ["SARS-CoV-2", "ORGANISM", 257, 267], ["SARS-CoV", "SPECIES", 257, 265], ["the prevention strategies", "TREATMENT", 162, 187], ["the general viral transmission", "PROBLEM", 200, 230], ["mortality rate", "TEST", 235, 249], ["SARS", "PROBLEM", 257, 261], ["CoV", "TEST", 262, 265]]], ["A controlled movement of population, increased and rapid testing followed by isolation, and a wider availability of healthcare services to reduce mortality are a few commonly practiced suggestions which have controlled this disease to a great extent.", [["A controlled movement of population", "PROBLEM", 0, 35], ["rapid testing", "TEST", 51, 64], ["healthcare services", "TREATMENT", 116, 135], ["this disease", "PROBLEM", 219, 231], ["controlled", "OBSERVATION_MODIFIER", 2, 12], ["movement", "OBSERVATION_MODIFIER", 13, 21], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["great extent", "OBSERVATION_MODIFIER", 237, 249]]], ["Since neurological disturbances were more frequent in severely ill and critical patients of COVID-19 as compared to mild ones (104) , this suggests that early diagnosis, lowering the viral load, and suppression of acute host inflammatory response is of paramount importance in combatting neurological disturbances.", [["neurological", "ANATOMY", 6, 18], ["neurological", "ANATOMY", 288, 300], ["neurological disturbances", "DISEASE", 6, 31], ["ill", "DISEASE", 63, 66], ["neurological disturbances", "DISEASE", 288, 313], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["neurological disturbances", "PROBLEM", 6, 31], ["severely ill", "PROBLEM", 54, 66], ["COVID", "TEST", 92, 97], ["lowering the viral load", "PROBLEM", 170, 193], ["acute host inflammatory response", "PROBLEM", 214, 246], ["neurological disturbances", "PROBLEM", 288, 313], ["early", "OBSERVATION_MODIFIER", 153, 158], ["viral load", "OBSERVATION", 183, 193], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["host", "OBSERVATION_MODIFIER", 220, 224], ["inflammatory", "OBSERVATION", 225, 237]]], ["Since an uncontrolled cytokine storm has been generally implicated in multi-organ failure and worsening of neurological symptoms, the main focus during medical care of COVID-19 patients has shifted largely to mitigate the host's inflammatory responses (111) .", [["multi-organ", "ANATOMY", 70, 81], ["neurological", "ANATOMY", 107, 119], ["multi-organ failure", "DISEASE", 70, 89], ["neurological symptoms", "DISEASE", 107, 128], ["multi-organ", "ORGAN", 70, 81], ["patients", "ORGANISM", 177, 185], ["cytokine", "PROTEIN", 22, 30], ["patients", "SPECIES", 177, 185], ["an uncontrolled cytokine storm", "PROBLEM", 6, 36], ["multi-organ failure", "PROBLEM", 70, 89], ["worsening of neurological symptoms", "PROBLEM", 94, 128], ["COVID", "TEST", 168, 173], ["uncontrolled", "OBSERVATION_MODIFIER", 9, 21], ["cytokine storm", "OBSERVATION", 22, 36], ["multi-organ", "ANATOMY", 70, 81], ["failure", "OBSERVATION", 82, 89], ["worsening", "OBSERVATION_MODIFIER", 94, 103], ["main", "OBSERVATION_MODIFIER", 134, 138]]], ["Several candidate drugs such as Baricitinib, fedratinib, and ruxolitinib (anti-inflammatory drugs used for rheumatoid arthritis), Hydroxychloroquine, Azithromycin, Remdesivir (a combination used as anti-viral treatments), a combination of lopinavir and ritonavir (LPV/r), Corticosteroid for calming down cytokine storms, recombinant Interferons, and many other popular anti-cancer drugs have been tested and reported to show partial relief in combatting the overall disease severity [reviewed in detail by [111] ].INFLUENZA VIRUS (IAV)Influenza viruses are a member of the Orthomyxoviridae family and contain negative-sense single-strand RNA as their genome (112) .", [["Baricitinib", "CHEMICAL", 32, 43], ["fedratinib", "CHEMICAL", 45, 55], ["ruxolitinib", "CHEMICAL", 61, 72], ["rheumatoid arthritis", "DISEASE", 107, 127], ["Hydroxychloroquine", "CHEMICAL", 130, 148], ["Azithromycin", "CHEMICAL", 150, 162], ["Remdesivir", "CHEMICAL", 164, 174], ["lopinavir", "CHEMICAL", 239, 248], ["ritonavir", "CHEMICAL", 253, 262], ["LPV", "CHEMICAL", 264, 267], ["Corticosteroid", "CHEMICAL", 272, 286], ["Influenza viruses", "DISEASE", 535, 552], ["Baricitinib", "CHEMICAL", 32, 43], ["fedratinib", "CHEMICAL", 45, 55], ["ruxolitinib", "CHEMICAL", 61, 72], ["Hydroxychloroquine", "CHEMICAL", 130, 148], ["Azithromycin", "CHEMICAL", 150, 162], ["Remdesivir", "CHEMICAL", 164, 174], ["lopinavir", "CHEMICAL", 239, 248], ["ritonavir", "CHEMICAL", 253, 262], ["LPV", "CHEMICAL", 264, 267], ["Corticosteroid", "CHEMICAL", 272, 286], ["Baricitinib", "SIMPLE_CHEMICAL", 32, 43], ["fedratinib", "SIMPLE_CHEMICAL", 45, 55], ["ruxolitinib", "SIMPLE_CHEMICAL", 61, 72], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 130, 148], ["Azithromycin", "SIMPLE_CHEMICAL", 150, 162], ["Remdesivir", "SIMPLE_CHEMICAL", 164, 174], ["lopinavir", "SIMPLE_CHEMICAL", 239, 248], ["ritonavir", "SIMPLE_CHEMICAL", 253, 262], ["Corticosteroid", "SIMPLE_CHEMICAL", 272, 286], ["INFLUENZA VIRUS (IAV)Influenza viruses", "ORGANISM", 514, 552], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 573, 589], ["cytokine", "PROTEIN", 304, 312], ["recombinant Interferons", "PROTEIN", 321, 344], ["Orthomyxoviridae family", "PROTEIN", 573, 596], ["negative-sense single-strand RNA", "RNA", 609, 641], ["Influenza", "SPECIES", 535, 544], ["Several candidate drugs", "TREATMENT", 0, 23], ["Baricitinib", "TREATMENT", 32, 43], ["fedratinib", "TREATMENT", 45, 55], ["ruxolitinib", "TREATMENT", 61, 72], ["anti-inflammatory drugs", "TREATMENT", 74, 97], ["rheumatoid arthritis", "PROBLEM", 107, 127], ["Hydroxychloroquine", "TREATMENT", 130, 148], ["Azithromycin", "TREATMENT", 150, 162], ["Remdesivir", "TREATMENT", 164, 174], ["anti-viral treatments", "TREATMENT", 198, 219], ["lopinavir", "TREATMENT", 239, 248], ["ritonavir (LPV/r)", "TREATMENT", 253, 270], ["Corticosteroid", "TREATMENT", 272, 286], ["calming down cytokine storms", "TREATMENT", 291, 319], ["recombinant Interferons", "TREATMENT", 321, 344], ["popular anti-cancer drugs", "TREATMENT", 361, 386], ["the overall disease severity", "PROBLEM", 454, 482], ["INFLUENZA VIRUS (IAV)Influenza viruses", "PROBLEM", 514, 552]]], ["There are four distinct types of Influenza viruses known so far: A, B, C, and Thogotovirus.", [["Influenza viruses", "DISEASE", 33, 50], ["Influenza viruses", "ORGANISM", 33, 50], ["B, C", "CELL", 68, 72], ["Influenza viruses", "PROBLEM", 33, 50], ["A, B, C, and Thogotovirus", "PROBLEM", 65, 90], ["four distinct", "OBSERVATION_MODIFIER", 10, 23], ["Influenza viruses", "OBSERVATION", 33, 50]]], ["However, only A and B type are clinically relevant for causing human diseases (112) .", [["B type", "CELL", 20, 26], ["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["human diseases", "PROBLEM", 63, 77]]], ["The symptoms are characteristic of respiratory illnesses such as flu, and include chills, cold, headache, muscular body pains, and sore throat (113) .", [["respiratory", "ANATOMY", 35, 46], ["muscular body", "ANATOMY", 106, 119], ["respiratory illnesses", "DISEASE", 35, 56], ["flu", "DISEASE", 65, 68], ["chills", "DISEASE", 82, 88], ["headache", "DISEASE", 96, 104], ["muscular body pains", "DISEASE", 106, 125], ["sore throat", "DISEASE", 131, 142], ["body", "ORGANISM_SUBDIVISION", 115, 119], ["The symptoms", "PROBLEM", 0, 12], ["respiratory illnesses", "PROBLEM", 35, 56], ["flu", "PROBLEM", 65, 68], ["chills", "PROBLEM", 82, 88], ["cold", "PROBLEM", 90, 94], ["headache", "PROBLEM", 96, 104], ["muscular body pains", "PROBLEM", 106, 125], ["sore throat", "PROBLEM", 131, 142], ["characteristic of", "UNCERTAINTY", 17, 34], ["respiratory illnesses", "OBSERVATION", 35, 56], ["muscular body", "ANATOMY", 106, 119], ["sore throat", "ANATOMY", 131, 142]]], ["Influenza causes widespread seasonal epidemics, affecting 3-5 million humans, of which 10% could turn lethal (114) .", [["Influenza", "DISEASE", 0, 9], ["humans", "ORGANISM", 70, 76], ["Influenza", "SPECIES", 0, 9], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76], ["Influenza", "PROBLEM", 0, 9], ["widespread seasonal epidemics", "PROBLEM", 17, 46], ["widespread", "OBSERVATION_MODIFIER", 17, 27], ["seasonal", "OBSERVATION_MODIFIER", 28, 36], ["epidemics", "OBSERVATION", 37, 46]]], ["It usually causes a localized infection of the upper respiratory tract, but in a few severe cases it can affect the lower tract and cause pneumonia-like symptoms (115) (116) (117) and even affect the CNS homeostasis (116, 117) .", [["upper respiratory tract", "ANATOMY", 47, 70], ["lower tract", "ANATOMY", 116, 127], ["CNS", "ANATOMY", 200, 203], ["infection of the upper respiratory tract", "DISEASE", 30, 70], ["pneumonia", "DISEASE", 138, 147], ["upper respiratory", "ORGANISM_SUBDIVISION", 47, 64], ["tract", "ORGANISM_SUBDIVISION", 65, 70], ["lower tract", "ORGANISM_SUBDIVISION", 116, 127], ["CNS", "ANATOMICAL_SYSTEM", 200, 203], ["a localized infection of the upper respiratory tract", "PROBLEM", 18, 70], ["pneumonia", "PROBLEM", 138, 147], ["symptoms", "PROBLEM", 153, 161], ["localized", "OBSERVATION_MODIFIER", 20, 29], ["infection", "OBSERVATION", 30, 39], ["upper", "ANATOMY_MODIFIER", 47, 52], ["respiratory tract", "ANATOMY", 53, 70], ["lower tract", "ANATOMY", 116, 127], ["pneumonia", "OBSERVATION", 138, 147], ["CNS", "ANATOMY", 200, 203]]], ["It was reported that Influenza infection could act as an aggravating factor for Parkinson's disease (PD) (118) .", [["Influenza infection", "DISEASE", 21, 40], ["Parkinson's disease", "DISEASE", 80, 99], ["PD", "DISEASE", 101, 103], ["Influenza", "ORGANISM", 21, 30], ["Influenza infection", "PROBLEM", 21, 40], ["an aggravating factor", "PROBLEM", 54, 75], ["Parkinson's disease", "PROBLEM", 80, 99], ["Influenza", "OBSERVATION_MODIFIER", 21, 30], ["infection", "OBSERVATION", 31, 40]]], ["Mouse experimental studies also suggested that Influenza virus can enhance ischemic brain injury by initiating a cytokine cascade and risk of cerebral hemorrhage via disrupting the tissue-type plasminogen activator (119) .INFLUENZA VIRUS (IAV)In the case of Influenza infections, there is an extensive history of patients reporting a variety of CNS disorders which collectively suggested that Influenza virus is a potentially neurotropic virus and is capable of giving long-lasting neurological sequelae (116) .", [["brain", "ANATOMY", 84, 89], ["cerebral", "ANATOMY", 142, 150], ["CNS", "ANATOMY", 345, 348], ["neurological", "ANATOMY", 482, 494], ["Influenza virus", "DISEASE", 47, 62], ["brain injury", "DISEASE", 84, 96], ["cerebral hemorrhage", "DISEASE", 142, 161], ["Influenza infections", "DISEASE", 258, 278], ["Influenza virus", "DISEASE", 393, 408], ["neurological sequelae", "DISEASE", 482, 503], ["Mouse", "ORGANISM", 0, 5], ["Influenza virus", "ORGANISM", 47, 62], ["brain", "ORGAN", 84, 89], ["cerebral", "ORGAN", 142, 150], ["tissue-type plasminogen activator", "GENE_OR_GENE_PRODUCT", 181, 214], ["Influenza", "ORGANISM", 258, 267], ["patients", "ORGANISM", 313, 321], ["CNS", "ANATOMICAL_SYSTEM", 345, 348], ["Influenza virus", "ORGANISM", 393, 408], ["cytokine", "PROTEIN", 113, 121], ["Mouse", "SPECIES", 0, 5], ["patients", "SPECIES", 313, 321], ["Influenza virus", "SPECIES", 393, 408], ["Influenza virus", "SPECIES", 47, 62], ["Influenza virus", "SPECIES", 393, 408], ["neurotropic virus", "SPECIES", 426, 443], ["Mouse experimental studies", "TEST", 0, 26], ["Influenza virus", "PROBLEM", 47, 62], ["ischemic brain injury", "PROBLEM", 75, 96], ["a cytokine cascade", "TREATMENT", 111, 129], ["cerebral hemorrhage", "PROBLEM", 142, 161], ["INFLUENZA VIRUS (IAV", "PROBLEM", 222, 242], ["Influenza infections", "PROBLEM", 258, 278], ["CNS disorders", "PROBLEM", 345, 358], ["Influenza virus", "PROBLEM", 393, 408], ["a potentially neurotropic virus", "PROBLEM", 412, 443], ["long-lasting neurological sequelae", "PROBLEM", 469, 503], ["cerebral", "ANATOMY", 142, 150], ["hemorrhage", "OBSERVATION", 151, 161], ["Influenza infections", "OBSERVATION", 258, 278], ["extensive", "OBSERVATION_MODIFIER", 292, 301], ["Influenza virus", "OBSERVATION", 393, 408]]], ["Even some recent outbreaks and the 2009 \"Swine Flu\" pandemic also gave similar indications that neurological consequences are a much likely after-effect of Influenza infection (120, 121) .", [["neurological", "ANATOMY", 96, 108], ["Flu", "CHEMICAL", 47, 50], ["Influenza infection", "DISEASE", 156, 175], ["Influenza", "ORGANISM", 156, 165], ["neurological consequences", "PROBLEM", 96, 121], ["Influenza infection", "PROBLEM", 156, 175], ["outbreaks", "OBSERVATION", 17, 26]]], ["Although being notorious for respiratory disease outcomes, their second most common disease manifestations are encephalitis and other CNS complications such as ataxia, myelopathy, seizures, and delirium, which usually appear after 1 week of respiratory symptoms of influenza (120, 121) .", [["respiratory", "ANATOMY", 29, 40], ["CNS", "ANATOMY", 134, 137], ["respiratory", "ANATOMY", 241, 252], ["respiratory disease", "DISEASE", 29, 48], ["encephalitis", "DISEASE", 111, 123], ["ataxia", "DISEASE", 160, 166], ["myelopathy", "DISEASE", 168, 178], ["seizures", "DISEASE", 180, 188], ["delirium", "DISEASE", 194, 202], ["influenza", "DISEASE", 265, 274], ["CNS", "ANATOMICAL_SYSTEM", 134, 137], ["respiratory disease outcomes", "PROBLEM", 29, 57], ["common disease manifestations", "PROBLEM", 77, 106], ["encephalitis", "PROBLEM", 111, 123], ["other CNS complications", "PROBLEM", 128, 151], ["ataxia", "PROBLEM", 160, 166], ["myelopathy", "PROBLEM", 168, 178], ["seizures", "PROBLEM", 180, 188], ["delirium", "PROBLEM", 194, 202], ["respiratory symptoms", "PROBLEM", 241, 261], ["influenza", "PROBLEM", 265, 274], ["disease", "OBSERVATION", 41, 48], ["encephalitis", "OBSERVATION", 111, 123], ["myelopathy", "OBSERVATION", 168, 178], ["influenza", "OBSERVATION", 265, 274]]], ["Multiple studies have confirmed the neurological sequences of Influenza infections like encephalitis, febrile seizure, Reye's syndrome, acute encephalomyelitis (ADEM), and acute necrotizing encephalopathy in humans (121) .", [["Influenza infections", "DISEASE", 62, 82], ["encephalitis", "DISEASE", 88, 100], ["febrile seizure", "DISEASE", 102, 117], ["Reye's syndrome", "DISEASE", 119, 134], ["acute encephalomyelitis", "DISEASE", 136, 159], ["ADEM", "DISEASE", 161, 165], ["encephalopathy", "DISEASE", 190, 204], ["Influenza", "ORGANISM", 62, 71], ["humans", "ORGANISM", 208, 214], ["humans", "SPECIES", 208, 214], ["humans", "SPECIES", 208, 214], ["Multiple studies", "TEST", 0, 16], ["the neurological sequences", "PROBLEM", 32, 58], ["Influenza infections", "PROBLEM", 62, 82], ["encephalitis", "PROBLEM", 88, 100], ["febrile seizure", "PROBLEM", 102, 117], ["Reye's syndrome", "PROBLEM", 119, 134], ["acute encephalomyelitis (ADEM)", "PROBLEM", 136, 166], ["acute necrotizing encephalopathy in humans", "PROBLEM", 172, 214], ["Influenza", "OBSERVATION", 62, 71], ["encephalitis", "OBSERVATION", 88, 100], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["encephalomyelitis", "OBSERVATION", 142, 159], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["necrotizing", "OBSERVATION_MODIFIER", 178, 189], ["encephalopathy", "OBSERVATION", 190, 204]]], ["By using murine models, it has been established that Influenza A virus enters the CNS via the olfactory nerve route and disrupts the hippocampal morphology and expression levels of synaptic regulatory genes to alter the cognition and behavior of the host (122) .", [["CNS", "ANATOMY", 82, 85], ["olfactory nerve", "ANATOMY", 94, 109], ["hippocampal", "ANATOMY", 133, 144], ["synaptic", "ANATOMY", 181, 189], ["murine", "ORGANISM", 9, 15], ["Influenza A virus", "ORGANISM", 53, 70], ["CNS", "ANATOMICAL_SYSTEM", 82, 85], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 94, 109], ["hippocampal", "ANATOMICAL_SYSTEM", 133, 144], ["synaptic regulatory genes", "DNA", 181, 206], ["murine", "SPECIES", 9, 15], ["Influenza A virus", "SPECIES", 53, 70], ["Influenza A virus", "SPECIES", 53, 70], ["Influenza A virus", "PROBLEM", 53, 70], ["synaptic regulatory genes", "TREATMENT", 181, 206], ["olfactory nerve", "ANATOMY", 94, 109]]], ["It can also infect the microvascular endothelial cells and breaks the BBB to enter the CNS (123) .", [["microvascular endothelial cells", "ANATOMY", 23, 54], ["BBB", "ANATOMY", 70, 73], ["CNS", "ANATOMY", 87, 90], ["microvascular endothelial cells", "CELL", 23, 54], ["BBB", "MULTI-TISSUE_STRUCTURE", 70, 73], ["CNS", "ANATOMICAL_SYSTEM", 87, 90], ["microvascular endothelial cells", "CELL_TYPE", 23, 54], ["the microvascular endothelial cells", "PROBLEM", 19, 54], ["microvascular endothelial cells", "OBSERVATION", 23, 54], ["CNS", "ANATOMY", 87, 90]]], ["However, in the case of Influenza infection, interestingly, just having the capacity to enter the CNS doesn't translate into it being neuro-pathogenic (7) .", [["CNS", "ANATOMY", 98, 101], ["Influenza infection", "DISEASE", 24, 43], ["Influenza", "ORGANISM", 24, 33], ["CNS", "ANATOMICAL_SYSTEM", 98, 101], ["Influenza infection", "PROBLEM", 24, 43], ["Influenza", "OBSERVATION_MODIFIER", 24, 33], ["infection", "OBSERVATION", 34, 43], ["CNS", "ANATOMY", 98, 101]]], ["It was best exemplified during the 2009 pandemic caused by H1N1 influenza, which never entered the CNS but was well-documented to have a strong association with encephalitis (124) .INFLUENZA VIRUS (IAV)However, this paradox can be explained from a neuroinflammation perspective.", [["CNS", "ANATOMY", 99, 102], ["influenza", "DISEASE", 64, 73], ["encephalitis", "DISEASE", 161, 173], ["H1N1 influenza", "ORGANISM", 59, 73], ["CNS", "ANATOMICAL_SYSTEM", 99, 102], ["H1N1 influenza", "SPECIES", 59, 73], ["H1N1 influenza", "PROBLEM", 59, 73], ["encephalitis", "PROBLEM", 161, 173], ["INFLUENZA VIRUS (IAV", "PROBLEM", 181, 201], ["encephalitis", "OBSERVATION", 161, 173]]], ["Peripheral \"Cytokine storm\" caused by viral infections can explain why being neurotropic is not an essential criteria for neurological abnormalities.", [["neurological", "ANATOMY", 122, 134], ["viral infections", "DISEASE", 38, 54], ["neurological abnormalities", "DISEASE", 122, 148], ["Cytokine", "GENE_OR_GENE_PRODUCT", 12, 20], ["Cytokine", "PROTEIN", 12, 20], ["Peripheral \"Cytokine storm", "PROBLEM", 0, 26], ["viral infections", "PROBLEM", 38, 54], ["neurological abnormalities", "PROBLEM", 122, 148], ["Cytokine storm", "OBSERVATION", 12, 26], ["viral infections", "OBSERVATION", 38, 54]]], ["The peripheral cytokines can travel to the CNS and indirectly activate or prime the brain resident microglia (as explained in the above sections) (125, 126) .", [["CNS", "ANATOMY", 43, 46], ["brain", "ANATOMY", 84, 89], ["microglia", "ANATOMY", 99, 108], ["sections", "ANATOMY", 136, 144], ["CNS", "ANATOMICAL_SYSTEM", 43, 46], ["brain resident microglia", "CELL", 84, 108], ["peripheral cytokines", "PROTEIN", 4, 24], ["brain resident microglia", "CELL_TYPE", 84, 108], ["The peripheral cytokines", "TREATMENT", 0, 24], ["peripheral", "ANATOMY_MODIFIER", 4, 14], ["cytokines", "OBSERVATION", 15, 24], ["CNS", "ANATOMY", 43, 46], ["brain", "ANATOMY", 84, 89]]], ["In the case of the non-neurotropic H1N1 strain (A/PR/8/34) infection, which couldn't enter the CNS but produced a massive central inflammatory response, altered the hippocampus, and caused subsequent cognitive deficits in mice (126) .", [["CNS", "ANATOMY", 95, 98], ["hippocampus", "ANATOMY", 165, 176], ["infection", "DISEASE", 59, 68], ["cognitive deficits", "DISEASE", 200, 218], ["H1N1 strain", "ORGANISM", 35, 46], ["A/PR/8/34", "ORGANISM", 48, 57], ["CNS", "ANATOMICAL_SYSTEM", 95, 98], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 165, 176], ["mice", "ORGANISM", 222, 226], ["mice", "SPECIES", 222, 226], ["A/PR/8/34", "SPECIES", 48, 57], ["mice", "SPECIES", 222, 226], ["the non-neurotropic H1N1 strain", "PROBLEM", 15, 46], ["infection", "PROBLEM", 59, 68], ["a massive central inflammatory response", "PROBLEM", 112, 151], ["altered the hippocampus", "PROBLEM", 153, 176], ["subsequent cognitive deficits in mice", "PROBLEM", 189, 226], ["H1N1", "OBSERVATION", 35, 39], ["infection", "OBSERVATION", 59, 68], ["massive", "OBSERVATION_MODIFIER", 114, 121], ["central", "OBSERVATION_MODIFIER", 122, 129], ["inflammatory response", "OBSERVATION", 130, 151], ["hippocampus", "ANATOMY", 165, 176]]], ["In this study, they checked the hippocampal status just 7 days post infections, however, an intriguing question is left regarding the long-term consequences of influenzarelated neuropathology.", [["hippocampal", "ANATOMY", 32, 43], ["infections", "DISEASE", 68, 78], ["neuropathology", "DISEASE", 177, 191], ["this study", "TEST", 3, 13], ["infections", "PROBLEM", 68, 78], ["influenzarelated neuropathology", "PROBLEM", 160, 191], ["infections", "OBSERVATION", 68, 78], ["left", "ANATOMY_MODIFIER", 115, 119], ["long-term", "OBSERVATION_MODIFIER", 134, 143]]], ["Another study by (127) also provided convincing experimental evidence that common Influenza (nonneurotropic strain) can alter the hippocampus and influence the behavior of patients even after infection was reclined (127) .NIPAH VIRUS (NiV)Nipah virus (NiV) is one of the most recent emerging members of the paramyxoviridae family and causes acute respiratory illness in human hosts (128) .", [["hippocampus", "ANATOMY", 130, 141], ["respiratory", "ANATOMY", 347, 358], ["Influenza", "DISEASE", 82, 91], ["infection", "DISEASE", 192, 201], ["acute respiratory illness", "DISEASE", 341, 366], ["Influenza", "ORGANISM", 82, 91], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 130, 141], ["patients", "ORGANISM", 172, 180], ["NIPAH VIRUS (NiV)Nipah virus", "ORGANISM", 222, 250], ["NiV", "ORGANISM", 252, 255], ["human", "ORGANISM", 370, 375], ["patients", "SPECIES", 172, 180], ["Nipah virus", "SPECIES", 239, 250], ["human", "SPECIES", 370, 375], ["Nipah virus", "SPECIES", 239, 250], ["NiV", "SPECIES", 252, 255], ["human", "SPECIES", 370, 375], ["Another study", "TEST", 0, 13], ["common Influenza (nonneurotropic strain)", "PROBLEM", 75, 115], ["infection", "PROBLEM", 192, 201], ["NIPAH VIRUS (NiV", "TREATMENT", 222, 238], ["Nipah virus (NiV", "TREATMENT", 239, 255], ["acute respiratory illness in human hosts", "PROBLEM", 341, 381], ["hippocampus", "ANATOMY", 130, 141], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["respiratory illness", "OBSERVATION", 347, 366]]], ["In critical cases, it is also reported to manifest necrotizing alveolitis, hemorrhage, pneumonia, and pulmonary edema (129) .", [["pulmonary", "ANATOMY", 102, 111], ["alveolitis", "DISEASE", 63, 73], ["hemorrhage", "DISEASE", 75, 85], ["pneumonia", "DISEASE", 87, 96], ["pulmonary edema", "DISEASE", 102, 117], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 102, 117], ["necrotizing alveolitis", "PROBLEM", 51, 73], ["hemorrhage", "PROBLEM", 75, 85], ["pneumonia", "PROBLEM", 87, 96], ["pulmonary edema", "PROBLEM", 102, 117], ["necrotizing", "OBSERVATION_MODIFIER", 51, 62], ["alveolitis", "OBSERVATION", 63, 73], ["hemorrhage", "OBSERVATION", 75, 85], ["pneumonia", "OBSERVATION", 87, 96], ["pulmonary", "ANATOMY", 102, 111], ["edema", "OBSERVATION", 112, 117]]], ["It first originated in Malaysia during 1998-1999 and has a very high mortality rate, up to 40% (130) .", [["very", "OBSERVATION_MODIFIER", 59, 63], ["high", "OBSERVATION_MODIFIER", 64, 68]]], ["Immunohistological studies of fatal patients confirmed the widespread presence of viral particles and other NiV antigens from endothelia and smooth muscle cells of blood vasculature (131) .", [["endothelia", "ANATOMY", 126, 136], ["smooth muscle cells", "ANATOMY", 141, 160], ["blood vasculature", "ANATOMY", 164, 181], ["patients", "ORGANISM", 36, 44], ["NiV antigens", "GENE_OR_GENE_PRODUCT", 108, 120], ["endothelia", "CELL", 126, 136], ["smooth muscle cells", "CELL", 141, 160], ["blood vasculature", "MULTI-TISSUE_STRUCTURE", 164, 181], ["NiV antigens", "PROTEIN", 108, 120], ["smooth muscle cells", "CELL_TYPE", 141, 160], ["patients", "SPECIES", 36, 44], ["NiV", "SPECIES", 108, 111], ["Immunohistological studies", "TEST", 0, 26], ["viral particles", "PROBLEM", 82, 97], ["blood vasculature", "TEST", 164, 181], ["viral particles", "OBSERVATION", 82, 97], ["smooth muscle cells", "OBSERVATION", 141, 160], ["blood vasculature", "ANATOMY", 164, 181]]], ["Parenchymal cells, like muscle cells and even neurons, were found to be abundantly infected with NiV (131).", [["Parenchymal cells", "ANATOMY", 0, 17], ["muscle cells", "ANATOMY", 24, 36], ["neurons", "ANATOMY", 46, 53], ["Parenchymal cells", "CELL", 0, 17], ["like muscle cells", "CELL", 19, 36], ["neurons", "CELL", 46, 53], ["NiV", "ORGANISM", 97, 100], ["Parenchymal cells", "CELL_TYPE", 0, 17], ["muscle cells", "CELL_TYPE", 24, 36], ["Parenchymal cells", "PROBLEM", 0, 17], ["muscle cells", "PROBLEM", 24, 36], ["NiV", "TREATMENT", 97, 100], ["cells", "OBSERVATION", 12, 17], ["muscle cells", "OBSERVATION", 24, 36], ["abundantly", "OBSERVATION_MODIFIER", 72, 82], ["infected", "OBSERVATION", 83, 91]]], ["Particularly, blood endothelial cells and neurons are suggested as the main site of infection in the CNS and vasculitis and thrombosis were considered critical for NiV pathogenesis (131, 132) .", [["blood endothelial cells", "ANATOMY", 14, 37], ["neurons", "ANATOMY", 42, 49], ["CNS", "ANATOMY", 101, 104], ["infection", "DISEASE", 84, 93], ["vasculitis", "DISEASE", 109, 119], ["thrombosis", "DISEASE", 124, 134], ["blood endothelial cells", "CELL", 14, 37], ["neurons", "CELL", 42, 49], ["CNS", "ANATOMICAL_SYSTEM", 101, 104], ["NiV", "ORGANISM", 164, 167], ["blood endothelial cells", "CELL_TYPE", 14, 37], ["neurons", "CELL_TYPE", 42, 49], ["NiV", "SPECIES", 164, 167], ["blood endothelial cells", "TEST", 14, 37], ["infection", "PROBLEM", 84, 93], ["the CNS", "PROBLEM", 97, 104], ["vasculitis", "PROBLEM", 109, 119], ["thrombosis", "PROBLEM", 124, 134], ["NiV pathogenesis", "PROBLEM", 164, 180], ["endothelial cells", "OBSERVATION", 20, 37], ["main", "OBSERVATION_MODIFIER", 71, 75], ["infection", "OBSERVATION", 84, 93], ["CNS", "ANATOMY", 101, 104], ["vasculitis", "OBSERVATION", 109, 119], ["thrombosis", "OBSERVATION", 124, 134]]], ["Mouse model studies have confirmed that NiV takes the olfactory nerve route from nasal epithelia to enter the CNS (133) .", [["olfactory nerve", "ANATOMY", 54, 69], ["nasal epithelia", "ANATOMY", 81, 96], ["CNS", "ANATOMY", 110, 113], ["Mouse", "ORGANISM", 0, 5], ["NiV", "ORGANISM", 40, 43], ["olfactory nerve", "MULTI-TISSUE_STRUCTURE", 54, 69], ["nasal epithelia", "TISSUE", 81, 96], ["CNS", "ANATOMICAL_SYSTEM", 110, 113], ["Mouse", "SPECIES", 0, 5], ["NiV", "SPECIES", 40, 43], ["Mouse model studies", "TEST", 0, 19], ["NiV", "TREATMENT", 40, 43], ["nasal epithelia", "ANATOMY", 81, 96], ["CNS", "ANATOMY", 110, 113]]], ["NiV is reported to cause many neurological pathologies such as confusion, motor deficits, reduced consciousness, seizures, and febrile encephalitic syndrome (134) .MEASLES VIRUS (MV)Measles virus (MV) is a common name for genus Morbillivirus, belonging to the subfamily Paramyxovirinae of the family Paramyxoviridae.", [["neurological", "ANATOMY", 30, 42], ["neurological pathologies", "DISEASE", 30, 54], ["confusion", "DISEASE", 63, 72], ["motor deficits", "DISEASE", 74, 88], ["reduced consciousness", "DISEASE", 90, 111], ["seizures", "DISEASE", 113, 121], ["febrile encephalitic syndrome", "DISEASE", 127, 156], ["Measles virus", "DISEASE", 182, 195], ["NiV", "ORGANISM", 0, 3], ["VIRUS (MV)Measles virus", "ORGANISM", 172, 195], ["Measles virus", "SPECIES", 182, 195], ["NiV", "SPECIES", 0, 3], ["MV", "SPECIES", 179, 181], ["Measles virus", "SPECIES", 182, 195], ["MV", "SPECIES", 197, 199], ["NiV", "TREATMENT", 0, 3], ["many neurological pathologies", "PROBLEM", 25, 54], ["confusion", "PROBLEM", 63, 72], ["motor deficits", "PROBLEM", 74, 88], ["reduced consciousness", "PROBLEM", 90, 111], ["seizures", "PROBLEM", 113, 121], ["febrile encephalitic syndrome", "PROBLEM", 127, 156], ["MEASLES VIRUS (MV)Measles virus", "PROBLEM", 164, 195], ["genus Morbillivirus", "PROBLEM", 222, 241], ["febrile", "OBSERVATION_MODIFIER", 127, 134], ["encephalitic syndrome", "OBSERVATION", 135, 156]]], ["MV falls in the category of an enveloped virus with a genome of a single-strand, negative sense RNA (135).", [["MV", "SPECIES", 0, 2], ["MV falls", "PROBLEM", 0, 8], ["an enveloped virus", "PROBLEM", 28, 46], ["enveloped", "OBSERVATION_MODIFIER", 31, 40], ["virus", "OBSERVATION", 41, 46]]], ["Measles virus is a very common virus that causes a respiratory disease with fever, cold, and congestions (135).MEASLES VIRUS (MV)MVs are speculated to enter the CNS by both routes: the hematogenous and neuronal transport pathways.", [["respiratory", "ANATOMY", 51, 62], ["CNS", "ANATOMY", 161, 164], ["neuronal", "ANATOMY", 202, 210], ["Measles virus", "DISEASE", 0, 13], ["respiratory disease", "DISEASE", 51, 70], ["fever", "DISEASE", 76, 81], ["congestions", "DISEASE", 93, 104], ["Measles virus", "ORGANISM", 0, 13], ["CNS", "ANATOMICAL_SYSTEM", 161, 164], ["neuronal", "CELL", 202, 210], ["Measles virus", "SPECIES", 0, 13], ["Measles virus", "SPECIES", 0, 13], ["MV", "SPECIES", 126, 128], ["Measles virus", "PROBLEM", 0, 13], ["a very common virus", "PROBLEM", 17, 36], ["a respiratory disease", "PROBLEM", 49, 70], ["fever", "PROBLEM", 76, 81], ["cold", "PROBLEM", 83, 87], ["congestions", "PROBLEM", 93, 104], ["MEASLES VIRUS (MV)MVs", "PROBLEM", 111, 132], ["respiratory disease", "OBSERVATION", 51, 70], ["fever", "OBSERVATION", 76, 81], ["CNS", "ANATOMY", 161, 164], ["hematogenous", "OBSERVATION", 185, 197]]], ["However, there is evidence showing both kinds of route taken by the MV virus to reach the CNS.", [["CNS", "ANATOMY", 90, 93], ["MV virus", "ORGANISM", 68, 76], ["CNS", "ANATOMICAL_SYSTEM", 90, 93], ["MV virus", "SPECIES", 68, 76], ["the MV virus", "TREATMENT", 64, 76], ["CNS", "ANATOMY", 90, 93]]], ["MV nucleocapsid protein has been consistently reported at the pre-synaptic membranes of infected neurons, which suggest that MV might spread in a contact dependent, trans-synaptic fashion.", [["pre-synaptic membranes", "ANATOMY", 62, 84], ["neurons", "ANATOMY", 97, 104], ["pre-synaptic membranes", "CELLULAR_COMPONENT", 62, 84], ["neurons", "CELL", 97, 104], ["MV nucleocapsid protein", "PROTEIN", 0, 23], ["infected neurons", "CELL_TYPE", 88, 104], ["MV", "SPECIES", 0, 2], ["MV", "SPECIES", 125, 127], ["MV nucleocapsid protein", "TEST", 0, 23], ["infected neurons", "PROBLEM", 88, 104], ["protein", "OBSERVATION", 16, 23], ["pre-synaptic membranes", "OBSERVATION_MODIFIER", 62, 84], ["infected neurons", "OBSERVATION", 88, 104]]], ["It is mostly a self-limiting disease, however, many severe patients are reported to have post-infectious encephalomyelitis (PIE) or acute disseminated encephalomyelitis (ADEM) (136) .", [["encephalomyelitis", "DISEASE", 105, 122], ["PIE", "DISEASE", 124, 127], ["acute disseminated encephalomyelitis", "DISEASE", 132, 168], ["ADEM", "DISEASE", 170, 174], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["a self-limiting disease", "PROBLEM", 13, 36], ["post-infectious encephalomyelitis", "PROBLEM", 89, 122], ["PIE", "PROBLEM", 124, 127], ["acute disseminated encephalomyelitis", "PROBLEM", 132, 168], ["self-limiting", "OBSERVATION_MODIFIER", 15, 28], ["disease", "OBSERVATION", 29, 36], ["severe", "OBSERVATION_MODIFIER", 52, 58], ["infectious", "OBSERVATION_MODIFIER", 94, 104], ["encephalomyelitis", "OBSERVATION", 105, 122], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["disseminated", "OBSERVATION_MODIFIER", 138, 150], ["encephalomyelitis", "OBSERVATION", 151, 168]]], ["In few immunocompromised patients, MV infection can lead to Measles inclusion body encephalitis (MIBE), which is a secondary CNS complication (138) .", [["body", "ANATOMY", 78, 82], ["CNS", "ANATOMY", 125, 128], ["MV infection", "DISEASE", 35, 47], ["Measles inclusion body encephalitis", "DISEASE", 60, 95], ["MIBE", "DISEASE", 97, 101], ["patients", "ORGANISM", 25, 33], ["CNS", "ANATOMICAL_SYSTEM", 125, 128], ["patients", "SPECIES", 25, 33], ["MV", "SPECIES", 35, 37], ["MV infection", "PROBLEM", 35, 47], ["Measles inclusion body encephalitis", "PROBLEM", 60, 95], ["a secondary CNS complication", "PROBLEM", 113, 141], ["few", "OBSERVATION_MODIFIER", 3, 6], ["immunocompromised", "OBSERVATION", 7, 24], ["infection", "OBSERVATION", 38, 47], ["secondary", "OBSERVATION_MODIFIER", 115, 124], ["CNS complication", "OBSERVATION", 125, 141]]], ["Another form of CNS disease, Subacute Sclerosis Pan Encephalitis (SSPE), has also been associated with some critical MV patients.", [["CNS", "ANATOMY", 16, 19], ["CNS disease", "DISEASE", 16, 27], ["Sclerosis Pan Encephalitis", "DISEASE", 38, 64], ["SSPE", "DISEASE", 66, 70], ["CNS", "ANATOMICAL_SYSTEM", 16, 19], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["MV", "SPECIES", 117, 119], ["CNS disease", "PROBLEM", 16, 27], ["Subacute Sclerosis Pan Encephalitis", "PROBLEM", 29, 64], ["CNS", "ANATOMY", 16, 19], ["disease", "OBSERVATION", 20, 27], ["Subacute", "OBSERVATION_MODIFIER", 29, 37], ["Sclerosis", "OBSERVATION", 38, 47], ["Encephalitis", "OBSERVATION", 52, 64]]], ["It is regarded as a slow-progressing neurological disease that only surfaces 6-10 years post MV infection (135-137).CONCLUSION, FUTURE DIRECTIONS, AND NEW INSIGHTSIn this review article, we have discussed how respiratory viruses take advantage of olfactory nerve cells and sometimes even the hematogenous route to reach the CNS.", [["neurological", "ANATOMY", 37, 49], ["olfactory nerve cells", "ANATOMY", 247, 268], ["CNS", "ANATOMY", 324, 327], ["neurological disease", "DISEASE", 37, 57], ["infection", "DISEASE", 96, 105], ["respiratory viruses", "DISEASE", 209, 228], ["olfactory nerve cells", "CELL", 247, 268], ["CNS", "ANATOMICAL_SYSTEM", 324, 327], ["olfactory nerve cells", "CELL_TYPE", 247, 268], ["MV", "SPECIES", 93, 95], ["a slow-progressing neurological disease", "PROBLEM", 18, 57], ["MV infection", "PROBLEM", 93, 105], ["how respiratory viruses", "PROBLEM", 205, 228], ["olfactory nerve cells", "TREATMENT", 247, 268], ["progressing", "OBSERVATION_MODIFIER", 25, 36], ["neurological disease", "OBSERVATION", 37, 57], ["infection", "OBSERVATION", 96, 105], ["olfactory nerve", "ANATOMY", 247, 262], ["CNS", "ANATOMY", 324, 327]]], ["Bystander damage to multiple organs such as the brain, kidney, and heart takes place, although the lungs remain its major battlefield.", [["organs", "ANATOMY", 29, 35], ["brain", "ANATOMY", 48, 53], ["kidney", "ANATOMY", 55, 61], ["heart", "ANATOMY", 67, 72], ["lungs", "ANATOMY", 99, 104], ["organs", "ORGAN", 29, 35], ["brain", "ORGAN", 48, 53], ["kidney", "ORGAN", 55, 61], ["heart", "ORGAN", 67, 72], ["lungs", "ORGAN", 99, 104], ["Bystander damage to multiple organs", "PROBLEM", 0, 35], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["organs", "OBSERVATION", 29, 35], ["brain", "ANATOMY", 48, 53], ["kidney", "ANATOMY", 55, 61], ["heart", "ANATOMY", 67, 72], ["lungs", "ANATOMY", 99, 104]]], ["Peripheral cytokine storms, elevated hypoxia injury, and inflammatory activation of CNS cells like microglia play key roles in causing neurological damage to patients infected with respiratory viruses.", [["CNS cells", "ANATOMY", 84, 93], ["microglia", "ANATOMY", 99, 108], ["neurological", "ANATOMY", 135, 147], ["hypoxia injury", "DISEASE", 37, 51], ["neurological damage", "DISEASE", 135, 154], ["respiratory viruses", "DISEASE", 181, 200], ["CNS cells", "CELL", 84, 93], ["microglia", "CELL", 99, 108], ["patients", "ORGANISM", 158, 166], ["cytokine", "PROTEIN", 11, 19], ["CNS cells", "CELL_TYPE", 84, 93], ["microglia", "CELL_TYPE", 99, 108], ["patients", "SPECIES", 158, 166], ["Peripheral cytokine storms", "PROBLEM", 0, 26], ["elevated hypoxia injury", "PROBLEM", 28, 51], ["inflammatory activation of CNS cells", "PROBLEM", 57, 93], ["neurological damage", "PROBLEM", 135, 154], ["respiratory viruses", "PROBLEM", 181, 200], ["cytokine storms", "OBSERVATION", 11, 26], ["elevated", "OBSERVATION_MODIFIER", 28, 36], ["hypoxia injury", "OBSERVATION", 37, 51], ["inflammatory", "OBSERVATION_MODIFIER", 57, 69], ["CNS cells", "OBSERVATION", 84, 93], ["respiratory viruses", "OBSERVATION", 181, 200]]], ["This review article presents the compilation of previously known interrelations of respiratory viruses and disruption of CNS homeostasis.", [["CNS", "ANATOMY", 121, 124], ["respiratory viruses", "DISEASE", 83, 102], ["CNS", "ANATOMICAL_SYSTEM", 121, 124], ["respiratory viruses", "PROBLEM", 83, 102], ["CNS homeostasis", "PROBLEM", 121, 136], ["respiratory viruses", "OBSERVATION", 83, 102], ["CNS homeostasis", "OBSERVATION", 121, 136]]], ["Specifically, all the previous members of the coronavirus family have been shown to impair neurological health as a long-term sequelae.", [["neurological", "ANATOMY", 91, 103], ["coronavirus", "ORGANISM", 46, 57], ["coronavirus", "SPECIES", 46, 57], ["a long-term sequelae", "PROBLEM", 114, 134], ["long-term sequelae", "OBSERVATION_MODIFIER", 116, 134]]], ["SARS-CoV-2 has already infected over 19 million people around the globe and killed more than 700,000 people globally.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["people", "ORGANISM", 48, 54], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 48, 54], ["people", "SPECIES", 101, 107], ["SARS-CoV", "SPECIES", 0, 8], ["infected", "OBSERVATION_MODIFIER", 23, 31], ["globe", "ANATOMY", 66, 71]]], ["In the future, a very large number of SARS-CoV-2 patients are likely to experience a myriad of neurological abnormalities.CONCLUSION, FUTURE DIRECTIONS, AND NEW INSIGHTSThere should be a global effort toward not only epidemiological mitigation measures, like controlling mass people movements, cross-continental travel, and developing effective vaccines, but also gathering more data about neurotropism, the disruption of glial cell biology, and the role of microglia in amplifying the cytokine storm by SARS-CoV-2.", [["neurological", "ANATOMY", 95, 107], ["glial cell", "ANATOMY", 422, 432], ["microglia", "ANATOMY", 458, 467], ["SARS", "DISEASE", 38, 42], ["neurological abnormalities", "DISEASE", 95, 121], ["SARS-CoV-2", "ORGANISM", 38, 48], ["patients", "ORGANISM", 49, 57], ["glial cell", "CELL", 422, 432], ["microglia", "CELL", 458, 467], ["SARS-CoV-2", "ORGANISM", 504, 514], ["microglia", "CELL_TYPE", 458, 467], ["cytokine", "PROTEIN", 486, 494], ["patients", "SPECIES", 49, 57], ["people", "SPECIES", 276, 282], ["SARS-CoV", "SPECIES", 38, 46], ["SARS-CoV", "SPECIES", 504, 512], ["neurological abnormalities", "PROBLEM", 95, 121], ["epidemiological mitigation measures", "TREATMENT", 217, 252], ["controlling mass people movements", "PROBLEM", 259, 292], ["neurotropism", "PROBLEM", 390, 402], ["very", "OBSERVATION_MODIFIER", 17, 21], ["large", "OBSERVATION_MODIFIER", 22, 27], ["glial cell", "OBSERVATION", 422, 432]]], ["Our previous works have specifically elucidated how a virus infection (HIV-1, DENV, JEV, etc.) or even viral toxic proteins can cross the blood-brain barrier and aggravate the neuroinflammatory response within the CNS.", [["blood-brain barrier", "ANATOMY", 138, 157], ["CNS", "ANATOMY", 214, 217], ["infection", "DISEASE", 60, 69], ["HIV-1", "ORGANISM", 71, 76], ["DENV", "ORGANISM", 78, 82], ["JEV", "ORGANISM", 84, 87], ["blood-", "MULTI-TISSUE_STRUCTURE", 138, 144], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 144, 157], ["CNS", "ANATOMICAL_SYSTEM", 214, 217], ["viral toxic proteins", "PROTEIN", 103, 123], ["HIV-1", "SPECIES", 71, 76], ["HIV-1", "SPECIES", 71, 76], ["DENV", "SPECIES", 78, 82], ["JEV", "SPECIES", 84, 87], ["a virus infection", "PROBLEM", 52, 69], ["HIV", "TEST", 71, 74], ["DENV", "PROBLEM", 78, 82], ["JEV", "PROBLEM", 84, 87], ["even viral toxic proteins", "PROBLEM", 98, 123], ["the neuroinflammatory response", "PROBLEM", 172, 202], ["brain", "ANATOMY", 144, 149], ["neuroinflammatory response", "OBSERVATION", 176, 202], ["CNS", "ANATOMY", 214, 217]]], ["We have also highlighted in our previous work how extracellular vesicles released by peripheral immune cells after Dengue virus infection have the capacity to trigger a cytokine storm phenomenon in the CNS.", [["extracellular vesicles", "ANATOMY", 50, 72], ["peripheral immune cells", "ANATOMY", 85, 108], ["CNS", "ANATOMY", 202, 205], ["Dengue virus infection", "DISEASE", 115, 137], ["extracellular vesicles", "CELLULAR_COMPONENT", 50, 72], ["peripheral immune cells", "CELL", 85, 108], ["Dengue virus", "ORGANISM", 115, 127], ["CNS", "ANATOMICAL_SYSTEM", 202, 205], ["peripheral immune cells", "CELL_TYPE", 85, 108], ["cytokine", "PROTEIN", 169, 177], ["Dengue virus", "SPECIES", 115, 127], ["Dengue virus", "SPECIES", 115, 127], ["extracellular vesicles", "PROBLEM", 50, 72], ["peripheral immune cells", "TREATMENT", 85, 108], ["Dengue virus infection", "PROBLEM", 115, 137], ["the capacity", "PROBLEM", 143, 155], ["a cytokine storm phenomenon", "PROBLEM", 167, 194], ["peripheral immune cells", "OBSERVATION", 85, 108], ["cytokine storm", "OBSERVATION", 169, 183], ["CNS", "ANATOMY", 202, 205]]], ["These recent works provide us with more clues about how we can block the interconnections of periphery cells and the CNS.", [["periphery cells", "ANATOMY", 93, 108], ["CNS", "ANATOMY", 117, 120], ["periphery cells", "CELL", 93, 108], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["periphery cells", "CELL_TYPE", 93, 108], ["CNS", "ANATOMY", 117, 120]]], ["We can further explore the trafficking biology to control the extracellular vesicle secretion which transfers the signals and transcriptional activators between organs.", [["extracellular vesicle", "ANATOMY", 62, 83], ["organs", "ANATOMY", 161, 167], ["extracellular vesicle", "CELLULAR_COMPONENT", 62, 83], ["organs", "ORGAN", 161, 167], ["transcriptional activators", "PROTEIN", 126, 152], ["the extracellular vesicle secretion", "PROBLEM", 58, 93]]], ["We can also explore various temporary measure to regulate BBB permeability, so that SARS-CoV-2 crossing over to CNS could be checked.", [["BBB", "ANATOMY", 58, 61], ["CNS", "ANATOMY", 112, 115], ["BBB", "MULTI-TISSUE_STRUCTURE", 58, 61], ["CNS", "ANATOMICAL_SYSTEM", 112, 115], ["various temporary measure", "TREATMENT", 20, 45], ["SARS", "PROBLEM", 84, 88], ["CoV", "TEST", 89, 92]]], ["Enhancers for mucosal immunity should be explored, which can contain SARS-CoV-2 at epithelial surfaces itself and not allow them to invade all the vital organs of the host, including the CNS.CONCLUSION, FUTURE DIRECTIONS, AND NEW INSIGHTSThis awareness would offer us an opportunity to adopt a much more holistic approach of neurological healthcare management while the acute phase of the SARS-Cov-2 is still ongoing, in order to improve the upcoming life-quality of SARS-CoV-2 and other respiratory patients.AUTHOR CONTRIBUTIONSRM and AB conceptualized the framework of this review article, corrected, read, and finalized the article.", [["mucosal", "ANATOMY", 14, 21], ["epithelial surfaces", "ANATOMY", 83, 102], ["organs", "ANATOMY", 153, 159], ["CNS", "ANATOMY", 187, 190], ["neurological", "ANATOMY", 325, 337], ["SARS", "DISEASE", 389, 393], ["SARS", "DISEASE", 467, 471], ["mucosal", "MULTI-TISSUE_STRUCTURE", 14, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["epithelial surfaces", "TISSUE", 83, 102], ["organs", "ORGAN", 153, 159], ["CNS", "ANATOMICAL_SYSTEM", 187, 190], ["SARS-CoV-2", "ORGANISM", 467, 477], ["patients", "ORGANISM", 500, 508], ["patients", "SPECIES", 500, 508], ["mucosal immunity", "TREATMENT", 14, 30], ["SARS", "TEST", 69, 73], ["neurological healthcare management", "TREATMENT", 325, 359], ["the SARS", "TEST", 385, 393], ["CoV", "TEST", 472, 475], ["CNS", "ANATOMY", 187, 190]]], ["AB is Emeritus Scientist at National Institute of Immunology, and recipient of fellowship from Institutional NII-core funding, DBT and ICMR, New Delhi, India.ACKNOWLEDGMENTSWe are grateful for all the research studies conducted worldwide to resolve this enigmatic scenario of neurological pathologies caused by respiratory viruses.", [["neurological", "ANATOMY", 276, 288], ["neurological pathologies", "DISEASE", 276, 300], ["respiratory viruses", "DISEASE", 311, 330], ["the research studies", "TEST", 197, 217], ["neurological pathologies", "PROBLEM", 276, 300], ["respiratory viruses", "PROBLEM", 311, 330], ["New", "OBSERVATION_MODIFIER", 141, 144], ["respiratory viruses", "OBSERVATION", 311, 330]]]], "dc85462812d1ba040a7b351535c4f703b4dd72c0": [["und die damit einhergehende Erkrankung COVID-19 (Coronavirus Disease 2019) stellt die medizinischen Versorgungssysteme vor gro\u00dfe Herausforderungen.", [["und die damit einhergehende Erkrankung COVID-19", "SPECIES", 0, 47], ["COVID", "TEST", 39, 44], ["Coronavirus Disease", "PROBLEM", 49, 68]]], ["Die vorliegende Arbeit fasst die Strategie, Organisation und Ma\u00dfnahmen der COVID-Taskforce des Universit\u00e4tsklinikums Freiburg zusammen und berichtet \u00fcber Erfahrungen und Behandlungsergebnisse von der Versorgung der ersten 115 COVID-19-Patienten.", [["Die vorliegende Arbeit fasst die Strategie, Organisation und Ma\u00dfnahmen der COVID-Taskforce des Universit\u00e4tsklinikums Freiburg zusammen und berichtet \u00fcber Erfahrungen und Behandlungsergebnisse von der Versorgung der ersten 115 COVID-19-Patienten", "SPECIES", 0, 244], ["COVID", "TEST", 226, 231]]]], "02578e87bd9c0caca0c97c3af9203ccb49fc7984": [["INTRODUCTIONMultiple sclerosis (MS) is an autoimmune disease in humans whose key pathology is demyelination and axonal loss as the result of immune cell production of proinflammatory molecules and active attack of both the myelin sheaths and the cells producing them, the oligodendrocytes.", [["axonal", "ANATOMY", 112, 118], ["immune cell", "ANATOMY", 141, 152], ["myelin sheaths", "ANATOMY", 223, 237], ["cells", "ANATOMY", 246, 251], ["oligodendrocytes", "ANATOMY", 272, 288], ["INTRODUCTIONMultiple sclerosis", "DISEASE", 0, 30], ["MS", "DISEASE", 32, 34], ["autoimmune disease", "DISEASE", 42, 60], ["demyelination", "DISEASE", 94, 107], ["axonal loss", "DISEASE", 112, 123], ["humans", "ORGANISM", 64, 70], ["immune cell", "CELL", 141, 152], ["myelin sheaths", "CELLULAR_COMPONENT", 223, 237], ["cells", "CELL", 246, 251], ["oligodendrocytes", "CELL", 272, 288], ["proinflammatory molecules", "PROTEIN", 167, 192], ["oligodendrocytes", "CELL_TYPE", 272, 288], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 64, 70], ["INTRODUCTIONMultiple sclerosis (MS)", "PROBLEM", 0, 35], ["an autoimmune disease in humans", "PROBLEM", 39, 70], ["demyelination", "PROBLEM", 94, 107], ["axonal loss", "PROBLEM", 112, 123], ["immune cell production", "PROBLEM", 141, 163], ["proinflammatory molecules", "PROBLEM", 167, 192], ["active attack", "PROBLEM", 197, 210], ["the myelin sheaths", "TREATMENT", 219, 237], ["sclerosis", "OBSERVATION", 21, 30], ["autoimmune disease", "OBSERVATION", 42, 60], ["demyelination", "OBSERVATION", 94, 107], ["axonal loss", "OBSERVATION", 112, 123], ["immune cell production", "OBSERVATION", 141, 163], ["proinflammatory molecules", "OBSERVATION", 167, 192], ["active", "OBSERVATION_MODIFIER", 197, 203], ["myelin sheaths", "ANATOMY", 223, 237]]], ["The hallmarks of the pathology are plaques which are found in myelin-rich white matter regions of the central nervous system (CNS), in both brain and spinal cord.", [["plaques", "ANATOMY", 35, 42], ["myelin-rich white matter", "ANATOMY", 62, 86], ["central nervous system", "ANATOMY", 102, 124], ["CNS", "ANATOMY", 126, 129], ["brain", "ANATOMY", 140, 145], ["spinal cord", "ANATOMY", 150, 161], ["myelin", "CELLULAR_COMPONENT", 62, 68], ["central nervous system", "ANATOMICAL_SYSTEM", 102, 124], ["CNS", "ANATOMICAL_SYSTEM", 126, 129], ["brain", "ORGAN", 140, 145], ["spinal cord", "ORGAN", 150, 161], ["plaques", "PROBLEM", 35, 42], ["hallmarks", "OBSERVATION_MODIFIER", 4, 13], ["pathology", "OBSERVATION", 21, 30], ["plaques", "OBSERVATION", 35, 42], ["rich", "ANATOMY_MODIFIER", 69, 73], ["white matter", "ANATOMY_MODIFIER", 74, 86], ["regions", "ANATOMY_MODIFIER", 87, 94], ["central", "ANATOMY_MODIFIER", 102, 109], ["nervous system", "ANATOMY", 110, 124], ["CNS", "ANATOMY", 126, 129], ["both", "ANATOMY_MODIFIER", 135, 139], ["brain", "ANATOMY", 140, 145], ["spinal cord", "ANATOMY", 150, 161]]], ["Destruction of myelin, oligodendrocytes, and ultimately axons is mediated by activated T cells, autoantibodies directed at self-antigens, enzymes, and free radicals secreted by macrophages and microglia (Prineas et al, 1984; Raine and Wu, 1993) .", [["myelin", "ANATOMY", 15, 21], ["oligodendrocytes", "ANATOMY", 23, 39], ["axons", "ANATOMY", 56, 61], ["T cells", "ANATOMY", 87, 94], ["macrophages", "ANATOMY", 177, 188], ["microglia", "ANATOMY", 193, 202], ["myelin", "CELLULAR_COMPONENT", 15, 21], ["oligodendrocytes", "CELL", 23, 39], ["axons", "CELLULAR_COMPONENT", 56, 61], ["T cells", "CELL", 87, 94], ["macrophages", "CELL", 177, 188], ["microglia", "CELL", 193, 202], ["oligodendrocytes", "CELL_TYPE", 23, 39], ["activated T cells", "CELL_TYPE", 77, 94], ["autoantibodies", "PROTEIN", 96, 110], ["enzymes", "PROTEIN", 138, 145], ["macrophages", "CELL_TYPE", 177, 188], ["microglia", "CELL_TYPE", 193, 202], ["Destruction of myelin, oligodendrocytes", "PROBLEM", 0, 39], ["activated T cells", "PROBLEM", 77, 94], ["autoantibodies", "PROBLEM", 96, 110], ["enzymes", "TEST", 138, 145], ["myelin", "OBSERVATION", 15, 21], ["oligodendrocytes", "OBSERVATION", 23, 39], ["macrophages", "ANATOMY", 177, 188]]], ["Oligodendrocyte progenitors reside throughout the CNS from birth well into old age in the human brain (Roy et al, 1999; Nunes et al, 2003) .", [["Oligodendrocyte progenitors", "ANATOMY", 0, 27], ["CNS", "ANATOMY", 50, 53], ["brain", "ANATOMY", 96, 101], ["Oligodendrocyte progenitors", "CELL", 0, 27], ["CNS", "ANATOMICAL_SYSTEM", 50, 53], ["human", "ORGANISM", 90, 95], ["brain", "ORGAN", 96, 101], ["Oligodendrocyte progenitors", "CELL_TYPE", 0, 27], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["Oligodendrocyte progenitors", "PROBLEM", 0, 27], ["human brain", "ANATOMY", 90, 101]]], ["It has been well documented that these cells are activated by the CNS pathology in MS to migrate to the lesion sites and attempt to repair the damage by differentiating and remyelinating naked axons (Prineas and Connell, 1979; Prineas et al, 1984 Prineas et al, , 1989 Prineas et al, , 1993 Raine and Wu, 1993; Lassmann et al, 1997) .", [["cells", "ANATOMY", 39, 44], ["CNS", "ANATOMY", 66, 69], ["lesion sites", "ANATOMY", 104, 116], ["axons", "ANATOMY", 193, 198], ["cells", "CELL", 39, 44], ["CNS", "ANATOMICAL_SYSTEM", 66, 69], ["lesion sites", "MULTI-TISSUE_STRUCTURE", 104, 116], ["axons", "MULTI-TISSUE_STRUCTURE", 193, 198], ["the lesion sites", "PROBLEM", 100, 116], ["repair", "TREATMENT", 132, 138], ["the damage", "PROBLEM", 139, 149], ["CNS", "ANATOMY", 66, 69], ["lesion", "OBSERVATION", 104, 110], ["damage", "OBSERVATION", 143, 149]]], ["This continuum of myelin breakdown and repair can be seen in the majority of lesions in MS tissues and has led to the exploration of the process of repair in the CNS using basic models of demyelination and remyelination in vitro and in modeling these events in animals.", [["myelin", "ANATOMY", 18, 24], ["lesions", "ANATOMY", 77, 84], ["MS tissues", "ANATOMY", 88, 98], ["CNS", "ANATOMY", 162, 165], ["MS", "DISEASE", 88, 90], ["demyelination", "DISEASE", 188, 201], ["remyelination", "DISEASE", 206, 219], ["myelin", "CELLULAR_COMPONENT", 18, 24], ["lesions", "PATHOLOGICAL_FORMATION", 77, 84], ["MS tissues", "TISSUE", 88, 98], ["CNS", "ANATOMICAL_SYSTEM", 162, 165], ["myelin breakdown", "PROBLEM", 18, 34], ["repair", "TREATMENT", 39, 45], ["lesions in MS tissues", "PROBLEM", 77, 98], ["the exploration", "TEST", 114, 129], ["repair", "TREATMENT", 148, 154], ["demyelination", "PROBLEM", 188, 201], ["remyelination in vitro", "PROBLEM", 206, 228], ["myelin breakdown", "OBSERVATION", 18, 34], ["repair", "OBSERVATION", 39, 45], ["lesions", "OBSERVATION", 77, 84], ["repair", "OBSERVATION", 148, 154], ["CNS", "ANATOMY", 162, 165], ["demyelination", "OBSERVATION", 188, 201]]], ["The understanding that remyelination recapitulates processes known to occur in primary myelination, the growing knowledge of the local environmental factors that cause demyelination or prevent/promote remyelination, and the recognition that through the use of small molecules and biologics pharmacological intervention might harness the endogenous repair process to treat MS will be explored in this chapter (Sim et al, 2002 (Sim et al, , 2006 Franklin and Blakemore, 1995; Blakemore and Franklin, 1991) .", [["demyelination", "DISEASE", 168, 181], ["MS", "DISEASE", 372, 374], ["remyelination recapitulates processes", "PROBLEM", 23, 60], ["demyelination", "PROBLEM", 168, 181], ["remyelination", "PROBLEM", 201, 214], ["small molecules", "TREATMENT", 260, 275], ["biologics pharmacological intervention", "TREATMENT", 280, 318], ["the endogenous repair process", "TREATMENT", 333, 362], ["MS", "PROBLEM", 372, 374], ["remyelination", "OBSERVATION", 23, 36], ["remyelination", "OBSERVATION", 201, 214]]], ["Specifically, a focus on which tools lend themselves to the drug discovery process and bridge the gap between models and man will be addressed.INTRODUCTIONSuch a large area of research using experimental models cannot be covered in its entirety.", [["man", "ORGANISM", 121, 124], ["man", "SPECIES", 121, 124], ["experimental models", "TREATMENT", 191, 210], ["large", "OBSERVATION_MODIFIER", 162, 167], ["area", "OBSERVATION_MODIFIER", 168, 172]]], ["This chapter is not intended to be a thorough review of the literature from the initial description through contemporary papers on all the models in vitro and in vivo for demyelination and remyelination.", [["demyelination", "DISEASE", 171, 184], ["remyelination", "DISEASE", 189, 202], ["demyelination", "PROBLEM", 171, 184], ["remyelination", "PROBLEM", 189, 202], ["demyelination", "OBSERVATION", 171, 184]]], ["It will not review every dosing regimen, explore every variation on disease induction paradigms in the models, or argue fine points about exceptional pathology that can be elicited in a given model.", [["every dosing regimen", "TREATMENT", 19, 39], ["disease induction paradigms", "TREATMENT", 68, 95], ["exceptional pathology", "PROBLEM", 138, 159]]], ["This chapter is also not intended to go beyond preclinical efficacy studies and the usefulness of models for such a purpose.", [["preclinical efficacy studies", "TEST", 47, 75]]], ["Therefore, the issues surrounding clinical trials and the ideal drug candidate are outside the realm of the chapter.", [["clinical trials", "TREATMENT", 34, 49]]], ["Neither the pros and cons of therapeutic modalities (in models or man) nor safety studies in in vivo models were intended to be a part of the discussion on use of models for evaluating the effectiveness of drugs.", [["man", "SPECIES", 66, 69], ["therapeutic modalities", "TREATMENT", 29, 51], ["safety studies", "TEST", 75, 89], ["drugs", "TREATMENT", 206, 211]]], ["Nevertheless, some examples of drugs currently in clinical trials and their use in these models will be discussed with respect to some of the hurdles in assessing remyelination in the clinic.Primary Cultures: RodentPrimary rodent culture systems lend themselves to evaluating oligodendrocytes at different stages of differentiation within the committed lineage (McCarthy and deVellis, 1980) .", [["oligodendrocytes", "ANATOMY", 276, 292], ["oligodendrocytes", "CELL", 276, 292], ["lineage", "CELL", 353, 360], ["RodentPrimary rodent culture systems", "CELL_LINE", 209, 245], ["oligodendrocytes", "CELL_TYPE", 276, 292], ["committed lineage", "CELL_TYPE", 343, 360], ["rodent", "SPECIES", 223, 229], ["drugs", "TREATMENT", 31, 36], ["Primary Cultures", "TEST", 191, 207], ["RodentPrimary rodent culture systems", "TEST", 209, 245], ["oligodendrocytes", "PROBLEM", 276, 292], ["committed lineage", "OBSERVATION", 343, 360]]], ["The proliferative, migratory, bipolar oligodendrocyte precursor in rats can be identified by monoclonal antibodies to gangliosides GD3 and A2B5; such cells are also positive for platelet-derived growth factor-a receptor (PDGFaR + ) and express, among others, such transcription factors as Olig1 and 2, id2, POU III, Sox 11, Krox 24 (Pfeiffer et al, 1993; Nicolay et al, 2007) .", [["oligodendrocyte precursor", "ANATOMY", 38, 63], ["cells", "ANATOMY", 150, 155], ["oligodendrocyte precursor", "CELL", 38, 63], ["rats", "ORGANISM", 67, 71], ["gangliosides GD3", "GENE_OR_GENE_PRODUCT", 118, 134], ["A2B5", "GENE_OR_GENE_PRODUCT", 139, 143], ["cells", "CELL", 150, 155], ["platelet-derived growth factor-a receptor", "GENE_OR_GENE_PRODUCT", 178, 219], ["PDGFaR", "GENE_OR_GENE_PRODUCT", 221, 227], ["Olig1", "GENE_OR_GENE_PRODUCT", 289, 294], ["2", "GENE_OR_GENE_PRODUCT", 299, 300], ["id2", "GENE_OR_GENE_PRODUCT", 302, 305], ["POU III", "GENE_OR_GENE_PRODUCT", 307, 314], ["Sox", "GENE_OR_GENE_PRODUCT", 316, 319], ["monoclonal antibodies", "PROTEIN", 93, 114], ["A2B5", "PROTEIN", 139, 143], ["platelet-derived growth factor-a receptor", "PROTEIN", 178, 219], ["PDGFaR", "PROTEIN", 221, 227], ["transcription factors", "PROTEIN", 264, 285], ["Olig1", "PROTEIN", 289, 294], ["2", "PROTEIN", 299, 300], ["id2", "PROTEIN", 302, 305], ["POU III", "PROTEIN", 307, 314], ["Sox 11", "PROTEIN", 316, 322], ["Krox 24", "PROTEIN", 324, 331], ["rats", "SPECIES", 67, 71], ["bipolar oligodendrocyte precursor", "PROBLEM", 30, 63], ["monoclonal antibodies", "TEST", 93, 114], ["gangliosides GD3", "TEST", 118, 134], ["A2B5", "TEST", 139, 143], ["such cells", "TEST", 145, 155], ["platelet", "TEST", 178, 186], ["derived growth factor", "PROBLEM", 187, 208], ["proliferative", "OBSERVATION_MODIFIER", 4, 17], ["migratory", "OBSERVATION_MODIFIER", 19, 28], ["bipolar oligodendrocyte", "OBSERVATION", 30, 53]]], ["Prooligodendrocytes are multipolar, postmigratory, proliferative cells identified by 04 antibody to the sulfated surface antigen POA; Sox 10 and 17, and Mash 1 are transcription factors seen at this stage.", [["Prooligodendrocytes", "ANATOMY", 0, 19], ["cells", "ANATOMY", 65, 70], ["surface", "ANATOMY", 113, 120], ["Prooligodendrocytes", "CELL", 0, 19], ["proliferative cells", "CELL", 51, 70], ["POA", "GENE_OR_GENE_PRODUCT", 129, 132], ["Sox 10", "GENE_OR_GENE_PRODUCT", 134, 140], ["17", "GENE_OR_GENE_PRODUCT", 145, 147], ["Mash 1", "GENE_OR_GENE_PRODUCT", 153, 159], ["Prooligodendrocytes", "CELL_TYPE", 0, 19], ["multipolar, postmigratory, proliferative cells", "CELL_TYPE", 24, 70], ["04 antibody", "PROTEIN", 85, 96], ["sulfated surface antigen", "PROTEIN", 104, 128], ["POA", "PROTEIN", 129, 132], ["Sox 10 and 17", "PROTEIN", 134, 147], ["Mash 1", "PROTEIN", 153, 159], ["transcription factors", "PROTEIN", 164, 185], ["Prooligodendrocytes", "TEST", 0, 19], ["multipolar, postmigratory, proliferative cells", "PROBLEM", 24, 70], ["antibody", "TEST", 88, 96], ["transcription factors", "PROBLEM", 164, 185], ["multipolar", "OBSERVATION_MODIFIER", 24, 34], ["proliferative cells", "OBSERVATION", 51, 70]]], ["Premyelin oligodendrocytes express galactocerebroside (GalC), sulfatide, and 2 0 -3 0 -cyclic nucleotide 3 0 -phosphohydrolase (CNP) as detected by anti-GalC (01), anti-sulfatide (04), and anti-CNP antibodies, respectively.", [["Premyelin oligodendrocytes", "ANATOMY", 0, 26], ["galactocerebroside", "CHEMICAL", 35, 53], ["sulfatide", "CHEMICAL", 62, 71], ["2 0 -3 0 -cyclic nucleotide 3 0 -phosphohydrolase", "CHEMICAL", 77, 126], ["galactocerebroside", "CHEMICAL", 35, 53], ["sulfatide", "CHEMICAL", 62, 71], ["2 0 -3 0 -cyclic nucleotide 3 0 -phosphohydrolase", "CHEMICAL", 77, 126], ["anti-sulfatide", "CHEMICAL", 164, 178], ["Premyelin oligodendrocytes", "CELL", 0, 26], ["galactocerebroside", "GENE_OR_GENE_PRODUCT", 35, 53], ["GalC", "GENE_OR_GENE_PRODUCT", 55, 59], ["sulfatide", "SIMPLE_CHEMICAL", 62, 71], ["2 0 -3 0 -cyclic nucleotide 3 0 -phosphohydrolase", "SIMPLE_CHEMICAL", 77, 126], ["CNP", "GENE_OR_GENE_PRODUCT", 128, 131], ["anti-GalC (01)", "SIMPLE_CHEMICAL", 148, 162], ["anti-sulfatide (04)", "SIMPLE_CHEMICAL", 164, 183], ["anti-CNP antibodies", "SIMPLE_CHEMICAL", 189, 208], ["Premyelin oligodendrocytes", "CELL_TYPE", 0, 26], ["GalC", "PROTEIN", 55, 59], ["phosphohydrolase", "PROTEIN", 110, 126], ["CNP", "PROTEIN", 128, 131], ["anti-GalC", "PROTEIN", 148, 157], ["anti-CNP antibodies", "PROTEIN", 189, 208], ["galactocerebroside", "TEST", 35, 53], ["sulfatide", "TEST", 62, 71], ["cyclic nucleotide", "TREATMENT", 87, 104], ["phosphohydrolase (CNP)", "TREATMENT", 110, 132], ["anti-sulfatide", "TREATMENT", 164, 178], ["anti-CNP antibodies", "TREATMENT", 189, 208]]], ["Cells at this stage express complex branching with secondary and tertiary processes.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["secondary and tertiary processes", "PROBLEM", 51, 83], ["complex", "OBSERVATION_MODIFIER", 28, 35], ["branching", "OBSERVATION_MODIFIER", 36, 45], ["secondary", "OBSERVATION_MODIFIER", 51, 60], ["tertiary processes", "OBSERVATION", 65, 83]]], ["Mature myelin-producing oligodendrocytes can be identified by antibodies to myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG).", [["myelin", "ANATOMY", 7, 13], ["oligodendrocytes", "ANATOMY", 24, 40], ["myelin", "GENE_OR_GENE_PRODUCT", 7, 13], ["oligodendrocytes", "CELL", 24, 40], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 76, 96], ["MBP", "GENE_OR_GENE_PRODUCT", 98, 101], ["proteolipid protein", "GENE_OR_GENE_PRODUCT", 104, 123], ["PLP", "GENE_OR_GENE_PRODUCT", 125, 128], ["myelin oligodendrocyte glycoprotein", "GENE_OR_GENE_PRODUCT", 135, 170], ["MOG", "GENE_OR_GENE_PRODUCT", 172, 175], ["myelin-producing oligodendrocytes", "CELL_TYPE", 7, 40], ["antibodies", "PROTEIN", 62, 72], ["myelin basic protein", "PROTEIN", 76, 96], ["MBP", "PROTEIN", 98, 101], ["proteolipid protein", "PROTEIN", 104, 123], ["PLP", "PROTEIN", 125, 128], ["myelin oligodendrocyte glycoprotein", "PROTEIN", 135, 170], ["MOG", "PROTEIN", 172, 175], ["Mature myelin", "PROBLEM", 0, 13], ["oligodendrocytes", "PROBLEM", 24, 40], ["myelin basic protein", "TEST", 76, 96], ["MBP", "TEST", 98, 101], ["proteolipid protein", "TEST", 104, 123], ["PLP", "TEST", 125, 128], ["myelin", "OBSERVATION", 7, 13]]], ["Complex myelin sheaths are readily seen and the transcription factor Nkx2.2 can be detected at this stage.", [["myelin sheaths", "ANATOMY", 8, 22], ["myelin sheaths", "CELLULAR_COMPONENT", 8, 22], ["Nkx2.2", "GENE_OR_GENE_PRODUCT", 69, 75], ["transcription factor", "PROTEIN", 48, 68], ["Nkx2.2", "PROTEIN", 69, 75], ["Complex myelin sheaths", "TREATMENT", 0, 22], ["myelin sheaths", "OBSERVATION", 8, 22]]], ["Reverse transcriptase (RT)-PCR or microfluidics cards can be used to identify mRNA signatures for receptors, myelin genes, and transcriptions factors.", [["myelin", "GENE_OR_GENE_PRODUCT", 109, 115], ["myelin genes", "DNA", 109, 121], ["transcriptions factors", "PROTEIN", 127, 149], ["Reverse transcriptase (RT", "TREATMENT", 0, 25], ["PCR", "TEST", 27, 30], ["microfluidics cards", "TREATMENT", 34, 53], ["mRNA signatures", "TEST", 78, 93], ["receptors", "PROBLEM", 98, 107], ["myelin genes", "PROBLEM", 109, 121]]], ["Antibodies to astrocytes (anti-glial fibrillary acidic protein, GFAP) and microglia (CD11b, ED1 (rat), F4/80 (mouse)) are typically used in these cultures to detect potential contaminating cells types.Primary Cultures: HumanHuman fetal oligodendrocyte precursors are obtained from postmortem human fetal spinal cord or brain (18-23 weeks of gestation).", [["astrocytes", "ANATOMY", 14, 24], ["microglia", "ANATOMY", 74, 83], ["cells", "ANATOMY", 189, 194], ["fetal oligodendrocyte precursors", "ANATOMY", 230, 262], ["fetal spinal cord", "ANATOMY", 298, 315], ["brain", "ANATOMY", 319, 324], ["astrocytes", "CELL", 14, 24], ["anti-glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 26, 62], ["GFAP", "GENE_OR_GENE_PRODUCT", 64, 68], ["microglia", "CELL", 74, 83], ["CD11b", "GENE_OR_GENE_PRODUCT", 85, 90], ["ED1", "GENE_OR_GENE_PRODUCT", 92, 95], ["rat", "ORGANISM", 97, 100], ["F4/80", "GENE_OR_GENE_PRODUCT", 103, 108], ["mouse", "ORGANISM", 110, 115], ["cells", "CELL", 189, 194], ["HumanHuman fetal oligodendrocyte precursors", "CELL", 219, 262], ["human", "ORGANISM", 292, 297], ["fetal spinal cord", "ORGAN", 298, 315], ["brain", "ORGAN", 319, 324], ["astrocytes", "CELL_TYPE", 14, 24], ["anti-glial fibrillary acidic protein", "PROTEIN", 26, 62], ["GFAP", "PROTEIN", 64, 68], ["microglia", "CELL_TYPE", 74, 83], ["CD11b", "PROTEIN", 85, 90], ["ED1", "PROTEIN", 92, 95], ["rat", "PROTEIN", 97, 100], ["F4", "PROTEIN", 103, 105], ["contaminating cells types", "CELL_TYPE", 175, 200], ["HumanHuman fetal oligodendrocyte precursors", "CELL_TYPE", 219, 262], ["rat", "SPECIES", 97, 100], ["mouse", "SPECIES", 110, 115], ["human", "SPECIES", 292, 297], ["mouse", "SPECIES", 110, 115], ["human", "SPECIES", 292, 297], ["Antibodies", "TEST", 0, 10], ["astrocytes", "TEST", 14, 24], ["anti-glial fibrillary acidic protein", "TEST", 26, 62], ["GFAP", "TEST", 64, 68], ["microglia", "TEST", 74, 83], ["CD11b", "TEST", 85, 90], ["ED1", "TEST", 92, 95], ["rat", "TEST", 97, 100], ["F4", "TEST", 103, 105], ["these cultures", "TEST", 140, 154], ["potential contaminating cells types", "PROBLEM", 165, 200], ["Primary Cultures", "TEST", 201, 217], ["HumanHuman fetal oligodendrocyte precursors", "TEST", 219, 262], ["postmortem human fetal spinal cord", "TEST", 281, 315], ["astrocytes", "ANATOMY", 14, 24], ["microglia", "ANATOMY", 74, 83], ["contaminating cells", "OBSERVATION", 175, 194], ["fetal", "ANATOMY_MODIFIER", 298, 303], ["spinal cord", "ANATOMY", 304, 315], ["brain", "ANATOMY", 319, 324]]], ["Enrichment of up to 90% is achieved by separation on immunomagnetic microbeads coated with rat anti-mouse IgM that captures the progenitors that have been labeled with A2B5 antibody.", [["progenitors", "ANATOMY", 128, 139], ["rat", "ORGANISM", 91, 94], ["IgM", "GENE_OR_GENE_PRODUCT", 106, 109], ["progenitors", "CELL", 128, 139], ["A2B5 antibody", "GENE_OR_GENE_PRODUCT", 168, 181], ["rat anti-mouse IgM", "PROTEIN", 91, 109], ["A2B5 antibody", "PROTEIN", 168, 181], ["rat", "SPECIES", 91, 94], ["rat", "SPECIES", 91, 94], ["immunomagnetic microbeads", "TREATMENT", 53, 78], ["rat anti-mouse IgM", "TREATMENT", 91, 109], ["A2B5 antibody", "TEST", 168, 181], ["immunomagnetic microbeads", "OBSERVATION", 53, 78], ["anti-mouse IgM", "OBSERVATION", 95, 109]]], ["Separation by differential adherence properties followed by growth in oligodendrocyte-enhancing N1 or N2B3 medium for 5-10 days and plating on poly-L-lysine-coated plates can yield up to approximately 80% enrichment for A2B5 + cells (Miron et al, 2007 (Miron et al, , 2008 Wilson et al, 2003; Zhang et al, 2006) .", [["oligodendrocyte", "ANATOMY", 70, 85], ["A2B5 + cells", "ANATOMY", 220, 232], ["poly-L-lysine", "CHEMICAL", 143, 156], ["poly-L-lysine", "CHEMICAL", 143, 156], ["oligodendrocyte", "CELL", 70, 85], ["N1", "CELL", 96, 98], ["poly-L-lysine", "SIMPLE_CHEMICAL", 143, 156], ["A2B5 + cells", "CELL", 220, 232], ["A2B5", "PROTEIN", 220, 224], ["N2B3 medium", "TREATMENT", 102, 113], ["plating on poly-L-lysine-coated plates", "TREATMENT", 132, 170], ["A2B5 + cells", "TEST", 220, 232], ["Miron et al", "TEST", 234, 245]]], ["PDGFaR can also be used to validate enrichment.", [["PDGFaR", "GENE_OR_GENE_PRODUCT", 0, 6], ["PDGFaR", "PROTEIN", 0, 6]]], ["Human adult preoligodendrocytes can be procured from surgical resections or biopsies of subcortical white matter from temporal lobe obtained from medication-refractory epilepsy patients.", [["preoligodendrocytes", "ANATOMY", 12, 31], ["biopsies", "ANATOMY", 76, 84], ["subcortical white matter", "ANATOMY", 88, 112], ["temporal lobe", "ANATOMY", 118, 131], ["epilepsy", "DISEASE", 168, 176], ["Human", "ORGANISM", 0, 5], ["preoligodendrocytes", "CELL", 12, 31], ["subcortical white matter", "CANCER", 88, 112], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 118, 131], ["patients", "ORGANISM", 177, 185], ["Human", "SPECIES", 0, 5], ["patients", "SPECIES", 177, 185], ["Human", "SPECIES", 0, 5], ["Human adult preoligodendrocytes", "PROBLEM", 0, 31], ["surgical resections", "TREATMENT", 53, 72], ["biopsies of subcortical white matter", "PROBLEM", 76, 112], ["medication", "TREATMENT", 146, 156], ["refractory epilepsy patients", "PROBLEM", 157, 185], ["surgical resections", "OBSERVATION", 53, 72], ["subcortical", "ANATOMY_MODIFIER", 88, 99], ["white matter", "ANATOMY", 100, 112], ["temporal lobe", "ANATOMY", 118, 131], ["refractory", "OBSERVATION_MODIFIER", 157, 167], ["epilepsy", "OBSERVATION", 168, 176]]], ["Enrichment can be achieved by differential adherence (Armstrong et al, 1992) , magnetic activated cell sorting using A2B5 antibody as with fetal cells (Sim et al, 2006) , or by differential density separation using a 30% Percoll gradient (Miron et al, 2007) .", [["cell", "ANATOMY", 98, 102], ["fetal cells", "ANATOMY", 139, 150], ["cell", "CELL", 98, 102], ["A2B5 antibody", "GENE_OR_GENE_PRODUCT", 117, 130], ["fetal cells", "CELL", 139, 150], ["A2B5 antibody", "PROTEIN", 117, 130], ["fetal cells", "CELL_TYPE", 139, 150], ["magnetic activated cell sorting", "TEST", 79, 110], ["A2B5 antibody", "TEST", 117, 130], ["fetal cells", "TEST", 139, 150], ["a 30% Percoll gradient", "TREATMENT", 215, 237]]], ["As in rodent cultures, antibodies to b-tubulin (bTubIII), neurofilament (NF), and microtubule associated-protein 2 (MAP2) are used to demonstrate the lack of neuronal contamination.", [["cultures", "ANATOMY", 13, 21], ["microtubule", "ANATOMY", 82, 93], ["neuronal", "ANATOMY", 158, 166], ["b-tubulin", "GENE_OR_GENE_PRODUCT", 37, 46], ["bTubIII", "GENE_OR_GENE_PRODUCT", 48, 55], ["neurofilament", "GENE_OR_GENE_PRODUCT", 58, 71], ["NF", "GENE_OR_GENE_PRODUCT", 73, 75], ["microtubule associated-protein 2", "GENE_OR_GENE_PRODUCT", 82, 114], ["MAP2", "GENE_OR_GENE_PRODUCT", 116, 120], ["neuronal", "CELL", 158, 166], ["antibodies", "PROTEIN", 23, 33], ["b-tubulin", "PROTEIN", 37, 46], ["bTubIII", "PROTEIN", 48, 55], ["neurofilament", "PROTEIN", 58, 71], ["NF", "PROTEIN", 73, 75], ["microtubule associated-protein 2", "PROTEIN", 82, 114], ["MAP2", "PROTEIN", 116, 120], ["rodent", "SPECIES", 6, 12], ["rodent cultures", "TEST", 6, 21], ["antibodies", "TEST", 23, 33], ["b-tubulin", "TEST", 37, 46], ["neurofilament (NF)", "TEST", 58, 76], ["microtubule associated-protein", "TEST", 82, 112], ["neuronal contamination", "PROBLEM", 158, 180], ["neuronal contamination", "OBSERVATION", 158, 180]]], ["Although these cultures are highly enriched, A2B5 is a marker of neural stem cells and not a guarantee that all the cells in the culture will be driven down the oligodendrocyte lineage.", [["cultures", "ANATOMY", 15, 23], ["neural stem cells", "ANATOMY", 65, 82], ["cells", "ANATOMY", 116, 121], ["oligodendrocyte lineage", "ANATOMY", 161, 184], ["cultures", "CELL", 15, 23], ["A2B5", "GENE_OR_GENE_PRODUCT", 45, 49], ["neural stem cells", "CELL", 65, 82], ["cells", "CELL", 116, 121], ["oligodendrocyte lineage", "CELL", 161, 184], ["A2B5", "PROTEIN", 45, 49], ["neural stem cells", "CELL_TYPE", 65, 82], ["oligodendrocyte lineage", "CELL_TYPE", 161, 184], ["these cultures", "TEST", 9, 23], ["A2B5", "TEST", 45, 49], ["neural stem cells", "PROBLEM", 65, 82], ["the culture", "TEST", 125, 136], ["neural stem cells", "OBSERVATION", 65, 82]]], ["In addition, the numbers of cells generated from adult tissues is usually under a million cells from any given tissue preparation, greatly limiting their use in transcript profiling or assessing compounds in vitro (Sim et al, 2006) .", [["cells", "ANATOMY", 28, 33], ["adult tissues", "ANATOMY", 49, 62], ["cells", "ANATOMY", 90, 95], ["tissue", "ANATOMY", 111, 117], ["cells", "CELL", 28, 33], ["adult tissues", "TISSUE", 49, 62], ["cells", "CELL", 90, 95], ["tissue", "TISSUE", 111, 117], ["adult tissues", "PROBLEM", 49, 62], ["a million cells", "TREATMENT", 80, 95], ["tissue preparation", "TREATMENT", 111, 129], ["transcript profiling", "TREATMENT", 161, 181]]], ["Assays used to demonstrate differentiation of these cells usually quantitate expression of markers at earlier stages (04) or resort to image-based analysis of increased process arborization.CONCLUSIONSPrimary cultures of rodent oligodendrocyte progenitors harvested from neonatal animals are the most widely used in vitro for modeling demyelination and remyelination.", [["cells", "ANATOMY", 52, 57], ["oligodendrocyte progenitors", "ANATOMY", 228, 255], ["demyelination", "DISEASE", 335, 348], ["cells", "CELL", 52, 57], ["rodent", "ORGANISM", 221, 227], ["oligodendrocyte progenitors", "CELL", 228, 255], ["rodent oligodendrocyte progenitors", "CELL_TYPE", 221, 255], ["rodent", "SPECIES", 221, 227], ["Assays", "TEST", 0, 6], ["these cells", "PROBLEM", 46, 57], ["image", "TEST", 135, 140], ["increased process arborization", "PROBLEM", 159, 189], ["CONCLUSIONSPrimary cultures", "TEST", 190, 217], ["rodent oligodendrocyte progenitors", "PROBLEM", 221, 255], ["modeling demyelination", "PROBLEM", 326, 348], ["remyelination", "PROBLEM", 353, 366], ["increased", "OBSERVATION_MODIFIER", 159, 168], ["process", "OBSERVATION", 169, 176], ["arborization", "OBSERVATION_MODIFIER", 177, 189], ["rodent oligodendrocyte progenitors harvested", "OBSERVATION", 221, 265], ["most widely", "OBSERVATION_MODIFIER", 296, 307], ["demyelination", "OBSERVATION", 335, 348]]], ["This is because such cultures generate easily purified cells in large enough numbers for medium throughput primary and secondary screens.", [["cells", "ANATOMY", 55, 60], ["cells", "CELL", 55, 60], ["such cultures", "TEST", 16, 29], ["easily purified cells", "PROBLEM", 39, 60], ["secondary screens", "TEST", 119, 136], ["large", "OBSERVATION_MODIFIER", 64, 69]]], ["Such primary screens might constitute up to tens of thousands of compounds whereas secondary screens could involve hundreds of compounds.", [["Such primary screens", "TEST", 0, 20], ["thousands of compounds", "PROBLEM", 52, 74], ["secondary screens", "PROBLEM", 83, 100]]], ["Rodent oligodendrocytes prepared from 1-to 2-day-old neonates generate cell targets that are identical and reproducible from experiment to experiment.", [["oligodendrocytes", "ANATOMY", 7, 23], ["cell", "ANATOMY", 71, 75], ["Rodent", "ORGANISM", 0, 6], ["oligodendrocytes", "CELL", 7, 23], ["neonates", "ORGANISM", 53, 61], ["cell", "CELL", 71, 75], ["Rodent oligodendrocytes", "CELL_TYPE", 0, 23], ["Rodent", "SPECIES", 0, 6], ["Rodent oligodendrocytes", "PROBLEM", 0, 23], ["oligodendrocytes", "OBSERVATION", 7, 23], ["cell targets", "OBSERVATION", 71, 83]]], ["There are adequate similarities between rodent and human cells in the differentiation and myelination processes for rodent cells to be of value in searching for drugs for the treatment of human disease.CONCLUSIONSTissues from which adult human oligodendrocytes or fetal human progenitors can be derived may be more difficult to obtain on a regular and consistent basis.", [["cells", "ANATOMY", 57, 62], ["cells", "ANATOMY", 123, 128], ["oligodendrocytes", "ANATOMY", 244, 260], ["fetal", "ANATOMY", 264, 269], ["progenitors", "ANATOMY", 276, 287], ["human", "ORGANISM", 51, 56], ["cells", "CELL", 57, 62], ["cells", "CELL", 123, 128], ["human", "ORGANISM", 188, 193], ["human", "ORGANISM", 238, 243], ["oligodendrocytes", "CELL", 244, 260], ["human", "ORGANISM", 270, 275], ["progenitors", "CELL", 276, 287], ["rodent and human cells", "CELL_TYPE", 40, 62], ["rodent cells", "CELL_TYPE", 116, 128], ["adult human oligodendrocytes", "CELL_TYPE", 232, 260], ["fetal human progenitors", "CELL_TYPE", 264, 287], ["rodent", "SPECIES", 40, 46], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 270, 275], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 270, 275], ["rodent cells", "PROBLEM", 116, 128], ["drugs", "TREATMENT", 161, 166], ["human disease.CONCLUSIONSTissues", "PROBLEM", 188, 220], ["fetal human progenitors", "PROBLEM", 264, 287], ["adequate", "OBSERVATION_MODIFIER", 10, 18], ["human cells", "OBSERVATION", 51, 62]]], ["Human cells are more difficult than rodent cells to acquire in large and enriched enough numbers for primary screens.", [["cells", "ANATOMY", 6, 11], ["cells", "ANATOMY", 43, 48], ["Human", "ORGANISM", 0, 5], ["cells", "CELL", 6, 11], ["cells", "CELL", 43, 48], ["Human cells", "CELL_TYPE", 0, 11], ["rodent cells", "CELL_TYPE", 36, 48], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human cells", "PROBLEM", 0, 11], ["primary screens", "TEST", 101, 116]]], ["The acquisition of cells from adult epilepsy tissues derived from different regions of brain with varying degrees of pathology, generate cell populations of variable purity.", [["cells", "ANATOMY", 19, 24], ["tissues", "ANATOMY", 45, 52], ["brain", "ANATOMY", 87, 92], ["cell", "ANATOMY", 137, 141], ["epilepsy", "DISEASE", 36, 44], ["cells", "CELL", 19, 24], ["epilepsy tissues", "TISSUE", 36, 52], ["brain", "ORGAN", 87, 92], ["cell populations", "CELL", 137, 153], ["adult epilepsy tissues", "PROBLEM", 30, 52], ["pathology", "PROBLEM", 117, 126], ["brain", "ANATOMY", 87, 92], ["varying degrees", "OBSERVATION_MODIFIER", 98, 113], ["pathology", "OBSERVATION", 117, 126], ["cell populations", "OBSERVATION", 137, 153], ["variable", "OBSERVATION_MODIFIER", 157, 165], ["purity", "OBSERVATION_MODIFIER", 166, 172]]], ["Fetal tissues may be of varying gestational stages.", [["Fetal tissues", "ANATOMY", 0, 13], ["Fetal tissues", "TISSUE", 0, 13], ["Fetal tissues", "PROBLEM", 0, 13], ["varying gestational stages", "PROBLEM", 24, 50], ["tissues", "ANATOMY", 6, 13], ["may be of", "UNCERTAINTY", 14, 23], ["varying", "OBSERVATION_MODIFIER", 24, 31]]], ["In contrast to rodent oligodendrocyte precursors, human oligodendrocyte precursors are not easily driven in vitro to express MBP, often having to be kept in culture for several weeks.", [["oligodendrocyte precursors", "ANATOMY", 22, 48], ["oligodendrocyte precursors", "ANATOMY", 56, 82], ["oligodendrocyte", "CELL", 22, 37], ["human", "ORGANISM", 50, 55], ["oligodendrocyte precursors", "CELL", 56, 82], ["MBP", "GENE_OR_GENE_PRODUCT", 125, 128], ["rodent oligodendrocyte precursors", "CELL_TYPE", 15, 48], ["human oligodendrocyte precursors", "CELL_TYPE", 50, 82], ["MBP", "PROTEIN", 125, 128], ["rodent", "SPECIES", 15, 21], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 50, 55], ["rodent oligodendrocyte precursors", "PROBLEM", 15, 48], ["human oligodendrocyte precursors", "PROBLEM", 50, 82], ["MBP", "TEST", 125, 128], ["culture", "TEST", 157, 164], ["oligodendrocyte precursors", "OBSERVATION", 22, 48]]], ["Nevertheless, when the number of compounds to assess is below a hundred, human cells can be generated in adequate numbers for orthologue validation assays of compounds originally selected from primary rodent library screens.Cell LinesThe spontaneous generation of a permanent cell line resembling an oligodendrocyte-type 2 astrocyte (O-2A) precursor from cultures of neonatal rat cerebral cortex gave rise to the bipotential cell line, CG4.", [["cells", "ANATOMY", 79, 84], ["Cell", "ANATOMY", 224, 228], ["cell line", "ANATOMY", 276, 285], ["oligodendrocyte-type 2 astrocyte", "ANATOMY", 300, 332], ["O-2A) precursor", "ANATOMY", 334, 349], ["cerebral cortex", "ANATOMY", 380, 395], ["bipotential cell line", "ANATOMY", 413, 434], ["CG4", "ANATOMY", 436, 439], ["human", "ORGANISM", 73, 78], ["cells", "CELL", 79, 84], ["Cell", "CELL", 224, 228], ["cell line", "CELL", 276, 285], ["oligodendrocyte", "CELL", 300, 315], ["type 2 astrocyte", "CELL", 316, 332], ["O-2A", "GENE_OR_GENE_PRODUCT", 334, 338], ["rat", "ORGANISM", 376, 379], ["cerebral cortex", "MULTI-TISSUE_STRUCTURE", 380, 395], ["bipotential cell line", "CELL", 413, 434], ["CG4", "CELL", 436, 439], ["human cells", "CELL_TYPE", 73, 84], ["permanent cell line", "CELL_LINE", 266, 285], ["oligodendrocyte-type 2 astrocyte (O-2A) precursor", "CELL_LINE", 300, 349], ["bipotential cell line", "CELL_LINE", 413, 434], ["CG4", "CELL_LINE", 436, 439], ["human", "SPECIES", 73, 78], ["rat", "SPECIES", 376, 379], ["human", "SPECIES", 73, 78], ["rat", "SPECIES", 376, 379], ["a hundred, human cells", "PROBLEM", 62, 84], ["orthologue validation assays", "TEST", 126, 154], ["Cell Lines", "TREATMENT", 224, 234], ["a permanent cell line", "TREATMENT", 264, 285], ["an oligodendrocyte", "TEST", 297, 315], ["cultures of neonatal rat cerebral cortex", "TEST", 355, 395], ["Cell Lines", "OBSERVATION", 224, 234], ["permanent cell line", "OBSERVATION", 266, 285], ["cerebral cortex", "ANATOMY", 380, 395], ["bipotential cell line", "OBSERVATION", 413, 434]]], ["When grown in PDGF and basic fibroblast growth factor (bFGF), CG4 cells proliferate.", [["CG4 cells", "ANATOMY", 62, 71], ["PDGF", "GENE_OR_GENE_PRODUCT", 14, 18], ["basic fibroblast growth factor", "GENE_OR_GENE_PRODUCT", 23, 53], ["bFGF", "GENE_OR_GENE_PRODUCT", 55, 59], ["CG4 cells", "CELL", 62, 71], ["PDGF", "PROTEIN", 14, 18], ["basic fibroblast growth factor", "PROTEIN", 23, 53], ["bFGF", "PROTEIN", 55, 59], ["CG4 cells", "CELL_LINE", 62, 71], ["basic fibroblast growth factor", "TEST", 23, 53], ["bFGF", "TEST", 55, 59], ["CG4 cells proliferate", "PROBLEM", 62, 83]]], ["Removal of growth factors leads to differentiation of these cells within 48 h into oligodendrocytes that eventually stain positively for MBP.", [["cells", "ANATOMY", 60, 65], ["oligodendrocytes", "ANATOMY", 83, 99], ["cells", "CELL", 60, 65], ["oligodendrocytes", "CELL", 83, 99], ["MBP", "GENE_OR_GENE_PRODUCT", 137, 140], ["growth factors", "PROTEIN", 11, 25], ["oligodendrocytes", "CELL_TYPE", 83, 99], ["MBP", "PROTEIN", 137, 140], ["Removal of growth factors", "TREATMENT", 0, 25], ["these cells", "PROBLEM", 54, 65], ["MBP", "TEST", 137, 140], ["growth factors", "OBSERVATION", 11, 25]]], ["Transfer of the line into 10% fetal calf serum (FCS) causes the line to differentiate into astrocytes (Louis et al, 1992) .", [["fetal calf serum", "ANATOMY", 30, 46], ["astrocytes", "ANATOMY", 91, 101], ["fetal calf", "ORGANISM_SUBSTANCE", 30, 40], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["FCS", "ORGANISM_SUBSTANCE", 48, 51], ["astrocytes", "CELL", 91, 101], ["astrocytes", "CELL_TYPE", 91, 101], ["calf", "SPECIES", 36, 40], ["the line", "TREATMENT", 12, 20], ["fetal calf serum", "TEST", 30, 46], ["the line", "PROBLEM", 60, 68], ["calf", "ANATOMY", 36, 40]]], ["The spontaneous differentiation of this line needs to be kept at a basal level to provide a window for agents to drive differentiation.", [["this line", "TREATMENT", 35, 44], ["a window for agents", "TREATMENT", 90, 109], ["spontaneous", "OBSERVATION_MODIFIER", 4, 15], ["differentiation", "OBSERVATION_MODIFIER", 16, 31]]], ["CG4 cells are also useful for assessing agents that induce and interfere with excitotoxicity and cell death (Casaccia-Bonnefil et al, 1996; Brogi et al, 1997; Yoshioka et al, 1998) .Cell LinesImmortalized oligodendrocyte cell lines from mice have also been created and used for assessment of agents driving differentiation and protecting against cell death.", [["CG4 cells", "ANATOMY", 0, 9], ["cell", "ANATOMY", 97, 101], ["Cell", "ANATOMY", 182, 186], ["oligodendrocyte cell lines", "ANATOMY", 205, 231], ["cell", "ANATOMY", 346, 350], ["excitotoxicity", "DISEASE", 78, 92], ["death", "DISEASE", 102, 107], ["death", "DISEASE", 351, 356], ["CG4 cells", "CELL", 0, 9], ["cell", "CELL", 97, 101], ["Cell", "CELL", 182, 186], ["oligodendrocyte cell lines", "CELL", 205, 231], ["mice", "ORGANISM", 237, 241], ["cell", "CELL", 346, 350], ["CG4 cells", "CELL_LINE", 0, 9], ["Cell LinesImmortalized oligodendrocyte cell lines", "CELL_LINE", 182, 231], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 237, 241], ["CG4 cells", "PROBLEM", 0, 9], ["excitotoxicity", "PROBLEM", 78, 92], ["cell death", "PROBLEM", 97, 107], ["Cell LinesImmortalized oligodendrocyte cell lines", "TREATMENT", 182, 231], ["assessment", "TEST", 278, 288], ["agents", "TREATMENT", 292, 298], ["cell death", "PROBLEM", 346, 356], ["oligodendrocyte cell lines", "OBSERVATION", 205, 231]]], ["Jensen et al (1993) produced the 6E12 line derived from the spinal cord of an MBP-SV40 large T-antigen transgenic mouse.", [["6E12 line", "ANATOMY", 33, 42], ["spinal cord", "ANATOMY", 60, 71], ["6E12 line", "CELL", 33, 42], ["spinal cord", "ORGAN", 60, 71], ["MBP", "GENE_OR_GENE_PRODUCT", 78, 81], ["SV40", "ORGANISM", 82, 86], ["large T-antigen", "GENE_OR_GENE_PRODUCT", 87, 102], ["mouse", "ORGANISM", 114, 119], ["6E12 line", "CELL_LINE", 33, 42], ["MBP", "PROTEIN", 78, 81], ["mouse", "SPECIES", 114, 119], ["mouse", "SPECIES", 114, 119], ["the 6E12 line", "TREATMENT", 29, 42], ["an MBP", "TEST", 75, 81], ["spinal cord", "ANATOMY", 60, 71]]], ["Before their activation these cells stained minimally for 04 or GalC.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["GalC", "GENE_OR_GENE_PRODUCT", 64, 68], ["GalC", "PROTEIN", 64, 68]]], ["After stimulation with forskolin or dibutyryl cyclic AMP (dbcAMP), these oligodendrocyte markers increased, as did PLP mRNA.", [["oligodendrocyte", "ANATOMY", 73, 88], ["forskolin", "CHEMICAL", 23, 32], ["dibutyryl", "CHEMICAL", 36, 45], ["AMP", "CHEMICAL", 53, 56], ["dbcAMP", "CHEMICAL", 58, 64], ["forskolin", "CHEMICAL", 23, 32], ["dibutyryl cyclic AMP", "CHEMICAL", 36, 56], ["dbcAMP", "CHEMICAL", 58, 64], ["PLP", "CHEMICAL", 115, 118], ["forskolin", "SIMPLE_CHEMICAL", 23, 32], ["dibutyryl cyclic AMP", "SIMPLE_CHEMICAL", 36, 56], ["dbcAMP", "SIMPLE_CHEMICAL", 58, 64], ["oligodendrocyte", "CELL", 73, 88], ["PLP", "GENE_OR_GENE_PRODUCT", 115, 118], ["oligodendrocyte markers", "PROTEIN", 73, 96], ["PLP mRNA", "RNA", 115, 123], ["forskolin or dibutyryl cyclic AMP (dbcAMP", "TREATMENT", 23, 64], ["these oligodendrocyte markers", "TEST", 67, 96]]], ["However, unlike normal oligodendrocyte precursors, 6E12 cells did not demonstrate an increase in MBP mRNA or protein, most likely due to the increase of the MBP repressor tSCIP/Tst-1.", [["oligodendrocyte precursors", "ANATOMY", 23, 49], ["6E12 cells", "ANATOMY", 51, 61], ["oligodendrocyte", "CELL", 23, 38], ["6E12 cells", "CELL", 51, 61], ["MBP", "GENE_OR_GENE_PRODUCT", 97, 100], ["MBP", "GENE_OR_GENE_PRODUCT", 157, 160], ["tSCIP", "GENE_OR_GENE_PRODUCT", 171, 176], ["Tst-1", "GENE_OR_GENE_PRODUCT", 177, 182], ["normal oligodendrocyte precursors", "CELL_TYPE", 16, 49], ["6E12 cells", "CELL_LINE", 51, 61], ["MBP mRNA", "RNA", 97, 105], ["MBP repressor", "PROTEIN", 157, 170], ["tSCIP", "PROTEIN", 171, 176], ["Tst-1", "PROTEIN", 177, 182], ["an increase in MBP mRNA", "PROBLEM", 82, 105], ["the MBP repressor", "TREATMENT", 153, 170], ["normal oligodendrocyte precursors", "OBSERVATION", 16, 49], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["MBP mRNA", "OBSERVATION", 97, 105], ["most likely due to", "UNCERTAINTY", 118, 136]]], ["Immortalized murine oligodendrocyte cell lines representing different stages of differentiation in the lineage were created in the laboratory of Anthony Campagnoni.", [["oligodendrocyte cell lines", "ANATOMY", 20, 46], ["murine", "ORGANISM", 13, 19], ["oligodendrocyte cell lines", "CELL", 20, 46], ["Immortalized murine oligodendrocyte cell lines", "CELL_LINE", 0, 46], ["murine", "SPECIES", 13, 19], ["Immortalized murine oligodendrocyte cell lines", "TREATMENT", 0, 46], ["murine oligodendrocyte cell lines", "OBSERVATION", 13, 46], ["different", "OBSERVATION_MODIFIER", 60, 69], ["stages", "OBSERVATION_MODIFIER", 70, 76], ["differentiation", "OBSERVATION_MODIFIER", 80, 95], ["lineage", "OBSERVATION_MODIFIER", 103, 110]]], ["These N cells were created from mouse cerebral primary cultures using the retroviral vector pZIPSVtsA58 (containing a temperature Tag gene) Foster et al, 1993) .", [["N cells", "ANATOMY", 6, 13], ["cerebral primary cultures", "ANATOMY", 38, 63], ["N cells", "CELL", 6, 13], ["mouse", "ORGANISM", 32, 37], ["retroviral", "ORGANISM", 74, 84], ["Tag", "GENE_OR_GENE_PRODUCT", 130, 133], ["N cells", "CELL_TYPE", 6, 13], ["mouse cerebral primary cultures", "CELL_LINE", 32, 63], ["pZIPSVtsA58", "DNA", 92, 103], ["temperature Tag gene", "DNA", 118, 138], ["mouse", "SPECIES", 32, 37], ["mouse", "SPECIES", 32, 37], ["These N cells", "PROBLEM", 0, 13], ["the retroviral vector pZIPSVts", "TREATMENT", 70, 100], ["a temperature Tag gene", "TREATMENT", 116, 138]]], ["Among the cell lines, the N1 cell line represented the least mature line and was shown to be the most sensitive to nitric oxide (NO)-induced mitochondrial damage and death.", [["cell lines", "ANATOMY", 10, 20], ["N1 cell line", "ANATOMY", 26, 38], ["mitochondrial", "ANATOMY", 141, 154], ["nitric oxide", "CHEMICAL", 115, 127], ["NO", "CHEMICAL", 129, 131], ["mitochondrial damage", "DISEASE", 141, 161], ["death", "DISEASE", 166, 171], ["nitric oxide", "CHEMICAL", 115, 127], ["NO", "CHEMICAL", 129, 131], ["cell lines", "CELL", 10, 20], ["N1 cell line", "CELL", 26, 38], ["nitric oxide", "SIMPLE_CHEMICAL", 115, 127], ["NO", "SIMPLE_CHEMICAL", 129, 131], ["mitochondrial", "CELLULAR_COMPONENT", 141, 154], ["cell lines", "CELL_LINE", 10, 20], ["N1 cell line", "CELL_LINE", 26, 38], ["the cell lines", "TREATMENT", 6, 20], ["the N1 cell line", "TREATMENT", 22, 38], ["nitric oxide", "TREATMENT", 115, 127], ["mitochondrial damage", "PROBLEM", 141, 161], ["death", "PROBLEM", 166, 171], ["cell lines", "OBSERVATION", 10, 20], ["N1 cell line", "OBSERVATION", 26, 38], ["least", "OBSERVATION_MODIFIER", 55, 60], ["mature line", "OBSERVATION", 61, 72], ["mitochondrial damage", "OBSERVATION", 141, 161]]], ["The N20.1 line, positive for sulfatide, GalC, CNP, and MBP mRNA, represented the most mature line and was least sensitive to cell death by NO (MacKenzie-Graham et al, 1994) .", [["N20.1 line", "ANATOMY", 4, 14], ["cell", "ANATOMY", 125, 129], ["death", "DISEASE", 130, 135], ["NO", "CHEMICAL", 139, 141], ["sulfatide", "CHEMICAL", 29, 38], ["NO", "CHEMICAL", 139, 141], ["N20.1 line", "CELL", 4, 14], ["sulfatide", "GENE_OR_GENE_PRODUCT", 29, 38], ["GalC", "GENE_OR_GENE_PRODUCT", 40, 44], ["CNP", "GENE_OR_GENE_PRODUCT", 46, 49], ["MBP", "GENE_OR_GENE_PRODUCT", 55, 58], ["cell", "CELL", 125, 129], ["NO", "SIMPLE_CHEMICAL", 139, 141], ["N20.1 line", "CELL_LINE", 4, 14], ["sulfatide, GalC, CNP, and MBP mRNA", "RNA", 29, 63], ["sulfatide", "TREATMENT", 29, 38], ["CNP", "TEST", 46, 49], ["MBP mRNA", "TEST", 55, 63], ["cell death", "PROBLEM", 125, 135], ["mature line", "OBSERVATION", 86, 97]]], ["These cell lines faithfully replicated the effects of free radicals seen using normal primary rodent oligodendrocytes and their progenitors (Merrill and Scolding, 1999; Casaccia-Bonnefil, 2000) .Cell LinesHuman oligodendroglioma cell lines HOG and TC620 (Merrill and Matsushima, 1988; Kashima et al, 1993) have also been evaluated for their potential use as substitutes for the more difficult to obtain human oligodendrocyte precursors.", [["cell lines", "ANATOMY", 6, 16], ["oligodendrocytes", "ANATOMY", 101, 117], ["progenitors", "ANATOMY", 128, 139], ["Cell LinesHuman oligodendroglioma cell lines", "ANATOMY", 195, 239], ["TC620", "ANATOMY", 248, 253], ["oligodendrocyte precursors", "ANATOMY", 409, 435], ["oligodendroglioma", "DISEASE", 211, 228], ["cell lines", "CELL", 6, 16], ["oligodendrocytes", "CELL", 101, 117], ["progenitors", "CELL", 128, 139], ["Cell", "CELL", 195, 199], ["oligodendroglioma cell lines HOG", "CELL", 211, 243], ["TC620", "CELL", 248, 253], ["human", "ORGANISM", 403, 408], ["oligodendrocyte", "CELL", 409, 424], ["cell lines", "CELL_LINE", 6, 16], ["normal primary rodent oligodendrocytes", "CELL_TYPE", 79, 117], ["LinesHuman oligodendroglioma cell lines", "CELL_LINE", 200, 239], ["TC620", "CELL_LINE", 248, 253], ["human oligodendrocyte precursors", "CELL_TYPE", 403, 435], ["rodent", "SPECIES", 94, 100], ["human", "SPECIES", 403, 408], ["human", "SPECIES", 403, 408], ["free radicals", "PROBLEM", 54, 67], ["Casaccia", "TEST", 169, 177], ["cell lines", "OBSERVATION", 6, 16], ["free radicals", "OBSERVATION", 54, 67], ["primary rodent oligodendrocytes", "OBSERVATION", 86, 117], ["oligodendroglioma cell lines", "OBSERVATION", 211, 239]]], ["Such tumors are rare and generally of mixed cell types.", [["tumors", "ANATOMY", 5, 11], ["cell", "ANATOMY", 44, 48], ["tumors", "DISEASE", 5, 11], ["tumors", "CANCER", 5, 11], ["cell", "CELL", 44, 48], ["Such tumors", "PROBLEM", 0, 11], ["tumors", "OBSERVATION", 5, 11], ["mixed cell types", "OBSERVATION", 38, 54]]], ["These two lines were confirmed to be oligodendrogliomas with an immature oligodendrocyte phenotype by molecular profiling.", [["oligodendrogliomas", "ANATOMY", 37, 55], ["oligodendrocyte", "ANATOMY", 73, 88], ["oligodendrogliomas", "DISEASE", 37, 55], ["oligodendrogliomas", "CANCER", 37, 55], ["oligodendrocyte", "CELL", 73, 88], ["These two lines", "TREATMENT", 0, 15], ["oligodendrogliomas", "PROBLEM", 37, 55], ["an immature oligodendrocyte phenotype", "PROBLEM", 61, 98], ["confirmed to be", "UNCERTAINTY", 21, 36], ["oligodendrogliomas", "OBSERVATION", 37, 55], ["immature oligodendrocyte phenotype", "OBSERVATION", 64, 98]]], ["TC620 cells expressed CNP mRNA and protein and MBP-related mRNA (Kashima et al, 1993) .", [["TC620 cells", "ANATOMY", 0, 11], ["TC620 cells", "CELL", 0, 11], ["CNP", "GENE_OR_GENE_PRODUCT", 22, 25], ["MBP", "GENE_OR_GENE_PRODUCT", 47, 50], ["TC620 cells", "CELL_LINE", 0, 11], ["CNP mRNA", "RNA", 22, 30], ["MBP", "PROTEIN", 47, 50], ["mRNA", "RNA", 59, 63], ["CNP mRNA", "TEST", 22, 30], ["protein", "TEST", 35, 42], ["MBP", "TEST", 47, 50]]], ["TC620 cells behave like primary oligodendrocytes in some assays such as proliferation in response to interleukin 2 (IL2; Benveniste and Merrill, 1986; Otero and Merrill, 1997) .", [["TC620 cells", "ANATOMY", 0, 11], ["primary oligodendrocytes", "ANATOMY", 24, 48], ["TC620 cells", "CELL", 0, 11], ["oligodendrocytes", "CELL", 32, 48], ["interleukin 2", "GENE_OR_GENE_PRODUCT", 101, 114], ["IL2", "GENE_OR_GENE_PRODUCT", 116, 119], ["TC620 cells", "CELL_LINE", 0, 11], ["primary oligodendrocytes", "CELL_TYPE", 24, 48], ["interleukin 2", "PROTEIN", 101, 114], ["IL2", "PROTEIN", 116, 119], ["TC620 cells", "PROBLEM", 0, 11], ["primary oligodendrocytes", "PROBLEM", 24, 48], ["interleukin 2 (IL2", "TREATMENT", 101, 119], ["primary oligodendrocytes", "OBSERVATION", 24, 48], ["proliferation", "OBSERVATION_MODIFIER", 72, 85]]], ["Although these transformed lines may be of some use as human oligodendrocyte precursor surrogates, it is clear that there is a limit to their reliability as indicators of normal cell function, especially differentiation.Cell LinesConclusions.", [["lines", "ANATOMY", 27, 32], ["oligodendrocyte precursor", "ANATOMY", 61, 86], ["cell", "ANATOMY", 178, 182], ["Cell", "ANATOMY", 220, 224], ["lines", "CELL", 27, 32], ["human", "ORGANISM", 55, 60], ["oligodendrocyte", "CELL", 61, 76], ["cell", "CELL", 178, 182], ["Cell", "CELL", 220, 224], ["transformed lines", "CELL_LINE", 15, 32], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["transformed lines", "OBSERVATION", 15, 32], ["normal cell function", "OBSERVATION", 171, 191]]], ["Drug discovery has been greatly aided by the use of cell lines derived from spontaneously transformed cells, genetically immortalized lines, and tumor lines.", [["cell lines", "ANATOMY", 52, 62], ["cells", "ANATOMY", 102, 107], ["lines", "ANATOMY", 134, 139], ["tumor lines", "ANATOMY", 145, 156], ["tumor", "DISEASE", 145, 150], ["cell lines", "CELL", 52, 62], ["cells", "CELL", 102, 107], ["lines", "CELL", 134, 139], ["tumor lines", "CELL", 145, 156], ["cell lines", "CELL_LINE", 52, 62], ["spontaneously transformed cells", "CELL_LINE", 76, 107], ["genetically immortalized lines", "CELL_LINE", 109, 139], ["tumor lines", "CELL_LINE", 145, 156], ["cell lines", "TREATMENT", 52, 62], ["genetically immortalized lines", "TREATMENT", 109, 139], ["tumor lines", "TREATMENT", 145, 156], ["immortalized lines", "OBSERVATION", 121, 139], ["tumor lines", "OBSERVATION", 145, 156]]], ["The cost-and time-effectiveness of their production and use, clonality, unlimited supply, uniform responsiveness, and similarity in function (when it exists) to normal cells have made them practical substitutes in primary screens entailing, five hundred thousand to one million compounds.Mixed and Organotypic CulturesMixed glial neuronal cultures that produce myelinated axons can be established from embryonic day 15 (E15) or E16 mouse or rat fetal telencephalons.", [["cells", "ANATOMY", 168, 173], ["glial neuronal cultures", "ANATOMY", 324, 347], ["myelinated axons", "ANATOMY", 361, 377], ["embryonic day 15", "ANATOMY", 402, 418], ["E15", "ANATOMY", 420, 423], ["fetal telencephalons", "ANATOMY", 445, 465], ["cells", "CELL", 168, 173], ["glial neuronal cultures", "CELL", 324, 347], ["myelinated axons", "MULTI-TISSUE_STRUCTURE", 361, 377], ["E16 mouse", "ORGANISM", 428, 437], ["rat", "ORGANISM", 441, 444], ["fetal telencephalons", "MULTI-TISSUE_STRUCTURE", 445, 465], ["normal cells", "CELL_TYPE", 161, 173], ["Mixed glial neuronal cultures", "CELL_LINE", 318, 347], ["mouse", "SPECIES", 432, 437], ["rat", "SPECIES", 441, 444], ["mouse", "SPECIES", 432, 437], ["rat", "SPECIES", 441, 444], ["Organotypic Cultures", "TEST", 298, 318], ["Mixed glial neuronal cultures", "PROBLEM", 318, 347], ["myelinated axons", "PROBLEM", 361, 377], ["E16 mouse or rat fetal telencephalons", "PROBLEM", 428, 465]]], ["After mechanical dissociation, sieving and placement in chemically defined medium, cells are either allowed to attach and grow as mixed stationary cultures (Lubetzki et al, 1993; Demerens et al, 1996) or are kept under constant rotation such that within 2 days, they form aggregates of glia and neurons (Tosic et al, 1992; Copelman et al, 2000) .", [["cells", "ANATOMY", 83, 88], ["glia", "ANATOMY", 286, 290], ["neurons", "ANATOMY", 295, 302], ["cells", "CELL", 83, 88], ["glia", "CELL", 286, 290], ["neurons", "CELL", 295, 302], ["glia", "CELL_TYPE", 286, 290], ["mechanical dissociation", "PROBLEM", 6, 29], ["sieving and placement in chemically defined medium, cells", "TREATMENT", 31, 88], ["mixed stationary cultures", "TEST", 130, 155], ["dissociation", "OBSERVATION", 17, 29], ["glia", "ANATOMY", 286, 290]]], ["In Bottenstein-Sato medium supplemented with PDGF AA , embryonic murine-mixed stationary cultures give rise to myelinated axons within 2 weeks.", [["embryonic", "ANATOMY", 55, 64], ["cultures", "ANATOMY", 89, 97], ["myelinated axons", "ANATOMY", 111, 127], ["AA", "CHEMICAL", 50, 52], ["PDGF AA", "GENE_OR_GENE_PRODUCT", 45, 52], ["murine", "ORGANISM", 65, 71], ["cultures", "CELL", 89, 97], ["myelinated axons", "MULTI-TISSUE_STRUCTURE", 111, 127], ["PDGF AA", "PROTEIN", 45, 52], ["embryonic murine-mixed stationary cultures", "CELL_LINE", 55, 97], ["murine", "SPECIES", 65, 71], ["PDGF AA", "TREATMENT", 45, 52], ["mixed stationary cultures", "TEST", 72, 97]]], ["The timing of differentiation of oligodendrocytes as determined by GalC and MBP staining and the formation of compact myelin in vitro is roughly the same as that in vivo: the first myelinating oligodendrocytes in mouse optic nerve appear at postnatal day 6 (P6) (Lubetzki et al, 1993; Demerens et al, 1996) .", [["oligodendrocytes", "ANATOMY", 33, 49], ["myelin", "ANATOMY", 118, 124], ["myelinating oligodendrocytes", "ANATOMY", 181, 209], ["optic nerve", "ANATOMY", 219, 230], ["oligodendrocytes", "CELL", 33, 49], ["GalC", "GENE_OR_GENE_PRODUCT", 67, 71], ["MBP", "GENE_OR_GENE_PRODUCT", 76, 79], ["myelin", "CELLULAR_COMPONENT", 118, 124], ["oligodendrocytes", "CELL", 193, 209], ["mouse", "ORGANISM", 213, 218], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 219, 230], ["oligodendrocytes", "CELL_TYPE", 33, 49], ["GalC", "PROTEIN", 67, 71], ["MBP", "PROTEIN", 76, 79], ["myelinating oligodendrocytes", "CELL_TYPE", 181, 209], ["mouse", "SPECIES", 213, 218], ["mouse", "SPECIES", 213, 218], ["oligodendrocytes", "PROBLEM", 33, 49], ["GalC and MBP staining", "TEST", 67, 88], ["compact myelin", "PROBLEM", 110, 124], ["MBP staining", "OBSERVATION", 76, 88], ["compact myelin", "OBSERVATION", 110, 124], ["optic nerve", "ANATOMY", 219, 230]]], ["In rotated cell suspension cultures from embryonic rat, dissociated cells form mixed aggregates within 2 days and mature to full axonal myelination in a time scale similar to the myelination that occurs in vivo (Honnegger, 1985; Loughlin et al, 1997) .", [["cell suspension cultures", "ANATOMY", 11, 35], ["embryonic", "ANATOMY", 41, 50], ["cells", "ANATOMY", 68, 73], ["axonal", "ANATOMY", 129, 135], ["cell suspension cultures", "CELL", 11, 35], ["rat", "ORGANISM", 51, 54], ["cells", "CELL", 68, 73], ["rotated cell suspension cultures", "CELL_LINE", 3, 35], ["dissociated cells", "CELL_TYPE", 56, 73], ["rat", "SPECIES", 51, 54], ["rat", "SPECIES", 51, 54], ["rotated cell suspension cultures", "TEST", 3, 35], ["embryonic rat", "PROBLEM", 41, 54], ["dissociated cells", "PROBLEM", 56, 73], ["mixed aggregates", "PROBLEM", 79, 95], ["rotated cell", "OBSERVATION_MODIFIER", 3, 15], ["mixed aggregates", "OBSERVATION", 79, 95], ["axonal myelination", "OBSERVATION", 129, 147]]], ["In yet a different mixed culture system, Murray and Dubois-Dalcq (1997) report that oligodendrocyte progenitors can be generated from tissues derived from 53 to 58 days after conception.", [["oligodendrocyte progenitors", "ANATOMY", 84, 111], ["tissues", "ANATOMY", 134, 141], ["oligodendrocyte progenitors", "CELL", 84, 111], ["tissues", "TISSUE", 134, 141], ["oligodendrocyte progenitors", "CELL_TYPE", 84, 111], ["oligodendrocyte progenitors", "PROBLEM", 84, 111]]], ["In this model, after 2-3 weeks in vitro in Bottenstein-Sato medium, dividing neural stem cells cluster, detach from the culture dish surface, and continue to expand as spheres.", [["neural stem cells", "ANATOMY", 77, 94], ["dish surface", "ANATOMY", 128, 140], ["neural stem cells", "CELL", 77, 94], ["neural stem cells", "CELL_TYPE", 77, 94], ["vitro in Bottenstein-Sato medium", "TREATMENT", 34, 66], ["dividing neural stem cells cluster", "TREATMENT", 68, 102], ["the culture dish surface", "TEST", 116, 140], ["neural", "ANATOMY", 77, 83], ["stem cells", "OBSERVATION", 84, 94]]], ["These spheres, containing mostly multipotential, polysialated neural cell adhesion molecule (PSA-NCAM) + , nestin + , mitotic neural precursors, can be passaged every 4 weeks with the generation of new spheres up to 7 months.", [["neural precursors", "ANATOMY", 126, 143], ["neural cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 62, 91], ["PSA-NCAM", "GENE_OR_GENE_PRODUCT", 93, 101], ["nestin", "GENE_OR_GENE_PRODUCT", 107, 113], ["polysialated neural cell adhesion molecule", "PROTEIN", 49, 91], ["PSA", "PROTEIN", 93, 96], ["NCAM", "PROTEIN", 97, 101], ["nestin", "PROTEIN", 107, 113], ["mitotic neural precursors", "CELL_TYPE", 118, 143], ["mostly multipotential, polysialated neural cell adhesion molecule", "PROBLEM", 26, 91], ["PSA", "TEST", 93, 96], ["mitotic neural precursors", "PROBLEM", 118, 143], ["spheres", "OBSERVATION_MODIFIER", 6, 13], ["mostly", "OBSERVATION_MODIFIER", 26, 32], ["multipotential", "OBSERVATION_MODIFIER", 33, 47], ["polysialated", "OBSERVATION_MODIFIER", 49, 61], ["neural cell adhesion molecule", "OBSERVATION", 62, 91], ["mitotic neural precursors", "OBSERVATION", 118, 143]]], ["Spheres can be frozen in 10% DMSO.", [["DMSO", "CHEMICAL", 29, 33], ["DMSO", "CHEMICAL", 29, 33], ["Spheres", "SIMPLE_CHEMICAL", 0, 7], ["DMSO", "SIMPLE_CHEMICAL", 29, 33]]], ["Withdrawal of mitogens permits development of 04 + cells to differentiate and express GalC and PLP/DM20.Mixed and Organotypic CulturesMyelinating cultures can also be produced by mixing together purified populations of neurons and oligodendrocyte progenitors that have been separately prepared.", [["04 + cells", "ANATOMY", 46, 56], ["neurons", "ANATOMY", 219, 226], ["oligodendrocyte progenitors", "ANATOMY", 231, 258], ["PLP", "CHEMICAL", 95, 98], ["04 + cells", "CELL", 46, 56], ["GalC", "GENE_OR_GENE_PRODUCT", 86, 90], ["PLP", "GENE_OR_GENE_PRODUCT", 95, 98], ["DM20", "GENE_OR_GENE_PRODUCT", 99, 103], ["neurons", "CELL", 219, 226], ["oligodendrocyte progenitors", "CELL", 231, 258], ["04 + cells", "CELL_LINE", 46, 56], ["GalC", "PROTEIN", 86, 90], ["PLP", "PROTEIN", 95, 98], ["DM20", "PROTEIN", 99, 103], ["Myelinating cultures", "CELL_LINE", 134, 154], ["neurons", "CELL_TYPE", 219, 226], ["oligodendrocyte progenitors", "CELL_TYPE", 231, 258], ["mitogens", "TREATMENT", 14, 22], ["04 + cells", "PROBLEM", 46, 56], ["DM20", "PROBLEM", 99, 103], ["Organotypic CulturesMyelinating cultures", "TEST", 114, 154], ["oligodendrocyte progenitors", "TREATMENT", 231, 258]]], ["The source of neurons is usually murine dorsal root ganglia (DRG) neurons isolated from E 13.5-14.5 whereas the oligodendrocyte progenitors may be derived from mouse or rat postnatal day 1 cerebral cortices (McCarthy and deVellis, 1980) .", [["neurons", "ANATOMY", 14, 21], ["dorsal root ganglia", "ANATOMY", 40, 59], ["DRG) neurons", "ANATOMY", 61, 73], ["oligodendrocyte progenitors", "ANATOMY", 112, 139], ["cerebral cortices", "ANATOMY", 189, 206], ["neurons", "CELL", 14, 21], ["murine", "ORGANISM", 33, 39], ["dorsal root ganglia (DRG) neurons", "CELL", 40, 73], ["oligodendrocyte progenitors", "CELL", 112, 139], ["mouse", "ORGANISM", 160, 165], ["rat", "ORGANISM", 169, 172], ["cerebral cortices", "MULTI-TISSUE_STRUCTURE", 189, 206], ["murine dorsal root ganglia (DRG) neurons", "CELL_TYPE", 33, 73], ["oligodendrocyte progenitors", "CELL_TYPE", 112, 139], ["murine", "SPECIES", 33, 39], ["mouse", "SPECIES", 160, 165], ["rat", "SPECIES", 169, 172], ["mouse", "SPECIES", 160, 165], ["the oligodendrocyte progenitors", "PROBLEM", 108, 139], ["dorsal", "ANATOMY_MODIFIER", 40, 46], ["root ganglia", "ANATOMY", 47, 59], ["cerebral cortices", "ANATOMY", 189, 206]]], ["DRG cultures are exposed to fluorodeoxyuridine (FUDR) to inhibit mitoses of nonneuronal cells for up to 4 days and cultured up to 4 weeks before addition of enriched oligodendrocyte progenitors (Stevens et al, 2002; Zhang et al, 2006; Ishibashi et al, 2006) .", [["DRG cultures", "ANATOMY", 0, 12], ["nonneuronal cells", "ANATOMY", 76, 93], ["oligodendrocyte progenitors", "ANATOMY", 166, 193], ["fluorodeoxyuridine", "CHEMICAL", 28, 46], ["FUDR", "CHEMICAL", 48, 52], ["fluorodeoxyuridine", "CHEMICAL", 28, 46], ["FUDR", "CHEMICAL", 48, 52], ["DRG cultures", "CELL", 0, 12], ["fluorodeoxyuridine", "SIMPLE_CHEMICAL", 28, 46], ["FUDR", "SIMPLE_CHEMICAL", 48, 52], ["nonneuronal cells", "CELL", 76, 93], ["oligodendrocyte progenitors", "CELL", 166, 193], ["DRG cultures", "CELL_LINE", 0, 12], ["nonneuronal cells", "CELL_TYPE", 76, 93], ["oligodendrocyte progenitors", "CELL_TYPE", 166, 193], ["DRG cultures", "TEST", 0, 12], ["fluorodeoxyuridine (FUDR", "TREATMENT", 28, 52], ["nonneuronal cells", "TREATMENT", 76, 93], ["enriched oligodendrocyte progenitors", "TREATMENT", 157, 193], ["nonneuronal cells", "OBSERVATION", 76, 93], ["oligodendrocyte progenitors", "OBSERVATION", 166, 193]]], ["Oligodendrocyte precursors differentiate within a week and myelinate within 2 weeks under these conditions.", [["Oligodendrocyte precursors", "ANATOMY", 0, 26], ["Oligodendrocyte precursors", "CELL", 0, 26], ["Oligodendrocyte precursors", "CELL_TYPE", 0, 26], ["Oligodendrocyte precursors", "TEST", 0, 26]]], ["Unlike embryonic mixed cultures, oligodendrocyte-neuronal cultures do not contain other glia or endothelial cells that might modulate myelinaxon interactions as well influence the effects of exogenous agents and drugs added to cultures to promote cell survival and differentiation.Mixed and Organotypic CulturesCerebellar organotypic slice cultures have also been used to examine the effects of agents on myelination.", [["embryonic mixed cultures", "ANATOMY", 7, 31], ["oligodendrocyte-neuronal cultures", "ANATOMY", 33, 66], ["glia", "ANATOMY", 88, 92], ["endothelial cells", "ANATOMY", 96, 113], ["cultures", "ANATOMY", 227, 235], ["cell", "ANATOMY", 247, 251], ["Cerebellar organotypic slice cultures", "ANATOMY", 311, 348], ["cultures", "CELL", 23, 31], ["oligodendrocyte", "CELL", 33, 48], ["neuronal cultures", "CELL", 49, 66], ["glia", "CELL", 88, 92], ["endothelial cells", "CELL", 96, 113], ["myelinaxon", "GENE_OR_GENE_PRODUCT", 134, 144], ["cell", "CELL", 247, 251], ["Cerebellar organotypic slice cultures", "CELL", 311, 348], ["embryonic mixed cultures", "CELL_LINE", 7, 31], ["oligodendrocyte-neuronal cultures", "CELL_LINE", 33, 66], ["glia", "CELL_TYPE", 88, 92], ["endothelial cells", "CELL_TYPE", 96, 113], ["embryonic mixed cultures", "PROBLEM", 7, 31], ["oligodendrocyte", "TEST", 33, 48], ["neuronal cultures", "TEST", 49, 66], ["endothelial cells", "PROBLEM", 96, 113], ["modulate myelinaxon interactions", "PROBLEM", 125, 157], ["exogenous agents", "TREATMENT", 191, 207], ["drugs", "TREATMENT", 212, 217], ["cultures", "TEST", 227, 235], ["Organotypic Cultures", "TEST", 291, 311], ["Cerebellar organotypic slice cultures", "TEST", 311, 348], ["agents on myelination", "TREATMENT", 395, 416], ["endothelial cells", "OBSERVATION", 96, 113]]], ["Sagittal slices (300 mm) from P2 neonatal rat cerebella can be prepared using a tissue chopper.", [["Sagittal slices", "ANATOMY", 0, 15], ["cerebella", "ANATOMY", 46, 55], ["tissue", "ANATOMY", 80, 86], ["Sagittal slices", "MULTI-TISSUE_STRUCTURE", 0, 15], ["rat", "ORGANISM", 42, 45], ["cerebella", "ORGAN", 46, 55], ["tissue", "TISSUE", 80, 86], ["rat", "SPECIES", 42, 45], ["rat", "SPECIES", 42, 45], ["Sagittal slices", "TEST", 0, 15], ["a tissue chopper", "TREATMENT", 78, 94]]], ["These slices can be treated with drugs or agents for up to 48 h, followed by mechanical dissociation of single cells and analysis of these cells for differentiation (Stevens et al, 2002).", [["slices", "ANATOMY", 6, 12], ["cells", "ANATOMY", 111, 116], ["cells", "ANATOMY", 139, 144], ["cells", "CELL", 111, 116], ["cells", "CELL", 139, 144], ["drugs", "TREATMENT", 33, 38], ["agents", "TREATMENT", 42, 48], ["mechanical dissociation of single cells", "PROBLEM", 77, 116]]], ["Mixed glial cultures are more complicated than single-cell cultures to establish and use but they can serve as an intermediate culture system for examination of demyelinating and remyelinating agents between simpler single-cell preparations and the resource-consuming in vivo models.", [["glial cultures", "ANATOMY", 6, 20], ["cell cultures", "ANATOMY", 54, 67], ["cell", "ANATOMY", 223, 227], ["glial cultures", "CELL", 6, 20], ["single-cell cultures", "CELL", 47, 67], ["single-cell", "CELL", 216, 227], ["Mixed glial cultures", "CELL_LINE", 0, 20], ["single-cell cultures", "CELL_LINE", 47, 67], ["Mixed glial cultures", "TEST", 0, 20], ["single-cell cultures", "TEST", 47, 67], ["an intermediate culture system", "TEST", 111, 141], ["examination", "TEST", 146, 157], ["demyelinating", "PROBLEM", 161, 174], ["remyelinating agents", "TREATMENT", 179, 199], ["simpler single-cell preparations", "TREATMENT", 208, 240], ["glial cultures", "OBSERVATION", 6, 20]]], ["Mixed aggregates or spheres, where oligodendrocyte precursors are a small fraction of the total cell number, can also be used to demonstrate the capacity of hormones and possibly small molecules to drive oligodendrocyte differentiation.", [["oligodendrocyte precursors", "ANATOMY", 35, 61], ["cell", "ANATOMY", 96, 100], ["oligodendrocyte", "ANATOMY", 204, 219], ["oligodendrocyte", "CELL", 35, 50], ["cell", "CELL", 96, 100], ["oligodendrocyte", "CELL", 204, 219], ["oligodendrocyte precursors", "CELL_TYPE", 35, 61], ["Mixed aggregates or spheres", "PROBLEM", 0, 27], ["the capacity of hormones", "PROBLEM", 141, 165], ["small molecules to drive oligodendrocyte differentiation", "PROBLEM", 179, 235], ["aggregates", "OBSERVATION", 6, 16], ["spheres", "OBSERVATION_MODIFIER", 20, 27], ["small", "OBSERVATION_MODIFIER", 68, 73], ["total cell", "OBSERVATION_MODIFIER", 90, 100], ["possibly", "UNCERTAINTY", 170, 178], ["small molecules", "OBSERVATION", 179, 194]]], ["Although the culture technique of organotypic slices allows for the preservation of the architecture of the nervous system and stimulation of complex electrical and biochemical pathways, it may not be as reproducible as single-cell or mixed-cell cultures and is a very low throughput assay system.ModelsThere is evidence that myelin damage and oligodendrocyte cell death occurs in MS lesions as the result of excitotoxicity (Yoshioka et al, 1998) , lack of or inappropriate growth factor signaling (Scolding and Compston, 1995) , immune cell-mediated mechanisms Selmaj et al, 1991 Selmaj et al, , 1992 , proinflammatory cytokines (Brogi et al, 1997; Vartanian et al, 1995; Casaccia-Bonnefil, 2000) , ceramide (Larocca et al, 1997; Casaccia-Bonnefil et al, 1996) , enzymes (James et al, 1998) , free radicals (Mitrovic et al, , 1996 Husain and Juurlink, 1995) , and anti-MOG antibody plus complement (Copelman et al, 2000) .", [["organotypic slices", "ANATOMY", 34, 52], ["nervous system", "ANATOMY", 108, 122], ["cell", "ANATOMY", 227, 231], ["cell cultures", "ANATOMY", 241, 254], ["myelin", "ANATOMY", 326, 332], ["oligodendrocyte cell", "ANATOMY", 344, 364], ["MS lesions", "ANATOMY", 381, 391], ["immune cell", "ANATOMY", 530, 541], ["myelin damage", "DISEASE", 326, 339], ["death", "DISEASE", 365, 370], ["MS", "DISEASE", 381, 383], ["excitotoxicity", "DISEASE", 409, 423], ["ceramide", "CHEMICAL", 700, 708], ["ceramide", "CHEMICAL", 700, 708], ["organotypic slices", "MULTI-TISSUE_STRUCTURE", 34, 52], ["nervous system", "ANATOMICAL_SYSTEM", 108, 122], ["cell", "CELL", 227, 231], ["mixed-cell cultures", "CELL", 235, 254], ["myelin", "CELLULAR_COMPONENT", 326, 332], ["oligodendrocyte cell", "CELL", 344, 364], ["MS lesions", "CANCER", 381, 391], ["immune cell", "CELL", 530, 541], ["ceramide", "SIMPLE_CHEMICAL", 700, 708], ["free radicals", "SIMPLE_CHEMICAL", 794, 807], ["anti-MOG antibody", "GENE_OR_GENE_PRODUCT", 865, 882], ["single-cell or mixed-cell cultures", "CELL_LINE", 220, 254], ["growth factor", "PROTEIN", 474, 487], ["proinflammatory cytokines", "PROTEIN", 604, 629], ["anti-MOG antibody", "PROTEIN", 865, 882], ["the culture technique", "TEST", 9, 30], ["organotypic slices", "TEST", 34, 52], ["mixed-cell cultures", "TEST", 235, 254], ["a very low throughput assay system", "PROBLEM", 262, 296], ["myelin damage", "PROBLEM", 326, 339], ["oligodendrocyte cell death", "PROBLEM", 344, 370], ["MS lesions", "PROBLEM", 381, 391], ["excitotoxicity", "PROBLEM", 409, 423], ["inappropriate growth factor signaling", "PROBLEM", 460, 497], ["immune cell", "TEST", 530, 541], ["proinflammatory cytokines", "TEST", 604, 629], ["Casaccia", "TEST", 673, 681], ["ceramide", "TREATMENT", 700, 708], ["Casaccia", "TEST", 731, 739], ["enzymes", "TEST", 764, 771], ["anti-MOG antibody", "TREATMENT", 865, 882], ["nervous system", "ANATOMY", 108, 122], ["evidence that", "UNCERTAINTY", 312, 325], ["myelin damage", "OBSERVATION", 326, 339], ["oligodendrocyte cell death", "OBSERVATION", 344, 370]]], ["All of these forms of cell cytotoxicity can be recreated as in vitro assays with quantitative endpoints.ModelsOligodendrocyte differentiation in vitro using rodent oligodendrocyte precursors can be accomplished within 5-7 days in vitro.", [["cell", "ANATOMY", 22, 26], ["Oligodendrocyte", "ANATOMY", 110, 125], ["oligodendrocyte precursors", "ANATOMY", 164, 190], ["cell", "CELL", 22, 26], ["Oligodendrocyte", "CELL", 110, 125], ["oligodendrocyte", "CELL", 164, 179], ["rodent oligodendrocyte precursors", "CELL_TYPE", 157, 190], ["rodent", "SPECIES", 157, 163], ["cell cytotoxicity", "PROBLEM", 22, 39], ["rodent oligodendrocyte precursors", "TREATMENT", 157, 190], ["cell cytotoxicity", "OBSERVATION", 22, 39], ["Oligodendrocyte differentiation", "OBSERVATION", 110, 141]]], ["Transcript profiling for myelin and other differentiation-related genes (MBP, PLP, MAG, MOG) using northern blots or in situ hybridization can be performed for a minimal number of compounds whereas RT-PCR (High Throughput Genomics Technologies ArrayPlate, HTG Inc. Tucson, AZ) and microfluidics cards (TLDA; Applied Biosystems, Foster City, CA) would be more useful for higher throughput (Blanchard and Friend, 1999; Martel et al, 2002) .", [["myelin", "ANATOMY", 25, 31], ["myelin", "GENE_OR_GENE_PRODUCT", 25, 31], ["MBP", "GENE_OR_GENE_PRODUCT", 73, 76], ["PLP", "GENE_OR_GENE_PRODUCT", 78, 81], ["MAG", "GENE_OR_GENE_PRODUCT", 83, 86], ["MOG", "GENE_OR_GENE_PRODUCT", 88, 91], ["MBP", "PROTEIN", 73, 76], ["PLP", "DNA", 78, 81], ["MAG", "DNA", 83, 86], ["MOG", "DNA", 88, 91], ["Transcript profiling", "TEST", 0, 20], ["myelin", "PROBLEM", 25, 31], ["MBP", "TEST", 73, 76], ["PLP", "TEST", 78, 81], ["MAG", "TEST", 83, 86], ["northern blots", "PROBLEM", 99, 113], ["a minimal number of compounds", "PROBLEM", 160, 189], ["RT", "TEST", 198, 200], ["PCR", "TEST", 201, 204], ["ArrayPlate", "TEST", 244, 254]]], ["For analysis of myelin proteins, microscopebased imaging systems to quantitate antibody fluorescence using the two-color detection LI-COR system (Odyssey Infrared Imaging System; LI-COR, Lincoln, NE) or immunohistochemical ELISA-based analyses are available.", [["myelin", "ANATOMY", 16, 22], ["myelin proteins", "GENE_OR_GENE_PRODUCT", 16, 31], ["myelin proteins", "PROTEIN", 16, 31], ["analysis of myelin proteins", "TEST", 4, 31], ["microscopebased imaging systems", "TEST", 33, 64], ["antibody fluorescence", "TEST", 79, 100], ["the two-color detection", "TEST", 107, 130], ["Odyssey Infrared Imaging System", "TEST", 146, 177], ["LI", "TEST", 179, 181], ["immunohistochemical ELISA", "TEST", 203, 228]]], ["Automated morphometric analyses for image-based highcontent screening (HCS) is based on determining shapes of cells, distinguishing increased branching, and quantitating secondary and tertiary process numbers and lengths using reagents like CellMask cytoplasmic/nuclear stains (Invitrogen, Carlsbad, CA).", [["cells", "ANATOMY", 110, 115], ["cytoplasmic", "ANATOMY", 250, 261], ["nuclear", "ANATOMY", 262, 269], ["cells", "CELL", 110, 115], ["cytoplasmic", "ORGANISM_SUBSTANCE", 250, 261], ["CellMask cytoplasmic/nuclear stains", "PROTEIN", 241, 276], ["Automated morphometric analyses", "TEST", 0, 31], ["image", "TEST", 36, 41], ["based highcontent screening", "TEST", 42, 69], ["increased branching", "PROBLEM", 132, 151], ["reagents", "TREATMENT", 227, 235], ["cytoplasmic/nuclear stains", "TEST", 250, 276], ["Invitrogen", "TEST", 278, 288], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["branching", "OBSERVATION_MODIFIER", 142, 151]]], ["HCS algorithms compatible with automated digital cell microimagers, data acquisition systems, and counting software can be used for analysis of single (Cellomics ArrayScan, Cellomics, Pittsburgh, PA; Fisher Biosciences, Fisher, Lafayette, CO) or multiple imaging channels (INCell 3000, Developer Toolkit; General Electric, INCell GE, Piscataway, NJ).", [["cell", "ANATOMY", 49, 53], ["cell", "CELL", 49, 53], ["HCS algorithms", "TEST", 0, 14], ["data acquisition systems", "TEST", 68, 92], ["counting software", "TEST", 98, 115], ["analysis", "TEST", 132, 140], ["single (Cellomics ArrayScan", "TREATMENT", 144, 171], ["multiple imaging channels", "TEST", 246, 271]]], ["These hardware/ software systems remove the subjectivity and time-consuming component of visualization and manual evaluation.ModelsDifferentiation of human oligodendrocyte precursors in vitro poses several distinct differences from cultures of rodent cells.", [["oligodendrocyte precursors", "ANATOMY", 156, 182], ["cells", "ANATOMY", 251, 256], ["human", "ORGANISM", 150, 155], ["oligodendrocyte", "CELL", 156, 171], ["rodent", "ORGANISM", 244, 250], ["cells", "CELL", 251, 256], ["human oligodendrocyte precursors", "CELL_TYPE", 150, 182], ["rodent cells", "CELL_TYPE", 244, 256], ["human", "SPECIES", 150, 155], ["rodent", "SPECIES", 244, 250], ["human", "SPECIES", 150, 155], ["These hardware", "TREATMENT", 0, 14], ["visualization", "TEST", 89, 102], ["manual evaluation", "TEST", 107, 124], ["human oligodendrocyte precursors", "PROBLEM", 150, 182], ["cultures of rodent cells", "PROBLEM", 232, 256], ["hardware", "OBSERVATION", 6, 14], ["human oligodendrocyte precursors", "OBSERVATION", 150, 182], ["rodent cells", "OBSERVATION", 244, 256]]], ["Although human precursors can be driven to differentiate morphologically within 7 days in vitro, in many cases a substantial number of cells expressing MBP do not develop in vitro until 2-3 weeks later (Wilson et al, 2003) .", [["cells", "ANATOMY", 135, 140], ["human", "ORGANISM", 9, 14], ["cells", "CELL", 135, 140], ["MBP", "GENE_OR_GENE_PRODUCT", 152, 155], ["human precursors", "CELL_TYPE", 9, 25], ["MBP", "PROTEIN", 152, 155], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14]]], ["Thus, the feasibility of using assays for differentiation of human precursors is more challenging than that of rodents cells and typically involves evaluating the transition of bipolar cells to 04 + or CNP + cells with intermediate to high-complexity branching of processes (Zhang et al, 2004) .ModelsIt is clear that myelination is regulated by the physical contact between mature oligodendrocytes and axons and that production of compact myelin occurs only when the axon is functioning.", [["cells", "ANATOMY", 119, 124], ["cells", "ANATOMY", 185, 190], ["CNP + cells", "ANATOMY", 202, 213], ["oligodendrocytes", "ANATOMY", 382, 398], ["axons", "ANATOMY", 403, 408], ["myelin", "ANATOMY", 440, 446], ["axon", "ANATOMY", 468, 472], ["bipolar", "DISEASE", 177, 184], ["human", "ORGANISM", 61, 66], ["cells", "CELL", 119, 124], ["bipolar cells", "CELL", 177, 190], ["oligodendrocytes", "CELL", 382, 398], ["axons", "CELLULAR_COMPONENT", 403, 408], ["myelin", "CELLULAR_COMPONENT", 440, 446], ["axon", "CELLULAR_COMPONENT", 468, 472], ["human precursors", "CELL_TYPE", 61, 77], ["rodents cells", "CELL_TYPE", 111, 124], ["bipolar cells", "CELL_TYPE", 177, 190], ["04 + or CNP + cells", "CELL_LINE", 194, 213], ["mature oligodendrocytes", "CELL_TYPE", 375, 398], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["assays", "TEST", 31, 37], ["human precursors", "PROBLEM", 61, 77], ["rodents cells", "PROBLEM", 111, 124], ["bipolar cells", "PROBLEM", 177, 190], ["CNP + cells", "PROBLEM", 202, 213], ["compact myelin", "PROBLEM", 432, 446], ["bipolar cells", "OBSERVATION", 177, 190], ["clear", "OBSERVATION", 307, 312]]], ["Targeting the inhibition of abnormal expression of axon-associated molecules that block myelination may be one way of allowing myelination to proceed.", [["axon-associated molecules", "PROTEIN", 51, 76], ["abnormal expression of axon-associated molecules", "PROBLEM", 28, 76], ["block myelination", "PROBLEM", 82, 99], ["abnormal", "OBSERVATION_MODIFIER", 28, 36], ["expression", "OBSERVATION_MODIFIER", 37, 47]]], ["This can be examined in complex cultures.", [["complex cultures", "CELL_LINE", 24, 40], ["complex cultures", "TEST", 24, 40]]], ["Demerens et al (1996) demonstrated in mixed stationary cultures that myelination could be blocked by tetrodotoxin or enhanced by a-scorpion toxin stimulation of electrical activity; the effect was confirmed in vivo using the developing optic nerve of the mouse.", [["optic nerve", "ANATOMY", 236, 247], ["tetrodotoxin", "CHEMICAL", 101, 113], ["tetrodotoxin", "CHEMICAL", 101, 113], ["tetrodotoxin", "SIMPLE_CHEMICAL", 101, 113], ["a-scorpion toxin", "SIMPLE_CHEMICAL", 129, 145], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 236, 247], ["mouse", "ORGANISM", 255, 260], ["mouse", "SPECIES", 255, 260], ["mouse", "SPECIES", 255, 260], ["mixed stationary cultures", "TEST", 38, 63], ["tetrodotoxin", "TREATMENT", 101, 113], ["a-scorpion toxin stimulation", "TREATMENT", 129, 157], ["optic nerve", "ANATOMY", 236, 247]]], ["Electrical activity regulates the expression of cell adhesion molecules on axons such as PSA-NCAM and axonal L1 (Coman et al, 2005) .", [["cell", "ANATOMY", 48, 52], ["axons", "ANATOMY", 75, 80], ["PSA-NCAM", "ANATOMY", 89, 97], ["axonal L1", "ANATOMY", 102, 111], ["cell", "CELL", 48, 52], ["axons", "CELLULAR_COMPONENT", 75, 80], ["PSA-NCAM", "GENE_OR_GENE_PRODUCT", 89, 97], ["cell adhesion molecules", "PROTEIN", 48, 71], ["PSA", "PROTEIN", 89, 92], ["NCAM", "PROTEIN", 93, 97], ["axonal L1", "PROTEIN", 102, 111], ["cell adhesion molecules", "PROBLEM", 48, 71], ["PSA", "TEST", 89, 92], ["cell adhesion", "OBSERVATION", 48, 61], ["axonal L1", "ANATOMY", 102, 111]]], ["In MS, PSA-NCAM is found on demyelinated axons in chronic lesions, but not on myelinated axons.", [["demyelinated axons", "ANATOMY", 28, 46], ["lesions", "ANATOMY", 58, 65], ["myelinated axons", "ANATOMY", 78, 94], ["MS", "DISEASE", 3, 5], ["PSA-NCAM", "GENE_OR_GENE_PRODUCT", 7, 15], ["axons", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 46], ["chronic lesions", "PATHOLOGICAL_FORMATION", 50, 65], ["myelinated axons", "MULTI-TISSUE_STRUCTURE", 78, 94], ["PSA", "PROTEIN", 7, 10], ["NCAM", "PROTEIN", 11, 15], ["PSA", "TEST", 7, 10], ["demyelinated axons", "PROBLEM", 28, 46], ["chronic lesions", "PROBLEM", 50, 65], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["lesions", "OBSERVATION", 58, 65]]], ["Myelin deposition occurs only on axons that have downregulated PSA-NCAM.", [["Myelin", "ANATOMY", 0, 6], ["axons", "ANATOMY", 33, 38], ["Myelin", "GENE_OR_GENE_PRODUCT", 0, 6], ["axons", "CELLULAR_COMPONENT", 33, 38], ["PSA-NCAM", "GENE_OR_GENE_PRODUCT", 63, 71], ["PSA", "PROTEIN", 63, 66], ["NCAM", "PROTEIN", 67, 71], ["Myelin deposition", "PROBLEM", 0, 17], ["downregulated PSA", "PROBLEM", 49, 66], ["deposition", "OBSERVATION", 7, 17]]], ["Internalization of PSA-NCAM by antibody or enzymatic removal of the polysialic acid moieties with endoneuraminidase increases myelination by fivefold in mixed cultures (Charles et al, 2000) .", [["polysialic acid", "CHEMICAL", 68, 83], ["endoneuraminidase", "CHEMICAL", 98, 115], ["polysialic acid", "CHEMICAL", 68, 83], ["endoneuraminidase", "CHEMICAL", 98, 115], ["PSA-NCAM", "GENE_OR_GENE_PRODUCT", 19, 27], ["polysialic acid", "SIMPLE_CHEMICAL", 68, 83], ["endoneuraminidase", "SIMPLE_CHEMICAL", 98, 115], ["PSA", "PROTEIN", 19, 22], ["NCAM", "PROTEIN", 23, 27], ["endoneuraminidase", "PROTEIN", 98, 115], ["mixed cultures", "CELL_LINE", 153, 167], ["PSA", "TEST", 19, 22], ["NCAM", "TREATMENT", 23, 27], ["enzymatic removal", "TREATMENT", 43, 60], ["the polysialic acid moieties", "TREATMENT", 64, 92], ["endoneuraminidase increases myelination", "PROBLEM", 98, 137], ["polysialic acid moieties", "OBSERVATION", 68, 92]]], ["Electrical stimulation of mixed cocultures stimulates ATP production which induces astrocytes in these cultures to produce leukemia inhibitory factor (LIF) (Ishibashi et al, 2006) .", [["astrocytes", "ANATOMY", 83, 93], ["cultures", "ANATOMY", 103, 111], ["ATP", "CHEMICAL", 54, 57], ["leukemia", "DISEASE", 123, 131], ["ATP", "CHEMICAL", 54, 57], ["ATP", "SIMPLE_CHEMICAL", 54, 57], ["astrocytes", "CELL", 83, 93], ["leukemia inhibitory factor", "GENE_OR_GENE_PRODUCT", 123, 149], ["LIF", "GENE_OR_GENE_PRODUCT", 151, 154], ["mixed cocultures", "CELL_LINE", 26, 42], ["astrocytes", "CELL_TYPE", 83, 93], ["leukemia inhibitory factor", "PROTEIN", 123, 149], ["LIF", "PROTEIN", 151, 154], ["Electrical stimulation", "TREATMENT", 0, 22], ["mixed cocultures", "PROBLEM", 26, 42], ["ATP production", "PROBLEM", 54, 68], ["astrocytes", "PROBLEM", 83, 93], ["these cultures", "TEST", 97, 111], ["leukemia inhibitory factor", "PROBLEM", 123, 149]]], ["This strong neurotrophic factor, in turn, stimulates myelin production by mature oligodendrocytes in the cultures.ModelsIn mixed co-cultures in vitro, it has been demonstrated that oligodendrocyte progenitors express functional adenosine receptors and detect action potentials from axons with large intracellular calcium fluxes.", [["myelin", "ANATOMY", 53, 59], ["oligodendrocytes", "ANATOMY", 81, 97], ["cultures", "ANATOMY", 105, 113], ["oligodendrocyte progenitors", "ANATOMY", 181, 208], ["axons", "ANATOMY", 282, 287], ["intracellular", "ANATOMY", 299, 312], ["adenosine", "CHEMICAL", 228, 237], ["calcium", "CHEMICAL", 313, 320], ["adenosine", "CHEMICAL", 228, 237], ["calcium", "CHEMICAL", 313, 320], ["myelin", "GENE_OR_GENE_PRODUCT", 53, 59], ["oligodendrocytes", "CELL", 81, 97], ["oligodendrocyte progenitors", "CELL", 181, 208], ["adenosine receptors", "GENE_OR_GENE_PRODUCT", 228, 247], ["axons", "MULTI-TISSUE_STRUCTURE", 282, 287], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 299, 312], ["calcium", "SIMPLE_CHEMICAL", 313, 320], ["neurotrophic factor", "PROTEIN", 12, 31], ["mature oligodendrocytes", "CELL_TYPE", 74, 97], ["oligodendrocyte progenitors", "CELL_TYPE", 181, 208], ["adenosine receptors", "PROTEIN", 228, 247], ["This strong neurotrophic factor", "PROBLEM", 0, 31], ["stimulates myelin production", "PROBLEM", 42, 70], ["the cultures", "TEST", 101, 113], ["oligodendrocyte progenitors", "PROBLEM", 181, 208], ["functional adenosine receptors", "TREATMENT", 217, 247], ["large intracellular calcium fluxes", "PROBLEM", 293, 327], ["mixed co-cultures", "OBSERVATION", 123, 140], ["large", "OBSERVATION_MODIFIER", 293, 298], ["intracellular calcium fluxes", "OBSERVATION", 299, 327]]], ["Adenosine (but not ATP) inhibits oligodendrocyte progenitor proliferation, promotes its interaction with axons, and drives myelination over the course of 14 days in vitro (Stevens et al, 2002) .", [["oligodendrocyte progenitor", "ANATOMY", 33, 59], ["axons", "ANATOMY", 105, 110], ["Adenosine", "CHEMICAL", 0, 9], ["ATP", "CHEMICAL", 19, 22], ["Adenosine", "CHEMICAL", 0, 9], ["ATP", "CHEMICAL", 19, 22], ["Adenosine", "SIMPLE_CHEMICAL", 0, 9], ["ATP", "SIMPLE_CHEMICAL", 19, 22], ["oligodendrocyte progenitor", "CELL", 33, 59], ["axons", "CELLULAR_COMPONENT", 105, 110], ["Adenosine", "TREATMENT", 0, 9], ["ATP", "PROBLEM", 19, 22], ["oligodendrocyte progenitor proliferation", "PROBLEM", 33, 73], ["oligodendrocyte progenitor proliferation", "OBSERVATION", 33, 73]]], ["Myelination in these cultures systems is quantitated by counting of MBP-stained cells or the number of internodes/myelin segments, by toluidine blue staining (Wilson) , and by validation of compact myelin using EM (Charles et al, 2000; Demerens et al, 1996; Stevens et al, 2002) .CONCLUSIONSExposure of isolated precursors or differentiated oligodendrocytes to agents that promote proliferation, migration, survival, and differentiation simplifies the interpretation of the functional outcome by providing quantifiable direct effects on the oligodendrocyte targets uninfluenced by other cells and their soluble products.", [["cells", "ANATOMY", 80, 85], ["internodes", "ANATOMY", 103, 113], ["myelin segments", "ANATOMY", 114, 129], ["myelin", "ANATOMY", 198, 204], ["precursors", "ANATOMY", 312, 322], ["oligodendrocytes", "ANATOMY", 341, 357], ["oligodendrocyte", "ANATOMY", 541, 556], ["cells", "ANATOMY", 587, 592], ["Myelination", "DISEASE", 0, 11], ["toluidine blue", "CHEMICAL", 134, 148], ["toluidine blue", "CHEMICAL", 134, 148], ["MBP", "GENE_OR_GENE_PRODUCT", 68, 71], ["cells", "CELL", 80, 85], ["internodes", "TISSUE", 103, 113], ["myelin segments", "CELLULAR_COMPONENT", 114, 129], ["toluidine", "SIMPLE_CHEMICAL", 134, 143], ["myelin", "CELLULAR_COMPONENT", 198, 204], ["oligodendrocytes", "CELL", 341, 357], ["oligodendrocyte", "CELL", 541, 556], ["cells", "CELL", 587, 592], ["MBP", "PROTEIN", 68, 71], ["myelin segments", "PROTEIN", 114, 129], ["isolated precursors", "CELL_TYPE", 303, 322], ["differentiated oligodendrocytes", "CELL_TYPE", 326, 357], ["Myelination", "PROBLEM", 0, 11], ["these cultures systems", "TEST", 15, 37], ["MBP-stained cells", "PROBLEM", 68, 85], ["internodes/myelin segments", "PROBLEM", 103, 129], ["isolated precursors", "PROBLEM", 303, 322], ["differentiated oligodendrocytes", "PROBLEM", 326, 357], ["the oligodendrocyte targets", "TREATMENT", 537, 564], ["their soluble products", "TREATMENT", 597, 619], ["internodes", "ANATOMY_MODIFIER", 103, 113], ["myelin segments", "ANATOMY", 114, 129], ["differentiated oligodendrocytes", "OBSERVATION", 326, 357], ["proliferation", "OBSERVATION_MODIFIER", 381, 394], ["migration", "OBSERVATION_MODIFIER", 396, 405]]], ["For phenotypic screens with small molecule libraries (Saxe et al, 2007) , desired functional outcomes like survival and differentiation can be further analyzed for gene biomarkers indicating the mechanism of drug action using affymetrix arrays, microfluidics cards, or high-throughput genomic (HTG) transcript profiling of relevant gene clusters (Sim et al, 2006) .", [["phenotypic screens", "TEST", 4, 22], ["small molecule libraries", "PROBLEM", 28, 52], ["gene biomarkers", "TEST", 164, 179], ["affymetrix arrays", "TREATMENT", 226, 243], ["microfluidics cards", "TEST", 245, 264], ["relevant gene clusters", "PROBLEM", 323, 345]]], ["These models allow for in vitro proof of concept, the assessment of whether small molecules can penetrate cell membranes, and the examination of the efficacy of biologics such as antibodies, cytokines, neurotrophic factors.", [["cell membranes", "ANATOMY", 106, 120], ["cell membranes", "CELLULAR_COMPONENT", 106, 120], ["neurotrophic factors", "GENE_OR_GENE_PRODUCT", 202, 222], ["antibodies", "PROTEIN", 179, 189], ["cytokines", "PROTEIN", 191, 200], ["neurotrophic factors", "PROTEIN", 202, 222], ["the assessment", "TEST", 50, 64], ["small molecules can penetrate cell membranes", "PROBLEM", 76, 120], ["the examination", "TEST", 126, 141], ["biologics", "TREATMENT", 161, 170], ["antibodies", "TEST", 179, 189], ["cytokines", "PROBLEM", 191, 200], ["neurotrophic factors", "PROBLEM", 202, 222], ["cell membranes", "OBSERVATION", 106, 120]]], ["This is an important part of the screening process as some of these agents may not yet have the physical or pharmacokinetic properties which would allow them to reach pharmacodynamic exposure levels or cross an intact blood-brain barrier (BBB) in vivo.CONCLUSIONSMixed culture systems are technically challenging and time consuming but allow for the assessment of pharma-cological parameters, the use of validating inhibitor molecules, as well as the ability to dissect mechanisms of action of drugs in more controlled and easily manipulated conditions than can be achieved in vivo.Mechanisms: Survival and DifferentiationCytokine and neurotrophic factors.", [["blood-brain barrier", "ANATOMY", 218, 237], ["BBB", "ANATOMY", 239, 242], ["blood-", "MULTI-TISSUE_STRUCTURE", 218, 224], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 224, 237], ["BBB", "MULTI-TISSUE_STRUCTURE", 239, 242], ["neurotrophic factors", "GENE_OR_GENE_PRODUCT", 635, 655], ["neurotrophic factors", "PROTEIN", 635, 655], ["pharmacodynamic exposure levels", "TEST", 167, 198], ["vivo.CONCLUSIONSMixed culture systems", "TEST", 247, 284], ["the assessment", "TEST", 346, 360], ["pharma-cological parameters", "TREATMENT", 364, 391], ["validating inhibitor molecules", "TREATMENT", 404, 434], ["drugs", "TREATMENT", 494, 499], ["DifferentiationCytokine and neurotrophic factors", "PROBLEM", 607, 655], ["brain", "ANATOMY", 224, 229], ["neurotrophic factors", "OBSERVATION", 635, 655]]], ["Among the cytokines and neurotrophic factors that positively affect oligodendrocyte precursor proliferation or precursor and mature oligodendrocyte survival, maturation, and differentiation, IL2, IL11, PDGF, bFGF, LIF, neurotrophin 3 (NT3), glial growth factor-2 (GGF2, neuregulin), insulin-like growth factor-1 (IGF-1), and ciliary neurotrophic factor (CNTF) are the best-studied proteins (Marmur et al, 1998; Copelman et al, 2000; Sperber and McMorris, 2001) .", [["oligodendrocyte precursor", "ANATOMY", 68, 93], ["precursor", "ANATOMY", 111, 120], ["oligodendrocyte", "ANATOMY", 132, 147], ["neurotrophic factors", "GENE_OR_GENE_PRODUCT", 24, 44], ["oligodendrocyte precursor", "CELL", 68, 93], ["oligodendrocyte", "CELL", 132, 147], ["IL2", "GENE_OR_GENE_PRODUCT", 191, 194], ["IL11", "GENE_OR_GENE_PRODUCT", 196, 200], ["PDGF", "GENE_OR_GENE_PRODUCT", 202, 206], ["bFGF", "GENE_OR_GENE_PRODUCT", 208, 212], ["LIF", "GENE_OR_GENE_PRODUCT", 214, 217], ["neurotrophin 3", "GENE_OR_GENE_PRODUCT", 219, 233], ["NT3", "GENE_OR_GENE_PRODUCT", 235, 238], ["glial growth factor-2", "GENE_OR_GENE_PRODUCT", 241, 262], ["GGF2", "GENE_OR_GENE_PRODUCT", 264, 268], ["neuregulin", "GENE_OR_GENE_PRODUCT", 270, 280], ["insulin-like growth factor-1", "GENE_OR_GENE_PRODUCT", 283, 311], ["IGF-1", "GENE_OR_GENE_PRODUCT", 313, 318], ["ciliary neurotrophic factor", "GENE_OR_GENE_PRODUCT", 325, 352], ["CNTF", "GENE_OR_GENE_PRODUCT", 354, 358], ["cytokines", "PROTEIN", 10, 19], ["neurotrophic factors", "PROTEIN", 24, 44], ["IL2", "PROTEIN", 191, 194], ["IL11", "PROTEIN", 196, 200], ["PDGF", "PROTEIN", 202, 206], ["bFGF", "PROTEIN", 208, 212], ["LIF", "PROTEIN", 214, 217], ["neurotrophin 3", "PROTEIN", 219, 233], ["NT3", "PROTEIN", 235, 238], ["glial growth factor-2", "PROTEIN", 241, 262], ["GGF2", "PROTEIN", 264, 268], ["neuregulin", "PROTEIN", 270, 280], ["insulin-like growth factor-1", "PROTEIN", 283, 311], ["IGF", "PROTEIN", 313, 316], ["ciliary neurotrophic factor", "PROTEIN", 325, 352], ["CNTF", "PROTEIN", 354, 358], ["the cytokines and neurotrophic factors", "PROBLEM", 6, 44], ["oligodendrocyte precursor proliferation", "PROBLEM", 68, 107], ["mature oligodendrocyte survival", "PROBLEM", 125, 156], ["IL2", "TEST", 191, 194], ["IL11", "TEST", 196, 200], ["PDGF", "TEST", 202, 206], ["bFGF", "TEST", 208, 212], ["neurotrophin", "TEST", 219, 231], ["glial growth factor", "TEST", 241, 260], ["insulin", "TEST", 283, 290], ["growth factor", "TEST", 296, 309], ["IGF", "TEST", 313, 316], ["ciliary neurotrophic factor (CNTF", "PROBLEM", 325, 358], ["mature", "OBSERVATION_MODIFIER", 125, 131], ["oligodendrocyte survival", "OBSERVATION", 132, 156], ["ciliary neurotrophic", "ANATOMY", 325, 345]]], ["These agents prove to be quite useful as positive controls in assays searching for unique small molecules to perform similar functions.", [["unique small molecules", "PROBLEM", 83, 105]]], ["Cell sources are important factors in evaluating such mechanisms.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4]]], ["In comparing human cells from fetal spinal cord with cells from adult human epilepsy temporal lobe, it has been reported that fetal cells proliferate in response to PDGF whereas adult cells do not.", [["cells", "ANATOMY", 19, 24], ["fetal spinal cord", "ANATOMY", 30, 47], ["cells", "ANATOMY", 53, 58], ["temporal lobe", "ANATOMY", 85, 98], ["fetal cells", "ANATOMY", 126, 137], ["adult cells", "ANATOMY", 178, 189], ["epilepsy", "DISEASE", 76, 84], ["human", "ORGANISM", 13, 18], ["cells", "CELL", 19, 24], ["fetal spinal cord", "ORGAN", 30, 47], ["cells", "CELL", 53, 58], ["human", "ORGANISM", 70, 75], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 85, 98], ["fetal cells", "CELL", 126, 137], ["PDGF", "GENE_OR_GENE_PRODUCT", 165, 169], ["adult cells", "CELL", 178, 189], ["human cells", "CELL_TYPE", 13, 24], ["fetal cells", "CELL_TYPE", 126, 137], ["PDGF", "PROTEIN", 165, 169], ["adult cells", "CELL_TYPE", 178, 189], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 70, 75], ["adult human epilepsy temporal lobe", "PROBLEM", 64, 98], ["fetal cells proliferate", "PROBLEM", 126, 149], ["human cells", "OBSERVATION", 13, 24], ["fetal", "ANATOMY_MODIFIER", 30, 35], ["spinal cord", "ANATOMY", 36, 47], ["temporal lobe", "ANATOMY", 85, 98], ["fetal cells proliferate", "OBSERVATION", 126, 149]]], ["However, IGF-1 drives differentiation of both fetal and adult precursors (Armstrong et al, 1992; Wilson et al, 2003) .", [["fetal", "ANATOMY", 46, 51], ["adult precursors", "ANATOMY", 56, 72], ["IGF-1", "GENE_OR_GENE_PRODUCT", 9, 14], ["fetal", "TISSUE", 46, 51], ["IGF-1", "PROTEIN", 9, 14], ["fetal and adult precursors", "CELL_TYPE", 46, 72], ["IGF", "TEST", 9, 12]]], ["There have been reports that basic FGF has no effect on proliferation on either fetal or adult human cells in vitro whereas it does drive cell division in cultures of rodent precursors (Eccleston and Silberberg, 1984; Armstrong et al, 1992; Grinspan et al, 1993; Marmur et al, 1998; Wilson et al, 2003) .", [["fetal", "ANATOMY", 80, 85], ["cells", "ANATOMY", 101, 106], ["cell", "ANATOMY", 138, 142], ["FGF", "GENE_OR_GENE_PRODUCT", 35, 38], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 85], ["human", "ORGANISM", 95, 100], ["cells", "CELL", 101, 106], ["cell", "CELL", 138, 142], ["rodent", "ORGANISM", 167, 173], ["basic FGF", "PROTEIN", 29, 38], ["fetal or adult human cells", "CELL_TYPE", 80, 106], ["rodent precursors", "CELL_TYPE", 167, 184], ["human", "SPECIES", 95, 100], ["rodent", "SPECIES", 167, 173], ["human", "SPECIES", 95, 100], ["basic FGF", "PROBLEM", 29, 38], ["proliferation", "PROBLEM", 56, 69], ["no", "UNCERTAINTY", 43, 45]]], ["Depending on the stimulus used, proliferation assays for progenitor cells can be established to run as an overnight assay or beyond up to 10 days in vitro with assessment using 3 H-thymidine uptake (added in the last 17 h of culture), bromodeoxyuridine (BrDU) staining, CyQuant NF Proliferation Assay kit (Invitrogen) or autoradiography (Otero and Merrill, 1997; Wilson et al, 2003; Grinspan et al, 1993; Armstrong et al, 1992) .", [["progenitor cells", "ANATOMY", 57, 73], ["H-thymidine", "CHEMICAL", 179, 190], ["bromodeoxyuridine", "CHEMICAL", 235, 252], ["BrDU", "CHEMICAL", 254, 258], ["3 H-thymidine", "CHEMICAL", 177, 190], ["bromodeoxyuridine", "CHEMICAL", 235, 252], ["progenitor cells", "CELL", 57, 73], ["3 H-thymidine", "SIMPLE_CHEMICAL", 177, 190], ["bromodeoxyuridine", "SIMPLE_CHEMICAL", 235, 252], ["BrDU", "SIMPLE_CHEMICAL", 254, 258], ["progenitor cells", "CELL_TYPE", 57, 73], ["the stimulus", "TEST", 13, 25], ["proliferation assays", "TEST", 32, 52], ["progenitor cells", "PROBLEM", 57, 73], ["an overnight assay", "TEST", 103, 121], ["assessment", "TEST", 160, 170], ["3 H-thymidine uptake", "TREATMENT", 177, 197], ["culture", "TEST", 225, 232]]], ["Quantitative readouts like radioisotope incorporation can be achieved in a 96-well to as small as a 384-well format.", [["Quantitative readouts like radioisotope incorporation", "PROBLEM", 0, 53]]], ["When cell numbers are limiting, as in human cell cultures, cell-specific antigens can be stained and cells manually counted (Zhang et al, 2004) .Mechanisms: Survival and DifferentiationHormones.", [["cell", "ANATOMY", 5, 9], ["cell cultures", "ANATOMY", 44, 57], ["cell", "ANATOMY", 59, 63], ["cells", "ANATOMY", 101, 106], ["cell", "CELL", 5, 9], ["human", "ORGANISM", 38, 43], ["cell cultures", "CELL", 44, 57], ["cell", "CELL", 59, 63], ["cells", "CELL", 101, 106], ["human cell cultures", "CELL_LINE", 38, 57], ["antigens", "PROTEIN", 73, 81], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["human cell cultures", "TEST", 38, 57], ["cell-specific antigens", "TEST", 59, 81]]], ["Estrogen and triiodothyronine (T3) are useful tools both in vitro and in vivo for assessing survival and differentiation of oligodendrocytes and their progenitors.", [["oligodendrocytes", "ANATOMY", 124, 140], ["progenitors", "ANATOMY", 151, 162], ["triiodothyronine", "CHEMICAL", 13, 29], ["Estrogen", "CHEMICAL", 0, 8], ["triiodothyronine", "CHEMICAL", 13, 29], ["Estrogen", "GENE_OR_GENE_PRODUCT", 0, 8], ["triiodothyronine", "SIMPLE_CHEMICAL", 13, 29], ["T3", "SIMPLE_CHEMICAL", 31, 33], ["oligodendrocytes", "CELL", 124, 140], ["progenitors", "CELL", 151, 162], ["oligodendrocytes", "CELL_TYPE", 124, 140], ["Estrogen and triiodothyronine (T3", "TREATMENT", 0, 33], ["oligodendrocytes", "PROBLEM", 124, 140]]], ["Estrogen receptor-a and b (ERa, ERb) have been detected on primary neonatal rat and mouse oligodendrocytes and their precursors in vitro and in vivo.", [["oligodendrocytes", "ANATOMY", 90, 106], ["Estrogen", "CHEMICAL", 0, 8], ["Estrogen receptor-a", "GENE_OR_GENE_PRODUCT", 0, 19], ["b", "GENE_OR_GENE_PRODUCT", 24, 25], ["ERa", "GENE_OR_GENE_PRODUCT", 27, 30], ["ERb", "GENE_OR_GENE_PRODUCT", 32, 35], ["rat", "ORGANISM", 76, 79], ["mouse", "ORGANISM", 84, 89], ["oligodendrocytes", "CELL", 90, 106], ["Estrogen receptor", "PROTEIN", 0, 17], ["ERa", "PROTEIN", 27, 30], ["ERb", "PROTEIN", 32, 35], ["primary neonatal rat and mouse oligodendrocytes", "CELL_TYPE", 59, 106], ["rat", "SPECIES", 76, 79], ["mouse", "SPECIES", 84, 89], ["rat", "SPECIES", 76, 79], ["mouse", "SPECIES", 84, 89], ["Estrogen receptor", "TREATMENT", 0, 17], ["mouse oligodendrocytes", "PROBLEM", 84, 106]]], ["Double staining for immature (A2B5 + ) and mature (MBP + ) cells with ERa or ERb-specific antibodies demonstrated subcellular localization in the nucleus and cytoplasm by confocal microscopy; nuclear compartmentalization became more pronounced with cell maturation (Takao et al, 2004) .", [["MBP + ) cells", "ANATOMY", 51, 64], ["subcellular", "ANATOMY", 114, 125], ["nucleus", "ANATOMY", 146, 153], ["cytoplasm", "ANATOMY", 158, 167], ["nuclear", "ANATOMY", 192, 199], ["cell", "ANATOMY", 249, 253], ["MBP", "GENE_OR_GENE_PRODUCT", 51, 54], ["ERa", "GENE_OR_GENE_PRODUCT", 70, 73], ["ERb", "GENE_OR_GENE_PRODUCT", 77, 80], ["nucleus", "CELLULAR_COMPONENT", 146, 153], ["cytoplasm", "ORGANISM_SUBSTANCE", 158, 167], ["nuclear", "CELLULAR_COMPONENT", 192, 199], ["cell", "CELL", 249, 253], ["A2B5", "PROTEIN", 30, 34], ["MBP", "PROTEIN", 51, 54], ["ERa", "PROTEIN", 70, 73], ["ERb", "PROTEIN", 77, 80], ["Double staining", "TEST", 0, 15], ["A2B5", "TEST", 30, 34], ["mature (MBP + ) cells", "PROBLEM", 43, 64], ["ERa or ERb", "TEST", 70, 80], ["specific antibodies", "TEST", 81, 100], ["confocal microscopy", "TEST", 171, 190], ["nuclear compartmentalization", "TEST", 192, 220], ["cell maturation", "PROBLEM", 249, 264], ["nucleus", "ANATOMY", 146, 153], ["more pronounced", "OBSERVATION_MODIFIER", 228, 243]]], ["Although 17bestradiol (E2) had no effects on cell proliferation, it did drive the increase in processes after 4 days in vitro at 50-500 nM (Zhang et al, 2004) .", [["cell", "ANATOMY", 45, 49], ["17bestradiol", "CHEMICAL", 9, 21], ["E2", "CHEMICAL", 23, 25], ["17bestradiol", "CHEMICAL", 9, 21], ["17bestradiol", "SIMPLE_CHEMICAL", 9, 21], ["E2", "SIMPLE_CHEMICAL", 23, 25], ["cell", "CELL", 45, 49], ["cell proliferation", "PROBLEM", 45, 63], ["cell proliferation", "OBSERVATION", 45, 63], ["increase", "OBSERVATION_MODIFIER", 82, 90]]], ["E2 also protected immature and mature primary and CG4 cells from SIN-1 cytotoxicity at 20-200 nM.", [["primary", "ANATOMY", 38, 45], ["CG4 cells", "ANATOMY", 50, 59], ["E2", "CHEMICAL", 0, 2], ["E2", "GENE_OR_GENE_PRODUCT", 0, 2], ["CG4 cells", "CELL", 50, 59], ["SIN-1", "GENE_OR_GENE_PRODUCT", 65, 70], ["immature and mature primary and CG4 cells", "CELL_TYPE", 18, 59], ["mature", "OBSERVATION_MODIFIER", 31, 37], ["primary", "OBSERVATION_MODIFIER", 38, 45]]], ["This protective mechanism required 17 h pretreatment with E2, as confirmed by LDH and MTT readouts, and was blocked by ICI 182780, an inhibitor blocking ERa and ERb receptors (Takao et al, 2004) .", [["E2", "CHEMICAL", 58, 60], ["ICI 182780", "CHEMICAL", 119, 129], ["MTT", "CHEMICAL", 86, 89], ["ICI 182780", "CHEMICAL", 119, 129], ["E2", "SIMPLE_CHEMICAL", 58, 60], ["LDH", "SIMPLE_CHEMICAL", 78, 81], ["MTT", "SIMPLE_CHEMICAL", 86, 89], ["ICI 182780", "SIMPLE_CHEMICAL", 119, 129], ["ERa", "GENE_OR_GENE_PRODUCT", 153, 156], ["ERb receptors", "GENE_OR_GENE_PRODUCT", 161, 174], ["ERa", "PROTEIN", 153, 156], ["ERb receptors", "PROTEIN", 161, 174], ["E2", "TREATMENT", 58, 60], ["LDH", "TEST", 78, 81], ["MTT readouts", "TEST", 86, 98], ["an inhibitor blocking ERa", "TREATMENT", 131, 156], ["ERb receptors", "TREATMENT", 161, 174]]], ["The SIN-1 exposure time was 6 h for CG4 and 17 h for primary cells, thus making this assay a convenient one for functional assessment before testing into animal models.", [["primary cells", "ANATOMY", 53, 66], ["SIN-1", "GENE_OR_GENE_PRODUCT", 4, 9], ["cells", "CELL", 61, 66], ["primary cells", "CELL_TYPE", 53, 66], ["CG4", "TEST", 36, 39], ["primary cells", "PROBLEM", 53, 66], ["this assay", "TEST", 80, 90], ["functional assessment", "TEST", 112, 133]]], ["Assessment of T3 effects on aggregates or neural spheres is less straightforward but still achieveable, requiring 2-4 weeks exposure to hormone.", [["neural spheres", "ANATOMY", 42, 56], ["T3", "SIMPLE_CHEMICAL", 14, 16], ["T3 effects", "PROBLEM", 14, 24], ["hormone", "TREATMENT", 136, 143], ["T3", "ANATOMY", 14, 16], ["neural spheres", "OBSERVATION", 42, 56]]], ["Assays demonstrating myelin-specific transcripts and proteins, immunohistochemistry for cell surface markers of mature oligodendrocytes, and morphometry confirm maturation of oligodendrocytes in the mixed cultures (Murray and Dubois-Dalcq, 1997; Tosic et al, 1992) .Mechanisms: Survival and DifferentiationSmall molecules.", [["myelin", "ANATOMY", 21, 27], ["cell surface", "ANATOMY", 88, 100], ["oligodendrocytes", "ANATOMY", 119, 135], ["oligodendrocytes", "ANATOMY", 175, 191], ["myelin", "GENE_OR_GENE_PRODUCT", 21, 27], ["cell", "CELL", 88, 92], ["oligodendrocytes", "CELL", 119, 135], ["oligodendrocytes", "CELL", 175, 191], ["cell surface markers", "PROTEIN", 88, 108], ["mature oligodendrocytes", "CELL_TYPE", 112, 135], ["oligodendrocytes", "CELL_TYPE", 175, 191], ["Assays", "TEST", 0, 6], ["myelin", "PROBLEM", 21, 27], ["immunohistochemistry", "TEST", 63, 83], ["cell surface markers", "TEST", 88, 108], ["mature oligodendrocytes", "PROBLEM", 112, 135], ["morphometry", "TEST", 141, 152], ["oligodendrocytes", "PROBLEM", 175, 191], ["the mixed cultures", "TEST", 195, 213], ["Small molecules", "PROBLEM", 306, 321], ["mature oligodendrocytes", "OBSERVATION", 112, 135], ["Small molecules", "OBSERVATION", 306, 321]]], ["Small molecules are useful standard tools because they can be reproducibly generated and cost less than biologics. cAMP analogues have been shown to be oligoprotective and to drive differentiation. dbcAMP or 8-bromo-cAMP at 1 mM, increase the number of oligodendrocytes expressing myelin components in vitro after 1 week (Raible and McMorris, 1989) . cAMP-elevating agents like 10 mM forskolin, 100 mM dbcAMP, and PDEIV antagonists, propentofylline (100 mM) and ibudilast (100 mM) all prevent kainateinduced LDH release in oligodendrocyte cultures.Mechanisms: Survival and DifferentiationRecently, a small molecule currently in clinical trials for the treatment of MS has been investigated for its effect on survival and differentiation of oligodendrocytes in vitro.", [["oligodendrocytes", "ANATOMY", 253, 269], ["myelin components", "ANATOMY", 281, 298], ["oligodendrocyte cultures", "ANATOMY", 523, 547], ["oligodendrocytes", "ANATOMY", 740, 756], ["cAMP", "CHEMICAL", 115, 119], ["dbcAMP", "CHEMICAL", 198, 204], ["8-bromo-cAMP", "CHEMICAL", 208, 220], ["cAMP", "CHEMICAL", 351, 355], ["forskolin", "CHEMICAL", 384, 393], ["dbcAMP", "CHEMICAL", 402, 408], ["propentofylline", "CHEMICAL", 433, 448], ["ibudilast", "CHEMICAL", 462, 471], ["MS", "DISEASE", 665, 667], ["cAMP", "CHEMICAL", 115, 119], ["dbcAMP", "CHEMICAL", 198, 204], ["8-bromo-cAMP", "CHEMICAL", 208, 220], ["cAMP", "CHEMICAL", 351, 355], ["forskolin", "CHEMICAL", 384, 393], ["dbcAMP", "CHEMICAL", 402, 408], ["propentofylline", "CHEMICAL", 433, 448], ["ibudilast", "CHEMICAL", 462, 471], ["cAMP", "SIMPLE_CHEMICAL", 115, 119], ["dbcAMP", "SIMPLE_CHEMICAL", 198, 204], ["8-bromo-cAMP", "SIMPLE_CHEMICAL", 208, 220], ["oligodendrocytes", "CELL", 253, 269], ["myelin components", "CELLULAR_COMPONENT", 281, 298], ["cAMP", "SIMPLE_CHEMICAL", 351, 355], ["forskolin", "SIMPLE_CHEMICAL", 384, 393], ["dbcAMP", "SIMPLE_CHEMICAL", 402, 408], ["PDEIV antagonists", "SIMPLE_CHEMICAL", 414, 431], ["propentofylline", "SIMPLE_CHEMICAL", 433, 448], ["ibudilast", "SIMPLE_CHEMICAL", 462, 471], ["LDH", "GENE_OR_GENE_PRODUCT", 508, 511], ["oligodendrocyte cultures", "CELL", 523, 547], ["oligodendrocytes", "CELL", 740, 756], ["oligodendrocytes", "CELL_TYPE", 253, 269], ["LDH", "PROTEIN", 508, 511], ["oligodendrocyte cultures", "CELL_LINE", 523, 547], ["oligodendrocytes", "CELL_TYPE", 740, 756], ["Small molecules", "PROBLEM", 0, 15], ["cAMP analogues", "PROBLEM", 115, 129], ["dbcAMP", "TREATMENT", 198, 204], ["cAMP-elevating agents", "TREATMENT", 351, 372], ["10 mM forskolin", "TREATMENT", 378, 393], ["100 mM dbcAMP", "TREATMENT", 395, 408], ["PDEIV antagonists", "TREATMENT", 414, 431], ["propentofylline", "TREATMENT", 433, 448], ["ibudilast", "TREATMENT", 462, 471], ["LDH release", "TEST", 508, 519], ["oligodendrocyte cultures", "TEST", 523, 547], ["a small molecule", "PROBLEM", 598, 614], ["MS", "PROBLEM", 665, 667], ["survival", "TREATMENT", 708, 716], ["oligodendrocytes", "PROBLEM", 740, 756], ["molecules", "OBSERVATION", 6, 15], ["small", "OBSERVATION_MODIFIER", 600, 605], ["molecule", "OBSERVATION", 606, 614]]], ["FTY720 is a lipophilic sphingosine-1-phosphate (S1P) analogue that crosses the BBB, currently in Phase III clinical trials for MS as an antiinflammatory agent (Kappos et al, 2006) .", [["BBB", "ANATOMY", 79, 82], ["FTY720", "CHEMICAL", 0, 6], ["sphingosine-1-phosphate", "CHEMICAL", 23, 46], ["S1P", "CHEMICAL", 48, 51], ["MS", "DISEASE", 127, 129], ["FTY720", "CHEMICAL", 0, 6], ["sphingosine-1-phosphate", "CHEMICAL", 23, 46], ["S1P", "CHEMICAL", 48, 51], ["FTY720", "SIMPLE_CHEMICAL", 0, 6], ["sphingosine-1-phosphate", "SIMPLE_CHEMICAL", 23, 46], ["S1P", "SIMPLE_CHEMICAL", 48, 51], ["BBB", "MULTI-TISSUE_STRUCTURE", 79, 82], ["a lipophilic sphingosine", "TEST", 10, 34], ["phosphate (S1P) analogue", "TREATMENT", 37, 61], ["MS", "PROBLEM", 127, 129], ["an antiinflammatory agent", "TREATMENT", 133, 158], ["BBB", "ANATOMY", 79, 82]]], ["FTY720 is an agonist of four G protein-coupled receptors S1P1, 3, 4, and 5, all members of the endothelial differentiation gene-related (Edg) family (Davis et al, 2005; Mandala et al, 2002) .", [["endothelial", "ANATOMY", 95, 106], ["FTY720", "CHEMICAL", 0, 6], ["FTY720", "CHEMICAL", 0, 6], ["FTY720", "SIMPLE_CHEMICAL", 0, 6], ["G protein-coupled receptors", "GENE_OR_GENE_PRODUCT", 29, 56], ["S1P1", "GENE_OR_GENE_PRODUCT", 57, 61], ["3", "GENE_OR_GENE_PRODUCT", 63, 64], ["4", "GENE_OR_GENE_PRODUCT", 66, 67], ["5", "GENE_OR_GENE_PRODUCT", 73, 74], ["endothelial", "CELL", 95, 106], ["Edg", "GENE_OR_GENE_PRODUCT", 137, 140], ["G protein-coupled receptors S1P1, 3, 4, and 5", "PROTEIN", 29, 74], ["endothelial differentiation gene", "DNA", 95, 127], ["four G protein", "TEST", 24, 38], ["endothelial", "ANATOMY", 95, 106]]], ["Different time and dose-dependent effects of S1P have been reported for rodent progenitors and mature oligodendrocytes in vitro including process retraction or cell survival (Jaillard et al, 2005) .", [["progenitors", "ANATOMY", 79, 90], ["oligodendrocytes", "ANATOMY", 102, 118], ["cell", "ANATOMY", 160, 164], ["S1P", "CHEMICAL", 45, 48], ["S1P", "CHEMICAL", 45, 48], ["S1P", "GENE_OR_GENE_PRODUCT", 45, 48], ["progenitors", "CELL", 79, 90], ["oligodendrocytes", "CELL", 102, 118], ["cell", "CELL", 160, 164], ["S1P", "PROTEIN", 45, 48], ["rodent progenitors", "CELL_TYPE", 72, 90], ["mature oligodendrocytes", "CELL_TYPE", 95, 118], ["rodent", "SPECIES", 72, 78], ["S1P", "TREATMENT", 45, 48], ["rodent progenitors", "PROBLEM", 72, 90], ["mature oligodendrocytes", "PROBLEM", 95, 118], ["process retraction", "TREATMENT", 138, 156], ["cell survival", "TREATMENT", 160, 173], ["mature oligodendrocytes", "OBSERVATION", 95, 118], ["retraction", "OBSERVATION_MODIFIER", 146, 156]]], ["Some of the same effects are seen in human progenitors exposed to FTY720 in vitro as reported by Miron et al, (2007) such as progenitor survival following growth factor removal in 2-day cultures after exposure to 10 nM FTY720.", [["progenitors", "ANATOMY", 43, 54], ["progenitor", "ANATOMY", 125, 135], ["FTY720", "CHEMICAL", 66, 72], ["FTY720", "CHEMICAL", 219, 225], ["FTY720", "CHEMICAL", 66, 72], ["FTY720", "CHEMICAL", 219, 225], ["human", "ORGANISM", 37, 42], ["progenitors", "CELL", 43, 54], ["FTY720", "SIMPLE_CHEMICAL", 66, 72], ["progenitor", "CELL", 125, 135], ["FTY720", "SIMPLE_CHEMICAL", 219, 225], ["human progenitors", "CELL_TYPE", 37, 54], ["growth factor", "PROTEIN", 155, 168], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["progenitor survival", "TREATMENT", 125, 144], ["growth factor removal", "TREATMENT", 155, 176]]], ["Nevertheless, previous studies showed that S1P could not rescue rodent preoligodendrocytes from growth factor withdrawal-induced death, suggesting differences in either relative S1P receptor levels or subtypes or associated signaling cascades between humans and rodents (Toman et al, 2004) .", [["S1P", "CHEMICAL", 43, 46], ["preoligodendrocytes", "DISEASE", 71, 90], ["death", "DISEASE", 129, 134], ["S1P", "CHEMICAL", 43, 46], ["S1P", "CHEMICAL", 178, 181], ["S1P", "GENE_OR_GENE_PRODUCT", 43, 46], ["S1P receptor", "GENE_OR_GENE_PRODUCT", 178, 190], ["humans", "ORGANISM", 251, 257], ["rodent preoligodendrocytes", "CELL_TYPE", 64, 90], ["growth factor", "PROTEIN", 96, 109], ["S1P receptor", "PROTEIN", 178, 190], ["rodent", "SPECIES", 64, 70], ["humans", "SPECIES", 251, 257], ["humans", "SPECIES", 251, 257], ["previous studies", "TEST", 14, 30], ["rodent preoligodendrocytes", "PROBLEM", 64, 90], ["growth factor withdrawal", "PROBLEM", 96, 120], ["induced death", "PROBLEM", 121, 134], ["signaling cascades", "OBSERVATION", 224, 242]]], ["Table 1 summarizes the benefits and liabilities of the in vitro models assays in drug discovery for modeling survival and repair.Mechanisms: Survival and DifferentiationAbbreviations: NA information not available; ON, optic nerve; oligo, oligodendrocyte; T3, thyroid hormone; no., number; mos, months.CONCLUSIONSIf the primary screen is performed with human cells, it is critical to have rodent oligodendrocyte in vitro assays as secondary or tertiary screens.", [["optic nerve", "ANATOMY", 218, 229], ["oligodendrocyte", "ANATOMY", 238, 253], ["cells", "ANATOMY", 358, 363], ["oligodendrocyte", "ANATOMY", 395, 410], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 218, 229], ["oligodendrocyte", "CELL", 238, 253], ["T3", "GENE_OR_GENE_PRODUCT", 255, 257], ["thyroid hormone", "GENE_OR_GENE_PRODUCT", 259, 274], ["human", "ORGANISM", 352, 357], ["cells", "CELL", 358, 363], ["oligodendrocyte", "CELL", 395, 410], ["human cells", "CELL_TYPE", 352, 363], ["human", "SPECIES", 352, 357], ["human", "SPECIES", 352, 357], ["modeling survival", "TREATMENT", 100, 117], ["repair", "TREATMENT", 122, 128], ["oligo, oligodendrocyte", "PROBLEM", 231, 253], ["the primary screen", "TEST", 315, 333], ["rodent oligodendrocyte in vitro assays", "PROBLEM", 388, 426], ["tertiary screens", "TEST", 443, 459], ["optic nerve", "ANATOMY", 218, 229], ["thyroid", "ANATOMY", 259, 266]]], ["It is essential to establish efficacy in vitro in rodent cells as these compounds will ultimately be evaluated in vivo in animal models of demyelination and remyelination.", [["cells", "ANATOMY", 57, 62], ["demyelination", "DISEASE", 139, 152], ["remyelination", "DISEASE", 157, 170], ["cells", "CELL", 57, 62], ["rodent cells", "CELL_TYPE", 50, 62], ["vitro in rodent cells", "TREATMENT", 41, 62], ["demyelination", "PROBLEM", 139, 152], ["remyelination", "PROBLEM", 157, 170], ["demyelination", "OBSERVATION", 139, 152]]], ["If the primary screen is performed with rodent cells or cell lines, it is equally critical, given the possibility of species specificity of drugs, to have an in vitro assessment of the positive effects of development candidate drugs in human cultures.", [["cells", "ANATOMY", 47, 52], ["cell lines", "ANATOMY", 56, 66], ["cells", "CELL", 47, 52], ["cell lines", "CELL", 56, 66], ["human", "ORGANISM", 236, 241], ["rodent cells", "CELL_TYPE", 40, 52], ["cell lines", "CELL_LINE", 56, 66], ["human cultures", "CELL_LINE", 236, 250], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["the primary screen", "TEST", 3, 21], ["cell lines", "TREATMENT", 56, 66], ["drugs", "TREATMENT", 140, 145], ["an in vitro assessment", "TEST", 155, 177], ["development candidate drugs", "TREATMENT", 205, 232], ["human cultures", "TEST", 236, 250], ["cell lines", "OBSERVATION", 56, 66]]], ["In addition to the limitations of using in vitro rodent surrogate cells for screening drugs that will ultimately be used in patients, the choice of human cells for drug screens in vitro may influence the testing outcome.", [["cells", "ANATOMY", 66, 71], ["cells", "ANATOMY", 154, 159], ["cells", "CELL", 66, 71], ["patients", "ORGANISM", 124, 132], ["human", "ORGANISM", 148, 153], ["cells", "CELL", 154, 159], ["in vitro rodent surrogate cells", "CELL_LINE", 40, 71], ["human cells", "CELL_TYPE", 148, 159], ["patients", "SPECIES", 124, 132], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 148, 153], ["vitro rodent surrogate cells", "TREATMENT", 43, 71], ["screening drugs", "TREATMENT", 76, 91], ["human cells", "TREATMENT", 148, 159], ["drug screens", "TEST", 164, 176], ["the testing outcome", "TEST", 200, 219]]], ["These caveats should be kept in mind with respect to expectations of compoundmediated effects in humans in clinical trials.Mechanisms: Cell Death and Myelin DamageProinflammatory cytokines.", [["Cell", "ANATOMY", 135, 139], ["humans", "ORGANISM", 97, 103], ["Cell", "CELL", 135, 139], ["Myelin DamageProinflammatory cytokines", "GENE_OR_GENE_PRODUCT", 150, 188], ["Myelin DamageProinflammatory cytokines", "PROTEIN", 150, 188], ["humans", "SPECIES", 97, 103], ["humans", "SPECIES", 97, 103], ["Cell Death", "PROBLEM", 135, 145], ["Myelin DamageProinflammatory cytokines", "PROBLEM", 150, 188], ["Cell Death", "OBSERVATION", 135, 145], ["Myelin DamageProinflammatory cytokines", "OBSERVATION", 150, 188]]], ["Although many studies use mature rodent oligodendrocytes, their progenitors, or mixed rodent cultures to examine mechanisms of cell death, there are very few studies using human cells (Merrill and Scolding, 1999; Casaccia-Bonnefil, 2000) .", [["oligodendrocytes", "ANATOMY", 40, 56], ["progenitors", "ANATOMY", 64, 75], ["cell", "ANATOMY", 127, 131], ["cells", "ANATOMY", 178, 183], ["death", "DISEASE", 132, 137], ["rodent", "ORGANISM", 33, 39], ["oligodendrocytes", "CELL", 40, 56], ["progenitors", "CELL", 64, 75], ["cell", "CELL", 127, 131], ["human", "ORGANISM", 172, 177], ["cells", "CELL", 178, 183], ["mature rodent oligodendrocytes", "CELL_TYPE", 26, 56], ["human cells", "CELL_TYPE", 172, 183], ["rodent", "SPECIES", 33, 39], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["mature rodent oligodendrocytes", "PROBLEM", 26, 56], ["mixed rodent cultures", "TEST", 80, 101], ["cell death", "PROBLEM", 127, 137], ["Casaccia", "TEST", 213, 221], ["cell death", "OBSERVATION", 127, 137]]], ["A review of the wide array of in vitro paradigms shows that mechanisms and pathways of cell death vary considerably.", [["cell", "ANATOMY", 87, 91], ["death", "DISEASE", 92, 97], ["cell", "CELL", 87, 91], ["vitro paradigms", "TEST", 33, 48], ["cell death", "PROBLEM", 87, 97]]], ["One striking example is NGF's activation of the low-affinity receptor (NGFR, in the absence of functional trkA) leading to cell death.", [["cell", "ANATOMY", 123, 127], ["death", "DISEASE", 128, 133], ["NGF", "GENE_OR_GENE_PRODUCT", 24, 27], ["low-affinity receptor", "GENE_OR_GENE_PRODUCT", 48, 69], ["NGFR", "GENE_OR_GENE_PRODUCT", 71, 75], ["trkA", "GENE_OR_GENE_PRODUCT", 106, 110], ["cell", "CELL", 123, 127], ["NGF", "PROTEIN", 24, 27], ["low-affinity receptor", "PROTEIN", 48, 69], ["NGFR", "PROTEIN", 71, 75], ["trkA", "PROTEIN", 106, 110], ["cell death", "PROBLEM", 123, 133], ["cell death", "OBSERVATION", 123, 133]]], ["In mature oligodendrocyte or cells where the ratio of p75 to trk is greater than 1 : 1 apoptosis occurs.", [["oligodendrocyte", "ANATOMY", 10, 25], ["cells", "ANATOMY", 29, 34], ["oligodendrocyte", "CELL", 10, 25], ["cells", "CELL", 29, 34], ["p75", "GENE_OR_GENE_PRODUCT", 54, 57], ["trk", "GENE_OR_GENE_PRODUCT", 61, 64], ["mature oligodendrocyte or cells", "CELL_TYPE", 3, 34], ["p75", "PROTEIN", 54, 57], ["trk", "PROTEIN", 61, 64], ["the ratio", "TEST", 41, 50], ["trk", "TEST", 61, 64], ["mature oligodendrocyte", "OBSERVATION", 3, 25]]], ["Proinflammatory cytokines like IL1b, IFNg, or TNFa can all induce ceramide production in oligodendrocytes leading to either apoptotic or necrotic cell death (Chakraborty et al, 1997; Casaccia-Bonnefil et al, 1996; Brogi et al, 1997) .Mechanisms: Cell Death and Myelin DamageCeramide.", [["oligodendrocytes", "ANATOMY", 89, 105], ["necrotic cell", "ANATOMY", 137, 150], ["Cell", "ANATOMY", 246, 250], ["ceramide", "CHEMICAL", 66, 74], ["necrotic", "DISEASE", 137, 145], ["death", "DISEASE", 151, 156], ["ceramide", "CHEMICAL", 66, 74], ["IL1b", "GENE_OR_GENE_PRODUCT", 31, 35], ["IFNg", "GENE_OR_GENE_PRODUCT", 37, 41], ["TNFa", "GENE_OR_GENE_PRODUCT", 46, 50], ["ceramide", "SIMPLE_CHEMICAL", 66, 74], ["oligodendrocytes", "CELL", 89, 105], ["necrotic cell", "CELL", 137, 150], ["Cell", "CELL", 246, 250], ["Myelin DamageCeramide", "GENE_OR_GENE_PRODUCT", 261, 282], ["Proinflammatory cytokines", "PROTEIN", 0, 25], ["IL1b", "PROTEIN", 31, 35], ["IFNg", "PROTEIN", 37, 41], ["TNFa", "PROTEIN", 46, 50], ["oligodendrocytes", "CELL_TYPE", 89, 105], ["Myelin DamageCeramide", "PROTEIN", 261, 282], ["Proinflammatory cytokines", "TEST", 0, 25], ["IL1b", "PROBLEM", 31, 35], ["TNFa", "PROBLEM", 46, 50], ["ceramide production in oligodendrocytes", "PROBLEM", 66, 105], ["apoptotic or necrotic cell death", "PROBLEM", 124, 156], ["Casaccia", "TEST", 183, 191], ["Cell Death", "PROBLEM", 246, 256], ["Myelin DamageCeramide", "TREATMENT", 261, 282], ["necrotic cell death", "OBSERVATION", 137, 156], ["Cell Death", "OBSERVATION", 246, 256]]], ["Ceramide, a sphingolipid generated by neutral or acidic sphingomyelinase action on sphingomyelin, is a second messenger capable of mediating oligodendrocyte cell death.", [["oligodendrocyte cell", "ANATOMY", 141, 161], ["Ceramide", "CHEMICAL", 0, 8], ["sphingomyelin", "CHEMICAL", 83, 96], ["death", "DISEASE", 162, 167], ["Ceramide", "CHEMICAL", 0, 8], ["sphingolipid", "CHEMICAL", 12, 24], ["sphingomyelin", "CHEMICAL", 83, 96], ["Ceramide", "SIMPLE_CHEMICAL", 0, 8], ["sphingomyelinase", "SIMPLE_CHEMICAL", 56, 72], ["sphingomyelin", "SIMPLE_CHEMICAL", 83, 96], ["oligodendrocyte cell", "CELL", 141, 161], ["acidic sphingomyelinase", "PROTEIN", 49, 72], ["Ceramide", "TREATMENT", 0, 8], ["sphingomyelin", "TREATMENT", 83, 96], ["oligodendrocyte cell death", "PROBLEM", 141, 167], ["oligodendrocyte cell death", "OBSERVATION", 141, 167]]], ["Apoptotic death occurs as a consequence of ceramide's elevation of c-jun through c-jun amino-terminal kinase (JNK) activity (Casaccia-Bonnefil, 2000) .", [["death", "DISEASE", 10, 15], ["ceramide", "CHEMICAL", 43, 51], ["ceramide", "CHEMICAL", 43, 51], ["amino", "CHEMICAL", 87, 92], ["ceramide", "SIMPLE_CHEMICAL", 43, 51], ["c-jun", "GENE_OR_GENE_PRODUCT", 67, 72], ["c-jun amino-terminal kinase", "GENE_OR_GENE_PRODUCT", 81, 108], ["JNK", "GENE_OR_GENE_PRODUCT", 110, 113], ["jun", "PROTEIN", 69, 72], ["c-jun amino-terminal kinase", "PROTEIN", 81, 108], ["JNK", "PROTEIN", 110, 113], ["Apoptotic death", "PROBLEM", 0, 15], ["ceramide's elevation", "PROBLEM", 43, 63], ["Casaccia", "TEST", 125, 133], ["terminal kinase", "ANATOMY", 93, 108]]], ["This agent can be used as a direct toxin in vitro to kill oligodendrocytes.", [["oligodendrocytes", "ANATOMY", 58, 74], ["oligodendrocytes", "CELL", 58, 74], ["oligodendrocytes", "CELL_TYPE", 58, 74], ["This agent", "TREATMENT", 0, 10], ["a direct toxin", "TREATMENT", 26, 40]]], ["Primary oligodendrocyte precursors and mature oligodendrocytes behave similarly to undifferentiated and differentiated CG4 cells, respectively, in response to C2 ceramide or C6 ceramide in that maximal cell death is achieved at 10 mM.", [["Primary oligodendrocyte precursors", "ANATOMY", 0, 34], ["oligodendrocytes", "ANATOMY", 46, 62], ["CG4 cells", "ANATOMY", 119, 128], ["cell", "ANATOMY", 202, 206], ["C2 ceramide", "CHEMICAL", 159, 170], ["C6 ceramide", "CHEMICAL", 174, 185], ["death", "DISEASE", 207, 212], ["C2 ceramide", "CHEMICAL", 159, 170], ["ceramide", "CHEMICAL", 177, 185], ["oligodendrocyte precursors", "CELL", 8, 34], ["oligodendrocytes", "CELL", 46, 62], ["CG4 cells", "CELL", 119, 128], ["C2 ceramide", "SIMPLE_CHEMICAL", 159, 170], ["C6 ceramide", "SIMPLE_CHEMICAL", 174, 185], ["cell", "CELL", 202, 206], ["Primary oligodendrocyte precursors", "CELL_TYPE", 0, 34], ["mature oligodendrocytes", "CELL_TYPE", 39, 62], ["CG4 cells", "CELL_LINE", 119, 128], ["Primary oligodendrocyte precursors", "TEST", 0, 34], ["mature oligodendrocytes", "PROBLEM", 39, 62], ["undifferentiated and differentiated CG4 cells", "PROBLEM", 83, 128], ["C2 ceramide", "TREATMENT", 159, 170], ["C6 ceramide", "TREATMENT", 174, 185], ["maximal cell death", "PROBLEM", 194, 212], ["oligodendrocyte precursors", "OBSERVATION", 8, 34], ["mature oligodendrocytes", "OBSERVATION", 39, 62], ["undifferentiated", "OBSERVATION_MODIFIER", 83, 99], ["differentiated", "OBSERVATION_MODIFIER", 104, 118], ["CG4 cells", "OBSERVATION", 119, 128], ["C6 ceramide", "ANATOMY", 174, 185], ["maximal cell death", "OBSERVATION", 194, 212]]], ["Primary progenitors are more sensitive to ceramide than mature primary oligodendrocytes but CG4 cells appear to be more sensitive than primary cells in this assay.", [["Primary progenitors", "ANATOMY", 0, 19], ["primary oligodendrocytes", "ANATOMY", 63, 87], ["CG4 cells", "ANATOMY", 92, 101], ["primary cells", "ANATOMY", 135, 148], ["ceramide", "CHEMICAL", 42, 50], ["ceramide", "CHEMICAL", 42, 50], ["Primary progenitors", "CELL", 0, 19], ["ceramide", "SIMPLE_CHEMICAL", 42, 50], ["oligodendrocytes", "CELL", 71, 87], ["CG4 cells", "CELL", 92, 101], ["cells", "CELL", 143, 148], ["Primary progenitors", "CELL_TYPE", 0, 19], ["mature primary oligodendrocytes", "CELL_TYPE", 56, 87], ["CG4 cells", "CELL_LINE", 92, 101], ["primary cells", "CELL_TYPE", 135, 148], ["mature primary oligodendrocytes", "PROBLEM", 56, 87], ["CG4 cells", "PROBLEM", 92, 101], ["this assay", "TEST", 152, 162], ["primary oligodendrocytes", "OBSERVATION", 63, 87]]], ["For CG4 cells, an assay time of 6 h is sufficient for achieving greater than 50% cell death.", [["CG4 cells", "ANATOMY", 4, 13], ["cell", "ANATOMY", 81, 85], ["death", "DISEASE", 86, 91], ["CG4 cells", "CELL", 4, 13], ["cell", "CELL", 81, 85], ["CG4 cells", "CELL_LINE", 4, 13], ["CG4 cells", "PROBLEM", 4, 13], ["an assay time", "TEST", 15, 28]]], ["Primary cells generally need to be exposed to the toxin for 24 h, especially at lower doses of C2.", [["Primary cells", "ANATOMY", 0, 13], ["Primary cells", "CELL", 0, 13], ["Primary cells", "PROBLEM", 0, 13], ["the toxin", "TEST", 46, 55], ["C2", "ANATOMY", 95, 97]]], ["Astrocytes and neurons are resistant to this form of cell death.", [["Astrocytes", "ANATOMY", 0, 10], ["neurons", "ANATOMY", 15, 22], ["cell", "ANATOMY", 53, 57], ["death", "DISEASE", 58, 63], ["Astrocytes", "CELL", 0, 10], ["neurons", "CELL", 15, 22], ["cell", "CELL", 53, 57], ["Astrocytes", "CELL_TYPE", 0, 10], ["neurons", "CELL_TYPE", 15, 22], ["cell death", "PROBLEM", 53, 63]]], ["Cell-based readouts for this assay include Live/Dead cell assay (Molecular Probes, Eugene, OR), apoptosis detection kit (ApopTag Plus; ONCOR, Gaithersburg, MD), or the MTT mitochondrial enzyme function assay using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (Boehringer, Mannheim, Germany).Mechanisms: Cell Death and Myelin DamageExcitotoxicity.", [["Cell", "ANATOMY", 0, 4], ["cell", "ANATOMY", 53, 57], ["mitochondrial", "ANATOMY", 172, 185], ["Cell", "ANATOMY", 320, 324], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 214, 275], ["MTT", "CHEMICAL", 168, 171], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "CHEMICAL", 214, 275], ["Cell", "CELL", 0, 4], ["Eugene", "SIMPLE_CHEMICAL", 83, 89], ["mitochondrial", "CELLULAR_COMPONENT", 172, 185], ["3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide", "SIMPLE_CHEMICAL", 214, 275], ["Cell", "CELL", 320, 324], ["Myelin", "GENE_OR_GENE_PRODUCT", 335, 341], ["this assay", "TEST", 24, 34], ["the MTT mitochondrial enzyme function assay", "TEST", 164, 207], ["dimethylthiazol", "TREATMENT", 221, 236], ["diphenyl tetrazolium bromide", "TREATMENT", 247, 275], ["Cell Death", "PROBLEM", 320, 330], ["Myelin DamageExcitotoxicity", "PROBLEM", 335, 362], ["Cell Death", "OBSERVATION", 320, 330], ["Myelin DamageExcitotoxicity", "OBSERVATION", 335, 362]]], ["Excitotoxicity, attributable to ischemia and inflammation, has been implicated in oligodendrocyte depletion within MS lesions (Raine, 1997; Prineas, 1985; Prineas et al, 1984 Prineas et al, , 1989 .", [["oligodendrocyte", "ANATOMY", 82, 97], ["MS lesions", "ANATOMY", 115, 125], ["Excitotoxicity", "DISEASE", 0, 14], ["ischemia", "DISEASE", 32, 40], ["inflammation", "DISEASE", 45, 57], ["oligodendrocyte", "CELL", 82, 97], ["MS lesions", "PATHOLOGICAL_FORMATION", 115, 125], ["Excitotoxicity", "PROBLEM", 0, 14], ["ischemia", "PROBLEM", 32, 40], ["inflammation", "PROBLEM", 45, 57], ["oligodendrocyte depletion", "PROBLEM", 82, 107], ["MS lesions", "PROBLEM", 115, 125], ["attributable to", "UNCERTAINTY", 16, 31], ["ischemia", "OBSERVATION", 32, 40], ["inflammation", "OBSERVATION", 45, 57], ["oligodendrocyte depletion", "OBSERVATION", 82, 107], ["lesions", "OBSERVATION", 118, 125]]], ["Cells of the oligodendrocyte lineage express both kainate and a-amino-3-hydroxy-5methyl-4-isoxazoleproprionate (AMPA)-type non-Nmethyl-D-aspartic acid glutamate receptors (Patneau et al, 1994; Yoshioka et al, 1995) .", [["Cells", "ANATOMY", 0, 5], ["oligodendrocyte lineage", "ANATOMY", 13, 36], ["kainate", "CHEMICAL", 50, 57], ["a-amino-3-hydroxy-5methyl-4-isoxazoleproprionate", "CHEMICAL", 62, 110], ["AMPA", "CHEMICAL", 112, 116], ["non-Nmethyl-D-aspartic acid", "CHEMICAL", 123, 150], ["glutamate", "CHEMICAL", 151, 160], ["kainate", "CHEMICAL", 50, 57], ["a-amino-3-hydroxy-5methyl-4-isoxazoleproprionate", "CHEMICAL", 62, 110], ["AMPA", "CHEMICAL", 112, 116], ["non-Nmethyl-D-aspartic acid", "CHEMICAL", 123, 150], ["glutamate", "CHEMICAL", 151, 160], ["Cells", "CELL", 0, 5], ["oligodendrocyte lineage", "CELL", 13, 36], ["kainate", "SIMPLE_CHEMICAL", 50, 57], ["a-amino-3-hydroxy-5methyl-4-isoxazoleproprionate", "SIMPLE_CHEMICAL", 62, 110], ["AMPA", "SIMPLE_CHEMICAL", 112, 116], ["non-Nmethyl-D-aspartic acid", "SIMPLE_CHEMICAL", 123, 150], ["oligodendrocyte lineage", "CELL_TYPE", 13, 36], ["kainate", "TEST", 50, 57], ["a-amino", "TEST", 62, 69], ["hydroxy", "TEST", 72, 79], ["5methyl", "TREATMENT", 80, 87], ["isoxazoleproprionate (AMPA)", "TREATMENT", 90, 117], ["type non-Nmethyl-D-aspartic acid glutamate receptors", "TREATMENT", 118, 170]]], ["Prolonged activation of these receptors leads to increased intracellular calcium (Ca + + ), increased inositol phosphates and early gene induction and an inhibition of proliferation and migration of precursors (Gallo et al, 1996; Wang et al, 1996; Knutson et al, 1997) .", [["intracellular", "ANATOMY", 59, 72], ["calcium", "CHEMICAL", 73, 80], ["Ca", "CHEMICAL", 82, 84], ["inositol phosphates", "CHEMICAL", 102, 121], ["calcium", "CHEMICAL", 73, 80], ["Ca + + )", "CHEMICAL", 82, 90], ["inositol phosphates", "CHEMICAL", 102, 121], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 72], ["calcium", "SIMPLE_CHEMICAL", 73, 80], ["Ca + +", "SIMPLE_CHEMICAL", 82, 88], ["inositol phosphates", "SIMPLE_CHEMICAL", 102, 121], ["these receptors", "TREATMENT", 24, 39], ["increased intracellular calcium", "TEST", 49, 80], ["Ca", "TEST", 82, 84], ["increased inositol phosphates", "TREATMENT", 92, 121], ["early gene induction", "TREATMENT", 126, 146], ["proliferation", "PROBLEM", 168, 181], ["migration of precursors", "PROBLEM", 186, 209], ["inositol phosphates", "OBSERVATION", 102, 121], ["proliferation", "OBSERVATION", 168, 181]]], ["Mature oligodendrocyte death has also been shown to occur and can be modeled in vitro using CG4 cells that have been differentiated.", [["oligodendrocyte", "ANATOMY", 7, 22], ["CG4 cells", "ANATOMY", 92, 101], ["oligodendrocyte death", "DISEASE", 7, 28], ["oligodendrocyte", "CELL", 7, 22], ["CG4 cells", "CELL", 92, 101], ["CG4 cells", "CELL_LINE", 92, 101], ["Mature oligodendrocyte death", "PROBLEM", 0, 28], ["oligodendrocyte death", "OBSERVATION", 7, 28]]], ["Cells are cultured for 24 h in the presence of 2 mM kainate and cell death is quantitated by measuring the activity of lactate dehydrogenase (LDH) (Yoshioka et al, 1995) .Mechanisms: Cell Death and Myelin DamageFree radicals.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 64, 68], ["Cell", "ANATOMY", 183, 187], ["kainate", "CHEMICAL", 52, 59], ["death", "DISEASE", 69, 74], ["lactate", "CHEMICAL", 119, 126], ["kainate", "CHEMICAL", 52, 59], ["lactate", "CHEMICAL", 119, 126], ["Cells", "CELL", 0, 5], ["kainate", "SIMPLE_CHEMICAL", 52, 59], ["cell", "CELL", 64, 68], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 119, 140], ["LDH", "GENE_OR_GENE_PRODUCT", 142, 145], ["Cell", "CELL", 183, 187], ["Myelin DamageFree radicals", "SIMPLE_CHEMICAL", 198, 224], ["lactate dehydrogenase", "PROTEIN", 119, 140], ["LDH", "PROTEIN", 142, 145], ["2 mM kainate and cell death", "PROBLEM", 47, 74], ["lactate dehydrogenase", "TEST", 119, 140], ["LDH", "TEST", 142, 145], ["Cell Death", "PROBLEM", 183, 193], ["Myelin DamageFree radicals", "TREATMENT", 198, 224], ["cell death", "OBSERVATION", 64, 74], ["Cell Death", "OBSERVATION", 183, 193]]], ["Human glial cells and macrophages are capable of making NO in vitro and in vivo.", [["glial cells", "ANATOMY", 6, 17], ["macrophages", "ANATOMY", 22, 33], ["NO", "CHEMICAL", 56, 58], ["NO", "CHEMICAL", 56, 58], ["Human", "ORGANISM", 0, 5], ["glial cells", "CELL", 6, 17], ["macrophages", "CELL", 22, 33], ["NO", "SIMPLE_CHEMICAL", 56, 58], ["Human glial cells", "CELL_TYPE", 0, 17], ["macrophages", "CELL_TYPE", 22, 33], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human glial cells", "TREATMENT", 0, 17], ["glial cells", "OBSERVATION", 6, 17]]], ["Increased inducible NO synthase (iNOS) responsible for pathologyinducing NO levels can be detected in MS tissue by RT-PCR (Bo et al, 1994) .", [["MS tissue", "ANATOMY", 102, 111], ["NO", "CHEMICAL", 20, 22], ["NO", "CHEMICAL", 73, 75], ["NO", "CHEMICAL", 20, 22], ["NO", "CHEMICAL", 73, 75], ["inducible NO synthase", "GENE_OR_GENE_PRODUCT", 10, 31], ["iNOS", "GENE_OR_GENE_PRODUCT", 33, 37], ["NO", "GENE_OR_GENE_PRODUCT", 73, 75], ["MS tissue", "TISSUE", 102, 111], ["NO synthase", "PROTEIN", 20, 31], ["iNOS", "PROTEIN", 33, 37], ["Increased inducible NO synthase (iNOS)", "PROBLEM", 0, 38], ["pathologyinducing NO levels", "PROBLEM", 55, 82], ["RT", "TEST", 115, 117], ["PCR", "TEST", 118, 121], ["NO", "UNCERTAINTY", 20, 22]]], ["That the enzyme is actively producing NO is evidenced by (1) NADPH diaphorase staining in astrocytes at the edge of chronic lesions (Brosnan et al, 1994) , (2) increased levels of nitrite (NO 2 \u00c0 ) and nitrate (NO 3 \u00c0 ) in MS cerebrospinal fluid (CSF) (Johnson et al, 1995) , and nitrotyrosine (NT) staining in MS tissues indicative of peroxynitrite formation by the chemical reaction of NO and superoxide anion.", [["astrocytes", "ANATOMY", 90, 100], ["lesions", "ANATOMY", 124, 131], ["cerebrospinal fluid", "ANATOMY", 226, 245], ["MS tissues", "ANATOMY", 311, 321], ["NO", "CHEMICAL", 38, 40], ["NADPH", "CHEMICAL", 61, 66], ["nitrite", "CHEMICAL", 180, 187], ["NO", "CHEMICAL", 189, 191], ["nitrate", "CHEMICAL", 202, 209], ["NO", "CHEMICAL", 211, 213], ["nitrotyrosine", "CHEMICAL", 280, 293], ["peroxynitrite", "CHEMICAL", 336, 349], ["NO", "CHEMICAL", 388, 390], ["superoxide", "CHEMICAL", 395, 405], ["NO", "CHEMICAL", 38, 40], ["NADPH", "CHEMICAL", 61, 66], ["nitrite", "CHEMICAL", 180, 187], ["NO 2 \u00c0", "CHEMICAL", 189, 195], ["nitrate", "CHEMICAL", 202, 209], ["NO 3 \u00c0", "CHEMICAL", 211, 217], ["nitrotyrosine", "CHEMICAL", 280, 293], ["peroxynitrite", "CHEMICAL", 336, 349], ["NO", "CHEMICAL", 388, 390], ["superoxide", "CHEMICAL", 395, 405], ["NO", "SIMPLE_CHEMICAL", 38, 40], ["NADPH diaphorase", "GENE_OR_GENE_PRODUCT", 61, 77], ["astrocytes", "CELL", 90, 100], ["lesions", "PATHOLOGICAL_FORMATION", 124, 131], ["nitrite", "SIMPLE_CHEMICAL", 180, 187], ["NO 2 \u00c0", "SIMPLE_CHEMICAL", 189, 195], ["nitrate", "SIMPLE_CHEMICAL", 202, 209], ["NO 3 \u00c0", "SIMPLE_CHEMICAL", 211, 217], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 226, 245], ["CSF", "ORGANISM_SUBSTANCE", 247, 250], ["nitrotyrosine", "SIMPLE_CHEMICAL", 280, 293], ["NT", "SIMPLE_CHEMICAL", 295, 297], ["MS tissues", "TISSUE", 311, 321], ["peroxynitrite", "SIMPLE_CHEMICAL", 336, 349], ["NO", "SIMPLE_CHEMICAL", 388, 390], ["superoxide anion", "SIMPLE_CHEMICAL", 395, 411], ["astrocytes", "CELL_TYPE", 90, 100], ["the enzyme", "TEST", 5, 15], ["NADPH diaphorase staining in astrocytes", "PROBLEM", 61, 100], ["chronic lesions", "PROBLEM", 116, 131], ["increased levels of nitrite", "PROBLEM", 160, 187], ["nitrate", "TEST", 202, 209], ["MS cerebrospinal fluid", "TEST", 223, 245], ["nitrotyrosine (NT) staining in MS tissues", "PROBLEM", 280, 321], ["peroxynitrite formation", "PROBLEM", 336, 359], ["the chemical reaction", "PROBLEM", 363, 384], ["superoxide anion", "TREATMENT", 395, 411], ["astrocytes", "ANATOMY", 90, 100], ["chronic", "OBSERVATION_MODIFIER", 116, 123], ["lesions", "OBSERVATION", 124, 131], ["cerebrospinal", "ANATOMY", 226, 239], ["fluid", "OBSERVATION", 240, 245], ["peroxynitrite formation", "OBSERVATION", 336, 359]]], ["Additional evidence that lipid peroxidation occurs in MS tissues has been put forth in other references (Prineas et al, 1984 (Prineas et al, , 1989 Hunter et al, 1985; Raine and Wu, 1993) .Mechanisms: Cell Death and Myelin DamageOligodendrocytes and their precursors are easily damaged by free radicals of nitrogen and oxygen, with the less mature cells being more sensitive than myelin-producing cells.Mechanisms: Cell Death and Myelin DamageOligodendrocytes are more sensitive to the effects of free radicals than are microglia and astrocytes Husain and Juurlink, 1995) .", [["MS tissues", "ANATOMY", 54, 64], ["Cell", "ANATOMY", 201, 205], ["cells", "ANATOMY", 348, 353], ["myelin", "ANATOMY", 380, 386], ["cells", "ANATOMY", 397, 402], ["Cell", "ANATOMY", 415, 419], ["microglia", "ANATOMY", 520, 529], ["astrocytes", "ANATOMY", 534, 544], ["nitrogen", "CHEMICAL", 306, 314], ["oxygen", "CHEMICAL", 319, 325], ["nitrogen", "CHEMICAL", 306, 314], ["oxygen", "CHEMICAL", 319, 325], ["lipid", "SIMPLE_CHEMICAL", 25, 30], ["MS tissues", "TISSUE", 54, 64], ["Cell", "CELL", 201, 205], ["Myelin DamageOligodendrocytes", "GENE_OR_GENE_PRODUCT", 216, 245], ["nitrogen", "SIMPLE_CHEMICAL", 306, 314], ["oxygen", "SIMPLE_CHEMICAL", 319, 325], ["cells", "CELL", 348, 353], ["myelin", "GENE_OR_GENE_PRODUCT", 380, 386], ["cells", "CELL", 397, 402], ["Cell", "CELL", 415, 419], ["Myelin DamageOligodendrocytes", "GENE_OR_GENE_PRODUCT", 430, 459], ["microglia", "CELL", 520, 529], ["astrocytes", "CELL", 534, 544], ["Myelin DamageOligodendrocytes", "CELL_TYPE", 216, 245], ["mature cells", "CELL_TYPE", 341, 353], ["myelin-producing cells", "CELL_TYPE", 380, 402], ["Myelin DamageOligodendrocytes", "CELL_TYPE", 430, 459], ["microglia", "CELL_TYPE", 520, 529], ["astrocytes", "CELL_TYPE", 534, 544], ["lipid peroxidation", "PROBLEM", 25, 43], ["MS tissues", "PROBLEM", 54, 64], ["Cell Death", "PROBLEM", 201, 211], ["Myelin DamageOligodendrocytes", "PROBLEM", 216, 245], ["nitrogen", "TREATMENT", 306, 314], ["oxygen", "TREATMENT", 319, 325], ["the less mature cells", "PROBLEM", 332, 353], ["Cell Death", "PROBLEM", 415, 425], ["Myelin DamageOligodendrocytes", "PROBLEM", 430, 459], ["lipid peroxidation", "OBSERVATION", 25, 43], ["Cell Death", "OBSERVATION", 201, 211], ["Myelin DamageOligodendrocytes", "OBSERVATION", 216, 245], ["Cell Death", "OBSERVATION", 415, 425]]], ["Cell death appears to be mainly necrotic both in MS lesions and in vitro cultures with hallmarks being process withdrawal, single-stranded DNA breaks, swollen nuclei and cytoplasm, organelle disruption, plasma membrane damage, and mitochondrial dysfunction (Prineas et al, 1984 (Prineas et al, , 1989 Mitrovic et al, 1994 Mitrovic et al, , 1995 .", [["Cell", "ANATOMY", 0, 4], ["MS lesions", "ANATOMY", 49, 59], ["swollen nuclei", "ANATOMY", 151, 165], ["cytoplasm", "ANATOMY", 170, 179], ["organelle", "ANATOMY", 181, 190], ["plasma membrane", "ANATOMY", 203, 218], ["mitochondrial", "ANATOMY", 231, 244], ["death", "DISEASE", 5, 10], ["necrotic", "DISEASE", 32, 40], ["mitochondrial dysfunction", "DISEASE", 231, 256], ["Cell", "CELL", 0, 4], ["MS lesions", "CANCER", 49, 59], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["nuclei", "CELLULAR_COMPONENT", 159, 165], ["cytoplasm", "ORGANISM_SUBSTANCE", 170, 179], ["organelle", "CELLULAR_COMPONENT", 181, 190], ["plasma membrane", "CELLULAR_COMPONENT", 203, 218], ["mitochondrial", "CELLULAR_COMPONENT", 231, 244], ["Cell death", "PROBLEM", 0, 10], ["necrotic", "PROBLEM", 32, 40], ["MS lesions", "PROBLEM", 49, 59], ["vitro cultures", "TEST", 67, 81], ["process withdrawal", "PROBLEM", 103, 121], ["stranded DNA breaks", "PROBLEM", 130, 149], ["swollen nuclei and cytoplasm", "PROBLEM", 151, 179], ["organelle disruption", "PROBLEM", 181, 201], ["plasma membrane damage", "PROBLEM", 203, 225], ["mitochondrial dysfunction", "PROBLEM", 231, 256], ["appears to be", "UNCERTAINTY", 11, 24], ["mainly", "OBSERVATION_MODIFIER", 25, 31], ["necrotic", "OBSERVATION_MODIFIER", 32, 40], ["MS", "OBSERVATION_MODIFIER", 49, 51], ["lesions", "OBSERVATION", 52, 59], ["swollen nuclei", "OBSERVATION", 151, 165], ["cytoplasm", "OBSERVATION_MODIFIER", 170, 179], ["organelle disruption", "OBSERVATION", 181, 201], ["plasma membrane damage", "OBSERVATION", 203, 225], ["mitochondrial dysfunction", "OBSERVATION", 231, 256]]], ["Thorburne and Juurlink (1996) reported that compared to astrocytes, oligodendrocytes have 23-fold more iron, lower levels of manganese superoxide dismutase, half the amount of reduced glutathione, and less than 15% the level of glutathione peroxidase.", [["astrocytes", "ANATOMY", 56, 66], ["oligodendrocytes", "ANATOMY", 68, 84], ["iron", "CHEMICAL", 103, 107], ["manganese", "CHEMICAL", 125, 134], ["superoxide", "CHEMICAL", 135, 145], ["glutathione", "CHEMICAL", 184, 195], ["glutathione", "CHEMICAL", 228, 239], ["iron", "CHEMICAL", 103, 107], ["manganese", "CHEMICAL", 125, 134], ["superoxide", "CHEMICAL", 135, 145], ["reduced glutathione", "CHEMICAL", 176, 195], ["glutathione", "CHEMICAL", 228, 239], ["astrocytes", "CELL", 56, 66], ["oligodendrocytes", "CELL", 68, 84], ["iron", "SIMPLE_CHEMICAL", 103, 107], ["manganese superoxide dismutase", "GENE_OR_GENE_PRODUCT", 125, 155], ["glutathione", "SIMPLE_CHEMICAL", 184, 195], ["glutathione peroxidase", "GENE_OR_GENE_PRODUCT", 228, 250], ["astrocytes", "CELL_TYPE", 56, 66], ["oligodendrocytes", "CELL_TYPE", 68, 84], ["manganese superoxide dismutase", "PROTEIN", 125, 155], ["glutathione peroxidase", "PROTEIN", 228, 250], ["oligodendrocytes", "TEST", 68, 84], ["iron", "TREATMENT", 103, 107], ["manganese superoxide dismutase", "TREATMENT", 125, 155], ["reduced glutathione", "TREATMENT", 176, 195], ["glutathione peroxidase", "TREATMENT", 228, 250]]], ["Thus, as a consequence of not being able to scavenge harmful radicals, oligodendrocytes are much more vulnerable to free radical-mediated death.Mechanisms: Cell Death and Myelin DamageThe details of in vitro assay systems to model free radicalmediated cell damage and death are described in detail elsewhere (Mitrovic et al, 1996) .", [["oligodendrocytes", "ANATOMY", 71, 87], ["Cell", "ANATOMY", 156, 160], ["cell", "ANATOMY", 252, 256], ["death", "DISEASE", 138, 143], ["death", "DISEASE", 268, 273], ["oligodendrocytes", "CELL", 71, 87], ["free radical", "SIMPLE_CHEMICAL", 116, 128], ["Cell", "CELL", 156, 160], ["cell", "CELL", 252, 256], ["oligodendrocytes", "CELL_TYPE", 71, 87], ["Cell Death", "PROBLEM", 156, 166], ["Myelin Damage", "PROBLEM", 171, 184], ["vitro assay systems", "TEST", 202, 221], ["model free radicalmediated cell damage", "PROBLEM", 225, 263], ["death", "PROBLEM", 268, 273], ["Cell Death", "OBSERVATION", 156, 166], ["Myelin Damage", "OBSERVATION", 171, 184], ["free", "OBSERVATION_MODIFIER", 231, 235], ["radicalmediated cell damage", "OBSERVATION", 236, 263]]], ["Mixed cultures can be set up to assess the effects of anoxia and varying degrees of hypoxia by purging closed incubation chambers with different ratios of O 2 , N 2 , and CO 2 .", [["hypoxia", "DISEASE", 84, 91], ["O 2 , N 2", "CHEMICAL", 155, 164], ["CO 2", "CHEMICAL", 171, 175], ["O 2", "SIMPLE_CHEMICAL", 155, 158], ["N 2", "SIMPLE_CHEMICAL", 161, 164], ["CO 2", "SIMPLE_CHEMICAL", 171, 175], ["Mixed cultures", "TEST", 0, 14], ["anoxia", "PROBLEM", 54, 60], ["hypoxia", "PROBLEM", 84, 91], ["purging closed incubation chambers", "TREATMENT", 95, 129], ["varying degrees", "OBSERVATION_MODIFIER", 65, 80], ["hypoxia", "OBSERVATION", 84, 91]]], ["Lipid peroxidation can be assessed using the cytochemical procedure demonstrating thiobarbituric acid fluorescent adducts in conjunction with morphological evaluation of cell death.", [["cell", "ANATOMY", 170, 174], ["thiobarbituric acid", "CHEMICAL", 82, 101], ["death", "DISEASE", 175, 180], ["thiobarbituric acid", "CHEMICAL", 82, 101], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["thiobarbituric acid", "SIMPLE_CHEMICAL", 82, 101], ["cell", "CELL", 170, 174], ["Lipid peroxidation", "TREATMENT", 0, 18], ["the cytochemical procedure", "TREATMENT", 41, 67], ["thiobarbituric acid fluorescent adducts", "PROBLEM", 82, 121], ["morphological evaluation", "TEST", 142, 166], ["cell death", "PROBLEM", 170, 180], ["cell death", "OBSERVATION", 170, 180]]], ["The ability to detect cellular free radical scavenging is achieved using 5-(and -6)-carboxy-2 0 ,7 0 -dichlorohydro-fluorescein as an intracellular probe of oxidative stress (Husain and Juurlink, 1995) .", [["cellular", "ANATOMY", 22, 30], ["intracellular", "ANATOMY", 134, 147], ["5-(and -6)-carboxy-2 0 ,7 0 -dichlorohydro-fluorescein", "CHEMICAL", 73, 127], ["5-(and -6)-carboxy-2 0 ,7 0 -dichlorohydro-fluorescein", "CHEMICAL", 73, 127], ["cellular", "CELL", 22, 30], ["5-(and -6)-carboxy-2 0 ,7 0 -dichlorohydro-fluorescein", "SIMPLE_CHEMICAL", 73, 127], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 147], ["cellular free radical scavenging", "PROBLEM", 22, 54], ["carboxy", "TEST", 84, 91], ["fluorescein", "TREATMENT", 116, 127], ["free", "OBSERVATION_MODIFIER", 31, 35], ["radical scavenging", "OBSERVATION", 36, 54]]], ["A simpler and higher throughput cytotoxicity in vitro system using purified oligodendrocyte progenitors, mature oligodendrocytes, microglia, neurons, or astrocytes is that which uses chemical donors of free radicals of nitrogen and oxygen.", [["oligodendrocyte progenitors", "ANATOMY", 76, 103], ["oligodendrocytes", "ANATOMY", 112, 128], ["microglia", "ANATOMY", 130, 139], ["neurons", "ANATOMY", 141, 148], ["astrocytes", "ANATOMY", 153, 163], ["nitrogen", "CHEMICAL", 219, 227], ["oxygen", "CHEMICAL", 232, 238], ["nitrogen", "CHEMICAL", 219, 227], ["oxygen", "CHEMICAL", 232, 238], ["oligodendrocyte progenitors", "CELL", 76, 103], ["oligodendrocytes", "CELL", 112, 128], ["microglia", "CELL", 130, 139], ["neurons", "CELL", 141, 148], ["astrocytes", "CELL", 153, 163], ["nitrogen", "SIMPLE_CHEMICAL", 219, 227], ["oxygen", "SIMPLE_CHEMICAL", 232, 238], ["oligodendrocyte progenitors", "CELL_TYPE", 76, 103], ["mature oligodendrocytes", "CELL_TYPE", 105, 128], ["microglia", "CELL_TYPE", 130, 139], ["neurons", "CELL_TYPE", 141, 148], ["astrocytes", "CELL_TYPE", 153, 163], ["A simpler and higher throughput cytotoxicity in vitro system", "PROBLEM", 0, 60], ["purified oligodendrocyte progenitors", "PROBLEM", 67, 103], ["mature oligodendrocytes", "PROBLEM", 105, 128], ["astrocytes", "PROBLEM", 153, 163], ["free radicals of nitrogen", "TREATMENT", 202, 227], ["oxygen", "TREATMENT", 232, 238], ["higher", "OBSERVATION_MODIFIER", 14, 20], ["oligodendrocyte progenitors", "OBSERVATION", 76, 103], ["mature oligodendrocytes", "OBSERVATION", 105, 128]]], ["NO is generated from S-nitroso-N-acetyl-DL-penicillamine (SNAP) whereas pyrogallol generates superoxide anion (O 2 \u00c0 ).", [["NO", "CHEMICAL", 0, 2], ["S-nitroso-N-acetyl-DL-penicillamine", "CHEMICAL", 21, 56], ["SNAP", "CHEMICAL", 58, 62], ["pyrogallol", "CHEMICAL", 72, 82], ["superoxide", "CHEMICAL", 93, 103], ["NO", "CHEMICAL", 0, 2], ["S-nitroso-N-acetyl-DL-penicillamine", "CHEMICAL", 21, 56], ["SNAP", "CHEMICAL", 58, 62], ["pyrogallol", "CHEMICAL", 72, 82], ["superoxide", "CHEMICAL", 93, 103], ["O 2 \u00c0", "CHEMICAL", 111, 116], ["NO", "SIMPLE_CHEMICAL", 0, 2], ["S-nitroso-N-acetyl-DL-penicillamine", "SIMPLE_CHEMICAL", 21, 56], ["SNAP", "SIMPLE_CHEMICAL", 58, 62], ["pyrogallol", "SIMPLE_CHEMICAL", 72, 82], ["superoxide anion", "SIMPLE_CHEMICAL", 93, 109], ["O 2 \u00c0", "SIMPLE_CHEMICAL", 111, 116], ["S-nitroso", "TREATMENT", 21, 30], ["acetyl", "TREATMENT", 33, 39], ["penicillamine (SNAP)", "TREATMENT", 43, 63], ["pyrogallol generates superoxide anion", "TREATMENT", 72, 109]]], ["Generation of both NO and O 2 \u00c0 which quickly react to generate peroxynitrite (ONOO \u00c0 ) can be achieved by using 3-morpholinosydnonimine-HCl (SIN-1); peroxynitrite can also be generated by mixing equal moles of pyrogallol and SNAP.", [["NO", "CHEMICAL", 19, 21], ["peroxynitrite", "CHEMICAL", 64, 77], ["ONOO \u00c0", "CHEMICAL", 79, 85], ["3-morpholinosydnonimine-HCl", "CHEMICAL", 113, 140], ["SIN-1", "CHEMICAL", 142, 147], ["peroxynitrite", "CHEMICAL", 150, 163], ["pyrogallol", "CHEMICAL", 211, 221], ["SNAP", "CHEMICAL", 226, 230], ["NO", "CHEMICAL", 19, 21], ["O 2 \u00c0", "CHEMICAL", 26, 31], ["peroxynitrite", "CHEMICAL", 64, 77], ["ONOO \u00c0", "CHEMICAL", 79, 85], ["3-morpholinosydnonimine", "CHEMICAL", 113, 136], ["HCl", "CHEMICAL", 137, 140], ["SIN-1", "CHEMICAL", 142, 147], ["peroxynitrite", "CHEMICAL", 150, 163], ["pyrogallol", "CHEMICAL", 211, 221], ["SNAP", "CHEMICAL", 226, 230], ["NO", "SIMPLE_CHEMICAL", 19, 21], ["O 2 \u00c0", "SIMPLE_CHEMICAL", 26, 31], ["peroxynitrite", "SIMPLE_CHEMICAL", 64, 77], ["ONOO \u00c0", "SIMPLE_CHEMICAL", 79, 85], ["3-morpholinosydnonimine-HCl", "SIMPLE_CHEMICAL", 113, 140], ["SIN-1", "SIMPLE_CHEMICAL", 142, 147], ["peroxynitrite", "SIMPLE_CHEMICAL", 150, 163], ["pyrogallol", "SIMPLE_CHEMICAL", 211, 221], ["SNAP", "SIMPLE_CHEMICAL", 226, 230], ["peroxynitrite (ONOO \u00c0", "TREATMENT", 64, 85], ["morpholinosydnonimine-HCl (SIN-1)", "TREATMENT", 115, 148], ["peroxynitrite", "TREATMENT", 150, 163], ["pyrogallol", "TREATMENT", 211, 221]]], ["SNAP causes significant mitochondrial enzyme damage in oligodendrocytes at 0.5 mM but less than 25% cell death even at 2 mM.", [["mitochondrial", "ANATOMY", 24, 37], ["oligodendrocytes", "ANATOMY", 55, 71], ["cell", "ANATOMY", 100, 104], ["SNAP", "CHEMICAL", 0, 4], ["death", "DISEASE", 105, 110], ["SNAP", "SIMPLE_CHEMICAL", 0, 4], ["mitochondrial", "CELLULAR_COMPONENT", 24, 37], ["oligodendrocytes", "CELL", 55, 71], ["cell", "CELL", 100, 104], ["mitochondrial enzyme", "PROTEIN", 24, 44], ["oligodendrocytes", "CELL_TYPE", 55, 71], ["significant mitochondrial enzyme damage in oligodendrocytes", "PROBLEM", 12, 71], ["cell death", "TEST", 100, 110], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["mitochondrial enzyme damage", "OBSERVATION", 24, 51], ["oligodendrocytes", "OBSERVATION_MODIFIER", 55, 71]]], ["SIN-1 and pyrogallol cause significant cell death at 0.5 mM and 100% death and mitochondrial damage at 2 mM after 18 h in vitro (Mitrovic et al, 1996) .", [["cell", "ANATOMY", 39, 43], ["mitochondrial", "ANATOMY", 79, 92], ["SIN-1", "CHEMICAL", 0, 5], ["pyrogallol", "CHEMICAL", 10, 20], ["death", "DISEASE", 44, 49], ["death", "DISEASE", 69, 74], ["mitochondrial damage", "DISEASE", 79, 99], ["SIN-1", "CHEMICAL", 0, 5], ["pyrogallol", "CHEMICAL", 10, 20], ["SIN-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["pyrogallol", "SIMPLE_CHEMICAL", 10, 20], ["cell", "CELL", 39, 43], ["mitochondrial", "CELLULAR_COMPONENT", 79, 92], ["significant cell death", "PROBLEM", 27, 49], ["100% death", "PROBLEM", 64, 74], ["mitochondrial damage", "PROBLEM", 79, 99], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["cell death", "OBSERVATION", 39, 49], ["mitochondrial damage", "OBSERVATION", 79, 99]]], ["Oxyhemoglobin is generally used as a positive control for inhibition of SNAP-induced mitochondrial damage .Mechanisms: Cell Death and Myelin DamageQuantitative multiplex assays for cell death include the release of incorporated label from proteins ( 51 Cr, 3 Hleucine) or nucleotides ( 3 H-thymidine), release of LDH, or uptake of propidium iodide, trypan blue, or vital dyes.", [["mitochondrial", "ANATOMY", 85, 98], ["Cell", "ANATOMY", 119, 123], ["cell", "ANATOMY", 181, 185], ["Oxyhemoglobin", "CHEMICAL", 0, 13], ["SNAP", "CHEMICAL", 72, 76], ["mitochondrial damage", "DISEASE", 85, 105], ["death", "DISEASE", 186, 191], ["3 H-thymidine", "CHEMICAL", 286, 299], ["propidium iodide", "CHEMICAL", 331, 347], ["trypan blue", "CHEMICAL", 349, 360], ["Oxyhemoglobin", "CHEMICAL", 0, 13], ["Cr", "CHEMICAL", 253, 255], ["Hleucine", "CHEMICAL", 259, 267], ["nucleotides", "CHEMICAL", 272, 283], ["3 H-thymidine", "CHEMICAL", 286, 299], ["propidium iodide", "CHEMICAL", 331, 347], ["trypan blue", "CHEMICAL", 349, 360], ["Oxyhemoglobin", "SIMPLE_CHEMICAL", 0, 13], ["SNAP", "SIMPLE_CHEMICAL", 72, 76], ["mitochondrial", "CELLULAR_COMPONENT", 85, 98], ["Cell", "CELL", 119, 123], ["cell", "CELL", 181, 185], ["Hleucine", "SIMPLE_CHEMICAL", 259, 267], ["3 H-thymidine", "SIMPLE_CHEMICAL", 286, 299], ["LDH", "SIMPLE_CHEMICAL", 313, 316], ["propidium iodide", "SIMPLE_CHEMICAL", 331, 347], ["trypan blue", "SIMPLE_CHEMICAL", 349, 360], ["LDH", "PROTEIN", 313, 316], ["Oxyhemoglobin", "TREATMENT", 0, 13], ["a positive control", "TREATMENT", 35, 53], ["SNAP", "PROBLEM", 72, 76], ["mitochondrial damage", "PROBLEM", 85, 105], ["Cell Death", "PROBLEM", 119, 129], ["cell death", "PROBLEM", 181, 191], ["Cr", "TEST", 253, 255], ["nucleotides", "TREATMENT", 272, 283], ["LDH", "TEST", 313, 316], ["uptake of propidium iodide", "PROBLEM", 321, 347], ["trypan blue", "TREATMENT", 349, 360], ["vital dyes", "PROBLEM", 365, 375], ["mitochondrial damage", "OBSERVATION", 85, 105], ["Cell Death", "OBSERVATION", 119, 129], ["LDH", "ANATOMY", 313, 316], ["propidium iodide", "OBSERVATION", 331, 347]]], ["Some cell types, like astrocytes, can be damaged without dying when exposed to free radicals.", [["cell", "ANATOMY", 5, 9], ["astrocytes", "ANATOMY", 22, 32], ["cell", "CELL", 5, 9], ["astrocytes", "CELL", 22, 32], ["free radicals", "SIMPLE_CHEMICAL", 79, 92], ["astrocytes", "CELL_TYPE", 22, 32], ["Some cell types", "PROBLEM", 0, 15], ["cell types", "OBSERVATION", 5, 15], ["astrocytes", "ANATOMY", 22, 32]]], ["Cell damage is detectable using the assay for activity of the ferrosulfur-containing enzyme succinate dehydrogenase with the Nonradioactive Proliferation/Cytotoxicity Kit or CytoTox Fluor Assay (Promega, Madison, WI).", [["Cell", "ANATOMY", 0, 4], ["ferrosulfur", "CHEMICAL", 62, 73], ["succinate", "CHEMICAL", 92, 101], ["ferrosulfur", "CHEMICAL", 62, 73], ["succinate", "CHEMICAL", 92, 101], ["Cell", "CELL", 0, 4], ["ferrosulfur", "SIMPLE_CHEMICAL", 62, 73], ["succinate dehydrogenase", "GENE_OR_GENE_PRODUCT", 92, 115], ["CytoTox Fluor", "SIMPLE_CHEMICAL", 174, 187], ["ferrosulfur-containing enzyme succinate dehydrogenase", "PROTEIN", 62, 115], ["Cell damage", "PROBLEM", 0, 11], ["the assay", "TEST", 32, 41], ["the ferrosulfur", "TREATMENT", 58, 73], ["enzyme succinate dehydrogenase", "TREATMENT", 85, 115], ["the Nonradioactive Proliferation/Cytotoxicity Kit", "TREATMENT", 121, 170]]], ["The assay is based on the ability of the intact enzyme to cleave MTT tetrazolium salt into the blue product formazan.", [["MTT tetrazolium", "CHEMICAL", 65, 80], ["formazan", "CHEMICAL", 108, 116], ["MTT tetrazolium", "CHEMICAL", 65, 80], ["formazan", "CHEMICAL", 108, 116], ["MTT tetrazolium salt", "SIMPLE_CHEMICAL", 65, 85], ["formazan", "SIMPLE_CHEMICAL", 108, 116], ["The assay", "TEST", 0, 9], ["MTT tetrazolium salt", "TREATMENT", 65, 85], ["the blue product formazan", "TREATMENT", 91, 116]]], ["Isocitrate dehydrogenase, a nonferrosulfur containing enzyme, is a useful control in the assay.", [["Isocitrate", "CHEMICAL", 0, 10], ["nonferrosulfur", "CHEMICAL", 28, 42], ["Isocitrate", "CHEMICAL", 0, 10], ["nonferrosulfur", "CHEMICAL", 28, 42], ["Isocitrate dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 24], ["nonferrosulfur", "SIMPLE_CHEMICAL", 28, 42], ["Isocitrate dehydrogenase", "PROTEIN", 0, 24], ["nonferrosulfur containing enzyme", "PROTEIN", 28, 60], ["Isocitrate dehydrogenase", "PROBLEM", 0, 24], ["a nonferrosulfur containing enzyme", "TREATMENT", 26, 60]]], ["For validation of the mechanism of cell death, techniques using EM, DNA-laddering gels, and differential alkaline precipitation of DNA to determine the proportion of DNA strands which are single-stranded as a fraction of the total cellular DNA should be employed (Mitrovic et al, , 1996 .CONCLUSIONSIn lieu of using cocultures of T cells or macrophages/microglia and oligodendrocyte targets, the proinflammatory mediators generated by the effector cells may be added directly to mature oligodendrocytes or their precursors.", [["cell", "ANATOMY", 35, 39], ["cellular", "ANATOMY", 231, 239], ["T cells", "ANATOMY", 330, 337], ["macrophages", "ANATOMY", 341, 352], ["microglia", "ANATOMY", 353, 362], ["oligodendrocyte", "ANATOMY", 367, 382], ["effector cells", "ANATOMY", 439, 453], ["oligodendrocytes", "ANATOMY", 486, 502], ["death", "DISEASE", 40, 45], ["cell", "CELL", 35, 39], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["DNA", "CELLULAR_COMPONENT", 131, 134], ["DNA", "CELLULAR_COMPONENT", 166, 169], ["cellular", "CELL", 231, 239], ["DNA", "CELLULAR_COMPONENT", 240, 243], ["T cells", "CELL", 330, 337], ["macrophages", "CELL", 341, 352], ["microglia", "CELL", 353, 362], ["oligodendrocyte", "CELL", 367, 382], ["cells", "CELL", 448, 453], ["oligodendrocytes", "CELL", 486, 502], ["T cells", "CELL_TYPE", 330, 337], ["macrophages", "CELL_TYPE", 341, 352], ["microglia", "CELL_TYPE", 353, 362], ["proinflammatory mediators", "PROTEIN", 396, 421], ["effector cells", "CELL_TYPE", 439, 453], ["mature oligodendrocytes", "CELL_TYPE", 479, 502], ["cell death", "PROBLEM", 35, 45], ["laddering gels", "TREATMENT", 72, 86], ["differential alkaline precipitation of DNA", "PROBLEM", 92, 134], ["DNA strands", "PROBLEM", 166, 177], ["the total cellular DNA", "TREATMENT", 221, 243], ["T cells", "PROBLEM", 330, 337], ["macrophages", "PROBLEM", 341, 352], ["microglia", "PROBLEM", 353, 362], ["the effector cells", "TREATMENT", 435, 453], ["DNA strands", "OBSERVATION", 166, 177], ["microglia", "ANATOMY", 353, 362]]], ["Determining the mechanism of cell death can be achieved by more direct and labor-intensive assays such as electron microscopy (EM) or for mixed cultures, the use of antibodies for specific cell typesChemically Induced DemyelinationCuprizone.", [["cell", "ANATOMY", 29, 33], ["cell", "ANATOMY", 189, 193], ["death", "DISEASE", 34, 39], ["DemyelinationCuprizone", "CHEMICAL", 218, 240], ["DemyelinationCuprizone", "CHEMICAL", 218, 240], ["cell", "CELL", 29, 33], ["cell", "CELL", 189, 193], ["DemyelinationCuprizone", "SIMPLE_CHEMICAL", 218, 240], ["antibodies", "PROTEIN", 165, 175], ["cell death", "PROBLEM", 29, 39], ["intensive assays", "TEST", 81, 97], ["electron microscopy", "TEST", 106, 125], ["mixed cultures", "PROBLEM", 138, 152], ["antibodies", "TREATMENT", 165, 175], ["specific cell types", "PROBLEM", 180, 199], ["Chemically Induced DemyelinationCuprizone", "PROBLEM", 199, 240], ["cell death", "OBSERVATION", 29, 39], ["cell types", "OBSERVATION", 189, 199], ["DemyelinationCuprizone", "OBSERVATION", 218, 240]]], ["Young adult male C57Bl/6 mice at 6-8 weeks old, are susceptible to demyelination produced by a 4 to 6-week diet of 0.2% cuprizone (bis-cyclohexanone oxaldihydrazone) (Ludwin, 1978) .", [["demyelination", "DISEASE", 67, 80], ["cuprizone", "CHEMICAL", 120, 129], ["bis-cyclohexanone oxaldihydrazone", "CHEMICAL", 131, 164], ["cuprizone", "CHEMICAL", 120, 129], ["bis-cyclohexanone oxaldihydrazone", "CHEMICAL", 131, 164], ["Ludwin", "CHEMICAL", 167, 173], ["C57Bl/6 mice", "ORGANISM", 17, 29], ["cuprizone", "SIMPLE_CHEMICAL", 120, 129], ["bis-cyclohexanone oxaldihydrazone", "SIMPLE_CHEMICAL", 131, 164], ["mice", "SPECIES", 25, 29], ["demyelination", "PROBLEM", 67, 80], ["0.2% cuprizone (bis-cyclohexanone oxaldihydrazone", "TREATMENT", 115, 164], ["demyelination", "OBSERVATION", 67, 80]]], ["Demyelination occurs globally throughout the white matter, but is most easily detected within the corpus callosum .", [["white matter", "ANATOMY", 45, 57], ["corpus callosum", "ANATOMY", 98, 113], ["Demyelination", "DISEASE", 0, 13], ["corpus callosum", "MULTI-TISSUE_STRUCTURE", 98, 113], ["Demyelination", "PROBLEM", 0, 13], ["globally", "OBSERVATION_MODIFIER", 21, 29], ["white matter", "OBSERVATION_MODIFIER", 45, 57], ["corpus callosum", "ANATOMY", 98, 113]]], ["Demyelination is evident within 3 weeks after starting the cuprizone diet and is complete by 5 weeks.", [["Demyelination", "DISEASE", 0, 13], ["cuprizone", "CHEMICAL", 59, 68], ["cuprizone", "CHEMICAL", 59, 68], ["cuprizone", "SIMPLE_CHEMICAL", 59, 68], ["Demyelination", "PROBLEM", 0, 13], ["the cuprizone diet", "TREATMENT", 55, 73]]], ["Replacement of the diet with normal food allows for almost complete remyelination within 4 weeks (Matsushima and Morell, 2001) .", [["Replacement of the diet", "TREATMENT", 0, 23]]], ["Adamo et al (2006) have produced a similar model of demyelination in 21-day-old Wistar rats after 0.6% cuprizone for 2 weeks; remyelination occurs significantly after 2 weeks on normal diet.", [["demyelination", "DISEASE", 52, 65], ["cuprizone", "CHEMICAL", 103, 112], ["cuprizone", "CHEMICAL", 103, 112], ["Wistar", "ORGANISM", 80, 86], ["rats", "ORGANISM", 87, 91], ["cuprizone", "SIMPLE_CHEMICAL", 103, 112], ["rats", "SPECIES", 87, 91], ["demyelination", "PROBLEM", 52, 65], ["remyelination", "PROBLEM", 126, 139], ["demyelination", "OBSERVATION", 52, 65]]], ["Immunohistochemical staining for axonal damage using amyloid precursor protein (APP) or Bielschowsky' silver impregnation did not reveal much axonal damage in 8-week-old mice , though axonal transection increases significantly in 6 to 7-month-old aged mice, thereby greatly impairing repair (Irvine and Blakemore, 2006) .", [["axonal", "ANATOMY", 33, 39], ["axonal", "ANATOMY", 142, 148], ["axonal", "ANATOMY", 184, 190], ["axonal damage", "DISEASE", 33, 46], ["axonal damage", "DISEASE", 142, 155], ["silver", "CHEMICAL", 102, 108], ["axonal", "MULTI-TISSUE_STRUCTURE", 33, 39], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 53, 78], ["APP", "GENE_OR_GENE_PRODUCT", 80, 83], ["silver", "SIMPLE_CHEMICAL", 102, 108], ["mice", "ORGANISM", 170, 174], ["axonal", "MULTI-TISSUE_STRUCTURE", 184, 190], ["mice", "ORGANISM", 252, 256], ["amyloid precursor protein", "PROTEIN", 53, 78], ["APP", "PROTEIN", 80, 83], ["mice", "SPECIES", 170, 174], ["mice", "SPECIES", 252, 256], ["Immunohistochemical staining", "TEST", 0, 28], ["axonal damage", "PROBLEM", 33, 46], ["amyloid precursor protein", "TEST", 53, 78], ["Bielschowsky' silver impregnation", "TEST", 88, 121], ["much axonal damage", "PROBLEM", 137, 155], ["axonal transection", "PROBLEM", 184, 202], ["axonal", "OBSERVATION_MODIFIER", 142, 148], ["damage", "OBSERVATION", 149, 155], ["axonal", "OBSERVATION_MODIFIER", 184, 190], ["transection", "OBSERVATION", 191, 202], ["impairing", "OBSERVATION_MODIFIER", 274, 283], ["repair", "OBSERVATION", 284, 290]]], ["Microglia and macrophages are required for efficient remyelination (Gilson and Blakemore, 1993) and these can be quantitated in tissue sections by staining for markers CD11b (Mac1) or biotininconjugated Ricinus communis agglutinin-1 (RCA-1; Sigma, Madison, WI).", [["Microglia", "ANATOMY", 0, 9], ["macrophages", "ANATOMY", 14, 25], ["tissue sections", "ANATOMY", 128, 143], ["Microglia", "CELL", 0, 9], ["macrophages", "CELL", 14, 25], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 128, 143], ["CD11b", "GENE_OR_GENE_PRODUCT", 168, 173], ["Mac1", "GENE_OR_GENE_PRODUCT", 175, 179], ["agglutinin-1", "GENE_OR_GENE_PRODUCT", 220, 232], ["RCA-1", "GENE_OR_GENE_PRODUCT", 234, 239], ["Sigma", "GENE_OR_GENE_PRODUCT", 241, 246], ["Madison", "ORGANISM", 248, 255], ["WI", "GENE_OR_GENE_PRODUCT", 257, 259], ["Microglia", "CELL_TYPE", 0, 9], ["macrophages", "CELL_TYPE", 14, 25], ["CD11b", "PROTEIN", 168, 173], ["Mac1", "PROTEIN", 175, 179], ["biotininconjugated Ricinus communis agglutinin-1", "PROTEIN", 184, 232], ["RCA", "PROTEIN", 234, 237], ["Ricinus communis", "SPECIES", 203, 219], ["Ricinus communis", "SPECIES", 203, 219], ["efficient remyelination", "PROBLEM", 43, 66], ["markers CD11b", "TEST", 160, 173], ["Mac1", "TEST", 175, 179], ["biotininconjugated Ricinus communis agglutinin", "TEST", 184, 230], ["RCA", "TEST", 234, 237], ["macrophages", "OBSERVATION", 14, 25]]], ["Mature oligodendrocytes numbers can be quantitated by staining with CC1 antibody (antiadenomatous polyposis coli; Calbiochem, San Diego, CA) (Adamo et al, 2006) or with an antibody to the p-isoform of glutathione-Stransferase (GST-p).", [["oligodendrocytes", "ANATOMY", 7, 23], ["antiadenomatous polyposis", "DISEASE", 82, 107], ["glutathione", "CHEMICAL", 201, 212], ["glutathione", "CHEMICAL", 201, 212], ["oligodendrocytes", "CELL", 7, 23], ["CC1", "GENE_OR_GENE_PRODUCT", 68, 71], ["glutathione-Stransferase", "GENE_OR_GENE_PRODUCT", 201, 225], ["GST-p", "GENE_OR_GENE_PRODUCT", 227, 232], ["CC1 antibody", "PROTEIN", 68, 80], ["p-isoform", "PROTEIN", 188, 197], ["glutathione-Stransferase", "PROTEIN", 201, 225], ["GST", "PROTEIN", 227, 230], ["antiadenomatous polyposis coli", "SPECIES", 82, 112], ["Mature oligodendrocytes numbers", "PROBLEM", 0, 31], ["CC1 antibody", "TEST", 68, 80], ["antiadenomatous polyposis coli", "PROBLEM", 82, 112], ["an antibody", "TEST", 169, 180], ["glutathione", "TEST", 201, 212], ["oligodendrocytes", "OBSERVATION", 7, 23]]], ["GST-p will not stain NG2 + immature oligodendrocytes (Mason et al, 2000 (Mason et al, , 2001 .", [["NG2 + immature oligodendrocytes", "ANATOMY", 21, 52], ["GST-p", "GENE_OR_GENE_PRODUCT", 0, 5], ["NG2", "GENE_OR_GENE_PRODUCT", 21, 24], ["oligodendrocytes", "CELL", 36, 52], ["GST", "PROTEIN", 0, 3], ["NG2", "PROTEIN", 21, 24], ["immature oligodendrocytes", "CELL_TYPE", 27, 52], ["immature oligodendrocytes", "OBSERVATION", 27, 52]]], ["A medium throughput assay for myelin loss can be achieved by harvesting the entire brain and running quantitative MBP protein dot blots.", [["myelin", "ANATOMY", 30, 36], ["brain", "ANATOMY", 83, 88], ["myelin loss", "DISEASE", 30, 41], ["myelin", "GENE_OR_GENE_PRODUCT", 30, 36], ["brain", "ORGAN", 83, 88], ["MBP", "GENE_OR_GENE_PRODUCT", 114, 117], ["MBP", "PROTEIN", 114, 117], ["A medium throughput assay", "TEST", 0, 25], ["myelin loss", "PROBLEM", 30, 41], ["brain", "ANATOMY", 83, 88]]], ["Alternatively, a more time-consuming identification of actual tissue myelin loss and repair involves quantitative stereology using the Computer Assisted Stereological Toolbox (CAST) system (CAST GRID; Olympus, Center Valley, PA) assessment of myelin in the corpus callosum using following LFB staining.", [["tissue myelin", "ANATOMY", 62, 75], ["myelin", "ANATOMY", 243, 249], ["corpus callosum", "ANATOMY", 257, 272], ["myelin loss", "DISEASE", 69, 80], ["tissue myelin", "TISSUE", 62, 75], ["myelin", "GENE_OR_GENE_PRODUCT", 243, 249], ["corpus callosum", "ORGAN", 257, 272], ["LFB", "GENE_OR_GENE_PRODUCT", 289, 292], ["actual tissue myelin loss", "PROBLEM", 55, 80], ["repair", "TREATMENT", 85, 91], ["the Computer Assisted Stereological Toolbox (CAST) system (CAST GRID", "TREATMENT", 131, 199], ["PA) assessment", "TEST", 225, 239], ["myelin in the corpus callosum", "PROBLEM", 243, 272], ["LFB staining", "PROBLEM", 289, 301], ["actual tissue", "OBSERVATION", 55, 68], ["myelin loss", "OBSERVATION", 69, 80], ["myelin", "OBSERVATION", 243, 249], ["corpus callosum", "ANATOMY", 257, 272]]], ["Toluidine blue and EM are necessary final steps to assure that compact myelin is investing naked axons.Chemically Induced DemyelinationWhen available, it is ideal to be able to apply measurements in animal models that might be used in the clinic.", [["myelin", "ANATOMY", 71, 77], ["axons", "ANATOMY", 97, 102], ["Toluidine blue", "CHEMICAL", 0, 14], ["Toluidine blue", "CHEMICAL", 0, 14], ["Toluidine blue", "SIMPLE_CHEMICAL", 0, 14], ["myelin", "CELLULAR_COMPONENT", 71, 77], ["axons", "MULTI-TISSUE_STRUCTURE", 97, 102]]], ["Merkler et al (2005) have recently demonstrated that they can produce an accurate magnetic resonance imaging (MRI) prediction of the status of myelin in the corpus callosum of cuprizone-fed mice using a combination of T 1 -weighted, T 2 -weighted, and magnetization transfer ratio (MTR) values with a 2.35 T Bruker (Billerica, MA) Biospin small animal MRI.", [["myelin", "ANATOMY", 143, 149], ["corpus callosum", "ANATOMY", 157, 172], ["cuprizone", "CHEMICAL", 176, 185], ["cuprizone", "CHEMICAL", 176, 185], ["myelin", "GENE_OR_GENE_PRODUCT", 143, 149], ["corpus callosum", "ORGAN", 157, 172], ["cuprizone", "SIMPLE_CHEMICAL", 176, 185], ["mice", "ORGANISM", 190, 194], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 190, 194], ["an accurate magnetic resonance imaging", "TEST", 70, 108], ["MRI", "TEST", 110, 113], ["myelin", "PROBLEM", 143, 149], ["Biospin small animal MRI", "TEST", 331, 355], ["corpus callosum", "ANATOMY", 157, 172]]], ["Franco-Pons et al (2007) have described the use of open field and rotorod tests in the cuprizone model, claiming functional deficits in the cuprizone-fed mice compared to normal fed controls.", [["cuprizone", "CHEMICAL", 87, 96], ["functional deficits", "DISEASE", 113, 132], ["cuprizone", "CHEMICAL", 140, 149], ["cuprizone", "CHEMICAL", 87, 96], ["cuprizone", "CHEMICAL", 140, 149], ["cuprizone", "SIMPLE_CHEMICAL", 140, 149], ["mice", "ORGANISM", 154, 158], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 154, 158], ["open field", "TREATMENT", 51, 61], ["rotorod tests", "TEST", 66, 79], ["the cuprizone model", "TREATMENT", 83, 102], ["functional deficits", "PROBLEM", 113, 132], ["the cuprizone", "TREATMENT", 136, 149]]], ["Whether either of these translational assays will prove sensitive enough to detect drug effects in the animal model remains to be determined.Chemically Induced DemyelinationEthidium bromide.", [["DemyelinationEthidium bromide", "CHEMICAL", 160, 189], ["DemyelinationEthidium bromide", "CHEMICAL", 160, 189], ["DemyelinationEthidium bromide", "SIMPLE_CHEMICAL", 160, 189], ["these translational assays", "TEST", 18, 44], ["drug effects", "PROBLEM", 83, 95], ["Chemically Induced DemyelinationEthidium bromide", "TREATMENT", 141, 189], ["DemyelinationEthidium bromide", "OBSERVATION", 160, 189]]], ["A 0.01-0.1% solution of ethidium bromide (EtBr) can be stereotactically injected, following surgical preparation, into the thoracolumbar dorsal funiculus of the spinal cord or the caudal cerebellar peduncle (CCP).", [["thoracolumbar dorsal funiculus", "ANATOMY", 123, 153], ["spinal cord", "ANATOMY", 161, 172], ["caudal cerebellar peduncle", "ANATOMY", 180, 206], ["ethidium bromide", "CHEMICAL", 24, 40], ["EtBr", "CHEMICAL", 42, 46], ["ethidium bromide", "CHEMICAL", 24, 40], ["EtBr", "CHEMICAL", 42, 46], ["ethidium bromide", "SIMPLE_CHEMICAL", 24, 40], ["EtBr", "SIMPLE_CHEMICAL", 42, 46], ["thoracolumbar dorsal funiculus", "MULTI-TISSUE_STRUCTURE", 123, 153], ["spinal cord", "ORGAN", 161, 172], ["caudal cerebellar peduncle", "MULTI-TISSUE_STRUCTURE", 180, 206], ["A 0.01-0.1% solution of ethidium bromide (EtBr", "TREATMENT", 0, 46], ["surgical preparation", "TREATMENT", 92, 112], ["thoracolumbar", "ANATOMY_MODIFIER", 123, 136], ["dorsal", "ANATOMY_MODIFIER", 137, 143], ["funiculus", "ANATOMY_MODIFIER", 144, 153], ["spinal cord", "ANATOMY", 161, 172], ["caudal cerebellar peduncle", "ANATOMY", 180, 206]]], ["EtBr has also been injected into the subarachnoid space thereby causing demyelination of the optic nerves and chiasm in Sprague-Dawley or Wistar rats (8-10 weeks old).", [["subarachnoid space", "ANATOMY", 37, 55], ["optic nerves", "ANATOMY", 93, 105], ["chiasm", "ANATOMY", 110, 116], ["EtBr", "CHEMICAL", 0, 4], ["demyelination", "DISEASE", 72, 85], ["EtBr", "CHEMICAL", 0, 4], ["EtBr", "SIMPLE_CHEMICAL", 0, 4], ["subarachnoid space", "MULTI-TISSUE_STRUCTURE", 37, 55], ["optic nerves", "MULTI-TISSUE_STRUCTURE", 93, 105], ["chiasm", "MULTI-TISSUE_STRUCTURE", 110, 116], ["Sprague-Dawley or Wistar rats", "ORGANISM", 120, 149], ["rats", "SPECIES", 145, 149], ["Sprague-Dawley", "SPECIES", 120, 134], ["EtBr", "TREATMENT", 0, 4], ["demyelination of the optic nerves", "PROBLEM", 72, 105], ["subarachnoid space", "ANATOMY", 37, 55], ["demyelination", "OBSERVATION", 72, 85], ["optic nerves", "ANATOMY", 93, 105], ["chiasm", "ANATOMY", 110, 116]]], ["EtBr demyelination begins within 48 h but may not be complete before 2 weeks depending on the concentration of EtBr.", [["EtBr", "CHEMICAL", 0, 4], ["demyelination", "DISEASE", 5, 18], ["EtBr", "CHEMICAL", 0, 4], ["EtBr", "SIMPLE_CHEMICAL", 0, 4], ["EtBr demyelination", "PROBLEM", 0, 18], ["demyelination", "OBSERVATION", 5, 18]]], ["As in the cuprizone model, macrophage and/or microglial cell removal of myelin debris is essential before repair (Graca and Blakemore, 1986; Guazzo, 2005) .", [["macrophage", "ANATOMY", 27, 37], ["microglial cell", "ANATOMY", 45, 60], ["myelin debris", "ANATOMY", 72, 85], ["cuprizone", "CHEMICAL", 10, 19], ["cuprizone", "CHEMICAL", 10, 19], ["cuprizone", "SIMPLE_CHEMICAL", 10, 19], ["macrophage", "CELL", 27, 37], ["microglial cell", "CELL", 45, 60], ["myelin debris", "CELLULAR_COMPONENT", 72, 85], ["the cuprizone model", "TREATMENT", 6, 25], ["macrophage", "PROBLEM", 27, 37], ["microglial cell removal", "TREATMENT", 45, 68], ["myelin debris", "PROBLEM", 72, 85], ["repair", "TREATMENT", 106, 112], ["macrophage", "OBSERVATION_MODIFIER", 27, 37], ["microglial cell", "OBSERVATION", 45, 60], ["myelin debris", "OBSERVATION", 72, 85]]], ["Demyelination is extensive but can be contained within a circumscribed area (such as CCP) by minimizing the volume of the injection; lesion size is also EtBr concentration-dependent.", [["area", "ANATOMY", 71, 75], ["lesion", "ANATOMY", 133, 139], ["Demyelination", "DISEASE", 0, 13], ["EtBr", "CHEMICAL", 153, 157], ["EtBr", "CHEMICAL", 153, 157], ["EtBr", "SIMPLE_CHEMICAL", 153, 157], ["Demyelination", "PROBLEM", 0, 13], ["the injection", "TREATMENT", 118, 131], ["lesion size", "PROBLEM", 133, 144], ["circumscribed", "OBSERVATION_MODIFIER", 57, 70], ["area", "OBSERVATION_MODIFIER", 71, 75], ["lesion", "OBSERVATION", 133, 139], ["size", "OBSERVATION_MODIFIER", 140, 144], ["EtBr", "OBSERVATION_MODIFIER", 153, 157], ["concentration", "OBSERVATION_MODIFIER", 158, 171], ["dependent", "OBSERVATION_MODIFIER", 172, 181]]], ["EtBr will injure all nucleated cell types because its mechanism of action is as a DNAintercolating agent.", [["cell", "ANATOMY", 31, 35], ["EtBr", "CHEMICAL", 0, 4], ["EtBr", "CHEMICAL", 0, 4], ["EtBr", "SIMPLE_CHEMICAL", 0, 4], ["cell", "CELL", 31, 35], ["nucleated cell types", "CELL_TYPE", 21, 41], ["EtBr", "PROBLEM", 0, 4], ["a DNAintercolating agent", "TREATMENT", 80, 104], ["all nucleated", "OBSERVATION_MODIFIER", 17, 30], ["cell types", "OBSERVATION", 31, 41]]], ["Because astrocytes are damaged within the EtBr lesion area, Schwann cells are able to migrate in and remyelinate before oligodendrocytes repopulate the area (Woodruff and Franklin, 1999; Sim et al, 2002) .", [["astrocytes", "ANATOMY", 8, 18], ["EtBr lesion area", "ANATOMY", 42, 58], ["Schwann cells", "ANATOMY", 60, 73], ["oligodendrocytes", "ANATOMY", 120, 136], ["EtBr", "CHEMICAL", 42, 46], ["astrocytes", "CELL", 8, 18], ["EtBr lesion area", "CELLULAR_COMPONENT", 42, 58], ["Schwann cells", "CELL", 60, 73], ["oligodendrocytes", "CELL", 120, 136], ["astrocytes", "CELL_TYPE", 8, 18], ["Schwann cells", "CELL_TYPE", 60, 73], ["oligodendrocytes", "CELL_TYPE", 120, 136], ["astrocytes", "PROBLEM", 8, 18], ["the EtBr lesion area", "PROBLEM", 38, 58], ["Schwann cells", "PROBLEM", 60, 73], ["EtBr", "ANATOMY", 42, 46], ["lesion", "OBSERVATION", 47, 53], ["Schwann cells", "OBSERVATION", 60, 73], ["area", "OBSERVATION_MODIFIER", 152, 156]]], ["Spontaneous remyelination occurs from the outside of the lesion inward toward the center and is not extensive until 3.5 months following lesion production.", [["lesion", "ANATOMY", 57, 63], ["lesion", "ANATOMY", 137, 143], ["lesion", "CANCER", 137, 143], ["Spontaneous remyelination", "PROBLEM", 0, 25], ["lesion production", "PROBLEM", 137, 154], ["remyelination", "OBSERVATION", 12, 25], ["lesion", "OBSERVATION", 57, 63], ["not", "UNCERTAINTY", 96, 99], ["extensive", "OBSERVATION_MODIFIER", 100, 109], ["lesion", "OBSERVATION", 137, 143]]], ["Axons are spared but a significant proportion of naked axons remain demyelinated in the CCP 6 weeks after EtBr injection.", [["Axons", "ANATOMY", 0, 5], ["axons", "ANATOMY", 55, 60], ["EtBr", "CHEMICAL", 106, 110], ["EtBr", "CHEMICAL", 106, 110], ["Axons", "MULTI-TISSUE_STRUCTURE", 0, 5], ["axons", "CELL", 55, 60], ["EtBr", "SIMPLE_CHEMICAL", 106, 110], ["demyelinated", "PROBLEM", 68, 80], ["EtBr injection", "TREATMENT", 106, 120], ["demyelinated", "OBSERVATION", 68, 80]]], ["As animals age (412 months), spontaneous remyelination in this model is less efficient (Ibanez et al, 2004; Sim et al, 2002) .", [["spontaneous remyelination", "PROBLEM", 29, 54], ["remyelination", "OBSERVATION", 41, 54]]], ["For the assignment of repair to exogenous stem cells during transplantation therapy, the model can be modified by local high-dose irradiation (40 Gy X-rays) before EtBr (Franklin and Blakemore, 1995; Blakemore and Franklin, 1991) .", [["stem cells", "ANATOMY", 42, 52], ["EtBr", "CHEMICAL", 164, 168], ["EtBr", "CHEMICAL", 164, 168], ["stem cells", "CELL", 42, 52], ["EtBr", "SIMPLE_CHEMICAL", 164, 168], ["exogenous stem cells", "CELL_TYPE", 32, 52], ["repair", "TREATMENT", 22, 28], ["exogenous stem cells", "TREATMENT", 32, 52], ["transplantation therapy", "TREATMENT", 60, 83], ["local high-dose irradiation", "TREATMENT", 114, 141], ["repair", "OBSERVATION", 22, 28], ["exogenous stem cells", "OBSERVATION", 32, 52]]], ["Evaluation of oligodendrocytes, the precursors, and intact myelin can be accomplished using assays similar to those previously described above, but require tedious dissection of the lesioned area to eliminate background noise from normal surrounding areas.", [["oligodendrocytes", "ANATOMY", 14, 30], ["precursors", "ANATOMY", 36, 46], ["myelin", "ANATOMY", 59, 65], ["oligodendrocytes", "CELL", 14, 30], ["myelin", "GENE_OR_GENE_PRODUCT", 59, 65], ["oligodendrocytes", "CELL_TYPE", 14, 30], ["Evaluation", "TEST", 0, 10], ["oligodendrocytes", "PROBLEM", 14, 30], ["tedious dissection of the lesioned area", "TREATMENT", 156, 195], ["background noise", "PROBLEM", 209, 225], ["oligodendrocytes", "OBSERVATION", 14, 30], ["dissection", "OBSERVATION", 164, 174], ["normal", "OBSERVATION", 231, 237], ["surrounding", "OBSERVATION_MODIFIER", 238, 249], ["areas", "OBSERVATION_MODIFIER", 250, 255]]], ["Honmou et al (1996) have been able to demonstrate conduction block by quantitating compound action potentials in the spinal cords of animals subjected to EtBr lesioning.", [["spinal cords", "ANATOMY", 117, 129], ["EtBr", "CHEMICAL", 154, 158], ["EtBr", "CHEMICAL", 154, 158], ["spinal cords", "ORGAN", 117, 129], ["EtBr", "SIMPLE_CHEMICAL", 154, 158], ["conduction block", "PROBLEM", 50, 66], ["EtBr lesioning", "PROBLEM", 154, 168], ["spinal cords", "ANATOMY", 117, 129]]], ["Functional repair by transplanted Schwann cells reversed this slowed conduction velocity as assessed by ex vivo using field potential and intraaxonal recordings of the segment of spinal cord involved in the lesion.LysolecithinLysolecithin (lysophosphatidylcholine; Sigma) is a detergent-like membrane solubilizing agent injected following surgical preparation of brain or spinal cord and stereotaxic positioning of the Hamilton syringe.", [["Schwann cells", "ANATOMY", 34, 47], ["spinal cord", "ANATOMY", 179, 190], ["lesion", "ANATOMY", 207, 213], ["membrane", "ANATOMY", 292, 300], ["brain", "ANATOMY", 363, 368], ["spinal cord", "ANATOMY", 372, 383], ["LysolecithinLysolecithin", "CHEMICAL", 214, 238], ["lysophosphatidylcholine", "CHEMICAL", 240, 263], ["LysolecithinLysolecithin", "CHEMICAL", 214, 238], ["lysophosphatidylcholine", "CHEMICAL", 240, 263], ["Schwann cells", "CELL", 34, 47], ["spinal cord", "ORGAN", 179, 190], ["LysolecithinLysolecithin", "SIMPLE_CHEMICAL", 214, 238], ["lysophosphatidylcholine", "SIMPLE_CHEMICAL", 240, 263], ["Sigma", "SIMPLE_CHEMICAL", 265, 270], ["brain", "ORGAN", 363, 368], ["spinal cord", "ORGAN", 372, 383], ["transplanted Schwann cells", "CELL_TYPE", 21, 47], ["Functional repair", "TREATMENT", 0, 17], ["transplanted Schwann cells", "TREATMENT", 21, 47], ["this slowed conduction velocity", "PROBLEM", 57, 88], ["intraaxonal recordings", "TEST", 138, 160], ["the lesion", "PROBLEM", 203, 213], ["LysolecithinLysolecithin (lysophosphatidylcholine", "TREATMENT", 214, 263], ["a detergent-like membrane solubilizing agent", "TREATMENT", 275, 319], ["surgical preparation of brain or spinal cord", "TREATMENT", 339, 383], ["the Hamilton syringe", "TREATMENT", 415, 435], ["repair", "OBSERVATION", 11, 17], ["Schwann cells", "OBSERVATION", 34, 47], ["conduction velocity", "OBSERVATION", 69, 88], ["segment", "ANATOMY_MODIFIER", 168, 175], ["spinal cord", "ANATOMY", 179, 190], ["lesion", "OBSERVATION", 207, 213], ["brain", "ANATOMY", 363, 368], ["spinal cord", "ANATOMY", 372, 383]]], ["A 1% solution of the agent creates demyelinating lesions in adult mice or rats when administered to the dorsal funiculus of the spinal cord or CCP (Gregg et al, 2007; Girard et al, 2005) or into the right centrum semiovale after craniometry in adult male Macaque monkeys (Dousset et al, 1995) .", [["lesions", "ANATOMY", 49, 56], ["dorsal funiculus", "ANATOMY", 104, 120], ["spinal cord", "ANATOMY", 128, 139], ["right centrum semiovale", "ANATOMY", 199, 222], ["demyelinating lesions", "DISEASE", 35, 56], ["demyelinating lesions", "PATHOLOGICAL_FORMATION", 35, 56], ["mice", "ORGANISM", 66, 70], ["rats", "ORGANISM", 74, 78], ["dorsal funiculus", "MULTI-TISSUE_STRUCTURE", 104, 120], ["spinal cord", "ORGAN", 128, 139], ["Macaque", "ORGANISM", 255, 262], ["monkeys", "ORGANISM", 263, 270], ["mice", "SPECIES", 66, 70], ["rats", "SPECIES", 74, 78], ["Macaque monkeys", "SPECIES", 255, 270], ["mice", "SPECIES", 66, 70], ["Macaque monkeys", "SPECIES", 255, 270], ["A 1% solution of the agent", "TREATMENT", 0, 26], ["demyelinating lesions", "PROBLEM", 35, 56], ["demyelinating", "OBSERVATION_MODIFIER", 35, 48], ["lesions", "OBSERVATION", 49, 56], ["dorsal", "ANATOMY_MODIFIER", 104, 110], ["funiculus", "ANATOMY_MODIFIER", 111, 120], ["spinal cord", "ANATOMY", 128, 139], ["right centrum semiovale", "ANATOMY", 199, 222]]], ["In mice and young adult rats, myelin debris is completely removed and remyelination has begun by 7 days after lesion in the spinal cord; total remyelination, albeit with thin myelin sheaths, was seen by 1 month (Jeffrey and Blakemore, 1995; Kotter et al, 2001) .", [["myelin debris", "ANATOMY", 30, 43], ["lesion", "ANATOMY", 110, 116], ["spinal cord", "ANATOMY", 124, 135], ["myelin sheaths", "ANATOMY", 175, 189], ["mice", "ORGANISM", 3, 7], ["rats", "ORGANISM", 24, 28], ["myelin debris", "CELLULAR_COMPONENT", 30, 43], ["spinal cord", "ORGAN", 124, 135], ["myelin sheaths", "TISSUE", 175, 189], ["mice", "SPECIES", 3, 7], ["rats", "SPECIES", 24, 28], ["mice", "SPECIES", 3, 7], ["myelin debris", "PROBLEM", 30, 43], ["remyelination", "PROBLEM", 70, 83], ["lesion in the spinal cord", "PROBLEM", 110, 135], ["total remyelination", "PROBLEM", 137, 156], ["thin myelin sheaths", "TREATMENT", 170, 189], ["debris", "OBSERVATION", 37, 43], ["lesion", "OBSERVATION", 110, 116], ["spinal cord", "ANATOMY", 124, 135], ["total", "OBSERVATION_MODIFIER", 137, 142], ["remyelination", "OBSERVATION", 143, 156]]], ["In old male rats (380 days old), the center of the lesion remained completely demyelinated at 1 month (Gilson and Blakemore, 1993) .", [["lesion", "ANATOMY", 51, 57], ["rats", "ORGANISM", 12, 16], ["lesion", "PATHOLOGICAL_FORMATION", 51, 57], ["rats", "SPECIES", 12, 16], ["the lesion", "PROBLEM", 47, 57], ["completely demyelinated", "PROBLEM", 67, 90], ["lesion", "OBSERVATION", 51, 57], ["completely", "OBSERVATION_MODIFIER", 67, 77], ["demyelinated", "OBSERVATION", 78, 90]]], ["Macrophage depletion, as with the other demyelinating models, impairs remyelination (Kotter et al, 2001) .", [["Macrophage", "ANATOMY", 0, 10], ["Macrophage", "CELL", 0, 10], ["Macrophage depletion", "PROBLEM", 0, 20], ["the other demyelinating models", "PROBLEM", 30, 60], ["impairs remyelination", "PROBLEM", 62, 83], ["depletion", "OBSERVATION", 11, 20]]], ["For rat CCP lesions, remyelination proceeded slower than in spinal cord, with patches of oligodendrocyte progenitors obvious at lesion edges not before 2 weeks.", [["CCP lesions", "ANATOMY", 8, 19], ["spinal cord", "ANATOMY", 60, 71], ["patches", "ANATOMY", 78, 85], ["oligodendrocyte progenitors", "ANATOMY", 89, 116], ["lesion edges", "ANATOMY", 128, 140], ["rat", "ORGANISM", 4, 7], ["CCP lesions", "PATHOLOGICAL_FORMATION", 8, 19], ["spinal cord", "ORGAN", 60, 71], ["oligodendrocyte progenitors", "CELL", 89, 116], ["lesion edges", "MULTI-TISSUE_STRUCTURE", 128, 140], ["oligodendrocyte progenitors", "CELL_TYPE", 89, 116], ["rat", "SPECIES", 4, 7], ["rat", "SPECIES", 4, 7], ["rat CCP lesions", "PROBLEM", 4, 19], ["remyelination", "PROBLEM", 21, 34], ["oligodendrocyte progenitors", "PROBLEM", 89, 116], ["CCP", "OBSERVATION_MODIFIER", 8, 11], ["lesions", "OBSERVATION", 12, 19], ["remyelination", "OBSERVATION", 21, 34], ["slower", "OBSERVATION_MODIFIER", 45, 51], ["spinal cord", "ANATOMY", 60, 71], ["oligodendrocyte progenitors", "OBSERVATION", 89, 116]]], ["Remyelination in the CCP was evident at 3 weeks and all axons appeared to have compact myelin by 6 weeks using EM (Woodruff and Franklin, 1999) .", [["axons", "ANATOMY", 56, 61], ["myelin", "ANATOMY", 87, 93], ["Remyelination", "DISEASE", 0, 13], ["CCP", "GENE_OR_GENE_PRODUCT", 21, 24], ["axons", "MULTI-TISSUE_STRUCTURE", 56, 61], ["myelin", "CELLULAR_COMPONENT", 87, 93], ["CCP", "PROTEIN", 21, 24], ["Remyelination in the CCP", "PROBLEM", 0, 24]]], ["In monkeys as in rodents, maximum myelin loss was seen by histology and magnetization transfer ratio (MTR) by day 7 (Dousset et al, 1995) .", [["myelin", "ANATOMY", 34, 40], ["myelin loss", "DISEASE", 34, 45], ["monkeys", "ORGANISM", 3, 10], ["myelin", "GENE_OR_GENE_PRODUCT", 34, 40], ["maximum myelin loss", "PROBLEM", 26, 45], ["myelin loss", "OBSERVATION", 34, 45]]], ["Astrocytes and axons are spared in this demyelinating model, so oligodendrocytes are the primary remyelinating cell.", [["Astrocytes", "ANATOMY", 0, 10], ["axons", "ANATOMY", 15, 20], ["oligodendrocytes", "ANATOMY", 64, 80], ["cell", "ANATOMY", 111, 115], ["Astrocytes", "CELL", 0, 10], ["axons", "MULTI-TISSUE_STRUCTURE", 15, 20], ["oligodendrocytes", "CELL", 64, 80], ["remyelinating cell", "CELL", 97, 115], ["Astrocytes", "CELL_TYPE", 0, 10], ["oligodendrocytes", "CELL_TYPE", 64, 80], ["primary remyelinating cell", "CELL_TYPE", 89, 115], ["this demyelinating model", "PROBLEM", 35, 59], ["axons", "ANATOMY", 15, 20], ["remyelinating cell", "OBSERVATION", 97, 115]]], ["Faster remyelination may occur because oligodendrocyte progenitors are spared to a greater extent in this model than in the EtBr model (Woodruff and Franklin, 1999) .", [["oligodendrocyte progenitors", "ANATOMY", 39, 66], ["EtBr", "CHEMICAL", 124, 128], ["oligodendrocyte progenitors", "CELL", 39, 66], ["EtBr", "SIMPLE_CHEMICAL", 124, 128], ["oligodendrocyte progenitors", "CELL_TYPE", 39, 66], ["Faster remyelination", "PROBLEM", 0, 20], ["oligodendrocyte progenitors", "PROBLEM", 39, 66], ["remyelination", "OBSERVATION", 7, 20], ["greater", "OBSERVATION_MODIFIER", 83, 90], ["extent", "OBSERVATION_MODIFIER", 91, 97]]], ["As with the EtBr model, targeted lesion areas must be dissected before analysis.", [["lesion areas", "ANATOMY", 33, 45], ["EtBr", "CHEMICAL", 12, 16], ["EtBr", "CHEMICAL", 12, 16], ["EtBr", "SIMPLE_CHEMICAL", 12, 16], ["the EtBr model", "TREATMENT", 8, 22], ["targeted lesion areas", "PROBLEM", 24, 45], ["lesion", "OBSERVATION", 33, 39]]], ["See Table 2 for a comparison of the chemically induced demyelinating models.CONCLUSIONSThere are several types of animal models that produce demyelination that can serve as useful in-life pharmacological tools for assessing compounds.", [["demyelination", "DISEASE", 141, 154], ["the chemically induced demyelinating models", "PROBLEM", 32, 75], ["animal models", "PROBLEM", 114, 127], ["demyelination", "PROBLEM", 141, 154], ["demyelinating", "OBSERVATION", 55, 68], ["demyelination", "OBSERVATION", 141, 154]]], ["Chemically induced CNS lesions, such as those generated with cuprizone feeding or injection of EtBr or lysolecithin have several distinct advantages: (1) dissociation of the demyelination event from the complexities introduced into the tissue pathology by chronic inflammatory cells and their soluble mediators, (2) reproducibly timed spontaneous remyelination, and (3) robust de-remyelination in anatomically distinct areas facilitating focused, quantitative assessment of lesion generation and repair (Graca and Blakemore, 1986; Jeffrey and Blakemore, 1995; Honmou et al, 1996; Woodruff and Franklin, 1999; Matsushima and Morell, 2001; Mason et al, 2000 Mason et al, , 2004 Ibanez et al, 2004; Girard et al, 2005; Guazzo, 2005) .Experimental Autoimmune EncephalomyelitisEAE in mice.", [["CNS lesions", "ANATOMY", 19, 30], ["tissue", "ANATOMY", 236, 242], ["chronic inflammatory cells", "ANATOMY", 256, 282], ["lesion", "ANATOMY", 474, 480], ["cuprizone", "CHEMICAL", 61, 70], ["EtBr", "CHEMICAL", 95, 99], ["lysolecithin", "CHEMICAL", 103, 115], ["demyelination", "DISEASE", 174, 187], ["Autoimmune EncephalomyelitisEAE", "DISEASE", 744, 775], ["cuprizone", "CHEMICAL", 61, 70], ["EtBr", "CHEMICAL", 95, 99], ["lysolecithin", "CHEMICAL", 103, 115], ["CNS lesions", "PATHOLOGICAL_FORMATION", 19, 30], ["cuprizone", "SIMPLE_CHEMICAL", 61, 70], ["EtBr", "SIMPLE_CHEMICAL", 95, 99], ["lysolecithin", "SIMPLE_CHEMICAL", 103, 115], ["tissue", "TISSUE", 236, 242], ["chronic inflammatory cells", "CELL", 256, 282], ["lesion", "CANCER", 474, 480], ["mice", "ORGANISM", 779, 783], ["chronic inflammatory cells", "CELL_TYPE", 256, 282], ["soluble mediators", "PROTEIN", 293, 310], ["mice", "SPECIES", 779, 783], ["mice", "SPECIES", 779, 783], ["Chemically induced CNS lesions", "PROBLEM", 0, 30], ["cuprizone feeding", "TREATMENT", 61, 78], ["EtBr", "TREATMENT", 95, 99], ["lysolecithin", "TREATMENT", 103, 115], ["the demyelination event", "PROBLEM", 170, 193], ["chronic inflammatory cells", "PROBLEM", 256, 282], ["their soluble mediators", "TREATMENT", 287, 310], ["reproducibly timed spontaneous remyelination", "PROBLEM", 316, 360], ["robust de-remyelination in anatomically distinct areas", "PROBLEM", 370, 424], ["quantitative assessment", "TEST", 447, 470], ["lesion generation", "PROBLEM", 474, 491], ["repair", "TREATMENT", 496, 502], ["Experimental Autoimmune EncephalomyelitisEAE in mice", "PROBLEM", 731, 783], ["CNS", "ANATOMY", 19, 22], ["lesions", "OBSERVATION", 23, 30], ["demyelination", "OBSERVATION", 174, 187], ["tissue", "ANATOMY", 236, 242], ["chronic", "OBSERVATION_MODIFIER", 256, 263], ["inflammatory cells", "OBSERVATION", 264, 282], ["lesion", "OBSERVATION", 474, 480], ["Autoimmune EncephalomyelitisEAE", "OBSERVATION", 744, 775]]], ["Experimental autoimmune encephalomyelitis (EAE) is an autoimmune model produced by active immunization of rats, mice, or marmosets using whole brain or spinal cord homogenates (SCHs) or purified myelin proteins (PLP, MOG, MBP) or by adoptive transfer using activated, myelin antigen-specific T cells.", [["brain", "ANATOMY", 143, 148], ["spinal cord homogenates", "ANATOMY", 152, 175], ["SCHs", "ANATOMY", 177, 181], ["T cells", "ANATOMY", 292, 299], ["autoimmune encephalomyelitis", "DISEASE", 13, 41], ["EAE", "DISEASE", 43, 46], ["rats", "ORGANISM", 106, 110], ["mice", "ORGANISM", 112, 116], ["marmosets", "ORGANISM", 121, 130], ["brain", "ORGAN", 143, 148], ["spinal cord homogenates", "ORGANISM_SUBSTANCE", 152, 175], ["SCHs", "CANCER", 177, 181], ["myelin proteins", "GENE_OR_GENE_PRODUCT", 195, 210], ["PLP", "GENE_OR_GENE_PRODUCT", 212, 215], ["MOG", "GENE_OR_GENE_PRODUCT", 217, 220], ["MBP", "GENE_OR_GENE_PRODUCT", 222, 225], ["myelin antigen", "GENE_OR_GENE_PRODUCT", 268, 282], ["T cells", "CELL", 292, 299], ["purified myelin proteins", "PROTEIN", 186, 210], ["PLP", "PROTEIN", 212, 215], ["MOG", "PROTEIN", 217, 220], ["MBP", "PROTEIN", 222, 225], ["activated, myelin antigen-specific T cells", "CELL_TYPE", 257, 299], ["rats", "SPECIES", 106, 110], ["mice", "SPECIES", 112, 116], ["marmosets", "SPECIES", 121, 130], ["mice", "SPECIES", 112, 116], ["Experimental autoimmune encephalomyelitis", "PROBLEM", 0, 41], ["an autoimmune model", "PROBLEM", 51, 70], ["active immunization of rats", "TREATMENT", 83, 110], ["whole brain or spinal cord homogenates", "PROBLEM", 137, 175], ["purified myelin proteins", "PROBLEM", 186, 210], ["PLP", "TEST", 212, 215], ["MOG", "TEST", 217, 220], ["MBP", "TEST", 222, 225], ["activated, myelin antigen", "TEST", 257, 282], ["autoimmune encephalomyelitis", "OBSERVATION", 13, 41], ["spinal cord", "ANATOMY", 152, 163]]], ["Analysis of inbred mouse strains has demonstrated that specific major histocompatability haplotypes (MHC) confer a susceptibility to the disease which is both gender and antigen specific.", [["mouse", "ORGANISM", 19, 24], ["MHC", "PROTEIN", 101, 104], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["inbred mouse strains", "PROBLEM", 12, 32], ["a susceptibility to the disease", "PROBLEM", 113, 144], ["disease", "OBSERVATION", 137, 144]]], ["Active subcutaneous immunization of female SJL/J mice with PLP 1-139 peptide emulsified in complete Freund's adjuvant (CFA) supplemented with Mycobacterium tuberculosis and two injections of pertussis toxin 3 days apart produces a relapsingremitting disease similar to MS. The disease is evident between days 7 and 10, peaking by the end of the second week in a first attack; the pathology of the first attack is strictly inflammatory.", [["subcutaneous", "ANATOMY", 7, 19], ["PLP 1-139 peptide", "CHEMICAL", 59, 76], ["Mycobacterium tuberculosis", "DISEASE", 142, 168], ["pertussis toxin", "CHEMICAL", 191, 206], ["relapsingremitting disease", "DISEASE", 231, 257], ["MS", "DISEASE", 269, 271], ["SJL/J mice", "ORGANISM", 43, 53], ["PLP 1-139 peptide", "SIMPLE_CHEMICAL", 59, 76], ["Freund", "ORGANISM", 100, 106], ["CFA", "SIMPLE_CHEMICAL", 119, 122], ["Mycobacterium tuberculosis", "ORGANISM", 142, 168], ["mice", "SPECIES", 49, 53], ["Mycobacterium tuberculosis", "SPECIES", 142, 168], ["mice", "SPECIES", 49, 53], ["Mycobacterium tuberculosis", "SPECIES", 142, 168], ["Active subcutaneous immunization", "TREATMENT", 0, 32], ["PLP", "TEST", 59, 62], ["complete Freund's adjuvant (CFA)", "TREATMENT", 91, 123], ["Mycobacterium tuberculosis", "PROBLEM", 142, 168], ["pertussis toxin", "PROBLEM", 191, 206], ["a relapsingremitting disease", "PROBLEM", 229, 257], ["The disease", "PROBLEM", 273, 284], ["inflammatory", "PROBLEM", 422, 434], ["subcutaneous", "ANATOMY", 7, 19], ["Mycobacterium tuberculosis", "OBSERVATION", 142, 168], ["relapsingremitting disease", "OBSERVATION", 231, 257], ["disease", "OBSERVATION", 277, 284], ["inflammatory", "OBSERVATION_MODIFIER", 422, 434]]], ["Following a remission, the subsequent attacks include inflammation, demyelination and axonal loss.", [["axonal", "ANATOMY", 86, 92], ["inflammation", "DISEASE", 54, 66], ["demyelination", "DISEASE", 68, 81], ["axonal loss", "DISEASE", 86, 97], ["inflammation", "PROBLEM", 54, 66], ["demyelination", "PROBLEM", 68, 81], ["axonal loss", "PROBLEM", 86, 97], ["inflammation", "OBSERVATION", 54, 66], ["demyelination", "OBSERVATION", 68, 81], ["axonal loss", "OBSERVATION", 86, 97]]], ["T cells, dendritic cells, macrophages, and endogenous glia all are involved in the disease (Butzkueven et al, 2002) .", [["T cells", "ANATOMY", 0, 7], ["dendritic cells", "ANATOMY", 9, 24], ["macrophages", "ANATOMY", 26, 37], ["glia", "ANATOMY", 54, 58], ["T cells", "CELL", 0, 7], ["dendritic cells", "CELL", 9, 24], ["macrophages", "CELL", 26, 37], ["glia", "CELL", 54, 58], ["T cells", "CELL_TYPE", 0, 7], ["dendritic cells", "CELL_TYPE", 9, 24], ["macrophages", "CELL_TYPE", 26, 37], ["endogenous glia", "CELL_TYPE", 43, 58], ["dendritic cells", "PROBLEM", 9, 24], ["macrophages", "PROBLEM", 26, 37], ["endogenous glia all", "PROBLEM", 43, 62], ["the disease", "PROBLEM", 79, 90], ["dendritic cells", "OBSERVATION", 9, 24], ["macrophages", "OBSERVATION_MODIFIER", 26, 37], ["endogenous glia", "OBSERVATION", 43, 58]]], ["In contrast, rMOG 35\u00c055 or hMOG 1\u00c0125 induce chronic EAE in female C57Bl/6 mice.", [["rMOG 35\u00c055", "CHEMICAL", 13, 23], ["hMOG 1\u00c0125", "CHEMICAL", 27, 37], ["EAE", "DISEASE", 53, 56], ["rMOG 35\u00c055", "CHEMICAL", 13, 23], ["hMOG 1\u00c0125", "CHEMICAL", 27, 37], ["rMOG 35\u00c055", "SIMPLE_CHEMICAL", 13, 23], ["hMOG 1\u00c0125", "SIMPLE_CHEMICAL", 27, 37], ["C57Bl/6 mice", "ORGANISM", 67, 79], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["rMOG", "TEST", 13, 17], ["chronic EAE", "PROBLEM", 45, 56], ["chronic", "OBSERVATION_MODIFIER", 45, 52]]], ["Inflammation, demyelination, oligodendrocyte and neuronal death, and axonal loss occur within the first 2 weeks of disease.", [["oligodendrocyte", "ANATOMY", 29, 44], ["neuronal", "ANATOMY", 49, 57], ["axonal", "ANATOMY", 69, 75], ["Inflammation", "DISEASE", 0, 12], ["demyelination", "DISEASE", 14, 27], ["neuronal death", "DISEASE", 49, 63], ["axonal loss", "DISEASE", 69, 80], ["oligodendrocyte", "CELL", 29, 44], ["neuronal", "CELL", 49, 57], ["Inflammation", "PROBLEM", 0, 12], ["demyelination", "PROBLEM", 14, 27], ["oligodendrocyte and neuronal death", "PROBLEM", 29, 63], ["axonal loss", "PROBLEM", 69, 80], ["disease", "PROBLEM", 115, 122], ["demyelination", "OBSERVATION", 14, 27], ["neuronal death", "OBSERVATION", 49, 63], ["axonal loss", "OBSERVATION", 69, 80], ["disease", "OBSERVATION", 115, 122]]], ["Human MOG 1\u00c0125 induces demyelination that is primarily antibody mediated and thus produces a pathology similar to that seen in MS lesions (Table 3 ; Tiwari- Woodruff et al, 2007; Kanwar et al, 2004; Lalive et al, 2006; Bernard, 1976; Arnon, 1981; Offner, 2004) .Experimental Autoimmune EncephalomyelitisThese two models are complementary in their utility for drug discovery.", [["MS lesions", "ANATOMY", 128, 138], ["MOG 1\u00c0125", "CHEMICAL", 6, 15], ["demyelination", "DISEASE", 24, 37], ["MS", "DISEASE", 128, 130], ["Autoimmune Encephalomyelitis", "DISEASE", 276, 304], ["Human", "ORGANISM", 0, 5], ["MOG 1\u00c0125", "GENE_OR_GENE_PRODUCT", 6, 15], ["MS lesions", "CANCER", 128, 138], ["Human MOG 1\u00c0125", "PROTEIN", 0, 15], ["Human", "SPECIES", 0, 5], ["Human MOG 1\u00c0125", "SPECIES", 0, 15], ["Human MOG", "TEST", 0, 9], ["demyelination", "PROBLEM", 24, 37], ["a pathology", "PROBLEM", 92, 103], ["MS lesions", "PROBLEM", 128, 138], ["Experimental Autoimmune Encephalomyelitis", "PROBLEM", 263, 304], ["lesions", "OBSERVATION", 131, 138], ["Autoimmune Encephalomyelitis", "OBSERVATION", 276, 304]]], ["Because of the temporal separation of pathologies (inflammation vs tissue damage) and the relapsing-remitting nature of the disease, the PLP model allows for the assessment of both anti-inflammatory and prorepair drugs as well as a comparison of prophylactic with therapeutic intervention.", [["tissue", "ANATOMY", 67, 73], ["inflammation", "DISEASE", 51, 63], ["PLP", "CHEMICAL", 137, 140], ["tissue", "TISSUE", 67, 73], ["PLP", "GENE_OR_GENE_PRODUCT", 137, 140], ["pathologies", "PROBLEM", 38, 49], ["inflammation", "PROBLEM", 51, 63], ["tissue damage", "PROBLEM", 67, 80], ["the disease", "PROBLEM", 120, 131], ["the PLP model", "TEST", 133, 146], ["the assessment", "TEST", 158, 172], ["both anti-inflammatory and prorepair drugs", "TREATMENT", 176, 218], ["therapeutic intervention", "TREATMENT", 264, 288], ["temporal", "OBSERVATION_MODIFIER", 15, 23], ["separation", "OBSERVATION_MODIFIER", 24, 34], ["pathologies", "OBSERVATION", 38, 49], ["inflammation", "OBSERVATION_MODIFIER", 51, 63], ["relapsing", "OBSERVATION_MODIFIER", 90, 99], ["remitting", "OBSERVATION_MODIFIER", 100, 109], ["disease", "OBSERVATION", 124, 131]]], ["The chronic C57Bl/6-MOG models (1) allow for the specific assessment of agents targeting B cells (hMOG 1\u00c0125 model), (2) demonstrate axonal damage and cell death at an earlier time point than is seen in the PLP model, thereby shortening the in-life dosing, and (3) are compatible with creation of knock out and transgenic mice for target and drug validation.", [["B cells", "ANATOMY", 89, 96], ["axonal", "ANATOMY", 133, 139], ["cell", "ANATOMY", 151, 155], ["axonal damage", "DISEASE", 133, 146], ["death", "DISEASE", 156, 161], ["PLP", "CHEMICAL", 207, 210], ["B cells", "CELL", 89, 96], ["hMOG 1\u00c0125", "CELL", 98, 108], ["cell", "CELL", 151, 155], ["PLP", "GENE_OR_GENE_PRODUCT", 207, 210], ["mice", "ORGANISM", 322, 326], ["B cells", "CELL_TYPE", 89, 96], ["hMOG 1\u00c0125 model", "CELL_LINE", 98, 114], ["mice", "SPECIES", 322, 326], ["mice", "SPECIES", 322, 326], ["The chronic C57Bl/6-MOG models", "TREATMENT", 0, 30], ["the specific assessment", "TEST", 45, 68], ["axonal damage", "PROBLEM", 133, 146], ["cell death", "PROBLEM", 151, 161], ["drug validation", "TEST", 342, 357], ["chronic", "OBSERVATION_MODIFIER", 4, 11], ["axonal damage", "OBSERVATION", 133, 146], ["cell death", "OBSERVATION", 151, 161]]], ["EAE in rats.", [["EAE", "DISEASE", 0, 3], ["rats", "ORGANISM", 7, 11], ["rats", "SPECIES", 7, 11]]], ["Even though rat models consume more drug substance than do mouse models, the rat EAE models may be necessary for proof of concept assessment due to the selectivity and/or pharmacokinetics or pharmacodynamics of the drug being tested.", [["EAE", "DISEASE", 81, 84], ["rat", "ORGANISM", 12, 15], ["mouse", "ORGANISM", 59, 64], ["rat", "ORGANISM", 77, 80], ["rat", "SPECIES", 12, 15], ["mouse", "SPECIES", 59, 64], ["rat", "SPECIES", 77, 80], ["rat", "SPECIES", 12, 15], ["mouse", "SPECIES", 59, 64], ["rat", "SPECIES", 77, 80], ["the rat EAE models", "TREATMENT", 73, 91], ["concept assessment", "TEST", 122, 140]]], ["In addition, assessment of drug effects using MRI or electrophysiology may be made more easily using rats (Bechtold et al, 2004; Brochet et al, 2006) .", [["rats", "ORGANISM", 101, 105], ["rats", "SPECIES", 101, 105], ["drug effects", "PROBLEM", 27, 39], ["MRI", "TEST", 46, 49]]], ["Acute, nonrelapsing EAE can be actively induced in Lewis rats using guinea pig SCH or MBP, CFA, and M. tuberculosis (Floris et al, 2004; Berger et al, 2006) .", [["EAE", "DISEASE", 20, 23], ["SCH", "CHEMICAL", 79, 82], ["tuberculosis", "DISEASE", 103, 115], ["rats", "ORGANISM", 57, 61], ["guinea pig", "ORGANISM", 68, 78], ["SCH", "ORGANISM", 79, 82], ["MBP", "GENE_OR_GENE_PRODUCT", 86, 89], ["CFA", "GENE_OR_GENE_PRODUCT", 91, 94], ["M. tuberculosis", "ORGANISM", 100, 115], ["MBP", "PROTEIN", 86, 89], ["rats", "SPECIES", 57, 61], ["guinea pig", "SPECIES", 68, 78], ["M. tuberculosis", "SPECIES", 100, 115], ["pig", "SPECIES", 75, 78], ["M. tuberculosis", "SPECIES", 100, 115], ["Acute, nonrelapsing EAE", "PROBLEM", 0, 23], ["guinea pig SCH", "TREATMENT", 68, 82], ["CFA", "ANATOMY", 91, 94], ["M.", "ANATOMY", 100, 102], ["tuberculosis", "OBSERVATION", 103, 115]]], ["By increasing the concentration of the encephalitogenic antigens and/or M. tuberculosis, the disease phase can be prolonged and induction of a relapsing pattern achieved in this strain of rat (Feurer et al, 1985) .", [["tuberculosis", "DISEASE", 75, 87], ["M. tuberculosis", "ORGANISM", 72, 87], ["rat", "ORGANISM", 188, 191], ["encephalitogenic antigens", "PROTEIN", 39, 64], ["M. tuberculosis", "SPECIES", 72, 87], ["rat", "SPECIES", 188, 191], ["M. tuberculosis", "SPECIES", 72, 87], ["rat", "SPECIES", 188, 191], ["the encephalitogenic antigens", "PROBLEM", 35, 64], ["M. tuberculosis", "PROBLEM", 72, 87], ["the disease phase", "PROBLEM", 89, 106], ["a relapsing pattern", "PROBLEM", 141, 160], ["tuberculosis", "OBSERVATION", 75, 87]]], ["The acute monophasic model in Lewis rats demonstrates neurological deficits by day 10, peaks at day 15, and resolves by day 20, at which time animals are resistant to reinduction of disease.", [["neurological", "ANATOMY", 54, 66], ["neurological deficits", "DISEASE", 54, 75], ["rats", "ORGANISM", 36, 40], ["rats", "SPECIES", 36, 40], ["neurological deficits", "PROBLEM", 54, 75], ["disease", "PROBLEM", 182, 189], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["monophasic", "OBSERVATION_MODIFIER", 10, 20], ["Lewis", "ANATOMY_MODIFIER", 30, 35], ["neurological deficits", "OBSERVATION", 54, 75], ["disease", "OBSERVATION", 182, 189]]], ["This model is one of relatively short duration which is an advantage, but as there is no demyelination, cell death, or axonal loss, its use is limited to the assessment of antiinflammatory drugs only.", [["cell", "ANATOMY", 104, 108], ["axonal", "ANATOMY", 119, 125], ["demyelination", "DISEASE", 89, 102], ["death", "DISEASE", 109, 114], ["axonal loss", "DISEASE", 119, 130], ["cell", "CELL", 104, 108], ["demyelination", "PROBLEM", 89, 102], ["cell death", "PROBLEM", 104, 114], ["axonal loss", "PROBLEM", 119, 130], ["the assessment", "TEST", 154, 168], ["antiinflammatory drugs", "TREATMENT", 172, 194], ["one of relatively short duration", "OBSERVATION_MODIFIER", 14, 46], ["no", "UNCERTAINTY", 86, 88], ["demyelination", "OBSERVATION", 89, 102], ["cell death", "OBSERVATION", 104, 114], ["axonal loss", "OBSERVATION", 119, 130]]], ["Rat MOG 1\u00c0125 will induce chronic, nonrelapsing EAE in female Brown Norway rats when given with CFA and M. tuberculosis (Mi et al, 2007; Diem et al, 2005) .", [["MOG 1\u00c0125", "CHEMICAL", 4, 13], ["EAE", "DISEASE", 48, 51], ["tuberculosis", "DISEASE", 107, 119], ["Brown Norway rats", "ORGANISM", 62, 79], ["CFA", "SIMPLE_CHEMICAL", 96, 99], ["M. tuberculosis", "ORGANISM", 104, 119], ["Rat", "SPECIES", 0, 3], ["rats", "SPECIES", 75, 79], ["M. tuberculosis", "SPECIES", 104, 119], ["M. tuberculosis", "SPECIES", 104, 119], ["Rat MOG", "TEST", 0, 7], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["tuberculosis", "OBSERVATION", 107, 119]]], ["When the same dose of MOG is given to female Dark Agouti (DA) rats or whole homologous rat SCH is given to male DA rats without M. tuberculosis, animals develop relapsing-remitting disease (Issazadeh et al, 1996; Lorentzen et al, 1995; Brochet et al, 2006; Fernandez et al, 2004 ; Figure 1 ).", [["DA", "CHEMICAL", 58, 60], ["SCH", "CHEMICAL", 91, 94], ["DA", "CHEMICAL", 112, 114], ["tuberculosis", "DISEASE", 131, 143], ["relapsing-remitting disease", "DISEASE", 161, 188], ["MOG", "GENE_OR_GENE_PRODUCT", 22, 25], ["Dark Agouti (DA) rats", "ORGANISM", 45, 66], ["rat", "ORGANISM", 87, 90], ["SCH", "SIMPLE_CHEMICAL", 91, 94], ["DA rats", "ORGANISM", 112, 119], ["M. tuberculosis", "ORGANISM", 128, 143], ["animals", "ORGANISM", 145, 152], ["MOG", "PROTEIN", 22, 25], ["rats", "SPECIES", 62, 66], ["rat", "SPECIES", 87, 90], ["rats", "SPECIES", 115, 119], ["M. tuberculosis", "SPECIES", 128, 143], ["rat", "SPECIES", 87, 90], ["M. tuberculosis", "SPECIES", 128, 143], ["whole homologous rat SCH", "TREATMENT", 70, 94], ["M. tuberculosis", "PROBLEM", 128, 143], ["remitting disease", "PROBLEM", 171, 188], ["tuberculosis", "OBSERVATION", 131, 143]]], ["As in the relapsing-remitting model in SJL/J mice, peak disease in DA rats is achieved by the end of the second week followed by remission and is strictly inflammatory in nature; animals experience disease through the first remission in a relatively synchronous manner.", [["DA", "CHEMICAL", 67, 69], ["SJL/J mice", "ORGANISM", 39, 49], ["DA rats", "ORGANISM", 67, 74], ["mice", "SPECIES", 45, 49], ["rats", "SPECIES", 70, 74], ["SJL/J mice", "SPECIES", 39, 49], ["peak disease in DA rats", "PROBLEM", 51, 74], ["animals experience disease", "PROBLEM", 179, 205], ["peak", "OBSERVATION_MODIFIER", 51, 55], ["disease", "OBSERVATION", 56, 63], ["inflammatory", "OBSERVATION_MODIFIER", 155, 167]]], ["Subsequent attacks are asynchronous among animals and involve demyelination involving macrophages and anti-myelin antibodies as well as axonal loss (Lorentzen et al, 1995; Issazadeh et al, 1996) .Experimental Autoimmune EncephalomyelitisInflammation can be verified in these models by RT-PCR and staining for proinflammatory markers of cells and their products.", [["macrophages", "ANATOMY", 86, 97], ["axonal", "ANATOMY", 136, 142], ["cells", "ANATOMY", 336, 341], ["demyelination", "DISEASE", 62, 75], ["axonal loss", "DISEASE", 136, 147], ["Autoimmune EncephalomyelitisInflammation", "DISEASE", 209, 249], ["macrophages", "CELL", 86, 97], ["anti-myelin antibodies", "GENE_OR_GENE_PRODUCT", 102, 124], ["cells", "CELL", 336, 341], ["macrophages", "CELL_TYPE", 86, 97], ["anti-myelin antibodies", "PROTEIN", 102, 124], ["proinflammatory markers", "PROTEIN", 309, 332], ["Subsequent attacks", "PROBLEM", 0, 18], ["asynchronous among animals", "PROBLEM", 23, 49], ["demyelination", "PROBLEM", 62, 75], ["macrophages", "PROBLEM", 86, 97], ["anti-myelin antibodies", "PROBLEM", 102, 124], ["axonal loss", "PROBLEM", 136, 147], ["Experimental Autoimmune EncephalomyelitisInflammation", "PROBLEM", 196, 249], ["RT-PCR", "TEST", 285, 291], ["staining", "TEST", 296, 304], ["proinflammatory markers of cells", "PROBLEM", 309, 341], ["axonal loss", "OBSERVATION", 136, 147], ["Autoimmune Encephalomyelitis", "OBSERVATION", 209, 237]]], ["In rat EAE models, it has recently been shown that macrophages can be tracked in vivo by T 2 -weighted MRI images of these cells labeled with ultra small particles of iron oxide (USPIO) (Sinarem; Guerbet, Paris, France).", [["macrophages", "ANATOMY", 51, 62], ["cells", "ANATOMY", 123, 128], ["EAE", "DISEASE", 7, 10], ["iron oxide", "CHEMICAL", 167, 177], ["USPIO", "CHEMICAL", 179, 184], ["iron oxide", "CHEMICAL", 167, 177], ["USPIO", "CHEMICAL", 179, 184], ["rat", "ORGANISM", 3, 6], ["macrophages", "CELL", 51, 62], ["cells", "CELL", 123, 128], ["iron oxide", "SIMPLE_CHEMICAL", 167, 177], ["USPIO", "SIMPLE_CHEMICAL", 179, 184], ["macrophages", "CELL_TYPE", 51, 62], ["rat", "SPECIES", 3, 6], ["rat", "SPECIES", 3, 6], ["MRI images", "TEST", 103, 113], ["these cells", "TEST", 117, 128], ["ultra small particles of iron oxide", "TREATMENT", 142, 177], ["macrophages", "OBSERVATION", 51, 62]]], ["The particles are phagocytosed by macrophages in the periphery and in the DA rat EAE model as these cells migrate first into the cervical cord and subsequently into the brain stem and cerebellum with disease progression, they can be detected as hypointense images.", [["macrophages", "ANATOMY", 34, 45], ["cells", "ANATOMY", 100, 105], ["cervical cord", "ANATOMY", 129, 142], ["brain stem", "ANATOMY", 169, 179], ["cerebellum", "ANATOMY", 184, 194], ["DA", "CHEMICAL", 74, 76], ["EAE", "DISEASE", 81, 84], ["macrophages", "CELL", 34, 45], ["rat", "ORGANISM", 77, 80], ["cells", "CELL", 100, 105], ["cervical cord", "ORGAN", 129, 142], ["brain stem", "TISSUE", 169, 179], ["cerebellum", "ORGAN", 184, 194], ["macrophages", "CELL_TYPE", 34, 45], ["rat", "SPECIES", 77, 80], ["rat", "SPECIES", 77, 80], ["disease progression", "PROBLEM", 200, 219], ["hypointense images", "TEST", 245, 263], ["particles", "OBSERVATION_MODIFIER", 4, 13], ["phagocytosed", "OBSERVATION", 18, 30], ["macrophages", "OBSERVATION", 34, 45], ["periphery", "ANATOMY_MODIFIER", 53, 62], ["cervical cord", "ANATOMY", 129, 142], ["brain stem", "ANATOMY", 169, 179], ["cerebellum", "ANATOMY", 184, 194], ["disease", "OBSERVATION", 200, 207]]], ["With a half-life of only a few hours, USPIOs can be injected repeatedly into animals.", [["USPIOs", "SIMPLE_CHEMICAL", 38, 44], ["USPIOs", "TREATMENT", 38, 44]]], ["Longitudinal studies mapping time and location of inflammatory cells in intact animals can thereby be accomplished.", [["inflammatory cells", "ANATOMY", 50, 68], ["cells", "CELL", 63, 68], ["inflammatory cells", "CELL_TYPE", 50, 68], ["Longitudinal studies mapping time", "TEST", 0, 33], ["inflammatory cells", "PROBLEM", 50, 68], ["inflammatory cells", "OBSERVATION", 50, 68]]], ["In addition, contrast agents such as gadolinium diethylenetriamine-pentaacetate (Gd-DPTA) (Magnevist; Schering, Berlin, Germany) and gadofluorine M (Schering) have been used in T 1-weighted MRI images for discerning leakage at the BBB.", [["BBB", "ANATOMY", 231, 234], ["gadolinium diethylenetriamine-pentaacetate", "CHEMICAL", 37, 79], ["Gd-DPTA", "CHEMICAL", 81, 88], ["gadofluorine M", "CHEMICAL", 133, 147], ["Schering", "CHEMICAL", 149, 157], ["gadolinium diethylenetriamine-pentaacetate", "CHEMICAL", 37, 79], ["Gd-DPTA", "CHEMICAL", 81, 88], ["Magnevist", "CHEMICAL", 91, 100], ["gadofluorine M", "CHEMICAL", 133, 147], ["gadolinium diethylenetriamine-pentaacetate", "SIMPLE_CHEMICAL", 37, 79], ["Gd-DPTA", "SIMPLE_CHEMICAL", 81, 88], ["gadofluorine M", "SIMPLE_CHEMICAL", 133, 147], ["BBB", "MULTI-TISSUE_STRUCTURE", 231, 234], ["contrast agents", "TREATMENT", 13, 28], ["gadolinium diethylenetriamine", "TREATMENT", 37, 66], ["pentaacetate (Gd-DPTA) (Magnevist; Schering, Berlin, Germany)", "TREATMENT", 67, 128], ["gadofluorine M (Schering)", "TREATMENT", 133, 158], ["MRI images", "TEST", 190, 200], ["discerning leakage at the BBB", "PROBLEM", 205, 234], ["leakage", "OBSERVATION", 216, 223], ["BBB", "ANATOMY", 231, 234]]], ["Correlations can then be made regarding BBB breakdown and inflammatory cell invasion of the CNS (Brochet et al, 2006; Berger et al, 2006) .", [["BBB", "ANATOMY", 40, 43], ["inflammatory cell", "ANATOMY", 58, 75], ["CNS", "ANATOMY", 92, 95], ["BBB", "MULTI-TISSUE_STRUCTURE", 40, 43], ["cell", "CELL", 71, 75], ["BBB breakdown", "PROBLEM", 40, 53], ["inflammatory cell invasion", "PROBLEM", 58, 84], ["inflammatory cell invasion", "OBSERVATION", 58, 84], ["CNS", "ANATOMY", 92, 95]]], ["Similar studies have been reported in murine adoptive transfer models of EAE Smorodchenko et al, 2007; Anderson et al, 2004) .", [["EAE", "DISEASE", 73, 76], ["murine", "ORGANISM", 38, 44], ["murine", "SPECIES", 38, 44], ["Similar studies", "TEST", 0, 15]]], ["MBP exon 2-containing transcripts, normally expressed at extremely low levels in adult CNS, are elevated during remyelination and can be detected in tissues using in situ hybridization (ISH) or immunohistochemistry (Jordan et al, 1990; Kanwar et al, 2004) .", [["adult CNS", "ANATOMY", 81, 90], ["tissues", "ANATOMY", 149, 156], ["MBP exon 2", "GENE_OR_GENE_PRODUCT", 0, 10], ["CNS", "ANATOMICAL_SYSTEM", 87, 90], ["tissues", "TISSUE", 149, 156], ["MBP exon 2", "RNA", 0, 10], ["MBP exon", "TEST", 0, 8], ["extremely low levels in adult CNS", "PROBLEM", 57, 90], ["elevated during remyelination", "PROBLEM", 96, 125], ["CNS", "ANATOMY", 87, 90], ["elevated", "OBSERVATION", 96, 104]]], ["In these models, myelin and axonal damage or loss are identified as described above for chemically induced lesions using myelin histology, toluidine blue, LFB, immunostaining for NF or APP, and EM.Experimental Autoimmune EncephalomyelitisAs in the lysolecithin-mediated demyelination model, MRI magnetization transfer ratios (MTRs) can be used as a measurement of myelin loss in EAE models.", [["myelin", "ANATOMY", 17, 23], ["axonal", "ANATOMY", 28, 34], ["lesions", "ANATOMY", 107, 114], ["myelin", "ANATOMY", 121, 127], ["myelin", "ANATOMY", 364, 370], ["axonal damage", "DISEASE", 28, 41], ["toluidine blue", "CHEMICAL", 139, 153], ["Autoimmune EncephalomyelitisAs", "DISEASE", 210, 240], ["lysolecithin", "CHEMICAL", 248, 260], ["demyelination", "DISEASE", 270, 283], ["myelin loss", "DISEASE", 364, 375], ["EAE", "DISEASE", 379, 382], ["toluidine blue", "CHEMICAL", 139, 153], ["lysolecithin", "CHEMICAL", 248, 260], ["myelin", "CELLULAR_COMPONENT", 17, 23], ["axonal", "CELLULAR_COMPONENT", 28, 34], ["lesions", "PATHOLOGICAL_FORMATION", 107, 114], ["toluidine blue", "SIMPLE_CHEMICAL", 139, 153], ["LFB", "SIMPLE_CHEMICAL", 155, 158], ["NF", "GENE_OR_GENE_PRODUCT", 179, 181], ["APP", "GENE_OR_GENE_PRODUCT", 185, 188], ["lysolecithin", "SIMPLE_CHEMICAL", 248, 260], ["myelin", "GENE_OR_GENE_PRODUCT", 364, 370], ["LFB", "PROTEIN", 155, 158], ["NF", "PROTEIN", 179, 181], ["APP", "PROTEIN", 185, 188], ["myelin", "PROBLEM", 17, 23], ["axonal damage", "PROBLEM", 28, 41], ["loss", "PROBLEM", 45, 49], ["chemically induced lesions", "PROBLEM", 88, 114], ["myelin histology", "TEST", 121, 137], ["toluidine blue", "TREATMENT", 139, 153], ["NF", "PROBLEM", 179, 181], ["Experimental Autoimmune EncephalomyelitisAs", "PROBLEM", 197, 240], ["the lysolecithin-mediated demyelination model", "TREATMENT", 244, 289], ["MRI magnetization transfer ratios", "TEST", 291, 324], ["myelin loss in EAE models", "PROBLEM", 364, 389], ["axonal damage", "OBSERVATION", 28, 41], ["lesions", "OBSERVATION", 107, 114], ["Autoimmune EncephalomyelitisAs", "OBSERVATION", 210, 240], ["myelin loss", "OBSERVATION", 364, 375]]], ["Diffusion tensor imaging (DTI) takes advantage of the anisotropic nature of water diffusion in tissue to allow for detailed REVIEW .. ........................................................................................................................................ .... microstructural information and is used to confirm axonal integrity.", [["tissue", "ANATOMY", 95, 101], ["axonal", "ANATOMY", 327, 333], ["tissue", "TISSUE", 95, 101], ["axonal", "MULTI-TISSUE_STRUCTURE", 327, 333], ["Diffusion tensor imaging", "TEST", 0, 24]]], ["Both MTR and DTI techniques have been used in rats and marmoset EAE models (Mi et al, 2007; Berger et al, 2006; Fujiyoshi et al, 2007; Brok et al, 2001) .", [["MTR", "SIMPLE_CHEMICAL", 5, 8], ["rats", "ORGANISM", 46, 50], ["marmoset", "ORGANISM", 55, 63], ["MTR", "PROTEIN", 5, 8], ["rats", "SPECIES", 46, 50], ["Both MTR and DTI techniques", "TREATMENT", 0, 27]]], ["Thus, small animal MRIs (1.5 T magnet, Philips, Best, The Netherlands 7 T Bruker; 4.7 T horizontal bore NMR spectrometer, Varian, Palo Alto, CA) are becoming more readily available and standardly used for chronic in-life monitoring of pathology in EAE models.Experimental Autoimmune EncephalomyelitisOther demyelinating models.", [["EAE", "DISEASE", 248, 251], ["Autoimmune EncephalomyelitisOther demyelinating", "DISEASE", 272, 319], ["small animal MRIs", "TEST", 6, 23], ["Philips", "TEST", 39, 46], ["Bruker", "TEST", 74, 80], ["T horizontal bore NMR spectrometer", "TREATMENT", 86, 120], ["Experimental Autoimmune EncephalomyelitisOther demyelinating models", "PROBLEM", 259, 326], ["small", "OBSERVATION_MODIFIER", 6, 11], ["Autoimmune EncephalomyelitisOther", "OBSERVATION", 272, 305], ["demyelinating models", "OBSERVATION", 306, 326]]], ["There are several models of spinal cord injury and focal ischemia that lead to demyelination with partial sparing of axons that can be produced in rodents and monkeys.", [["spinal cord", "ANATOMY", 28, 39], ["axons", "ANATOMY", 117, 122], ["cord injury", "DISEASE", 35, 46], ["ischemia", "DISEASE", 57, 65], ["demyelination", "DISEASE", 79, 92], ["spinal cord", "MULTI-TISSUE_STRUCTURE", 28, 39], ["axons", "MULTI-TISSUE_STRUCTURE", 117, 122], ["monkeys", "ORGANISM", 159, 166], ["spinal cord injury", "PROBLEM", 28, 46], ["focal ischemia", "PROBLEM", 51, 65], ["demyelination", "PROBLEM", 79, 92], ["several", "OBSERVATION_MODIFIER", 10, 17], ["spinal cord", "ANATOMY", 28, 39], ["injury", "OBSERVATION", 40, 46], ["focal", "OBSERVATION_MODIFIER", 51, 56], ["ischemia", "OBSERVATION", 57, 65], ["demyelination", "OBSERVATION", 79, 92], ["partial", "OBSERVATION_MODIFIER", 98, 105], ["sparing", "OBSERVATION_MODIFIER", 106, 113]]], ["Spinal cord lesions can be created weight drop contusion and hemisection and ischemic insult can be produced by a 90 min middle cerebral occlusion (MCAO).", [["Spinal cord lesions", "ANATOMY", 0, 19], ["cerebral", "ANATOMY", 128, 136], ["cord lesions", "DISEASE", 7, 19], ["contusion", "DISEASE", 47, 56], ["ischemic insult", "DISEASE", 77, 92], ["cerebral occlusion", "DISEASE", 128, 146], ["Spinal cord lesions", "PATHOLOGICAL_FORMATION", 0, 19], ["cerebral", "ORGAN", 128, 136], ["Spinal cord lesions", "PROBLEM", 0, 19], ["weight drop contusion", "PROBLEM", 35, 56], ["hemisection", "PROBLEM", 61, 72], ["ischemic insult", "PROBLEM", 77, 92], ["a 90 min middle cerebral occlusion", "PROBLEM", 112, 146], ["cord", "ANATOMY", 7, 11], ["lesions", "OBSERVATION", 12, 19], ["drop", "OBSERVATION_MODIFIER", 42, 46], ["contusion", "OBSERVATION", 47, 56], ["hemisection", "OBSERVATION_MODIFIER", 61, 72], ["ischemic", "OBSERVATION_MODIFIER", 77, 85], ["middle cerebral", "ANATOMY", 121, 136], ["occlusion", "OBSERVATION", 137, 146]]], ["Although these models cannot be fully explored in this chapter, they are mentioned because they induce endogenous repair responses that lend themselves to the same quantitative biochemical, histological, and MRI analyses, drug intervention, and stem cell therapy as seen in EAE models (Tanaka et al, 2003; Ohori et al, 2006; Fujiyoshi et al, 2007; Yang et al, 2006) .Experimental Autoimmune EncephalomyelitisThe location of injection, the length of time for infusion, and the properties of the toxic agent will define whether damage is limited and reversible, is restricted to oligodendrocytes but without long-term macroscopic alterations, leads to short-term direct attack on myelin, or results in long-term damage to myelin indirectly due to oligodendrocyte loss.", [["stem cell", "ANATOMY", 245, 254], ["oligodendrocytes", "ANATOMY", 577, 593], ["myelin", "ANATOMY", 678, 684], ["myelin", "ANATOMY", 720, 726], ["oligodendrocyte", "ANATOMY", 745, 760], ["EAE", "DISEASE", 274, 277], ["Autoimmune Encephalomyelitis", "DISEASE", 380, 408], ["oligodendrocyte loss", "DISEASE", 745, 765], ["stem cell", "CELL", 245, 254], ["oligodendrocytes", "CELL", 577, 593], ["myelin", "CELLULAR_COMPONENT", 678, 684], ["myelin", "CELLULAR_COMPONENT", 720, 726], ["oligodendrocyte", "CELL", 745, 760], ["oligodendrocytes", "CELL_TYPE", 577, 593], ["endogenous repair", "TREATMENT", 103, 120], ["MRI analyses", "TEST", 208, 220], ["drug intervention", "TREATMENT", 222, 239], ["stem cell therapy", "TREATMENT", 245, 262], ["Experimental Autoimmune Encephalomyelitis", "PROBLEM", 367, 408], ["injection", "TREATMENT", 424, 433], ["infusion", "TREATMENT", 458, 466], ["the toxic agent", "TREATMENT", 490, 505], ["damage", "PROBLEM", 526, 532], ["oligodendrocytes", "PROBLEM", 577, 593], ["long-term macroscopic alterations", "PROBLEM", 606, 639], ["short-term direct attack on myelin", "PROBLEM", 650, 684], ["long-term damage to myelin", "PROBLEM", 700, 726], ["oligodendrocyte loss", "PROBLEM", 745, 765], ["stem cell therapy", "OBSERVATION", 245, 262], ["Autoimmune Encephalomyelitis", "OBSERVATION", 380, 408], ["short-term", "OBSERVATION_MODIFIER", 650, 660], ["long-term damage", "OBSERVATION_MODIFIER", 700, 716], ["oligodendrocyte loss", "OBSERVATION", 745, 765]]], ["The injection of the peroxynitrite donor SIN-1 into white matter corpus callosum in rats leads to severe myelin alteration within 2 days starting with vacuolization of the myelin membrane as a consequence of S-nitrosylation of proteins including PLP (Boullerne and Benjamins, 2006) .Experimental Autoimmune EncephalomyelitisA brief infusion of kainate causes some oligodendrocyte apoptosis but an infusion that lasts for several days produces massive oligodendrocyte and progenitor cell death, demyelinating plaques, axonal damage, and inflammation (Matute et al, 2001) .", [["white matter corpus callosum", "ANATOMY", 52, 80], ["myelin", "ANATOMY", 105, 111], ["myelin membrane", "ANATOMY", 172, 187], ["oligodendrocyte", "ANATOMY", 364, 379], ["oligodendrocyte", "ANATOMY", 451, 466], ["progenitor cell", "ANATOMY", 471, 486], ["plaques", "ANATOMY", 508, 515], ["axonal", "ANATOMY", 517, 523], ["peroxynitrite", "CHEMICAL", 21, 34], ["SIN-1", "CHEMICAL", 41, 46], ["kainate", "CHEMICAL", 344, 351], ["death", "DISEASE", 487, 492], ["demyelinating plaques", "DISEASE", 494, 515], ["axonal damage", "DISEASE", 517, 530], ["inflammation", "DISEASE", 536, 548], ["peroxynitrite", "CHEMICAL", 21, 34], ["SIN-1", "CHEMICAL", 41, 46], ["PLP", "CHEMICAL", 246, 249], ["kainate", "CHEMICAL", 344, 351], ["peroxynitrite", "SIMPLE_CHEMICAL", 21, 34], ["SIN-1", "GENE_OR_GENE_PRODUCT", 41, 46], ["white matter", "TISSUE", 52, 64], ["corpus callosum", "ORGAN", 65, 80], ["rats", "ORGANISM", 84, 88], ["myelin", "GENE_OR_GENE_PRODUCT", 105, 111], ["myelin membrane", "CELLULAR_COMPONENT", 172, 187], ["PLP", "GENE_OR_GENE_PRODUCT", 246, 249], ["kainate", "SIMPLE_CHEMICAL", 344, 351], ["oligodendrocyte", "CELL", 364, 379], ["oligodendrocyte", "CELL", 451, 466], ["progenitor cell", "CELL", 471, 486], ["plaques", "PATHOLOGICAL_FORMATION", 508, 515], ["axonal", "MULTI-TISSUE_STRUCTURE", 517, 523], ["PLP", "PROTEIN", 246, 249], ["rats", "SPECIES", 84, 88], ["the peroxynitrite donor SIN", "TREATMENT", 17, 44], ["severe myelin alteration", "PROBLEM", 98, 122], ["vacuolization of the myelin membrane", "PROBLEM", 151, 187], ["S-nitrosylation of proteins", "PROBLEM", 208, 235], ["PLP (Boullerne and Benjamins", "TREATMENT", 246, 274], ["Experimental Autoimmune EncephalomyelitisA brief infusion of kainate", "TREATMENT", 283, 351], ["some oligodendrocyte apoptosis", "PROBLEM", 359, 389], ["an infusion", "TREATMENT", 394, 405], ["massive oligodendrocyte and progenitor cell death", "PROBLEM", 443, 492], ["demyelinating plaques", "PROBLEM", 494, 515], ["axonal damage", "PROBLEM", 517, 530], ["inflammation", "PROBLEM", 536, 548], ["white matter", "ANATOMY", 52, 64], ["corpus callosum", "ANATOMY", 65, 80], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["myelin alteration", "OBSERVATION", 105, 122], ["myelin membrane", "OBSERVATION", 172, 187], ["Autoimmune", "OBSERVATION", 296, 306], ["oligodendrocyte apoptosis", "OBSERVATION", 364, 389], ["massive oligodendrocyte", "OBSERVATION", 443, 466], ["progenitor cell death", "OBSERVATION", 471, 492], ["demyelinating", "OBSERVATION_MODIFIER", 494, 507], ["plaques", "OBSERVATION", 508, 515], ["axonal damage", "OBSERVATION", 517, 530], ["inflammation", "OBSERVATION", 536, 548]]], ["A single dose of 8 or 22 Gy irradiation to rodent C2-T2 cervical spinal cord produces apoptotic oligodendrocytes after 24 h but no demyelination until 16-18 weeks later (Atkinson et al, 2003) .", [["C2-T2 cervical spinal cord", "ANATOMY", 50, 76], ["oligodendrocytes", "ANATOMY", 96, 112], ["demyelination", "DISEASE", 131, 144], ["cervical spinal cord", "TISSUE", 56, 76], ["oligodendrocytes", "CELL", 96, 112], ["apoptotic oligodendrocytes", "CELL_TYPE", 86, 112], ["Gy irradiation", "TREATMENT", 25, 39], ["apoptotic oligodendrocytes", "PROBLEM", 86, 112], ["demyelination", "PROBLEM", 131, 144], ["cervical", "ANATOMY_MODIFIER", 56, 64], ["spinal cord", "ANATOMY", 65, 76], ["apoptotic oligodendrocytes", "OBSERVATION", 86, 112], ["no", "UNCERTAINTY", 128, 130], ["demyelination", "OBSERVATION", 131, 144]]], ["Injections of kainate or anti-galactocerebroside (anti-Gal C) may be made into the optic nerve, dorsal spinal cord or CCP, thereby focusing the lesion formation and facilitating subsequent analysis of damage and repair (Sergott et al, 1985; Woodruff and Franklin, 1999; Barres et al, 1992) .Experimental Autoimmune EncephalomyelitisAlthough most published studies employing anti-Gal C used a conventional polyclonal antibody or serum from rabbits in combination with guinea pig complement, Barres et al (1992) implanted a mouse hybridoma cell line secreting anti-Gal C into the p5 rat optic nerve.", [["optic nerve", "ANATOMY", 83, 94], ["dorsal spinal cord", "ANATOMY", 96, 114], ["lesion", "ANATOMY", 144, 150], ["serum", "ANATOMY", 428, 433], ["hybridoma cell line", "ANATOMY", 528, 547], ["optic nerve", "ANATOMY", 585, 596], ["kainate", "CHEMICAL", 14, 21], ["anti-galactocerebroside", "CHEMICAL", 25, 48], ["anti-Gal C", "CHEMICAL", 50, 60], ["Autoimmune Encephalomyelitis", "DISEASE", 304, 332], ["kainate", "CHEMICAL", 14, 21], ["anti-galactocerebroside", "CHEMICAL", 25, 48], ["Gal C", "CHEMICAL", 55, 60], ["anti-Gal C", "CHEMICAL", 374, 384], ["kainate", "SIMPLE_CHEMICAL", 14, 21], ["anti-galactocerebroside", "SIMPLE_CHEMICAL", 25, 48], ["anti-Gal C", "GENE_OR_GENE_PRODUCT", 50, 60], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 83, 94], ["dorsal spinal cord", "ORGAN", 96, 114], ["CCP", "GENE_OR_GENE_PRODUCT", 118, 121], ["lesion", "PATHOLOGICAL_FORMATION", 144, 150], ["anti-Gal C", "SIMPLE_CHEMICAL", 374, 384], ["serum", "ORGANISM_SUBSTANCE", 428, 433], ["rabbits", "ORGANISM", 439, 446], ["guinea pig", "ORGANISM", 467, 477], ["mouse", "ORGANISM", 522, 527], ["hybridoma cell line", "CELL", 528, 547], ["anti-Gal C", "GENE_OR_GENE_PRODUCT", 558, 568], ["rat", "ORGANISM", 581, 584], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 585, 596], ["anti-Gal C", "PROTEIN", 374, 384], ["polyclonal antibody", "PROTEIN", 405, 424], ["mouse hybridoma cell line", "CELL_LINE", 522, 547], ["anti-Gal C", "PROTEIN", 558, 568], ["rabbits", "SPECIES", 439, 446], ["guinea pig", "SPECIES", 467, 477], ["mouse", "SPECIES", 522, 527], ["rat", "SPECIES", 581, 584], ["rabbits", "SPECIES", 439, 446], ["pig", "SPECIES", 474, 477], ["mouse", "SPECIES", 522, 527], ["Injections of kainate", "TREATMENT", 0, 21], ["anti-galactocerebroside (anti-Gal C)", "TREATMENT", 25, 61], ["the lesion formation", "PROBLEM", 140, 160], ["damage", "PROBLEM", 201, 207], ["repair", "TREATMENT", 212, 218], ["Experimental Autoimmune Encephalomyelitis", "PROBLEM", 291, 332], ["anti-Gal C", "PROBLEM", 374, 384], ["a conventional polyclonal antibody", "TREATMENT", 390, 424], ["serum from rabbits", "TREATMENT", 428, 446], ["guinea pig complement", "TREATMENT", 467, 488], ["a mouse hybridoma cell line", "TREATMENT", 520, 547], ["optic nerve", "ANATOMY", 83, 94], ["dorsal", "ANATOMY_MODIFIER", 96, 102], ["spinal cord", "ANATOMY", 103, 114], ["lesion", "OBSERVATION", 144, 150], ["Autoimmune Encephalomyelitis", "OBSERVATION", 304, 332], ["hybridoma cell line", "OBSERVATION", 528, 547], ["secreting anti-Gal", "OBSERVATION", 548, 566], ["p5", "ANATOMY_MODIFIER", 578, 580], ["rat", "ANATOMY_MODIFIER", 581, 584], ["optic nerve", "ANATOMY", 585, 596]]], ["Injection of antibody and complement into the adult rat lumbar cord showed demyelination by day 3, remyelination commencing by day 14, and complete remyelination by day 60 (Keirstead et al, 1998 ) Sergott et al (1985 injected antibody and complement into the guinea pig optic nerve and demonstrated myelin vesiculation by day 5, naked axons between days 7 and 14, and remyelination beginning between days 21 and 35.", [["lumbar cord", "ANATOMY", 56, 67], ["optic nerve", "ANATOMY", 270, 281], ["myelin", "ANATOMY", 299, 305], ["axons", "ANATOMY", 335, 340], ["demyelination", "DISEASE", 75, 88], ["remyelination", "DISEASE", 148, 161], ["rat", "ORGANISM", 52, 55], ["lumbar cord", "ORGAN", 56, 67], ["guinea pig", "ORGANISM", 259, 269], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 270, 281], ["myelin vesiculation", "CELLULAR_COMPONENT", 299, 318], ["rat", "SPECIES", 52, 55], ["guinea pig", "SPECIES", 259, 269], ["guinea pig", "SPECIES", 259, 269], ["Injection of antibody", "TREATMENT", 0, 21], ["demyelination", "PROBLEM", 75, 88], ["Sergott et al (1985 injected antibody", "TREATMENT", 197, 234], ["myelin vesiculation", "PROBLEM", 299, 318], ["lumbar cord", "ANATOMY", 56, 67], ["demyelination", "OBSERVATION", 75, 88], ["optic nerve", "ANATOMY", 270, 281]]], ["Injection of antibody and complement into the CCP produced the greatest delay in demyelination and repair: demyelination was seen at 2 weeks and remyelination by oligodendrocytes started by 6 weeks after injection.", [["oligodendrocytes", "ANATOMY", 162, 178], ["demyelination", "DISEASE", 81, 94], ["demyelination", "DISEASE", 107, 120], ["CCP", "GENE_OR_GENE_PRODUCT", 46, 49], ["oligodendrocytes", "CELL", 162, 178], ["CCP", "PROTEIN", 46, 49], ["oligodendrocytes", "CELL_TYPE", 162, 178], ["Injection of antibody", "TREATMENT", 0, 21], ["the CCP", "TEST", 42, 49], ["demyelination", "PROBLEM", 81, 94], ["repair", "TREATMENT", 99, 105], ["demyelination", "PROBLEM", 107, 120], ["injection", "TREATMENT", 204, 213], ["greatest", "OBSERVATION_MODIFIER", 63, 71], ["delay", "OBSERVATION_MODIFIER", 72, 77], ["demyelination", "OBSERVATION", 81, 94], ["repair", "OBSERVATION", 99, 105], ["demyelination", "OBSERVATION", 107, 120]]], ["Extensive remyelination within the CCP was apparent at 8 weeks but it took 3.5 months for the repair to be complete (Woodruff and Franklin, 1999) .", [["Extensive remyelination within the CCP", "PROBLEM", 0, 38], ["the repair", "TREATMENT", 90, 100], ["remyelination", "OBSERVATION", 10, 23], ["repair", "OBSERVATION", 94, 100]]], ["A comparison of these demyelinating models is summarized in Table 2 .CONCLUSIONSBypassing induction of global inflammation as an alternative strategy for in vivo demyelination can be achieved by administering agents that directly damage oligodendrocytes, their precursors, or myelin.", [["oligodendrocytes", "ANATOMY", 237, 253], ["precursors", "ANATOMY", 261, 271], ["myelin", "ANATOMY", 276, 282], ["inflammation", "DISEASE", 110, 122], ["demyelination", "DISEASE", 162, 175], ["oligodendrocytes", "CELL", 237, 253], ["myelin", "CELLULAR_COMPONENT", 276, 282], ["oligodendrocytes", "CELL_TYPE", 237, 253], ["these demyelinating models", "PROBLEM", 16, 42], ["global inflammation", "PROBLEM", 103, 122], ["an alternative strategy", "TREATMENT", 126, 149], ["vivo demyelination", "PROBLEM", 157, 175], ["agents", "TREATMENT", 209, 215], ["directly damage oligodendrocytes", "PROBLEM", 221, 253], ["myelin", "PROBLEM", 276, 282], ["demyelinating", "OBSERVATION", 22, 35], ["inflammation", "OBSERVATION", 110, 122]]], ["Anti-GalC plus complement, kainite, SIN-1, irradiation, and Theiler's or corona virus infection are examples of such models (Dal Canto and Lipton, 1976; Jordan et al, 1990; Touil et al, 2001; Matute et al, 2001; Atkinson et al, 2003; Boullerne and Benjamins, 2006) .", [["GalC", "CHEMICAL", 5, 9], ["kainite", "CHEMICAL", 27, 34], ["Theiler's or corona virus infection", "DISEASE", 60, 95], ["GalC", "GENE_OR_GENE_PRODUCT", 5, 9], ["kainite", "SIMPLE_CHEMICAL", 27, 34], ["SIN-1", "GENE_OR_GENE_PRODUCT", 36, 41], ["Theiler", "ORGANISM", 60, 67], ["corona virus", "ORGANISM", 73, 85], ["GalC", "PROTEIN", 5, 9], ["Theiler", "SPECIES", 60, 67], ["Theiler", "SPECIES", 60, 67], ["corona virus", "SPECIES", 73, 85], ["Anti-GalC plus complement", "TREATMENT", 0, 25], ["irradiation", "TREATMENT", 43, 54], ["Theiler's", "PROBLEM", 60, 69], ["corona virus infection", "PROBLEM", 73, 95], ["corona virus", "ANATOMY", 73, 85]]], ["In general, the use of mouse models is preferred because less drug substance is required; this of considerable importance when daily dosing paradigms are chronic, lasting several weeks.", [["mouse", "ORGANISM", 23, 28], ["mouse", "SPECIES", 23, 28], ["mouse", "SPECIES", 23, 28], ["daily dosing paradigms", "TREATMENT", 127, 149], ["chronic", "OBSERVATION_MODIFIER", 154, 161]]], ["However, in the case of (1) particular requirements of model generation or analysis that lend themselves to one species over another, (2) the lack of identical molecular targets or adequate homology at the target molecule in some species of rodents compared to humans, (3) species-specific potency of certain drugs, and (4) pharmacokinetic properties peculiar to a given species, the use of rats, guinea pigs, and nonhuman primates may be necessary for in vivo drug screening.CONCLUSIONSEAE models are of interest in drug screening as they most faithfully represent the pathology seen in MS The use of the marmoset EAE model can take advantage of the potential for cross-reactivity in the monkey of therapeutic agents as well as human reagents for cell and biomarker identification.", [["cell", "ANATOMY", 748, 752], ["humans", "ORGANISM", 261, 267], ["rats", "ORGANISM", 391, 395], ["guinea pigs", "ORGANISM", 397, 408], ["nonhuman", "ORGANISM", 414, 422], ["primates", "ORGANISM", 423, 431], ["marmoset", "ORGANISM", 606, 614], ["monkey", "ORGANISM", 689, 695], ["human", "ORGANISM", 729, 734], ["cell", "CELL", 748, 752], ["humans", "SPECIES", 261, 267], ["rats", "SPECIES", 391, 395], ["guinea pigs", "SPECIES", 397, 408], ["human", "SPECIES", 729, 734], ["humans", "SPECIES", 261, 267], ["guinea pigs", "SPECIES", 397, 408], ["human", "SPECIES", 729, 734], ["model generation", "TREATMENT", 55, 71], ["identical molecular targets", "PROBLEM", 150, 177], ["certain drugs", "TREATMENT", 301, 314], ["pharmacokinetic properties", "TREATMENT", 324, 350], ["guinea pigs", "TREATMENT", 397, 408], ["vivo drug screening", "TEST", 456, 475], ["drug screening", "TEST", 517, 531], ["the pathology", "PROBLEM", 566, 579], ["the marmoset EAE model", "TREATMENT", 602, 624], ["therapeutic agents", "TREATMENT", 699, 717], ["human reagents", "TREATMENT", 729, 743], ["cell and biomarker identification", "TEST", 748, 781], ["pathology", "OBSERVATION", 570, 579]]], ["In addition, MRI and electrophysiological techniques may be employed in the model.", [["MRI", "TEST", 13, 16], ["electrophysiological techniques", "TEST", 21, 52]]], ["Cognitive and visual acuity assessments and chronic safety can also be conducted in this model providing an advantage over rodent models.IN VIVO PHARMACOLOGICAL TOOLSRemyelination can be achieved in vivo in demyelinating animal models using several different approaches.", [["visual acuity assessments", "TEST", 14, 39], ["VIVO PHARMACOLOGICAL TOOLSRemyelination", "TREATMENT", 140, 179]]], ["The use of antiinflammatory drugs may create a permissive environment for endogenous repair to occur in the absence of ongoing disease (Floris et al, 2004; Dalal et al, 1997; Kanwar et al, 2004; Tiwari-Woodruff et al, 2007) .", [["antiinflammatory drugs", "TREATMENT", 11, 33], ["endogenous repair", "TREATMENT", 74, 91], ["ongoing disease", "PROBLEM", 119, 134], ["repair", "OBSERVATION", 85, 91]]], ["There are many published studies demonstrating the efficacy of growth factors or small molecules that induce expansion of precursors, recruit them to sites of pathology, and drive differentiation of endogenous oligodendrocyte progenitors (Okano et al, 2007; Stangel, 2004; Franklin, 2002; Webster, 1997; Oudega et al, 1997; Lachapelle et al, 2002; Adamo et al, 2006) .", [["precursors", "ANATOMY", 122, 132], ["sites", "ANATOMY", 150, 155], ["oligodendrocyte progenitors", "ANATOMY", 210, 237], ["oligodendrocyte progenitors", "CELL", 210, 237], ["growth factors", "PROTEIN", 63, 77], ["endogenous oligodendrocyte progenitors", "CELL_TYPE", 199, 237], ["many published studies", "TEST", 10, 32], ["growth factors", "PROBLEM", 63, 77], ["small molecules", "PROBLEM", 81, 96], ["expansion of precursors", "PROBLEM", 109, 132], ["pathology", "TEST", 159, 168], ["small molecules", "OBSERVATION", 81, 96], ["endogenous oligodendrocyte progenitors", "OBSERVATION", 199, 237]]], ["Neuroprotective drugs and hormones that preserve the integrity and function of cells, axons, and myelin in spite of ongoing pathology have been successfully used in animal models to permit repair (Diem et al, 2004; Stangel, 2004; Butzkueven et al, 2002; Mason et al, 2000; Tiwari-Woodruff et al, 2007 , Kanwar et al, 2004 .", [["cells", "ANATOMY", 79, 84], ["axons", "ANATOMY", 86, 91], ["myelin", "ANATOMY", 97, 103], ["cells", "CELL", 79, 84], ["axons", "CELLULAR_COMPONENT", 86, 91], ["myelin", "CELLULAR_COMPONENT", 97, 103], ["Neuroprotective drugs", "TREATMENT", 0, 21], ["hormones", "TREATMENT", 26, 34], ["ongoing pathology", "PROBLEM", 116, 133]]], ["Antibody neutralization of inhibitory molecules which block remyelination is also effective in vivo (Mi et al, 2007) .", [["inhibitory molecules", "PROTEIN", 27, 47], ["Antibody neutralization of inhibitory molecules", "TREATMENT", 0, 47], ["block remyelination", "PROBLEM", 54, 73]]], ["Stem cells, which will not be reviewed in any depth in this chapter, can either replace precursors that have been depleted by chronic demyelination and/or produce factors that reduce glial scarring, inflammation, and axonal loss (Mason et al, 2004; Pluchino et al, 2003) .Small MoleculesSmall molecules that have been chemically engineered to be potent, selective, soluble, and orally available may be preferable to biologics in that they can be taken by the patient him/herself as a pill and they may have fewer side effects such as irritation at injection site or flu-like symptoms.", [["Stem cells", "ANATOMY", 0, 10], ["glial", "ANATOMY", 183, 188], ["axonal", "ANATOMY", 217, 223], ["demyelination", "DISEASE", 134, 147], ["glial scarring", "DISEASE", 183, 197], ["inflammation", "DISEASE", 199, 211], ["axonal loss", "DISEASE", 217, 228], ["Stem cells", "CELL", 0, 10], ["glial", "TISSUE", 183, 188], ["patient", "ORGANISM", 459, 466], ["Stem cells", "CELL_TYPE", 0, 10], ["patient", "SPECIES", 459, 466], ["Stem cells", "PROBLEM", 0, 10], ["chronic demyelination", "PROBLEM", 126, 147], ["glial scarring", "PROBLEM", 183, 197], ["inflammation", "PROBLEM", 199, 211], ["axonal loss", "PROBLEM", 217, 228], ["Small MoleculesSmall molecules", "PROBLEM", 272, 302], ["side effects", "PROBLEM", 513, 525], ["irritation at injection site", "PROBLEM", 534, 562], ["flu-like symptoms", "PROBLEM", 566, 583], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["demyelination", "OBSERVATION", 134, 147], ["glial", "OBSERVATION_MODIFIER", 183, 188], ["scarring", "OBSERVATION", 189, 197], ["inflammation", "OBSERVATION", 199, 211], ["axonal loss", "OBSERVATION", 217, 228], ["Molecules", "OBSERVATION_MODIFIER", 278, 287], ["Small molecules", "OBSERVATION", 287, 302], ["potent", "OBSERVATION_MODIFIER", 346, 352]]], ["One such molecule is teriflunomide, an inhibitor of dihydroorotate dehydrogenase, currently in Phase III trials for the treatment of MS. It is an antiinflammatory agent that inhibits T-and B-cell proliferation and function.", [["B-cell", "ANATOMY", 189, 195], ["teriflunomide", "CHEMICAL", 21, 34], ["dihydroorotate", "CHEMICAL", 52, 66], ["MS", "DISEASE", 133, 135], ["teriflunomide", "CHEMICAL", 21, 34], ["dihydroorotate", "CHEMICAL", 52, 66], ["teriflunomide", "SIMPLE_CHEMICAL", 21, 34], ["dihydroorotate dehydrogenase", "GENE_OR_GENE_PRODUCT", 52, 80], ["T", "CELL", 183, 184], ["B-cell", "CELL", 189, 195], ["dihydroorotate dehydrogenase", "PROTEIN", 52, 80], ["teriflunomide", "TREATMENT", 21, 34], ["dihydroorotate dehydrogenase", "PROBLEM", 52, 80], ["Phase III trials", "TREATMENT", 95, 111], ["MS", "PROBLEM", 133, 135], ["an antiinflammatory agent", "TREATMENT", 143, 168], ["T", "TEST", 183, 184], ["antiinflammatory", "OBSERVATION_MODIFIER", 146, 162], ["cell proliferation", "OBSERVATION", 191, 209]]], ["This drug is a contender to be among the first orally available drugs to treat the disease .", [["drugs", "TREATMENT", 64, 69], ["the disease", "PROBLEM", 79, 90], ["disease", "OBSERVATION", 83, 90]]], ["Teriflunomide is very active in several EAE models when administered by oral route once daily.", [["oral", "ANATOMY", 72, 76], ["Teriflunomide", "CHEMICAL", 0, 13], ["EAE", "DISEASE", 40, 43], ["Teriflunomide", "CHEMICAL", 0, 13], ["Teriflunomide", "SIMPLE_CHEMICAL", 0, 13], ["oral", "ORGANISM_SUBDIVISION", 72, 76], ["Teriflunomide", "TREATMENT", 0, 13], ["very", "OBSERVATION_MODIFIER", 17, 21], ["active", "OBSERVATION_MODIFIER", 22, 28]]], ["In DA rats it reduces induction and severity of EAE, inhibits demyelination, prevents axonal loss, and increases conduction velocity (manuscript accepted, J Neurol).", [["axonal", "ANATOMY", 86, 92], ["DA", "CHEMICAL", 3, 5], ["EAE", "DISEASE", 48, 51], ["demyelination", "DISEASE", 62, 75], ["axonal loss", "DISEASE", 86, 97], ["DA rats", "ORGANISM", 3, 10], ["axonal", "MULTI-TISSUE_STRUCTURE", 86, 92], ["rats", "SPECIES", 6, 10], ["EAE", "PROBLEM", 48, 51], ["demyelination", "PROBLEM", 62, 75], ["axonal loss", "PROBLEM", 86, 97], ["increases conduction velocity", "PROBLEM", 103, 132], ["demyelination", "OBSERVATION", 62, 75], ["prevents", "UNCERTAINTY", 77, 85], ["axonal loss", "OBSERVATION", 86, 97], ["conduction velocity", "OBSERVATION", 113, 132]]], ["The in vivo effects of teriflunomide provide an example of the species and straindependent differences that are seen in different EAE models with respect to minimal effective dose and efficacy ( Figures 2 and 3) .", [["teriflunomide", "CHEMICAL", 23, 36], ["EAE", "DISEASE", 130, 133], ["teriflunomide", "CHEMICAL", 23, 36], ["teriflunomide", "SIMPLE_CHEMICAL", 23, 36], ["teriflunomide", "TREATMENT", 23, 36], ["the species", "PROBLEM", 59, 70], ["straindependent differences", "PROBLEM", 75, 102]]], ["In both the acute Lewis rat and relapsingremitting DA rat EAE models, the drug is efficacious at a minimal effective dose of 3 mg/kg; at this dose the disease is virtually eliminated in the acute model whereas delayed and reduced in severity in the relapsing-remitting model ( Figure 2 ).", [["DA", "CHEMICAL", 51, 53], ["EAE", "DISEASE", 58, 61], ["rat", "ORGANISM", 24, 27], ["rat", "ORGANISM", 54, 57], ["rat", "SPECIES", 24, 27], ["rat", "SPECIES", 54, 57], ["rat", "SPECIES", 24, 27], ["rat", "SPECIES", 54, 57], ["relapsingremitting DA rat EAE models", "TREATMENT", 32, 68], ["the disease", "PROBLEM", 147, 158], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["Lewis", "OBSERVATION", 18, 23], ["disease", "OBSERVATION", 151, 158], ["acute", "OBSERVATION_MODIFIER", 190, 195], ["reduced", "OBSERVATION_MODIFIER", 222, 229], ["relapsing", "OBSERVATION_MODIFIER", 249, 258]]], ["In the PLP-induced SJL/J EAE mouse model, a prophylactic dose of 10 mg/kg has no effect at all whereas 20 mg/kg delays onset of disease.", [["PLP", "CHEMICAL", 7, 10], ["EAE", "DISEASE", 25, 28], ["PLP", "CHEMICAL", 7, 10], ["PLP", "GENE_OR_GENE_PRODUCT", 7, 10], ["SJL/J EAE mouse", "ORGANISM", 19, 34], ["mouse", "SPECIES", 29, 34], ["mouse", "SPECIES", 29, 34], ["the PLP", "TEST", 3, 10], ["SJL/J EAE mouse model", "TREATMENT", 19, 40], ["a prophylactic dose", "TREATMENT", 42, 61], ["disease", "PROBLEM", 128, 135], ["disease", "OBSERVATION", 128, 135]]], ["Although delayed, these mice eventually get EAE disease as severe as the vehicle controls.", [["EAE", "DISEASE", 44, 47], ["mice", "ORGANISM", 24, 28], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["EAE disease", "PROBLEM", 44, 55], ["severe", "OBSERVATION_MODIFIER", 59, 65]]], ["However, 10 mg/kg teriflunomide given prophylactically to MOG-induced C57Bl/6 mice eliminates disease induction ( Figure 2 ).", [["teriflunomide", "CHEMICAL", 18, 31], ["teriflunomide", "CHEMICAL", 18, 31], ["teriflunomide", "SIMPLE_CHEMICAL", 18, 31], ["MOG", "SIMPLE_CHEMICAL", 58, 61], ["C57Bl/6 mice", "ORGANISM", 70, 82], ["MOG", "PROTEIN", 58, 61], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 78, 82], ["teriflunomide", "TREATMENT", 18, 31], ["MOG", "TEST", 58, 61], ["C57Bl/6 mice eliminates disease induction", "TREATMENT", 70, 111]]], ["Teriflunomide is more effective at 3 mg/kg given therapeutically during remission in the DA rat model than when given prophylactically in this model.", [["Teriflunomide", "CHEMICAL", 0, 13], ["DA", "CHEMICAL", 89, 91], ["Teriflunomide", "CHEMICAL", 0, 13], ["Teriflunomide", "SIMPLE_CHEMICAL", 0, 13], ["rat", "ORGANISM", 92, 95], ["rat", "SPECIES", 92, 95], ["Teriflunomide", "TREATMENT", 0, 13]]], ["Therapeutic administration of teriflunomide in relapsing-remitting experimental autoimmune encephalomyelitis (EAE) models in rats and mice.", [["teriflunomide", "CHEMICAL", 30, 43], ["autoimmune encephalomyelitis", "DISEASE", 80, 108], ["EAE", "DISEASE", 110, 113], ["teriflunomide", "CHEMICAL", 30, 43], ["teriflunomide", "SIMPLE_CHEMICAL", 30, 43], ["rats", "ORGANISM", 125, 129], ["mice", "ORGANISM", 134, 138], ["rats", "SPECIES", 125, 129], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 134, 138], ["teriflunomide", "TREATMENT", 30, 43], ["remitting experimental autoimmune encephalomyelitis", "PROBLEM", 57, 108], ["autoimmune encephalomyelitis", "OBSERVATION", 80, 108]]], ["EAE was induced in rats and mice to produce relapsing-remitting disease.", [["EAE", "DISEASE", 0, 3], ["relapsing-remitting disease", "DISEASE", 44, 71], ["rats", "ORGANISM", 19, 23], ["mice", "ORGANISM", 28, 32], ["rats", "SPECIES", 19, 23], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 28, 32], ["EAE", "PROBLEM", 0, 3], ["relapsing-remitting disease", "PROBLEM", 44, 71], ["relapsing", "OBSERVATION_MODIFIER", 44, 53], ["remitting disease", "OBSERVATION", 54, 71]]], ["Vehicle controls were not treated with teriflunomide.", [["teriflunomide", "CHEMICAL", 39, 52], ["teriflunomide", "CHEMICAL", 39, 52], ["teriflunomide", "SIMPLE_CHEMICAL", 39, 52], ["teriflunomide", "TREATMENT", 39, 52]]], ["EAE in Dark Agouti (DA) rats was induced with 50% spinal cord homogenate (SCH) w/v in saline ( Figure 1 ).", [["spinal cord", "ANATOMY", 50, 61], ["EAE", "DISEASE", 0, 3], ["DA", "CHEMICAL", 20, 22], ["SCH", "CHEMICAL", 74, 77], ["Dark Agouti (DA) rats", "ORGANISM", 7, 28], ["cord homogenate", "ORGANISM_SUBSTANCE", 57, 72], ["saline", "SIMPLE_CHEMICAL", 86, 92], ["rats", "SPECIES", 24, 28], ["EAE", "PROBLEM", 0, 3], ["50% spinal cord homogenate (SCH", "TREATMENT", 46, 77], ["v in saline ( Figure", "TREATMENT", 81, 101], ["Dark Agouti", "OBSERVATION", 7, 18], ["spinal cord", "ANATOMY", 50, 61]]], ["DEX is dexamethasone and was dosed at 5.6 mg/kg per day.", [["DEX", "CHEMICAL", 0, 3], ["dexamethasone", "CHEMICAL", 7, 20], ["DEX", "CHEMICAL", 0, 3], ["dexamethasone", "CHEMICAL", 7, 20], ["DEX", "SIMPLE_CHEMICAL", 0, 3], ["dexamethasone", "SIMPLE_CHEMICAL", 7, 20], ["DEX", "TREATMENT", 0, 3], ["dexamethasone", "TREATMENT", 7, 20]]], ["The doses of teriflunomide and the day of first dosing post-disease induction are indicated by red arrows.Small MoleculesBut the drug is totally ineffective when given therapeutically at disease onset in the SJL/J mouse model (Figure 3 ).", [["teriflunomide", "CHEMICAL", 13, 26], ["teriflunomide", "CHEMICAL", 13, 26], ["teriflunomide", "SIMPLE_CHEMICAL", 13, 26], ["SJL/J mouse", "ORGANISM", 208, 219], ["mouse", "SPECIES", 214, 219], ["mouse", "SPECIES", 214, 219], ["teriflunomide", "TREATMENT", 13, 26], ["first dosing post-disease induction", "TREATMENT", 42, 77], ["Small Molecules", "PROBLEM", 106, 121], ["the SJL/J mouse model", "TREATMENT", 204, 225], ["red arrows", "OBSERVATION", 95, 105], ["Molecules", "OBSERVATION", 112, 121]]], ["An explanation as to the difference between drug effects in the relapsing-remitting models in SJL/J mouse and DA rat may be that teriflunomide is 6-fold less potent in enzyme binding and inhibition in the mouse than in the rat and 100fold lower in its antiproliferative activity on mouse lymphocytes than rat lymphocytes (Fox et al, 1999) .", [["lymphocytes", "ANATOMY", 288, 299], ["lymphocytes", "ANATOMY", 309, 320], ["DA", "CHEMICAL", 110, 112], ["teriflunomide", "CHEMICAL", 129, 142], ["teriflunomide", "CHEMICAL", 129, 142], ["SJL/J mouse", "ORGANISM", 94, 105], ["DA rat", "ORGANISM", 110, 116], ["teriflunomide", "SIMPLE_CHEMICAL", 129, 142], ["mouse", "ORGANISM", 205, 210], ["rat", "ORGANISM", 223, 226], ["mouse", "ORGANISM", 282, 287], ["lymphocytes", "CELL", 288, 299], ["rat", "ORGANISM", 305, 308], ["lymphocytes", "CELL", 309, 320], ["mouse lymphocytes", "CELL_TYPE", 282, 299], ["rat lymphocytes", "CELL_TYPE", 305, 320], ["mouse", "SPECIES", 100, 105], ["rat", "SPECIES", 113, 116], ["mouse", "SPECIES", 205, 210], ["rat", "SPECIES", 223, 226], ["mouse", "SPECIES", 282, 287], ["rat", "SPECIES", 305, 308], ["mouse", "SPECIES", 100, 105], ["mouse", "SPECIES", 205, 210], ["mouse", "SPECIES", 282, 287], ["drug effects", "PROBLEM", 44, 56], ["SJL/J mouse", "TREATMENT", 94, 105], ["teriflunomide", "TREATMENT", 129, 142], ["enzyme binding", "PROBLEM", 168, 182], ["antiproliferative activity", "OBSERVATION", 252, 278]]], ["Clearly, there is a different explanation for the difference between the drug's effects in the two different mouse EAE models.", [["EAE", "DISEASE", 115, 118], ["mouse", "ORGANISM", 109, 114], ["mouse", "SPECIES", 109, 114], ["mouse", "SPECIES", 109, 114], ["the drug's effects", "TREATMENT", 69, 87]]], ["Because the time course of pathology in these two mouse EAE models differs so significantly (see above), it might be anticipated that the drug may affect additional cell types than T and B cells involved in the MOG model.", [["cell", "ANATOMY", 165, 169], ["T", "ANATOMY", 181, 182], ["B cells", "ANATOMY", 187, 194], ["EAE", "DISEASE", 56, 59], ["mouse", "ORGANISM", 50, 55], ["cell", "CELL", 165, 169], ["T", "CELL", 181, 182], ["B cells", "CELL", 187, 194], ["MOG", "GENE_OR_GENE_PRODUCT", 211, 214], ["T and B cells", "CELL_TYPE", 181, 194], ["mouse", "SPECIES", 50, 55], ["mouse", "SPECIES", 50, 55], ["pathology", "TEST", 27, 36]]], ["This aspect of the therapeutic efficacy is currently being investigated.AntibodiesAntibodies as biological agents will not cross an intact BBB and they cannot be delivered orally, but need to be injected.", [["BBB", "ANATOMY", 139, 142], ["BBB", "MULTI-TISSUE_STRUCTURE", 139, 142], ["AntibodiesAntibodies", "TREATMENT", 72, 92], ["biological agents", "TREATMENT", 96, 113], ["therapeutic", "OBSERVATION_MODIFIER", 19, 30], ["efficacy", "OBSERVATION", 31, 39], ["intact", "OBSERVATION", 132, 138]]], ["In animal models, antibodies are generally injected intraperitoneally (i.p.) or intravenously (i.v.) by tail vein injection.", [["intraperitoneally", "ANATOMY", 52, 69], ["intravenously", "ANATOMY", 80, 93], ["tail vein", "ANATOMY", 104, 113], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["tail vein", "MULTI-TISSUE_STRUCTURE", 104, 113], ["antibodies", "PROTEIN", 18, 28], ["antibodies", "TREATMENT", 18, 28], ["tail vein injection", "TREATMENT", 104, 123], ["tail vein", "ANATOMY", 104, 113]]], ["Antiinflammatory antibodies act on cells in the peripheral blood to prevent their accessing of or functioning in the CNS and can be administered less frequently (ie not once a day chronically) than small molecules and still be effective.", [["cells", "ANATOMY", 35, 40], ["peripheral blood", "ANATOMY", 48, 64], ["CNS", "ANATOMY", 117, 120], ["cells", "CELL", 35, 40], ["peripheral blood", "ORGANISM_SUBSTANCE", 48, 64], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["Antiinflammatory antibodies", "PROTEIN", 0, 27], ["Antiinflammatory antibodies", "TEST", 0, 27], ["small molecules", "PROBLEM", 198, 213], ["CNS", "ANATOMY", 117, 120]]], ["Kanwar et al (2004) describe the antiinflammatory antibody to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) whose effects, after only three injections of 10 mg/kg IV, were sustained for several months as a monotherapy.", [["mucosal addressin cell adhesion molecule-1", "GENE_OR_GENE_PRODUCT", 62, 104], ["MAdCAM-1", "GENE_OR_GENE_PRODUCT", 106, 114], ["antiinflammatory antibody", "PROTEIN", 33, 58], ["mucosal addressin cell adhesion molecule-1", "PROTEIN", 62, 104], ["MAdCAM", "PROTEIN", 106, 112], ["the antiinflammatory antibody", "TREATMENT", 29, 58], ["mucosal addressin cell adhesion molecule", "TREATMENT", 62, 102], ["a monotherapy", "TREATMENT", 212, 225]]], ["The effects of this antiinflammatory antibody in conjunction with an IGF-1 peptide for repair and an AMPA/kainate receptor antagonist 2,3-dihydroxy-6-nitro-7sulfamoylbenzo-(f)-quinoxaline (NBQX) for neuroprotection were even better than antibody alone.", [["AMPA", "CHEMICAL", 101, 105], ["kainate", "CHEMICAL", 106, 113], ["2,3-dihydroxy-6-nitro-7sulfamoylbenzo-(f)-quinoxaline", "CHEMICAL", 134, 187], ["NBQX", "CHEMICAL", 189, 193], ["AMPA", "CHEMICAL", 101, 105], ["kainate", "CHEMICAL", 106, 113], ["2,3-dihydroxy-6-nitro-7sulfamoylbenzo-(f)-quinoxaline", "CHEMICAL", 134, 187], ["NBQX", "CHEMICAL", 189, 193], ["IGF-1", "GENE_OR_GENE_PRODUCT", 69, 74], ["AMPA", "SIMPLE_CHEMICAL", 101, 105], ["kainate", "SIMPLE_CHEMICAL", 106, 113], ["2,3-dihydroxy-6-nitro-7sulfamoylbenzo-(f)-quinoxaline", "SIMPLE_CHEMICAL", 134, 187], ["NBQX", "SIMPLE_CHEMICAL", 189, 193], ["antiinflammatory antibody", "PROTEIN", 20, 45], ["this antiinflammatory antibody", "TREATMENT", 15, 45], ["an IGF", "TEST", 66, 72], ["repair", "TREATMENT", 87, 93], ["an AMPA/kainate receptor antagonist", "TREATMENT", 98, 133], ["dihydroxy", "TREATMENT", 138, 147], ["nitro", "TREATMENT", 150, 155], ["7sulfamoylbenzo", "TREATMENT", 156, 171], ["quinoxaline (NBQX)", "TREATMENT", 176, 194], ["neuroprotection", "PROBLEM", 199, 214]]], ["This study represents an example of combination therapy of complimentary drugs treating different aspects of the disease that might be envisioned for the treatment of MS.AntibodiesHowever, if the cellular or molecular target for the antibody treatment resides within the CNS, and the BBB is intact, then a strategy for delivery of the antibody to the site of the pathology is required.", [["cellular", "ANATOMY", 196, 204], ["CNS", "ANATOMY", 271, 274], ["BBB", "ANATOMY", 284, 287], ["MS", "DISEASE", 167, 169], ["cellular", "CELL", 196, 204], ["CNS", "ANATOMICAL_SYSTEM", 271, 274], ["BBB", "MULTI-TISSUE_STRUCTURE", 284, 287], ["This study", "TEST", 0, 10], ["combination therapy", "TREATMENT", 36, 55], ["complimentary drugs", "TREATMENT", 59, 78], ["the disease", "PROBLEM", 109, 120], ["MS", "PROBLEM", 167, 169], ["Antibodies", "TEST", 170, 180], ["the antibody treatment", "TREATMENT", 229, 251], ["delivery of the antibody", "TREATMENT", 319, 343], ["the pathology", "TEST", 359, 372], ["disease", "OBSERVATION", 113, 120], ["CNS", "ANATOMY", 271, 274], ["intact", "OBSERVATION", 291, 297], ["pathology", "OBSERVATION", 363, 372]]], ["Anti-LINGO-1 antibody was delivered intrathecally by way of an Alzet mini-osmotic pump into animals with MOG-induced EAE where it inhibited a key negative regulator of oligodendrocyte differentiation and myelination.", [["oligodendrocyte", "ANATOMY", 168, 183], ["EAE", "DISEASE", 117, 120], ["Anti-LINGO-1 antibody", "GENE_OR_GENE_PRODUCT", 0, 21], ["MOG", "GENE_OR_GENE_PRODUCT", 105, 108], ["oligodendrocyte", "CELL", 168, 183], ["Anti-LINGO-1 antibody", "PROTEIN", 0, 21], ["MOG", "PROTEIN", 105, 108], ["Anti-LINGO", "TEST", 0, 10], ["an Alzet mini-osmotic pump", "TREATMENT", 60, 86], ["oligodendrocyte differentiation", "OBSERVATION", 168, 199]]], ["Within 2-3 weeks of treatment, EAE disease was slowed, axonal integrity preserved, and spinal cord remyelination initiated (Mi et al, 2007) .Neurotrophic Factors and HormonesNeurotrophic factor proteins are difficult to deliver chronically as exogenous therapeutic agents in animal models because they need to be injected frequently or released in a sustained fashion, they may have a short plasma half-life, and they may induce neutralizing anti-bodies rendering them ineffective with time.", [["axonal", "ANATOMY", 55, 61], ["spinal cord", "ANATOMY", 87, 98], ["plasma", "ANATOMY", 391, 397], ["EAE", "DISEASE", 31, 34], ["cord remyelination", "DISEASE", 94, 112], ["spinal cord", "ORGAN", 87, 98], ["HormonesNeurotrophic factor", "GENE_OR_GENE_PRODUCT", 166, 193], ["plasma", "ORGANISM_SUBSTANCE", 391, 397], ["Neurotrophic Factors", "PROTEIN", 141, 161], ["HormonesNeurotrophic factor proteins", "PROTEIN", 166, 202], ["treatment", "TREATMENT", 20, 29], ["EAE disease", "PROBLEM", 31, 42], ["spinal cord remyelination", "PROBLEM", 87, 112], ["Neurotrophic Factors", "TEST", 141, 161], ["Neurotrophic factor proteins", "PROBLEM", 174, 202], ["exogenous therapeutic agents", "TREATMENT", 243, 271], ["neutralizing anti-bodies", "TREATMENT", 429, 453], ["EAE disease", "OBSERVATION", 31, 42], ["axonal integrity", "OBSERVATION", 55, 71], ["spinal cord", "ANATOMY", 87, 98], ["remyelination", "OBSERVATION", 99, 112]]], ["Some investigators have applied innovative strategies to demonstrate the positive role of neurotrophic factors in oligodendrocyte cell survival in demyelinating models.", [["oligodendrocyte cell", "ANATOMY", 114, 134], ["neurotrophic factors", "GENE_OR_GENE_PRODUCT", 90, 110], ["oligodendrocyte cell", "CELL", 114, 134], ["neurotrophic factors", "PROTEIN", 90, 110], ["innovative strategies", "TREATMENT", 32, 53], ["neurotrophic factors", "PROBLEM", 90, 110], ["oligodendrocyte cell survival", "TREATMENT", 114, 143], ["oligodendrocyte cell survival", "OBSERVATION", 114, 143]]], ["Mason et al (2000) solved the problem of chronic IGF-1 delivery by creating the cuprizone model in IGF-1 + / + transgenic mice, whereas Barres et al, (1992) delivered PDGF on the CNS side of the BBB by implanting a hybridoma cell line secreting the neurotrophic factor.", [["CNS", "ANATOMY", 179, 182], ["BBB", "ANATOMY", 195, 198], ["hybridoma cell line", "ANATOMY", 215, 234], ["cuprizone", "CHEMICAL", 80, 89], ["cuprizone", "CHEMICAL", 80, 89], ["IGF-1", "GENE_OR_GENE_PRODUCT", 49, 54], ["cuprizone", "SIMPLE_CHEMICAL", 80, 89], ["IGF-1", "GENE_OR_GENE_PRODUCT", 99, 104], ["mice", "ORGANISM", 122, 126], ["PDGF", "GENE_OR_GENE_PRODUCT", 167, 171], ["CNS side", "MULTI-TISSUE_STRUCTURE", 179, 187], ["BBB", "MULTI-TISSUE_STRUCTURE", 195, 198], ["hybridoma cell line", "CELL", 215, 234], ["IGF", "PROTEIN", 49, 52], ["IGF", "PROTEIN", 99, 102], ["PDGF", "PROTEIN", 167, 171], ["hybridoma cell line", "CELL_LINE", 215, 234], ["neurotrophic factor", "PROTEIN", 249, 268], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 122, 126], ["chronic IGF", "PROBLEM", 41, 52], ["IGF", "TEST", 99, 102], ["transgenic mice", "PROBLEM", 111, 126], ["a hybridoma cell line", "TREATMENT", 213, 234], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["IGF", "OBSERVATION", 49, 52], ["BBB", "ANATOMY", 195, 198], ["hybridoma cell line", "OBSERVATION", 215, 234], ["neurotrophic factor", "OBSERVATION", 249, 268]]], ["Oudega et al (1997) used semipermeable polymer tubes containing Matrigel implants of Schwann cells bathed in IGF-1 and PDGF.", [["Schwann cells", "ANATOMY", 85, 98], ["Schwann cells", "CELL", 85, 98], ["IGF-1", "GENE_OR_GENE_PRODUCT", 109, 114], ["PDGF", "GENE_OR_GENE_PRODUCT", 119, 123], ["Schwann cells", "CELL_TYPE", 85, 98], ["IGF-1", "PROTEIN", 109, 114], ["PDGF", "PROTEIN", 119, 123], ["semipermeable polymer tubes", "TREATMENT", 25, 52], ["Matrigel implants of Schwann cells", "TREATMENT", 64, 98], ["polymer tubes", "OBSERVATION", 39, 52], ["Schwann cells", "OBSERVATION", 85, 98]]], ["Alzet mini pumps can be implanted SC or IP as in the case of prolactin delivery to drive remyelination (Gregg et al, 2007) .", [["SC", "ANATOMY", 34, 36], ["prolactin", "GENE_OR_GENE_PRODUCT", 61, 70], ["Alzet mini pumps", "TREATMENT", 0, 16], ["IP", "TREATMENT", 40, 42], ["prolactin delivery", "TREATMENT", 61, 79]]], ["Subcutaneous sustained release pellets have been used for delivery of estrogen for oligodendrocyte protection, progesterone for producing myelin repair within 3-5 weeks, and testosterone, whose therapeutic administration eliminated MBP-induced EAE in SJL/J mice (Offner, 2004; Ibanez et al, 2004; Dalal et al, 1997) .Neurotrophic Factors and HormonesA simpler mode of drug delivery that avoids the need for genetic manipulation of cells or animals, the use of devices, or complexities of surgical implantation but accommodates sustained drug exposure and BBB penetration is daily subcutaneous injection.", [["Subcutaneous", "ANATOMY", 0, 12], ["oligodendrocyte", "ANATOMY", 83, 98], ["myelin", "ANATOMY", 138, 144], ["cells", "ANATOMY", 431, 436], ["BBB", "ANATOMY", 555, 558], ["subcutaneous", "ANATOMY", 580, 592], ["estrogen", "CHEMICAL", 70, 78], ["progesterone", "CHEMICAL", 111, 123], ["testosterone", "CHEMICAL", 174, 186], ["EAE", "DISEASE", 244, 247], ["estrogen", "CHEMICAL", 70, 78], ["progesterone", "CHEMICAL", 111, 123], ["testosterone", "CHEMICAL", 174, 186], ["estrogen", "SIMPLE_CHEMICAL", 70, 78], ["oligodendrocyte", "CELL", 83, 98], ["progesterone", "SIMPLE_CHEMICAL", 111, 123], ["myelin", "TISSUE", 138, 144], ["testosterone", "SIMPLE_CHEMICAL", 174, 186], ["MBP", "GENE_OR_GENE_PRODUCT", 232, 235], ["SJL/J mice", "ORGANISM", 251, 261], ["cells", "CELL", 431, 436], ["BBB", "MULTI-TISSUE_STRUCTURE", 555, 558], ["MBP", "PROTEIN", 232, 235], ["mice", "SPECIES", 257, 261], ["Subcutaneous sustained release pellets", "TREATMENT", 0, 38], ["delivery", "TREATMENT", 58, 66], ["estrogen", "TREATMENT", 70, 78], ["oligodendrocyte protection", "TREATMENT", 83, 109], ["progesterone", "TREATMENT", 111, 123], ["myelin repair", "TREATMENT", 138, 151], ["testosterone", "TREATMENT", 174, 186], ["MBP", "TEST", 232, 235], ["Neurotrophic Factors", "PROBLEM", 317, 337], ["HormonesA", "TREATMENT", 342, 351], ["drug delivery", "TREATMENT", 368, 381], ["genetic manipulation of cells", "TREATMENT", 407, 436], ["devices", "TREATMENT", 460, 467], ["surgical implantation", "TREATMENT", 488, 509], ["sustained drug exposure", "PROBLEM", 527, 550], ["BBB penetration", "TREATMENT", 555, 570], ["subcutaneous injection", "TREATMENT", 580, 602], ["surgical implantation", "OBSERVATION", 488, 509]]], ["This has been successfully used for administration of the neurotrophic factor LIF and hormones like thyroid hormone (T4) and estrogen (E2) in EAE (Butzkueven et al, 2002; Tiwari-Woodruff et al, 2007; Fernandez et al, 2004) .", [["estrogen", "CHEMICAL", 125, 133], ["E2", "CHEMICAL", 135, 137], ["EAE", "DISEASE", 142, 145], ["estrogen", "CHEMICAL", 125, 133], ["LIF", "GENE_OR_GENE_PRODUCT", 78, 81], ["thyroid hormone", "GENE_OR_GENE_PRODUCT", 100, 115], ["T4", "SIMPLE_CHEMICAL", 117, 119], ["estrogen", "SIMPLE_CHEMICAL", 125, 133], ["E2", "SIMPLE_CHEMICAL", 135, 137], ["neurotrophic factor", "PROTEIN", 58, 77], ["LIF", "PROTEIN", 78, 81], ["the neurotrophic factor LIF", "TREATMENT", 54, 81], ["estrogen (E2)", "TREATMENT", 125, 138], ["thyroid", "ANATOMY", 100, 107]]], ["It has been documented that LIF can enter the CNS and mediate survival of oligodendrocytes; it is equally effective given IP but ineffective when administered IV (Butzkueven et al, 2002) .", [["CNS", "ANATOMY", 46, 49], ["oligodendrocytes", "ANATOMY", 74, 90], ["LIF", "GENE_OR_GENE_PRODUCT", 28, 31], ["CNS", "ANATOMICAL_SYSTEM", 46, 49], ["oligodendrocytes", "CELL", 74, 90], ["IP", "SIMPLE_CHEMICAL", 122, 124], ["LIF", "PROTEIN", 28, 31], ["oligodendrocytes", "CELL_TYPE", 74, 90], ["oligodendrocytes", "PROBLEM", 74, 90], ["IP", "TREATMENT", 122, 124], ["IV (Butzkueven et al", "TREATMENT", 159, 179]]], ["Estrogen is both antiinflammatory and neuroprotective in ovariectomized mice with EAE.", [["EAE", "DISEASE", 82, 85], ["Estrogen", "CHEMICAL", 0, 8], ["Estrogen", "GENE_OR_GENE_PRODUCT", 0, 8], ["ovariectomized mice", "ORGANISM", 57, 76], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 72, 76], ["Estrogen", "TREATMENT", 0, 8], ["neuroprotective in ovariectomized mice", "TREATMENT", 38, 76], ["antiinflammatory", "OBSERVATION_MODIFIER", 17, 33]]], ["If given prophylactically, estrogen's neuroprotective effect is not evident until after day 20 in the MOG EAE model.", [["estrogen", "CHEMICAL", 27, 35], ["EAE", "DISEASE", 106, 109], ["estrogen", "CHEMICAL", 27, 35], ["estrogen", "SIMPLE_CHEMICAL", 27, 35], ["estrogen's neuroprotective effect", "TREATMENT", 27, 60]]], ["However, delaying treatment until that time shows that estrogen has no effect.", [["estrogen", "CHEMICAL", 55, 63], ["estrogen", "CHEMICAL", 55, 63], ["estrogen", "SIMPLE_CHEMICAL", 55, 63], ["treatment", "TREATMENT", 18, 27]]], ["Indeed the hormone works better in murine EAE models if started 7 days before disease induction (Offner, 2004; Tiwari-Woodruff et al, 2007) .", [["EAE", "DISEASE", 42, 45], ["murine", "ORGANISM", 35, 41], ["murine", "SPECIES", 35, 41]]], ["As has been mentioned for small molecules above, there are significant mouse strain differences with respect to sensitivity to the neuroprotective effects of estrogen that should influence the choice of the model and the impact of the results (Offner, 2004) .", [["estrogen", "CHEMICAL", 158, 166], ["estrogen", "CHEMICAL", 158, 166], ["mouse", "ORGANISM", 71, 76], ["estrogen", "SIMPLE_CHEMICAL", 158, 166], ["mouse", "SPECIES", 71, 76], ["mouse", "SPECIES", 71, 76], ["small molecules", "PROBLEM", 26, 41], ["significant mouse strain differences", "PROBLEM", 59, 95], ["estrogen", "TREATMENT", 158, 166], ["small", "OBSERVATION_MODIFIER", 26, 31], ["molecules", "OBSERVATION", 32, 41], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["mouse strain", "OBSERVATION", 71, 83]]], ["A summary and comparison of some of these features of the in vivo models is shown in Table 2 .CONCLUSIONSIn vivo repair can be greatly influenced by the animal models chosen as proof of concept models.", [["vivo repair", "TREATMENT", 108, 119], ["repair", "OBSERVATION", 113, 119]]], ["Additional complexity is added by the fact that neurotrophic factors like IGF-1 and GGF are not only neuroprotective agents and promote remyelination but can also act as antiinflammatory molecules.", [["IGF-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["GGF", "GENE_OR_GENE_PRODUCT", 84, 87], ["neurotrophic factors", "PROTEIN", 48, 68], ["IGF-1", "PROTEIN", 74, 79], ["GGF", "PROTEIN", 84, 87], ["antiinflammatory molecules", "PROTEIN", 170, 196], ["IGF", "TEST", 74, 77], ["neuroprotective agents", "TREATMENT", 101, 123], ["remyelination", "PROBLEM", 136, 149]]], ["Lymphocytes may produce neurotrophic factors (T-cell production of BDNF) and proinflammatory cytokines (IFNg, TNFa) may act as pro-repair molecules (reviewed by Stangel, 2004) .", [["Lymphocytes", "ANATOMY", 0, 11], ["T-cell", "ANATOMY", 46, 52], ["Lymphocytes", "CELL", 0, 11], ["T-cell", "CELL", 46, 52], ["BDNF", "GENE_OR_GENE_PRODUCT", 67, 71], ["IFNg", "GENE_OR_GENE_PRODUCT", 104, 108], ["TNFa", "GENE_OR_GENE_PRODUCT", 110, 114], ["Lymphocytes", "CELL_TYPE", 0, 11], ["neurotrophic factors", "PROTEIN", 24, 44], ["BDNF", "PROTEIN", 67, 71], ["proinflammatory cytokines", "PROTEIN", 77, 102], ["IFNg", "PROTEIN", 104, 108], ["TNFa", "PROTEIN", 110, 114], ["pro-repair molecules", "PROTEIN", 127, 147], ["Lymphocytes", "TEST", 0, 11], ["neurotrophic factors", "PROBLEM", 24, 44], ["BDNF", "PROBLEM", 67, 71], ["proinflammatory cytokines (IFNg, TNFa)", "PROBLEM", 77, 115], ["neurotrophic factors", "OBSERVATION", 24, 44], ["proinflammatory cytokines", "OBSERVATION", 77, 102]]], ["The route/location and timing of drug delivery that is chosen to be used in various models may be dictated by the physical characteristics of the drug and targeted pathology to be affected.", [["drug delivery", "TREATMENT", 33, 46]]], ["The ease or difficulty of drug delivery to the site of action in models depends on the nature of the therapy (small molecule vs biological agent vs transplanted cells), pharmacokinetics of exposure (metabolism, clearance, drug on-off rate kinetics), bloodbrain penetrability, and solubility, among other characteristics.COMPOUND SCREENING TREE: AN EXAMPLETo illustrate the flow of a screening tree for a library of small molecular weight compounds starting with the primary screen through to the proof of concept (POC) models, we can consider a receptor whose activation is necessary for oligodendrocyte differentiation and ultimately remyelination as a hypothetical target.", [["cells", "ANATOMY", 161, 166], ["bloodbrain", "ANATOMY", 250, 260], ["oligodendrocyte", "ANATOMY", 588, 603], ["cells", "CELL", 161, 166], ["bloodbrain", "SIMPLE_CHEMICAL", 250, 260], ["oligodendrocyte", "CELL", 588, 603], ["transplanted cells", "CELL_TYPE", 148, 166], ["drug delivery", "TREATMENT", 26, 39], ["the therapy", "TREATMENT", 97, 108], ["small molecule vs biological agent", "TREATMENT", 110, 144], ["transplanted cells", "PROBLEM", 148, 166], ["rate kinetics", "TREATMENT", 234, 247], ["bloodbrain penetrability", "PROBLEM", 250, 274], ["small molecular weight compounds", "PROBLEM", 415, 447], ["the primary screen", "TEST", 462, 480], ["a receptor whose activation", "TREATMENT", 543, 570], ["oligodendrocyte differentiation", "PROBLEM", 588, 619], ["bloodbrain penetrability", "OBSERVATION", 250, 274], ["small", "OBSERVATION_MODIFIER", 415, 420]]], ["The primary screen could be a promoter-reporter based screen for a gene directly and specifically activated by ligand binding to the receptor.", [["The primary screen", "TEST", 0, 18]]], ["Such a screen could be performed in a 1536-well plate format using a half million compounds at a single dose and would require 10 9 cells.", [["cells", "ANATOMY", 132, 137], ["cells", "CELL", 132, 137], ["a screen", "TEST", 5, 13], ["a half million compounds", "TREATMENT", 67, 91]]], ["Following validation of an assay system with standard tools as positive controls, such a primary screen could be conducted using a stably transfected rodent oligodendrocyte cell line such as CG4.", [["oligodendrocyte cell line", "ANATOMY", 157, 182], ["CG4", "ANATOMY", 191, 194], ["oligodendrocyte cell line", "CELL", 157, 182], ["CG4", "CELL", 191, 194], ["rodent oligodendrocyte cell line", "CELL_LINE", 150, 182], ["CG4", "CELL_LINE", 191, 194], ["rodent", "SPECIES", 150, 156], ["an assay system", "TEST", 24, 39], ["a primary screen", "TEST", 87, 103], ["a stably transfected rodent oligodendrocyte cell line", "TREATMENT", 129, 182], ["oligodendrocyte cell line", "OBSERVATION", 157, 182]]], ["If the hit rate is 0.5% (2500 compounds), reconfirmation and IC 50 s would be performed with 10 million CG4 cells.", [["CG4 cells", "ANATOMY", 104, 113], ["CG4 cells", "CELL", 104, 113], ["CG4 cells", "CELL_LINE", 104, 113], ["the hit rate", "TEST", 3, 15]]], ["The orthogonal secondary screen, usually performed on hundreds of active compounds, could be carried out with CG4 cells or primary oligodendrocytes and might be a receptor binding assay; this assay would also require millions of cells.", [["CG4 cells", "ANATOMY", 110, 119], ["primary oligodendrocytes", "ANATOMY", 123, 147], ["cells", "ANATOMY", 229, 234], ["CG4 cells", "CELL", 110, 119], ["oligodendrocytes", "CELL", 131, 147], ["cells", "CELL", 229, 234], ["CG4 cells", "CELL_LINE", 110, 119], ["primary oligodendrocytes", "CELL_TYPE", 123, 147], ["The orthogonal secondary screen", "TEST", 0, 31], ["CG4 cells", "PROBLEM", 110, 119], ["primary oligodendrocytes", "PROBLEM", 123, 147], ["a receptor binding assay", "TEST", 161, 185], ["this assay", "TEST", 187, 197]]], ["The tertiary screen, involving differentiation of primary rodent oligodendrocyte precursors, would likely involve tens to hundreds of compounds and could be performed in a 96-well format requiring 5-10 million cells.", [["oligodendrocyte precursors", "ANATOMY", 65, 91], ["cells", "ANATOMY", 210, 215], ["rodent", "ORGANISM", 58, 64], ["oligodendrocyte", "CELL", 65, 80], ["cells", "CELL", 210, 215], ["primary rodent oligodendrocyte precursors", "CELL_TYPE", 50, 91], ["rodent", "SPECIES", 58, 64], ["The tertiary screen", "TEST", 0, 19], ["primary rodent oligodendrocyte precursors", "PROBLEM", 50, 91], ["oligodendrocyte precursors", "OBSERVATION", 65, 91]]], ["The human orthologue assay to screen fewer than 50 compounds should be performed using primary human fetal or adult-derived progenitors.", [["fetal", "ANATOMY", 101, 106], ["adult-derived progenitors", "ANATOMY", 110, 135], ["human", "ORGANISM", 4, 9], ["human", "ORGANISM", 95, 100], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 101, 106], ["adult-derived progenitors", "CELL", 110, 135], ["primary human fetal or adult-derived progenitors", "CELL_TYPE", 87, 135], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 95, 100], ["The human orthologue assay", "TEST", 0, 26]]], ["An additional screen for induction of myelination using a mixed cell culture is optional at this stage.", [["cell", "ANATOMY", 64, 68], ["cell", "CELL", 64, 68], ["mixed cell culture", "CELL_LINE", 58, 76], ["An additional screen", "TEST", 0, 20], ["induction of myelination", "TREATMENT", 25, 49], ["a mixed cell culture", "TEST", 56, 76]]], ["With fewer than 10 compounds to be pursued, an acute in vivo model for assessment of the ability of the molecule to enter the brain and hit its molecular target would be performed next.", [["brain", "ANATOMY", 126, 131], ["brain", "ORGAN", 126, 131], ["assessment", "TEST", 71, 81], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["brain", "ANATOMY", 126, 131]]], ["The assessment of remyelination would then be performed in a remyelination model such as the cuprizone model; this would be reserved for 1-2 lead compounds.", [["cuprizone", "CHEMICAL", 93, 102], ["cuprizone", "CHEMICAL", 93, 102], ["cuprizone", "SIMPLE_CHEMICAL", 93, 102], ["1-2 lead compounds", "SIMPLE_CHEMICAL", 137, 155], ["The assessment", "TEST", 0, 14], ["remyelination", "PROBLEM", 18, 31], ["a remyelination model", "TREATMENT", 59, 80], ["the cuprizone model", "TREATMENT", 89, 108]]], ["With the development candidate chosen, the final assessment of the compound's ability to drive remyelination would be performed in a disease POC model such as in EAE, the model of choice for development of drugs to treat MS.FUTURE RESEARCH DIRECTIONSThe future holds promise for the use of drugs which drive repair of the CNS.", [["CNS", "ANATOMY", 322, 325], ["EAE", "DISEASE", 162, 165], ["MS", "DISEASE", 221, 223], ["CNS", "ANATOMICAL_SYSTEM", 322, 325], ["the final assessment", "TEST", 39, 59], ["remyelination", "PROBLEM", 95, 108], ["drugs", "TREATMENT", 206, 211], ["MS", "PROBLEM", 221, 223], ["drugs", "TREATMENT", 290, 295], ["repair", "TREATMENT", 308, 314], ["CNS", "ANATOMY", 322, 325]]], ["As the MRI technologies such as MTR and DTI for distinguishing and quantitating repair of the nervous system in humans become refined and standardized, they will be incorporated into the growing use of small animal MRI for assessing drugs that drive remyelination in animal models and used more routinely in human clinical trials.", [["nervous system", "ANATOMY", 94, 108], ["MTR", "SIMPLE_CHEMICAL", 32, 35], ["nervous system", "ANATOMICAL_SYSTEM", 94, 108], ["humans", "ORGANISM", 112, 118], ["human", "ORGANISM", 308, 313], ["MTR", "PROTEIN", 32, 35], ["humans", "SPECIES", 112, 118], ["human", "SPECIES", 308, 313], ["humans", "SPECIES", 112, 118], ["human", "SPECIES", 308, 313], ["the MRI technologies", "TEST", 3, 23], ["MTR", "TEST", 32, 35], ["DTI", "TEST", 40, 43], ["quantitating repair", "TREATMENT", 67, 86], ["small animal MRI", "TEST", 202, 218], ["drugs", "TREATMENT", 233, 238], ["nervous system", "ANATOMY", 94, 108]]], ["Peripheral biomarkers of drug-target interaction and surrogate peripheral blood or tissue markers for drug efficacy within the CNS may well be established in animal models but will ultimately assist in dose-range finding and prediction of responders vs nonresponders in human trials.", [["peripheral blood", "ANATOMY", 63, 79], ["tissue", "ANATOMY", 83, 89], ["CNS", "ANATOMY", 127, 130], ["peripheral blood", "ORGANISM_SUBSTANCE", 63, 79], ["tissue", "TISSUE", 83, 89], ["CNS", "ANATOMICAL_SYSTEM", 127, 130], ["human", "ORGANISM", 270, 275], ["human", "SPECIES", 270, 275], ["human", "SPECIES", 270, 275], ["Peripheral biomarkers", "TEST", 0, 21], ["tissue markers", "TEST", 83, 97], ["drug efficacy", "PROBLEM", 102, 115]]], ["Drug mechanisms of action will be better defined using transcript profiling both in animal models and in drug responders in clinical trials.", [["transcript profiling", "TREATMENT", 55, 75]]], ["Combination therapy with drugs that drive repair and preserve the integrity of axons and myelin need to be evaluated for their use in a chronic disease like MS as well as for their compatibility, safety, and efficacy when given with antiinflammatory drugs.", [["axons", "ANATOMY", 79, 84], ["myelin", "ANATOMY", 89, 95], ["MS", "DISEASE", 157, 159], ["axons", "CELLULAR_COMPONENT", 79, 84], ["myelin", "CELLULAR_COMPONENT", 89, 95], ["Combination therapy", "TREATMENT", 0, 19], ["drugs", "TREATMENT", 25, 30], ["drive repair", "TREATMENT", 36, 48], ["a chronic disease like MS", "PROBLEM", 134, 159], ["antiinflammatory drugs", "TREATMENT", 233, 255]]]], "PMC7192724": [["Infectious bronchitis (IB) is a highly infectious and contagious disease in chickens andinduces numerous economic losses in the poultry farms.", [["Infectious bronchitis (IB)", "DISEASE", 0, 26], ["chickens", "ORGANISM", 76, 84], ["chickens", "SPECIES", 76, 84], ["chickens", "SPECIES", 76, 84], ["Infectious bronchitis (IB)", "PROBLEM", 0, 26], ["a highly infectious", "PROBLEM", 30, 49], ["contagious disease", "PROBLEM", 54, 72], ["numerous economic losses in the poultry farms", "PROBLEM", 96, 141], ["bronchitis", "OBSERVATION", 11, 21], ["highly", "OBSERVATION_MODIFIER", 32, 38], ["infectious", "OBSERVATION_MODIFIER", 39, 49], ["contagious", "OBSERVATION_MODIFIER", 54, 64], ["numerous", "OBSERVATION_MODIFIER", 96, 104], ["economic", "OBSERVATION_MODIFIER", 105, 113], ["losses", "OBSERVATION_MODIFIER", 114, 120], ["poultry farms", "OBSERVATION", 128, 141]]], ["The IB virus (IBV), which is acausative agent of IB, primarily infects the respiratory tract and some variants or severalfield isolates affect the kidney and reproductive system, and subsequently induces variousdisorders to the host.", [["respiratory tract", "ANATOMY", 75, 92], ["kidney", "ANATOMY", 147, 153], ["infects the respiratory tract", "DISEASE", 63, 92], ["IB virus", "ORGANISM", 4, 12], ["IBV", "ORGANISM", 14, 17], ["respiratory tract", "ORGANISM_SUBDIVISION", 75, 92], ["kidney", "ORGAN", 147, 153], ["reproductive system", "ANATOMICAL_SYSTEM", 158, 177], ["IB virus", "SPECIES", 4, 12], ["IBV", "SPECIES", 14, 17], ["The IB virus (IBV)", "PROBLEM", 0, 18], ["IB", "PROBLEM", 49, 51], ["the respiratory tract", "PROBLEM", 71, 92], ["some variants", "PROBLEM", 97, 110], ["severalfield isolates affect the kidney and reproductive system", "PROBLEM", 114, 177], ["respiratory tract", "ANATOMY", 75, 92], ["kidney", "ANATOMY", 147, 153]]], ["The pathogenicity of IBV is very complex and constantly alters in thefield strain, making it difficult to take control and protection measures for IB.", [["IBV", "ORGANISM", 21, 24], ["IBV", "SPECIES", 21, 24], ["IBV", "PROBLEM", 21, 24], ["protection measures", "TREATMENT", 123, 142], ["IBV", "OBSERVATION", 21, 24], ["very", "OBSERVATION_MODIFIER", 28, 32], ["complex", "OBSERVATION_MODIFIER", 33, 40]]]], "ff0588f7bf49bc6109148de63e298bf3f95a62b4": [["INTRODUCTIONCytomegalovirus (CMV) infection is a leading cause of morbidity and mortality in severely immunosuppressed patients, such as those undergoing allogeneic hematopoietic stem cell or solid organ transplantation [Solano and Navarro, 2010] .", [["hematopoietic stem cell", "ANATOMY", 165, 188], ["solid organ", "ANATOMY", 192, 203], ["INTRODUCTIONCytomegalovirus (CMV) infection", "DISEASE", 0, 43], ["CMV", "ORGANISM", 29, 32], ["patients", "ORGANISM", 119, 127], ["hematopoietic stem cell", "CELL", 165, 188], ["organ", "ORGAN", 198, 203], ["patients", "SPECIES", 119, 127], ["CMV", "SPECIES", 29, 32], ["INTRODUCTIONCytomegalovirus (CMV) infection", "PROBLEM", 0, 43], ["morbidity", "PROBLEM", 66, 75], ["severely immunosuppressed patients", "PROBLEM", 93, 127], ["allogeneic hematopoietic stem cell", "TREATMENT", 154, 188], ["solid organ transplantation", "TREATMENT", 192, 219], ["Solano and Navarro", "TREATMENT", 221, 239], ["severely", "OBSERVATION_MODIFIER", 93, 101], ["immunosuppressed", "OBSERVATION", 102, 118], ["hematopoietic stem cell", "OBSERVATION", 165, 188]]], ["Nevertheless, recent data suggest that CMV may also be a relevant cause of morbidity in patients lacking canonical immunosuppression and displaying various inflammatory processes, including cardiovascular, autoimmune, and chronic bowel diseases [S\u00f6derberg-Naucl\u00e9r, 2008; N\u00fa \u00f1 ez et al., 2010 N\u00fa \u00f1 ez et al., , 2012 .", [["cardiovascular", "ANATOMY", 190, 204], ["bowel", "ANATOMY", 230, 235], ["cardiovascular, autoimmune, and chronic bowel diseases", "DISEASE", 190, 244], ["CMV", "ORGANISM", 39, 42], ["patients", "ORGANISM", 88, 96], ["bowel", "ORGAN", 230, 235], ["patients", "SPECIES", 88, 96], ["CMV", "SPECIES", 39, 42], ["CMV", "PROBLEM", 39, 42], ["morbidity", "PROBLEM", 75, 84], ["canonical immunosuppression", "TREATMENT", 105, 132], ["various inflammatory processes", "PROBLEM", 148, 178], ["cardiovascular, autoimmune", "PROBLEM", 190, 216], ["chronic bowel diseases", "PROBLEM", 222, 244], ["CMV", "OBSERVATION", 39, 42], ["morbidity", "OBSERVATION", 75, 84], ["various", "OBSERVATION_MODIFIER", 148, 155], ["inflammatory", "OBSERVATION", 156, 168], ["cardiovascular", "ANATOMY", 190, 204], ["autoimmune", "OBSERVATION", 206, 216], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["bowel", "ANATOMY", 230, 235], ["diseases", "OBSERVATION", 236, 244]]], ["In these patients, active CMV infection is detected frequently in either the inflamed tissues or even the blood compartment.", [["tissues", "ANATOMY", 86, 93], ["blood compartment", "ANATOMY", 106, 123], ["CMV infection", "DISEASE", 26, 39], ["patients", "ORGANISM", 9, 17], ["CMV", "ORGANISM", 26, 29], ["tissues", "TISSUE", 86, 93], ["blood compartment", "MULTI-TISSUE_STRUCTURE", 106, 123], ["patients", "SPECIES", 9, 17], ["CMV", "SPECIES", 26, 29], ["active CMV infection", "PROBLEM", 19, 39], ["active", "OBSERVATION_MODIFIER", 19, 25], ["CMV infection", "OBSERVATION", 26, 39], ["inflamed tissues", "ANATOMY", 77, 93], ["blood compartment", "OBSERVATION", 106, 123]]], ["Furthermore, active CMV infection, either restricted to the lower respiratory tract or involving both the lower respiratory airways and the systemic compartment, has been shown to occur frequently during critically illness in adult CMV-seropositive patients Blanquer et al., 2011] , and has been associated with prolonged intensive care unit hospitalization, extended periods of mechanical ventilation, higher rates of nosocomial infection, and overall mortality [for review, see Kalil and Florescu, 2009] .", [["lower respiratory tract", "ANATOMY", 60, 83], ["lower respiratory airways", "ANATOMY", 106, 131], ["systemic compartment", "ANATOMY", 140, 160], ["CMV infection", "DISEASE", 20, 33], ["critically illness", "DISEASE", 204, 222], ["nosocomial infection", "DISEASE", 419, 439], ["CMV", "ORGANISM", 20, 23], ["lower", "ORGANISM_SUBDIVISION", 60, 65], ["respiratory tract", "ORGANISM_SUBDIVISION", 66, 83], ["airways", "MULTI-TISSUE_STRUCTURE", 124, 131], ["CMV", "ORGANISM", 232, 235], ["patients", "ORGANISM", 249, 257], ["patients", "SPECIES", 249, 257], ["CMV", "SPECIES", 20, 23], ["active CMV infection", "PROBLEM", 13, 33], ["the lower respiratory tract", "PROBLEM", 56, 83], ["mechanical ventilation", "TREATMENT", 379, 401], ["nosocomial infection", "PROBLEM", 419, 439], ["active", "OBSERVATION_MODIFIER", 13, 19], ["CMV infection", "OBSERVATION", 20, 33], ["lower", "ANATOMY_MODIFIER", 60, 65], ["respiratory tract", "ANATOMY", 66, 83], ["lower", "ANATOMY_MODIFIER", 106, 111], ["respiratory airways", "ANATOMY", 112, 131], ["systemic compartment", "ANATOMY", 140, 160], ["mechanical ventilation", "OBSERVATION", 379, 401], ["nosocomial", "OBSERVATION_MODIFIER", 419, 429], ["infection", "OBSERVATION", 430, 439]]], ["From a pathogenetic perspective, data obtained in the murine CMV model indicate that a pro-inflammatory state is a critical factor in promoting CMV replication [Cook et al., 2002] , and that TNF-a, a cytokine known to transactivate the expression of CMV immediate-early genes, plays a critical role in triggering CMV reactivation [Pr\u00f6sch et al., 1995] .", [["murine", "ORGANISM", 54, 60], ["CMV", "ORGANISM", 61, 64], ["CMV", "ORGANISM", 144, 147], ["TNF-a", "GENE_OR_GENE_PRODUCT", 191, 196], ["CMV", "ORGANISM", 250, 253], ["CMV", "ORGANISM", 313, 316], ["TNF", "PROTEIN", 191, 194], ["cytokine", "PROTEIN", 200, 208], ["CMV immediate-early genes", "DNA", 250, 275], ["murine", "SPECIES", 54, 60], ["CMV", "SPECIES", 144, 147], ["CMV", "SPECIES", 313, 316], ["the murine CMV model", "TEST", 50, 70], ["a pro-inflammatory state", "PROBLEM", 85, 109], ["CMV reactivation", "PROBLEM", 313, 329]]], ["In this context, active CMV infection may occur in pediatric patients with chronic or recurrent bronchopulmonary diseases in which inflammation plays potentially a major pathogenic role.", [["bronchopulmonary", "ANATOMY", 96, 112], ["CMV infection", "DISEASE", 24, 37], ["bronchopulmonary diseases", "DISEASE", 96, 121], ["inflammation", "DISEASE", 131, 143], ["CMV", "ORGANISM", 24, 27], ["patients", "ORGANISM", 61, 69], ["bronchopulmonary", "ORGAN", 96, 112], ["patients", "SPECIES", 61, 69], ["CMV", "SPECIES", 24, 27], ["active CMV infection", "PROBLEM", 17, 37], ["chronic or recurrent bronchopulmonary diseases", "PROBLEM", 75, 121], ["active", "OBSERVATION_MODIFIER", 17, 23], ["CMV infection", "OBSERVATION", 24, 37], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["recurrent", "OBSERVATION_MODIFIER", 86, 95], ["bronchopulmonary", "ANATOMY", 96, 112], ["diseases", "OBSERVATION", 113, 121], ["inflammation", "OBSERVATION", 131, 143]]], ["The current study was undertaken to investigate this hypothesis.Patients and SpecimensA total of 42 lower respiratory tract specimens (bronchoaspirate, n \u00bc 22; bronchoalveolar lavage, n \u00bc 19; tracheal aspirate, n \u00bc 1) and 11 paired plasma samples from 42 children (22 females and 20 males; median age, 4 years old; range, 6 months to 18 years old) attended at the Pneumology, Unit of the University Clinic Hospital of Valencia were analyzed.", [["lower respiratory tract specimens", "ANATOMY", 100, 133], ["bronchoaspirate", "ANATOMY", 135, 150], ["bronchoalveolar lavage", "ANATOMY", 160, 182], ["tracheal aspirate", "ANATOMY", 192, 209], ["plasma samples", "ANATOMY", 232, 246], ["Patients", "ORGANISM", 64, 72], ["bronchoalveolar lavage", "CANCER", 160, 182], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 192, 209], ["plasma samples", "CANCER", 232, 246], ["children", "ORGANISM", 255, 263], ["Patients", "SPECIES", 64, 72], ["children", "SPECIES", 255, 263], ["The current study", "TEST", 0, 17], ["this hypothesis", "PROBLEM", 48, 63], ["SpecimensA", "TEST", 77, 87], ["lower respiratory tract specimens", "TEST", 100, 133], ["bronchoaspirate", "TEST", 135, 150], ["n \u00bc", "TEST", 152, 155], ["bronchoalveolar lavage", "TEST", 160, 182], ["tracheal aspirate", "TEST", 192, 209], ["paired plasma samples", "TEST", 225, 246], ["respiratory tract", "ANATOMY", 106, 123], ["bronchoalveolar lavage", "OBSERVATION", 160, 182], ["tracheal", "ANATOMY", 192, 200]]], ["Patients had a previous history of chronic/recurrent lower tract respiratory symptoms and/or persistent/recurrent radiographic abnormalities (infiltrates, a telectasis, or air trapping images).", [["lower tract", "ANATOMY", 53, 64], ["telectasis", "DISEASE", 157, 167], ["Patients", "ORGANISM", 0, 8], ["lower tract", "ORGANISM_SUBDIVISION", 53, 64], ["Patients", "SPECIES", 0, 8], ["chronic/recurrent lower tract respiratory symptoms", "PROBLEM", 35, 85], ["persistent/recurrent radiographic abnormalities", "PROBLEM", 93, 140], ["infiltrates", "PROBLEM", 142, 153], ["a telectasis", "PROBLEM", 155, 167], ["air trapping images", "TEST", 172, 191], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["lower tract", "ANATOMY", 53, 64], ["respiratory", "ANATOMY", 65, 76], ["symptoms", "OBSERVATION", 77, 85], ["persistent", "OBSERVATION_MODIFIER", 93, 103], ["recurrent", "OBSERVATION_MODIFIER", 104, 113], ["radiographic", "OBSERVATION_MODIFIER", 114, 126], ["abnormalities", "OBSERVATION", 127, 140], ["infiltrates", "OBSERVATION", 142, 153], ["air trapping", "OBSERVATION", 172, 184]]], ["Fibrobronchoscopies were performed between May 2009 and July 2011, either for primary diagnosis, for diagnosis re-evaluation in patients responding unsatisfactorily to conventional therapies or as a complementary diagnostic procedure or for assessing the eradication of Pseudomonas aeruginosa in cystic fibrosis patients with negative sputum cultures after a 1-year-long course of antibiotic therapy, according to local protocols.", [["cystic", "ANATOMY", 296, 302], ["sputum cultures", "ANATOMY", 335, 350], ["Pseudomonas aeruginosa", "DISEASE", 270, 292], ["cystic fibrosis", "DISEASE", 296, 311], ["patients", "ORGANISM", 128, 136], ["Pseudomonas aeruginosa", "ORGANISM", 270, 292], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 128, 136], ["Pseudomonas aeruginosa", "SPECIES", 270, 292], ["patients", "SPECIES", 312, 320], ["Pseudomonas aeruginosa", "SPECIES", 270, 292], ["Fibrobronchoscopies", "TEST", 0, 19], ["diagnosis re-evaluation", "TEST", 101, 124], ["conventional therapies", "TREATMENT", 168, 190], ["a complementary diagnostic procedure", "TREATMENT", 197, 233], ["Pseudomonas aeruginosa", "PROBLEM", 270, 292], ["cystic fibrosis", "PROBLEM", 296, 311], ["sputum cultures", "TEST", 335, 350], ["antibiotic therapy", "TREATMENT", 381, 399], ["Pseudomonas", "OBSERVATION", 270, 281], ["cystic", "OBSERVATION_MODIFIER", 296, 302], ["fibrosis", "OBSERVATION", 303, 311]]], ["No patient had acute upper or lower respiratory tract signs or symptoms at the time of the fibrobronchoscopy.", [["lower respiratory tract", "ANATOMY", 30, 53], ["patient", "ORGANISM", 3, 10], ["upper", "ORGANISM_SUBDIVISION", 21, 26], ["lower", "ORGANISM_SUBDIVISION", 30, 35], ["respiratory tract", "ORGANISM_SUBDIVISION", 36, 53], ["patient", "SPECIES", 3, 10], ["acute upper or lower respiratory tract signs", "PROBLEM", 15, 59], ["symptoms", "PROBLEM", 63, 71], ["the fibrobronchoscopy", "TREATMENT", 87, 108], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["upper", "ANATOMY_MODIFIER", 21, 26], ["lower", "ANATOMY_MODIFIER", 30, 35], ["respiratory tract", "ANATOMY", 36, 53]]], ["The patients had the following underlying bronchopulmonary conditions: atelectasis rounded or middle lobe syndrome (n \u00bc 14), cystic fibrosis (n \u00bc 11), bronchiectasis (n \u00bc 5), chronic asthma not responding to conventional treatments (n \u00bc 3), tracheomalacia (n \u00bc 3), bronchiolitis obliterans (n \u00bc 2), chronic interstitial pneumopathy (n \u00bc 2), bronchopulmonary dysplasia (n \u00bc 1), or bronchial hypoplasia (n \u00bc 1).", [["bronchopulmonary", "ANATOMY", 42, 58], ["middle lobe", "ANATOMY", 94, 105], ["cystic", "ANATOMY", 125, 131], ["interstitial", "ANATOMY", 307, 319], ["bronchopulmonary dysplasia", "ANATOMY", 341, 367], ["bronchial", "ANATOMY", 380, 389], ["atelectasis rounded or middle lobe syndrome", "DISEASE", 71, 114], ["cystic fibrosis", "DISEASE", 125, 140], ["bronchiectasis", "DISEASE", 151, 165], ["asthma", "DISEASE", 183, 189], ["tracheomalacia", "DISEASE", 241, 255], ["bronchiolitis obliterans", "DISEASE", 265, 289], ["interstitial pneumopathy", "DISEASE", 307, 331], ["bronchopulmonary dysplasia", "DISEASE", 341, 367], ["bronchial hypoplasia", "DISEASE", 380, 400], ["patients", "ORGANISM", 4, 12], ["lobe", "ORGAN", 101, 105], ["bronchopulmonary dysplasia", "PATHOLOGICAL_FORMATION", 341, 367], ["patients", "SPECIES", 4, 12], ["underlying bronchopulmonary conditions", "PROBLEM", 31, 69], ["atelectasis rounded", "PROBLEM", 71, 90], ["middle lobe syndrome", "PROBLEM", 94, 114], ["cystic fibrosis", "PROBLEM", 125, 140], ["bronchiectasis (n \u00bc 5", "PROBLEM", 151, 172], ["chronic asthma", "PROBLEM", 175, 189], ["conventional treatments", "TREATMENT", 208, 231], ["tracheomalacia (n \u00bc 3)", "PROBLEM", 241, 263], ["bronchiolitis obliterans (n \u00bc 2)", "PROBLEM", 265, 297], ["chronic interstitial pneumopathy (n \u00bc 2)", "PROBLEM", 299, 339], ["bronchopulmonary dysplasia (n \u00bc 1)", "PROBLEM", 341, 375], ["bronchial hypoplasia", "PROBLEM", 380, 400], ["bronchopulmonary", "ANATOMY", 42, 58], ["atelectasis", "OBSERVATION", 71, 82], ["middle lobe", "ANATOMY", 94, 105], ["cystic", "OBSERVATION_MODIFIER", 125, 131], ["fibrosis", "OBSERVATION", 132, 140], ["bronchiectasis", "OBSERVATION", 151, 165], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["asthma", "OBSERVATION", 183, 189], ["tracheomalacia", "OBSERVATION", 241, 255], ["bronchiolitis obliterans", "OBSERVATION", 265, 289], ["chronic", "OBSERVATION_MODIFIER", 299, 306], ["interstitial", "ANATOMY_MODIFIER", 307, 319], ["pneumopathy", "OBSERVATION", 320, 331], ["bronchopulmonary", "ANATOMY", 341, 357], ["dysplasia", "OBSERVATION", 358, 367], ["bronchial", "ANATOMY", 380, 389], ["hypoplasia", "OBSERVATION", 390, 400]]], ["All patients lacked a known cause of immunosuppression.Patients and SpecimensThe lower respiratory tract specimens were processed using conventional quantitative bacterial and fungal cultures.", [["lower respiratory tract specimens", "ANATOMY", 81, 114], ["patients", "ORGANISM", 4, 12], ["Patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 4, 12], ["Patients", "SPECIES", 55, 63], ["immunosuppression", "TREATMENT", 37, 54], ["Specimens", "TEST", 68, 77], ["The lower respiratory tract specimens", "PROBLEM", 77, 114], ["conventional quantitative bacterial and fungal cultures", "TEST", 136, 191], ["immunosuppression", "OBSERVATION", 37, 54], ["lower", "ANATOMY_MODIFIER", 81, 86], ["respiratory tract", "ANATOMY", 87, 104]]], ["Growths of !10 4 or !10 5 CFU/ml of bacterial or fungal species in bronchoaspitates or bronchoalveolar lavages respectively were considered significant.", [["bronchoaspitates", "ANATOMY", 67, 83], ["bronchoalveolar lavages", "ANATOMY", 87, 110], ["bronchoaspitates", "CELL", 67, 83], ["bronchoalveolar lavages", "MULTI-TISSUE_STRUCTURE", 87, 110], ["bacterial", "PROBLEM", 36, 45], ["fungal species in bronchoaspitates", "PROBLEM", 49, 83], ["bronchoalveolar lavages", "TEST", 87, 110], ["bacterial", "OBSERVATION_MODIFIER", 36, 45], ["fungal species", "OBSERVATION", 49, 63], ["bronchoalveolar lavages", "OBSERVATION", 87, 110]]], ["Microbial identification was accomplished by conventional procedures.", [["Microbial identification", "TEST", 0, 24], ["conventional procedures", "TREATMENT", 45, 68]]], ["For some patients, molecular detection of respiratory viruses was also performed shortly after fibrobronchoscopy.", [["respiratory viruses", "DISEASE", 42, 61], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["respiratory viruses", "PROBLEM", 42, 61], ["fibrobronchoscopy", "TEST", 95, 112], ["respiratory viruses", "OBSERVATION", 42, 61]]], ["Bronchoalveolar lavages and bronchial or tracheal aspirates pre-treated with 0.1% dithiothreitol (in the ratio of 2 ml to 1 g bronchoaspirate) were vortexed and centrifuged at 462g for 5 min at 48C to pellet the cells.", [["Bronchoalveolar lavages", "ANATOMY", 0, 23], ["bronchial", "ANATOMY", 28, 37], ["tracheal aspirates", "ANATOMY", 41, 59], ["cells", "ANATOMY", 212, 217], ["dithiothreitol", "CHEMICAL", 82, 96], ["dithiothreitol", "CHEMICAL", 82, 96], ["Bronchoalveolar lavages", "ORGANISM_SUBSTANCE", 0, 23], ["bronchial", "MULTI-TISSUE_STRUCTURE", 28, 37], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 41, 59], ["dithiothreitol", "SIMPLE_CHEMICAL", 82, 96], ["cells", "CELL", 212, 217], ["Bronchoalveolar lavages", "TEST", 0, 23], ["bronchial or tracheal aspirates", "PROBLEM", 28, 59], ["0.1% dithiothreitol", "TREATMENT", 77, 96], ["lavages", "OBSERVATION", 16, 23], ["bronchial", "ANATOMY", 28, 37], ["tracheal", "ANATOMY", 41, 49], ["aspirates", "OBSERVATION", 50, 59], ["cells", "ANATOMY", 212, 217]]], ["Cell supernatants were stored at \u00c0208C and were retrieved for further molecular analyses and cytokine measurements.", [["Cell supernatants", "ANATOMY", 0, 17], ["Cell", "CELL", 0, 4], ["cytokine", "PROTEIN", 93, 101], ["Cell supernatants", "TEST", 0, 17], ["further molecular analyses", "TEST", 62, 88], ["cytokine measurements", "TEST", 93, 114]]], ["Serum specimens for the assessment of CMV-serostatus were available from 26 patients.", [["Serum specimens", "ANATOMY", 0, 15], ["Serum specimens", "ORGANISM_SUBSTANCE", 0, 15], ["CMV", "ORGANISM", 38, 41], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["CMV", "SPECIES", 38, 41], ["Serum specimens", "TEST", 0, 15], ["the assessment", "TEST", 20, 34], ["CMV", "TEST", 38, 41]]], ["These specimens were obtained either prior to, or at the time of, fibrobronchoscopy.", [["specimens", "ANATOMY", 6, 15], ["specimens", "CANCER", 6, 15], ["These specimens", "TEST", 0, 15], ["fibrobronchoscopy", "TEST", 66, 83]]], ["Sera were frozen at \u00c0208C and retrieved for serological testing.Patients and SpecimensThis study conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the local ethics committee.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["Patients", "ORGANISM", 64, 72], ["Patients", "SPECIES", 64, 72], ["Sera", "TEST", 0, 4], ["serological testing", "TEST", 44, 63], ["Specimens", "TEST", 77, 86], ["This study", "TEST", 86, 96]]], ["Written informed consent was obtained from parents.Molecular AnalysesCMV DNA load was quantified by real-time PCR with an Abbott CMV PCR kit (produced by Qiagen GmbH, Hilden, Germany, for Abbott Diagnostics, Des Plaines, IL), as previously described [Gimeno et al., 2008; Chilet et al., 2010; Bravo et al., 2011] .", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["CMV", "ORGANISM", 129, 132], ["IL", "GENE_OR_GENE_PRODUCT", 221, 223], ["Molecular AnalysesCMV DNA load", "TEST", 51, 81], ["an Abbott CMV PCR kit", "TEST", 119, 140]]], ["This assay is able to reliably quantify CMV DNA loads of >10 copies/ml .", [["CMV", "ORGANISM", 40, 43], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["CMV", "SPECIES", 40, 43], ["This assay", "TEST", 0, 10], ["CMV DNA loads", "TEST", 40, 53]]], ["DNA extractions were performed from a volume of 500 ml (plasma, or lower respiratory tract specimens) using an Abbott mSample preparation system DNA kit on an m24 SP instrument (Abbott Molecular, IL).", [["plasma", "ANATOMY", 56, 62], ["lower respiratory tract specimens", "ANATOMY", 67, 100], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["DNA extractions", "TREATMENT", 0, 15], ["plasma", "TEST", 56, 62], ["an Abbott mSample preparation system", "TREATMENT", 108, 144], ["an m24 SP instrument", "TREATMENT", 156, 176], ["respiratory tract", "ANATOMY", 73, 90]]], ["Detection and quantification of human herpesvirus-6 (HHV-6) and human herpesvirus-7 (HHV-7) was performed in respiratory specimens by real-time PCR (Realquality RS-HHV6 and RS-HHV7; AB Analitica, Padova, Italy).", [["respiratory specimens", "ANATOMY", 109, 130], ["human herpesvirus-6", "ORGANISM", 32, 51], ["HHV-6", "ORGANISM", 53, 58], ["human herpesvirus-7", "ORGANISM", 64, 83], ["HHV-7", "ORGANISM", 85, 90], ["human", "SPECIES", 32, 37], ["herpesvirus-6", "SPECIES", 38, 51], ["HHV-6", "SPECIES", 53, 58], ["human", "SPECIES", 64, 69], ["herpesvirus-7", "SPECIES", 70, 83], ["human herpesvirus-6 (HHV-6", "SPECIES", 32, 58], ["human herpesvirus-7 (HHV-7", "SPECIES", 64, 90], ["Detection", "TEST", 0, 9], ["human herpesvirus", "TEST", 32, 49], ["HHV", "TEST", 53, 56], ["human herpesvirus", "TEST", 64, 81], ["HHV", "TEST", 85, 88], ["respiratory specimens", "TEST", 109, 130], ["PCR", "TEST", 144, 147], ["Realquality", "TEST", 149, 160], ["RS", "TEST", 161, 163], ["HHV6", "TEST", 164, 168], ["RS", "TEST", 173, 175], ["HHV7", "TEST", 176, 180]]], ["The detection limit of these assays is approximately 25 copies/ml.", [["these assays", "TEST", 23, 35]]], ["DNA was extracted from respiratory specimens (400 ml) using an EZ1 Virus 2.0 kit (Qiagen, Valencia, CA) on the BioRobot EZ1 extraction platform (Qiagen), following the manufacturers' instructions.Molecular AnalysesDetection of respiratory viruses was performed by multiplex PCR using an RVP Fast assay (Luminex Molecular Diagnostics, Toronto, Canada), following the manufacturer's instructions.", [["respiratory specimens", "ANATOMY", 23, 44], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "PROBLEM", 0, 3], ["respiratory specimens", "TEST", 23, 44], ["an EZ1 Virus", "TREATMENT", 60, 72], ["the BioRobot EZ1 extraction platform", "TREATMENT", 107, 143], ["respiratory viruses", "PROBLEM", 227, 246], ["multiplex PCR", "TEST", 264, 277], ["an RVP Fast assay", "TEST", 284, 301], ["respiratory viruses", "OBSERVATION", 227, 246]]], ["The analysis was performed using an xMAP 100 IS instrument (Luminex Molecular Diagnostics).", [["The analysis", "TEST", 0, 12], ["an xMAP", "TEST", 33, 40]]], ["The RVP Fast assay simultaneously detects: influenza A virus, H1, H3, or H5 subtypes; influenza B virus; RSV-A and -B; PIV-1, -2, -3, and -4; adenovirus; human metapneumovirus; coronaviruses 229E, NL63, OC43, and HKU1; enterovirus/ rhinovirus; and human bocavirus.", [["influenza B", "DISEASE", 86, 97], ["enterovirus/ rhinovirus", "DISEASE", 219, 242], ["influenza A virus", "ORGANISM", 43, 60], ["H1", "GENE_OR_GENE_PRODUCT", 62, 64], ["H3", "GENE_OR_GENE_PRODUCT", 66, 68], ["H5 subtypes;", "ORGANISM", 73, 85], ["influenza B virus", "ORGANISM", 86, 103], ["RSV-A", "ORGANISM", 105, 110], ["-B;", "ORGANISM", 115, 118], ["PIV-1", "ORGANISM", 119, 124], ["-2", "GENE_OR_GENE_PRODUCT", 126, 128], ["-3", "GENE_OR_GENE_PRODUCT", 130, 132], ["-4", "ORGANISM", 138, 140], ["adenovirus", "ORGANISM", 142, 152], ["human metapneumovirus", "ORGANISM", 154, 175], ["coronaviruses 229E", "ORGANISM", 177, 195], ["NL63", "GENE_OR_GENE_PRODUCT", 197, 201], ["OC43", "GENE_OR_GENE_PRODUCT", 203, 207], ["HKU1", "GENE_OR_GENE_PRODUCT", 213, 217], ["enterovirus", "ORGANISM", 219, 230], ["rhinovirus", "ORGANISM", 232, 242], ["human", "ORGANISM", 248, 253], ["bocavirus", "ORGANISM", 254, 263], ["influenza A virus", "SPECIES", 43, 60], ["influenza B virus", "SPECIES", 86, 103], ["PIV-1", "SPECIES", 119, 124], ["human", "SPECIES", 154, 159], ["metapneumovirus", "SPECIES", 160, 175], ["human", "SPECIES", 248, 253], ["influenza A virus", "SPECIES", 43, 60], ["H1", "SPECIES", 62, 64], ["influenza B virus", "SPECIES", 86, 103], ["RSV-A", "SPECIES", 105, 110], ["human metapneumovirus", "SPECIES", 154, 175], ["human", "SPECIES", 248, 253], ["The RVP", "TEST", 0, 7], ["influenza A virus", "PROBLEM", 43, 60], ["H1", "PROBLEM", 62, 64], ["H3", "PROBLEM", 66, 68], ["H5 subtypes", "PROBLEM", 73, 84], ["influenza B virus", "PROBLEM", 86, 103], ["RSV", "TEST", 105, 108], ["PIV", "TEST", 119, 122], ["adenovirus", "PROBLEM", 142, 152], ["human metapneumovirus", "PROBLEM", 154, 175], ["coronaviruses", "TEST", 177, 190], ["NL63", "TEST", 197, 201], ["OC43", "TEST", 203, 207], ["HKU1", "TEST", 213, 217], ["enterovirus", "PROBLEM", 219, 230], ["rhinovirus", "PROBLEM", 232, 242], ["human bocavirus", "PROBLEM", 248, 263], ["human metapneumovirus", "ANATOMY", 154, 175]]], ["Nucleic acid extractions were performed on 400 ml respiratory samples with an EZ-1 virus 2.0 Kit on a BioRobot EZ-1.Cytokine MeasurementsA commercial capture immunoassay was used to quantify IL-6 in respiratory specimens (Human IL-6 ELISA Ready-set Go; eBioscience, San Diego, CA), following the manufacturer's instructions.", [["respiratory samples", "ANATOMY", 50, 69], ["respiratory specimens", "ANATOMY", 199, 220], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["IL-6", "GENE_OR_GENE_PRODUCT", 191, 195], ["Human", "ORGANISM", 222, 227], ["Cytokine", "PROTEIN", 116, 124], ["IL-6", "PROTEIN", 191, 195], ["Human", "SPECIES", 222, 227], ["Nucleic acid extractions", "TREATMENT", 0, 24], ["respiratory samples", "TEST", 50, 69], ["an EZ", "TEST", 75, 80], ["a BioRobot EZ", "TEST", 100, 113], ["Cytokine MeasurementsA commercial capture immunoassay", "TEST", 116, 169], ["IL", "TEST", 191, 193], ["Human IL", "TREATMENT", 222, 230]]], ["For bronchoalveolar lavage specimens, epithelial lining fluid volume was calculated using urea as a dilution marker [Zedtwitz-Liebenstein et al., 2005 ].", [["bronchoalveolar lavage specimens", "ANATOMY", 4, 36], ["epithelial lining fluid", "ANATOMY", 38, 61], ["urea", "CHEMICAL", 90, 94], ["urea", "CHEMICAL", 90, 94], ["bronchoalveolar lavage specimens", "TISSUE", 4, 36], ["epithelial lining fluid", "TISSUE", 38, 61], ["urea", "SIMPLE_CHEMICAL", 90, 94], ["bronchoalveolar lavage specimens", "TEST", 4, 36], ["epithelial lining fluid volume", "TEST", 38, 68], ["urea", "TEST", 90, 94], ["a dilution marker", "TEST", 98, 115], ["bronchoalveolar lavage", "OBSERVATION", 4, 26], ["lining", "OBSERVATION_MODIFIER", 49, 55], ["fluid volume", "OBSERVATION", 56, 68]]], ["The detection limit of this assay is 2 pg/ml.CMV Serological TestingCMV IgGs were detected using a DiaSorin LIAI-SON 1 CMV IgG assay (DiaSorin, Saluggia, Italy).Statistical AnalysisThe data were analyzed with the aid of the SPSS statistical package, version 17.0 (SPSS, North Chicago, IL).", [["CMV", "ORGANISM", 45, 48], ["IgGs", "GENE_OR_GENE_PRODUCT", 72, 76], ["CMV", "ORGANISM", 119, 122], ["CMV Serological TestingCMV IgGs", "PROTEIN", 45, 76], ["CMV", "SPECIES", 45, 48], ["TestingCMV", "SPECIES", 61, 71], ["this assay", "TEST", 23, 33], ["CMV Serological TestingCMV IgGs", "TEST", 45, 76], ["a DiaSorin LIAI", "TREATMENT", 97, 112], ["Statistical Analysis", "TEST", 161, 181], ["version", "TEST", 250, 257]]], ["Comparisons were undertaken using the x 2test for categorical variables and the non-parametric Mann-Whitney U-test for unpaired continuous data.", [["categorical variables", "TEST", 50, 71], ["unpaired continuous data", "TEST", 119, 143]]], ["Two-sided exact P values are presented.", [["Two-sided exact P values", "TEST", 0, 24], ["sided", "ANATOMY_MODIFIER", 4, 9]]], ["A P value <0.05 was considered statistically significant.Detection of CMV DNA in the Lower Respiratory Tract and in PlasmaEleven patients were CMV-seropositive at the time of fibrobronchoscopy, 15 were CMV-seronegative, and the CMV-serostatus of 15 was unknown.", [["CMV", "ORGANISM", 70, 73], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["patients", "ORGANISM", 129, 137], ["CMV", "ORGANISM", 143, 146], ["CMV", "ORGANISM", 202, 205], ["CMV", "ORGANISM", 228, 231], ["CMV DNA", "DNA", 70, 77], ["patients", "SPECIES", 129, 137], ["CMV", "SPECIES", 70, 73], ["A P value", "TEST", 0, 9], ["CMV DNA in the Lower Respiratory Tract", "PROBLEM", 70, 108], ["CMV", "TEST", 143, 146], ["fibrobronchoscopy", "TEST", 175, 192], ["CMV", "TEST", 202, 205], ["the CMV-serostatus", "TEST", 224, 242], ["CMV DNA", "OBSERVATION", 70, 77], ["Lower", "ANATOMY_MODIFIER", 85, 90], ["Respiratory Tract", "ANATOMY", 91, 108]]], ["The presence of CMVDNA in the lower respiratory tract specimens was assessed for all patients.", [["lower respiratory tract specimens", "ANATOMY", 30, 63], ["CMVDNA", "GENE_OR_GENE_PRODUCT", 16, 22], ["lower", "ORGANISM_SUBDIVISION", 30, 35], ["respiratory tract", "ORGAN", 36, 53], ["patients", "ORGANISM", 85, 93], ["CMVDNA", "PROTEIN", 16, 22], ["patients", "SPECIES", 85, 93], ["CMVDNA in the lower respiratory tract specimens", "PROBLEM", 16, 63], ["CMVDNA", "OBSERVATION", 16, 22], ["lower", "ANATOMY_MODIFIER", 30, 35], ["respiratory tract", "ANATOMY", 36, 53]]], ["It was detected in six of the 11 (54.5%) CMV-seropositive patients (median, 258 copies/ml; range, 27-815 copies/ml), and in none of the remaining patients.", [["CMV", "ORGANISM", 41, 44], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 146, 154], ["CMV", "TEST", 41, 44], ["range", "TEST", 91, 96]]], ["The presence of CMV DNA in the blood compartment (plasma) was investigated exclusively in CMV-seropositive patients.", [["blood compartment", "ANATOMY", 31, 48], ["plasma", "ANATOMY", 50, 56], ["CMV", "ORGANISM", 16, 19], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["blood compartment", "MULTI-TISSUE_STRUCTURE", 31, 48], ["plasma", "ORGANISM_SUBSTANCE", 50, 56], ["CMV", "ORGANISM", 90, 93], ["patients", "ORGANISM", 107, 115], ["CMV DNA", "DNA", 16, 23], ["patients", "SPECIES", 107, 115], ["CMV", "SPECIES", 16, 19], ["CMV", "SPECIES", 90, 93], ["CMV DNA in the blood compartment", "PROBLEM", 16, 48], ["CMV", "TEST", 90, 93], ["CMV DNA", "OBSERVATION", 16, 23], ["blood", "ANATOMY", 31, 36]]], ["Plasma CMV DNAemia was detected in two patients (18.8%).", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["CMV", "ORGANISM", 7, 10], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["CMV", "SPECIES", 7, 10], ["Plasma CMV DNAemia", "TEST", 0, 18], ["CMV DNAemia", "OBSERVATION", 7, 18]]], ["In both these patients, CMV DNA was also detected in the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 57, 80], ["patients", "ORGANISM", 14, 22], ["CMV", "ORGANISM", 24, 27], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["lower", "ORGANISM_SUBDIVISION", 57, 62], ["respiratory tract", "ORGANISM_SUBDIVISION", 63, 80], ["CMV DNA", "DNA", 24, 31], ["patients", "SPECIES", 14, 22], ["CMV", "SPECIES", 24, 27], ["CMV DNA", "PROBLEM", 24, 31], ["CMV DNA", "OBSERVATION", 24, 31], ["lower", "ANATOMY_MODIFIER", 57, 62], ["respiratory tract", "ANATOMY", 63, 80]]], ["Clinical and microbiological features of these patients are shown in Table I .", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["It is noteworthy that two of the three patients with cystic fibrosis who were CMV-seropositive at the time of fibrobronchoscopy had CMV DNA detected in their lower respiratory tract.", [["cystic", "ANATOMY", 53, 59], ["lower respiratory tract", "ANATOMY", 158, 181], ["cystic fibrosis", "DISEASE", 53, 68], ["patients", "ORGANISM", 39, 47], ["CMV", "ORGANISM", 78, 81], ["CMV", "ORGANISM", 132, 135], ["DNA", "CELLULAR_COMPONENT", 136, 139], ["lower", "ORGANISM_SUBDIVISION", 158, 163], ["respiratory tract", "ORGANISM_SUBDIVISION", 164, 181], ["CMV DNA", "DNA", 132, 139], ["patients", "SPECIES", 39, 47], ["CMV", "SPECIES", 132, 135], ["cystic fibrosis", "PROBLEM", 53, 68], ["CMV", "TEST", 78, 81], ["fibrobronchoscopy", "TEST", 110, 127], ["CMV DNA", "PROBLEM", 132, 139], ["cystic", "OBSERVATION_MODIFIER", 53, 59], ["fibrosis", "OBSERVATION", 60, 68], ["CMV DNA", "OBSERVATION", 132, 139], ["lower", "ANATOMY_MODIFIER", 158, 163], ["respiratory tract", "ANATOMY", 164, 181]]], ["Despite the fact that five of the six patients with CMV DNA detected in the lower respiratory tract were under corticosteroid treatment at the time of fibrobronchoscopy (Fluticasone), no significant association was found between the use of corticosteroids and the detection of CMV DNA (P \u00bc 0.435).Microbiological Features of Patients With or Without Detectable CMV DNAA comprehensive microbiological analysis of the lower respiratory tract specimens from the patients was performed.", [["lower respiratory tract", "ANATOMY", 76, 99], ["lower respiratory tract specimens", "ANATOMY", 416, 449], ["Fluticasone", "CHEMICAL", 170, 181], ["corticosteroids", "CHEMICAL", 240, 255], ["corticosteroids", "CHEMICAL", 240, 255], ["patients", "ORGANISM", 38, 46], ["CMV", "ORGANISM", 52, 55], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["lower", "ORGANISM_SUBDIVISION", 76, 81], ["respiratory tract", "ORGANISM_SUBDIVISION", 82, 99], ["Fluticasone", "SIMPLE_CHEMICAL", 170, 181], ["CMV", "ORGANISM", 277, 280], ["DNA", "CELLULAR_COMPONENT", 281, 284], ["Patients", "ORGANISM", 325, 333], ["CMV", "ORGANISM", 361, 364], ["lower respiratory", "ORGANISM_SUBDIVISION", 416, 433], ["tract specimens", "CANCER", 434, 449], ["patients", "ORGANISM", 459, 467], ["CMV DNA", "DNA", 52, 59], ["CMV DNA", "DNA", 277, 284], ["patients", "SPECIES", 38, 46], ["Patients", "SPECIES", 325, 333], ["patients", "SPECIES", 459, 467], ["CMV", "SPECIES", 52, 55], ["CMV", "SPECIES", 277, 280], ["CMV", "SPECIES", 361, 364], ["CMV DNA", "PROBLEM", 52, 59], ["the lower respiratory tract", "PROBLEM", 72, 99], ["corticosteroid treatment", "TREATMENT", 111, 135], ["fibrobronchoscopy", "TREATMENT", 151, 168], ["Fluticasone", "TREATMENT", 170, 181], ["corticosteroids", "TREATMENT", 240, 255], ["the detection", "TEST", 260, 273], ["CMV DNA", "PROBLEM", 277, 284], ["Detectable CMV DNAA", "PROBLEM", 350, 369], ["CMV DNA", "OBSERVATION", 52, 59], ["lower", "ANATOMY_MODIFIER", 76, 81], ["respiratory tract", "ANATOMY", 82, 99], ["lower", "ANATOMY_MODIFIER", 416, 421], ["respiratory tract", "ANATOMY", 422, 439]]], ["The presence of respiratory viruses was investigated by multiplex PCR, while the occurrence of common bacterial and fungal species was assessed by conventional culture methods.", [["respiratory viruses", "PROBLEM", 16, 35], ["multiplex PCR", "TEST", 56, 69], ["common bacterial and fungal species", "PROBLEM", 95, 130], ["conventional culture methods", "TEST", 147, 175], ["respiratory viruses", "OBSERVATION", 16, 35], ["fungal species", "OBSERVATION", 116, 130]]], ["Respiratory viruses were detected in 13 of the 42 patients (rhinovirus, n \u00bc 6; respiratory syncytial virus, n \u00bc 2; bocavirus, n \u00bc 2; metapneumovirus, n \u00bc 1; coronaviruses HKN1, n \u00bc 1; and adenovirus, n \u00bc 1).", [["Respiratory viruses", "DISEASE", 0, 19], ["respiratory syncytial virus", "DISEASE", 79, 106], ["patients", "ORGANISM", 50, 58], ["rhinovirus", "ORGANISM", 60, 70], ["n \u00bc 6;", "ORGANISM", 72, 78], ["respiratory syncytial virus", "ORGANISM", 79, 106], ["metapneumovirus", "ORGANISM", 133, 148], ["coronaviruses", "ORGANISM", 157, 170], ["adenovirus", "ORGANISM", 188, 198], ["patients", "SPECIES", 50, 58], ["respiratory syncytial virus", "SPECIES", 79, 106], ["respiratory syncytial virus", "SPECIES", 79, 106], ["Respiratory viruses", "TEST", 0, 19], ["rhinovirus", "TEST", 60, 70], ["respiratory syncytial virus", "TEST", 79, 106], ["bocavirus", "TEST", 115, 124], ["metapneumovirus", "PROBLEM", 133, 148], ["coronaviruses HKN1", "TEST", 157, 175], ["adenovirus", "PROBLEM", 188, 198], ["viruses", "OBSERVATION", 12, 19], ["respiratory syncytial", "ANATOMY", 79, 100]]], ["Two of these 13 patients tested positive for CMV DNA in the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 60, 83], ["patients", "ORGANISM", 16, 24], ["CMV", "ORGANISM", 45, 48], ["DNA", "CELLULAR_COMPONENT", 49, 52], ["lower respiratory", "ORGANISM_SUBDIVISION", 60, 77], ["tract", "ORGANISM_SUBDIVISION", 78, 83], ["CMV DNA", "DNA", 45, 52], ["patients", "SPECIES", 16, 24], ["CMV", "SPECIES", 45, 48], ["CMV DNA in the lower respiratory tract", "PROBLEM", 45, 83], ["CMV DNA", "OBSERVATION", 45, 52], ["lower", "ANATOMY_MODIFIER", 60, 65], ["respiratory tract", "ANATOMY", 66, 83]]], ["Significant growth of one or more bacterial species was observed in 17 of the 42 patients (Haemophilus influenzae biotypes VIII or III, n \u00bc 7; Staphylococcus aureus, n \u00bc 5; Streptococcus pneumoniae, n \u00bc 3; Moraxella catharralis, n \u00bc 2; Pseudomonas aeruginosa, n \u00bc 1; and Achromobacter xyloxosidans, n \u00bc 1).", [["Haemophilus influenzae biotypes VIII", "DISEASE", 91, 127], ["Staphylococcus aureus", "DISEASE", 143, 164], ["Streptococcus pneumoniae", "DISEASE", 173, 197], ["Moraxella catharralis", "DISEASE", 206, 227], ["patients", "ORGANISM", 81, 89], ["Haemophilus influenzae biotypes VIII", "ORGANISM", 91, 127], ["n \u00bc 7", "ORGANISM", 136, 141], ["Staphylococcus aureus", "ORGANISM", 143, 164], ["n \u00bc 5", "ORGANISM", 166, 171], ["Streptococcus pneumoniae", "ORGANISM", 173, 197], ["n \u00bc 3", "ORGANISM", 199, 204], ["Moraxella catharralis", "ORGANISM", 206, 227], ["Pseudomonas aeruginosa", "ORGANISM", 236, 258], ["n \u00bc 1", "ORGANISM", 260, 265], ["Achromobacter xyloxosidans", "ORGANISM", 271, 297], ["patients", "SPECIES", 81, 89], ["Haemophilus influenzae", "SPECIES", 91, 113], ["Staphylococcus aureus", "SPECIES", 143, 164], ["Streptococcus pneumoniae", "SPECIES", 173, 197], ["Moraxella catharralis", "SPECIES", 206, 227], ["Pseudomonas aeruginosa", "SPECIES", 236, 258], ["Achromobacter xyloxosidans", "SPECIES", 271, 297], ["Haemophilus influenzae", "SPECIES", 91, 113], ["Staphylococcus aureus", "SPECIES", 143, 164], ["Streptococcus pneumoniae", "SPECIES", 173, 197], ["Moraxella catharralis", "SPECIES", 206, 227], ["Pseudomonas aeruginosa, n \u00bc 1", "SPECIES", 236, 265], ["Achromobacter xyloxosidans", "SPECIES", 271, 297], ["Significant growth", "PROBLEM", 0, 18], ["more bacterial species", "PROBLEM", 29, 51], ["Haemophilus influenzae biotypes VIII", "TEST", 91, 127], ["III, n \u00bc", "TEST", 131, 139], ["Staphylococcus aureus", "PROBLEM", 143, 164], ["Streptococcus pneumoniae", "TEST", 173, 197], ["Moraxella catharralis", "TEST", 206, 227], ["Pseudomonas aeruginosa", "PROBLEM", 236, 258], ["Achromobacter xyloxosidans", "PROBLEM", 271, 297], ["growth", "OBSERVATION_MODIFIER", 12, 18], ["bacterial species", "OBSERVATION", 34, 51]]], ["Candida parapsilosis was isolated from three patients.", [["Candida parapsilosis", "DISEASE", 0, 20], ["Candida parapsilosis", "ORGANISM", 0, 20], ["patients", "ORGANISM", 45, 53], ["Candida parapsilosis", "SPECIES", 0, 20], ["patients", "SPECIES", 45, 53], ["Candida parapsilosis", "SPECIES", 0, 20], ["Candida parapsilosis", "PROBLEM", 0, 20], ["parapsilosis", "OBSERVATION", 8, 20]]], ["Two out of the six patients with detectable CMV DNA had a positive bacterial culture.", [["patients", "ORGANISM", 19, 27], ["CMV", "ORGANISM", 44, 47], ["DNA", "CELLULAR_COMPONENT", 48, 51], ["CMV DNA", "DNA", 44, 51], ["patients", "SPECIES", 19, 27], ["CMV", "SPECIES", 44, 47], ["detectable CMV DNA", "PROBLEM", 33, 51], ["a positive bacterial culture", "PROBLEM", 56, 84], ["CMV DNA", "OBSERVATION", 44, 51], ["bacterial culture", "OBSERVATION", 67, 84]]], ["No significant correlation (P \u00bc > 0.5) was found between the presence of CMV DNA infection and that of respiratory viruses, or bacterial or fungal species, either when all patients were considered collectively, irrespective of their CMV serostatus, or when the subgroup of CMV-seropositive patients was analyzed separately.Detection of Other Beta-Herpesviruses in the Lower Respiratory TractThe presence of HHV-6 and HHV-7 DNA in the lower respiratory tract was assessed in the 11 CMVseropositive patients.", [["lower respiratory tract", "ANATOMY", 434, 457], ["CMV DNA infection", "DISEASE", 73, 90], ["respiratory viruses", "DISEASE", 103, 122], ["CMV", "ORGANISM", 73, 76], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["patients", "ORGANISM", 172, 180], ["CMV", "ORGANISM", 233, 236], ["CMV", "ORGANISM", 273, 276], ["patients", "ORGANISM", 290, 298], ["Beta-Herpesviruses", "GENE_OR_GENE_PRODUCT", 342, 360], ["HHV-6", "ORGANISM", 407, 412], ["HHV-7", "ORGANISM", 417, 422], ["DNA", "CELLULAR_COMPONENT", 423, 426], ["lower respiratory", "ORGANISM_SUBDIVISION", 434, 451], ["tract", "ORGANISM_SUBDIVISION", 452, 457], ["patients", "ORGANISM", 497, 505], ["HHV-6 and HHV-7 DNA", "DNA", 407, 426], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 290, 298], ["patients", "SPECIES", 497, 505], ["CMV", "SPECIES", 73, 76], ["CMV", "SPECIES", 233, 236], ["CMV", "SPECIES", 273, 276], ["HHV-6", "SPECIES", 407, 412], ["HHV-7", "SPECIES", 417, 422], ["P \u00bc", "TEST", 28, 31], ["CMV DNA infection", "PROBLEM", 73, 90], ["respiratory viruses", "PROBLEM", 103, 122], ["bacterial or fungal species", "PROBLEM", 127, 154], ["their CMV serostatus", "PROBLEM", 227, 247], ["CMV", "TEST", 273, 276], ["Other Beta-Herpesviruses", "PROBLEM", 336, 360], ["HHV", "TEST", 407, 410], ["HHV", "TEST", 417, 420], ["DNA in the lower respiratory tract", "PROBLEM", 423, 457], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["correlation", "OBSERVATION", 15, 26], ["CMV DNA infection", "OBSERVATION", 73, 90], ["respiratory viruses", "OBSERVATION", 103, 122], ["bacterial", "OBSERVATION_MODIFIER", 127, 136], ["fungal species", "OBSERVATION", 140, 154], ["Herpesviruses", "OBSERVATION", 347, 360], ["Lower", "ANATOMY_MODIFIER", 368, 373], ["Respiratory Tract", "ANATOMY", 374, 391], ["HHV", "OBSERVATION", 407, 410], ["lower", "ANATOMY_MODIFIER", 434, 439], ["respiratory tract", "ANATOMY", 440, 457]]], ["HHV-6 DNA was detected in three patients (35, 52, and 2,350 copies/ml), two of which had CMV DNA present in the lower respiratory tract.", [["lower respiratory tract", "ANATOMY", 112, 135], ["HHV-6", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["patients", "ORGANISM", 32, 40], ["CMV", "ORGANISM", 89, 92], ["DNA", "CELLULAR_COMPONENT", 93, 96], ["lower", "ORGANISM_SUBDIVISION", 112, 117], ["respiratory tract", "ORGANISM_SUBDIVISION", 118, 135], ["HHV-6 DNA", "DNA", 0, 9], ["CMV DNA", "DNA", 89, 96], ["patients", "SPECIES", 32, 40], ["HHV-6", "SPECIES", 0, 5], ["CMV", "SPECIES", 89, 92], ["HHV", "TEST", 0, 3], ["DNA", "PROBLEM", 6, 9], ["CMV DNA", "PROBLEM", 89, 96], ["6 DNA", "OBSERVATION_MODIFIER", 4, 9], ["CMV DNA", "OBSERVATION", 89, 96], ["lower", "ANATOMY_MODIFIER", 112, 117], ["respiratory tract", "ANATOMY", 118, 135]]], ["HHV-7 DNA was detected in one patient (408 copies/ml) who had no CMV DNA detected in the lower respiratory tract.IL-6 Levels in the Lower Respiratory Tract in Patients With or Without Detectable CMV DNAIL-6 has been shown to be a reliable marker of inflammation of the lower respiratory airways.", [["lower respiratory tract", "ANATOMY", 89, 112], ["lower respiratory airways", "ANATOMY", 269, 294], ["DNAIL-6", "CHEMICAL", 199, 206], ["inflammation", "DISEASE", 249, 261], ["HHV-7", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["patient", "ORGANISM", 30, 37], ["CMV", "ORGANISM", 65, 68], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["lower", "ORGANISM_SUBDIVISION", 89, 94], ["respiratory tract", "ORGANISM_SUBDIVISION", 95, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 113, 117], ["Patients", "ORGANISM", 159, 167], ["CMV", "ORGANISM", 195, 198], ["DNAIL-6", "GENE_OR_GENE_PRODUCT", 199, 206], ["lower respiratory airways", "MULTI-TISSUE_STRUCTURE", 269, 294], ["HHV-7 DNA", "DNA", 0, 9], ["CMV DNA", "DNA", 65, 72], ["IL-6", "PROTEIN", 113, 117], ["patient", "SPECIES", 30, 37], ["Patients", "SPECIES", 159, 167], ["HHV-7", "SPECIES", 0, 5], ["CMV", "SPECIES", 65, 68], ["CMV", "SPECIES", 195, 198], ["HHV", "TEST", 0, 3], ["DNA", "PROBLEM", 6, 9], ["CMV DNA", "PROBLEM", 65, 72], ["IL", "TEST", 113, 115], ["inflammation of the lower respiratory airways", "PROBLEM", 249, 294], ["no", "UNCERTAINTY", 62, 64], ["CMV DNA", "OBSERVATION", 65, 72], ["lower", "ANATOMY_MODIFIER", 89, 94], ["respiratory tract", "ANATOMY", 95, 112], ["Lower", "ANATOMY_MODIFIER", 132, 137], ["Respiratory Tract", "ANATOMY", 138, 155], ["inflammation", "OBSERVATION", 249, 261], ["lower", "ANATOMY_MODIFIER", 269, 274], ["respiratory airways", "ANATOMY", 275, 294]]], ["The level of IL-6 in lower respiratory tract specimens was quantified for all 42 patients.", [["lower respiratory tract specimens", "ANATOMY", 21, 54], ["IL-6", "GENE_OR_GENE_PRODUCT", 13, 17], ["lower", "ORGAN", 21, 26], ["respiratory tract", "ORGAN", 27, 44], ["patients", "ORGANISM", 81, 89], ["IL-6", "PROTEIN", 13, 17], ["patients", "SPECIES", 81, 89], ["IL", "TEST", 13, 15], ["lower", "ANATOMY_MODIFIER", 21, 26], ["respiratory tract", "ANATOMY", 27, 44]]], ["As shown in Figure 1 , significantly higher levels of IL-6 (P \u00bc 0.001) were found in patients with detectable CMV DNA (median, 99.8 pg/ml; range, 9.6-590 pg/ml) compared to patients without it (median, <2 pg/ml; range, <2-1,200 pg/ml).", [["IL-6", "GENE_OR_GENE_PRODUCT", 54, 58], ["patients", "ORGANISM", 85, 93], ["CMV", "ORGANISM", 110, 113], ["DNA", "CELLULAR_COMPONENT", 114, 117], ["patients", "ORGANISM", 173, 181], ["IL-6", "PROTEIN", 54, 58], ["CMV DNA", "DNA", 110, 117], ["patients", "SPECIES", 85, 93], ["patients", "SPECIES", 173, 181], ["CMV", "SPECIES", 110, 113], ["IL", "TEST", 54, 56], ["detectable CMV DNA", "PROBLEM", 99, 117], ["range", "TEST", 139, 144]]], ["No differences in IL-6 levels were found between CMVseropositive patients with no detectable CMV DNA and patients known to be CMV-seronegative (P \u00bc 0.34).DISCUSSIONActive CMV infection is known to occur frequently in adult patients lacking canonical immunosuppression with inflammatory diseases, and may lead to increased morbidity [S\u00f6derberg-Naucl\u00e9r, 2008] .", [["CMV-seronegative", "DISEASE", 126, 142], ["CMV infection", "DISEASE", 171, 184], ["inflammatory diseases", "DISEASE", 273, 294], ["IL-6", "GENE_OR_GENE_PRODUCT", 18, 22], ["patients", "ORGANISM", 65, 73], ["CMV", "ORGANISM", 93, 96], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["patients", "ORGANISM", 105, 113], ["CMV", "ORGANISM", 126, 129], ["CMV", "ORGANISM", 171, 174], ["patients", "ORGANISM", 223, 231], ["IL-6", "PROTEIN", 18, 22], ["CMV DNA", "DNA", 93, 100], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 105, 113], ["patients", "SPECIES", 223, 231], ["CMV", "SPECIES", 93, 96], ["CMV", "SPECIES", 171, 174], ["IL", "TEST", 18, 20], ["detectable CMV DNA", "PROBLEM", 82, 100], ["CMV", "TEST", 126, 129], ["seronegative", "PROBLEM", 130, 142], ["DISCUSSIONActive CMV infection", "PROBLEM", 154, 184], ["canonical immunosuppression", "TREATMENT", 240, 267], ["inflammatory diseases", "PROBLEM", 273, 294], ["increased morbidity", "PROBLEM", 312, 331], ["differences", "OBSERVATION_MODIFIER", 3, 14], ["CMV DNA", "OBSERVATION", 93, 100], ["CMV", "OBSERVATION", 126, 129], ["infection", "OBSERVATION", 175, 184], ["inflammatory", "OBSERVATION_MODIFIER", 273, 285]]], ["The current study investigated whether CMV DNA was detectable in the lower respiratory tract or plasma in children with various underlying bronchopulmonary diseases characterized by the presence of a chronic or recurrent inflammation of the lower respiratory airways.DISCUSSIONOverall, CMV DNA was detected in the lower respiratory tract of 14.2% patients.", [["lower respiratory tract", "ANATOMY", 69, 92], ["plasma", "ANATOMY", 96, 102], ["bronchopulmonary", "ANATOMY", 139, 155], ["lower respiratory airways", "ANATOMY", 241, 266], ["lower respiratory tract", "ANATOMY", 314, 337], ["bronchopulmonary diseases", "DISEASE", 139, 164], ["CMV", "ORGANISM", 39, 42], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["lower", "ORGANISM_SUBDIVISION", 69, 74], ["respiratory tract", "ORGANISM_SUBDIVISION", 75, 92], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["children", "ORGANISM", 106, 114], ["bronchopulmonary", "ORGAN", 139, 155], ["respiratory airways", "MULTI-TISSUE_STRUCTURE", 247, 266], ["CMV", "ORGANISM", 286, 289], ["DNA", "CELLULAR_COMPONENT", 290, 293], ["lower", "ORGANISM_SUBDIVISION", 314, 319], ["respiratory tract", "ORGANISM_SUBDIVISION", 320, 337], ["patients", "ORGANISM", 347, 355], ["CMV DNA", "DNA", 39, 46], ["CMV DNA", "DNA", 286, 293], ["children", "SPECIES", 106, 114], ["patients", "SPECIES", 347, 355], ["CMV", "SPECIES", 39, 42], ["CMV", "SPECIES", 286, 289], ["The current study", "TEST", 0, 17], ["CMV DNA", "PROBLEM", 39, 46], ["the lower respiratory tract", "PROBLEM", 65, 92], ["various underlying bronchopulmonary diseases", "PROBLEM", 120, 164], ["a chronic or recurrent inflammation of the lower respiratory airways", "PROBLEM", 198, 266], ["CMV DNA", "PROBLEM", 286, 293], ["the lower respiratory tract", "TEST", 310, 337], ["lower", "ANATOMY_MODIFIER", 69, 74], ["respiratory tract", "ANATOMY", 75, 92], ["bronchopulmonary", "ANATOMY", 139, 155], ["diseases", "OBSERVATION", 156, 164], ["chronic", "OBSERVATION_MODIFIER", 200, 207], ["recurrent", "OBSERVATION_MODIFIER", 211, 220], ["inflammation", "OBSERVATION", 221, 233], ["lower", "ANATOMY_MODIFIER", 241, 246], ["respiratory airways", "ANATOMY", 247, 266], ["CMV DNA", "OBSERVATION", 286, 293], ["lower", "ANATOMY_MODIFIER", 314, 319], ["respiratory tract", "ANATOMY", 320, 337]]], ["However, this percentage increased to 54.6% when only patients known to be CMV-seropositive at the time of fibrobronchoscopy were considered.", [["patients", "ORGANISM", 54, 62], ["CMV", "ORGANISM", 75, 78], ["patients", "SPECIES", 54, 62], ["CMV", "PROBLEM", 75, 78], ["seropositive", "PROBLEM", 79, 91], ["fibrobronchoscopy", "TREATMENT", 107, 124], ["CMV", "OBSERVATION", 75, 78]]], ["As the lungs are a major site of CMV latency [Cook et al., 2002] , it would be interesting to know the rate of CMV DNA detection in the lower respiratory tract in healthy CMV-seropositive children; It is highly unlikely though this being as high as that found in this study.", [["lungs", "ANATOMY", 7, 12], ["lower respiratory tract", "ANATOMY", 136, 159], ["lungs", "ORGAN", 7, 12], ["CMV", "ORGANISM", 33, 36], ["CMV", "ORGANISM", 111, 114], ["DNA", "CELLULAR_COMPONENT", 115, 118], ["lower", "ORGANISM_SUBDIVISION", 136, 141], ["respiratory tract", "ORGANISM_SUBDIVISION", 142, 159], ["CMV", "ORGANISM", 171, 174], ["children", "ORGANISM", 188, 196], ["children", "SPECIES", 188, 196], ["CMV", "SPECIES", 33, 36], ["CMV", "SPECIES", 111, 114], ["CMV", "SPECIES", 171, 174], ["CMV latency", "PROBLEM", 33, 44], ["CMV DNA detection", "PROBLEM", 111, 128], ["this study", "TEST", 263, 273], ["lungs", "ANATOMY", 7, 12], ["CMV latency", "OBSERVATION", 33, 44], ["lower", "ANATOMY_MODIFIER", 136, 141], ["respiratory tract", "ANATOMY", 142, 159], ["highly unlikely", "UNCERTAINTY", 204, 219]]], ["Involvement of the systemic compartment was demonstrated in two of the six patients with detectable CMV DNA in the lower respiratory tract.", [["systemic compartment", "ANATOMY", 19, 39], ["lower respiratory tract", "ANATOMY", 115, 138], ["patients", "ORGANISM", 75, 83], ["CMV", "ORGANISM", 100, 103], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["lower respiratory", "ORGANISM_SUBDIVISION", 115, 132], ["tract", "ORGANISM_SUBDIVISION", 133, 138], ["CMV DNA", "DNA", 100, 107], ["patients", "SPECIES", 75, 83], ["CMV", "SPECIES", 100, 103], ["detectable CMV DNA in the lower respiratory tract", "PROBLEM", 89, 138], ["systemic compartment", "ANATOMY", 19, 39], ["detectable", "OBSERVATION_MODIFIER", 89, 99], ["CMV DNA", "OBSERVATION", 100, 107], ["lower", "ANATOMY_MODIFIER", 115, 120], ["respiratory tract", "ANATOMY", 121, 138]]], ["Low CMV DNA loads were usually observed in both compartments.", [["compartments", "ANATOMY", 48, 60], ["CMV", "ORGANISM", 4, 7], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["CMV", "SPECIES", 4, 7], ["Low CMV DNA loads", "PROBLEM", 0, 17], ["CMV DNA loads", "OBSERVATION", 4, 17], ["both", "ANATOMY_MODIFIER", 43, 47], ["compartments", "ANATOMY_MODIFIER", 48, 60]]], ["The above scenario resembles that seen in critically ill patients subjected to mechanical ventilation.", [["critically ill", "DISEASE", 42, 56], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["mechanical ventilation", "TREATMENT", 79, 101], ["mechanical ventilation", "OBSERVATION", 79, 101]]], ["In these patients, it was demonstrated that a rapid expansion of CMV-specific functional CD8 \u00fe T cells occurs upon CMV reactivation, keeping viral loads at low levels in both compartments and eventually controlling the episode Blanquer et al., 2011] .DISCUSSIONParticularly noteworthy, was the discovery that CMV DNA was detectable in the lower respiratory tract in two of three CMV-seropositive cystic fibrosis patients.", [["CD8 \u00fe T cells", "ANATOMY", 89, 102], ["lower respiratory tract", "ANATOMY", 339, 362], ["cystic", "ANATOMY", 396, 402], ["cystic fibrosis", "DISEASE", 396, 411], ["patients", "ORGANISM", 9, 17], ["CMV", "ORGANISM", 65, 68], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["CMV", "ORGANISM", 115, 118], ["CMV", "ORGANISM", 309, 312], ["DNA", "CELLULAR_COMPONENT", 313, 316], ["lower", "ORGANISM_SUBDIVISION", 339, 344], ["respiratory tract", "ORGANISM_SUBDIVISION", 345, 362], ["CMV", "ORGANISM", 379, 382], ["patients", "ORGANISM", 412, 420], ["CD8 \u00fe T cells", "CELL_TYPE", 89, 102], ["CMV DNA", "DNA", 309, 316], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 412, 420], ["CMV", "SPECIES", 115, 118], ["CMV", "SPECIES", 309, 312], ["CMV", "SPECIES", 379, 382], ["a rapid expansion of CMV", "PROBLEM", 44, 68], ["T cells", "PROBLEM", 95, 102], ["CMV reactivation", "PROBLEM", 115, 131], ["viral loads", "TEST", 141, 152], ["CMV DNA", "PROBLEM", 309, 316], ["the lower respiratory tract", "PROBLEM", 335, 362], ["three CMV-seropositive cystic fibrosis patients", "PROBLEM", 373, 420], ["CMV", "OBSERVATION", 65, 68], ["CMV reactivation", "OBSERVATION", 115, 131], ["CMV DNA", "OBSERVATION", 309, 316], ["lower", "ANATOMY_MODIFIER", 339, 344], ["respiratory tract", "ANATOMY", 345, 362], ["CMV", "OBSERVATION", 379, 382], ["seropositive", "OBSERVATION_MODIFIER", 383, 395], ["cystic", "OBSERVATION_MODIFIER", 396, 402], ["fibrosis", "OBSERVATION", 403, 411]]], ["The levels of IL-6 in the lower respiratory tract were significantly higher in patients with detectable CMV DNA than in those without it, further supporting the possibility of a bidirectional pathogenic relationship between CMV and inflammation [S\u00f6derberg-Naucl\u00e9r, 2008] .DISCUSSIONHHV-6 replication was also detected in the lower respiratory tract in 50% of patients with active CMV infection.", [["lower respiratory tract", "ANATOMY", 26, 49], ["lower respiratory tract", "ANATOMY", 325, 348], ["inflammation", "DISEASE", 232, 244], ["CMV infection", "DISEASE", 380, 393], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["lower", "ORGANISM_SUBDIVISION", 26, 31], ["respiratory tract", "ORGAN", 32, 49], ["patients", "ORGANISM", 79, 87], ["CMV", "ORGANISM", 104, 107], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["CMV", "ORGANISM", 224, 227], ["lower", "ORGANISM_SUBDIVISION", 325, 330], ["respiratory tract", "ORGANISM_SUBDIVISION", 331, 348], ["patients", "ORGANISM", 359, 367], ["CMV", "ORGANISM", 380, 383], ["IL-6", "PROTEIN", 14, 18], ["CMV DNA", "DNA", 104, 111], ["patients", "SPECIES", 79, 87], ["patients", "SPECIES", 359, 367], ["CMV", "SPECIES", 104, 107], ["CMV", "SPECIES", 224, 227], ["CMV", "SPECIES", 380, 383], ["IL", "TEST", 14, 16], ["detectable CMV DNA", "PROBLEM", 93, 111], ["CMV", "PROBLEM", 224, 227], ["inflammation", "PROBLEM", 232, 244], ["replication", "TREATMENT", 288, 299], ["active CMV infection", "PROBLEM", 373, 393], ["lower", "ANATOMY_MODIFIER", 26, 31], ["respiratory tract", "ANATOMY", 32, 49], ["significantly", "OBSERVATION_MODIFIER", 55, 68], ["higher", "OBSERVATION_MODIFIER", 69, 75], ["CMV DNA", "OBSERVATION", 104, 111], ["CMV", "OBSERVATION", 224, 227], ["lower", "ANATOMY_MODIFIER", 325, 330], ["respiratory tract", "ANATOMY", 331, 348], ["active", "OBSERVATION_MODIFIER", 373, 379], ["CMV infection", "OBSERVATION", 380, 393]]], ["In turn, active HHV-7 infection was detected in 1 out of the 11 CMV-seropositive patients.", [["infection", "DISEASE", 22, 31], ["HHV-7", "ORGANISM", 16, 21], ["CMV", "ORGANISM", 64, 67], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["HHV-7", "SPECIES", 16, 21], ["active HHV", "PROBLEM", 9, 19], ["7 infection", "PROBLEM", 20, 31], ["active", "OBSERVATION_MODIFIER", 9, 15], ["HHV", "OBSERVATION", 16, 19], ["infection", "OBSERVATION", 22, 31]]], ["This is consistent with the assumption that pro-inflammatory states also may trigger reactivation of other beta-herpes viruses which may in turn result in an increase in the net inflammatory state in the lower respiratory tract [Flamand et al., 2010] .DISCUSSIONAs a part of the routine systematic analysis of the lower tract specimens from these patients, PCR analyses were performed to detect respiratory viruses, in addition to conventional bacterial and fungal cultures.", [["lower respiratory tract", "ANATOMY", 204, 227], ["lower tract specimens", "ANATOMY", 314, 335], ["respiratory viruses", "DISEASE", 395, 414], ["beta-herpes viruses", "ORGANISM", 107, 126], ["lower respiratory", "ORGANISM_SUBDIVISION", 204, 221], ["tract", "ORGANISM_SUBDIVISION", 222, 227], ["lower tract specimens", "CANCER", 314, 335], ["patients", "ORGANISM", 347, 355], ["patients", "SPECIES", 347, 355], ["pro-inflammatory states", "PROBLEM", 44, 67], ["other beta-herpes viruses", "PROBLEM", 101, 126], ["the net inflammatory state in the lower respiratory tract", "PROBLEM", 170, 227], ["the routine systematic analysis", "TEST", 275, 306], ["the lower tract specimens", "TEST", 310, 335], ["PCR analyses", "TEST", 357, 369], ["respiratory viruses", "PROBLEM", 395, 414], ["conventional bacterial and fungal cultures", "TEST", 431, 473], ["consistent with", "UNCERTAINTY", 8, 23], ["pro-inflammatory", "OBSERVATION", 44, 60], ["increase", "OBSERVATION_MODIFIER", 158, 166], ["net", "OBSERVATION_MODIFIER", 174, 177], ["inflammatory state", "OBSERVATION", 178, 196], ["lower", "ANATOMY_MODIFIER", 204, 209], ["respiratory tract", "ANATOMY", 210, 227], ["lower tract", "ANATOMY", 314, 325], ["respiratory viruses", "OBSERVATION", 395, 414]]], ["Despite the stable clinical condition of the patients at the time of fibrobronchoscopy, respiratory viruses were detected in almost one-third of the patients.", [["respiratory viruses", "DISEASE", 88, 107], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 149, 157], ["fibrobronchoscopy", "TEST", 69, 86], ["respiratory viruses", "PROBLEM", 88, 107], ["stable", "OBSERVATION_MODIFIER", 12, 18], ["respiratory viruses", "OBSERVATION", 88, 107]]], ["Although contamination with viruses present in the upper respiratory tract could not be formally excluded, this feature is consistent with either a delayed clearance of a recent acute viral infection episode or with a persistent viral infection of the lower respiratory airways.", [["upper respiratory tract", "ANATOMY", 51, 74], ["lower respiratory airways", "ANATOMY", 252, 277], ["viral infection", "DISEASE", 184, 199], ["viral infection", "DISEASE", 229, 244], ["upper respiratory", "ORGANISM_SUBDIVISION", 51, 68], ["tract", "ORGANISM_SUBDIVISION", 69, 74], ["airways", "MULTI-TISSUE_STRUCTURE", 270, 277], ["contamination", "PROBLEM", 9, 22], ["viruses", "PROBLEM", 28, 35], ["the upper respiratory tract", "PROBLEM", 47, 74], ["a recent acute viral infection episode", "PROBLEM", 169, 207], ["a persistent viral infection of the lower respiratory airways", "PROBLEM", 216, 277], ["contamination", "OBSERVATION", 9, 22], ["viruses", "OBSERVATION", 28, 35], ["upper", "ANATOMY_MODIFIER", 51, 56], ["respiratory tract", "ANATOMY", 57, 74], ["could not be formally excluded", "UNCERTAINTY", 75, 105], ["consistent with", "UNCERTAINTY", 123, 138], ["delayed", "OBSERVATION_MODIFIER", 148, 155], ["clearance", "OBSERVATION", 156, 165], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["viral", "OBSERVATION_MODIFIER", 184, 189], ["infection", "OBSERVATION", 190, 199], ["persistent", "OBSERVATION_MODIFIER", 218, 228], ["viral", "OBSERVATION_MODIFIER", 229, 234], ["infection", "OBSERVATION", 235, 244], ["lower", "ANATOMY_MODIFIER", 252, 257], ["respiratory airways", "ANATOMY", 258, 277]]], ["The plausibility of the latter explanation is supported by data obtained in experimental animal models, and also in humans for respiratory syncytial virus, rhinovirus, and human metapneumovirus infections [Schwarze et al., 2004; Liu et al., 2009] .", [["respiratory syncytial virus", "DISEASE", 127, 154], ["rhinovirus", "DISEASE", 156, 166], ["human metapneumovirus infections", "DISEASE", 172, 204], ["humans", "ORGANISM", 116, 122], ["respiratory syncytial virus", "ORGANISM", 127, 154], ["rhinovirus", "ORGANISM", 156, 166], ["human", "ORGANISM", 172, 177], ["metapneumovirus", "ORGANISM", 178, 193], ["humans", "SPECIES", 116, 122], ["human", "SPECIES", 172, 177], ["metapneumovirus", "SPECIES", 178, 193], ["humans", "SPECIES", 116, 122], ["respiratory syncytial virus", "SPECIES", 127, 154], ["human metapneumovirus", "SPECIES", 172, 193], ["respiratory syncytial virus", "PROBLEM", 127, 154], ["rhinovirus", "PROBLEM", 156, 166], ["human metapneumovirus infections", "PROBLEM", 172, 204], ["respiratory syncytial", "ANATOMY", 127, 148], ["metapneumovirus infections", "OBSERVATION", 178, 204]]], ["Persistent replication of these viruses in the lower respiratory tract induces inflammation [Papadopoulos et al., 2000] , and may thereby promote local CMV reactivation.", [["lower respiratory tract", "ANATOMY", 47, 70], ["inflammation", "DISEASE", 79, 91], ["lower respiratory", "ORGANISM_SUBDIVISION", 47, 64], ["tract", "ORGANISM_SUBDIVISION", 65, 70], ["CMV", "ORGANISM", 152, 155], ["CMV", "SPECIES", 152, 155], ["these viruses", "PROBLEM", 26, 39], ["the lower respiratory tract", "PROBLEM", 43, 70], ["inflammation", "PROBLEM", 79, 91], ["local CMV reactivation", "TREATMENT", 146, 168], ["replication", "OBSERVATION", 11, 22], ["these viruses", "OBSERVATION", 26, 39], ["lower", "ANATOMY_MODIFIER", 47, 52], ["respiratory tract", "ANATOMY", 53, 70], ["inflammation", "OBSERVATION", 79, 91], ["local CMV reactivation", "OBSERVATION", 146, 168]]], ["In turn, CMV may also potentiate respiratory virus replication in the lower respiratory tract by virtue of its immunosuppressive capacity [Solano and Navarro, 2010] .", [["lower respiratory tract", "ANATOMY", 70, 93], ["CMV", "ORGANISM", 9, 12], ["respiratory virus", "ORGANISM", 33, 50], ["lower", "ORGANISM_SUBDIVISION", 70, 75], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["CMV", "SPECIES", 9, 12], ["CMV", "TREATMENT", 9, 12], ["respiratory virus replication", "PROBLEM", 33, 62], ["its immunosuppressive capacity", "TREATMENT", 107, 137], ["Solano and Navarro", "TREATMENT", 139, 157], ["CMV", "OBSERVATION", 9, 12], ["respiratory virus", "OBSERVATION", 33, 50], ["lower", "ANATOMY_MODIFIER", 70, 75], ["respiratory tract", "ANATOMY", 76, 93]]], ["Nevertheless, no significant association was found between the presence of CMV DNA in the lower respiratory tract and the occurrence of respiratory viruses.", [["lower respiratory tract", "ANATOMY", 90, 113], ["respiratory", "ANATOMY", 136, 147], ["respiratory viruses", "DISEASE", 136, 155], ["CMV", "ORGANISM", 75, 78], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["lower", "ORGANISM_SUBDIVISION", 90, 95], ["respiratory tract", "ORGANISM_SUBDIVISION", 96, 113], ["CMV DNA", "DNA", 75, 82], ["CMV", "SPECIES", 75, 78], ["CMV DNA in the lower respiratory tract", "PROBLEM", 75, 113], ["respiratory viruses", "PROBLEM", 136, 155], ["CMV DNA", "OBSERVATION", 75, 82], ["lower", "ANATOMY_MODIFIER", 90, 95], ["respiratory tract", "ANATOMY", 96, 113], ["respiratory viruses", "OBSERVATION", 136, 155]]], ["Likewise, the occurrence of active CMV infection in critically ill patients has been related to an increased incidence of bacterial and fungal super infection [Jaber et al., 2005; Chiche et al., 2009] .", [["CMV infection", "DISEASE", 35, 48], ["critically ill", "DISEASE", 52, 66], ["bacterial and fungal super infection", "DISEASE", 122, 158], ["CMV", "ORGANISM", 35, 38], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["CMV", "SPECIES", 35, 38], ["active CMV infection", "PROBLEM", 28, 48], ["bacterial and fungal super infection", "PROBLEM", 122, 158], ["active", "OBSERVATION_MODIFIER", 28, 34], ["CMV", "OBSERVATION_MODIFIER", 35, 38], ["infection", "OBSERVATION", 39, 48], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["bacterial", "OBSERVATION_MODIFIER", 122, 131], ["fungal", "OBSERVATION_MODIFIER", 136, 142], ["super", "OBSERVATION_MODIFIER", 143, 148], ["infection", "OBSERVATION", 149, 158]]], ["The current investigation also found no association between the presence of CMV DNA in the lower respiratory tract and the occurrence of bacterial or fungal species.", [["lower respiratory tract", "ANATOMY", 91, 114], ["CMV", "ORGANISM", 76, 79], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["lower", "ORGANISM_SUBDIVISION", 91, 96], ["respiratory tract", "ORGANISM_SUBDIVISION", 97, 114], ["CMV DNA", "DNA", 76, 83], ["CMV", "SPECIES", 76, 79], ["The current investigation", "TEST", 0, 25], ["CMV DNA in the lower respiratory tract", "PROBLEM", 76, 114], ["bacterial or fungal species", "PROBLEM", 137, 164], ["CMV DNA", "OBSERVATION", 76, 83], ["lower", "ANATOMY_MODIFIER", 91, 96], ["respiratory tract", "ANATOMY", 97, 114], ["bacterial", "OBSERVATION_MODIFIER", 137, 146], ["fungal species", "OBSERVATION", 150, 164]]], ["However, this study was not specifically designed to investigate these potential pathogenic interactions, and so no definitive conclusions may be drawn on this issue.DISCUSSIONThe current study had several limitations.", [["this study", "TEST", 9, 19], ["current study", "TEST", 180, 193]]], ["Firstly, this was a cross-sectional study with a limited sample size.", [["a cross-sectional study", "TEST", 18, 41], ["size", "OBSERVATION_MODIFIER", 64, 68]]], ["Secondly, it included a highly heterogeneous cohort.", [["highly", "OBSERVATION_MODIFIER", 24, 30], ["heterogeneous", "OBSERVATION_MODIFIER", 31, 44], ["cohort", "OBSERVATION", 45, 51]]], ["Thirdly, given its retrospective nature, the CMV-serostatus was unknown for a large number of patients.", [["CMV", "ORGANISM", 45, 48], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["the CMV", "TEST", 41, 48], ["CMV", "OBSERVATION", 45, 48], ["large", "OBSERVATION_MODIFIER", 78, 83]]], ["Fourthly, although cell supernatants were used for PCR analyses, the possibility that the detection of CMV DNA reflected a latent rather than an active viral infection in some patients, specially those with low CMV DNA loads, could not be formally ruled out, as neither detection of viral mRNA nor inoculation of conventional cell cultures for recovery of live virus were performed.", [["cell supernatants", "ANATOMY", 19, 36], ["cell cultures", "ANATOMY", 326, 339], ["viral infection", "DISEASE", 152, 167], ["cell", "CELL", 19, 23], ["CMV", "ORGANISM", 103, 106], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["patients", "ORGANISM", 176, 184], ["CMV", "ORGANISM", 211, 214], ["DNA", "CELLULAR_COMPONENT", 215, 218], ["cell cultures", "CELL", 326, 339], ["CMV DNA", "DNA", 103, 110], ["viral mRNA", "RNA", 283, 293], ["conventional cell cultures", "CELL_LINE", 313, 339], ["patients", "SPECIES", 176, 184], ["CMV", "SPECIES", 103, 106], ["CMV", "SPECIES", 211, 214], ["cell supernatants", "PROBLEM", 19, 36], ["PCR analyses", "TEST", 51, 63], ["CMV DNA", "PROBLEM", 103, 110], ["an active viral infection", "PROBLEM", 142, 167], ["low CMV DNA loads", "PROBLEM", 207, 224], ["viral mRNA", "PROBLEM", 283, 293], ["conventional cell cultures", "TEST", 313, 339], ["live virus", "PROBLEM", 356, 366], ["active", "OBSERVATION_MODIFIER", 145, 151], ["viral", "OBSERVATION_MODIFIER", 152, 157], ["infection", "OBSERVATION", 158, 167]]], ["Nevertheless, the data reported warrant further prospective observational studies to confirm the findings presented, explore the possibility of the existence of pathogenetic interactions between CMV, HHV-6, and respiratory viruses, or bacterial and fungal species, colonizing the lower respiratory airways of these patients and assess the potential impact of CMV replication in the lower respiratory tract on the clinical course and outcome of the patients.", [["lower respiratory airways", "ANATOMY", 280, 305], ["lower respiratory tract", "ANATOMY", 382, 405], ["respiratory viruses", "DISEASE", 211, 230], ["CMV", "ORGANISM", 195, 198], ["HHV-6", "ORGANISM", 200, 205], ["respiratory viruses", "ORGANISM", 211, 230], ["respiratory airways", "MULTI-TISSUE_STRUCTURE", 286, 305], ["patients", "ORGANISM", 315, 323], ["CMV", "ORGANISM", 359, 362], ["lower", "ORGANISM_SUBDIVISION", 382, 387], ["respiratory tract", "ORGANISM_SUBDIVISION", 388, 405], ["patients", "ORGANISM", 448, 456], ["patients", "SPECIES", 315, 323], ["patients", "SPECIES", 448, 456], ["CMV", "SPECIES", 195, 198], ["HHV-6", "SPECIES", 200, 205], ["CMV", "SPECIES", 359, 362], ["further prospective observational studies", "TEST", 40, 81], ["pathogenetic interactions", "PROBLEM", 161, 186], ["CMV", "PROBLEM", 195, 198], ["HHV", "TEST", 200, 203], ["respiratory viruses", "PROBLEM", 211, 230], ["bacterial and fungal species", "PROBLEM", 235, 263], ["CMV replication", "PROBLEM", 359, 374], ["respiratory", "ANATOMY", 211, 222], ["viruses", "OBSERVATION", 223, 230], ["bacterial", "OBSERVATION_MODIFIER", 235, 244], ["fungal species", "OBSERVATION", 249, 263], ["lower", "ANATOMY_MODIFIER", 280, 285], ["respiratory airways", "ANATOMY", 286, 305], ["CMV replication", "OBSERVATION", 359, 374], ["lower", "ANATOMY_MODIFIER", 382, 387], ["respiratory tract", "ANATOMY", 388, 405]]], ["In light of the data presented, children with cystic fibrosis should be the primary focus of these studies.", [["cystic", "ANATOMY", 46, 52], ["cystic fibrosis", "DISEASE", 46, 61], ["children", "ORGANISM", 32, 40], ["children", "SPECIES", 32, 40], ["cystic fibrosis", "PROBLEM", 46, 61], ["these studies", "TEST", 93, 106], ["cystic", "OBSERVATION_MODIFIER", 46, 52], ["fibrosis", "OBSERVATION", 53, 61]]]], "PMC7102005": [["IntroductionInvasive bacterial infections are common complications following hematopoietic cell transplantation (HSCT) and are associated with significant morbidity and mortality.", [["hematopoietic cell", "ANATOMY", 77, 95], ["bacterial infections", "DISEASE", 21, 41], ["hematopoietic cell", "CELL", 77, 95], ["Invasive bacterial infections", "PROBLEM", 12, 41], ["common complications", "PROBLEM", 46, 66], ["hematopoietic cell transplantation", "TREATMENT", 77, 111], ["significant morbidity", "PROBLEM", 143, 164], ["Invasive", "OBSERVATION_MODIFIER", 12, 20], ["bacterial infections", "OBSERVATION", 21, 41], ["hematopoietic cell transplantation", "OBSERVATION", 77, 111], ["significant", "OBSERVATION_MODIFIER", 143, 154], ["morbidity", "OBSERVATION", 155, 164]]], ["During the early post-transplant period, HSCT recipients have two critical risk factors for invasive infections: prolonged neutropenia and breaks in the mucocutaneous barrier, resulting from the HSCT preparative regimen and from frequent vascular access required for patient care.", [["mucocutaneous barrier", "ANATOMY", 153, 174], ["vascular", "ANATOMY", 238, 246], ["infections", "DISEASE", 101, 111], ["neutropenia", "DISEASE", 123, 134], ["recipients", "ORGANISM", 46, 56], ["vascular", "MULTI-TISSUE_STRUCTURE", 238, 246], ["patient", "ORGANISM", 267, 274], ["patient", "SPECIES", 267, 274], ["HSCT recipients", "TREATMENT", 41, 56], ["invasive infections", "PROBLEM", 92, 111], ["prolonged neutropenia", "PROBLEM", 113, 134], ["the mucocutaneous barrier", "TREATMENT", 149, 174], ["the HSCT preparative regimen", "TREATMENT", 191, 219], ["frequent vascular access", "TREATMENT", 229, 253], ["patient care", "TREATMENT", 267, 279], ["invasive", "OBSERVATION_MODIFIER", 92, 100], ["infections", "OBSERVATION", 101, 111], ["prolonged", "OBSERVATION_MODIFIER", 113, 122], ["neutropenia", "OBSERVATION", 123, 134], ["mucocutaneous barrier", "OBSERVATION", 153, 174], ["vascular", "ANATOMY", 238, 246]]], ["The use of long-term central venous catheters (CVC) has become an essential part of the management of bone marrow transplant recipients and its importance in the pathogenesis of bacterial, as well as invasive fungal blood stream infections is well established [1\u20133].", [["venous", "ANATOMY", 29, 35], ["bone marrow", "ANATOMY", 102, 113], ["blood", "ANATOMY", 216, 221], ["fungal blood stream infections", "DISEASE", 209, 239], ["central venous catheters", "MULTI-TISSUE_STRUCTURE", 21, 45], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 102, 113], ["blood", "ORGANISM_SUBSTANCE", 216, 221], ["long-term central venous catheters (CVC", "TREATMENT", 11, 50], ["the management", "TREATMENT", 84, 98], ["bone marrow transplant recipients", "TREATMENT", 102, 135], ["bacterial", "PROBLEM", 178, 187], ["invasive fungal blood stream infections", "PROBLEM", 200, 239], ["central", "ANATOMY_MODIFIER", 21, 28], ["venous", "ANATOMY", 29, 35], ["catheters", "OBSERVATION", 36, 45], ["bone", "ANATOMY", 102, 106], ["marrow transplant", "OBSERVATION", 107, 124], ["bacterial", "OBSERVATION", 178, 187]]], ["A recent German multicenter study of a total of 1899 patients who had undergone bone marrow transplant or peripheral blood stem cell transplant demonstrated incidences of bloodstream infections (BSIs) of 22.4 BSIs per 100 patients following allogeneic transplantation and 18.2 BSIs per 100 patients following autologous transplantation.", [["bone marrow", "ANATOMY", 80, 91], ["peripheral blood stem cell", "ANATOMY", 106, 132], ["bloodstream", "ANATOMY", 171, 182], ["bloodstream infections", "DISEASE", 171, 193], ["BSIs", "DISEASE", 195, 199], ["BSIs", "DISEASE", 209, 213], ["BSIs", "DISEASE", 277, 281], ["patients", "ORGANISM", 53, 61], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 80, 91], ["peripheral blood stem cell", "CELL", 106, 132], ["patients", "ORGANISM", 222, 230], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 222, 230], ["patients", "SPECIES", 290, 298], ["A recent German multicenter study", "TEST", 0, 33], ["bone marrow transplant", "TREATMENT", 80, 102], ["peripheral blood stem cell transplant", "TREATMENT", 106, 143], ["bloodstream infections", "PROBLEM", 171, 193], ["allogeneic transplantation", "TREATMENT", 241, 267], ["BSIs", "PROBLEM", 277, 281], ["autologous transplantation", "TREATMENT", 309, 335], ["bone", "ANATOMY", 80, 84], ["marrow", "ANATOMY", 85, 91], ["transplant", "OBSERVATION", 92, 102], ["peripheral", "ANATOMY_MODIFIER", 106, 116], ["blood", "ANATOMY", 117, 122], ["stem cell transplant", "OBSERVATION", 123, 143], ["bloodstream infections", "OBSERVATION", 171, 193]]], ["The majority (57%) of pathogens associated with BSI were coagulase-negative staphylococci [4].IntroductionStenotrophomonas maltophilia is a glucose nonfermentative Gram-negative bacillus previously known as Pseudomonas maltophilia or Xanthomonas maltophilia, the sole member of the genus Stenotrophomonas.", [["BSI", "DISEASE", 48, 51], ["Stenotrophomonas maltophilia", "DISEASE", 106, 134], ["glucose", "CHEMICAL", 140, 147], ["Pseudomonas maltophilia or Xanthomonas maltophilia", "DISEASE", 207, 257], ["glucose", "CHEMICAL", 140, 147], ["Stenotrophomonas maltophilia", "ORGANISM", 106, 134], ["glucose", "SIMPLE_CHEMICAL", 140, 147], ["Gram", "GENE_OR_GENE_PRODUCT", 164, 168], ["Pseudomonas maltophilia", "ORGANISM", 207, 230], ["Xanthomonas maltophilia", "ORGANISM", 234, 257], ["Stenotrophomonas maltophilia", "SPECIES", 106, 134], ["Pseudomonas maltophilia", "SPECIES", 207, 230], ["Xanthomonas maltophilia", "SPECIES", 234, 257], ["Stenotrophomonas maltophilia", "SPECIES", 106, 134], ["Pseudomonas maltophilia", "SPECIES", 207, 230], ["Xanthomonas maltophilia", "SPECIES", 234, 257], ["pathogens", "PROBLEM", 22, 31], ["BSI", "TEST", 48, 51], ["coagulase", "TEST", 57, 66], ["staphylococci", "PROBLEM", 76, 89], ["IntroductionStenotrophomonas maltophilia", "PROBLEM", 94, 134], ["a glucose nonfermentative Gram", "TEST", 138, 168], ["Pseudomonas maltophilia", "PROBLEM", 207, 230], ["Xanthomonas maltophilia", "PROBLEM", 234, 257], ["the genus Stenotrophomonas", "PROBLEM", 278, 304], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["negative staphylococci", "OBSERVATION", 67, 89], ["maltophilia", "OBSERVATION", 123, 134], ["negative bacillus", "OBSERVATION", 169, 186], ["Xanthomonas maltophilia", "OBSERVATION", 234, 257], ["genus Stenotrophomonas", "OBSERVATION", 282, 304]]], ["Despite reports in the earlier literature that Stenotrophomonas was of strictly limited pathogenicity, S. maltophilia has risen to prominence over the last two decades as an important nosocomial pathogen associated with significant case/fatality ratios in certain patient populations, especially in severely debilitated or immunosuppressed patients [5].", [["S. maltophilia", "DISEASE", 103, 117], ["S. maltophilia", "ORGANISM", 103, 117], ["patient", "ORGANISM", 264, 271], ["patients", "ORGANISM", 340, 348], ["S. maltophilia", "SPECIES", 103, 117], ["patient", "SPECIES", 264, 271], ["patients", "SPECIES", 340, 348], ["S. maltophilia", "SPECIES", 103, 117], ["Stenotrophomonas", "PROBLEM", 47, 63], ["strictly limited pathogenicity", "PROBLEM", 71, 101], ["S. maltophilia", "PROBLEM", 103, 117], ["an important nosocomial pathogen", "PROBLEM", 171, 203], ["significant case/fatality ratios", "PROBLEM", 220, 252], ["Stenotrophomonas", "OBSERVATION", 47, 63], ["maltophilia", "OBSERVATION", 106, 117], ["prominence", "OBSERVATION_MODIFIER", 131, 141]]], ["Therefore, HSCT recipients may be at particularly high risk for severe infections caused by S. maltophilia.IntroductionThe objective of this study was to investigate the incidence, clinical characteristics, treatment, antibiotic susceptibility patterns and outcomes of HSCT recipients with S. maltophilia infections in a single center in Israel.Patient identification and data collection ::: Materials and methodsThis retrospective cohort study included all patients who underwent HSCT at the Chaim Sheba Medical Center, Israel, during a 4 year period.", [["infections", "DISEASE", 71, 81], ["S. maltophilia", "DISEASE", 92, 106], ["S. maltophilia infections", "DISEASE", 290, 315], ["recipients", "ORGANISM", 16, 26], ["S. maltophilia", "ORGANISM", 92, 106], ["S. maltophilia", "ORGANISM", 290, 304], ["patients", "ORGANISM", 458, 466], ["S. maltophilia", "SPECIES", 92, 106], ["S. maltophilia", "SPECIES", 290, 304], ["Patient", "SPECIES", 345, 352], ["patients", "SPECIES", 458, 466], ["S. maltophilia", "SPECIES", 92, 106], ["S. maltophilia", "SPECIES", 290, 304], ["HSCT recipients", "TREATMENT", 11, 26], ["severe infections", "PROBLEM", 64, 81], ["S. maltophilia", "PROBLEM", 92, 106], ["this study", "TEST", 136, 146], ["treatment", "TREATMENT", 207, 216], ["antibiotic susceptibility patterns", "TREATMENT", 218, 252], ["HSCT recipients", "TREATMENT", 269, 284], ["S. maltophilia infections", "PROBLEM", 290, 315], ["This retrospective cohort study", "TEST", 413, 444], ["severe", "OBSERVATION_MODIFIER", 64, 70], ["infections", "OBSERVATION", 71, 81], ["maltophilia", "OBSERVATION", 95, 106], ["maltophilia infections", "OBSERVATION", 293, 315]]], ["Patients with invasive infections caused by S. maltophilia were retrospectively identified from patients\u2019 records and from the computerized microbiological database of the hospital.", [["infections", "DISEASE", 23, 33], ["Patients", "ORGANISM", 0, 8], ["S. maltophilia", "ORGANISM", 44, 58], ["patients", "ORGANISM", 96, 104], ["Patients", "SPECIES", 0, 8], ["S. maltophilia", "SPECIES", 44, 58], ["patients", "SPECIES", 96, 104], ["S. maltophilia", "SPECIES", 44, 58], ["invasive infections", "PROBLEM", 14, 33], ["S. maltophilia", "PROBLEM", 44, 58], ["invasive", "OBSERVATION_MODIFIER", 14, 22], ["infections", "OBSERVATION", 23, 33], ["maltophilia", "OBSERVATION", 47, 58]]], ["Data from the medical charts were recorded and analyzed including demographic features, indication for transplantation, conditioning regimens (myeloablative vs. reduced intensity), source of transplanted graft (autologous vs. allogeneic), presence and duration of neutropenia (neutrophils <500/mcl), bacterial isolation site, number of positive cultures, concomitant isolates of other infectious agents, presence of mucositis, clinical presentation (e.g. fever, rigors, septic shock, hypoxemia), recent antimicrobial therapy during the month before the present infection by S. maltophilia, antimicrobial susceptibility, medical interventions and patients\u2019 outcomes.", [["graft", "ANATOMY", 204, 209], ["neutrophils", "ANATOMY", 277, 288], ["site", "ANATOMY", 320, 324], ["cultures", "ANATOMY", 345, 353], ["neutropenia", "DISEASE", 264, 275], ["mucositis", "DISEASE", 416, 425], ["fever", "DISEASE", 455, 460], ["rigors", "DISEASE", 462, 468], ["septic shock", "DISEASE", 470, 482], ["hypoxemia", "DISEASE", 484, 493], ["infection", "DISEASE", 561, 570], ["S. maltophilia", "DISEASE", 574, 588], ["graft", "TISSUE", 204, 209], ["neutrophils", "CELL", 277, 288], ["S. maltophilia", "ORGANISM", 574, 588], ["patients", "ORGANISM", 646, 654], ["neutrophils", "CELL_TYPE", 277, 288], ["S. maltophilia", "SPECIES", 574, 588], ["patients", "SPECIES", 646, 654], ["S. maltophilia", "SPECIES", 574, 588], ["transplantation", "TREATMENT", 103, 118], ["conditioning regimens", "TREATMENT", 120, 141], ["reduced intensity", "PROBLEM", 161, 178], ["transplanted graft", "TREATMENT", 191, 209], ["neutropenia", "PROBLEM", 264, 275], ["neutrophils", "TEST", 277, 288], ["bacterial isolation site", "PROBLEM", 300, 324], ["positive cultures", "PROBLEM", 336, 353], ["other infectious agents", "TREATMENT", 379, 402], ["mucositis", "PROBLEM", 416, 425], ["clinical presentation", "PROBLEM", 427, 448], ["fever", "PROBLEM", 455, 460], ["rigors", "PROBLEM", 462, 468], ["septic shock", "PROBLEM", 470, 482], ["hypoxemia", "PROBLEM", 484, 493], ["recent antimicrobial therapy", "TREATMENT", 496, 524], ["the present infection", "PROBLEM", 549, 570], ["S. maltophilia", "PROBLEM", 574, 588], ["antimicrobial susceptibility", "PROBLEM", 590, 618], ["medical interventions", "TREATMENT", 620, 641], ["intensity", "OBSERVATION_MODIFIER", 169, 178], ["transplanted", "OBSERVATION_MODIFIER", 191, 203], ["graft", "OBSERVATION", 204, 209], ["bacterial isolation", "OBSERVATION", 300, 319], ["mucositis", "OBSERVATION", 416, 425], ["septic shock", "OBSERVATION", 470, 482], ["antimicrobial therapy", "OBSERVATION", 503, 524], ["infection", "OBSERVATION", 561, 570]]], ["In our center antibacterial prophylaxis with fluoroquinolones following HSCT was not routinely administered.Definitions ::: Materials and methodsAn episode of S. maltophilia bacteremia was defined as one or more positive blood cultures for S. maltophilia with clinical symptoms and signs of infection.", [["blood", "ANATOMY", 221, 226], ["fluoroquinolones", "CHEMICAL", 45, 61], ["S. maltophilia bacteremia", "DISEASE", 159, 184], ["S. maltophilia", "DISEASE", 240, 254], ["infection", "DISEASE", 291, 300], ["fluoroquinolones", "CHEMICAL", 45, 61], ["fluoroquinolones", "SIMPLE_CHEMICAL", 45, 61], ["S. maltophilia", "ORGANISM", 159, 173], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["S. maltophilia", "ORGANISM", 240, 254], ["S. maltophilia", "SPECIES", 159, 173], ["S. maltophilia", "SPECIES", 240, 254], ["S. maltophilia", "SPECIES", 159, 173], ["S. maltophilia", "SPECIES", 240, 254], ["our center antibacterial prophylaxis", "TREATMENT", 3, 39], ["fluoroquinolones", "TREATMENT", 45, 61], ["HSCT", "TREATMENT", 72, 76], ["S. maltophilia bacteremia", "PROBLEM", 159, 184], ["blood cultures", "TEST", 221, 235], ["S. maltophilia", "PROBLEM", 240, 254], ["clinical symptoms", "PROBLEM", 260, 277], ["infection", "PROBLEM", 291, 300], ["antibacterial prophylaxis", "OBSERVATION", 14, 39], ["maltophilia", "OBSERVATION_MODIFIER", 162, 173], ["bacteremia", "OBSERVATION", 174, 184], ["infection", "OBSERVATION", 291, 300]]], ["Isolations of coagulase-negative staphylococci or Gram-positive bacilli in a single bottle were considered contaminants and excluded from this analysis.Definitions ::: Materials and methodsStenotrophomonas maltophilia infections other than bacteremia were defined as invasive in cases of isolation from tissue biopsy, broncho-alveolar lavage or sinus lavage.Definitions ::: Materials and methodsPrior antibiotic therapy was defined as administration of intravenous antibiotics for more than 24 h within 30 days before the onset of the S. maltophilia infection.Microbiology ::: Materials and methodsBlood culture samples were processed by the Bactec 9240 microbial system (Becton\u2013Dickinson, Franklin Lakes, NJ, USA).", [["tissue", "ANATOMY", 303, 309], ["broncho-alveolar lavage", "ANATOMY", 318, 341], ["sinus lavage", "ANATOMY", 345, 357], ["intravenous", "ANATOMY", 453, 464], ["Blood culture samples", "ANATOMY", 598, 619], ["Stenotrophomonas maltophilia infections", "DISEASE", 189, 228], ["bacteremia", "DISEASE", 240, 250], ["S. maltophilia infection", "DISEASE", 535, 559], ["coagulase-negative staphylococci", "GENE_OR_GENE_PRODUCT", 14, 46], ["Stenotrophomonas maltophilia", "ORGANISM", 189, 217], ["tissue biopsy", "MULTI-TISSUE_STRUCTURE", 303, 316], ["alveolar lavage", "MULTI-TISSUE_STRUCTURE", 326, 341], ["sinus lavage", "MULTI-TISSUE_STRUCTURE", 345, 357], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 453, 464], ["S. maltophilia", "ORGANISM", 535, 549], ["Blood culture samples", "ORGANISM_SUBSTANCE", 598, 619], ["S. maltophilia", "SPECIES", 535, 549], ["Stenotrophomonas maltophilia", "SPECIES", 189, 217], ["S. maltophilia", "SPECIES", 535, 549], ["coagulase", "TEST", 14, 23], ["staphylococci", "PROBLEM", 33, 46], ["Gram-positive bacilli", "PROBLEM", 50, 71], ["this analysis", "TEST", 138, 151], ["Materials", "TREATMENT", 168, 177], ["methodsStenotrophomonas maltophilia infections", "PROBLEM", 182, 228], ["bacteremia", "PROBLEM", 240, 250], ["tissue biopsy", "TEST", 303, 316], ["broncho-alveolar lavage", "TEST", 318, 341], ["sinus lavage", "TREATMENT", 345, 357], ["Materials", "TREATMENT", 374, 383], ["methodsPrior antibiotic therapy", "TREATMENT", 388, 419], ["intravenous antibiotics", "TREATMENT", 453, 476], ["the S. maltophilia infection", "PROBLEM", 531, 559], ["Blood culture samples", "TEST", 598, 619], ["the Bactec", "TEST", 638, 648], ["negative staphylococci", "OBSERVATION", 24, 46], ["positive bacilli", "OBSERVATION", 55, 71], ["Stenotrophomonas", "OBSERVATION_MODIFIER", 189, 205], ["maltophilia", "OBSERVATION", 206, 217], ["bacteremia", "OBSERVATION", 240, 250], ["tissue", "ANATOMY", 303, 309], ["biopsy", "OBSERVATION", 310, 316], ["alveolar", "ANATOMY", 326, 334], ["lavage", "OBSERVATION", 335, 341], ["sinus", "ANATOMY", 345, 350], ["lavage", "OBSERVATION", 351, 357], ["maltophilia", "OBSERVATION_MODIFIER", 538, 549], ["infection", "OBSERVATION", 550, 559]]], ["Susceptibility to antibiotics was tested by the disk diffusion method on Mueller\u2013Hinton agar, according to Clinical and Laboratory Standards Institute (formerly NCCLS) procedures.Clinical settings ::: Patient characteristics ::: ResultsStenotrophomonas maltophilia infections were detected in three clinical settings: as a complication of prolonged neutropenia (n = 9), as a CVC-related non-neutropenic infection (n = 8) and as a respiratory tract infection (n = 2).Clinical settings ::: Patient characteristics ::: ResultsFour patients presented with septic shock and/or multi-organ failure.", [["respiratory tract", "ANATOMY", 430, 447], ["multi-organ", "ANATOMY", 572, 583], ["ResultsStenotrophomonas maltophilia infections", "DISEASE", 229, 275], ["neutropenia", "DISEASE", 349, 360], ["non-neutropenic infection", "DISEASE", 387, 412], ["respiratory tract infection", "DISEASE", 430, 457], ["septic shock", "DISEASE", 552, 564], ["multi-organ failure", "DISEASE", 572, 591], ["ResultsStenotrophomonas maltophilia", "ORGANISM", 229, 264], ["patients", "ORGANISM", 528, 536], ["Patient", "SPECIES", 201, 208], ["Patient", "SPECIES", 488, 495], ["patients", "SPECIES", 528, 536], ["ResultsStenotrophomonas maltophilia", "SPECIES", 229, 264], ["antibiotics", "TREATMENT", 18, 29], ["ResultsStenotrophomonas maltophilia infections", "PROBLEM", 229, 275], ["prolonged neutropenia", "PROBLEM", 339, 360], ["a CVC", "PROBLEM", 373, 378], ["non-neutropenic infection", "PROBLEM", 387, 412], ["a respiratory tract infection", "PROBLEM", 428, 457], ["septic shock", "PROBLEM", 552, 564], ["multi-organ failure", "PROBLEM", 572, 591], ["prolonged", "OBSERVATION_MODIFIER", 339, 348], ["neutropenia", "OBSERVATION", 349, 360], ["CVC", "ANATOMY", 375, 378], ["non-neutropenic", "OBSERVATION_MODIFIER", 387, 402], ["infection", "OBSERVATION", 403, 412], ["respiratory tract", "ANATOMY", 430, 447], ["infection", "OBSERVATION", 448, 457], ["septic shock", "OBSERVATION", 552, 564], ["multi-organ", "ANATOMY", 572, 583], ["failure", "OBSERVATION", 584, 591]]], ["Eight patients had concomitant mucositis, one had severe intestinal graft-versus-host disease (GVHD) and one had a paralytic ileus.Clinical settings ::: Patient characteristics ::: ResultsSeventeen patients had a CVC at the time of infection, of these 15 were bacteremic and two had other invasive infections.Clinical settings ::: Patient characteristics ::: ResultsEight patients, all non-neutropenic, developed bacteremia shortly after CVC manipulation by the nursing team.", [["intestinal", "ANATOMY", 57, 67], ["mucositis", "DISEASE", 31, 40], ["intestinal graft-versus-host disease", "DISEASE", 57, 93], ["GVHD", "DISEASE", 95, 99], ["paralytic ileus", "DISEASE", 115, 130], ["infection", "DISEASE", 232, 241], ["bacteremic", "DISEASE", 260, 270], ["infections", "DISEASE", 298, 308], ["bacteremia", "DISEASE", 413, 423], ["patients", "ORGANISM", 6, 14], ["intestinal", "ORGAN", 57, 67], ["patients", "ORGANISM", 198, 206], ["patients", "ORGANISM", 372, 380], ["patients", "SPECIES", 6, 14], ["Patient", "SPECIES", 153, 160], ["patients", "SPECIES", 198, 206], ["Patient", "SPECIES", 331, 338], ["patients", "SPECIES", 372, 380], ["concomitant mucositis", "PROBLEM", 19, 40], ["severe intestinal graft", "PROBLEM", 50, 73], ["host disease", "PROBLEM", 81, 93], ["GVHD", "PROBLEM", 95, 99], ["a paralytic ileus", "PROBLEM", 113, 130], ["a CVC", "TREATMENT", 211, 216], ["infection", "PROBLEM", 232, 241], ["bacteremic", "PROBLEM", 260, 270], ["other invasive infections", "PROBLEM", 283, 308], ["all non-neutropenic", "PROBLEM", 382, 401], ["bacteremia", "PROBLEM", 413, 423], ["CVC manipulation", "TREATMENT", 438, 454], ["concomitant", "OBSERVATION_MODIFIER", 19, 30], ["mucositis", "OBSERVATION", 31, 40], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["intestinal", "ANATOMY", 57, 67], ["graft", "OBSERVATION", 68, 73], ["host disease", "OBSERVATION", 81, 93], ["GVHD", "OBSERVATION", 95, 99], ["paralytic", "OBSERVATION_MODIFIER", 115, 124], ["ileus", "OBSERVATION", 125, 130], ["infection", "OBSERVATION", 232, 241], ["invasive", "OBSERVATION_MODIFIER", 289, 297], ["infections", "OBSERVATION", 298, 308], ["non-neutropenic", "OBSERVATION", 386, 401], ["bacteremia", "OBSERVATION", 413, 423]]], ["They presented clinically with shivers, fever, shortness of breath, hypotension or shock within 2 h following routine flushing of heparin locked CVCs with aseptic precautions.", [["fever", "DISEASE", 40, 45], ["shortness of breath", "DISEASE", 47, 66], ["hypotension", "DISEASE", 68, 79], ["shock", "DISEASE", 83, 88], ["heparin", "CHEMICAL", 130, 137], ["heparin", "SIMPLE_CHEMICAL", 130, 137], ["shivers", "PROBLEM", 31, 38], ["fever", "PROBLEM", 40, 45], ["shortness of breath", "PROBLEM", 47, 66], ["hypotension", "PROBLEM", 68, 79], ["shock", "PROBLEM", 83, 88], ["routine flushing of heparin locked CVCs", "TREATMENT", 110, 149], ["aseptic precautions", "TREATMENT", 155, 174], ["hypotension", "OBSERVATION", 68, 79], ["aseptic precautions", "OBSERVATION", 155, 174]]], ["Patients with bacteremia following CVC manipulation had their CVCs installed a median of 4.5 months before infection (range, 1\u201314 months), while those with bacteremia unrelated to CVC manipulation were mostly neutropenic (7 of 9) and had their CVCs installed a median of 2 months before infection (range, 1\u20136 months).Clinical settings ::: Patient characteristics ::: ResultsThere were two patients with respiratory infection: one with sinusitis, one with pneumonia.", [["respiratory", "ANATOMY", 403, 414], ["bacteremia", "DISEASE", 14, 24], ["infection", "DISEASE", 107, 116], ["bacteremia", "DISEASE", 156, 166], ["neutropenic", "DISEASE", 209, 220], ["infection", "DISEASE", 287, 296], ["respiratory infection", "DISEASE", 403, 424], ["sinusitis", "DISEASE", 435, 444], ["pneumonia", "DISEASE", 455, 464], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 389, 397], ["Patients", "SPECIES", 0, 8], ["Patient", "SPECIES", 339, 346], ["patients", "SPECIES", 389, 397], ["bacteremia", "PROBLEM", 14, 24], ["CVC manipulation", "TREATMENT", 35, 51], ["their CVCs", "TREATMENT", 56, 66], ["infection", "PROBLEM", 107, 116], ["bacteremia", "PROBLEM", 156, 166], ["CVC manipulation", "TREATMENT", 180, 196], ["neutropenic", "PROBLEM", 209, 220], ["their CVCs", "TREATMENT", 238, 248], ["infection", "PROBLEM", 287, 296], ["respiratory infection", "PROBLEM", 403, 424], ["sinusitis", "PROBLEM", 435, 444], ["pneumonia", "PROBLEM", 455, 464], ["bacteremia", "OBSERVATION", 14, 24], ["bacteremia", "OBSERVATION", 156, 166], ["neutropenic", "OBSERVATION", 209, 220], ["respiratory", "ANATOMY", 403, 414], ["infection", "OBSERVATION", 415, 424], ["sinusitis", "OBSERVATION", 435, 444], ["pneumonia", "OBSERVATION", 455, 464]]], ["Both patients were non-neutropenic.Stenotrophomonas maltophilia isolates ::: ResultsConcomitant isolation of other infectious agents was common both in neutropenic (66%) and non-neutropenic (50%) patients, as well as in blood stream (53%) and soft tissue (100%) infections.", [["blood stream", "ANATOMY", 220, 232], ["soft tissue", "ANATOMY", 243, 254], ["Stenotrophomonas maltophilia", "DISEASE", 35, 63], ["neutropenic", "DISEASE", 152, 163], ["infections", "DISEASE", 262, 272], ["patients", "ORGANISM", 5, 13], ["Stenotrophomonas maltophilia", "ORGANISM", 35, 63], ["patients", "ORGANISM", 196, 204], ["blood stream", "MULTI-TISSUE_STRUCTURE", 220, 232], ["soft tissue", "TISSUE", 243, 254], ["patients", "SPECIES", 5, 13], ["Stenotrophomonas maltophilia", "SPECIES", 35, 63], ["patients", "SPECIES", 196, 204], ["Stenotrophomonas maltophilia", "SPECIES", 35, 63], ["non-neutropenic", "PROBLEM", 19, 34], ["Stenotrophomonas maltophilia isolates", "PROBLEM", 35, 72], ["other infectious agents", "PROBLEM", 109, 132], ["neutropenic", "TEST", 152, 163], ["non-neutropenic", "PROBLEM", 174, 189], ["blood stream", "TEST", 220, 232], ["soft tissue (100%) infections", "PROBLEM", 243, 272], ["non-neutropenic", "OBSERVATION", 19, 34], ["infectious", "OBSERVATION_MODIFIER", 115, 125], ["neutropenic", "OBSERVATION_MODIFIER", 152, 163], ["soft tissue", "ANATOMY", 243, 254], ["infections", "OBSERVATION", 262, 272]]], ["Nine patients had bacteremia with S. maltophilia and one or more of the following infective organisms: coagulase negative Staphylococci, Corynebacterium, Pseudomonas, Acinetobacter and Candida.", [["bacteremia", "DISEASE", 18, 28], ["S. maltophilia", "DISEASE", 34, 48], ["patients", "ORGANISM", 5, 13], ["S. maltophilia", "ORGANISM", 34, 48], ["patients", "SPECIES", 5, 13], ["S. maltophilia", "SPECIES", 34, 48], ["S. maltophilia", "SPECIES", 34, 48], ["bacteremia", "PROBLEM", 18, 28], ["S. maltophilia", "PROBLEM", 34, 48], ["coagulase", "TEST", 103, 112], ["Staphylococci", "PROBLEM", 122, 135], ["Corynebacterium", "PROBLEM", 137, 152], ["Pseudomonas", "PROBLEM", 154, 165], ["Acinetobacter", "PROBLEM", 167, 180], ["Candida", "PROBLEM", 185, 192], ["bacteremia", "OBSERVATION", 18, 28], ["maltophilia", "OBSERVATION", 37, 48]]], ["The patient with pneumonia had concomitant respiratory syncytial virus (RSV) in his broncho-alveolar lavage, and the patient with sinusitis had concomitant Pseudomonas in his sinus lavage.Stenotrophomonas maltophilia isolates ::: ResultsAll isolates were susceptible in vitro to TMP-SMX, none were susceptible to carbapenems, and 10.6% were susceptible to fluoroquinolones.", [["broncho-alveolar lavage", "ANATOMY", 84, 107], ["sinus lavage", "ANATOMY", 175, 187], ["pneumonia", "DISEASE", 17, 26], ["respiratory syncytial virus", "DISEASE", 43, 70], ["RSV", "DISEASE", 72, 75], ["sinusitis", "DISEASE", 130, 139], ["Stenotrophomonas maltophilia", "DISEASE", 188, 216], ["TMP", "CHEMICAL", 279, 282], ["SMX", "CHEMICAL", 283, 286], ["carbapenems", "CHEMICAL", 313, 324], ["fluoroquinolones", "CHEMICAL", 356, 372], ["TMP-SMX", "CHEMICAL", 279, 286], ["carbapenems", "CHEMICAL", 313, 324], ["fluoroquinolones", "CHEMICAL", 356, 372], ["patient", "ORGANISM", 4, 11], ["respiratory syncytial virus", "ORGANISM", 43, 70], ["RSV", "ORGANISM", 72, 75], ["patient", "ORGANISM", 117, 124], ["sinus lavage", "MULTI-TISSUE_STRUCTURE", 175, 187], ["Stenotrophomonas maltophilia", "ORGANISM", 188, 216], ["TMP-SMX", "SIMPLE_CHEMICAL", 279, 286], ["carbapenems", "SIMPLE_CHEMICAL", 313, 324], ["fluoroquinolones", "SIMPLE_CHEMICAL", 356, 372], ["patient", "SPECIES", 4, 11], ["respiratory syncytial virus", "SPECIES", 43, 70], ["patient", "SPECIES", 117, 124], ["Stenotrophomonas maltophilia", "SPECIES", 188, 216], ["respiratory syncytial virus", "SPECIES", 43, 70], ["RSV", "SPECIES", 72, 75], ["Stenotrophomonas maltophilia", "SPECIES", 188, 216], ["pneumonia", "PROBLEM", 17, 26], ["concomitant respiratory syncytial virus", "PROBLEM", 31, 70], ["his broncho-alveolar lavage", "TEST", 80, 107], ["sinusitis", "PROBLEM", 130, 139], ["concomitant Pseudomonas", "PROBLEM", 144, 167], ["his sinus lavage", "TEST", 171, 187], ["Stenotrophomonas maltophilia isolates", "PROBLEM", 188, 225], ["All isolates", "TEST", 237, 249], ["TMP", "TEST", 279, 282], ["carbapenems", "TREATMENT", 313, 324], ["fluoroquinolones", "TREATMENT", 356, 372], ["pneumonia", "OBSERVATION", 17, 26], ["respiratory syncytial virus", "OBSERVATION", 43, 70], ["-alveolar", "ANATOMY", 91, 100], ["lavage", "OBSERVATION", 101, 107], ["sinusitis", "OBSERVATION", 130, 139], ["Pseudomonas", "OBSERVATION", 156, 167], ["sinus", "ANATOMY", 175, 180], ["lavage", "OBSERVATION", 181, 187]]], ["Ten patients (52.6%) received prior antibiotic therapy during the previous month with carbapenems.Treatment and outcome ::: ResultsThe treatment for all patients included empiric broad spectrum antibiotic therapy at the onset of signs of infection, and after identification of S. maltophilia, antibiotics were changed according to susceptibility.", [["carbapenems", "CHEMICAL", 86, 97], ["infection", "DISEASE", 238, 247], ["S. maltophilia", "DISEASE", 277, 291], ["carbapenems", "CHEMICAL", 86, 97], ["patients", "ORGANISM", 4, 12], ["carbapenems", "SIMPLE_CHEMICAL", 86, 97], ["patients", "ORGANISM", 153, 161], ["S. maltophilia", "ORGANISM", 277, 291], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 153, 161], ["S. maltophilia", "SPECIES", 277, 291], ["S. maltophilia", "SPECIES", 277, 291], ["prior antibiotic therapy", "TREATMENT", 30, 54], ["carbapenems", "TREATMENT", 86, 97], ["The treatment", "TREATMENT", 131, 144], ["empiric broad spectrum antibiotic therapy", "TREATMENT", 171, 212], ["infection", "PROBLEM", 238, 247], ["S. maltophilia", "PROBLEM", 277, 291], ["antibiotics", "TREATMENT", 293, 304], ["infection", "OBSERVATION", 238, 247], ["maltophilia", "OBSERVATION", 280, 291]]], ["Specific therapy against S. maltophilia consisted of high dose (>15 mg/kg/day) trimethoprime\u2013\u2013sulfamethoxazole (TMP-SMX) (two patients), ofloxacin (two patients) or both (four patients).", [["S. maltophilia", "DISEASE", 25, 39], ["trimethoprime\u2013\u2013sulfamethoxazole", "CHEMICAL", 79, 110], ["TMP-SMX", "CHEMICAL", 112, 119], ["ofloxacin", "CHEMICAL", 137, 146], ["trimethoprime\u2013\u2013sulfamethoxazole", "CHEMICAL", 79, 110], ["TMP-SMX", "CHEMICAL", 112, 119], ["ofloxacin", "CHEMICAL", 137, 146], ["S. maltophilia", "ORGANISM", 25, 39], ["trimethoprime\u2013\u2013sulfamethoxazole", "SIMPLE_CHEMICAL", 79, 110], ["TMP-SMX", "SIMPLE_CHEMICAL", 112, 119], ["patients", "ORGANISM", 126, 134], ["ofloxacin", "SIMPLE_CHEMICAL", 137, 146], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 176, 184], ["S. maltophilia", "SPECIES", 25, 39], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 176, 184], ["S. maltophilia", "SPECIES", 25, 39], ["Specific therapy", "TREATMENT", 0, 16], ["S. maltophilia", "PROBLEM", 25, 39], ["trimethoprime\u2013\u2013sulfamethoxazole (TMP-SMX)", "TREATMENT", 79, 120], ["ofloxacin", "TREATMENT", 137, 146]]], ["Five patients died before specific identification of S. maltophilia and therefore did not receive appropriate antibiotics.", [["S. maltophilia", "DISEASE", 53, 67], ["patients", "ORGANISM", 5, 13], ["S. maltophilia", "ORGANISM", 53, 67], ["patients", "SPECIES", 5, 13], ["S. maltophilia", "SPECIES", 53, 67], ["S. maltophilia", "PROBLEM", 53, 67], ["appropriate antibiotics", "TREATMENT", 98, 121], ["maltophilia", "OBSERVATION", 56, 67]]], ["There were no cases of persistent bacteremia despite adequate therapy.Treatment and outcome ::: ResultsSeventeen patients had a CVC at the time of infection, 15 of them were bacteremic and two had other invasive infections.", [["bacteremia", "DISEASE", 34, 44], ["infection", "DISEASE", 147, 156], ["bacteremic", "DISEASE", 174, 184], ["infections", "DISEASE", 212, 222], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["persistent bacteremia", "PROBLEM", 23, 44], ["adequate therapy", "TREATMENT", 53, 69], ["a CVC", "TREATMENT", 126, 131], ["infection", "PROBLEM", 147, 156], ["bacteremic", "PROBLEM", 174, 184], ["other invasive infections", "PROBLEM", 197, 222], ["no cases of", "UNCERTAINTY", 11, 22], ["persistent", "OBSERVATION_MODIFIER", 23, 33], ["bacteremia", "OBSERVATION", 34, 44], ["adequate therapy", "OBSERVATION", 53, 69], ["infection", "OBSERVATION", 147, 156], ["invasive", "OBSERVATION_MODIFIER", 203, 211], ["infections", "OBSERVATION", 212, 222]]], ["Twelve patients out of the 17 patients with CVCs at the time of infection had their CVCs removed (70%).", [["CVCs", "DISEASE", 44, 48], ["infection", "DISEASE", 64, 73], ["patients", "ORGANISM", 7, 15], ["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 7, 15], ["patients", "SPECIES", 30, 38], ["CVCs", "TREATMENT", 44, 48], ["infection", "PROBLEM", 64, 73], ["their CVCs", "TREATMENT", 78, 88], ["infection", "OBSERVATION", 64, 73]]], ["All of them were bacteremic.", [["bacteremic", "PROBLEM", 17, 27], ["bacteremic", "OBSERVATION", 17, 27]]], ["Only three patients with S. maltophilia bacteremia, two neutropenic and one non-neutropenic, did not have their CVCs removed.", [["S. maltophilia bacteremia", "DISEASE", 25, 50], ["neutropenic", "DISEASE", 56, 67], ["patients", "ORGANISM", 11, 19], ["S. maltophilia", "ORGANISM", 25, 39], ["patients", "SPECIES", 11, 19], ["S. maltophilia", "SPECIES", 25, 39], ["S. maltophilia", "SPECIES", 25, 39], ["S. maltophilia bacteremia", "PROBLEM", 25, 50], ["two neutropenic", "PROBLEM", 52, 67], ["one non-neutropenic", "PROBLEM", 72, 91], ["their CVCs", "TREATMENT", 106, 116], ["maltophilia", "OBSERVATION_MODIFIER", 28, 39], ["bacteremia", "OBSERVATION", 40, 50], ["neutropenic", "OBSERVATION_MODIFIER", 56, 67], ["one", "OBSERVATION_MODIFIER", 72, 75], ["non-neutropenic", "OBSERVATION", 76, 91], ["CVCs", "OBSERVATION", 112, 116]]], ["In the two neutropenic patients this was due to non-reversible multi-organ failure and non-engraftment, which technically did not enable CVC removal.Treatment and outcome ::: ResultsOf the eight non-neutropenic patients with bacteremia, six had their CVCs removed within hours following CVC manipulation and corresponding sepsis, without awaiting culture results.", [["multi-organ", "ANATOMY", 63, 74], ["neutropenic", "DISEASE", 11, 22], ["multi-organ failure", "DISEASE", 63, 82], ["non-engraftment", "DISEASE", 87, 102], ["bacteremia", "DISEASE", 225, 235], ["sepsis", "DISEASE", 322, 328], ["patients", "ORGANISM", 23, 31], ["multi-organ", "ORGAN", 63, 74], ["CVC", "PATHOLOGICAL_FORMATION", 137, 140], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 211, 219], ["non-reversible multi-organ failure", "PROBLEM", 48, 82], ["non-engraftment", "TREATMENT", 87, 102], ["CVC removal", "TREATMENT", 137, 148], ["bacteremia", "PROBLEM", 225, 235], ["their CVCs", "TREATMENT", 245, 255], ["CVC manipulation", "TREATMENT", 287, 303], ["corresponding sepsis", "PROBLEM", 308, 328], ["culture", "TEST", 347, 354], ["neutropenic", "OBSERVATION", 11, 22], ["multi-organ", "ANATOMY", 63, 74], ["failure", "OBSERVATION", 75, 82], ["eight", "OBSERVATION_MODIFIER", 189, 194], ["non-neutropenic", "OBSERVATION_MODIFIER", 195, 210], ["bacteremia", "OBSERVATION", 225, 235], ["CVCs", "OBSERVATION", 251, 255], ["sepsis", "OBSERVATION", 322, 328]]], ["Indeed, five of them had an uneventful recovery and only one patient died with multi-organ failure.", [["multi-organ", "ANATOMY", 79, 90], ["multi-organ failure", "DISEASE", 79, 98], ["patient", "ORGANISM", 61, 68], ["multi-organ", "ORGAN", 79, 90], ["patient", "SPECIES", 61, 68], ["multi-organ failure", "PROBLEM", 79, 98], ["multi-organ", "ANATOMY", 79, 90], ["failure", "OBSERVATION", 91, 98]]], ["One additional patient had his CVC removed only upon identification of S. maltophilia in blood cultures; he fully recovered.", [["blood cultures", "ANATOMY", 89, 103], ["S. maltophilia", "DISEASE", 71, 85], ["patient", "ORGANISM", 15, 22], ["S. maltophilia", "ORGANISM", 71, 85], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["patient", "SPECIES", 15, 22], ["S. maltophilia", "SPECIES", 71, 85], ["S. maltophilia", "SPECIES", 71, 85], ["his CVC", "TREATMENT", 27, 34], ["S. maltophilia", "PROBLEM", 71, 85], ["blood cultures", "TEST", 89, 103], ["CVC", "ANATOMY", 31, 34], ["removed", "OBSERVATION", 35, 42], ["maltophilia", "OBSERVATION", 74, 85]]], ["The eighth patient had his CVC preserved and was successfully treated with intravenous (IV) antibiotics.Treatment and outcome ::: ResultsBoth non-neutropenic patients with respiratory tract infections (pneumonia and sinusitis) had their CVCs preserved.", [["intravenous", "ANATOMY", 75, 86], ["respiratory tract", "ANATOMY", 172, 189], ["respiratory tract infections", "DISEASE", 172, 200], ["pneumonia", "DISEASE", 202, 211], ["sinusitis", "DISEASE", 216, 225], ["patient", "ORGANISM", 11, 18], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["patients", "ORGANISM", 158, 166], ["tract", "ORGANISM_SUBDIVISION", 184, 189], ["patient", "SPECIES", 11, 18], ["patients", "SPECIES", 158, 166], ["his CVC", "TEST", 23, 30], ["intravenous (IV) antibiotics", "TREATMENT", 75, 103], ["respiratory tract infections", "PROBLEM", 172, 200], ["pneumonia", "PROBLEM", 202, 211], ["sinusitis", "PROBLEM", 216, 225], ["their CVCs", "TREATMENT", 231, 241], ["CVC", "ANATOMY", 27, 30], ["preserved", "OBSERVATION", 31, 40], ["non-neutropenic", "OBSERVATION", 142, 157], ["respiratory tract", "ANATOMY", 172, 189], ["infections", "OBSERVATION", 190, 200], ["pneumonia", "OBSERVATION", 202, 211], ["sinusitis", "OBSERVATION", 216, 225]]], ["The patient with sinusitis fully recovered, and the patient with pneumonia died from multi-organ failure.Treatment and outcome ::: ResultsIn all, six patients with S. maltophilia bacteremia died (a mortality rate of 31.5%).", [["multi-organ", "ANATOMY", 85, 96], ["sinusitis", "DISEASE", 17, 26], ["pneumonia", "DISEASE", 65, 74], ["multi-organ failure", "DISEASE", 85, 104], ["S. maltophilia bacteremia", "DISEASE", 164, 189], ["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 52, 59], ["multi-organ", "ORGAN", 85, 96], ["patients", "ORGANISM", 150, 158], ["S. maltophilia", "ORGANISM", 164, 178], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 52, 59], ["patients", "SPECIES", 150, 158], ["S. maltophilia", "SPECIES", 164, 178], ["S. maltophilia", "SPECIES", 164, 178], ["sinusitis", "PROBLEM", 17, 26], ["pneumonia", "PROBLEM", 65, 74], ["multi-organ failure", "PROBLEM", 85, 104], ["S. maltophilia bacteremia", "PROBLEM", 164, 189], ["a mortality rate", "TEST", 196, 212], ["sinusitis", "OBSERVATION", 17, 26], ["pneumonia", "OBSERVATION", 65, 74], ["multi-organ", "ANATOMY", 85, 96], ["failure", "OBSERVATION", 97, 104]]]], "be902d89e87bf2337dc2ff1df92a8c05cdfedb96": [["IntroductionEpidemiological studies have uncovered a strong association between viral infections, especially those caused by rhinovirus, and exacerbations of asthma attacks [1] [2] [3] .", [["viral infections", "DISEASE", 80, 96], ["rhinovirus", "DISEASE", 125, 135], ["asthma", "DISEASE", 158, 164], ["rhinovirus", "ORGANISM", 125, 135], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 173, 184], ["Epidemiological studies", "TEST", 12, 35], ["viral infections", "PROBLEM", 80, 96], ["rhinovirus", "PROBLEM", 125, 135], ["asthma attacks", "PROBLEM", 158, 172], ["infections", "OBSERVATION", 86, 96], ["rhinovirus", "OBSERVATION", 125, 135]]], ["However, the mechanisms by which viruses induce exacerbations of chronic airways disease are not well understood.", [["airways", "ANATOMY", 73, 80], ["chronic airways disease", "DISEASE", 65, 88], ["airways", "MULTI-TISSUE_STRUCTURE", 73, 80], ["chronic airways disease", "PROBLEM", 65, 88], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["airways disease", "OBSERVATION", 73, 88]]], ["In response to viral infection, the airway epithelium, and to a lesser extent immune cells such as monocytes, macrophages, and dendritic cells [4] [5] [6] [7] , release pro-inflammatory cytokines, interferons (IFNs), and antimicrobial substances, which in turn, promote clearance of microorganisms, and activation of the adaptive immune system.", [["airway epithelium", "ANATOMY", 36, 53], ["immune cells", "ANATOMY", 78, 90], ["monocytes", "ANATOMY", 99, 108], ["macrophages", "ANATOMY", 110, 121], ["dendritic cells", "ANATOMY", 127, 142], ["viral infection", "DISEASE", 15, 30], ["airway epithelium", "TISSUE", 36, 53], ["immune cells", "CELL", 78, 90], ["monocytes", "CELL", 99, 108], ["macrophages", "CELL", 110, 121], ["dendritic cells", "CELL", 127, 142], ["interferons", "GENE_OR_GENE_PRODUCT", 197, 208], ["IFNs", "GENE_OR_GENE_PRODUCT", 210, 214], ["immune cells", "CELL_TYPE", 78, 90], ["monocytes", "CELL_TYPE", 99, 108], ["macrophages", "CELL_TYPE", 110, 121], ["dendritic cells", "CELL_TYPE", 127, 142], ["pro-inflammatory cytokines", "PROTEIN", 169, 195], ["interferons", "PROTEIN", 197, 208], ["IFNs", "PROTEIN", 210, 214], ["viral infection", "PROBLEM", 15, 30], ["the airway epithelium", "PROBLEM", 32, 53], ["monocytes", "TEST", 99, 108], ["macrophages", "PROBLEM", 110, 121], ["dendritic cells", "PROBLEM", 127, 142], ["release pro-inflammatory cytokines", "TEST", 161, 195], ["interferons (IFNs)", "TREATMENT", 197, 215], ["antimicrobial substances", "TREATMENT", 221, 245], ["microorganisms", "PROBLEM", 283, 297], ["the adaptive immune system", "TREATMENT", 317, 343], ["viral infection", "OBSERVATION", 15, 30], ["airway epithelium", "ANATOMY", 36, 53], ["lesser extent", "OBSERVATION_MODIFIER", 64, 77], ["immune cells", "OBSERVATION", 78, 90], ["dendritic cells", "OBSERVATION", 127, 142]]], ["However, in patients with chronic respiratory illnesses, the innate immune response may also be responsible for disease exacerbation [8] .IntroductionAlthough the inflammatory response to experimental rhinovirus infection has been monitored [9] [10] [11] [12] [13] [14] , few studies have examined the innate immune response of patients with asthma to natural colds.", [["respiratory", "ANATOMY", 34, 45], ["respiratory illnesses", "DISEASE", 34, 55], ["rhinovirus infection", "DISEASE", 201, 221], ["[9] [10] [11] [12] [13", "CHEMICAL", 241, 263], ["asthma", "DISEASE", 342, 348], ["colds", "DISEASE", 360, 365], ["patients", "ORGANISM", 12, 20], ["rhinovirus", "ORGANISM", 201, 211], ["[9] [10] [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 241, 269], ["patients", "ORGANISM", 328, 336], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 328, 336], ["chronic respiratory illnesses", "PROBLEM", 26, 55], ["disease exacerbation", "PROBLEM", 112, 132], ["the inflammatory response", "PROBLEM", 159, 184], ["experimental rhinovirus infection", "PROBLEM", 188, 221], ["few studies", "TEST", 272, 283], ["asthma", "PROBLEM", 342, 348], ["natural colds", "PROBLEM", 352, 365], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["respiratory", "ANATOMY", 34, 45], ["illnesses", "OBSERVATION", 46, 55], ["may also be responsible for", "UNCERTAINTY", 84, 111], ["inflammatory", "OBSERVATION_MODIFIER", 163, 175], ["rhinovirus", "OBSERVATION", 201, 211]]], ["Increases in respiratory tract CXCL8/IL-8, CCL5/RANTES, CCL19/ MIP-1a, IL-10, CCL7/MCP-3, and CCL13/MCP-4 have been detected [15] [16] [17] [18] .", [["respiratory tract", "ANATOMY", 13, 30], ["CXCL8", "GENE_OR_GENE_PRODUCT", 31, 36], ["IL-8", "GENE_OR_GENE_PRODUCT", 37, 41], ["CCL5", "GENE_OR_GENE_PRODUCT", 43, 47], ["RANTES", "GENE_OR_GENE_PRODUCT", 48, 54], ["CCL19", "GENE_OR_GENE_PRODUCT", 56, 61], ["MIP-1a", "GENE_OR_GENE_PRODUCT", 63, 69], ["IL-10", "GENE_OR_GENE_PRODUCT", 71, 76], ["CCL7", "GENE_OR_GENE_PRODUCT", 78, 82], ["MCP-3", "GENE_OR_GENE_PRODUCT", 83, 88], ["CCL13", "GENE_OR_GENE_PRODUCT", 94, 99], ["MCP-4", "GENE_OR_GENE_PRODUCT", 100, 105], ["[15] [16] [17] [18]", "SIMPLE_CHEMICAL", 125, 144], ["CXCL8", "PROTEIN", 31, 36], ["IL-8", "PROTEIN", 37, 41], ["CCL5", "PROTEIN", 43, 47], ["RANTES", "PROTEIN", 48, 54], ["CCL19", "PROTEIN", 56, 61], ["MIP", "PROTEIN", 63, 66], ["IL-10", "PROTEIN", 71, 76], ["CCL7", "PROTEIN", 78, 82], ["MCP", "PROTEIN", 83, 86], ["CCL13", "PROTEIN", 94, 99], ["MCP", "PROTEIN", 100, 103], ["respiratory tract CXCL8", "TEST", 13, 36], ["IL", "TEST", 37, 39], ["CCL5", "TEST", 43, 47], ["RANTES", "TEST", 48, 54], ["CCL19", "TEST", 56, 61], ["MIP", "TEST", 63, 66], ["IL", "TEST", 71, 73], ["CCL7", "TEST", 78, 82], ["MCP", "TEST", 83, 86], ["CCL13", "TEST", 94, 99], ["MCP", "TEST", 100, 103], ["respiratory tract", "ANATOMY", 13, 30]]], ["To further examine the innate immune response to viral infection in children with asthma, we measured nasal aspirate cytokine levels in 16 asthmatic children before and after upper respiratory tract infections.", [["nasal aspirate", "ANATOMY", 102, 116], ["upper respiratory tract", "ANATOMY", 175, 198], ["viral infection", "DISEASE", 49, 64], ["asthma", "DISEASE", 82, 88], ["respiratory tract infections", "DISEASE", 181, 209], ["children", "ORGANISM", 68, 76], ["nasal aspirate", "MULTI-TISSUE_STRUCTURE", 102, 116], ["children", "ORGANISM", 149, 157], ["upper", "ORGANISM_SUBDIVISION", 175, 180], ["respiratory tract", "ORGANISM_SUBDIVISION", 181, 198], ["cytokine", "PROTEIN", 117, 125], ["children", "SPECIES", 68, 76], ["children", "SPECIES", 149, 157], ["viral infection", "PROBLEM", 49, 64], ["asthma", "PROBLEM", 82, 88], ["nasal aspirate cytokine levels", "TEST", 102, 132], ["upper respiratory tract infections", "PROBLEM", 175, 209], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["infection", "OBSERVATION", 55, 64], ["nasal", "ANATOMY", 102, 107], ["upper", "ANATOMY_MODIFIER", 175, 180], ["respiratory tract", "ANATOMY", 181, 198], ["infections", "OBSERVATION", 199, 209]]], ["In contrast to the previous studies, we examined at least three time points before and in association with symptomatic illness.", [["the previous studies", "TEST", 15, 35], ["symptomatic illness", "PROBLEM", 107, 126], ["symptomatic", "OBSERVATION_MODIFIER", 107, 118], ["illness", "OBSERVATION", 119, 126]]], ["We evaluated the associations between viral infection and cytokine expression, and between cytokine expression and symptom score.", [["viral infection", "DISEASE", 38, 53], ["cytokine", "PROTEIN", 58, 66], ["cytokine", "PROTEIN", 91, 99], ["viral infection", "PROBLEM", 38, 53], ["cytokine expression", "PROBLEM", 58, 77], ["symptom score", "TEST", 115, 128], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 44, 53], ["cytokine expression", "OBSERVATION", 58, 77]]], ["We also examined the effects of upper respiratory tract infection on mRNA levels of selected markers of viral infection, including IFNs.", [["upper respiratory tract", "ANATOMY", 32, 55], ["respiratory tract infection", "DISEASE", 38, 65], ["viral infection", "DISEASE", 104, 119], ["upper respiratory", "ORGANISM_SUBDIVISION", 32, 49], ["tract", "ORGANISM_SUBDIVISION", 50, 55], ["IFNs", "GENE_OR_GENE_PRODUCT", 131, 135], ["IFNs", "PROTEIN", 131, 135], ["upper respiratory tract infection", "PROBLEM", 32, 65], ["mRNA levels", "TEST", 69, 80], ["viral infection", "PROBLEM", 104, 119], ["IFNs", "PROBLEM", 131, 135], ["upper", "ANATOMY_MODIFIER", 32, 37], ["respiratory tract", "ANATOMY", 38, 55], ["infection", "OBSERVATION", 56, 65], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["infection", "OBSERVATION", 110, 119]]], ["Finally, we evaluated a new method of virus detection using a single polymerase chain reaction-ligation detection reaction (PCR-LDR) multiplex assay.", [["virus detection", "TREATMENT", 38, 53], ["a single polymerase chain reaction", "TREATMENT", 60, 94], ["ligation detection reaction", "TREATMENT", 95, 122], ["PCR", "TEST", 124, 127], ["multiplex assay", "TEST", 133, 148]]], ["We hypothesized that respiratory viral infection of children with asthma causes robust elaboration of pro-inflammatory cytokines and IFNs, and that the level of pro-inflammatory cytokines correlates with symptom severity.Study designWe conducted an observational cohort study of 16 children with asthma.", [["respiratory viral infection", "DISEASE", 21, 48], ["asthma", "DISEASE", 66, 72], ["asthma", "DISEASE", 296, 302], ["children", "ORGANISM", 52, 60], ["IFNs", "GENE_OR_GENE_PRODUCT", 133, 137], ["children", "ORGANISM", 282, 290], ["pro-inflammatory cytokines", "PROTEIN", 102, 128], ["IFNs", "PROTEIN", 133, 137], ["pro-inflammatory cytokines", "PROTEIN", 161, 187], ["children", "SPECIES", 52, 60], ["children", "SPECIES", 282, 290], ["respiratory viral infection", "PROBLEM", 21, 48], ["asthma", "PROBLEM", 66, 72], ["pro-inflammatory cytokines", "PROBLEM", 102, 128], ["IFNs", "PROBLEM", 133, 137], ["pro-inflammatory cytokines", "TEST", 161, 187], ["symptom severity", "PROBLEM", 204, 220], ["an observational cohort study", "TEST", 246, 275], ["asthma", "PROBLEM", 296, 302], ["respiratory", "OBSERVATION_MODIFIER", 21, 32], ["viral infection", "OBSERVATION", 33, 48], ["pro-inflammatory cytokines", "OBSERVATION", 102, 128]]], ["Children were eligible for the study if they received care from a University of Michigan physician for asthma, were aged 6-18 years, and lived within a 30 mile radius of Ann Arbor.", [["asthma", "DISEASE", 103, 109], ["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8], ["the study", "TEST", 27, 36], ["asthma", "PROBLEM", 103, 109]]], ["Outpatients were enrolled for 3-6 months, with the goal of assessing cytokines at baseline and in association with at least one viral-induced exacerbation during that period.", [["cytokines", "PROTEIN", 69, 78], ["one viral-induced exacerbation", "PROBLEM", 124, 154], ["viral", "OBSERVATION", 128, 133], ["exacerbation", "OBSERVATION", 142, 154]]], ["Initial consent and first evaluation was conducted at the University of Michigan, but all subsequent evaluations were performed in the participant's home.", [["participant", "SPECIES", 135, 146], ["first evaluation", "TEST", 20, 36], ["all subsequent evaluations", "TEST", 86, 112]]], ["This study was approved by the University of Michigan Institutional Review Board (approval number HUM00018442).", [["This study", "TEST", 0, 10]]], ["All clinical investigations were conducted according to principles expressed in the Declaration of Helsinki (http://www.wma.net).Child characteristicsAt the initial assessment, parents or guardians completed an extensive questionnaire, which included standardized questions about presence and frequency of asthma symptoms, an inventory of a child's asthma medications and current usage, and queries about environmental exposures, and child and family demographic information.", [["asthma", "DISEASE", 306, 312], ["asthma", "DISEASE", 349, 355], ["All clinical investigations", "TEST", 0, 27], ["the initial assessment", "TEST", 153, 175], ["asthma symptoms", "PROBLEM", 306, 321], ["a child's asthma medications", "TREATMENT", 339, 367]]], ["Baseline asthma severity was assessed using National Asthma Education and Prevention Program Guidelines [19] incorporating an adjustment for asthma controller therapy use [20] .Data and sample collectionWe performed home measurements of respiratory symptoms and collected nasal secretions (for detection of viral RNA by PCR and host biomarkers by PCR and ELISA) on 3 days during a week when children were healthy (not reporting upper respiratory tract infection or asthma symptoms), and again during a week when they experienced cold or flu-like symptoms.", [["respiratory", "ANATOMY", 237, 248], ["nasal secretions", "ANATOMY", 272, 288], ["upper respiratory tract", "ANATOMY", 428, 451], ["asthma", "DISEASE", 9, 15], ["Asthma", "DISEASE", 53, 59], ["asthma", "DISEASE", 141, 147], ["respiratory symptoms", "DISEASE", 237, 257], ["respiratory tract infection", "DISEASE", 434, 461], ["asthma", "DISEASE", 465, 471], ["nasal secretions", "ORGANISM_SUBDIVISION", 272, 288], ["children", "ORGANISM", 391, 399], ["upper respiratory", "ORGANISM_SUBDIVISION", 428, 445], ["tract", "ORGANISM_SUBDIVISION", 446, 451], ["viral RNA", "RNA", 307, 316], ["children", "SPECIES", 391, 399], ["Baseline asthma severity", "PROBLEM", 0, 24], ["asthma controller therapy", "TREATMENT", 141, 166], ["sample collectionWe", "TEST", 186, 205], ["respiratory symptoms", "PROBLEM", 237, 257], ["collected nasal secretions", "PROBLEM", 262, 288], ["viral RNA", "PROBLEM", 307, 316], ["PCR", "TEST", 320, 323], ["host biomarkers", "TEST", 328, 343], ["PCR", "TEST", 347, 350], ["upper respiratory tract infection", "PROBLEM", 428, 461], ["asthma symptoms", "PROBLEM", 465, 480], ["cold", "PROBLEM", 529, 533], ["flu-like symptoms", "PROBLEM", 537, 554], ["asthma", "OBSERVATION", 9, 15], ["respiratory", "ANATOMY", 237, 248], ["nasal", "ANATOMY", 272, 277], ["secretions", "OBSERVATION", 278, 288], ["respiratory tract", "ANATOMY", 434, 451], ["infection", "OBSERVATION", 452, 461]]], ["Families were given a calendar and a simple respiratory symptom scale and asked to mark the level of their symptoms.", [["a simple respiratory symptom scale", "TREATMENT", 35, 69], ["their symptoms", "PROBLEM", 101, 115]]], ["We used a modified version of the respiratory symptom score developed by the Child Origins of Asthma Study [21] , which assessed fever, cough, nasal symptoms, wheezing, difficulty breathing, waking up at night with cough, and interference with usual activities.", [["nasal", "ANATOMY", 143, 148], ["Asthma", "DISEASE", 94, 100], ["fever", "DISEASE", 129, 134], ["cough", "DISEASE", 136, 141], ["nasal symptoms", "DISEASE", 143, 157], ["wheezing", "DISEASE", 159, 167], ["difficulty breathing", "DISEASE", 169, 189], ["cough", "DISEASE", 215, 220], ["nasal", "ORGANISM_SUBDIVISION", 143, 148], ["a modified version", "TREATMENT", 8, 26], ["the respiratory symptom score", "PROBLEM", 30, 59], ["Asthma Study", "PROBLEM", 94, 106], ["fever", "PROBLEM", 129, 134], ["cough", "PROBLEM", 136, 141], ["nasal symptoms", "PROBLEM", 143, 157], ["wheezing", "PROBLEM", 159, 167], ["difficulty breathing", "PROBLEM", 169, 189], ["cough", "PROBLEM", 215, 220], ["nasal", "ANATOMY", 143, 148]]], ["When the patient experienced a symptomatic respiratory illness, as defined by a symptom score of two or higher on a scale of 0-13, the family notified the study staff and scheduled a visit within 48 h of the beginning of symptoms (defined as day 1 of the illness).", [["respiratory", "ANATOMY", 43, 54], ["respiratory illness", "DISEASE", 43, 62], ["patient", "ORGANISM", 9, 16], ["patient", "SPECIES", 9, 16], ["a symptomatic respiratory illness", "PROBLEM", 29, 62], ["a symptom score", "TEST", 78, 93], ["symptoms", "PROBLEM", 221, 229], ["symptomatic", "OBSERVATION_MODIFIER", 31, 42], ["respiratory illness", "OBSERVATION", 43, 62]]], ["Information regarding impact of respiratory symptoms on daily activities and recent use of asthma medicines was also collected.", [["respiratory", "ANATOMY", 32, 43], ["asthma", "DISEASE", 91, 97], ["respiratory symptoms", "PROBLEM", 32, 52], ["asthma medicines", "TREATMENT", 91, 107]]], ["As noted above, study technicians visited the home every 2-3 days to retrieve additional nasal washing samples, for a total of three visits during the week following reporting of symptoms.", [["nasal", "ANATOMY", 89, 94], ["additional nasal washing samples", "TREATMENT", 78, 110], ["symptoms", "PROBLEM", 179, 187]]], ["The three specific days of the week selected for analysis were based on the convenience of the subjects and laboratory technician.", [["analysis", "TEST", 49, 57]]], ["Although specimens were most often collected on days 1, 4, and 7 of a given week, specimen collection was sometimes compressed into a 5 or 6-day period.Data and sample collectionTo collect a nasal lavage sample, we utilized a protocol developed by Powell and Shorr [22] and modified by James Gern (University of Wisconsin, personal communication).", [["specimens", "ANATOMY", 9, 18], ["specimen", "ANATOMY", 82, 90], ["nasal lavage sample", "ANATOMY", 191, 210], ["specimens", "CANCER", 9, 18], ["specimens", "TEST", 9, 18], ["specimen collection", "PROBLEM", 82, 101], ["sample collection", "TEST", 161, 178], ["a nasal lavage sample", "TEST", 189, 210], ["a protocol", "TREATMENT", 224, 234], ["nasal", "ANATOMY", 191, 196], ["lavage", "OBSERVATION", 197, 203]]], ["Two squirts of isotonic 0.65% sodium chloride were instilled into the child's nostrils (estimated at < 1 mL per nostril) using a commercially available nasal saline spray (B.F. Ascher, Lenexa, KS, USA).", [["nostrils", "ANATOMY", 78, 86], ["nasal", "ANATOMY", 152, 157], ["sodium chloride", "CHEMICAL", 30, 45], ["sodium chloride", "CHEMICAL", 30, 45], ["sodium chloride", "SIMPLE_CHEMICAL", 30, 45], ["child", "ORGANISM", 70, 75], ["nostrils", "ORGANISM_SUBDIVISION", 78, 86], ["nostril", "ORGANISM_SUBDIVISION", 112, 119], ["isotonic 0.65% sodium chloride", "TREATMENT", 15, 45], ["a commercially available nasal saline spray", "TREATMENT", 127, 170]]], ["The subject then blew their nose into a zippered plastic bag, and 3 ml of M4RT viral transport medium (Remel, Lenexa, KS, USA) was added.", [["nose", "ANATOMY", 28, 32], ["nose", "ORGANISM_SUBDIVISION", 28, 32], ["a zippered plastic bag", "TREATMENT", 38, 60], ["M4RT viral transport medium", "TREATMENT", 74, 101]]], ["In general, samples were collected in the presence of study staff and were transported from homes to the laboratory within 3 h of collection in a cooler with ice packs.", [["samples", "ANATOMY", 12, 19], ["ice packs", "TREATMENT", 158, 167]]], ["However, due to logistical issues scheduling home visits, families were also provided with kits for independent collection of nasal washings specimens at home.", [["nasal washings specimens", "ANATOMY", 126, 150], ["nasal washings specimens", "MULTI-TISSUE_STRUCTURE", 126, 150], ["nasal washings specimens", "TREATMENT", 126, 150], ["nasal", "ANATOMY", 126, 131]]], ["If a visit could not be scheduled within 48 h, families were instructed to collect the sample, double bag the sample, place in a tightly sealed collection box, and to keep it in the refrigerator until the staff could collect the sample.", [["double bag the sample", "TREATMENT", 95, 116], ["a tightly sealed collection box", "TREATMENT", 127, 158], ["the sample", "TEST", 225, 235]]], ["We required a 1 week interval between sample collections for sequential illnesses.Detection of respiratory virusesNasal aspirates were homogenized using a handheld homogenizer to allow pipetting of viscous samples and frozen at \u00c070\u00b0C to allow for batched analysis.", [["Nasal aspirates", "ANATOMY", 114, 129], ["samples", "ANATOMY", 206, 213], ["Nasal aspirates", "MULTI-TISSUE_STRUCTURE", 114, 129], ["a 1 week interval between sample collections", "TREATMENT", 12, 56], ["sequential illnesses", "PROBLEM", 61, 81], ["respiratory virusesNasal aspirates", "PROBLEM", 95, 129], ["a handheld homogenizer", "TREATMENT", 153, 175], ["pipetting of viscous samples", "TREATMENT", 185, 213], ["batched analysis", "TEST", 247, 263], ["respiratory", "ANATOMY", 95, 106], ["aspirates", "OBSERVATION", 120, 129]]], ["Viral RNA and DNA were extracted using a MinElute kit (Qiagen, Valencia, CA, USA).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["Viral RNA", "RNA", 0, 9], ["Viral RNA and DNA", "PROBLEM", 0, 17], ["a MinElute kit", "TREATMENT", 39, 53]]], ["Samples were assessed for the presence of viral RNA or DNA via PCR using the Seegene Seeplex RV-12 detection kit (Seegene, Rockville, MD, USA).", [["Samples", "ANATOMY", 0, 7], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["viral RNA", "RNA", 42, 51], ["Samples", "TEST", 0, 7], ["viral RNA", "PROBLEM", 42, 51], ["PCR", "TEST", 63, 66], ["the Seegene Seeplex RV", "TEST", 73, 95], ["viral RNA", "OBSERVATION", 42, 51]]], ["This kit detects human parainfluenza viruses 1, 2, and 3, human metapneumovirus, human coronavirus 229E/NL63, and OC43, human adenovirus, influenza viruses A and B, human respiratory syncytial virus (RSV) A and B, and human rhinovirus A.Detection of respiratory virusesWe also analysed specimens for respiratory viruses using a novel polymerase chain PCR-LDR multiplex assay [23] .", [["specimens", "ANATOMY", 286, 295], ["parainfluenza viruses", "DISEASE", 23, 44], ["influenza viruses", "DISEASE", 138, 155], ["respiratory syncytial virus", "DISEASE", 171, 198], ["respiratory viruses", "DISEASE", 300, 319], ["human", "ORGANISM", 17, 22], ["parainfluenza viruses 1", "ORGANISM", 23, 46], ["2", "GENE_OR_GENE_PRODUCT", 48, 49], ["3", "GENE_OR_GENE_PRODUCT", 55, 56], ["human", "ORGANISM", 58, 63], ["metapneumovirus", "ORGANISM", 64, 79], ["human", "ORGANISM", 81, 86], ["coronavirus 229E", "ORGANISM", 87, 103], ["NL63", "GENE_OR_GENE_PRODUCT", 104, 108], ["OC43", "GENE_OR_GENE_PRODUCT", 114, 118], ["human adenovirus, influenza viruses A and B,", "ORGANISM", 120, 164], ["human respiratory syncytial virus", "ORGANISM", 165, 198], ["RSV", "ORGANISM", 200, 203], ["B", "GENE_OR_GENE_PRODUCT", 211, 212], ["human", "ORGANISM", 218, 223], ["rhinovirus", "ORGANISM", 224, 234], ["human", "SPECIES", 17, 22], ["parainfluenza", "SPECIES", 23, 36], ["human", "SPECIES", 58, 63], ["metapneumovirus", "SPECIES", 64, 79], ["human", "SPECIES", 81, 86], ["coronavirus", "SPECIES", 87, 98], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 165, 170], ["respiratory syncytial virus", "SPECIES", 171, 198], ["human", "SPECIES", 218, 223], ["rhinovirus", "SPECIES", 224, 234], ["human parainfluenza viruses", "SPECIES", 17, 44], ["human metapneumovirus", "SPECIES", 58, 79], ["human coronavirus 229E/NL63", "SPECIES", 81, 108], ["OC43", "SPECIES", 114, 118], ["human", "SPECIES", 120, 125], ["human respiratory syncytial virus", "SPECIES", 165, 198], ["RSV", "SPECIES", 200, 203], ["human rhinovirus", "SPECIES", 218, 234], ["This kit", "TEST", 0, 8], ["human parainfluenza viruses", "TEST", 17, 44], ["human metapneumovirus", "TEST", 58, 79], ["human coronavirus", "TEST", 81, 98], ["OC43", "TEST", 114, 118], ["human adenovirus", "TREATMENT", 120, 136], ["influenza viruses", "PROBLEM", 138, 155], ["human respiratory syncytial virus", "PROBLEM", 165, 198], ["human rhinovirus", "TREATMENT", 218, 234], ["respiratory virusesWe", "PROBLEM", 250, 271], ["respiratory viruses", "PROBLEM", 300, 319], ["a novel polymerase chain PCR", "TEST", 326, 354], ["LDR multiplex assay", "TEST", 355, 374], ["parainfluenza viruses", "OBSERVATION", 23, 44], ["respiratory syncytial", "ANATOMY", 171, 192]]], ["The original system, which was designed to detect influenza viruses, was expanded to include parainfluenza 1, 2, 3, 4A and 4B, coronaviruses 229E and OC43, influenza A and B, rhinoviruses A, B, and C, adenoviruses A-E, metapneumovirus, and RSV A and B. We have detected all the viruses included in this multiplex system in clinical samples (i.e. nasal aspirates), with the exception of the adenoviruses, for which we used laboratory positive controls.", [["samples", "ANATOMY", 332, 339], ["nasal aspirates", "ANATOMY", 346, 361], ["influenza viruses", "DISEASE", 50, 67], ["parainfluenza 1", "ORGANISM", 93, 108], ["2", "GENE_OR_GENE_PRODUCT", 110, 111], ["3", "GENE_OR_GENE_PRODUCT", 113, 114], ["4A", "GENE_OR_GENE_PRODUCT", 116, 118], ["4B", "GENE_OR_GENE_PRODUCT", 123, 125], ["coronaviruses 229E", "ORGANISM", 127, 145], ["OC43", "GENE_OR_GENE_PRODUCT", 150, 154], ["influenza A", "ORGANISM", 156, 167], ["B", "GENE_OR_GENE_PRODUCT", 172, 173], ["rhinoviruses A", "ORGANISM", 175, 189], ["B", "GENE_OR_GENE_PRODUCT", 191, 192], ["C", "GENE_OR_GENE_PRODUCT", 198, 199], ["adenoviruses A-E", "ORGANISM", 201, 217], ["metapneumovirus", "ORGANISM", 219, 234], ["RSV A", "ORGANISM", 240, 245], ["samples", "CANCER", 332, 339], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 346, 361], ["adenoviruses", "ORGANISM", 390, 402], ["parainfluenza", "SPECIES", 93, 106], ["RSV", "SPECIES", 240, 243], ["influenza viruses", "PROBLEM", 50, 67], ["parainfluenza", "TEST", 93, 106], ["4A", "TEST", 116, 118], ["4B", "TEST", 123, 125], ["coronaviruses", "TEST", 127, 140], ["OC43", "TEST", 150, 154], ["influenza A", "TEST", 156, 167], ["rhinoviruses", "TEST", 175, 187], ["adenoviruses", "TEST", 201, 213], ["metapneumovirus", "PROBLEM", 219, 234], ["all the viruses", "PROBLEM", 270, 285], ["clinical samples", "TEST", 323, 339], ["nasal aspirates", "TEST", 346, 361], ["the adenoviruses", "PROBLEM", 386, 402], ["viruses", "OBSERVATION", 278, 285], ["adenoviruses", "OBSERVATION", 390, 402]]], ["The viral sequences for the multiplex assay are listed in Table 1 .Detection of nasal aspirate cytokine protein levelsProtein levels of IFN-c, CXCL8/IL-8, CXCL10/IP-10, CCL5/RANTES, CCL11/eotaxin-1, CCL2/MCP-1, CCL4/ MIP-1b, CCL7/MCP-3, CCL19/MIP-3b, and CCL20/MIP-3a were determined using a magnetic bead-based multiplex immune assay (Bio-Rad, Hercules, CA, USA).", [["nasal aspirate", "ANATOMY", 80, 94], ["IFN-c", "GENE_OR_GENE_PRODUCT", 136, 141], ["CXCL8", "GENE_OR_GENE_PRODUCT", 143, 148], ["IL-8", "GENE_OR_GENE_PRODUCT", 149, 153], ["CXCL10", "GENE_OR_GENE_PRODUCT", 155, 161], ["IP-10", "GENE_OR_GENE_PRODUCT", 162, 167], ["CCL5", "GENE_OR_GENE_PRODUCT", 169, 173], ["RANTES", "GENE_OR_GENE_PRODUCT", 174, 180], ["CCL11", "GENE_OR_GENE_PRODUCT", 182, 187], ["eotaxin-1", "GENE_OR_GENE_PRODUCT", 188, 197], ["CCL2", "GENE_OR_GENE_PRODUCT", 199, 203], ["MCP-1", "GENE_OR_GENE_PRODUCT", 204, 209], ["CCL4", "GENE_OR_GENE_PRODUCT", 211, 215], ["MIP-1b", "GENE_OR_GENE_PRODUCT", 217, 223], ["CCL7", "GENE_OR_GENE_PRODUCT", 225, 229], ["MCP-3", "GENE_OR_GENE_PRODUCT", 230, 235], ["CCL19", "GENE_OR_GENE_PRODUCT", 237, 242], ["MIP-3b", "GENE_OR_GENE_PRODUCT", 243, 249], ["CCL20", "GENE_OR_GENE_PRODUCT", 255, 260], ["MIP-3a", "GENE_OR_GENE_PRODUCT", 261, 267], ["viral sequences", "DNA", 4, 19], ["nasal aspirate cytokine protein", "PROTEIN", 80, 111], ["IFN", "PROTEIN", 136, 139], ["CXCL8", "PROTEIN", 143, 148], ["IL", "PROTEIN", 149, 151], ["CXCL10", "PROTEIN", 155, 161], ["IP", "PROTEIN", 162, 164], ["CCL5", "PROTEIN", 169, 173], ["RANTES", "PROTEIN", 174, 180], ["CCL11", "PROTEIN", 182, 187], ["eotaxin", "PROTEIN", 188, 195], ["CCL2", "PROTEIN", 199, 203], ["MCP", "PROTEIN", 204, 207], ["CCL4", "PROTEIN", 211, 215], ["MIP", "PROTEIN", 217, 220], ["CCL7", "PROTEIN", 225, 229], ["MCP", "PROTEIN", 230, 233], ["CCL19", "PROTEIN", 237, 242], ["CCL20", "PROTEIN", 255, 260], ["MIP", "PROTEIN", 261, 264], ["The viral sequences", "TEST", 0, 19], ["the multiplex assay", "TEST", 24, 43], ["nasal aspirate cytokine protein levels", "TEST", 80, 118], ["Protein levels", "TEST", 118, 132], ["IFN", "TEST", 136, 139], ["c", "TEST", 140, 141], ["CXCL8", "TEST", 143, 148], ["IL", "TEST", 149, 151], ["CXCL10", "TEST", 155, 161], ["IP", "TEST", 162, 164], ["CCL5", "TEST", 169, 173], ["RANTES", "TEST", 174, 180], ["CCL11", "TEST", 182, 187], ["eotaxin", "TEST", 188, 195], ["CCL2", "TEST", 199, 203], ["MCP", "TEST", 204, 207], ["CCL4", "TEST", 211, 215], ["MIP", "TEST", 217, 220], ["CCL7", "TEST", 225, 229], ["MCP", "TEST", 230, 233], ["CCL19", "TEST", 237, 242], ["MIP", "TEST", 243, 246], ["CCL20/MIP", "TEST", 255, 264], ["a magnetic bead", "TEST", 290, 305], ["multiplex immune assay", "TEST", 312, 334], ["Bio", "TEST", 336, 339], ["nasal", "ANATOMY", 80, 85], ["aspirate", "OBSERVATION", 86, 94]]], ["Our interest on the above CC chemokines was prompted by gene array results from RV1B-infected, ovalbumin-sensitized, and -challenged mice (data not shown).", [["CC", "CHEMICAL", 26, 28], ["RV1B", "GENE_OR_GENE_PRODUCT", 80, 84], ["ovalbumin", "ORGANISM", 95, 104], ["mice", "ORGANISM", 133, 137], ["CC chemokines", "PROTEIN", 26, 39], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 133, 137], ["the above CC chemokines", "TREATMENT", 16, 39], ["RV1B", "TEST", 80, 84], ["ovalbumin", "TREATMENT", 95, 104]]], ["IFN-a and IFN-b levels were measured using standard ELISA (R&D Systems, Minneapolis, MN, USA).Detection of nasal aspirate mRNA expressionAspirates were homogenized and mRNA extracted as described above, using the RNEasy or the RNEasyPlus kit (Qiagen). mRNA was analysed for CXCL8/IL-8, CXCL10/ IP10, CCL5/RANTES, CCL11/eotaxin, IFN-k1, IFN-k2/3, IFN-a, IFN-b, ICAM-1, TLR3, MDA-5, RIG-I, and IRF7 using quantitative real time PCR using specific primers and probes.", [["nasal aspirate", "ANATOMY", 107, 121], ["IFN-a", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-b", "GENE_OR_GENE_PRODUCT", 10, 15], ["nasal aspirate", "MULTI-TISSUE_STRUCTURE", 107, 121], ["CXCL8", "GENE_OR_GENE_PRODUCT", 274, 279], ["IL-8", "GENE_OR_GENE_PRODUCT", 280, 284], ["CXCL10", "GENE_OR_GENE_PRODUCT", 286, 292], ["IP10", "GENE_OR_GENE_PRODUCT", 294, 298], ["CCL5", "GENE_OR_GENE_PRODUCT", 300, 304], ["RANTES", "GENE_OR_GENE_PRODUCT", 305, 311], ["CCL11", "GENE_OR_GENE_PRODUCT", 313, 318], ["eotaxin", "GENE_OR_GENE_PRODUCT", 319, 326], ["IFN-k1", "GENE_OR_GENE_PRODUCT", 328, 334], ["IFN-k2/3", "GENE_OR_GENE_PRODUCT", 336, 344], ["IFN-a", "GENE_OR_GENE_PRODUCT", 346, 351], ["IFN-b", "GENE_OR_GENE_PRODUCT", 353, 358], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 360, 366], ["TLR3", "GENE_OR_GENE_PRODUCT", 368, 372], ["MDA-5", "GENE_OR_GENE_PRODUCT", 374, 379], ["RIG-I", "GENE_OR_GENE_PRODUCT", 381, 386], ["IRF7", "GENE_OR_GENE_PRODUCT", 392, 396], ["IFN", "PROTEIN", 0, 3], ["IFN", "PROTEIN", 10, 13], ["nasal aspirate mRNA expressionAspirates", "RNA", 107, 146], ["mRNA", "RNA", 168, 172], ["RNEasyPlus kit", "PROTEIN", 227, 241], ["mRNA", "RNA", 252, 256], ["CXCL8", "PROTEIN", 274, 279], ["IL", "PROTEIN", 280, 282], ["CXCL10", "PROTEIN", 286, 292], ["IP10", "PROTEIN", 294, 298], ["CCL5", "PROTEIN", 300, 304], ["RANTES", "PROTEIN", 305, 311], ["CCL11", "PROTEIN", 313, 318], ["eotaxin", "PROTEIN", 319, 326], ["IFN", "PROTEIN", 328, 331], ["IFN", "PROTEIN", 336, 339], ["k2/3", "PROTEIN", 340, 344], ["IFN", "PROTEIN", 346, 349], ["IFN", "PROTEIN", 353, 356], ["ICAM", "PROTEIN", 360, 364], ["TLR3", "PROTEIN", 368, 372], ["MDA", "PROTEIN", 374, 377], ["RIG", "PROTEIN", 381, 384], ["IRF7", "PROTEIN", 392, 396], ["IFN", "TEST", 0, 3], ["a and IFN-b levels", "TEST", 4, 22], ["nasal aspirate mRNA expressionAspirates", "PROBLEM", 107, 146], ["the RNEasyPlus kit", "TREATMENT", 223, 241], ["mRNA", "TEST", 252, 256], ["CXCL8", "TEST", 274, 279], ["IL", "TEST", 280, 282], ["CXCL10", "TEST", 286, 292], ["IP10", "TEST", 294, 298], ["CCL5", "TEST", 300, 304], ["RANTES", "TEST", 305, 311], ["CCL11", "TEST", 313, 318], ["eotaxin", "TEST", 319, 326], ["IFN", "TEST", 328, 331], ["IFN", "TEST", 336, 339], ["k2/3", "TEST", 340, 344], ["IFN", "TEST", 346, 349], ["IFN", "TEST", 353, 356], ["ICAM", "TEST", 360, 364], ["TLR3", "TEST", 368, 372], ["MDA", "TEST", 374, 377], ["quantitative real time PCR", "TEST", 403, 429], ["specific primers", "TREATMENT", 436, 452], ["nasal", "ANATOMY", 107, 112], ["aspirate mRNA", "OBSERVATION", 113, 126]]], ["Signals were normalized to GAPDH.Fraction of exhaled nitric oxide in exhaled breath (FeNO)We assessed FeNO in exhaled breath on 3 days during a week when the child was well, and on at least 3 days during a viral infection.", [["nitric oxide", "CHEMICAL", 53, 65], ["FeNO", "CHEMICAL", 102, 106], ["viral infection", "DISEASE", 206, 221], ["nitric oxide", "CHEMICAL", 53, 65], ["GAPDH", "GENE_OR_GENE_PRODUCT", 27, 32], ["exhaled nitric oxide", "SIMPLE_CHEMICAL", 45, 65], ["FeNO", "SIMPLE_CHEMICAL", 102, 106], ["child", "ORGANISM", 158, 163], ["GAPDH", "PROTEIN", 27, 32], ["exhaled nitric oxide", "TREATMENT", 45, 65], ["exhaled breath", "TEST", 69, 83], ["FeNO", "TEST", 102, 106], ["a viral infection", "PROBLEM", 204, 221], ["exhaled", "OBSERVATION", 45, 52], ["nitric oxide", "OBSERVATION", 53, 65], ["viral", "OBSERVATION_MODIFIER", 206, 211], ["infection", "OBSERVATION", 212, 221]]], ["To measure FeNO, we employed the NIOX MINO (Aerocrine, New Providence, NJ, USA).", [["FeNO", "GENE_OR_GENE_PRODUCT", 11, 15], ["FeNO", "TREATMENT", 11, 15], ["the NIOX MINO", "TREATMENT", 29, 42]]], ["Because FeNO measurement can be influenced by diet and exercise, participants were asked to refrain from eating or drinking within 1 h of their exhaled breath assessment.", [["FeNO", "GENE_OR_GENE_PRODUCT", 8, 12], ["participants", "SPECIES", 65, 77], ["FeNO measurement", "TEST", 8, 24], ["their exhaled breath assessment", "TEST", 138, 169]]], ["Triplicate samples were obtained to assess reliability.Statistical designMean, standard deviation and interquartile range were used to describe measured values of nasal cytokine levels, nasal mRNA, and symptom score before and during viral illnesses.", [["samples", "ANATOMY", 11, 18], ["nasal", "ANATOMY", 163, 168], ["nasal", "ANATOMY", 186, 191], ["viral illnesses", "DISEASE", 234, 249], ["nasal", "ORGANISM_SUBDIVISION", 163, 168], ["nasal", "ORGAN", 186, 191], ["cytokine", "PROTEIN", 169, 177], ["nasal mRNA", "RNA", 186, 196], ["Triplicate samples", "TEST", 0, 18], ["Statistical designMean", "PROBLEM", 55, 77], ["standard deviation and interquartile range", "PROBLEM", 79, 121], ["nasal cytokine levels", "TEST", 163, 184], ["nasal mRNA", "PROBLEM", 186, 196], ["symptom score", "PROBLEM", 202, 215], ["viral illnesses", "PROBLEM", 234, 249], ["nasal cytokine", "ANATOMY", 163, 177], ["nasal mRNA", "ANATOMY", 186, 196]]], ["Box plots were used to represent the change in biomarkers at different points of the cold relative to the baseline.", [["Box plots", "TEST", 0, 9], ["the change in biomarkers", "PROBLEM", 33, 57], ["change", "OBSERVATION_MODIFIER", 37, 43]]], ["Whiskers of the boxplots represent the minimum and maximum values.", [["minimum", "OBSERVATION_MODIFIER", 39, 46]]], ["The effects of viral illness, as defined by the Seegene kit results, on biomarker protein levels, and of biomarker level on symptom score were determined using a generalized mixed models (PROC MIXED), with an auto-regressive correlation structure using SAS statistical software (SAS, Cary, NC, USA).", [["viral illness", "DISEASE", 15, 28], ["viral illness", "PROBLEM", 15, 28], ["biomarker protein levels", "TEST", 72, 96], ["symptom score", "TEST", 124, 137], ["a generalized mixed models (PROC MIXED)", "PROBLEM", 160, 199], ["viral illness", "OBSERVATION", 15, 28]]], ["We evaluated and adjusted for relevant covariates such as age, gender, ethnicity/race, and nasal steroid use.", [["nasal", "ANATOMY", 91, 96], ["steroid", "CHEMICAL", 97, 104], ["steroid", "CHEMICAL", 97, 104], ["nasal", "ORGANISM_SUBDIVISION", 91, 96], ["steroid", "SIMPLE_CHEMICAL", 97, 104], ["nasal steroid use", "TREATMENT", 91, 108], ["nasal", "ANATOMY", 91, 96]]], ["Other potential explanatory variables, such as family income, baseline asthma severity, tobacco smoke exposure, and oral antihistamine use were evaluated, but not included in final models as they were not significant predictors.", [["oral", "ANATOMY", 116, 120], ["asthma", "DISEASE", 71, 77], ["smoke", "CHEMICAL", 96, 101], ["antihistamine", "CHEMICAL", 121, 134], ["tobacco", "ORGANISM", 88, 95], ["oral", "ORGANISM_SUBDIVISION", 116, 120], ["baseline asthma severity", "PROBLEM", 62, 86], ["oral antihistamine use", "TREATMENT", 116, 138]]], ["For all mRNA outcomes except IFN-b, levels were undetectable in a large number of samples.", [["samples", "ANATOMY", 82, 89], ["IFN-b", "GENE_OR_GENE_PRODUCT", 29, 34], ["samples", "CANCER", 82, 89], ["IFN", "PROTEIN", 29, 32], ["all mRNA outcomes", "TEST", 4, 21], ["IFN-b, levels", "TEST", 29, 42]]], ["We therefore categorized our results into detectable/non-detectable levels, and analysed as a binary variable using the generalized estimating equation (GEE) approach with the Tobit link [24] .", [["the generalized estimating equation", "TREATMENT", 116, 151]]], ["We analysed IFN-b mRNA levels as a continuous variable using the GEE approach with Identity link.", [["IFN-b", "GENE_OR_GENE_PRODUCT", 12, 17], ["IFN-b mRNA", "RNA", 12, 22], ["mRNA levels", "TEST", 18, 29], ["the GEE approach", "TREATMENT", 61, 77]]], ["Unadjusted models are shown.Study participantsSixteen children with physician-diagnosed asthma were recruited.", [["asthma", "DISEASE", 88, 94], ["children", "ORGANISM", 54, 62], ["participants", "SPECIES", 34, 46], ["children", "SPECIES", 54, 62], ["asthma", "PROBLEM", 88, 94], ["asthma", "OBSERVATION", 88, 94]]], ["Participants ranged in age from 6 to 16 years old, were 69% boys, 36% non-white, and reported symptoms or medication use consistent with persistent asthma ( Table 2) .Participant respiratory illnessesParticipants completed a total of 37 weeks of assessment ( Table 3 ).", [["respiratory", "ANATOMY", 179, 190], ["asthma", "DISEASE", 148, 154], ["respiratory illnesses", "DISEASE", 179, 200], ["Participants", "SPECIES", 0, 12], ["boys", "SPECIES", 60, 64], ["Participant", "SPECIES", 167, 178], ["Participants", "SPECIES", 200, 212], ["symptoms", "PROBLEM", 94, 102], ["persistent asthma", "PROBLEM", 137, 154], ["Participant respiratory illnesses", "PROBLEM", 167, 200], ["assessment", "TEST", 246, 256], ["persistent", "OBSERVATION_MODIFIER", 137, 147], ["asthma", "OBSERVATION", 148, 154]]], ["The current report focuses on the 28 weeks where there was concordance between self- reported illness and viral detection using the Seegene kit (16 virus-positive 'sick' weeks, and 12 virus-negative 'well' weeks).", [["illness", "DISEASE", 94, 101], ["viral detection", "TEST", 106, 121], ["the Seegene kit", "TEST", 128, 143]]], ["We re-tested eight positive and seven negative samples (by Seeplex) using the PCR-ligation detection multiplex assay.", [["samples", "ANATOMY", 47, 54], ["the PCR", "TEST", 74, 81], ["ligation detection multiplex assay", "TEST", 82, 116]]], ["Twelve of 15 samples were concordant between the two assays.", [["samples", "ANATOMY", 13, 20], ["samples", "CANCER", 13, 20], ["the two assays", "TEST", 45, 59]]], ["Two samples were positive by Seeplex and negative by PCR-LDR.", [["samples", "ANATOMY", 4, 11], ["Two samples", "TEST", 0, 11], ["Seeplex", "TEST", 29, 36], ["PCR", "TEST", 53, 56], ["LDR", "PROBLEM", 57, 60]]], ["One sample showed RSV by Seeplex assay and coronavirus OC43 by PCR-LDR.Participant respiratory illnessesSymptom scores, which qualitatively evaluated the severity of illness, rose during the sick weeks (Fig. 1a) .Participant respiratory illnessesRespiratory symptoms were highest at the first assessment during sick weeks, 1-3 days after initial report of illness.", [["sample", "ANATOMY", 4, 10], ["respiratory", "ANATOMY", 225, 236], ["respiratory illnesses", "DISEASE", 83, 104], ["illness", "DISEASE", 166, 173], ["respiratory illnesses", "DISEASE", 225, 246], ["illness", "DISEASE", 356, 363], ["RSV", "ORGANISM", 18, 21], ["coronavirus", "ORGANISM", 43, 54], ["Participant", "SPECIES", 71, 82], ["Participant", "SPECIES", 213, 224], ["RSV", "SPECIES", 18, 21], ["One sample", "TEST", 0, 10], ["RSV", "PROBLEM", 18, 21], ["Seeplex assay", "TEST", 25, 38], ["coronavirus OC43", "TEST", 43, 59], ["PCR", "TEST", 63, 66], ["LDR", "PROBLEM", 67, 70], ["Participant respiratory illnessesSymptom scores", "PROBLEM", 71, 118], ["illness", "PROBLEM", 166, 173], ["Participant respiratory illnesses", "PROBLEM", 213, 246], ["Respiratory symptoms", "PROBLEM", 246, 266], ["illness", "PROBLEM", 356, 363], ["RSV", "OBSERVATION", 18, 21]]], ["Children with confirmed viral illnesses experienced significant increases in cough, wheeze, and chest tightness, indicative of asthma exacerbation (Table 4) .Nasal cytokine profilesSelected nasal aspirate cytokines were measured using magnetic bead-based multiplex immune assay.", [["chest", "ANATOMY", 96, 101], ["Nasal", "ANATOMY", 158, 163], ["nasal aspirate", "ANATOMY", 190, 204], ["viral illnesses", "DISEASE", 24, 39], ["cough", "DISEASE", 77, 82], ["wheeze", "DISEASE", 84, 90], ["chest tightness", "DISEASE", 96, 111], ["asthma", "DISEASE", 127, 133], ["Children", "ORGANISM", 0, 8], ["chest", "ORGANISM_SUBDIVISION", 96, 101], ["cytokine", "PROTEIN", 164, 172], ["nasal aspirate cytokines", "PROTEIN", 190, 214], ["Children", "SPECIES", 0, 8], ["viral illnesses", "PROBLEM", 24, 39], ["cough", "PROBLEM", 77, 82], ["wheeze", "PROBLEM", 84, 90], ["chest tightness", "PROBLEM", 96, 111], ["asthma exacerbation", "PROBLEM", 127, 146], ["Nasal cytokine profiles", "TEST", 158, 181], ["Selected nasal aspirate cytokines", "TEST", 181, 214], ["magnetic bead", "TEST", 235, 248], ["significant", "OBSERVATION_MODIFIER", 52, 63], ["increases", "OBSERVATION_MODIFIER", 64, 73], ["cough", "OBSERVATION", 77, 82], ["chest", "ANATOMY", 96, 101], ["indicative of", "UNCERTAINTY", 113, 126], ["asthma", "OBSERVATION", 127, 133], ["cytokine profiles", "OBSERVATION", 164, 181], ["nasal", "ANATOMY", 190, 195], ["aspirate cytokines", "OBSERVATION", 196, 214]]], ["There were significant increases in all cytokines examined during weeks of reported symptoms, with the single exception of CCL7 (Table 5 , Fig. 1b) .", [["CCL7", "GENE_OR_GENE_PRODUCT", 123, 127], ["cytokines", "PROTEIN", 40, 49], ["CCL7", "PROTEIN", 123, 127], ["significant increases in all cytokines", "PROBLEM", 11, 49], ["reported symptoms", "PROBLEM", 75, 92], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["increases", "OBSERVATION_MODIFIER", 23, 32], ["all", "OBSERVATION_MODIFIER", 36, 39], ["cytokines", "OBSERVATION", 40, 49]]], ["This pattern was more striking when samples with documented viral infections were compared to those confirmed to be virus-negative.", [["samples", "ANATOMY", 36, 43], ["viral infections", "DISEASE", 60, 76], ["documented viral infections", "PROBLEM", 49, 76], ["virus", "TEST", 116, 121]]], ["Unadjusted estimates of the association of confirmed viral infection and cytokine level were highly significant (not shown) and did not change appreciably when adjusted for age, gender, race, and nasal steroid use.Nasal cytokine profilesChanges in cytokines over the course of the illness are shown in Fig. 2 .", [["nasal", "ANATOMY", 196, 201], ["Nasal", "ANATOMY", 214, 219], ["viral infection", "DISEASE", 53, 68], ["steroid", "CHEMICAL", 202, 209], ["illness", "DISEASE", 281, 288], ["steroid", "CHEMICAL", 202, 209], ["nasal", "ORGANISM_SUBDIVISION", 196, 201], ["steroid", "SIMPLE_CHEMICAL", 202, 209], ["cytokine", "PROTEIN", 73, 81], ["cytokine", "PROTEIN", 220, 228], ["cytokines", "PROTEIN", 248, 257], ["viral infection", "PROBLEM", 53, 68], ["cytokine level", "TEST", 73, 87], ["nasal steroid use", "TREATMENT", 196, 213], ["Nasal cytokine profiles", "TEST", 214, 237], ["Changes in cytokines", "PROBLEM", 237, 257], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infection", "OBSERVATION", 59, 68], ["nasal", "ANATOMY", 196, 201], ["cytokine profiles", "OBSERVATION", 220, 237], ["cytokines", "OBSERVATION", 248, 257]]], ["In most cases, cytokines increased during the first 2 days of infection and persisted throughout the week.Nasal cytokine profilesWe also examined the relationship between cytokines and symptom score.", [["Nasal", "ANATOMY", 106, 111], ["infection", "DISEASE", 62, 71], ["cytokines", "PROTEIN", 15, 24], ["cytokine", "PROTEIN", 112, 120], ["cytokines", "PROTEIN", 171, 180], ["cytokines", "PROBLEM", 15, 24], ["infection", "PROBLEM", 62, 71], ["Nasal cytokine profiles", "TEST", 106, 129], ["symptom score", "TEST", 185, 198], ["infection", "OBSERVATION", 62, 71], ["cytokine profiles", "OBSERVATION", 112, 129]]], ["Unadjusted estimates of the association of confirmed viral infection and cytokine level with symptom score were significant for IFN-c, CXCL8, CCL5, CCL20, CCL2, and CCL4 (Table 6) .", [["viral infection", "DISEASE", 53, 68], ["IFN-c", "GENE_OR_GENE_PRODUCT", 128, 133], ["CXCL8", "GENE_OR_GENE_PRODUCT", 135, 140], ["CCL5", "GENE_OR_GENE_PRODUCT", 142, 146], ["CCL20", "GENE_OR_GENE_PRODUCT", 148, 153], ["CCL2", "GENE_OR_GENE_PRODUCT", 155, 159], ["CCL4", "GENE_OR_GENE_PRODUCT", 165, 169], ["cytokine", "PROTEIN", 73, 81], ["IFN", "PROTEIN", 128, 131], ["CXCL8", "PROTEIN", 135, 140], ["CCL5", "PROTEIN", 142, 146], ["CCL20", "PROTEIN", 148, 153], ["CCL2", "PROTEIN", 155, 159], ["CCL4", "PROTEIN", 165, 169], ["viral infection", "PROBLEM", 53, 68], ["cytokine level", "TEST", 73, 87], ["symptom score", "TEST", 93, 106], ["IFN", "TEST", 128, 131], ["c", "TEST", 132, 133], ["CXCL8", "TEST", 135, 140], ["CCL5", "TEST", 142, 146], ["CCL20", "TEST", 148, 153], ["CCL2", "TEST", 155, 159], ["CCL4", "TEST", 165, 169], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["infection", "OBSERVATION", 59, 68]]], ["CXCL10, CCL11, CCL19, and CCL7 cytokine levels did not correlate with symptom score.Nasal cytokine profilesWe also attempted to measure IFN-a and IFN-b protein levels in the nasal aspirates by ELISA.", [["Nasal", "ANATOMY", 84, 89], ["nasal aspirates", "ANATOMY", 174, 189], ["CXCL10", "GENE_OR_GENE_PRODUCT", 0, 6], ["CCL11", "GENE_OR_GENE_PRODUCT", 8, 13], ["CCL19", "GENE_OR_GENE_PRODUCT", 15, 20], ["CCL7", "GENE_OR_GENE_PRODUCT", 26, 30], ["IFN-a", "GENE_OR_GENE_PRODUCT", 136, 141], ["IFN-b", "GENE_OR_GENE_PRODUCT", 146, 151], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 174, 189], ["CXCL10", "PROTEIN", 0, 6], ["CCL11", "PROTEIN", 8, 13], ["CCL19", "PROTEIN", 15, 20], ["CCL7", "PROTEIN", 26, 30], ["cytokine", "PROTEIN", 31, 39], ["cytokine", "PROTEIN", 90, 98], ["IFN", "PROTEIN", 136, 139], ["IFN", "PROTEIN", 146, 149], ["CXCL10", "TEST", 0, 6], ["CCL11", "TEST", 8, 13], ["CCL19", "TEST", 15, 20], ["CCL7 cytokine levels", "TEST", 26, 46], ["symptom score", "PROBLEM", 70, 83], ["Nasal cytokine profiles", "TEST", 84, 107], ["IFN", "TEST", 136, 139], ["IFN-b protein levels", "TEST", 146, 166], ["the nasal aspirates", "TEST", 170, 189], ["ELISA", "TEST", 193, 198], ["cytokine profiles", "OBSERVATION", 90, 107], ["nasal", "ANATOMY", 174, 179], ["aspirates", "OBSERVATION", 180, 189]]], ["IFN-a levels over the lower detection limit (12.5 pg/mL) were found in only five of 116 specimens (all virus-positive weeks).", [["specimens", "ANATOMY", 88, 97], ["IFN", "CHEMICAL", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["IFN", "PROTEIN", 0, 3], ["IFN", "TEST", 0, 3], ["a levels", "TEST", 4, 12], ["the lower detection limit", "TEST", 18, 43], ["all virus", "TEST", 99, 108]]], ["For IFN-b, levels over the detection limit (25 pg/mL) were found in only 12 samples (five virus-negative, seven virus-positive).Nasal aspirate mRNA levelsMany aspirates were dilute and a number of specimens showed no mRNA signal (Table 7) .", [["samples", "ANATOMY", 76, 83], ["Nasal aspirate", "ANATOMY", 128, 142], ["aspirates", "ANATOMY", 159, 168], ["specimens", "ANATOMY", 197, 206], ["IFN-b", "GENE_OR_GENE_PRODUCT", 4, 9], ["Nasal aspirate", "MULTI-TISSUE_STRUCTURE", 128, 142], ["specimens", "CANCER", 197, 206], ["IFN", "PROTEIN", 4, 7], ["IFN", "TEST", 4, 7], ["the detection limit", "TEST", 23, 42], ["five virus", "TEST", 85, 95], ["seven virus", "TEST", 106, 117], ["Nasal aspirate mRNA levels", "TEST", 128, 154], ["Many aspirates", "TEST", 154, 168], ["a number of specimens", "TEST", 185, 206], ["mRNA signal", "TEST", 217, 228], ["aspirate", "OBSERVATION", 134, 142], ["aspirates", "OBSERVATION", 159, 168], ["no", "UNCERTAINTY", 214, 216]]], ["Nevertheless, we detected transcripts for ICAM-1, CXCL-10, IFN-k1, CXCL-8, RIG-I, MDA-5, TLR3, IFNk2/3, IRF7, IFN-a, and IFN-b from patients both before and during viral infections.", [["viral infections", "DISEASE", 164, 180], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 42, 48], ["CXCL-10", "GENE_OR_GENE_PRODUCT", 50, 57], ["IFN-k1", "GENE_OR_GENE_PRODUCT", 59, 65], ["CXCL-8", "GENE_OR_GENE_PRODUCT", 67, 73], ["RIG-I", "GENE_OR_GENE_PRODUCT", 75, 80], ["MDA-5", "GENE_OR_GENE_PRODUCT", 82, 87], ["TLR3", "GENE_OR_GENE_PRODUCT", 89, 93], ["IFNk2", "GENE_OR_GENE_PRODUCT", 95, 100], ["3", "GENE_OR_GENE_PRODUCT", 101, 102], ["IRF7", "GENE_OR_GENE_PRODUCT", 104, 108], ["IFN-a", "GENE_OR_GENE_PRODUCT", 110, 115], ["IFN-b", "GENE_OR_GENE_PRODUCT", 121, 126], ["patients", "ORGANISM", 132, 140], ["ICAM", "PROTEIN", 42, 46], ["IFN", "PROTEIN", 59, 62], ["RIG", "PROTEIN", 75, 78], ["MDA", "PROTEIN", 82, 85], ["TLR3", "PROTEIN", 89, 93], ["IFNk2", "PROTEIN", 95, 100], ["IRF7", "PROTEIN", 104, 108], ["IFN", "PROTEIN", 110, 113], ["IFN", "PROTEIN", 121, 124], ["patients", "SPECIES", 132, 140], ["ICAM", "TEST", 42, 46], ["CXCL", "TEST", 50, 54], ["IFN", "TEST", 59, 62], ["k1", "TEST", 63, 65], ["CXCL", "TEST", 67, 71], ["RIG", "TEST", 75, 78], ["MDA", "TEST", 82, 85], ["TLR3", "TEST", 89, 93], ["IFNk2", "TEST", 95, 100], ["IRF7", "TEST", 104, 108], ["IFN", "TEST", 110, 113], ["IFN", "TEST", 121, 124], ["viral infections", "PROBLEM", 164, 180], ["viral infections", "OBSERVATION", 164, 180]]], ["We could not detect CCL5 and CCL11 mRNA in any specimens.", [["specimens", "ANATOMY", 47, 56], ["CCL5", "GENE_OR_GENE_PRODUCT", 20, 24], ["CCL11", "GENE_OR_GENE_PRODUCT", 29, 34], ["CCL5 and CCL11 mRNA", "RNA", 20, 39], ["CCL5", "TEST", 20, 24], ["CCL11 mRNA", "TEST", 29, 39], ["any specimens", "TEST", 43, 56], ["could not detect", "UNCERTAINTY", 3, 19]]], ["Finally, infection significantly increased the number of samples that were positive for CXCL8, IFN-k1, IFN-k2/3, TLR3, RIG-I, and IRF7 mRNA.FeNO measurementsWe measured FeNO before and during virus-positive sick weeks (Fig. 3) .", [["samples", "ANATOMY", 57, 64], ["infection", "DISEASE", 9, 18], ["FeNO", "CHEMICAL", 169, 173], ["CXCL8", "GENE_OR_GENE_PRODUCT", 88, 93], ["IFN-k1", "GENE_OR_GENE_PRODUCT", 95, 101], ["IFN-k2/3", "GENE_OR_GENE_PRODUCT", 103, 111], ["TLR3", "GENE_OR_GENE_PRODUCT", 113, 117], ["RIG-I", "GENE_OR_GENE_PRODUCT", 119, 124], ["IRF7", "GENE_OR_GENE_PRODUCT", 130, 134], ["FeNO", "GENE_OR_GENE_PRODUCT", 140, 144], ["FeNO", "GENE_OR_GENE_PRODUCT", 169, 173], ["CXCL8", "PROTEIN", 88, 93], ["IFN-k1, IFN-k2/3, TLR3, RIG-I, and IRF7 mRNA", "RNA", 95, 139], ["FeNO", "PROTEIN", 169, 173], ["infection", "PROBLEM", 9, 18], ["CXCL8", "TEST", 88, 93], ["IFN", "TEST", 95, 98], ["IFN", "TEST", 103, 106], ["k2/3", "TEST", 107, 111], ["TLR3", "TEST", 113, 117], ["RIG", "TEST", 119, 122], ["IRF7 mRNA", "PROBLEM", 130, 139], ["FeNO measurements", "TEST", 140, 157], ["FeNO", "TEST", 169, 173], ["virus", "TEST", 192, 197], ["infection", "OBSERVATION", 9, 18], ["IRF7 mRNA", "OBSERVATION", 130, 139]]], ["There was no significant change in FeNO measurement with viral infection.DiscussionViral infections are the most frequent cause of asthma attacks [1] [2] [3] .", [["viral infection", "DISEASE", 57, 72], ["DiscussionViral infections", "DISEASE", 73, 99], ["asthma", "DISEASE", 131, 137], ["FeNO", "GENE_OR_GENE_PRODUCT", 35, 39], ["significant change", "PROBLEM", 13, 31], ["FeNO measurement", "TEST", 35, 51], ["viral infection", "PROBLEM", 57, 72], ["DiscussionViral infections", "PROBLEM", 73, 99], ["asthma attacks", "PROBLEM", 131, 145], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["change", "OBSERVATION", 25, 31], ["FeNO", "OBSERVATION", 35, 39], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["infection", "OBSERVATION", 63, 72]]], ["In theory, chemokine production by virus-infected epithelial cells induces the recruitment of inflammatory cells to the airways, which in turn elaborate cytokines and mediators capable of increasing airway responses.", [["epithelial cells", "ANATOMY", 50, 66], ["inflammatory cells", "ANATOMY", 94, 112], ["airways", "ANATOMY", 120, 127], ["airway", "ANATOMY", 199, 205], ["epithelial cells", "CELL", 50, 66], ["inflammatory cells", "CELL", 94, 112], ["airways", "MULTI-TISSUE_STRUCTURE", 120, 127], ["airway", "MULTI-TISSUE_STRUCTURE", 199, 205], ["chemokine", "PROTEIN", 11, 20], ["virus-infected epithelial cells", "CELL_TYPE", 35, 66], ["inflammatory cells", "CELL_TYPE", 94, 112], ["cytokines", "PROTEIN", 153, 162], ["virus", "PROBLEM", 35, 40], ["infected epithelial cells", "PROBLEM", 41, 66], ["inflammatory cells to the airways", "PROBLEM", 94, 127], ["increasing airway responses", "PROBLEM", 188, 215], ["infected epithelial cells", "OBSERVATION", 41, 66], ["recruitment", "OBSERVATION_MODIFIER", 79, 90], ["inflammatory cells", "OBSERVATION", 94, 112], ["airways", "ANATOMY", 120, 127], ["increasing", "OBSERVATION_MODIFIER", 188, 198], ["airway", "ANATOMY", 199, 205]]], ["Data suggest that immune cells may also be infected by respiratory viruses and produce chemokines [7, [25] [26] [27] [28] [29] [30] .", [["immune cells", "ANATOMY", 18, 30], ["immune cells", "CELL", 18, 30], ["[25] [26] [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 102, 131], ["immune cells", "CELL_TYPE", 18, 30], ["chemokines", "PROTEIN", 87, 97], ["immune cells", "PROBLEM", 18, 30], ["respiratory viruses", "PROBLEM", 55, 74], ["chemokines", "TEST", 87, 97], ["immune cells", "OBSERVATION", 18, 30]]], ["In the present study, we found that, during natural colds, respiratory tract cytokine levels significantly increase in children with asthma.", [["respiratory tract", "ANATOMY", 59, 76], ["colds", "DISEASE", 52, 57], ["asthma", "DISEASE", 133, 139], ["tract", "ORGANISM_SUBDIVISION", 71, 76], ["children", "ORGANISM", 119, 127], ["cytokine", "PROTEIN", 77, 85], ["children", "SPECIES", 119, 127], ["the present study", "TEST", 3, 20], ["natural colds", "PROBLEM", 44, 57], ["respiratory tract cytokine levels", "PROBLEM", 59, 92], ["asthma", "PROBLEM", 133, 139], ["respiratory tract", "ANATOMY", 59, 76], ["increase", "OBSERVATION_MODIFIER", 107, 115], ["asthma", "OBSERVATION", 133, 139]]], ["Levels of a subset of cytokines correlated with the degree and time course of respiratory symptoms.", [["respiratory", "ANATOMY", 78, 89], ["respiratory symptoms", "DISEASE", 78, 98], ["cytokines", "PROTEIN", 22, 31], ["respiratory symptoms", "PROBLEM", 78, 98]]], ["The chemokines detected are responsible for recruitment of a broad array of inflammatory cells including neutrophils, monocytes, macrophages, and eosinophils.DiscussionFinally, we detected changes in nasal lavage specimens, which were collected at home on a repeated basis, both before and in association with infection.", [["inflammatory cells", "ANATOMY", 76, 94], ["neutrophils", "ANATOMY", 105, 116], ["monocytes", "ANATOMY", 118, 127], ["macrophages", "ANATOMY", 129, 140], ["eosinophils", "ANATOMY", 146, 157], ["nasal lavage specimens", "ANATOMY", 200, 222], ["infection", "DISEASE", 310, 319], ["inflammatory cells", "CELL", 76, 94], ["neutrophils", "CELL", 105, 116], ["monocytes", "CELL", 118, 127], ["macrophages", "CELL", 129, 140], ["eosinophils", "CELL", 146, 157], ["nasal lavage specimens", "ORGANISM_SUBSTANCE", 200, 222], ["chemokines", "PROTEIN", 4, 14], ["inflammatory cells", "CELL_TYPE", 76, 94], ["neutrophils", "CELL_TYPE", 105, 116], ["monocytes", "CELL_TYPE", 118, 127], ["macrophages", "CELL_TYPE", 129, 140], ["eosinophils", "CELL_TYPE", 146, 157], ["The chemokines", "TEST", 0, 14], ["inflammatory cells", "PROBLEM", 76, 94], ["neutrophils", "TEST", 105, 116], ["monocytes", "TEST", 118, 127], ["macrophages", "TEST", 129, 140], ["eosinophils", "TEST", 146, 157], ["nasal lavage specimens", "TEST", 200, 222], ["infection", "PROBLEM", 310, 319], ["chemokines", "OBSERVATION", 4, 14], ["responsible for", "UNCERTAINTY", 28, 43], ["inflammatory cells", "OBSERVATION", 76, 94], ["monocytes", "ANATOMY", 118, 127], ["macrophages", "ANATOMY", 129, 140], ["nasal", "ANATOMY", 200, 205], ["lavage", "OBSERVATION", 206, 212], ["infection", "OBSERVATION", 310, 319]]], ["Although we did not measure cytokine levels in normal subjects, these data show that children with asthma are apparently capable of a robust cytokine response to viral infection, even during mild exacerbations.", [["asthma", "DISEASE", 99, 105], ["viral infection", "DISEASE", 162, 177], ["children", "ORGANISM", 85, 93], ["cytokine", "PROTEIN", 28, 36], ["cytokine", "PROTEIN", 141, 149], ["children", "SPECIES", 85, 93], ["cytokine levels", "TEST", 28, 43], ["these data", "TEST", 64, 74], ["asthma", "PROBLEM", 99, 105], ["viral infection", "PROBLEM", 162, 177], ["mild exacerbations", "PROBLEM", 191, 209], ["viral", "OBSERVATION_MODIFIER", 162, 167], ["infection", "OBSERVATION", 168, 177], ["mild", "OBSERVATION_MODIFIER", 191, 195], ["exacerbations", "OBSERVATION", 196, 209]]], ["In addition, home collection of nasal lavage specimens appears to be a practical tool for studying the natural history of viral infection in children.DiscussionOur results expand upon prior work characterizing cytokine responses detectable in respiratory secretions of asthmatics in association with viral illnesses.", [["nasal lavage specimens", "ANATOMY", 32, 54], ["respiratory secretions", "ANATOMY", 243, 265], ["viral infection", "DISEASE", 122, 137], ["viral illnesses", "DISEASE", 300, 315], ["nasal lavage", "ORGANISM_SUBSTANCE", 32, 44], ["children", "ORGANISM", 141, 149], ["asthmatics", "ORGANISM", 269, 279], ["cytokine", "PROTEIN", 210, 218], ["children", "SPECIES", 141, 149], ["home collection of nasal lavage specimens", "TEST", 13, 54], ["viral infection", "PROBLEM", 122, 137], ["cytokine responses", "TEST", 210, 228], ["respiratory secretions", "PROBLEM", 243, 265], ["asthmatics", "PROBLEM", 269, 279], ["viral illnesses", "PROBLEM", 300, 315], ["nasal", "ANATOMY", 32, 37], ["lavage", "OBSERVATION", 38, 44], ["viral", "OBSERVATION_MODIFIER", 122, 127], ["infection", "OBSERVATION", 128, 137], ["respiratory secretions", "OBSERVATION", 243, 265], ["asthmatics", "OBSERVATION", 269, 279], ["viral illnesses", "OBSERVATION", 300, 315]]], ["Pizzichini et al. [15] found that, compared to 21 days after infection, sputum levels of CXCL8, eosinophil cationic protein and fibrinogen from six adult asthmatics were significantly elevated 4 days after the start of a coldinduced exacerbation.", [["sputum", "ANATOMY", 72, 78], ["infection", "DISEASE", 61, 70], ["CXCL8", "GENE_OR_GENE_PRODUCT", 89, 94], ["eosinophil cationic protein", "GENE_OR_GENE_PRODUCT", 96, 123], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 128, 138], ["asthmatics", "ORGANISM", 154, 164], ["CXCL8", "PROTEIN", 89, 94], ["eosinophil cationic protein", "PROTEIN", 96, 123], ["fibrinogen", "PROTEIN", 128, 138], ["infection", "PROBLEM", 61, 70], ["sputum levels", "TEST", 72, 85], ["CXCL8", "TEST", 89, 94], ["eosinophil cationic protein", "TEST", 96, 123], ["fibrinogen", "TEST", 128, 138], ["six adult asthmatics", "PROBLEM", 144, 164], ["significantly elevated", "PROBLEM", 170, 192], ["a coldinduced exacerbation", "PROBLEM", 219, 245], ["asthmatics", "OBSERVATION", 154, 164], ["exacerbation", "OBSERVATION", 233, 245]]], ["Furthermore, CXCL8 levels correlated with the number of sputum neutrophils.", [["sputum neutrophils", "ANATOMY", 56, 74], ["CXCL8", "GENE_OR_GENE_PRODUCT", 13, 18], ["sputum neutrophils", "CELL", 56, 74], ["CXCL8", "PROTEIN", 13, 18], ["sputum neutrophils", "CELL_TYPE", 56, 74], ["CXCL8 levels", "TEST", 13, 25], ["sputum neutrophils", "TEST", 56, 74], ["sputum neutrophils", "OBSERVATION", 56, 74]]], ["Teran et al. asthma [16] found that, compared to asymptomatic periods, levels of major basic protein, CCL5 and CCL19 were increased in the nasal aspirates of 26 children during acute viral-induced exacerbations.", [["nasal aspirates", "ANATOMY", 139, 154], ["asthma", "DISEASE", 13, 19], ["CCL5", "GENE_OR_GENE_PRODUCT", 102, 106], ["CCL19", "GENE_OR_GENE_PRODUCT", 111, 116], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 139, 154], ["children", "ORGANISM", 161, 169], ["major basic protein", "PROTEIN", 81, 100], ["CCL5", "PROTEIN", 102, 106], ["CCL19", "PROTEIN", 111, 116], ["children", "SPECIES", 161, 169], ["asthma", "PROBLEM", 13, 19], ["asymptomatic periods", "PROBLEM", 49, 69], ["major basic protein", "TEST", 81, 100], ["CCL5", "TEST", 102, 106], ["CCL19", "TEST", 111, 116], ["the nasal aspirates", "TEST", 135, 154], ["acute viral-induced exacerbations", "PROBLEM", 177, 210], ["increased", "OBSERVATION_MODIFIER", 122, 131], ["nasal", "ANATOMY", 139, 144], ["aspirates", "OBSERVATION", 145, 154], ["acute", "OBSERVATION_MODIFIER", 177, 182], ["viral", "OBSERVATION", 183, 188], ["exacerbations", "OBSERVATION", 197, 210]]], ["Grissell et al. asthma [17] found that compared to a group of stable asthmatics, levels of CCL5 and IL-10 were significantly elevated in the induced sputa of older children and adults suffering from acute viral-induced asthma exacerbations, along with neutrophils and eosinophils.", [["neutrophils", "ANATOMY", 252, 263], ["eosinophils", "ANATOMY", 268, 279], ["asthma", "DISEASE", 16, 22], ["asthma exacerbations", "DISEASE", 219, 239], ["asthmatics", "ORGANISM", 69, 79], ["CCL5", "GENE_OR_GENE_PRODUCT", 91, 95], ["IL-10", "GENE_OR_GENE_PRODUCT", 100, 105], ["children", "ORGANISM", 164, 172], ["neutrophils", "CELL", 252, 263], ["eosinophils", "CELL", 268, 279], ["CCL5", "PROTEIN", 91, 95], ["IL", "PROTEIN", 100, 102], ["neutrophils", "CELL_TYPE", 252, 263], ["eosinophils", "CELL_TYPE", 268, 279], ["children", "SPECIES", 164, 172], ["asthma", "PROBLEM", 16, 22], ["stable asthmatics", "PROBLEM", 62, 79], ["CCL5 and IL", "TEST", 91, 102], ["significantly elevated", "PROBLEM", 111, 133], ["acute viral-induced asthma exacerbations", "PROBLEM", 199, 239], ["neutrophils", "TEST", 252, 263], ["eosinophils", "TEST", 268, 279], ["et al", "OBSERVATION", 9, 14], ["stable", "OBSERVATION_MODIFIER", 62, 68], ["asthmatics", "OBSERVATION", 69, 79], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["viral", "OBSERVATION", 205, 210], ["asthma", "OBSERVATION", 219, 225]]], ["CXCL8 and CCL19 were also increased, although not significantly.", [["CXCL8", "GENE_OR_GENE_PRODUCT", 0, 5], ["CCL19", "GENE_OR_GENE_PRODUCT", 10, 15], ["CXCL8", "PROTEIN", 0, 5], ["CCL19", "PROTEIN", 10, 15], ["CXCL8", "TEST", 0, 5], ["CCL19", "TEST", 10, 15], ["increased", "OBSERVATION_MODIFIER", 26, 35]]], ["Finally, Santiago et al. [18] found that compared to control samples, CCL7 and CCL13 were increased in the nasal aspirates of asthmatic children 12 -24 h after upper respiratory tract infections.", [["samples", "ANATOMY", 61, 68], ["nasal aspirates", "ANATOMY", 107, 122], ["upper respiratory tract", "ANATOMY", 160, 183], ["asthmatic", "DISEASE", 126, 135], ["respiratory tract infections", "DISEASE", 166, 194], ["CCL7", "GENE_OR_GENE_PRODUCT", 70, 74], ["CCL13", "GENE_OR_GENE_PRODUCT", 79, 84], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 107, 122], ["children", "ORGANISM", 136, 144], ["upper", "ORGANISM_SUBDIVISION", 160, 165], ["respiratory tract", "ORGANISM_SUBDIVISION", 166, 183], ["CCL7", "PROTEIN", 70, 74], ["CCL13", "PROTEIN", 79, 84], ["children", "SPECIES", 136, 144], ["CCL7", "TEST", 70, 74], ["CCL13", "TEST", 79, 84], ["upper respiratory tract infections", "PROBLEM", 160, 194], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["nasal", "ANATOMY", 107, 112], ["aspirates", "OBSERVATION", 113, 122], ["upper", "ANATOMY_MODIFIER", 160, 165], ["respiratory tract", "ANATOMY", 166, 183], ["infections", "OBSERVATION", 184, 194]]], ["Chemokine levels correlated with macrophages in the nasal aspirate and upper respiratory symptoms scores.", [["macrophages", "ANATOMY", 33, 44], ["nasal aspirate", "ANATOMY", 52, 66], ["respiratory", "ANATOMY", 77, 88], ["Chemokine", "GENE_OR_GENE_PRODUCT", 0, 9], ["macrophages", "CELL", 33, 44], ["nasal aspirate", "MULTI-TISSUE_STRUCTURE", 52, 66], ["upper respiratory", "ORGANISM_SUBDIVISION", 71, 88], ["Chemokine", "PROTEIN", 0, 9], ["macrophages", "CELL_TYPE", 33, 44], ["Chemokine levels", "TEST", 0, 16], ["macrophages", "PROBLEM", 33, 44], ["the nasal aspirate", "TEST", 48, 66], ["upper respiratory symptoms scores", "PROBLEM", 71, 104], ["nasal", "ANATOMY", 52, 57], ["aspirate", "OBSERVATION", 58, 66], ["upper", "ANATOMY_MODIFIER", 71, 76], ["respiratory", "ANATOMY", 77, 88]]], ["In the present study, in which patients were used as their own controls, we confirmed the above changes in CXCL8, CCL5, CCL19, and CCL7, and provide new data showing significant increases in CXCL10, CCL11, CCL2, and CCL4.", [["patients", "ORGANISM", 31, 39], ["CXCL8", "GENE_OR_GENE_PRODUCT", 107, 112], ["CCL5", "GENE_OR_GENE_PRODUCT", 114, 118], ["CCL19", "GENE_OR_GENE_PRODUCT", 120, 125], ["CCL7", "GENE_OR_GENE_PRODUCT", 131, 135], ["CXCL10", "GENE_OR_GENE_PRODUCT", 191, 197], ["CCL11", "GENE_OR_GENE_PRODUCT", 199, 204], ["CCL2", "GENE_OR_GENE_PRODUCT", 206, 210], ["CCL4", "GENE_OR_GENE_PRODUCT", 216, 220], ["CXCL8", "PROTEIN", 107, 112], ["CCL5", "PROTEIN", 114, 118], ["CCL19", "PROTEIN", 120, 125], ["CCL7", "PROTEIN", 131, 135], ["CXCL10", "PROTEIN", 191, 197], ["CCL11", "PROTEIN", 199, 204], ["CCL2", "PROTEIN", 206, 210], ["CCL4", "PROTEIN", 216, 220], ["patients", "SPECIES", 31, 39], ["the present study", "TEST", 3, 20], ["CXCL8", "TEST", 107, 112], ["CCL5", "TEST", 114, 118], ["CCL19", "TEST", 120, 125], ["CCL7", "TEST", 131, 135], ["new data", "TEST", 149, 157], ["significant increases", "PROBLEM", 166, 187], ["CXCL10", "TEST", 191, 197], ["CCL11", "TEST", 199, 204], ["CCL2", "TEST", 206, 210], ["significant", "OBSERVATION_MODIFIER", 166, 177], ["increases", "OBSERVATION_MODIFIER", 178, 187], ["CCL4", "ANATOMY", 216, 220]]], ["Importantly, we found that increases in these chemokines were sustained throughout the week following viral infection.", [["viral infection", "DISEASE", 102, 117], ["chemokines", "PROTEIN", 46, 56], ["these chemokines", "PROBLEM", 40, 56], ["viral infection", "PROBLEM", 102, 117], ["increases", "OBSERVATION_MODIFIER", 27, 36], ["chemokines", "OBSERVATION", 46, 56], ["viral", "OBSERVATION_MODIFIER", 102, 107], ["infection", "OBSERVATION", 108, 117]]], ["We also examined the relationship between cytokines and respiratory symptom score.", [["respiratory", "ANATOMY", 56, 67], ["cytokines", "PROTEIN", 42, 51], ["respiratory symptom score", "PROBLEM", 56, 81], ["respiratory", "ANATOMY", 56, 67]]], ["Interestingly, we found that some cytokines correlated with symptom score (IFN-c, CXCL8, CCL5 , CCL20, CCL2, and CCL4) whereas others did not (CXCL10, CCL11, CCL19 or CCL7).", [["IFN-c", "GENE_OR_GENE_PRODUCT", 75, 80], ["CXCL8", "GENE_OR_GENE_PRODUCT", 82, 87], ["CCL5", "GENE_OR_GENE_PRODUCT", 89, 93], ["CCL20", "GENE_OR_GENE_PRODUCT", 96, 101], ["CCL2", "GENE_OR_GENE_PRODUCT", 103, 107], ["CCL4", "GENE_OR_GENE_PRODUCT", 113, 117], ["CXCL10", "GENE_OR_GENE_PRODUCT", 143, 149], ["CCL11", "GENE_OR_GENE_PRODUCT", 151, 156], ["CCL19", "GENE_OR_GENE_PRODUCT", 158, 163], ["CCL7", "GENE_OR_GENE_PRODUCT", 167, 171], ["cytokines", "PROTEIN", 34, 43], ["IFN", "PROTEIN", 75, 78], ["CXCL8", "PROTEIN", 82, 87], ["CCL5", "PROTEIN", 89, 93], ["CCL20", "PROTEIN", 96, 101], ["CCL2", "PROTEIN", 103, 107], ["CCL4", "PROTEIN", 113, 117], ["CXCL10", "PROTEIN", 143, 149], ["CCL11", "PROTEIN", 151, 156], ["CCL19", "PROTEIN", 158, 163], ["CCL7", "PROTEIN", 167, 171], ["some cytokines", "PROBLEM", 29, 43], ["symptom score", "TEST", 60, 73], ["IFN", "TEST", 75, 78], ["CXCL8", "TEST", 82, 87], ["CCL5", "TEST", 89, 93], ["CCL20", "TEST", 96, 101], ["CCL2", "TEST", 103, 107], ["CXCL10", "TEST", 143, 149], ["CCL11", "TEST", 151, 156]]], ["Although we did not examine lower airway cytokine levels, it is tempting to speculate that the former set of cytokines is responsible for the acute asthmatic response to viral infection, whereas the latter set may modulate future immune responses.", [["airway", "ANATOMY", 34, 40], ["viral infection", "DISEASE", 170, 185], ["airway", "MULTI-TISSUE_STRUCTURE", 34, 40], ["cytokine", "PROTEIN", 41, 49], ["cytokines", "PROTEIN", 109, 118], ["lower airway cytokine levels", "PROBLEM", 28, 56], ["the acute asthmatic response", "PROBLEM", 138, 166], ["viral infection", "PROBLEM", 170, 185], ["lower", "ANATOMY_MODIFIER", 28, 33], ["airway", "ANATOMY", 34, 40], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["asthmatic", "OBSERVATION", 148, 157], ["viral infection", "OBSERVATION", 170, 185]]], ["Based on differences in IFN-b and IFN-k production between cells isolated from controls and asthmatic subjects [31] [32] [33] , it has been proposed that patients with asthma are prone to rhinovirus-induced exacerbations due to deficient IFN production On the other hand, other in vitro studies showed no differences in rhinovirus-induced gene expression in epithelial cells isolated from asthmatic and healthy subjects [34, 35] , and con-trol and asthmatic subjects experimentally infected with rhinovirus show no difference in respiratory tract viral titre or copy number [14] .", [["cells", "ANATOMY", 59, 64], ["epithelial cells", "ANATOMY", 358, 374], ["asthma", "DISEASE", 168, 174], ["rhinovirus", "DISEASE", 188, 198], ["exacerbations", "DISEASE", 207, 220], ["IFN-b", "GENE_OR_GENE_PRODUCT", 24, 29], ["IFN-k", "GENE_OR_GENE_PRODUCT", 34, 39], ["cells", "CELL", 59, 64], ["patients", "ORGANISM", 154, 162], ["rhinovirus", "ORGANISM", 188, 198], ["IFN", "GENE_OR_GENE_PRODUCT", 238, 241], ["rhinovirus", "ORGANISM", 320, 330], ["epithelial cells", "CELL", 358, 374], ["rhinovirus", "ORGANISM", 496, 506], ["respiratory tract", "ORGANISM_SUBDIVISION", 529, 546], ["IFN", "PROTEIN", 24, 27], ["IFN", "PROTEIN", 34, 37], ["IFN", "PROTEIN", 238, 241], ["epithelial cells", "CELL_TYPE", 358, 374], ["patients", "SPECIES", 154, 162], ["IFN", "TEST", 24, 27], ["IFN", "TEST", 34, 37], ["asthmatic subjects", "PROBLEM", 92, 110], ["asthma", "PROBLEM", 168, 174], ["rhinovirus", "PROBLEM", 188, 198], ["induced exacerbations", "PROBLEM", 199, 220], ["deficient IFN production", "PROBLEM", 228, 252], ["vitro studies", "TEST", 281, 294], ["rhinovirus", "PROBLEM", 320, 330], ["epithelial cells", "PROBLEM", 358, 374], ["asthmatic and healthy subjects", "PROBLEM", 389, 419], ["asthmatic subjects", "PROBLEM", 448, 466], ["rhinovirus", "PROBLEM", 496, 506], ["difference in respiratory tract viral titre", "PROBLEM", 515, 558], ["rhinovirus", "OBSERVATION", 320, 330], ["epithelial cells", "OBSERVATION", 358, 374]]], ["We found that viral infection during natural colds significantly increased the levels of IFN-c protein and IFN-k mRNA in the nasal aspirates.", [["nasal aspirates", "ANATOMY", 125, 140], ["viral infection", "DISEASE", 14, 29], ["colds", "DISEASE", 45, 50], ["IFN-c", "GENE_OR_GENE_PRODUCT", 89, 94], ["IFN-k", "GENE_OR_GENE_PRODUCT", 107, 112], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 125, 140], ["IFN-c protein", "PROTEIN", 89, 102], ["IFN-k mRNA", "RNA", 107, 117], ["viral infection", "PROBLEM", 14, 29], ["natural colds", "PROBLEM", 37, 50], ["the levels", "TEST", 75, 85], ["IFN", "TEST", 89, 92], ["protein", "TEST", 95, 102], ["IFN", "TEST", 107, 110], ["the nasal aspirates", "TEST", 121, 140], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infection", "OBSERVATION", 20, 29], ["nasal", "ANATOMY", 125, 130], ["aspirates", "OBSERVATION", 131, 140]]], ["Viral infection also significantly increased the expression level of RIG-I and IRF-7, each of which are inducible by type I IFNs [36, 37] .", [["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["RIG-I", "GENE_OR_GENE_PRODUCT", 69, 74], ["IRF-7", "GENE_OR_GENE_PRODUCT", 79, 84], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 117, 128], ["RIG", "PROTEIN", 69, 72], ["IRF-7", "PROTEIN", 79, 84], ["type I IFNs", "PROTEIN", 117, 128], ["Viral infection", "PROBLEM", 0, 15], ["IRF", "TEST", 79, 82], ["infection", "OBSERVATION", 6, 15], ["significantly", "OBSERVATION_MODIFIER", 21, 34], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["RIG-I", "OBSERVATION_MODIFIER", 69, 74], ["IRF", "OBSERVATION", 79, 82]]], ["Together, these data suggest that asthmatic children are capable of a functional IFN response.", [["asthmatic", "DISEASE", 34, 43], ["children", "ORGANISM", 44, 52], ["IFN", "GENE_OR_GENE_PRODUCT", 81, 84], ["IFN", "PROTEIN", 81, 84], ["children", "SPECIES", 44, 52]]], ["On the other hand, we failed to detect IFN-a or IFN-b protein in nasal aspirates, and there was no significant change in mRNA levels during natural colds.", [["nasal aspirates", "ANATOMY", 65, 80], ["colds", "DISEASE", 148, 153], ["IFN-a", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFN-b", "GENE_OR_GENE_PRODUCT", 48, 53], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 65, 80], ["IFN", "PROTEIN", 39, 42], ["IFN-b protein", "PROTEIN", 48, 61], ["IFN", "TEST", 39, 42], ["IFN-b protein", "TEST", 48, 61], ["nasal aspirates", "TEST", 65, 80], ["significant change in mRNA levels", "PROBLEM", 99, 132], ["nasal", "ANATOMY", 65, 70], ["aspirates", "OBSERVATION", 71, 80], ["no", "UNCERTAINTY", 96, 98], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["change", "OBSERVATION", 111, 117], ["mRNA levels", "OBSERVATION", 121, 132]]], ["Detection of type I IFNs in respiratory secretions is made difficult by the low sensitivity of commercially available assays, physiologically low levels of these cytokines in biological fluids (particularly in fluids without sufficient numbers of plasmacytoid dendritic cells) and presence of natural inhibitors (e.g. soluble receptors).", [["respiratory secretions", "ANATOMY", 28, 50], ["fluids", "ANATOMY", 210, 216], ["plasmacytoid dendritic cells", "ANATOMY", 247, 275], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 13, 24], ["plasmacytoid dendritic cells", "CELL", 247, 275], ["type I IFNs", "PROTEIN", 13, 24], ["cytokines", "PROTEIN", 162, 171], ["plasmacytoid dendritic cells", "CELL_TYPE", 247, 275], ["soluble receptors", "PROTEIN", 318, 335], ["type I IFNs in respiratory secretions", "PROBLEM", 13, 50], ["assays", "TEST", 118, 124], ["physiologically low levels", "PROBLEM", 126, 152], ["these cytokines in biological fluids", "TREATMENT", 156, 192], ["plasmacytoid dendritic cells", "TREATMENT", 247, 275], ["natural inhibitors", "TREATMENT", 293, 311], ["respiratory secretions", "OBSERVATION", 28, 50], ["plasmacytoid dendritic cells", "OBSERVATION", 247, 275]]], ["Also, we could not compare the results from our experimental subjects to children without asthma.", [["asthma", "DISEASE", 90, 96], ["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["asthma", "PROBLEM", 90, 96]]], ["Our finding that IRF7 mRNA is elevated after respiratory viral infection in children with asthma is validated by a recent study analysing patterns of gene expression in nasal lavage samples from children experiencing picornavirus-induced asthma exacerbations [38] .", [["nasal lavage samples", "ANATOMY", 169, 189], ["respiratory viral infection", "DISEASE", 45, 72], ["asthma", "DISEASE", 90, 96], ["picornavirus", "DISEASE", 217, 229], ["asthma exacerbations", "DISEASE", 238, 258], ["IRF7", "GENE_OR_GENE_PRODUCT", 17, 21], ["children", "ORGANISM", 76, 84], ["nasal lavage samples", "ORGANISM_SUBSTANCE", 169, 189], ["children", "ORGANISM", 195, 203], ["IRF7 mRNA", "RNA", 17, 26], ["children", "SPECIES", 76, 84], ["children", "SPECIES", 195, 203], ["IRF7 mRNA", "PROBLEM", 17, 26], ["respiratory viral infection", "PROBLEM", 45, 72], ["asthma", "PROBLEM", 90, 96], ["a recent study", "TEST", 113, 127], ["gene expression", "PROBLEM", 150, 165], ["nasal lavage samples", "TREATMENT", 169, 189], ["picornavirus", "PROBLEM", 217, 229], ["asthma exacerbations", "PROBLEM", 238, 258], ["IRF7 mRNA", "OBSERVATION", 17, 26], ["elevated", "OBSERVATION_MODIFIER", 30, 38], ["viral infection", "OBSERVATION", 57, 72], ["asthma", "OBSERVATION", 90, 96], ["nasal", "ANATOMY", 169, 174], ["lavage", "OBSERVATION", 175, 181], ["asthma", "OBSERVATION", 238, 244]]], ["Consistent with our previous work examining the requirement of IRF7 for rhinovirus-induced gene expression in cultured airway epithelial cells [39] , coexpression analysis demonstrated IRF7 to be a major hub connecting IFN-mediated responses in virus-induced asthma exacerbations.DiscussionIn this study, we piloted a new PCR-LDR-based method for respiratory virus detection.", [["airway epithelial cells", "ANATOMY", 119, 142], ["asthma", "DISEASE", 259, 265], ["IRF7", "GENE_OR_GENE_PRODUCT", 63, 67], ["rhinovirus", "ORGANISM", 72, 82], ["airway epithelial cells [39", "CELL", 119, 146], ["IRF7", "GENE_OR_GENE_PRODUCT", 185, 189], ["IFN", "GENE_OR_GENE_PRODUCT", 219, 222], ["IRF7", "PROTEIN", 63, 67], ["cultured airway epithelial cells", "CELL_LINE", 110, 142], ["IRF7", "PROTEIN", 185, 189], ["IFN", "PROTEIN", 219, 222], ["IRF7", "TREATMENT", 63, 67], ["rhinovirus", "PROBLEM", 72, 82], ["cultured airway epithelial cells", "TEST", 110, 142], ["coexpression analysis", "TEST", 150, 171], ["IRF7", "PROBLEM", 185, 189], ["virus", "PROBLEM", 245, 250], ["asthma exacerbations", "PROBLEM", 259, 279], ["this study", "TEST", 293, 303], ["a new PCR", "TEST", 316, 325], ["respiratory virus detection", "PROBLEM", 347, 374], ["airway", "ANATOMY", 119, 125], ["epithelial cells", "OBSERVATION", 126, 142], ["asthma", "OBSERVATION", 259, 265], ["respiratory virus", "OBSERVATION", 347, 364]]], ["Twelve of 15 samples were concordant between the two viral detection techniques; in two cases, samples were positive by Seeplex and negative by PCR-LDR.", [["samples", "ANATOMY", 13, 20], ["samples", "ANATOMY", 95, 102], ["samples", "CANCER", 13, 20], ["samples", "CANCER", 95, 102], ["the two viral detection techniques", "TEST", 45, 79], ["samples", "TEST", 95, 102], ["Seeplex", "TEST", 120, 127], ["PCR", "TEST", 144, 147], ["LDR", "PROBLEM", 148, 151]]], ["The precise cause of the discrepancy between the two tests is not certain, but the Seeplex test, which relies on visual detection of bands on agarose electrophoresis gels, may be liable to false positives.", [["agarose", "SIMPLE_CHEMICAL", 142, 149], ["the discrepancy", "PROBLEM", 21, 36], ["the two tests", "TEST", 45, 58], ["the Seeplex test", "TEST", 79, 95], ["visual detection", "TEST", 113, 129], ["bands on agarose electrophoresis gels", "PROBLEM", 133, 170], ["false positives", "PROBLEM", 189, 204], ["false positives", "OBSERVATION", 189, 204]]], ["We also optimized our PCR-LDR test for maximum specificity, with the goal of avoiding false positives.", [["our PCR", "TEST", 18, 25], ["LDR test", "TEST", 26, 34], ["maximum specificity", "TEST", 39, 58], ["false positives", "PROBLEM", 86, 101], ["false positives", "OBSERVATION", 86, 101]]], ["This may have resulted in a reduction in sensitivity if copy number of viral nucleic acid was low.DiscussionWe measured the effect of natural colds on FeNO.", [["nucleic acid", "CHEMICAL", 77, 89], ["colds", "DISEASE", 142, 147], ["FeNO", "CHEMICAL", 151, 155], ["FeNO", "SIMPLE_CHEMICAL", 151, 155], ["a reduction in sensitivity", "PROBLEM", 26, 52], ["viral nucleic acid", "TEST", 71, 89], ["natural colds", "PROBLEM", 134, 147], ["FeNO", "TREATMENT", 151, 155], ["reduction", "OBSERVATION_MODIFIER", 28, 37], ["nucleic acid", "OBSERVATION", 77, 89]]], ["Previous studies have shown FeNO to be a reliable measure of eosinophilic airway inflammation, steroid responsiveness, and clinical control in children and adults with allergic asthma [40] [41] [42] [43] .", [["eosinophilic airway", "ANATOMY", 61, 80], ["inflammation", "DISEASE", 81, 93], ["steroid", "CHEMICAL", 95, 102], ["allergic asthma", "DISEASE", 168, 183], ["steroid", "CHEMICAL", 95, 102], ["FeNO", "GENE_OR_GENE_PRODUCT", 28, 32], ["airway", "MULTI-TISSUE_STRUCTURE", 74, 80], ["children", "ORGANISM", 143, 151], ["children", "SPECIES", 143, 151], ["Previous studies", "TEST", 0, 16], ["FeNO", "TEST", 28, 32], ["eosinophilic airway inflammation", "PROBLEM", 61, 93], ["steroid responsiveness", "PROBLEM", 95, 117], ["allergic asthma", "PROBLEM", 168, 183], ["eosinophilic", "OBSERVATION_MODIFIER", 61, 73], ["airway", "ANATOMY", 74, 80], ["inflammation", "OBSERVATION", 81, 93]]], ["FeNO levels have also been shown to increase during emergency steroid treatment of acute asthma exacerbations [44, 45] .", [["steroid", "CHEMICAL", 62, 69], ["asthma", "DISEASE", 89, 95], ["steroid", "CHEMICAL", 62, 69], ["FeNO", "GENE_OR_GENE_PRODUCT", 0, 4], ["steroid", "SIMPLE_CHEMICAL", 62, 69], ["FeNO levels", "TEST", 0, 11], ["emergency steroid treatment", "TREATMENT", 52, 79], ["acute asthma exacerbations", "PROBLEM", 83, 109], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["asthma", "OBSERVATION", 89, 95]]], ["In contrast, we found that despite increases in airway cytokines and respiratory symptoms, there was no increase in FeNO during natural colds in children relative to their baseline state.", [["airway", "ANATOMY", 48, 54], ["respiratory symptoms", "DISEASE", 69, 89], ["FeNO", "CHEMICAL", 116, 120], ["colds", "DISEASE", 136, 141], ["airway", "MULTI-TISSUE_STRUCTURE", 48, 54], ["FeNO", "GENE_OR_GENE_PRODUCT", 116, 120], ["children", "ORGANISM", 145, 153], ["airway cytokines", "PROTEIN", 48, 64], ["children", "SPECIES", 145, 153], ["increases in airway cytokines", "PROBLEM", 35, 64], ["respiratory symptoms", "PROBLEM", 69, 89], ["increase in FeNO", "PROBLEM", 104, 120], ["increases", "OBSERVATION_MODIFIER", 35, 44], ["airway", "ANATOMY", 48, 54], ["respiratory symptoms", "OBSERVATION", 69, 89], ["no", "UNCERTAINTY", 101, 103], ["increase", "OBSERVATION_MODIFIER", 104, 112]]], ["These data are consistent with the notion that airway inflammation in the context of viral-induced asthma exacerbations is different in character than that associated with chronic asthma.DiscussionThere are several limitations to our study.", [["airway", "ANATOMY", 47, 53], ["airway inflammation", "DISEASE", 47, 66], ["asthma", "DISEASE", 99, 105], ["asthma", "DISEASE", 180, 186], ["airway", "MULTI-TISSUE_STRUCTURE", 47, 53], ["airway inflammation", "PROBLEM", 47, 66], ["viral-induced asthma exacerbations", "PROBLEM", 85, 119], ["chronic asthma", "PROBLEM", 172, 186], ["our study", "TEST", 230, 239], ["consistent with", "UNCERTAINTY", 15, 30], ["airway", "ANATOMY", 47, 53], ["inflammation", "OBSERVATION", 54, 66], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["asthma", "OBSERVATION", 99, 105], ["chronic", "OBSERVATION_MODIFIER", 172, 179], ["asthma", "OBSERVATION", 180, 186]]], ["First, although nasal sampling has the advantage of increased safety and decreased participant burden, sputum speci-mens more closely reflect the response of the lower airways to viral infection.", [["nasal", "ANATOMY", 16, 21], ["sputum", "ANATOMY", 103, 109], ["lower airways", "ANATOMY", 162, 175], ["viral infection", "DISEASE", 179, 194], ["lower airways", "ORGANISM_SUBDIVISION", 162, 175], ["nasal sampling", "TREATMENT", 16, 30], ["decreased participant burden", "PROBLEM", 73, 101], ["sputum speci-mens", "TEST", 103, 120], ["viral infection", "PROBLEM", 179, 194], ["nasal", "ANATOMY", 16, 21], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["lower", "ANATOMY_MODIFIER", 162, 167], ["airways", "ANATOMY", 168, 175], ["viral infection", "OBSERVATION", 179, 194]]], ["However, as noted above, levels of IFN-c, CXCL8, CCL5, CCL20, CCL2, and CCL4 significantly correlated with respiratory symptoms, including lower respiratory tract symptoms such as cough, wheeze, chest tightness, and shortness of breath, each of which are indicative of asthma exacerbation.", [["respiratory", "ANATOMY", 107, 118], ["lower respiratory tract", "ANATOMY", 139, 162], ["chest", "ANATOMY", 195, 200], ["respiratory symptoms", "DISEASE", 107, 127], ["lower respiratory tract symptoms", "DISEASE", 139, 171], ["cough", "DISEASE", 180, 185], ["wheeze", "DISEASE", 187, 193], ["chest tightness", "DISEASE", 195, 210], ["shortness of breath", "DISEASE", 216, 235], ["asthma", "DISEASE", 269, 275], ["IFN-c", "GENE_OR_GENE_PRODUCT", 35, 40], ["CXCL8", "GENE_OR_GENE_PRODUCT", 42, 47], ["CCL5", "GENE_OR_GENE_PRODUCT", 49, 53], ["CCL20", "GENE_OR_GENE_PRODUCT", 55, 60], ["CCL2", "GENE_OR_GENE_PRODUCT", 62, 66], ["CCL4", "GENE_OR_GENE_PRODUCT", 72, 76], ["respiratory tract", "ORGANISM_SUBDIVISION", 145, 162], ["chest", "ORGANISM_SUBDIVISION", 195, 200], ["IFN", "PROTEIN", 35, 38], ["CXCL8", "PROTEIN", 42, 47], ["CCL5", "PROTEIN", 49, 53], ["CCL20", "PROTEIN", 55, 60], ["CCL2", "PROTEIN", 62, 66], ["CCL4", "PROTEIN", 72, 76], ["levels", "TEST", 25, 31], ["IFN", "TEST", 35, 38], ["CXCL8", "TEST", 42, 47], ["CCL5", "TEST", 49, 53], ["CCL20", "TEST", 55, 60], ["CCL2", "TEST", 62, 66], ["CCL4", "TEST", 72, 76], ["respiratory symptoms", "PROBLEM", 107, 127], ["lower respiratory tract symptoms", "PROBLEM", 139, 171], ["cough", "PROBLEM", 180, 185], ["wheeze", "PROBLEM", 187, 193], ["chest tightness", "PROBLEM", 195, 210], ["shortness of breath", "PROBLEM", 216, 235], ["asthma exacerbation", "PROBLEM", 269, 288], ["lower", "ANATOMY_MODIFIER", 139, 144], ["respiratory tract", "ANATOMY", 145, 162], ["chest", "ANATOMY", 195, 200], ["indicative of", "UNCERTAINTY", 255, 268], ["asthma", "OBSERVATION", 269, 275]]], ["In addition, previous studies have found similar changes in nasal aspirate and sputum cytokine concentrations following viral exacerbations of asthma [16, 17] .", [["nasal aspirate", "ANATOMY", 60, 74], ["sputum", "ANATOMY", 79, 85], ["asthma", "DISEASE", 143, 149], ["nasal aspirate", "MULTI-TISSUE_STRUCTURE", 60, 74], ["sputum", "ORGANISM_SUBSTANCE", 79, 85], ["cytokine", "PROTEIN", 86, 94], ["previous studies", "TEST", 13, 29], ["similar changes in nasal aspirate", "PROBLEM", 41, 74], ["sputum cytokine concentrations", "PROBLEM", 79, 109], ["viral exacerbations", "PROBLEM", 120, 139], ["asthma", "PROBLEM", 143, 149], ["nasal", "ANATOMY", 60, 65], ["aspirate", "OBSERVATION", 66, 74], ["asthma", "OBSERVATION", 143, 149]]], ["Finally, observations demonstrate consistent effects of nasal and bronchial provocation [46] .DiscussionSecond, we did not measure inflammatory cells in the nasal aspirates.", [["nasal", "ANATOMY", 56, 61], ["bronchial", "ANATOMY", 66, 75], ["inflammatory cells", "ANATOMY", 131, 149], ["nasal aspirates", "ANATOMY", 157, 172], ["nasal", "ORGANISM_SUBDIVISION", 56, 61], ["inflammatory cells", "CELL", 131, 149], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 157, 172], ["inflammatory cells", "CELL_TYPE", 131, 149], ["nasal and bronchial provocation", "TREATMENT", 56, 87], ["inflammatory cells", "PROBLEM", 131, 149], ["the nasal aspirates", "PROBLEM", 153, 172], ["nasal", "ANATOMY", 56, 61], ["bronchial", "ANATOMY", 66, 75], ["inflammatory cells", "OBSERVATION", 131, 149], ["nasal", "ANATOMY", 157, 162], ["aspirates", "OBSERVATION", 163, 172]]], ["We therefore could not assess the functional effects of chemokine release in our subjects.", [["chemokine", "PROTEIN", 56, 65], ["chemokine release", "TREATMENT", 56, 73]]], ["Previous studies have shown recruitment of neutrophils, eosinophils, and macrophages to the respiratory tract following rhinoviral infection of asthmatic subjects [9, 15, 17, 18, [47] [48] [49] [50] .", [["neutrophils", "ANATOMY", 43, 54], ["eosinophils", "ANATOMY", 56, 67], ["macrophages", "ANATOMY", 73, 84], ["respiratory tract", "ANATOMY", 92, 109], ["infection", "DISEASE", 131, 140], ["asthmatic", "DISEASE", 144, 153], ["neutrophils", "CELL", 43, 54], ["eosinophils", "CELL", 56, 67], ["macrophages", "CELL", 73, 84], ["respiratory tract", "ORGANISM_SUBDIVISION", 92, 109], ["neutrophils", "CELL_TYPE", 43, 54], ["eosinophils", "CELL_TYPE", 56, 67], ["macrophages", "CELL_TYPE", 73, 84], ["Previous studies", "TEST", 0, 16], ["neutrophils", "TEST", 43, 54], ["eosinophils", "TEST", 56, 67], ["macrophages", "PROBLEM", 73, 84], ["rhinoviral infection", "PROBLEM", 120, 140], ["asthmatic subjects", "PROBLEM", 144, 162], ["recruitment", "OBSERVATION_MODIFIER", 28, 39], ["respiratory tract", "ANATOMY", 92, 109], ["infection", "OBSERVATION", 131, 140]]], ["Also, we cannot determine the cellular source of the mRNAs measured in our study.", [["cellular", "ANATOMY", 30, 38], ["cellular", "CELL", 30, 38], ["mRNAs", "RNA", 53, 58], ["our study", "TEST", 71, 80]]], ["Pilot analysis showed primarily epithelial cells and neutrophils in the nasal aspirates, suggesting that epithelial cells were the primary source of mRNA.DiscussionThird, as noted above, we did not compare responses of asthmatic subjects to controls.", [["epithelial cells", "ANATOMY", 32, 48], ["neutrophils", "ANATOMY", 53, 64], ["nasal aspirates", "ANATOMY", 72, 87], ["epithelial cells", "ANATOMY", 105, 121], ["asthmatic", "DISEASE", 219, 228], ["epithelial cells", "CELL", 32, 48], ["neutrophils", "CELL", 53, 64], ["nasal aspirates", "MULTI-TISSUE_STRUCTURE", 72, 87], ["epithelial cells", "CELL", 105, 121], ["epithelial cells", "CELL_TYPE", 32, 48], ["neutrophils", "CELL_TYPE", 53, 64], ["epithelial cells", "CELL_TYPE", 105, 121], ["mRNA", "RNA", 149, 153], ["Pilot analysis", "TEST", 0, 14], ["primarily epithelial cells", "PROBLEM", 22, 48], ["neutrophils", "TEST", 53, 64], ["the nasal aspirates", "TEST", 68, 87], ["epithelial cells", "PROBLEM", 105, 121], ["mRNA", "PROBLEM", 149, 153], ["asthmatic subjects to controls", "PROBLEM", 219, 249], ["primarily", "OBSERVATION_MODIFIER", 22, 31], ["epithelial cells", "OBSERVATION", 32, 48], ["neutrophils", "OBSERVATION_MODIFIER", 53, 64], ["nasal", "ANATOMY", 72, 77], ["aspirates", "OBSERVATION", 78, 87], ["epithelial cells", "OBSERVATION", 105, 121]]], ["A recent study showed that asthmatics and non-atopic subjects experience similar colds, including chemokine responses, following experimental rhinovirus infection [17] .DiscussionFourth, although we were able to detect significant differences in many cytokines following upper respiratory tract infection, a fraction of the samples were too dilute to detect mRNA.", [["upper respiratory tract", "ANATOMY", 271, 294], ["samples", "ANATOMY", 324, 331], ["colds", "DISEASE", 81, 86], ["rhinovirus infection", "DISEASE", 142, 162], ["respiratory tract infection", "DISEASE", 277, 304], ["rhinovirus", "ORGANISM", 142, 152], ["upper respiratory", "ORGANISM_SUBDIVISION", 271, 288], ["tract", "ORGANISM_SUBDIVISION", 289, 294], ["chemokine", "PROTEIN", 98, 107], ["cytokines", "PROTEIN", 251, 260], ["mRNA", "RNA", 358, 362], ["A recent study", "TEST", 0, 14], ["asthmatics", "PROBLEM", 27, 37], ["non-atopic subjects", "PROBLEM", 42, 61], ["similar colds", "PROBLEM", 73, 86], ["chemokine responses", "TEST", 98, 117], ["experimental rhinovirus infection", "PROBLEM", 129, 162], ["significant differences in many cytokines", "PROBLEM", 219, 260], ["upper respiratory tract infection", "PROBLEM", 271, 304], ["mRNA", "PROBLEM", 358, 362], ["asthmatics", "OBSERVATION", 27, 37], ["upper", "ANATOMY_MODIFIER", 271, 276], ["respiratory tract", "ANATOMY", 277, 294], ["infection", "OBSERVATION", 295, 304]]], ["(There may have been other reasons for the loss of RNA, for example sample ribonucleases).", [["ribonucleases", "GENE_OR_GENE_PRODUCT", 75, 88], ["RNA", "RNA", 51, 54], ["ribonucleases", "PROTEIN", 75, 88], ["the loss of RNA", "PROBLEM", 39, 54]]], ["Dilution may also affect the concentration of measured biomarkers.", [["Dilution", "TREATMENT", 0, 8], ["measured biomarkers", "TEST", 46, 65]]], ["We did not adjust measurements by total protein content, as vascular leakage due to inflammation may alter protein concentrations in children with upper respiratory infections [51] .", [["vascular", "ANATOMY", 60, 68], ["respiratory", "ANATOMY", 153, 164], ["vascular leakage", "DISEASE", 60, 76], ["inflammation", "DISEASE", 84, 96], ["upper respiratory infections", "DISEASE", 147, 175], ["vascular", "MULTI-TISSUE_STRUCTURE", 60, 68], ["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141], ["vascular leakage", "PROBLEM", 60, 76], ["inflammation", "PROBLEM", 84, 96], ["upper respiratory infections", "PROBLEM", 147, 175], ["vascular", "ANATOMY", 60, 68], ["leakage", "OBSERVATION", 69, 76], ["inflammation", "OBSERVATION", 84, 96], ["upper", "ANATOMY_MODIFIER", 147, 152], ["respiratory", "ANATOMY", 153, 164], ["infections", "OBSERVATION", 165, 175]]], ["In our experience, total protein is difficult to measure in many nasal (and tracheal) aspirate specimens, even when cytokines are readily detectable, and therefore normalization for total protein does not increase the reliability of the concentrations.DiscussionFinally, studying naturally occurring colds in children using home-based methods inherently involves some variability in sample timing and handling that is not present in the controlled environment of the laboratory.", [["nasal", "ANATOMY", 65, 70], ["tracheal) aspirate specimens", "ANATOMY", 76, 104], ["colds", "DISEASE", 300, 305], ["nasal", "ORGANISM_SUBDIVISION", 65, 70], ["tracheal", "MULTI-TISSUE_STRUCTURE", 76, 84], ["children", "ORGANISM", 309, 317], ["cytokines", "PROTEIN", 116, 125], ["children", "SPECIES", 309, 317], ["total protein", "TEST", 19, 32], ["tracheal) aspirate specimens", "TEST", 76, 104], ["total protein", "TEST", 182, 195], ["home-based methods", "TREATMENT", 324, 342], ["tracheal", "ANATOMY", 76, 84]]], ["Our ability to detect statistically significant changes in specific mRNAs and proteins using the current study design suggests that this is a viable approach for use in future investigations, for example, studies examining whether an early adjustment of asthma medications could abort or temper the impact of respiratory viral infections.DiscussionWe conclude that in children with asthma, naturally occurring viral infections apparently induce a robust innate immune response including expression of specific chemokines, IFNs, and IFN-responsive genes.", [["asthma", "DISEASE", 254, 260], ["respiratory viral infections", "DISEASE", 309, 337], ["asthma", "DISEASE", 382, 388], ["viral infections", "DISEASE", 410, 426], ["children", "ORGANISM", 368, 376], ["IFNs", "GENE_OR_GENE_PRODUCT", 522, 526], ["IFN", "GENE_OR_GENE_PRODUCT", 532, 535], ["mRNAs", "RNA", 68, 73], ["chemokines", "PROTEIN", 510, 520], ["IFNs", "PROTEIN", 522, 526], ["IFN-responsive genes", "DNA", 532, 552], ["children", "SPECIES", 368, 376], ["statistically significant changes in specific mRNAs and proteins", "PROBLEM", 22, 86], ["the current study", "TEST", 93, 110], ["future investigations", "TEST", 169, 190], ["studies", "TEST", 205, 212], ["asthma medications", "TREATMENT", 254, 272], ["respiratory viral infections", "PROBLEM", 309, 337], ["asthma", "PROBLEM", 382, 388], ["viral infections", "PROBLEM", 410, 426], ["specific chemokines", "TEST", 501, 520], ["IFNs", "TEST", 522, 526], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["changes", "OBSERVATION", 48, 55], ["asthma", "OBSERVATION", 254, 260], ["respiratory", "ANATOMY", 309, 320], ["viral infections", "OBSERVATION", 321, 337], ["responsive genes", "OBSERVATION", 536, 552]]], ["Cytokine responses are sustained the first week following viral infection.", [["viral infection", "DISEASE", 58, 73], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine responses", "TEST", 0, 18], ["viral infection", "PROBLEM", 58, 73], ["viral", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 64, 73]]], ["Future analyses of controls and asthmatics which combine the determination of cytokine responses and asthma health outcomes will provide further insight into the cellular pathways responsible for virus-induced asthma exacerbations.", [["cellular", "ANATOMY", 162, 170], ["asthma", "DISEASE", 101, 107], ["asthma", "DISEASE", 210, 216], ["cellular", "CELL", 162, 170], ["cytokine", "PROTEIN", 78, 86], ["asthmatics", "PROBLEM", 32, 42], ["cytokine responses", "PROBLEM", 78, 96], ["asthma health outcomes", "PROBLEM", 101, 123], ["virus", "PROBLEM", 196, 201], ["asthma exacerbations", "PROBLEM", 210, 230], ["asthma", "OBSERVATION", 210, 216]]]], "PMC6369128": [["IntroductionNewcastle disease virus (NDV) is the etiological agent of Newcastle disease (ND), one of the most infectious diseases affecting poultry.", [["Newcastle disease virus (NDV)", "DISEASE", 12, 41], ["Newcastle disease", "DISEASE", 70, 87], ["ND", "DISEASE", 89, 91], ["Newcastle disease virus", "ORGANISM", 12, 35], ["NDV", "ORGANISM", 37, 40], ["NDV", "SPECIES", 37, 40], ["Newcastle disease virus", "SPECIES", 12, 35], ["NDV", "SPECIES", 37, 40], ["IntroductionNewcastle disease virus (NDV", "PROBLEM", 0, 40], ["Newcastle disease", "PROBLEM", 70, 87], ["infectious", "OBSERVATION_MODIFIER", 110, 120], ["diseases", "OBSERVATION", 121, 129]]], ["The virus has an enveloped non-segmented negative stranded RNA genome and is member of the genus Avulavirus in the family Paramyxoviridae.", [["Avulavirus", "GENE_OR_GENE_PRODUCT", 97, 107], ["enveloped non-segmented negative stranded RNA genome", "DNA", 17, 69], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["enveloped", "OBSERVATION_MODIFIER", 17, 26], ["non-segmented", "OBSERVATION_MODIFIER", 27, 40], ["negative", "OBSERVATION_MODIFIER", 41, 49], ["stranded RNA genome", "OBSERVATION", 50, 69], ["genus Avulavirus", "OBSERVATION", 91, 107]]], ["ND outbreaks cause mortality rate up to 100% in susceptible poultry and is a notifiable disease to the World Organisation for Animal Health (OIE) [1].", [["ND", "DISEASE", 0, 2], ["poultry", "SPECIES", 60, 67], ["mortality rate", "TEST", 19, 33], ["a notifiable disease", "PROBLEM", 75, 95]]], ["The NDV genome consists of 55 nt leader at its 3\u2032 end and 114 nt trailer at its 5\u2032 end, flanking six essential genes encoding nucleoprotein (NP), matrix protein (M), phosphoprotein (P), fusion protein (F), hemagglutinin-neuraminidase protein (HN), and large polymerase protein (L) [2].IntroductionInternal structural protein NP is a highly conserved protein involved in virus replication cycle as well as in inducing high level of NDV-specific antibody in chickens [3].", [["NDV", "ORGANISM", 4, 7], ["nucleoprotein (NP)", "GENE_OR_GENE_PRODUCT", 126, 144], ["matrix protein (M)", "GENE_OR_GENE_PRODUCT", 146, 164], ["F", "GENE_OR_GENE_PRODUCT", 202, 203], ["hemagglutinin-neuraminidase protein", "GENE_OR_GENE_PRODUCT", 206, 241], ["HN", "GENE_OR_GENE_PRODUCT", 243, 245], ["large polymerase protein (L)", "GENE_OR_GENE_PRODUCT", 252, 280], ["NDV", "ORGANISM", 431, 434], ["chickens", "ORGANISM", 456, 464], ["NDV genome", "DNA", 4, 14], ["55 nt leader", "DNA", 27, 39], ["3\u2032 end", "DNA", 47, 53], ["114 nt trailer", "DNA", 58, 72], ["5\u2032 end", "DNA", 80, 86], ["essential genes", "DNA", 101, 116], ["nucleoprotein", "PROTEIN", 126, 139], ["NP", "PROTEIN", 141, 143], ["matrix protein", "PROTEIN", 146, 160], ["M", "PROTEIN", 162, 163], ["phosphoprotein (P)", "PROTEIN", 166, 184], ["fusion protein", "PROTEIN", 186, 200], ["F", "PROTEIN", 202, 203], ["hemagglutinin", "PROTEIN", 206, 219], ["neuraminidase protein", "PROTEIN", 220, 241], ["HN", "PROTEIN", 243, 245], ["large polymerase protein", "PROTEIN", 252, 276], ["L", "PROTEIN", 278, 279], ["Internal structural protein NP", "PROTEIN", 297, 327], ["NDV-specific antibody", "PROTEIN", 431, 452], ["NDV", "SPECIES", 4, 7], ["chickens", "SPECIES", 456, 464], ["NDV", "SPECIES", 4, 7], ["NDV", "SPECIES", 431, 434], ["chickens", "SPECIES", 456, 464], ["55 nt leader", "PROBLEM", 27, 39], ["114 nt trailer", "TREATMENT", 58, 72], ["matrix protein", "TEST", 146, 160], ["phosphoprotein", "TEST", 166, 180], ["fusion protein (F", "TEST", 186, 203], ["hemagglutinin", "TEST", 206, 219], ["neuraminidase protein", "TEST", 220, 241], ["large polymerase protein", "TEST", 252, 276], ["Internal structural protein NP", "TREATMENT", 297, 327], ["virus replication cycle", "TREATMENT", 370, 393], ["NDV", "PROBLEM", 431, 434]]], ["N- and C-terminal regions of the NP serve as B-cell epitopes in host [45].", [["B-cell", "ANATOMY", 45, 51], ["N", "CHEMICAL", 0, 1], ["C", "CHEMICAL", 7, 8], ["B-cell epitopes", "GENE_OR_GENE_PRODUCT", 45, 60], ["N- and C-terminal regions", "PROTEIN", 0, 25], ["B-cell epitopes", "PROTEIN", 45, 60], ["N", "TEST", 0, 1]]], ["In particular, C-terminal immunological region that forms alpha helical structure is permissible for modification.", [["C", "CHEMICAL", 15, 16], ["C-terminal immunological region", "PROTEIN", 15, 46], ["alpha helical structure", "PROTEIN", 58, 81], ["C-terminal immunological region", "PROBLEM", 15, 46], ["alpha helical structure", "PROBLEM", 58, 81], ["terminal", "ANATOMY_MODIFIER", 17, 25], ["alpha helical structure", "OBSERVATION", 58, 81]]], ["Thus this epitopic region can serve as negative marker if replaced with a foreign epitope [6].", [["epitopic region", "DNA", 10, 25], ["a foreign epitope", "TREATMENT", 72, 89]]], ["For example, amino acid sequence ETQFLDLMRAVANSMR (aa 444\u2013459) on NDV NP is an epitope, which serves as linear immunodominant epitope (IDE) and can be replaced or deleted [4].", [["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "AMINO_ACID", 13, 23], ["NDV NP", "ORGANISM", 66, 72], ["linear immunodominant epitope", "PROTEIN", 104, 133], ["IDE", "PROTEIN", 135, 138], ["NDV", "SPECIES", 66, 69], ["amino acid sequence ETQFLDLMRAVANSMR", "TEST", 13, 49], ["NDV NP", "TREATMENT", 66, 72], ["an epitope", "TREATMENT", 76, 86], ["linear immunodominant epitope (IDE)", "TREATMENT", 104, 139]]], ["This antigen should facilitate differentiation of vaccinated animal to that of infected during serosurveillance in the case of the marker vaccine applying vaccination program.", [["This antigen", "TREATMENT", 0, 12], ["the marker vaccine", "TREATMENT", 127, 145], ["vaccination program", "TREATMENT", 155, 174], ["infected", "OBSERVATION", 79, 87]]], ["A multiepitope protein as a vaccine candidate [789101112] or as diagnostic reagent [131415] has been explored in multiple instances.", [["789101112", "CHEMICAL", 47, 56], ["multiepitope protein", "PROTEIN", 2, 22], ["A multiepitope protein", "TREATMENT", 0, 22]]], ["Multiepitope recombinant proteins are advantageous as they can be designed rationally and offers higher specificity and sensitivity [16].IntroductionThe aim of the present study was to develop a serodiagnostic test for differentiation infected from vaccinated animal (DIVA) strategy accompanying an NDV marker vaccine lacking the NP IDE.", [["differentiation infected", "DISEASE", 219, 243], ["NDV", "ORGANISM", 299, 302], ["IDE", "GENE_OR_GENE_PRODUCT", 333, 336], ["Multiepitope recombinant proteins", "PROTEIN", 0, 33], ["NP IDE", "PROTEIN", 330, 336], ["NDV", "SPECIES", 299, 302], ["Multiepitope recombinant proteins", "TREATMENT", 0, 33], ["sensitivity", "TEST", 120, 131], ["the present study", "TEST", 160, 177], ["a serodiagnostic test", "TEST", 193, 214], ["differentiation infected", "PROBLEM", 219, 243], ["vaccinated animal (DIVA) strategy", "TREATMENT", 249, 282], ["an NDV marker vaccine", "TREATMENT", 296, 317], ["the NP IDE", "TREATMENT", 326, 336]]], ["For this purpose, an indirect enzyme-linked immunosorbent assay (ELISA) format employing a recombinant protein, which carries multimers of IDE, was developed.", [["IDE", "GENE_OR_GENE_PRODUCT", 139, 142], ["recombinant protein", "PROTEIN", 91, 110], ["IDE", "PROTEIN", 139, 142], ["an indirect enzyme", "TEST", 18, 36], ["immunosorbent assay", "TEST", 44, 63], ["a recombinant protein", "PROBLEM", 89, 110]]], ["The recombinant protein was expressed in baculovirus system.", [["baculovirus", "ORGANISM", 41, 52], ["recombinant protein", "PROTEIN", 4, 23], ["baculovirus", "SPECIES", 41, 52], ["The recombinant protein", "TEST", 0, 23], ["baculovirus system", "OBSERVATION", 41, 59]]], ["Specificity and sensitivity of recombinant protein was evaluated.Design of synthetic gene and tertiary structure prediction ::: Materials and MethodsEpitope repeat protein (ERP) gene encoding eight repeats of an IDE sequence containing ETQFLDLMRAVANSMR (C-terminal IDE aa 444\u2013459) on NDV NP separated by tetra-glycine linker was synthesized commercially using codon optimization for baculovirus expression.", [["tetra-glycine", "CHEMICAL", 304, 317], ["tetra-glycine", "CHEMICAL", 304, 317], ["MethodsEpitope repeat protein", "GENE_OR_GENE_PRODUCT", 142, 171], ["IDE", "GENE_OR_GENE_PRODUCT", 212, 215], ["tetra-glycine linker", "SIMPLE_CHEMICAL", 304, 324], ["baculovirus", "ORGANISM", 383, 394], ["recombinant protein", "PROTEIN", 31, 50], ["MethodsEpitope repeat protein (ERP) gene", "DNA", 142, 182], ["IDE sequence", "DNA", 212, 224], ["ETQFLDLMRAVANSMR", "PROTEIN", 236, 252], ["C-terminal IDE aa 444\u2013459", "PROTEIN", 254, 279], ["NDV NP", "PROTEIN", 284, 290], ["NDV", "SPECIES", 284, 287], ["baculovirus", "SPECIES", 383, 394], ["Specificity", "TEST", 0, 11], ["recombinant protein", "TEST", 31, 50], ["MethodsEpitope repeat protein", "TEST", 142, 171], ["ERP", "TEST", 173, 176], ["an IDE sequence", "TREATMENT", 209, 224], ["ETQFLDLMRAVANSMR (C-terminal IDE aa", "TREATMENT", 236, 271], ["NDV NP", "TREATMENT", 284, 290], ["tetra-glycine linker", "TREATMENT", 304, 324], ["codon optimization", "TREATMENT", 360, 378], ["baculovirus expression", "TREATMENT", 383, 405]]], ["The recognition enzyme sites of EcoRI and HindIII were built in the upstream and downstream of coding sequence, respectively.", [["EcoRI", "GENE_OR_GENE_PRODUCT", 32, 37], ["HindIII", "GENE_OR_GENE_PRODUCT", 42, 49], ["recognition enzyme sites", "DNA", 4, 28], ["EcoRI", "DNA", 32, 37], ["HindIII", "DNA", 42, 49], ["upstream and downstream of coding sequence", "DNA", 68, 110], ["EcoRI and HindIII", "TREATMENT", 32, 49], ["EcoRI", "ANATOMY", 32, 37], ["HindIII", "ANATOMY", 42, 49]]], ["The synthetic gene cloned in vector backbone PMK-RQ (KanR) was received as 5 \u00b5g of lyophilized plasmid preparation.", [["plasmid", "ANATOMY", 95, 102], ["PMK-RQ", "GENE_OR_GENE_PRODUCT", 45, 51], ["KanR", "GENE_OR_GENE_PRODUCT", 53, 57], ["synthetic gene", "DNA", 4, 18], ["vector backbone PMK-RQ (KanR)", "DNA", 29, 58], ["The synthetic gene", "TREATMENT", 0, 18], ["RQ (KanR)", "TREATMENT", 49, 58], ["lyophilized plasmid preparation", "TREATMENT", 83, 114]]], ["The conceptual translated sequence was submitted to I-TASSER server for homology modeling [17] and top five predicted structures were visualized with PyMOL software [18].Preparation of recombinant bacmid ::: Materials and MethodsSynthetic gene was subcloned into pFastBac HT b vector using EcoRI and HindIII restriction sites.", [["EcoRI", "GENE_OR_GENE_PRODUCT", 290, 295], ["HindIII", "GENE_OR_GENE_PRODUCT", 300, 307], ["I-TASSER server", "DNA", 52, 67], ["MethodsSynthetic gene", "DNA", 222, 243], ["pFastBac HT b vector", "DNA", 263, 283], ["EcoRI and HindIII restriction sites", "DNA", 290, 325], ["homology modeling", "TEST", 72, 89], ["PyMOL software", "TEST", 150, 164], ["Materials", "TREATMENT", 208, 217], ["MethodsSynthetic gene", "TREATMENT", 222, 243], ["EcoRI and HindIII restriction sites", "TREATMENT", 290, 325]]], ["The recombinant plasmid (50 ng) was transformed in Escherichia coli DH B10 cells.", [["plasmid", "ANATOMY", 16, 23], ["DH B10 cells", "ANATOMY", 68, 80], ["Escherichia coli DH B10 cells", "CELL", 51, 80], ["recombinant plasmid", "DNA", 4, 23], ["Escherichia coli DH B10 cells", "CELL_LINE", 51, 80], ["Escherichia coli", "SPECIES", 51, 67], ["Escherichia coli", "SPECIES", 51, 67], ["The recombinant plasmid", "TREATMENT", 0, 23], ["Escherichia coli", "OBSERVATION", 51, 67], ["B10 cells", "OBSERVATION", 71, 80]]], ["Transformed cells were plated onto the Luria-Bertani agar containing kanamycin (50 \u00b5g/mL), gentamicin (7 \u00b5g/mL), tetracycline (10 \u00b5g/mL), Bluo-gal (100 \u00b5g/mL), and isopropylthio-\u03b2-galactoside (IPTG, 40 \u00b5g/mL) and incubated at 37\u2103 for 36 to 48 hours.", [["cells", "ANATOMY", 12, 17], ["kanamycin", "CHEMICAL", 69, 78], ["gentamicin", "CHEMICAL", 91, 101], ["tetracycline", "CHEMICAL", 113, 125], ["Bluo-gal", "CHEMICAL", 138, 146], ["isopropylthio-\u03b2-galactoside", "CHEMICAL", 164, 191], ["IPTG", "CHEMICAL", 193, 197], ["kanamycin", "CHEMICAL", 69, 78], ["gentamicin", "CHEMICAL", 91, 101], ["tetracycline", "CHEMICAL", 113, 125], ["isopropylthio-\u03b2-galactoside", "CHEMICAL", 164, 191], ["IPTG", "CHEMICAL", 193, 197], ["Transformed cells", "CELL", 0, 17], ["kanamycin", "SIMPLE_CHEMICAL", 69, 78], ["gentamicin", "SIMPLE_CHEMICAL", 91, 101], ["tetracycline", "SIMPLE_CHEMICAL", 113, 125], ["Bluo-gal", "SIMPLE_CHEMICAL", 138, 146], ["isopropylthio-\u03b2-galactoside", "SIMPLE_CHEMICAL", 164, 191], ["IPTG", "SIMPLE_CHEMICAL", 193, 197], ["the Luria", "TEST", 35, 44], ["Bertani agar", "TREATMENT", 45, 57], ["kanamycin", "TREATMENT", 69, 78], ["gentamicin", "TREATMENT", 91, 101], ["tetracycline", "TREATMENT", 113, 125], ["Bluo-gal", "TREATMENT", 138, 146], ["isopropylthio", "TREATMENT", 164, 177], ["galactoside (IPTG", "TREATMENT", 180, 197]]], ["The high molecular weight bacmid DNA was isolated from the overnight cultures by alkaline lysis purification according to the manufacturer's manual of Bac-to-Bac baculovirus expression system (Invitrogen, Carlsbad, CA, USA).Generation of recombinant baculovirus ::: Materials and MethodsSpodoptera frugiperda 9 (Sf9) cells were cultured at 27\u2103 in Sf-900 II serum free medium (Invitrogen), supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen), 50 U/mL penicillin and 50 \u00b5g/mL streptomycin.", [["cultures", "ANATOMY", 69, 77], ["Sf9) cells", "ANATOMY", 312, 322], ["serum", "ANATOMY", 357, 362], ["fetal bovine serum", "ANATOMY", 428, 446], ["FBS", "ANATOMY", 448, 451], ["Sf-900 II", "CHEMICAL", 347, 356], ["penicillin", "CHEMICAL", 475, 485], ["streptomycin", "CHEMICAL", 499, 511], ["penicillin", "CHEMICAL", 475, 485], ["streptomycin", "CHEMICAL", 499, 511], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["alkaline", "SIMPLE_CHEMICAL", 81, 89], ["baculovirus", "ORGANISM", 162, 173], ["baculovirus", "ORGANISM", 250, 261], ["Spodoptera frugiperda", "ORGANISM", 287, 308], ["9", "ORGANISM", 309, 310], ["Sf9) cells", "CELL", 312, 322], ["serum", "ORGANISM_SUBSTANCE", 357, 362], ["bovine", "ORGANISM", 434, 440], ["serum", "ORGANISM_SUBSTANCE", 441, 446], ["FBS", "ORGANISM_SUBSTANCE", 448, 451], ["penicillin", "SIMPLE_CHEMICAL", 475, 485], ["streptomycin", "SIMPLE_CHEMICAL", 499, 511], ["bacmid DNA", "DNA", 26, 36], ["overnight cultures", "CELL_LINE", 59, 77], ["Spodoptera frugiperda 9 (Sf9) cells", "CELL_LINE", 287, 322], ["Spodoptera frugiperda", "SPECIES", 287, 308], ["bovine", "SPECIES", 434, 440], ["Bac baculovirus", "SPECIES", 158, 173], ["baculovirus", "SPECIES", 250, 261], ["Spodoptera frugiperda", "SPECIES", 287, 308], ["Sf9", "SPECIES", 312, 315], ["bovine", "SPECIES", 434, 440], ["The high molecular weight bacmid DNA", "PROBLEM", 0, 36], ["the overnight cultures", "TEST", 55, 77], ["alkaline lysis purification", "TREATMENT", 81, 108], ["Bac", "TEST", 151, 154], ["Bac baculovirus expression system", "PROBLEM", 158, 191], ["MethodsSpodoptera frugiperda", "TREATMENT", 280, 308], ["Sf", "TEST", 347, 349], ["serum free medium (Invitrogen)", "TREATMENT", 357, 387], ["inactivated fetal bovine serum (FBS", "TREATMENT", 416, 451], ["penicillin", "TREATMENT", 475, 485], ["streptomycin", "TREATMENT", 499, 511], ["high", "OBSERVATION_MODIFIER", 4, 8], ["recombinant baculovirus", "OBSERVATION", 238, 261]]], ["Sf9 cells were transfected with recombinant bacmid DNA using Cellfectin II, a cationic lipid for the transfection of the baculovirus particles according to the manufacturer's instructions.", [["Sf9 cells", "ANATOMY", 0, 9], ["Cellfectin II", "CHEMICAL", 61, 74], ["Sf9 cells", "CELL", 0, 9], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["Cellfectin II", "GENE_OR_GENE_PRODUCT", 61, 74], ["lipid", "SIMPLE_CHEMICAL", 87, 92], ["baculovirus", "ORGANISM", 121, 132], ["Sf9 cells", "CELL_LINE", 0, 9], ["recombinant bacmid DNA", "DNA", 32, 54], ["Cellfectin II", "PROTEIN", 61, 74], ["Sf9", "SPECIES", 0, 3], ["baculovirus", "SPECIES", 121, 132], ["Sf9 cells", "TREATMENT", 0, 9], ["recombinant bacmid DNA", "TREATMENT", 32, 54], ["Cellfectin II", "TREATMENT", 61, 74], ["a cationic lipid", "TREATMENT", 76, 92], ["the transfection of the baculovirus particles", "TREATMENT", 97, 142]]], ["Briefly, for each transfection, 2 mL of Grace's Insect Medium, unsupplemented (without antibiotics and serum) was added in each well, 8\u00d7105 cells per well were seeded in a 6-well plate and allowed to attach for 2 hours.", [["serum", "ANATOMY", 103, 108], ["cells", "ANATOMY", 140, 145], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["cells", "CELL", 140, 145], ["8\u00d7105 cells", "CELL_LINE", 134, 145], ["Grace's Insect Medium", "TREATMENT", 40, 61], ["antibiotics", "TREATMENT", 87, 98]]], ["The bacmid DNA and Cellfectin II (8 \u00b5L of reagent) were diluted separately in 100 \u00b5L of Grace's medium, unsupplemented (without antibiotics and serum), then mixed and incubated for 30 minutes at room temperature to form lipid-DNA complexes.", [["serum", "ANATOMY", 144, 149], ["Cellfectin II", "CHEMICAL", 19, 32], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["Cellfectin II", "GENE_OR_GENE_PRODUCT", 19, 32], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["DNA", "CELLULAR_COMPONENT", 226, 229], ["bacmid DNA", "DNA", 4, 14], ["Cellfectin II", "PROTEIN", 19, 32], ["lipid-DNA complexes", "PROTEIN", 220, 239], ["The bacmid DNA", "TREATMENT", 0, 14], ["Cellfectin II", "TREATMENT", 19, 32], ["antibiotics", "TREATMENT", 128, 139], ["serum", "TEST", 144, 149]]], ["The cells were washed with fresh medium, and incubated with lipid-DNA complex at 27\u2103 for 5 hours.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["lipid-DNA complex", "PROTEIN", 60, 77], ["fresh medium", "TREATMENT", 27, 39], ["lipid-DNA complex", "TREATMENT", 60, 77]]], ["The transfection solution was removed and 2 mL supplemented Sf-900 II SFM containing 10% FBS was added.", [["FBS", "ANATOMY", 89, 92], ["Sf-900 II", "CHEMICAL", 60, 69], ["FBS", "ORGANISM_SUBSTANCE", 89, 92], ["The transfection solution", "TREATMENT", 0, 25], ["10% FBS", "TREATMENT", 85, 92]]], ["Transfected Sf9 cells were incubated at 27\u2103 for 72 hours for baculovirus production.", [["Sf9 cells", "ANATOMY", 12, 21], ["Sf9 cells", "CELL", 12, 21], ["baculovirus", "ORGANISM", 61, 72], ["Sf9 cells", "CELL_LINE", 12, 21], ["Sf9", "SPECIES", 12, 15], ["baculovirus", "SPECIES", 61, 72], ["Transfected Sf9 cells", "PROBLEM", 0, 21], ["baculovirus production", "PROBLEM", 61, 83]]], ["Recombinant baculovirus production was monitored daily by visualization of the cytopathic effects.", [["baculovirus", "ORGANISM", 12, 23], ["baculovirus", "SPECIES", 12, 23], ["Recombinant baculovirus production", "TREATMENT", 0, 34], ["the cytopathic effects", "PROBLEM", 75, 97], ["cytopathic effects", "OBSERVATION", 79, 97]]], ["Three to four days after transfection, recombinant baculovirus was harvested from the cell culture medium and stored at 4\u2103.", [["cell", "ANATOMY", 86, 90], ["baculovirus", "ORGANISM", 51, 62], ["cell", "CELL", 86, 90], ["recombinant baculovirus", "PROTEIN", 39, 62], ["baculovirus", "SPECIES", 51, 62], ["transfection", "TREATMENT", 25, 37], ["recombinant baculovirus", "TREATMENT", 39, 62], ["the cell culture", "TEST", 82, 98]]], ["Recombinant viruses were identified by polymerase chain reaction using gene vector specific primers (Invitrogen).", [["gene vector specific primers", "DNA", 71, 99], ["Recombinant viruses", "PROBLEM", 0, 19], ["polymerase chain reaction", "PROBLEM", 39, 64], ["gene vector specific primers", "TREATMENT", 71, 99], ["viruses", "OBSERVATION", 12, 19]]], ["The resulting baculovirus was passaged three times by infecting more Sf9 cells.Protein expression and purification ::: Materials and MethodsSF9 suspension cultures (2\u00d7106 cells/mL) grown in 2 L of Sf900 II medium supplemented with 1% of FBS were infected with recombinant baculovirus at multiplicity of infection of 5 plaque-forming unit/cell.", [["Sf9 cells", "ANATOMY", 69, 78], ["cells", "ANATOMY", 171, 176], ["FBS", "ANATOMY", 237, 240], ["plaque", "ANATOMY", 318, 324], ["cell", "ANATOMY", 338, 342], ["Sf900 II", "CHEMICAL", 197, 205], ["infection", "DISEASE", 303, 312], ["baculovirus", "ORGANISM", 14, 25], ["Sf9 cells", "CELL", 69, 78], ["2\u00d7106 cells", "CELL", 165, 176], ["FBS", "ORGANISM_SUBSTANCE", 237, 240], ["baculovirus", "ORGANISM", 272, 283], ["cell", "CELL", 338, 342], ["Sf9 cells", "CELL_LINE", 69, 78], ["MethodsSF9 suspension cultures", "CELL_LINE", 133, 163], ["2\u00d7106 cells", "CELL_LINE", 165, 176], ["baculovirus", "SPECIES", 14, 25], ["Sf9", "SPECIES", 69, 72], ["baculovirus", "SPECIES", 272, 283], ["The resulting baculovirus", "TREATMENT", 0, 25], ["Materials", "TEST", 119, 128], ["MethodsSF9 suspension cultures", "TEST", 133, 163], ["cells", "TEST", 171, 176], ["FBS", "TREATMENT", 237, 240], ["recombinant baculovirus", "TREATMENT", 260, 283], ["infection of 5 plaque", "PROBLEM", 303, 324], ["baculovirus", "OBSERVATION", 14, 25], ["Sf9 cells", "OBSERVATION", 69, 78], ["infection", "OBSERVATION", 303, 312]]], ["Cells were grown for 72 hours and cell pellets were washed in phosphate buffered saline (PBS).", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 34, 38], ["phosphate", "CHEMICAL", 62, 71], ["phosphate", "CHEMICAL", 62, 71], ["Cells", "CELL", 0, 5], ["cell", "CELL", 34, 38], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 62, 87], ["Cells", "TEST", 0, 5], ["cell pellets", "TEST", 34, 46], ["phosphate buffered saline (PBS", "TREATMENT", 62, 92]]], ["As recombinant ERP (rERP) carried 6\u00d7 His tag at N-terminal, it was purified by using Ni-NTA spin columns under denaturant condition with 8 M urea according to Ni-NTA spin handbook (Qiagen, Hilden, Germany).", [["Ni-NTA", "CHEMICAL", 85, 91], ["urea", "CHEMICAL", 141, 145], ["Ni-NTA", "CHEMICAL", 159, 165], ["His", "CHEMICAL", 37, 40], ["N", "CHEMICAL", 48, 49], ["Ni-NTA", "CHEMICAL", 85, 91], ["urea", "CHEMICAL", 141, 145], ["Ni-NTA", "CHEMICAL", 159, 165], ["urea", "SIMPLE_CHEMICAL", 141, 145], ["Ni-NTA", "SIMPLE_CHEMICAL", 159, 165], ["ERP", "PROTEIN", 15, 18], ["rERP", "PROTEIN", 20, 24], ["His tag", "TEST", 37, 44], ["Ni-NTA spin columns", "TREATMENT", 85, 104], ["8 M urea", "TREATMENT", 137, 145]]], ["The collected cells were lysed in 10 mL buffer B (10 mM NaH2PO4, 300 mM NaCl, 8 M urea, pH 8.0) and centrifuged the lysate at 10,000\u00d7g for 30 minutes and collecting supernatant.", [["cells", "ANATOMY", 14, 19], ["lysate", "ANATOMY", 116, 122], ["supernatant", "ANATOMY", 165, 176], ["NaCl", "CHEMICAL", 72, 76], ["urea", "CHEMICAL", 82, 86], ["NaH2PO4", "CHEMICAL", 56, 63], ["NaCl", "CHEMICAL", 72, 76], ["urea", "CHEMICAL", 82, 86], ["cells", "CELL", 14, 19], ["urea", "SIMPLE_CHEMICAL", 82, 86], ["The collected cells", "TREATMENT", 0, 19], ["NaCl", "TEST", 72, 76], ["urea", "TEST", 82, 86], ["pH", "TEST", 88, 90], ["the lysate", "TREATMENT", 112, 122]]], ["Loading up to 600 \u00b5L of the cleared lysate supernatant containing the 6\u00d7 His-tagged protein onto a pre-equilibrated Ni-NTA spin column, centrifuged 2 minutes at 700\u00d7g and washing the column with 600 \u00b5L buffer C (10 mM NaH2PO4, 300 mM NaCl, 8 M urea, pH 6.3) and centrifuged 2 minutes at 700\u00d7g, the recombinant protein was finally eluted with buffer E (10 mM NaH2PO4, 300 mM NaCl, 8 M urea, pH 4.3).", [["lysate supernatant", "ANATOMY", 36, 54], ["Ni-NTA", "CHEMICAL", 116, 122], ["NaCl", "CHEMICAL", 234, 238], ["urea", "CHEMICAL", 244, 248], ["NaCl", "CHEMICAL", 374, 378], ["Ni-NTA", "CHEMICAL", 116, 122], ["NaH2PO4", "CHEMICAL", 218, 225], ["NaCl", "CHEMICAL", 234, 238], ["urea", "CHEMICAL", 244, 248], ["NaH2PO4", "CHEMICAL", 358, 365], ["NaCl", "CHEMICAL", 374, 378], ["urea", "CHEMICAL", 384, 388], ["His-", "SIMPLE_CHEMICAL", 73, 77], ["urea", "SIMPLE_CHEMICAL", 244, 248], ["urea", "SIMPLE_CHEMICAL", 384, 388], ["His-tagged protein", "PROTEIN", 73, 91], ["recombinant protein", "PROTEIN", 298, 317], ["the cleared lysate supernatant", "TREATMENT", 24, 54], ["a pre-equilibrated Ni-NTA spin column", "TREATMENT", 97, 134], ["600 \u00b5L buffer C", "TREATMENT", 195, 210], ["pH", "TEST", 250, 252], ["the recombinant protein", "TEST", 294, 317], ["buffer E", "TREATMENT", 342, 350], ["NaCl", "TEST", 374, 378], ["urea", "TEST", 384, 388], ["pH", "TEST", 390, 392]]], ["The recombinant protein was allowed to refold using refolding buffer (50 mM Tris pH 7.5, 0.5 M NaCl, 0.3% CHAPS, 1 mM DTT, 5% glycerol). rERP was dialyzed against refolding buffer (40 mM CHAPS and 10 mM DTT).Electrophoresis and Western blotting ::: Materials and MethodsProteins extracted from infected Sf9 cells were fractionated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions.", [["Sf9 cells", "ANATOMY", 303, 312], ["NaCl", "CHEMICAL", 95, 99], ["glycerol", "CHEMICAL", 126, 134], ["rERP", "CHEMICAL", 137, 141], ["sodium dodecyl sulfate", "CHEMICAL", 338, 360], ["NaCl", "CHEMICAL", 95, 99], ["CHAPS", "CHEMICAL", 106, 111], ["DTT", "CHEMICAL", 118, 121], ["glycerol", "CHEMICAL", 126, 134], ["CHAPS", "CHEMICAL", 187, 192], ["DTT", "CHEMICAL", 203, 206], ["sodium dodecyl sulfate", "CHEMICAL", 338, 360], ["polyacrylamide", "CHEMICAL", 361, 375], ["CHAPS", "SIMPLE_CHEMICAL", 106, 111], ["DTT", "SIMPLE_CHEMICAL", 118, 121], ["glycerol", "SIMPLE_CHEMICAL", 126, 134], ["rERP", "SIMPLE_CHEMICAL", 137, 141], ["Sf9 cells", "CELL", 303, 312], ["sodium dodecyl sulfate polyacrylamide", "SIMPLE_CHEMICAL", 338, 375], ["recombinant protein", "PROTEIN", 4, 23], ["MethodsProteins", "PROTEIN", 263, 278], ["Sf9 cells", "CELL_LINE", 303, 312], ["Sf9", "SPECIES", 303, 306], ["The recombinant protein", "TEST", 0, 23], ["refolding buffer", "TREATMENT", 52, 68], ["Tris pH", "TEST", 76, 83], ["NaCl", "TREATMENT", 95, 99], ["DTT", "TEST", 118, 121], ["5% glycerol", "TREATMENT", 123, 134], ["40 mM CHAPS", "TREATMENT", 181, 192], ["Materials", "TREATMENT", 249, 258], ["MethodsProteins", "TREATMENT", 263, 278], ["infected Sf9 cells", "TREATMENT", 294, 312], ["10% sodium dodecyl sulfate polyacrylamide gel electrophoresis", "TREATMENT", 334, 395], ["Sf9 cells", "OBSERVATION", 303, 312]]], ["The separated proteins were blotted onto an Immun-Blot polyvinylidene fluoride membrane (Bio-Rad, Richmond, CA, USA) using a wet transfer system (Bio-Rad).", [["polyvinylidene fluoride", "CHEMICAL", 55, 78], ["polyvinylidene fluoride", "CHEMICAL", 55, 78], ["polyvinylidene fluoride membrane", "SIMPLE_CHEMICAL", 55, 87], ["an Immun", "TEST", 41, 49], ["Blot polyvinylidene fluoride membrane", "TREATMENT", 50, 87], ["a wet transfer system", "TREATMENT", 123, 144]]], ["The membrane was blocked with 5% skim milk in PBS containing 0.1% Tween 20 (PBST) at room temperature for 1 hour.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 38, 42], ["Tween 20", "CHEMICAL", 66, 74], ["Tween 20", "CHEMICAL", 66, 74], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 38, 42], ["PBS", "SIMPLE_CHEMICAL", 46, 49], ["Tween 20", "SIMPLE_CHEMICAL", 66, 74], ["5% skim milk in PBS", "TREATMENT", 30, 49]]], ["After washing 3 times with PBST, the blocked membrane was subsequently incubated with NDV chicken antiserum (diluted 1:100) for 1 hour, rinsed in PBST, and incubated with alkaline phosphatase-conjugated goat anti-chicken immunoglobulin (diluted 1:1,000, Pierce, Rockford, IL, USA) for 1 hour.", [["membrane", "ANATOMY", 45, 53], ["membrane", "CELLULAR_COMPONENT", 45, 53], ["NDV", "ORGANISM", 86, 89], ["chicken", "ORGANISM", 90, 97], ["antiserum", "ORGANISM_SUBSTANCE", 98, 107], ["alkaline phosphatase", "SIMPLE_CHEMICAL", 171, 191], ["goat", "ORGANISM", 203, 207], ["anti-chicken immunoglobulin", "SIMPLE_CHEMICAL", 208, 235], ["alkaline phosphatase", "PROTEIN", 171, 191], ["conjugated goat anti-chicken immunoglobulin", "PROTEIN", 192, 235], ["chicken", "SPECIES", 90, 97], ["goat", "SPECIES", 203, 207], ["NDV", "SPECIES", 86, 89], ["chicken", "SPECIES", 90, 97], ["goat", "SPECIES", 203, 207], ["PBST", "TREATMENT", 27, 31], ["the blocked membrane", "PROBLEM", 33, 53], ["NDV chicken antiserum", "TREATMENT", 86, 107], ["alkaline phosphatase", "TEST", 171, 191], ["conjugated goat anti-chicken immunoglobulin", "TREATMENT", 192, 235]]], ["Protein bands were visualized by enhanced chemiluminescence using NBT/BCIP solution (Sigma-Aldrich, St. Louis, MO, USA).Standardization of the indirect ELISA ::: Materials and MethodsOptimal dilutions of rERP and sera were determined by a checkerboard titration test with NDV positive and negative sera previously confirmed by hemagglutionation inhibition (HI) test.", [["sera", "ANATOMY", 213, 217], ["sera", "ANATOMY", 298, 302], ["NBT", "CHEMICAL", 66, 69], ["NBT", "CHEMICAL", 66, 69], ["BCIP", "CHEMICAL", 70, 74], ["NBT", "SIMPLE_CHEMICAL", 66, 69], ["BCIP", "SIMPLE_CHEMICAL", 70, 74], ["St. Louis", "ORGANISM", 100, 109], ["rERP", "SIMPLE_CHEMICAL", 204, 208], ["sera", "ORGANISM_SUBSTANCE", 213, 217], ["NDV", "ORGANISM", 272, 275], ["sera", "ORGANISM_SUBSTANCE", 298, 302], ["rERP", "PROTEIN", 204, 208], ["NDV", "SPECIES", 272, 275], ["Protein bands", "TEST", 0, 13], ["enhanced chemiluminescence", "TEST", 33, 59], ["NBT/BCIP solution", "TREATMENT", 66, 83], ["MethodsOptimal dilutions of rERP and sera", "TEST", 176, 217], ["a checkerboard titration test", "TEST", 237, 266], ["NDV", "PROBLEM", 272, 275]]], ["The antigen was coated in 96-well ELISA plates (PolySorb, Nunc, Roskilde, Denmark) ranging in concentration from 2 \u00b5g/mL to 0.0625 \u00b5g/mL in 50 mM carbonate/bicarbonate buffer (pH 9.6).", [["bicarbonate", "CHEMICAL", 156, 167], ["carbonate", "CHEMICAL", 146, 155], ["bicarbonate", "CHEMICAL", 156, 167], ["carbonate", "SIMPLE_CHEMICAL", 146, 155], ["bicarbonate", "SIMPLE_CHEMICAL", 156, 167], ["The antigen", "TEST", 0, 11], ["50 mM carbonate/bicarbonate buffer", "TREATMENT", 140, 174], ["pH", "TEST", 176, 178]]], ["Reference positive and negative sera were both diluted serially from 1:100\u20131:6,400 and tested to determine the optimal serum dilution.", [["sera", "ANATOMY", 32, 36], ["serum", "ANATOMY", 119, 124], ["sera", "ORGANISM_SUBSTANCE", 32, 36], ["serum", "ORGANISM_SUBSTANCE", 119, 124]]], ["The dilutions that gave the optimum difference in absorbance at 450 nm between positive and negative sera were selected to test the sera panel.", [["sera", "ANATOMY", 101, 105], ["sera", "ANATOMY", 132, 136], ["sera", "ORGANISM_SUBSTANCE", 101, 105], ["sera", "ORGANISM_SUBSTANCE", 132, 136], ["The dilutions", "TREATMENT", 0, 13], ["the sera panel", "TEST", 128, 142]]], ["The working dilution of goat anti-chicken HRP-IgG (Sigma-Aldrich), the reaction temperature, time and other conditions also were optimized.Standardization of the indirect ELISA ::: Materials and MethodsTen NDV negative serum samples from specific pathogen free (SPF) chickens were used to determine a cutoff value for the ELISA assay.", [["serum samples", "ANATOMY", 219, 232], ["goat", "ORGANISM", 24, 28], ["HRP-IgG", "GENE_OR_GENE_PRODUCT", 42, 49], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 51, 64], ["NDV", "ORGANISM", 206, 209], ["serum samples", "ORGANISM_SUBSTANCE", 219, 232], ["chickens", "ORGANISM", 267, 275], ["goat anti-chicken HRP", "PROTEIN", 24, 45], ["IgG", "PROTEIN", 46, 49], ["goat", "SPECIES", 24, 28], ["chickens", "SPECIES", 267, 275], ["goat", "SPECIES", 24, 28], ["NDV", "SPECIES", 206, 209], ["chickens", "SPECIES", 267, 275], ["goat anti-chicken HRP", "TREATMENT", 24, 45], ["the reaction temperature", "PROBLEM", 67, 91], ["MethodsTen NDV", "TEST", 195, 209], ["serum samples", "TEST", 219, 232], ["a cutoff value", "TEST", 299, 313], ["the ELISA assay", "TEST", 318, 333]]], ["The mean negative serum optical density (OD) value plus three standard deviations (SD) was used as the cutoff value.", [["serum", "ANATOMY", 18, 23], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["three standard deviations (SD)", "PROBLEM", 56, 86], ["the cutoff value", "TEST", 99, 115], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["serum optical", "OBSERVATION_MODIFIER", 18, 31], ["density", "OBSERVATION_MODIFIER", 32, 39]]], ["Each sample was repeated in triplicate wells and the mean value was calculated.", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11], ["the mean value", "TEST", 49, 63]]], ["In addition to SPF chicken serum, different hyper-immune chicken sera to NDV, H9N2 avian influenza virus (AIV), infectious bronchitis virus (IBV), and infectious bursal disease virus (IBDV) were tested for specificity of rERP using an indirect ELISA assay.", [["serum", "ANATOMY", 27, 32], ["sera", "ANATOMY", 65, 69], ["avian influenza virus", "DISEASE", 83, 104], ["infectious bronchitis virus", "DISEASE", 112, 139], ["infectious bursal disease", "DISEASE", 151, 176], ["chicken", "ORGANISM", 19, 26], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["chicken", "ORGANISM", 57, 64], ["sera", "ORGANISM_SUBSTANCE", 65, 69], ["NDV, H9N2 avian influenza virus", "ORGANISM", 73, 104], ["AIV", "ORGANISM", 106, 109], ["infectious bronchitis virus", "ORGANISM", 112, 139], ["IBV", "ORGANISM", 141, 144], ["infectious bursal disease virus", "ORGANISM", 151, 182], ["IBDV", "ORGANISM", 184, 188], ["rERP", "SIMPLE_CHEMICAL", 221, 225], ["rERP", "PROTEIN", 221, 225], ["chicken", "SPECIES", 19, 26], ["chicken", "SPECIES", 57, 64], ["NDV", "SPECIES", 73, 76], ["H9N2 avian influenza virus", "SPECIES", 78, 104], ["infectious bronchitis virus", "SPECIES", 112, 139], ["infectious bursal disease virus", "SPECIES", 151, 182], ["SPF", "SPECIES", 15, 18], ["chicken", "SPECIES", 19, 26], ["chicken", "SPECIES", 57, 64], ["NDV", "SPECIES", 73, 76], ["H9N2 avian influenza virus", "SPECIES", 78, 104], ["AIV", "SPECIES", 106, 109], ["infectious bronchitis virus", "SPECIES", 112, 139], ["IBV", "SPECIES", 141, 144], ["infectious bursal disease virus", "SPECIES", 151, 182], ["IBDV", "SPECIES", 184, 188], ["SPF chicken serum", "TEST", 15, 32], ["different hyper-immune chicken sera", "PROBLEM", 34, 69], ["NDV", "PROBLEM", 73, 76], ["H9N2 avian influenza virus", "PROBLEM", 78, 104], ["infectious bronchitis virus (IBV)", "PROBLEM", 112, 145], ["infectious bursal disease virus", "PROBLEM", 151, 182], ["an indirect ELISA assay", "TEST", 232, 255], ["infectious", "OBSERVATION_MODIFIER", 112, 122], ["infectious", "OBSERVATION_MODIFIER", 151, 161], ["bursal", "ANATOMY", 162, 168]]], ["To test the sensitivity of the rERP, the chicken anti-NDV serum was diluted serially (1:100\u20131:6,400) and the serum with each dilution was used to react with the expressed rERP in an indirect ELISA.rERP ELISA ::: Materials and MethodsA total of 30 chicken sera comprising three groups with each group of 10 were used in the study.", [["serum", "ANATOMY", 58, 63], ["serum", "ANATOMY", 109, 114], ["sera", "ANATOMY", 255, 259], ["chicken", "ORGANISM", 41, 48], ["anti-NDV serum", "ORGANISM_SUBSTANCE", 49, 63], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["chicken", "ORGANISM", 247, 254], ["sera", "ORGANISM_SUBSTANCE", 255, 259], ["rERP", "PROTEIN", 31, 35], ["rERP", "PROTEIN", 171, 175], ["chicken", "SPECIES", 41, 48], ["chicken", "SPECIES", 247, 254], ["chicken", "SPECIES", 41, 48], ["anti-NDV", "SPECIES", 49, 57], ["chicken", "SPECIES", 247, 254], ["the chicken anti-NDV serum", "TEST", 37, 63], ["the serum", "TEST", 105, 114], ["each dilution", "TEST", 120, 133], ["MethodsA total of 30 chicken sera", "TREATMENT", 226, 259], ["the study", "TEST", 319, 328]]], ["These sera were kept at the OIE reference laboratory for Newcastle disease, Animal and Plant Quarantine Agency (APQA), Korea.", [["sera", "ANATOMY", 6, 10], ["Newcastle disease", "DISEASE", 57, 74], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["These sera", "TEST", 0, 10], ["Newcastle disease", "PROBLEM", 57, 74]]], ["First group were sera taken from mock-infected SPF chicken (NDV antibody negative).", [["sera", "ANATOMY", 17, 21], ["sera", "ORGANISM_SUBSTANCE", 17, 21], ["SPF chicken", "ORGANISM", 47, 58], ["NDV", "ORGANISM", 60, 63], ["chicken", "SPECIES", 51, 58], ["NDV", "SPECIES", 60, 63], ["chicken", "SPECIES", 51, 58], ["NDV", "SPECIES", 60, 63], ["sera", "TEST", 17, 21], ["infected SPF chicken", "PROBLEM", 38, 58], ["NDV antibody", "TEST", 60, 72]]], ["Second and third groups were sera taken 14 dpi from SPF chickens vaccinated with IDE deleted recombinant Newcastle disease virus (rNDV) [4] and NDV LaSota strain [19], respectively, which kindly supplied by the OIE reference laboratory for ND, Korea.", [["sera", "ANATOMY", 29, 33], ["Newcastle disease", "DISEASE", 105, 122], ["sera", "ORGANISM_SUBSTANCE", 29, 33], ["chickens", "ORGANISM", 56, 64], ["IDE", "GENE_OR_GENE_PRODUCT", 81, 84], ["recombinant", "ORGANISM", 93, 104], ["Newcastle disease virus", "ORGANISM", 105, 128], ["rNDV", "ORGANISM", 130, 134], ["NDV", "ORGANISM", 144, 147], ["IDE", "PROTEIN", 81, 84], ["chickens", "SPECIES", 56, 64], ["Newcastle disease virus", "SPECIES", 105, 128], ["NDV", "SPECIES", 144, 147], ["chickens", "SPECIES", 56, 64], ["Newcastle disease virus", "SPECIES", 105, 128], ["NDV", "SPECIES", 131, 134], ["NDV", "SPECIES", 144, 147], ["sera", "TEST", 29, 33], ["SPF chickens vaccinated", "TREATMENT", 52, 75], ["IDE deleted recombinant Newcastle disease virus", "PROBLEM", 81, 128], ["NDV LaSota strain", "TREATMENT", 144, 161]]], ["All vaccinated sera were proved to be serologically positive by a HI test using NDV antigen.", [["sera", "ANATOMY", 15, 19], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["NDV", "ORGANISM", 80, 83], ["NDV antigen", "PROTEIN", 80, 91], ["NDV", "SPECIES", 80, 83], ["All vaccinated sera", "TEST", 0, 19], ["a HI test", "TEST", 64, 73], ["NDV antigen", "TREATMENT", 80, 91]]], ["All sera were available with the laboratory.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["All sera", "TEST", 0, 8]]], ["Microtiter plates were coated with 100 \u00b5L of 1 \u00b5g/mL rERP protein in 50 mM carbonate/bicarbonate buffer pH 9.6, and incubated overnight at 4\u2103.", [["bicarbonate", "CHEMICAL", 85, 96], ["carbonate", "CHEMICAL", 75, 84], ["bicarbonate", "CHEMICAL", 85, 96], ["carbonate", "SIMPLE_CHEMICAL", 75, 84], ["bicarbonate", "SIMPLE_CHEMICAL", 85, 96], ["rERP protein", "PROTEIN", 53, 65], ["Microtiter plates", "TEST", 0, 17], ["protein", "TEST", 58, 65], ["bicarbonate buffer pH", "TEST", 85, 106]]], ["Plates were washed three times with PBST and blocked with 150 \u00b5L per well PBST with 5% skim milk powder solution at 37\u2103 for 2 hours.", [["skim", "ORGANISM_SUBSTANCE", 87, 91], ["milk", "ORGANISM_SUBSTANCE", 92, 96], ["Plates", "TREATMENT", 0, 6], ["PBST", "TREATMENT", 36, 40], ["5% skim milk powder solution", "TREATMENT", 84, 112]]], ["The chicken anti-NDV serum (1:400) was added to each.", [["serum", "ANATOMY", 21, 26], ["chicken", "ORGANISM", 4, 11], ["NDV", "ORGANISM", 17, 20], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["chicken", "SPECIES", 4, 11], ["NDV", "SPECIES", 17, 20], ["chicken", "SPECIES", 4, 11], ["NDV", "SPECIES", 17, 20], ["The chicken anti-NDV serum", "TEST", 0, 26]]], ["After 1-hour incubation at 37\u2103, plates were washed three times with PBST.", [["PBST", "TREATMENT", 68, 72]]], ["One hundred microliters horseradish peroxidase-conjugated goat anti-chicken IgG (Pierce) at 1:2,000 dilution was added to each well and plates were incubated at 37\u2103 for 1 hour.", [["horseradish peroxidase", "SIMPLE_CHEMICAL", 24, 46], ["goat", "ORGANISM", 58, 62], ["horseradish peroxidase", "PROTEIN", 24, 46], ["conjugated goat anti-chicken IgG", "PROTEIN", 47, 79], ["Pierce", "PROTEIN", 81, 87], ["horseradish", "SPECIES", 24, 35], ["goat", "SPECIES", 58, 62], ["goat", "SPECIES", 58, 62], ["One hundred microliters horseradish peroxidase", "TREATMENT", 0, 46], ["conjugated goat anti-chicken IgG (Pierce)", "TREATMENT", 47, 88]]], ["Then plates were washed three times with PBST and 100 \u00b5L TMB (3,3,5,5-tetramethylbenzidine) was added to each well.", [["TMB", "CHEMICAL", 57, 60], ["3,3,5,5-tetramethylbenzidine", "CHEMICAL", 62, 90], ["TMB", "CHEMICAL", 57, 60], ["3,3,5,5-tetramethylbenzidine", "CHEMICAL", 62, 90], ["TMB", "SIMPLE_CHEMICAL", 57, 60], ["3,3,5,5-tetramethylbenzidine", "SIMPLE_CHEMICAL", 62, 90], ["PBST", "TEST", 41, 45], ["tetramethylbenzidine", "TREATMENT", 70, 90]]], ["After 10-minute incubation at 37\u2103, reactions were stopped with 2 M H2SO4 and the OD at 450 nm was measured with microplate reader (Sunrise, Tekan, M\u00e4nnedorf, Switzerland).Statistical analysis ::: Materials and MethodsMean ELISA titer and SDs of each group were calculated using Microsoft Excel (Microsoft, Redmond, WA, USA).", [["H2SO4", "CHEMICAL", 67, 72], ["H2SO4", "CHEMICAL", 67, 72], ["2 M H2SO4", "TREATMENT", 63, 72], ["Materials", "TEST", 196, 205], ["Methods", "TEST", 210, 217], ["Mean ELISA titer", "TEST", 217, 233], ["Microsoft Excel", "TEST", 278, 293]]], ["Differences in ELISA absorbance between groups were analyzed by the one-way analysis of variance (ANOVA).", [["ELISA absorbance", "TEST", 15, 31]]], ["A p-value of <0.05 was considered statistically significant.Construction of bacmid and tertiary structure prediction of recombinant protein ::: ResultsThe construct encoding ERP on NDV NP was designed as shown in Fig. 1A.", [["1A.", "CHEMICAL", 218, 221], ["NDV", "ORGANISM", 181, 184], ["recombinant protein", "PROTEIN", 120, 139], ["ERP", "PROTEIN", 174, 177], ["NDV", "SPECIES", 181, 184], ["A p-value", "TEST", 0, 9], ["NDV NP", "TREATMENT", 181, 187]]], ["The codon optimized gene (486 bp) was designed to have 8 repeats of 16 amino acids (ETQFLDLMRAVANSMR) mimicking C-terminal IDE (aa 444\u2013459) on NDV NP. rERP gene insert was excised from the plasmid after digestion with EcoRI and HindIII enzymes.", [["plasmid", "ANATOMY", 189, 196], ["amino acids", "CHEMICAL", 71, 82], ["amino acids", "CHEMICAL", 71, 82], ["C", "CHEMICAL", 112, 113], ["amino acids", "AMINO_ACID", 71, 82], ["NDV", "ORGANISM", 143, 146], ["rERP", "GENE_OR_GENE_PRODUCT", 151, 155], ["EcoRI", "GENE_OR_GENE_PRODUCT", 218, 223], ["HindIII", "GENE_OR_GENE_PRODUCT", 228, 235], ["codon optimized gene", "DNA", 4, 24], ["C-terminal IDE", "PROTEIN", 112, 126], ["aa 444\u2013459", "PROTEIN", 128, 138], ["rERP gene insert", "DNA", 151, 167], ["plasmid", "DNA", 189, 196], ["EcoRI", "DNA", 218, 223], ["HindIII enzymes", "PROTEIN", 228, 243], ["NDV", "SPECIES", 143, 146], ["bp", "TEST", 30, 32], ["amino acids", "TEST", 71, 82], ["NDV NP", "TREATMENT", 143, 149], ["rERP gene insert", "TREATMENT", 151, 167], ["EcoRI and HindIII enzymes", "TEST", 218, 243]]], ["Resulting fragment (486 bp) was subcloned into the pFastBac HT b vector using above mentioned restriction sites.", [["pFastBac HT b vector", "DNA", 51, 71], ["restriction sites", "DNA", 94, 111], ["Resulting fragment", "PROBLEM", 0, 18], ["bp", "TEST", 24, 26], ["the pFastBac HT b vector", "TREATMENT", 47, 71], ["above mentioned restriction sites", "TREATMENT", 78, 111], ["fragment", "OBSERVATION_MODIFIER", 10, 18]]], ["Recombinant baculovirus containing the recombined ERP gene insert (bac-rERP) was generated by transposition of recombinant vector into the SF9 cells by transfection.", [["SF9 cells", "ANATOMY", 139, 148], ["baculovirus", "ORGANISM", 12, 23], ["bac-rERP", "GENE_OR_GENE_PRODUCT", 67, 75], ["SF9 cells", "CELL", 139, 148], ["recombined ERP gene insert", "DNA", 39, 65], ["bac", "DNA", 67, 70], ["rERP", "DNA", 71, 75], ["SF9 cells", "CELL_LINE", 139, 148], ["baculovirus", "SPECIES", 12, 23], ["Recombinant baculovirus", "TREATMENT", 0, 23], ["the recombined ERP gene insert (bac-rERP)", "TREATMENT", 35, 76], ["transposition of recombinant vector", "TREATMENT", 94, 129], ["SF9 cells", "ANATOMY", 139, 148]]], ["The codon optimized gene was commercially synthesized from GeneArt (Regensburg, Germany) and subcloned into baculovirus transfer vector.", [["baculovirus", "ORGANISM", 108, 119], ["codon optimized gene", "DNA", 4, 24], ["baculovirus transfer vector", "DNA", 108, 135], ["baculovirus", "SPECIES", 108, 119]]], ["Alignment of obtained nucleotide and deduced amino acid sequences of the rERP gene insert revealed 100% match with the designed construct (data not shown).", [["nucleotide", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 45, 55], ["nucleotide", "CHEMICAL", 22, 32], ["amino acid", "CHEMICAL", 45, 55], ["amino acid", "AMINO_ACID", 45, 55], ["rERP", "GENE_OR_GENE_PRODUCT", 73, 77], ["rERP gene insert", "DNA", 73, 89], ["deduced amino acid sequences", "TEST", 37, 65], ["the rERP gene insert", "TREATMENT", 69, 89]]], ["I-TASSER server predicted 5 models, all of which showed optimal spacing in epitopes separated by linkers (Fig. 1B).", [["TASSER server", "DNA", 2, 15], ["epitopes", "PROTEIN", 75, 83], ["optimal spacing in epitopes", "PROBLEM", 56, 83]]], ["Graphic visualization of tertiary structure of top predicted models for rERP protein suggests that IDE reactive antibodies would be freely accessible to epitopes separated by tetra-glycine linkers in tertiary dimensional space.Expression, purification, and characterization of rERP ::: ResultsBac-to-Bac expression system was used to produce a baculovirus encoding N-terminally 6\u00d7 His tagged rERP protein under the transcriptional control of polyhedrin promoter.", [["tetra-glycine", "CHEMICAL", 175, 188], ["tetra-glycine", "CHEMICAL", 175, 188], ["N", "CHEMICAL", 365, 366], ["His", "CHEMICAL", 381, 384], ["rERP", "GENE_OR_GENE_PRODUCT", 72, 76], ["IDE", "GENE_OR_GENE_PRODUCT", 99, 102], ["tetra-glycine", "SIMPLE_CHEMICAL", 175, 188], ["ResultsBac", "GENE_OR_GENE_PRODUCT", 286, 296], ["baculovirus", "ORGANISM", 344, 355], ["rERP", "GENE_OR_GENE_PRODUCT", 392, 396], ["polyhedrin", "GENE_OR_GENE_PRODUCT", 442, 452], ["rERP protein", "PROTEIN", 72, 84], ["IDE reactive antibodies", "PROTEIN", 99, 122], ["epitopes", "PROTEIN", 153, 161], ["rERP", "PROTEIN", 277, 281], ["N-terminally 6", "PROTEIN", 365, 379], ["rERP protein", "PROTEIN", 392, 404], ["polyhedrin promoter", "DNA", 442, 461], ["baculovirus", "SPECIES", 344, 355], ["Graphic visualization", "TEST", 0, 21], ["rERP protein", "TEST", 72, 84], ["IDE reactive antibodies", "PROBLEM", 99, 122], ["tetra-glycine linkers", "TREATMENT", 175, 196], ["ResultsBac", "TEST", 286, 296], ["a baculovirus encoding N", "TREATMENT", 342, 366], ["His tagged rERP protein", "TREATMENT", 381, 404], ["the transcriptional control of polyhedrin promoter", "TREATMENT", 411, 461], ["tertiary structure", "OBSERVATION", 25, 43]]], ["Recombinant baculovirus bac-rERP infected cells were lysed under denaturing conditions and rERP was purified using His tag purification.", [["cells", "ANATOMY", 42, 47], ["His", "CHEMICAL", 115, 118], ["baculovirus", "ORGANISM", 12, 23], ["bac-rERP", "CELL", 24, 32], ["cells", "CELL", 42, 47], ["rERP", "SIMPLE_CHEMICAL", 91, 95], ["Recombinant baculovirus bac-rERP infected cells", "CELL_LINE", 0, 47], ["rERP", "PROTEIN", 91, 95], ["baculovirus", "SPECIES", 12, 23], ["Recombinant baculovirus bac-rERP infected cells", "TREATMENT", 0, 47], ["His tag purification", "TREATMENT", 115, 135], ["infected cells", "OBSERVATION", 33, 47]]], ["The protein was allowed to refold using refolding buffer.", [["refolding buffer", "TREATMENT", 40, 56]]], ["To identify the expressed rERP, the purified protein was analyzed by western blot assay.", [["rERP", "GENE_OR_GENE_PRODUCT", 26, 30], ["rERP", "PROTEIN", 26, 30], ["the purified protein", "TEST", 32, 52], ["blot assay", "TEST", 77, 87]]], ["The chicken anti-NDV serum raised by infecting SPF chickens with La Sota strain of NDV [19] was used as the primary antibody in the analysis.", [["anti-NDV serum", "ANATOMY", 12, 26], ["chicken", "ORGANISM", 4, 11], ["anti-NDV serum", "ORGANISM_SUBSTANCE", 12, 26], ["SPF chickens", "ORGANISM", 47, 59], ["La Sota strain", "ORGANISM", 65, 79], ["NDV [19", "ORGANISM", 83, 90], ["primary antibody", "PROTEIN", 108, 124], ["chicken", "SPECIES", 4, 11], ["chickens", "SPECIES", 51, 59], ["chicken", "SPECIES", 4, 11], ["anti-NDV", "SPECIES", 12, 20], ["chickens", "SPECIES", 51, 59], ["NDV", "SPECIES", 83, 86], ["The chicken anti-NDV serum", "TEST", 0, 26], ["La Sota strain of NDV", "TREATMENT", 65, 86], ["the analysis", "TEST", 128, 140]]], ["The results showed purified rERP with molecular weight of approximately 20 kDa reacted specifically (lanes 1 to 6 in Fig. 2) to the NDV positive serum.", [["serum", "ANATOMY", 145, 150], ["rERP", "GENE_OR_GENE_PRODUCT", 28, 32], ["NDV", "ORGANISM", 132, 135], ["serum", "ORGANISM_SUBSTANCE", 145, 150], ["rERP", "PROTEIN", 28, 32], ["NDV", "SPECIES", 132, 135], ["molecular weight", "TEST", 38, 54], ["the NDV positive serum", "TEST", 128, 150], ["serum", "OBSERVATION_MODIFIER", 145, 150]]], ["No specific band was detected with negative controls (lanes N1 and N2 in Fig. 2), which indicated that the rERP is expressed correctly, and has good reaction ability with chicken specific anti-NDV serum.Specificity and sensitivity of the rERP ::: ResultsThe optimal concentration of the rERP (1 \u00b5g/mL) and the dilution rate of sera (1:400) for indirect ELISA assays to evaluate the specificity and sensitivity of the expresses rERP were determined.", [["serum", "ANATOMY", 197, 202], ["sera", "ANATOMY", 327, 331], ["rERP", "CHEMICAL", 287, 291], ["N2", "CHEMICAL", 67, 69], ["rERP", "GENE_OR_GENE_PRODUCT", 107, 111], ["chicken", "ORGANISM", 171, 178], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["rERP", "SIMPLE_CHEMICAL", 287, 291], ["sera", "ORGANISM_SUBSTANCE", 327, 331], ["rERP", "GENE_OR_GENE_PRODUCT", 427, 431], ["rERP", "PROTEIN", 107, 111], ["rERP", "PROTEIN", 427, 431], ["chicken", "SPECIES", 171, 178], ["chicken", "SPECIES", 171, 178], ["anti-NDV", "SPECIES", 188, 196], ["specific band", "PROBLEM", 3, 16], ["the rERP", "TREATMENT", 283, 291], ["the dilution rate", "TEST", 306, 323], ["sera", "TEST", 327, 331], ["indirect ELISA assays", "TEST", 344, 365], ["the specificity", "TEST", 378, 393]]], ["To set up a cutoff value for indirect ELISA assay, 10 SPF chicken serum samples were analyzed.", [["serum samples", "ANATOMY", 66, 79], ["chicken", "ORGANISM", 58, 65], ["serum samples", "ORGANISM_SUBSTANCE", 66, 79], ["chicken", "SPECIES", 58, 65], ["SPF", "SPECIES", 54, 57], ["chicken", "SPECIES", 58, 65], ["a cutoff value", "TEST", 10, 24], ["indirect ELISA assay", "TEST", 29, 49], ["SPF chicken serum samples", "TEST", 54, 79]]], ["The mean OD450 value of these samples as measured by ELISA was 0.231 with a SD of 0.00022.", [["samples", "ANATOMY", 30, 37], ["samples", "CANCER", 30, 37], ["OD450", "PROTEIN", 9, 14], ["these samples", "TEST", 24, 37], ["ELISA", "TEST", 53, 58], ["a SD", "TEST", 74, 78]]], ["For a 99% confidence interval, the cutoff value determined was 0.232 (mean OD of SPF sera samples+3 SD).", [["the cutoff value", "TEST", 31, 47], ["SPF sera samples", "TEST", 81, 97]]], ["Based on the cutoff value, the reactivity of rERP with chicken anti-AIV, anti-IBV, anti-IBDV, and normal sera was measured.", [["sera", "ANATOMY", 105, 109], ["rERP", "GENE_OR_GENE_PRODUCT", 45, 49], ["chicken", "ORGANISM", 55, 62], ["anti-AIV", "GENE_OR_GENE_PRODUCT", 63, 71], ["anti-IBV", "GENE_OR_GENE_PRODUCT", 73, 81], ["anti-IBDV", "GENE_OR_GENE_PRODUCT", 83, 92], ["sera", "ORGANISM_SUBSTANCE", 105, 109], ["rERP", "PROTEIN", 45, 49], ["chicken anti-AIV", "PROTEIN", 55, 71], ["anti-IBV", "PROTEIN", 73, 81], ["anti-IBDV", "PROTEIN", 83, 92], ["chicken", "SPECIES", 55, 62], ["chicken", "SPECIES", 55, 62], ["anti-IBV", "SPECIES", 73, 81], ["anti-IBDV", "SPECIES", 83, 92], ["the cutoff value", "TEST", 9, 25], ["chicken anti-AIV", "TREATMENT", 55, 71], ["anti-IBV", "TREATMENT", 73, 81], ["anti-IBDV", "TREATMENT", 83, 92]]], ["The result showed that OD450 nm values of non-NDV sera were lower than cutoff value (Fig. 3A).", [["sera", "ANATOMY", 50, 54], ["OD450", "SIMPLE_CHEMICAL", 23, 28], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["non-NDV", "SPECIES", 42, 49], ["OD450 nm values", "TEST", 23, 38], ["non-NDV sera", "TEST", 42, 54]]], ["The minimum dilution titer of chicken anti-NDV serum detected was 1:1,600 according to cutoff value of 0.232 (Fig. 3B).rERP ELISA ::: ResultsA battery of 30 chicken sera samples divided in ten chickens per group in three was tested.", [["anti-NDV serum", "ANATOMY", 38, 52], ["sera samples", "ANATOMY", 165, 177], ["chicken", "ORGANISM", 30, 37], ["anti-NDV serum", "ORGANISM_SUBSTANCE", 38, 52], ["chicken", "ORGANISM", 157, 164], ["sera", "ORGANISM", 165, 169], ["chickens", "ORGANISM", 193, 201], ["chicken", "SPECIES", 30, 37], ["chicken", "SPECIES", 157, 164], ["chickens", "SPECIES", 193, 201], ["chicken", "SPECIES", 30, 37], ["anti-NDV", "SPECIES", 38, 46], ["chicken", "SPECIES", 157, 164], ["chickens", "SPECIES", 193, 201], ["The minimum dilution titer", "TEST", 0, 26], ["chicken anti-NDV serum", "TEST", 30, 52], ["cutoff value", "TEST", 87, 99], ["ResultsA battery", "TEST", 134, 150], ["chicken sera samples", "TEST", 157, 177]]], ["Samples in groups of mock infected chicken sera and chicken vaccinated with the IDE deleted rNDV showed OD values below cut-off value.", [["Samples", "ANATOMY", 0, 7], ["sera", "ANATOMY", 43, 47], ["chicken", "ORGANISM", 35, 42], ["sera", "ORGANISM_SUBSTANCE", 43, 47], ["chicken", "ORGANISM", 52, 59], ["IDE", "GENE_OR_GENE_PRODUCT", 80, 83], ["IDE deleted rNDV", "DNA", 80, 96], ["chicken", "SPECIES", 35, 42], ["chicken", "SPECIES", 52, 59], ["chicken", "SPECIES", 35, 42], ["chicken", "SPECIES", 52, 59], ["Samples", "TEST", 0, 7], ["mock infected chicken sera", "TREATMENT", 21, 47], ["chicken vaccinated", "TREATMENT", 52, 70], ["the IDE deleted rNDV", "TEST", 76, 96], ["OD values", "TEST", 104, 113]]], ["The OD value for samples from wildtype NDV LaSota vaccinated chicken group were in the range of 0.255 to 1.77, which was above determined cut-off value (Fig. 4).", [["samples", "ANATOMY", 17, 24], ["NDV LaSota", "ORGANISM", 39, 49], ["chicken", "ORGANISM", 61, 68], ["NDV", "SPECIES", 39, 42], ["chicken", "SPECIES", 61, 68], ["NDV", "SPECIES", 39, 42], ["chicken", "SPECIES", 61, 68], ["The OD value", "TEST", 0, 12], ["samples", "TEST", 17, 24], ["wildtype NDV LaSota vaccinated chicken group", "TREATMENT", 30, 74]]], ["The indirect ELISA showed good repeatability through the multiple experiments.DiscussionMarker NDV vaccines in conjugation with serological diagnostic test has substantial value in poultry industry for demonstration of the freedom of ND.", [["ND", "DISEASE", 234, 236], ["NDV", "ORGANISM", 95, 98], ["NDV", "SPECIES", 95, 98], ["The indirect ELISA", "TEST", 0, 18], ["Marker NDV vaccines", "TREATMENT", 88, 107], ["serological diagnostic test", "TEST", 128, 155], ["ND", "PROBLEM", 234, 236], ["good repeatability", "OBSERVATION", 26, 44], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["ND", "OBSERVATION", 234, 236]]], ["A serologic marker antigen is a viral protein or an epitope that is absent from the vaccine strains but consistently present in the corresponding wild-type viruses [5].", [["wild-type viruses", "ORGANISM", 146, 163], ["serologic marker antigen", "PROTEIN", 2, 26], ["viral protein", "PROTEIN", 32, 45], ["A serologic marker antigen", "TEST", 0, 26], ["a viral protein", "PROBLEM", 30, 45], ["an epitope", "PROBLEM", 49, 59], ["the vaccine strains", "PROBLEM", 80, 99]]], ["Therefore, only animals that have been infected with wild-type virus will develop antibodies against the serologic marker antigen while the vaccinated animals will not.", [["wild-type virus", "ORGANISM", 53, 68], ["antibodies", "PROTEIN", 82, 92], ["serologic marker antigen", "PROTEIN", 105, 129], ["wild-type virus", "PROBLEM", 53, 68], ["antibodies", "TEST", 82, 92], ["the serologic marker antigen", "TEST", 101, 129], ["infected", "OBSERVATION_MODIFIER", 39, 47]]], ["The marker antigen should be conserved and immunodominant to ensure that the companion diagnostic test based on this marker antigen will produce reliable diagnostic results [20].", [["The marker antigen", "TEST", 0, 18], ["the companion diagnostic test", "TEST", 73, 102], ["this marker antigen", "TEST", 112, 131]]], ["In addition, the marker antigen should be dispensable for the viral life cycle but should not contribute significantly to the overall immunogenicity of the vaccine.", [["the marker antigen", "TEST", 13, 31], ["the vaccine", "TREATMENT", 152, 163]]], ["Subunit vaccines using F and HN protein [21] can serve as marker vaccines but are less effective than whole virus vaccines [22].", [["Subunit vaccines", "TREATMENT", 0, 16], ["F and HN protein", "TREATMENT", 23, 39], ["marker vaccines", "TREATMENT", 58, 73], ["whole virus vaccines", "TREATMENT", 102, 122]]], ["This necessitates NDV marker vaccine based on chimeric live virus.DiscussionNDV NP is known to be carry three antigenic regions, two of which are located at N terminal [5].", [["N", "CHEMICAL", 157, 158], ["NDV", "ORGANISM", 18, 21], ["chimeric live virus", "ORGANISM", 46, 65], ["NDV", "SPECIES", 18, 21], ["NDV marker vaccine", "TREATMENT", 18, 36], ["chimeric live virus", "PROBLEM", 46, 65]]], ["C terminal IDE (aa residues 444\u2013459) ETQFLDLMRAVANSMR is a dispensable epitope on NP protein, which can be replaced with foreign epitope [4].", [["C", "CHEMICAL", 0, 1], ["C terminal IDE", "GENE_OR_GENE_PRODUCT", 0, 14], ["C terminal IDE", "PROTEIN", 0, 14], ["aa residues 444\u2013459) ETQFLDLMRAVANSMR", "PROTEIN", 16, 53], ["NP protein", "PROTEIN", 82, 92], ["C terminal IDE (aa residues", "TREATMENT", 0, 27], ["a dispensable epitope on NP protein", "TREATMENT", 57, 92], ["foreign epitope", "TREATMENT", 121, 136]]], ["In preliminary study, when chickens were immunized with viable recombinant NDV lacking this IDE with reverse genetics technique, monomeric IDE peptide based ELISA showed poor sensitivity most likely due to small hapten size of 16 aa and immunosteric hindrance to bovine serum albumin conjugated peptide (data not shown).", [["serum", "ANATOMY", 270, 275], ["chickens", "ORGANISM", 27, 35], ["NDV", "ORGANISM", 75, 78], ["IDE", "GENE_OR_GENE_PRODUCT", 92, 95], ["IDE", "GENE_OR_GENE_PRODUCT", 139, 142], ["bovine", "ORGANISM", 263, 269], ["serum", "ORGANISM_SUBSTANCE", 270, 275], ["albumin conjugated peptide", "SIMPLE_CHEMICAL", 276, 302], ["IDE", "PROTEIN", 92, 95], ["chickens", "SPECIES", 27, 35], ["bovine", "SPECIES", 263, 269], ["chickens", "SPECIES", 27, 35], ["NDV", "SPECIES", 75, 78], ["bovine", "SPECIES", 263, 269], ["preliminary study", "TEST", 3, 20], ["reverse genetics technique", "TREATMENT", 101, 127], ["monomeric IDE peptide based ELISA", "TEST", 129, 162], ["poor sensitivity", "PROBLEM", 170, 186], ["small hapten size", "PROBLEM", 206, 223], ["immunosteric hindrance", "TREATMENT", 237, 259], ["bovine serum albumin conjugated peptide", "TEST", 263, 302], ["small", "OBSERVATION_MODIFIER", 206, 211], ["hapten size", "OBSERVATION", 212, 223]]], ["To address this issue, this problem can be solved by using multimers of IDE in the form of recombinant protein antigen.DiscussionIn the study, we designed, expressed and characterized the rERP in baculovirus expression system.", [["IDE", "GENE_OR_GENE_PRODUCT", 72, 75], ["recombinant protein antigen", "GENE_OR_GENE_PRODUCT", 91, 118], ["rERP", "GENE_OR_GENE_PRODUCT", 188, 192], ["baculovirus", "ORGANISM", 196, 207], ["IDE", "PROTEIN", 72, 75], ["recombinant protein antigen", "PROTEIN", 91, 118], ["rERP", "DNA", 188, 192], ["baculovirus", "SPECIES", 196, 207], ["multimers of IDE", "TREATMENT", 59, 75], ["recombinant protein antigen", "TREATMENT", 91, 118], ["the study", "TEST", 132, 141], ["the rERP in baculovirus expression system", "PROBLEM", 184, 225]]], ["This protein carried tandem repeats of IDE on NDV NP.", [["IDE", "GENE_OR_GENE_PRODUCT", 39, 42], ["NDV NP", "ORGANISM", 46, 52], ["IDE", "PROTEIN", 39, 42], ["NDV", "SPECIES", 46, 49], ["NDV NP", "TREATMENT", 46, 52]]], ["The protein carried N terminal his tag allowing one-step purification under Ni NTA agar column [2324].", [["Ni NTA", "CHEMICAL", 76, 82], ["N", "CHEMICAL", 20, 21], ["Ni", "CHEMICAL", 76, 78], ["Ni NTA", "SIMPLE_CHEMICAL", 76, 82], ["N terminal his tag", "PROTEIN", 20, 38]]], ["The construct designed to express recombinant protein was codon optimized for Sf9 cells.", [["Sf9 cells", "ANATOMY", 78, 87], ["Sf9 cells", "CELL", 78, 87], ["recombinant protein", "PROTEIN", 34, 53], ["Sf9 cells", "CELL_LINE", 78, 87], ["Sf9", "SPECIES", 78, 81], ["Sf9 cells", "PROBLEM", 78, 87]]], ["Codon optimization involves codon adaptability, mRNA structure, tRNA usage.", [["mRNA structure", "RNA", 48, 62], ["Codon optimization", "TREATMENT", 0, 18], ["codon adaptability", "PROBLEM", 28, 46]]], ["It significantly increases protein expression [252627].", [["significantly", "OBSERVATION_MODIFIER", 3, 16], ["increases", "OBSERVATION_MODIFIER", 17, 26], ["protein expression", "OBSERVATION", 27, 45]]], ["We used tetra-glycine linker as linker in between epitopes as it provides flexibility due to lack of \u03b2-carbon and is preferred linker in multi-epitope proteins [28].", [["tetra-glycine", "CHEMICAL", 8, 21], ["\u03b2-carbon", "CHEMICAL", 101, 109], ["tetra-glycine", "CHEMICAL", 8, 21], ["\u03b2-carbon", "CHEMICAL", 101, 109], ["tetra-glycine", "SIMPLE_CHEMICAL", 8, 21], ["\u03b2-carbon", "SIMPLE_CHEMICAL", 101, 109], ["\u03b2-carbon", "PROTEIN", 101, 109], ["multi-epitope proteins", "PROTEIN", 137, 159], ["tetra-glycine linker as linker in between epitopes", "TREATMENT", 8, 58], ["lack of \u03b2-carbon", "PROBLEM", 93, 109]]], ["Computer modeling showed that all the epitopes are freely accessible in three-dimensional space.", [["epitopes", "PROTEIN", 38, 46], ["Computer modeling", "TEST", 0, 17]]], ["This rERP was expressed at high concentration in insect cells when titrated by ELISA.", [["cells", "ANATOMY", 56, 61], ["rERP", "GENE_OR_GENE_PRODUCT", 5, 9], ["insect cells", "CELL", 49, 61], ["rERP", "PROTEIN", 5, 9], ["insect cells", "CELL_TYPE", 49, 61]]], ["We purified protein under denaturing condition on a Ni-NTA matrix with a high degree of purity [29].DiscussionWestern blot analysis showed the purified rERP was recognized by chicken anti-NDV serum with a specific band at approximately 20 kDa (lanes 1\u20136 in Fig. 2), while no specific band was observed when using negative control serum.", [["anti-NDV serum", "ANATOMY", 183, 197], ["serum", "ANATOMY", 330, 335], ["Ni-NTA", "CHEMICAL", 52, 58], ["Ni-NTA", "CHEMICAL", 52, 58], ["rERP", "GENE_OR_GENE_PRODUCT", 152, 156], ["chicken", "ORGANISM", 175, 182], ["anti-NDV", "ORGANISM_SUBSTANCE", 183, 191], ["serum", "ORGANISM_SUBSTANCE", 192, 197], ["serum", "ORGANISM_SUBSTANCE", 330, 335], ["rERP", "PROTEIN", 152, 156], ["chicken", "SPECIES", 175, 182], ["chicken", "SPECIES", 175, 182], ["anti-NDV", "SPECIES", 183, 191], ["denaturing condition", "PROBLEM", 26, 46], ["a Ni-NTA matrix", "TREATMENT", 50, 65], ["DiscussionWestern blot analysis", "TEST", 100, 131], ["high degree", "OBSERVATION_MODIFIER", 73, 84]]], ["This indicates that the expressed rERP has the molecular weight as expected.", [["rERP", "GENE_OR_GENE_PRODUCT", 34, 38], ["rERP", "PROTEIN", 34, 38]]], ["We employed the indirect ELISA to evaluate the specificity and sensitivity of the expressed rERP using confirmed positive and negative sera samples. rERP could react specifically with the anti-NDV serum and showed no reactivity towards anti-IBV, anti-IBDV, anti-AIV, and normal sera.", [["sera samples", "ANATOMY", 135, 147], ["anti-NDV serum", "ANATOMY", 188, 202], ["sera", "ANATOMY", 278, 282], ["rERP", "CHEMICAL", 149, 153], ["rERP", "GENE_OR_GENE_PRODUCT", 92, 96], ["rERP", "SIMPLE_CHEMICAL", 149, 153], ["anti-NDV", "ORGANISM_SUBSTANCE", 188, 196], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["anti-IBV", "SIMPLE_CHEMICAL", 236, 244], ["anti-IBDV", "SIMPLE_CHEMICAL", 246, 255], ["anti-AIV", "SIMPLE_CHEMICAL", 257, 265], ["sera", "ORGANISM_SUBSTANCE", 278, 282], ["rERP", "PROTEIN", 92, 96], ["rERP", "PROTEIN", 149, 153], ["anti-IBV", "PROTEIN", 236, 244], ["anti-IBDV", "PROTEIN", 246, 255], ["anti-AIV", "PROTEIN", 257, 265], ["anti-NDV", "SPECIES", 188, 196], ["anti-IBV", "SPECIES", 236, 244], ["anti-IBDV", "SPECIES", 246, 255], ["anti-AIV", "SPECIES", 257, 265], ["the indirect ELISA", "TEST", 12, 30], ["positive and negative sera samples", "PROBLEM", 113, 147], ["the anti-NDV serum", "TEST", 184, 202], ["reactivity", "PROBLEM", 217, 227], ["anti-IBV", "TREATMENT", 236, 244], ["anti-IBDV", "TREATMENT", 246, 255], ["anti-AIV", "TREATMENT", 257, 265]]], ["It suggests that rERP can specifically recognize anti-NDV antibodies.", [["rERP", "SIMPLE_CHEMICAL", 17, 21], ["anti-NDV antibodies", "GENE_OR_GENE_PRODUCT", 49, 68], ["rERP", "PROTEIN", 17, 21], ["anti-NDV antibodies", "PROTEIN", 49, 68], ["anti-NDV", "SPECIES", 49, 57], ["anti-NDV antibodies", "PROBLEM", 49, 68]]], ["The potential of rERP ELISA to serve as discriminatory test in combination with the IDE deleted marker vaccine was investigated using three panels of sera.", [["sera", "ANATOMY", 150, 154], ["rERP", "GENE_OR_GENE_PRODUCT", 17, 21], ["IDE", "GENE_OR_GENE_PRODUCT", 84, 87], ["sera", "ORGANISM_SUBSTANCE", 150, 154], ["rERP", "PROTEIN", 17, 21], ["IDE", "PROTEIN", 84, 87], ["rERP ELISA", "TEST", 17, 27], ["discriminatory test", "TEST", 40, 59], ["the IDE deleted marker vaccine", "TREATMENT", 80, 110], ["sera", "TREATMENT", 150, 154]]], ["The test correctly classified the marker vaccinated and SPF chicken sera as antibody negative but sera from wildtype NDV immunized chickens as antibody positive.", [["sera", "ANATOMY", 68, 72], ["sera", "ANATOMY", 98, 102], ["chicken", "ORGANISM", 60, 67], ["sera", "ORGANISM_SUBSTANCE", 68, 72], ["sera", "ORGANISM_SUBSTANCE", 98, 102], ["NDV", "ORGANISM", 117, 120], ["chickens", "ORGANISM", 131, 139], ["chicken", "SPECIES", 60, 67], ["NDV", "SPECIES", 117, 120], ["chickens", "SPECIES", 131, 139], ["SPF", "SPECIES", 56, 59], ["chicken", "SPECIES", 60, 67], ["NDV", "SPECIES", 117, 120], ["chickens", "SPECIES", 131, 139], ["The test", "TEST", 0, 8], ["the marker vaccinated", "TEST", 30, 51], ["SPF chicken sera", "TEST", 56, 72], ["antibody", "TEST", 76, 84], ["sera", "TEST", 98, 102], ["wildtype NDV immunized chickens as antibody positive", "PROBLEM", 108, 160]]], ["These results revealed that rERP possessed good reactivity, specificity and sensitivity.DiscussionFuture work involves testing sera samples under field trials.", [["sera samples", "ANATOMY", 127, 139], ["rERP", "CHEMICAL", 28, 32], ["rERP", "SIMPLE_CHEMICAL", 28, 32], ["sera", "ORGANISM", 127, 131], ["rERP", "PROTEIN", 28, 32], ["sensitivity", "TEST", 76, 87], ["testing sera samples", "TEST", 119, 139]]], ["If proven satisfactory, the recombinant protein represents a promising candidate as companion diagnostic test in NDV DIVA vaccination program.", [["NDV", "ORGANISM", 113, 116], ["DIVA", "CANCER", 117, 121], ["recombinant protein", "PROTEIN", 28, 47], ["NDV", "SPECIES", 113, 116], ["companion diagnostic test", "TEST", 84, 109], ["NDV DIVA vaccination program", "TREATMENT", 113, 141]]], ["This strategy of epitope-based recombinant proteins as ELISA antigens against modification permissible regions of viruses makes it a highly effective approach in DIVA vaccination.", [["DIVA", "CANCER", 162, 166], ["epitope", "PROTEIN", 17, 24], ["recombinant proteins", "PROTEIN", 31, 51], ["ELISA antigens", "PROTEIN", 55, 69], ["DIVA", "SPECIES", 162, 166], ["epitope-based recombinant proteins", "TREATMENT", 17, 51], ["ELISA antigens", "TEST", 55, 69], ["modification permissible regions of viruses", "PROBLEM", 78, 121], ["DIVA vaccination", "TREATMENT", 162, 178], ["viruses", "OBSERVATION", 114, 121]]]], "2840929d7782a3eba7faa5e6c11d31122b1d5642": [["IntroductionThe outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) associated disease has rapidly escalated to pandemic proportions.", [["acute respiratory syndrome coronavirus", "DISEASE", 39, 77], ["SARS-CoV-2)", "CHEMICAL", 81, 92], ["SARS-CoV-2", "ORGANISM", 81, 91], ["severe acute respiratory syndrome coronavirus", "SPECIES", 32, 77], ["SARS-CoV-2", "SPECIES", 81, 91], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 28, 77], ["SARS", "TEST", 81, 85], ["associated disease", "PROBLEM", 93, 111], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome coronavirus", "OBSERVATION", 45, 77], ["disease", "OBSERVATION", 104, 111], ["rapidly", "OBSERVATION_MODIFIER", 116, 123], ["escalated", "OBSERVATION_MODIFIER", 124, 133]]], ["By the beginning of April 2020, over 1,000,000 cases of confirmed infections and over 66,000 deaths from COVID-19 were reported worldwide [www.worldometers.info/coronavirus].", [["infections", "DISEASE", 66, 76], ["deaths", "DISEASE", 93, 99], ["infections", "PROBLEM", 66, 76], ["COVID", "TEST", 105, 110], ["coronavirus", "PROBLEM", 161, 172], ["infections", "OBSERVATION", 66, 76]]], ["The most common symptoms of COVID-19 are new onset of a continuous cough and/or temperature \u226537.8\u02daC 1 .", [["COVID", "DISEASE", 28, 33], ["cough", "DISEASE", 67, 72], ["COVID-19", "CHEMICAL", 28, 36], ["COVID", "TEST", 28, 33], ["a continuous cough", "PROBLEM", 54, 72], ["temperature", "TEST", 80, 91], ["new", "OBSERVATION_MODIFIER", 41, 44], ["cough", "OBSERVATION", 67, 72]]], ["Ageusia and anosmia are also frequent symptoms at the early phase of diagnosis 1 .", [["Ageusia", "DISEASE", 0, 7], ["anosmia", "DISEASE", 12, 19], ["Ageusia", "PROBLEM", 0, 7], ["anosmia", "PROBLEM", 12, 19], ["frequent symptoms", "PROBLEM", 29, 46], ["anosmia", "OBSERVATION", 12, 19]]], ["While most patients have no or mild symptoms, about a quarter of patients develop severe symptoms and 5% will have critical symptoms.", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 65, 73], ["mild symptoms", "PROBLEM", 31, 44], ["severe symptoms", "PROBLEM", 82, 97], ["critical symptoms", "PROBLEM", 115, 132], ["mild", "OBSERVATION_MODIFIER", 31, 35], ["symptoms", "OBSERVATION", 36, 44]]], ["The clinical manifestations, as well as case fatality rates have been higher in the elderly, those with comorbidities such as respiratory and cardiovascular disease, males and smokers 2 .", [["respiratory", "ANATOMY", 126, 137], ["cardiovascular", "ANATOMY", 142, 156], ["respiratory and cardiovascular disease", "DISEASE", 126, 164], ["comorbidities", "PROBLEM", 104, 117], ["respiratory and cardiovascular disease", "PROBLEM", 126, 164], ["higher", "OBSERVATION_MODIFIER", 70, 76], ["respiratory", "ANATOMY", 126, 137], ["cardiovascular disease", "OBSERVATION", 142, 164]]], ["There is currently no approved nor proven effective treatment or vaccine available for COVID-19, but there are several ongoing trials of potential therapies.IntroductionCOVID-19 has led to a severe overloading of hospital systems in most affected regions and countries 3 .IntroductionHealthcare resources (human as well as material) have been rearranged to manage the influx of a large number of patients requiring intensive monitoring, artificial ventilation, and in selected cases extracorporeal membrane oxygenation 4 .", [["membrane", "ANATOMY", 498, 506], ["human", "ORGANISM", 306, 311], ["patients", "ORGANISM", 396, 404], ["human", "SPECIES", 306, 311], ["patients", "SPECIES", 396, 404], ["human", "SPECIES", 306, 311], ["vaccine", "TREATMENT", 65, 72], ["COVID", "TEST", 87, 92], ["potential therapies", "TREATMENT", 137, 156], ["IntroductionCOVID", "TEST", 157, 174], ["a severe overloading of hospital systems", "PROBLEM", 189, 229], ["intensive monitoring", "TEST", 415, 435], ["artificial ventilation", "TREATMENT", 437, 459], ["selected cases extracorporeal membrane oxygenation", "TREATMENT", 468, 518], ["severe", "OBSERVATION_MODIFIER", 191, 197], ["overloading", "OBSERVATION", 198, 209], ["large", "OBSERVATION_MODIFIER", 380, 385]]], ["Even in countries where COVID19 has not attained very high incidence rates, containment measures are recommended and are being implemented, to prevent infections both of patients and healthcare professionals.", [["infections", "DISEASE", 151, 161], ["COVID19", "GENE_OR_GENE_PRODUCT", 24, 31], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["containment measures", "TREATMENT", 76, 96], ["infections", "PROBLEM", 151, 161]]], ["The response to this pandemic has led to a sudden disruption of routine medical care, including the treatment of cancer patients, an especially vulnerable population, whose outcomes are dependent on timely and high-quality multidisciplinary interventions 5 .IntroductionTravel restrictions have made it difficult for some cancer patients to reach the hospital and the fear of infection while visiting the hospital has caused many others to cancel their appointments.", [["cancer", "ANATOMY", 113, 119], ["cancer", "ANATOMY", 322, 328], ["cancer", "DISEASE", 113, 119], ["cancer", "DISEASE", 322, 328], ["infection", "DISEASE", 376, 385], ["cancer", "CANCER", 113, 119], ["patients", "ORGANISM", 120, 128], ["cancer", "CANCER", 322, 328], ["patients", "ORGANISM", 329, 337], ["patients", "SPECIES", 120, 128], ["patients", "SPECIES", 329, 337], ["routine medical care", "TREATMENT", 64, 84], ["cancer", "PROBLEM", 113, 119], ["high-quality multidisciplinary interventions", "TREATMENT", 210, 254], ["infection", "PROBLEM", 376, 385], ["cancer", "OBSERVATION", 113, 119], ["infection", "OBSERVATION", 376, 385]]], ["Staffing gaps within the oncology departments have arisen as a result of redeployment and sequestering of medical and supporting staff to other areas of critical need -such as respiratory units, emergency departments, and intensive care units (ICUs), as well as self-isolation or quarantine of staff members with suspicious symptoms and/or positive SARS-CoV-2 test 6 .", [["suspicious symptoms", "PROBLEM", 313, 332], ["positive SARS", "PROBLEM", 340, 353], ["CoV-2 test", "TEST", 354, 364]]], ["Consequently, many routine visits to the outpatient clinics have been either replaced by telephone/video consultation or deferred.IntroductionIndependently of whether in a general hospital or in an oncology facility, measures need to be put in place to protect patients and health professionals, and to create a safe circuit to treat or transfer (according to country/regional directives) SARS-CoV-2 infected patients with cancer.", [["cancer", "ANATOMY", 423, 429], ["SARS-CoV-2 infected", "DISEASE", 389, 408], ["cancer", "DISEASE", 423, 429], ["patients", "ORGANISM", 261, 269], ["SARS-CoV-2", "ORGANISM", 389, 399], ["patients", "ORGANISM", 409, 417], ["cancer", "CANCER", 423, 429], ["patients", "SPECIES", 261, 269], ["patients", "SPECIES", 409, 417], ["a safe circuit", "TREATMENT", 310, 324], ["cancer", "PROBLEM", 423, 429], ["cancer", "OBSERVATION", 423, 429]]], ["These actions have also a strong impact on available resources and routine processes that need to be considered to avoid system disruption.IntroductionAs breast cancer specialists, our main goal is to take care of breast cancer patients within a multidisciplinary environment, able to provide high level treatment within the shortest period of time and according to established quality indicators.", [["breast cancer", "ANATOMY", 154, 167], ["breast cancer", "ANATOMY", 214, 227], ["breast cancer", "DISEASE", 154, 167], ["breast cancer", "DISEASE", 214, 227], ["breast cancer", "CANCER", 154, 167], ["breast cancer", "CANCER", 214, 227], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["routine processes", "TREATMENT", 67, 84], ["system disruption", "PROBLEM", 121, 138], ["breast cancer", "PROBLEM", 214, 227], ["high level treatment", "TREATMENT", 293, 313], ["breast", "ANATOMY", 154, 160], ["cancer", "OBSERVATION", 161, 167], ["breast", "ANATOMY", 214, 220], ["cancer", "OBSERVATION", 221, 227]]], ["However, the current extraordinary worldwide situation requires an urgent re-organization and adapted allocation of healthcare resources, staff as well as infrastructures without compromising patients' outcomes.IntroductionThe aim of the present recommendations is to provide guidelines, including selection criteria to service provision and prioritization of treatments, according to the pandemic scenario in each country/region (Table 1) , for breast cancer patients care during this critical moment when benefits and risks are influenced by a serious external health threat.", [["breast cancer", "ANATOMY", 446, 459], ["breast cancer", "DISEASE", 446, 459], ["patients", "ORGANISM", 192, 200], ["breast cancer", "CANCER", 446, 459], ["patients", "ORGANISM", 460, 468], ["patients", "SPECIES", 192, 200], ["patients", "SPECIES", 460, 468], ["an urgent re-organization", "TREATMENT", 64, 89], ["treatments", "TREATMENT", 360, 370], ["breast cancer patients care", "TREATMENT", 446, 473], ["breast", "ANATOMY", 446, 452], ["cancer", "OBSERVATION", 453, 459]]], ["This necessitates that all current medical decisions must be carefully weighed taking into account unusual parameters and be balanced not only for the safety of individual patients but also for the community.", [["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180]]], ["The PDCA (plan-do-check-act or plan-do-check-adjust) approach is aimed at continuously following, monitoring and improving the organization based on the obtained results in every single hospital and/or department ( Figure 1 ).", [["approach", "TREATMENT", 53, 61]]], ["We highlight that these considerations do not overcome the individual physician judgment or available treatment guidelines but represent an expert-opinion-based guidance for optimal allocation of resources during an unprecedented critical period, drawing on current knowledge in a rapidly emerging and evolving situation.IntroductionProposed risk stratifications 8,9 : I) Breast cancer patients recently suspected or recently diagnosed II) Breast cancer patients on active treatment (i.e. chemotherapy, immunotherapy, anti-HER2 therapy, endocrine therapy with or without targeted therapies) III) Breast cancer patients in follow-up (non-active treatment) or on adjuvant endocrine therapy alone Supplementary risk factors: age over 60 / pre-existing cardiovascular disease/ pre-existing respiratory disease/ smokers / males General recommendations (Table 2) 1.", [["Breast cancer", "ANATOMY", 372, 385], ["Breast cancer", "ANATOMY", 440, 453], ["endocrine", "ANATOMY", 537, 546], ["Breast cancer", "ANATOMY", 596, 609], ["endocrine", "ANATOMY", 670, 679], ["cardiovascular", "ANATOMY", 749, 763], ["respiratory", "ANATOMY", 786, 797], ["Breast cancer", "DISEASE", 372, 385], ["Breast cancer", "DISEASE", 440, 453], ["Breast cancer", "DISEASE", 596, 609], ["cardiovascular disease", "DISEASE", 749, 771], ["respiratory disease", "DISEASE", 786, 805], ["Breast cancer", "CANCER", 372, 385], ["patients", "ORGANISM", 386, 394], ["Breast cancer", "CANCER", 440, 453], ["patients", "ORGANISM", 454, 462], ["anti-HER2", "SIMPLE_CHEMICAL", 518, 527], ["Breast cancer", "CANCER", 596, 609], ["patients", "ORGANISM", 610, 618], ["cardiovascular", "ANATOMICAL_SYSTEM", 749, 763], ["patients", "SPECIES", 386, 394], ["patients", "SPECIES", 454, 462], ["patients", "SPECIES", 610, 618], ["treatment guidelines", "TREATMENT", 102, 122], ["Breast cancer", "PROBLEM", 372, 385], ["Breast cancer", "PROBLEM", 440, 453], ["active treatment", "TREATMENT", 466, 482], ["chemotherapy", "TREATMENT", 489, 501], ["immunotherapy", "TREATMENT", 503, 516], ["anti-HER2 therapy", "TREATMENT", 518, 535], ["endocrine therapy", "TREATMENT", 537, 554], ["targeted therapies", "TREATMENT", 571, 589], ["Breast cancer", "PROBLEM", 596, 609], ["non-active treatment", "TREATMENT", 633, 653], ["adjuvant endocrine therapy", "TREATMENT", 661, 687], ["pre-existing cardiovascular disease", "PROBLEM", 736, 771], ["pre-existing respiratory disease", "PROBLEM", 773, 805], ["Breast", "ANATOMY", 372, 378], ["cancer", "OBSERVATION", 379, 385], ["Breast", "ANATOMY", 440, 446], ["cancer", "OBSERVATION", 447, 453], ["Breast", "ANATOMY", 596, 602], ["cancer", "OBSERVATION", 603, 609], ["cardiovascular", "ANATOMY", 749, 763], ["disease", "OBSERVATION", 764, 771], ["respiratory disease", "OBSERVATION", 786, 805]]], ["Patients should be informed and guided to follow all measures of social distancing and wearing personal protective equipment (i.e. mask) when travelling to the hospital, always in compliance with each country public health regulations.Introduction2.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["personal protective equipment", "TREATMENT", 95, 124]]], ["Early identification of symptoms suspicious of SARS-CoV-2 infection is crucial, as well as of symptoms or adverse events caused by the malignancy or antitumor treatments.", [["antitumor", "ANATOMY", 149, 158], ["SARS", "DISEASE", 47, 51], ["infection", "DISEASE", 58, 67], ["malignancy", "DISEASE", 135, 145], ["SARS-CoV-2", "ORGANISM", 47, 57], ["antitumor", "CANCER", 149, 158], ["SARS-CoV", "SPECIES", 47, 55], ["symptoms", "PROBLEM", 24, 32], ["SARS", "PROBLEM", 47, 51], ["CoV", "PROBLEM", 52, 55], ["2 infection", "PROBLEM", 56, 67], ["symptoms", "PROBLEM", 94, 102], ["adverse events", "PROBLEM", 106, 120], ["the malignancy", "PROBLEM", 131, 145], ["antitumor treatments", "TREATMENT", 149, 169], ["SARS", "OBSERVATION", 47, 51], ["infection", "OBSERVATION", 58, 67], ["malignancy", "OBSERVATION", 135, 145]]], ["Body temperature should be measured at the entry of the hospital.", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["Body temperature", "TEST", 0, 16]]], ["Patients with symptoms suspicious of SARS-CoV-2 infection, should be tested and managed in a COVID-19 hospital or in the COVID-19-dedicated departments/areas of the cancer center.Introduction3.", [["cancer", "ANATOMY", 165, 171], ["SARS-CoV-2 infection", "DISEASE", 37, 57], ["cancer", "DISEASE", 165, 171], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 37, 47], ["cancer", "CANCER", 165, 171], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 37, 45], ["symptoms", "PROBLEM", 14, 22], ["SARS", "PROBLEM", 37, 41], ["CoV", "PROBLEM", 42, 45], ["2 infection", "PROBLEM", 46, 57], ["SARS", "OBSERVATION", 37, 41], ["infection", "OBSERVATION", 48, 57], ["cancer", "OBSERVATION", 165, 171]]], ["Patients who need to be hospitalized for cancer treatment should be treated in COVID-19-free hospitals or COVID-19-free departments/areas of the hospital and be, as much as possible, shielded from potential SARS-CoV-2 infection, with a dedicated diagnostic and therapeutic internal pathway.", [["cancer", "ANATOMY", 41, 47], ["cancer", "DISEASE", 41, 47], ["SARS-CoV-2 infection", "DISEASE", 207, 227], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 41, 47], ["CoV-2", "ORGANISM", 212, 217], ["Patients", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 207, 215], ["cancer treatment", "TREATMENT", 41, 57], ["potential SARS", "PROBLEM", 197, 211], ["CoV-2 infection", "PROBLEM", 212, 227], ["therapeutic internal pathway", "TREATMENT", 261, 289]]], ["No visits should be allowed in the inpatient facilities and no accompanying care giver should enter the hospital with the patient for appointments or treatments.Introduction5.", [["patient", "ORGANISM", 122, 129], ["patient", "SPECIES", 122, 129], ["treatments", "TREATMENT", 150, 160]]], ["Staff should be organized by shifts, limiting the number of people working simultaneously to the minimum required.Introduction6.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66]]], ["The multidisciplinary tumour boards (MDM) should be continued but performed via web meetings or restricted to one element of each discipline of the core team 10 .", [["tumour", "ANATOMY", 22, 28], ["tumour", "DISEASE", 22, 28], ["tumour", "CANCER", 22, 28], ["The multidisciplinary tumour boards", "TREATMENT", 0, 35]]], ["All decisions of the MDM should continue to be discussed with the patient and the final decision must account for the patients' preferences.Introduction7.", [["patient", "ORGANISM", 66, 73], ["patients", "ORGANISM", 118, 126], ["MDM", "CELL_TYPE", 21, 24], ["patient", "SPECIES", 66, 73], ["patients", "SPECIES", 118, 126]]], ["Due to different availability of tests and different public health measures taken in each country, we recommend that testing guidelines of the national health authorities are followed.", [["tests", "TEST", 33, 38], ["different public health measures", "TREATMENT", 43, 75]]], ["If tests are available, patients should be tested for SARS-CoV-2 before surgery or any invasive procedure and before initiating immunosuppressive therapies, independently of symptoms.", [["SARS", "DISEASE", 54, 58], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["tests", "TEST", 3, 8], ["SARS", "PROBLEM", 54, 58], ["CoV", "TEST", 59, 62], ["surgery", "TREATMENT", 72, 79], ["any invasive procedure", "TREATMENT", 83, 105], ["immunosuppressive therapies", "TREATMENT", 128, 155], ["symptoms", "PROBLEM", 174, 182]]], ["If positive, the procedure and/or treatment should be postponed and resumed only after the patient is considered recovered.", [["patient", "ORGANISM", 91, 98], ["patient", "SPECIES", 91, 98], ["positive", "PROBLEM", 3, 11], ["the procedure", "TREATMENT", 13, 26], ["treatment", "TREATMENT", 34, 43]]], ["However, it is important to realize that even with this approach, some cases will be missed in view of the false negative rate of the PCR test on pharyngeal swabs.", [["pharyngeal swabs", "ANATOMY", 146, 162], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 146, 162], ["this approach", "TREATMENT", 51, 64], ["the PCR test", "TEST", 130, 142], ["pharyngeal swabs", "TEST", 146, 162]]], ["(Table 2) 1.Screening and DiagnosisDue to the foreseeable reduction of resources and to ensure the safety of patients and staff, population mammographic screening should be suspended until the pandemic has subsided 4,5,11,12 .2.Diagnostic procedures in symptomatic patients should be scheduled according to local availability and resources.", [["patients", "ORGANISM", 109, 117], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 265, 273], ["Screening", "TEST", 12, 21], ["population mammographic screening", "TEST", 129, 162], ["Diagnostic procedures", "TEST", 228, 249]]], ["However, all efforts should be made to avoid delayed diagnosis in those with suspicious symptoms or clinical or imaging findings [BIRADS 5 (high priority) or BIRADS 4 (medium priority)] and its potential impact on cancer outcomes 4, 5, 11, 12 .Locoregional Treatment in Early Breast Cancer (EBC)Surgery versus primary systemic treatment (Table 3) Under normal circumstances, primary systemic therapy (PST) is increasingly used and preferred over upfront surgery, not only for locally advanced disease but also in the EBC setting, both within and outside clinical trials.", [["cancer", "ANATOMY", 214, 220], ["Breast Cancer", "ANATOMY", 276, 289], ["cancer", "DISEASE", 214, 220], ["Breast Cancer", "DISEASE", 276, 289], ["cancer", "CANCER", 214, 220], ["Breast Cancer", "CANCER", 276, 289], ["suspicious symptoms", "PROBLEM", 77, 96], ["imaging findings", "TEST", 112, 128], ["BIRADS", "TEST", 130, 136], ["BIRADS", "TEST", 158, 164], ["cancer outcomes", "PROBLEM", 214, 229], [".Locoregional Treatment", "TREATMENT", 243, 266], ["Early Breast Cancer", "PROBLEM", 270, 289], ["Surgery", "TREATMENT", 295, 302], ["primary systemic treatment", "TREATMENT", 310, 336], ["primary systemic therapy", "TREATMENT", 375, 399], ["upfront surgery", "TREATMENT", 446, 461], ["locally advanced disease", "PROBLEM", 476, 500], ["cancer", "OBSERVATION", 214, 220], ["Breast", "ANATOMY", 276, 282], ["Cancer", "OBSERVATION", 283, 289], ["systemic therapy", "OBSERVATION", 383, 399], ["advanced", "OBSERVATION_MODIFIER", 484, 492], ["disease", "OBSERVATION", 493, 500]]], ["This is due to the established benefits of this approach in terms of surgical de-escalation and more recently to optimize further adjuvant treatments.", [["this approach", "TREATMENT", 43, 56], ["surgical de-escalation", "TREATMENT", 69, 91], ["further adjuvant treatments", "TREATMENT", 122, 149]]], ["PST includes both neo-adjuvant/primary chemotherapy \u00b1 anti-HER2 therapy (NAC) and neo-adjuvant/primary endocrine therapy (PET).Locoregional Treatment in Early Breast Cancer (EBC)During the COVID-19 pandemic, PST indications in EBC patients may be temporarily reconsidered taking into account the availability of facilities and healthcare resources, the number of required hospital visits and the risks of compromising the immune system associated with different type of treatments 9,12-14 .", [["endocrine", "ANATOMY", 103, 112], ["Breast Cancer", "ANATOMY", 159, 172], ["NAC", "CHEMICAL", 73, 76], ["Breast Cancer", "DISEASE", 159, 172], ["anti-HER2", "SIMPLE_CHEMICAL", 54, 63], ["NAC", "SIMPLE_CHEMICAL", 73, 76], ["Early Breast Cancer", "CANCER", 153, 172], ["patients", "ORGANISM", 231, 239], ["patients", "SPECIES", 231, 239], ["both neo-adjuvant", "TREATMENT", 13, 30], ["primary chemotherapy", "TREATMENT", 31, 51], ["anti-HER2 therapy", "TREATMENT", 54, 71], ["NAC)", "TREATMENT", 73, 77], ["neo-adjuvant", "TREATMENT", 82, 94], ["primary endocrine therapy", "TREATMENT", 95, 120], ["Locoregional Treatment", "TREATMENT", 127, 149], ["Early Breast Cancer", "PROBLEM", 153, 172], ["the COVID", "TEST", 185, 194], ["compromising the immune system", "PROBLEM", 405, 435], ["treatments", "TREATMENT", 470, 480], ["Breast", "ANATOMY", 159, 165], ["Cancer", "OBSERVATION", 166, 172]]], ["Therefore, it is even more critical that indications for treatment are taken in a multidisciplinary setting, in light of what is deemed to be the best option for each patient in that specific time and place.", [["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["treatment", "TREATMENT", 57, 66]]], ["A crucial balance is needed between maintaining a high quality of breast cancer care, not jeopardizing cancer outcomes, and minimizing both the risks of infection by SARS-CoV-2 and the risks of complications of anticancer treatments.", [["breast cancer", "ANATOMY", 66, 79], ["cancer", "ANATOMY", 103, 109], ["anticancer", "ANATOMY", 211, 221], ["breast cancer", "DISEASE", 66, 79], ["cancer", "DISEASE", 103, 109], ["infection", "DISEASE", 153, 162], ["SARS", "DISEASE", 166, 170], ["breast cancer", "CANCER", 66, 79], ["cancer", "CANCER", 103, 109], ["SARS-CoV-2", "ORGANISM", 166, 176], ["anticancer", "CANCER", 211, 221], ["SARS-CoV", "SPECIES", 166, 174], ["breast cancer care", "TREATMENT", 66, 84], ["jeopardizing cancer outcomes", "PROBLEM", 90, 118], ["infection", "PROBLEM", 153, 162], ["anticancer treatments", "TREATMENT", 211, 232], ["crucial balance", "OBSERVATION", 2, 17], ["breast", "ANATOMY", 66, 72], ["cancer", "OBSERVATION", 73, 79], ["infection", "OBSERVATION", 153, 162]]], ["The decision between primary surgery or PST should also take into account the pandemic scenario (Table 1) in each centre (i.e. early stages vs mitigation phase vs recovery phase).", [["primary surgery", "TREATMENT", 21, 36], ["PST", "TREATMENT", 40, 43]]], ["For instance, some patients with EBC who under normal circumstances would receive PST might be treated with primary surgery especially when a limited procedure is feasible in an outpatient setting.", [["patients", "ORGANISM", 19, 27], ["EBC", "CANCER", 33, 36], ["patients", "SPECIES", 19, 27], ["PST", "TREATMENT", 82, 85], ["primary surgery", "TREATMENT", 108, 123], ["a limited procedure", "TREATMENT", 140, 159]]], ["In contrast, some patients who, under normal circumstances, could be treated with primary surgery, such as postmenopausal women with limited luminal A/B disease, might be treated with primary endocrine therapy in order to delay invasive procedures and hospitalization.Locoregional Treatment in Early Breast Cancer (EBC)Surgery (Table 3) At this point in time, when surgery is indicated, preference should be given to the most effective minimal surgical procedure with the fastest recovery time, that lower risks for the individual patient and reduce the need of healthcare resources.", [["luminal A/B", "ANATOMY", 141, 152], ["endocrine", "ANATOMY", 192, 201], ["Breast Cancer", "ANATOMY", 300, 313], ["luminal A/B disease", "DISEASE", 141, 160], ["Breast Cancer", "DISEASE", 300, 313], ["patients", "ORGANISM", 18, 26], ["women", "ORGANISM", 122, 127], ["luminal A/B", "CANCER", 141, 152], ["Breast Cancer", "CANCER", 300, 313], ["patient", "ORGANISM", 531, 538], ["patients", "SPECIES", 18, 26], ["women", "SPECIES", 122, 127], ["patient", "SPECIES", 531, 538], ["primary surgery", "TREATMENT", 82, 97], ["limited luminal A/B disease", "PROBLEM", 133, 160], ["primary endocrine therapy", "TREATMENT", 184, 209], ["invasive procedures", "TREATMENT", 228, 247], ["hospitalization", "TREATMENT", 252, 267], ["Locoregional Treatment", "TREATMENT", 268, 290], ["Early Breast Cancer", "PROBLEM", 294, 313], ["surgery", "TREATMENT", 365, 372], ["minimal surgical procedure", "TREATMENT", 436, 462], ["healthcare resources", "TREATMENT", 562, 582], ["Breast", "ANATOMY", 300, 306], ["Cancer", "OBSERVATION", 307, 313]]], ["These general recommendations should be applied even in countries where the outbreak has not yet dramatically affected the health system and the surgical activity is still maintained with a reduction that is less than half the usual production 13,15-17 .1.Defer all benign, cosmetic, and risk-reducing procedures.2.Offer outpatient surgery whenever possible.3.Postpone all delayed breast reconstructions.4.Minimize the use of oncoplastic procedures if they require prolonged hospitalization and/or have a high risk for complications.5.In case immediate breast reconstruction is considered, recommend simpler (less intensive) procedures with fast recovery (microsurgery should not be undertaken -high resources needed).5.The following is meant to be a grid of priority in order to minimize the possible detrimental effect of treatment delay in a worst-case scenario when the availability of surgical slots is highly reduced (e.g. 10-5.20% of the usual activity).", [["breast", "ANATOMY", 381, 387], ["breast", "ANATOMY", 553, 559], ["breast", "ORGAN", 381, 387], ["breast", "ORGAN", 553, 559], ["a reduction", "TREATMENT", 188, 199], ["reducing procedures", "TREATMENT", 293, 312], ["outpatient surgery", "TREATMENT", 321, 339], ["all delayed breast reconstructions", "TREATMENT", 369, 403], ["oncoplastic procedures", "TREATMENT", 426, 448], ["prolonged hospitalization", "TREATMENT", 465, 490], ["complications", "PROBLEM", 519, 532], ["immediate breast reconstruction", "TREATMENT", 543, 574], ["microsurgery", "TREATMENT", 656, 668], ["treatment delay", "TREATMENT", 824, 839], ["surgical slots", "TREATMENT", 890, 904], ["surgical activity", "OBSERVATION", 145, 162], ["reduction", "OBSERVATION_MODIFIER", 190, 199], ["less", "OBSERVATION_MODIFIER", 208, 212], ["breast", "ANATOMY", 381, 387], ["breast", "ANATOMY", 553, 559], ["reconstruction", "OBSERVATION", 560, 574], ["surgical", "OBSERVATION", 890, 898], ["reduced", "OBSERVATION_MODIFIER", 915, 922]]], ["We propose to prioritize patients with diagnosed malignancy into 4 categories.", [["malignancy", "DISEASE", 49, 59], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["diagnosed malignancy", "PROBLEM", 39, 59], ["malignancy", "OBSERVATION", 49, 59]]], ["1) Urgent: surgery within 2 weeks; 2) High priority: surgery within 4 weeks; 3) Medium priority: surgery within 8 weeks; 4) Low priority: surgery after 8 weeks allowed. b.5.Post-menopausal patients with Luminal A-like cancer.", [["Luminal A-like cancer", "ANATOMY", 203, 224], ["Luminal A-like cancer", "DISEASE", 203, 224], ["patients", "ORGANISM", 189, 197], ["Luminal A-like cancer", "CANCER", 203, 224], ["patients", "SPECIES", 189, 197], ["surgery", "TREATMENT", 138, 145], ["Luminal A-like cancer", "PROBLEM", 203, 224], ["Luminal", "ANATOMY_MODIFIER", 203, 210], ["A-like", "OBSERVATION_MODIFIER", 211, 217], ["cancer", "OBSERVATION", 218, 224]]], ["In these women primary endocrine therapy could be initiated, and surgery could be postponed.", [["endocrine", "ANATOMY", 23, 32], ["women", "ORGANISM", 9, 14], ["endocrine", "ANATOMICAL_SYSTEM", 23, 32], ["women", "SPECIES", 9, 14], ["surgery", "TREATMENT", 65, 72]]], ["(Table 4 )Early breast cancer (EBC)Radiation therapy (RT) for breast cancer is most often delivered after completion of other treatments, including surgery and chemotherapy.", [["breast cancer", "ANATOMY", 16, 29], ["EBC", "ANATOMY", 31, 34], ["breast cancer", "ANATOMY", 62, 75], ["breast cancer", "DISEASE", 16, 29], ["breast cancer", "DISEASE", 62, 75], ["Early breast cancer", "CANCER", 10, 29], ["breast cancer", "CANCER", 62, 75], ["Early breast cancer", "PROBLEM", 10, 29], ["Radiation therapy (RT)", "TREATMENT", 35, 57], ["breast cancer", "PROBLEM", 62, 75], ["other treatments", "TREATMENT", 120, 136], ["surgery", "TREATMENT", 148, 155], ["chemotherapy", "TREATMENT", 160, 172], ["breast", "ANATOMY", 16, 22], ["cancer", "OBSERVATION", 23, 29], ["breast", "ANATOMY", 62, 68], ["cancer", "OBSERVATION", 69, 75]]], ["Conventional treatment duration is between 3 and 7 weeks.", [["Conventional treatment duration", "TREATMENT", 0, 31]]], ["During the COVID-19 pandemic, we need to contribute to the statement of the World Health Organisation (WHO)Early breast cancer (EBC)\"to stop, contain, control, delay and reduce the impact of this virus at every opportunity\".", [["breast cancer", "ANATOMY", 113, 126], ["EBC", "ANATOMY", 128, 131], ["breast cancer", "DISEASE", 113, 126], ["breast cancer", "CANCER", 113, 126], ["the COVID", "TEST", 7, 16], ["Early breast cancer", "PROBLEM", 107, 126], ["this virus", "PROBLEM", 191, 201], ["breast", "ANATOMY", 113, 119], ["cancer", "OBSERVATION", 120, 126]]], ["This translates into minimising exposure and burden to both patients and healthcare personnel without compromising oncological outcome, by minimising the number of hospital visits and limiting the complexity of RT planning/treatment 18 .", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["RT planning/treatment", "TREATMENT", 211, 232]]], ["A useful approach during the pandemic is to give preference, to the least resourceintensive treatment regimen, provided that there are data supporting the use of this type of regimen.Early breast cancer (EBC)The following recommendations can be considered and discussed with the patients, based on the particular circumstances that may be influenced by social restrictions to contain viral spread, the proportion of the population that is affected, the percentage of the personnel that is present and the pre-existing treatment capacity:Early breast cancer (EBC)1.Early breast cancer (EBC)Postpone RT up to 3 months for high-risk and up to 6 months for low-risk patients 19 .Early breast cancer (EBC)In the past, protocols were based on the common position that RT should start as soon as possible following surgery in order to increase treatment efficacy.", [["breast cancer", "ANATOMY", 189, 202], ["EBC", "ANATOMY", 204, 207], ["breast cancer", "ANATOMY", 543, 556], ["breast cancer", "ANATOMY", 570, 583], ["EBC", "ANATOMY", 585, 588], ["breast cancer", "ANATOMY", 681, 694], ["EBC", "ANATOMY", 696, 699], ["breast cancer", "DISEASE", 189, 202], ["breast cancer", "DISEASE", 543, 556], ["breast cancer", "DISEASE", 570, 583], ["breast cancer", "DISEASE", 681, 694], ["breast cancer", "CANCER", 189, 202], ["EBC", "CANCER", 204, 207], ["patients", "ORGANISM", 279, 287], ["breast cancer", "CANCER", 543, 556], ["breast cancer", "CANCER", 570, 583], ["patients", "ORGANISM", 662, 670], ["breast cancer", "CANCER", 681, 694], ["patients", "SPECIES", 279, 287], ["patients", "SPECIES", 662, 670], ["the least resourceintensive treatment regimen", "TREATMENT", 64, 109], ["this type of regimen", "TREATMENT", 162, 182], ["Early breast cancer", "PROBLEM", 183, 202], ["viral spread", "PROBLEM", 384, 396], ["Early breast cancer", "PROBLEM", 537, 556], ["Early breast cancer", "PROBLEM", 564, 583], ["Early breast cancer", "PROBLEM", 675, 694], ["protocols", "TREATMENT", 713, 722], ["RT", "TREATMENT", 762, 764], ["surgery", "TREATMENT", 808, 815], ["treatment efficacy", "TREATMENT", 837, 855], ["breast", "ANATOMY", 189, 195], ["cancer", "OBSERVATION", 196, 202], ["viral spread", "OBSERVATION", 384, 396], ["breast", "ANATOMY", 543, 549], ["cancer", "OBSERVATION", 550, 556], ["breast", "ANATOMY", 570, 576], ["cancer", "OBSERVATION", 577, 583], ["breast", "ANATOMY", 681, 687], ["cancer", "OBSERVATION", 688, 694]]], ["Following population-based data from a more recent cohort of breast cancer patients, starting RT shortly after surgery does not seem to be associated with a better long-term outcome 19 .2.Moderate hypofractionation should be used for all breast/chest wall and nodal RT, e.g. 40Gy in 152.fractions over 3 weeks [19] [20] [21] .2.The use of moderate hypofractionation is already the standard of care in many countries and in the altered risk-benefit context of a pandemic should be strongly considered for all patients, including those after breast reconstruction.3.Deliver RT in 5 fractions for all patients requiring RT with node negative tumours that do not require a boost.", [["breast cancer", "ANATOMY", 61, 74], ["breast", "ANATOMY", 238, 244], ["chest wall", "ANATOMY", 245, 255], ["nodal", "ANATOMY", 260, 265], ["breast", "ANATOMY", 540, 546], ["node", "ANATOMY", 625, 629], ["tumours", "ANATOMY", 639, 646], ["breast cancer", "DISEASE", 61, 74], ["breast cancer", "CANCER", 61, 74], ["patients", "ORGANISM", 75, 83], ["breast", "CANCER", 238, 244], ["chest wall", "MULTI-TISSUE_STRUCTURE", 245, 255], ["patients", "ORGANISM", 508, 516], ["breast", "ORGANISM_SUBDIVISION", 540, 546], ["patients", "ORGANISM", 598, 606], ["node", "MULTI-TISSUE_STRUCTURE", 625, 629], ["tumours", "CANCER", 639, 646], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 508, 516], ["patients", "SPECIES", 598, 606], ["breast cancer", "PROBLEM", 61, 74], ["surgery", "TREATMENT", 111, 118], ["Moderate hypofractionation", "TREATMENT", 188, 214], ["all breast/chest wall", "TREATMENT", 234, 255], ["nodal RT", "TREATMENT", 260, 268], ["moderate hypofractionation", "TREATMENT", 339, 365], ["breast reconstruction", "TREATMENT", 540, 561], ["RT in 5 fractions", "TREATMENT", 572, 589], ["node negative tumours", "PROBLEM", 625, 646], ["a boost", "TREATMENT", 667, 674], ["breast", "ANATOMY", 61, 67], ["cancer", "OBSERVATION", 68, 74], ["hypofractionation", "OBSERVATION", 197, 214], ["breast", "ANATOMY", 238, 244], ["chest wall", "ANATOMY", 245, 255], ["nodal", "ANATOMY", 260, 265], ["moderate", "OBSERVATION_MODIFIER", 339, 347], ["hypofractionation", "OBSERVATION", 348, 365], ["breast", "ANATOMY", 540, 546]]], ["Options include 28-30Gy in one weekly fraction over 5 weeks or 26Gy in 5 daily fractions over 1 week as per the FAST and FAST Forward trials, respectively [22] [23] [24] .3.Five-year local relapse data for FAST Forward will be published soon but data on 3-year normal tissue toxicity has already been demonstrated to be equivalent with 40Gy in 15 fractions.4.Boost RT should be omitted to reduce fractions and/or complexity in the vast majority of patients unless those 40 years old and under, or over 40 years with significant risk factors for local relapse 25 Boost RT reduces the local recurrence risk without improving survival.", [["tissue", "ANATOMY", 268, 274], ["toxicity", "DISEASE", 275, 283], ["tissue", "TISSUE", 268, 274], ["patients", "ORGANISM", 448, 456], ["patients", "SPECIES", 448, 456], ["the FAST", "TEST", 108, 116], ["Boost RT", "TREATMENT", 359, 367], ["significant risk factors", "PROBLEM", 516, 540], ["local relapse", "PROBLEM", 545, 558], ["the local recurrence risk", "PROBLEM", 579, 604]]], ["An example of a significant risk factor is the presence of involved resection margins where further surgery is not possible.", [["a significant risk factor", "PROBLEM", 14, 39], ["resection margins", "TREATMENT", 68, 85], ["further surgery", "TREATMENT", 92, 107], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["resection", "OBSERVATION_MODIFIER", 68, 77], ["margins", "OBSERVATION_MODIFIER", 78, 85], ["surgery", "OBSERVATION", 100, 107], ["not possible", "UNCERTAINTY", 111, 123]]], ["Any boost should be with a minimum supplementary number of fractions or given concurrently with the treatment fractions.5.Accelerated partial breast RT can also be considered for selected low-risk patients [26] [27] [28] [29] .5.Accumulating data support the use of partial breast irradiation.", [["breast", "ANATOMY", 142, 148], ["breast", "ANATOMY", 274, 280], ["breast", "ORGAN", 142, 148], ["patients", "ORGANISM", 197, 205], ["[26] [27] [28] [29] .5", "SIMPLE_CHEMICAL", 206, 228], ["breast", "ORGAN", 274, 280], ["patients", "SPECIES", 197, 205], ["Any boost", "TREATMENT", 0, 9], ["a minimum supplementary number of fractions", "TREATMENT", 25, 68], ["the treatment fractions", "TREATMENT", 96, 119], ["Accelerated partial breast RT", "TREATMENT", 122, 151], ["partial breast irradiation", "TREATMENT", 266, 292], ["partial", "OBSERVATION_MODIFIER", 134, 141], ["breast", "ANATOMY", 142, 148], ["partial", "OBSERVATION_MODIFIER", 266, 273], ["breast", "ANATOMY", 274, 280], ["irradiation", "OBSERVATION", 281, 292]]], ["The duration could be further reduced by condensing the schedule into a 1-week fractionation schedule (reducing the total dose) or delivery of intraoperative electron-based RT that is delivered as a one-step procedure together with the lumpectomy.6.Omission of RT might be considered in elderly patients at low risk of recurrence 30 .6.The elderly constitutes the population at higher risk to develop severe consequences from COVID-Advanced breast cancer (ABC)For ABC, radiation therapy is urgent for the following situations:Advanced breast cancer (ABC)1.", [["breast cancer", "ANATOMY", 441, 454], ["breast cancer", "ANATOMY", 535, 548], ["COVID", "DISEASE", 426, 431], ["breast cancer", "DISEASE", 441, 454], ["breast cancer", "DISEASE", 535, 548], ["electron", "SIMPLE_CHEMICAL", 158, 166], ["patients", "ORGANISM", 295, 303], ["breast cancer", "CANCER", 441, 454], ["breast cancer", "CANCER", 535, 548], ["patients", "SPECIES", 295, 303], ["a 1-week fractionation schedule", "TREATMENT", 70, 101], ["the total dose)", "TREATMENT", 112, 127], ["intraoperative electron-based RT", "TREATMENT", 143, 175], ["a one-step procedure", "TREATMENT", 197, 217], ["the lumpectomy", "TREATMENT", 232, 246], ["RT", "TREATMENT", 261, 263], ["recurrence", "PROBLEM", 319, 329], ["severe consequences", "PROBLEM", 401, 420], ["Advanced breast cancer", "PROBLEM", 432, 454], ["ABC", "PROBLEM", 464, 467], ["radiation therapy", "TREATMENT", 469, 486], ["Advanced breast cancer", "PROBLEM", 526, 548], ["lumpectomy", "OBSERVATION", 236, 246], ["recurrence", "OBSERVATION", 319, 329], ["breast", "ANATOMY", 441, 447], ["cancer", "OBSERVATION", 448, 454], ["breast", "ANATOMY", 535, 541], ["cancer", "OBSERVATION", 542, 548]]], ["Treatment of spinal cord compression.Advanced breast cancer (ABC)2.", [["spinal cord", "ANATOMY", 13, 24], ["breast cancer", "ANATOMY", 46, 59], ["cord compression", "DISEASE", 20, 36], ["breast cancer", "DISEASE", 46, 59], ["spinal cord", "ORGAN", 13, 24], ["breast cancer", "CANCER", 46, 59], ["spinal cord compression", "PROBLEM", 13, 36], ["Advanced breast cancer", "PROBLEM", 37, 59], ["spinal cord", "ANATOMY", 13, 24], ["compression", "OBSERVATION", 25, 36], ["breast", "ANATOMY", 46, 52], ["cancer", "OBSERVATION", 53, 59]]], ["Treatment of brain and leptomeningeal metastases.Advanced breast cancer (ABC)3.", [["brain", "ANATOMY", 13, 18], ["leptomeningeal metastases", "ANATOMY", 23, 48], ["breast cancer", "ANATOMY", 58, 71], ["brain and leptomeningeal metastases", "DISEASE", 13, 48], ["breast cancer", "DISEASE", 58, 71], ["brain", "ORGAN", 13, 18], ["leptomeningeal metastases", "CANCER", 23, 48], ["breast cancer", "CANCER", 58, 71], ["brain and leptomeningeal metastases", "PROBLEM", 13, 48], ["Advanced breast cancer", "PROBLEM", 49, 71], ["brain", "ANATOMY", 13, 18], ["leptomeningeal", "ANATOMY", 23, 37], ["metastases", "OBSERVATION", 38, 48], ["breast", "ANATOMY", 58, 64], ["cancer", "OBSERVATION", 65, 71]]], ["Palliative treatments (e.g. of bone metastases) not responding to pharmaceutical interventions Systemic therapy (Table 5 )Early breast cancer (EBC)Early \u2022 Steroids use should be limited to the indispensable, to avoid increasing the risk of immunosuppression.Early breast cancer (EBC)\u2022 To decrease the number of visits to the hospital, 2-weekly (dose-dense) or 3-weekly regimens should be preferred.", [["bone metastases", "ANATOMY", 31, 46], ["breast cancer", "ANATOMY", 128, 141], ["breast cancer", "ANATOMY", 264, 277], ["EBC", "ANATOMY", 279, 282], ["bone metastases", "DISEASE", 31, 46], ["breast cancer", "DISEASE", 128, 141], ["breast cancer", "DISEASE", 264, 277], ["bone", "ORGAN", 31, 35], ["breast cancer", "CANCER", 128, 141], ["breast cancer", "CANCER", 264, 277], ["EBC", "CANCER", 279, 282], ["Palliative treatments", "TREATMENT", 0, 21], ["bone metastases", "PROBLEM", 31, 46], ["pharmaceutical interventions", "TREATMENT", 66, 94], ["Systemic therapy", "TREATMENT", 95, 111], ["Early breast cancer", "PROBLEM", 122, 141], ["Early \u2022 Steroids", "TREATMENT", 147, 163], ["immunosuppression", "TREATMENT", 240, 257], ["Early breast cancer", "PROBLEM", 258, 277], ["3-weekly regimens", "TREATMENT", 360, 377], ["bone", "ANATOMY", 31, 35], ["metastases", "OBSERVATION", 36, 46], ["breast", "ANATOMY", 128, 134], ["cancer", "OBSERVATION", 135, 141], ["immunosuppression", "OBSERVATION", 240, 257], ["breast", "ANATOMY", 264, 270], ["cancer", "OBSERVATION", 271, 277]]], ["However, in patients above the age of 65 years, the number of visits should be balanced with the substantially better tolerability of weekly paclitaxel when compared to 3-weekly docetaxel.", [["paclitaxel", "CHEMICAL", 141, 151], ["docetaxel", "CHEMICAL", 178, 187], ["paclitaxel", "CHEMICAL", 141, 151], ["docetaxel", "CHEMICAL", 178, 187], ["patients", "ORGANISM", 12, 20], ["paclitaxel", "SIMPLE_CHEMICAL", 141, 151], ["docetaxel", "SIMPLE_CHEMICAL", 178, 187], ["patients", "SPECIES", 12, 20], ["weekly paclitaxel", "TREATMENT", 134, 151], ["docetaxel", "TREATMENT", 178, 187]]], ["Dose-dense regimens allow for the shortest duration of treatment.Early breast cancer (EBC)\u2022 For triple negative EBC, when deciding on the addition of platinum to anthracyclines and taxanes, the higher haematological toxicity and consequent risk of immunosuppression of these agents must be taken into account during this pandemic, in particular, considering that the potential additional benefit of these agents is still controversial.Early breast cancer (EBC)\u2022 For HER2+ EBC, the use of anti-HER2 agents is highly recommended, as per guidelines, in view of the substantial survival benefit and the absence of data suggesting any detrimental effect of their use during this pandemic.", [["breast cancer", "ANATOMY", 71, 84], ["EBC", "ANATOMY", 86, 89], ["EBC", "ANATOMY", 112, 115], ["breast cancer", "ANATOMY", 441, 454], ["EBC", "ANATOMY", 456, 459], ["HER2+ EBC", "ANATOMY", 466, 475], ["breast cancer", "DISEASE", 71, 84], ["platinum", "CHEMICAL", 150, 158], ["anthracyclines", "CHEMICAL", 162, 176], ["taxanes", "CHEMICAL", 181, 188], ["toxicity", "DISEASE", 216, 224], ["breast cancer", "DISEASE", 441, 454], ["platinum", "CHEMICAL", 150, 158], ["anthracyclines", "CHEMICAL", 162, 176], ["taxanes", "CHEMICAL", 181, 188], ["breast cancer", "CANCER", 71, 84], ["EBC", "CANCER", 86, 89], ["platinum", "SIMPLE_CHEMICAL", 150, 158], ["anthracyclines", "SIMPLE_CHEMICAL", 162, 176], ["taxanes", "SIMPLE_CHEMICAL", 181, 188], ["breast cancer", "CANCER", 441, 454], ["EBC", "CANCER", 456, 459], ["HER2", "GENE_OR_GENE_PRODUCT", 466, 470], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 488, 497], ["HER2", "PROTEIN", 466, 470], ["dense regimens", "TREATMENT", 5, 19], ["the shortest duration of treatment", "TREATMENT", 30, 64], ["Early breast cancer", "PROBLEM", 65, 84], ["triple negative EBC", "PROBLEM", 96, 115], ["platinum", "TREATMENT", 150, 158], ["anthracyclines", "TREATMENT", 162, 176], ["taxanes", "TREATMENT", 181, 188], ["the higher haematological toxicity", "PROBLEM", 190, 224], ["immunosuppression", "TREATMENT", 248, 265], ["these agents", "TREATMENT", 269, 281], ["these agents", "TREATMENT", 399, 411], ["Early breast cancer", "PROBLEM", 435, 454], ["HER2+ EBC", "PROBLEM", 466, 475], ["anti-HER2 agents", "TREATMENT", 488, 504], ["breast", "ANATOMY", 71, 77], ["cancer", "OBSERVATION", 78, 84], ["breast", "ANATOMY", 441, 447], ["cancer", "OBSERVATION", 448, 454]]], ["In lower risk patients shortening trastuzumab administration to half year may be considered 32 , except for those treated with the APT (weekly paclitaxel and trastuzumab) regimen.Early breast cancer (EBC)Trastuzumab subcutaneous formulation is preferred and, when resources allow it, home administration can be used.Early breast cancer (EBC)\u2022 For ER+/HER2 negative EBC, the most difficult decision is related to the use of adjuvant chemotherapy.", [["breast cancer", "ANATOMY", 185, 198], ["EBC", "ANATOMY", 200, 203], ["subcutaneous", "ANATOMY", 216, 228], ["breast cancer", "ANATOMY", 322, 335], ["EBC", "ANATOMY", 337, 340], ["ER+/HER2 negative EBC", "ANATOMY", 347, 368], ["trastuzumab", "CHEMICAL", 34, 45], ["paclitaxel", "CHEMICAL", 143, 153], ["trastuzumab", "CHEMICAL", 158, 169], ["breast cancer", "DISEASE", 185, 198], ["Trastuzumab", "CHEMICAL", 204, 215], ["breast cancer", "DISEASE", 322, 335], ["paclitaxel", "CHEMICAL", 143, 153], ["patients", "ORGANISM", 14, 22], ["trastuzumab", "SIMPLE_CHEMICAL", 34, 45], ["paclitaxel", "SIMPLE_CHEMICAL", 143, 153], ["trastuzumab", "SIMPLE_CHEMICAL", 158, 169], ["breast cancer", "CANCER", 185, 198], ["Trastuzumab", "SIMPLE_CHEMICAL", 204, 215], ["breast cancer", "CANCER", 322, 335], ["EBC", "CANCER", 337, 340], ["ER", "GENE_OR_GENE_PRODUCT", 347, 349], ["HER2", "GENE_OR_GENE_PRODUCT", 351, 355], ["ER", "PROTEIN", 347, 349], ["HER2", "PROTEIN", 351, 355], ["patients", "SPECIES", 14, 22], ["shortening trastuzumab administration", "TREATMENT", 23, 60], ["the APT (weekly paclitaxel", "TREATMENT", 127, 153], ["trastuzumab) regimen", "TREATMENT", 158, 178], ["Early breast cancer", "PROBLEM", 179, 198], ["Trastuzumab subcutaneous formulation", "TREATMENT", 204, 240], ["Early breast cancer", "PROBLEM", 316, 335], ["adjuvant chemotherapy", "TREATMENT", 423, 444], ["breast", "ANATOMY", 185, 191], ["cancer", "OBSERVATION", 192, 198], ["breast", "ANATOMY", 322, 328], ["cancer", "OBSERVATION", 329, 335]]], ["In cases where the benefit of this treatment is uncertain, the risk/benefit balance, during this pandemic, might more often be in favour of not administering chemotherapy.", [["this treatment", "TREATMENT", 30, 44], ["chemotherapy", "TREATMENT", 158, 170]]], ["As for all decisionmaking process in oncology, the ultimate decision must be taken by the patient, after adequate information, since the attitude towards risks and benefits is highly variable according to individuals' values and preferences and may be different in the current pandemic situation.", [["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97]]], ["Genomic tests may be used to help treatment decision-making in doubtful cases.Early breast cancer (EBC)\u2022 Adjuvant endocrine therapy, including the use of ovarian function suppression in pre-menopausal women, should follow the usual international guidelines, since no additional risk is foreseen from these agents.", [["breast cancer", "ANATOMY", 84, 97], ["EBC", "ANATOMY", 99, 102], ["endocrine", "ANATOMY", 114, 123], ["ovarian", "ANATOMY", 154, 161], ["breast cancer", "DISEASE", 84, 97], ["ovarian function suppression", "DISEASE", 154, 182], ["breast cancer", "CANCER", 84, 97], ["EBC", "CANCER", 99, 102], ["ovarian", "ORGAN", 154, 161], ["women", "ORGANISM", 201, 206], ["women", "SPECIES", 201, 206], ["Genomic tests", "TEST", 0, 13], ["Early breast cancer", "PROBLEM", 78, 97], ["Adjuvant endocrine therapy", "TREATMENT", 105, 131], ["ovarian function suppression", "TREATMENT", 154, 182], ["these agents", "TREATMENT", 300, 312], ["breast", "ANATOMY", 84, 90], ["cancer", "OBSERVATION", 91, 97]]], ["In selected cases, 3-monthly administration of LHRH agonist can be used, provided that confirmation of ovarian suppression is done; however, in very young women and/or women taking an aromatase inhibitor, the risk of inadequate ovarian suppression with the 3-monthly administration is higher.", [["ovarian", "ANATOMY", 103, 110], ["ovarian", "ANATOMY", 228, 235], ["LHRH agonist", "CHEMICAL", 47, 59], ["ovarian suppression", "DISEASE", 103, 122], ["ovarian suppression", "DISEASE", 228, 247], ["LHRH", "SIMPLE_CHEMICAL", 47, 51], ["ovarian", "ORGAN", 103, 110], ["women", "ORGANISM", 155, 160], ["women", "ORGANISM", 168, 173], ["aromatase", "GENE_OR_GENE_PRODUCT", 184, 193], ["ovarian", "ORGAN", 228, 235], ["women", "SPECIES", 155, 160], ["women", "SPECIES", 168, 173], ["LHRH agonist", "TREATMENT", 47, 59], ["ovarian suppression", "PROBLEM", 103, 122], ["an aromatase inhibitor", "TREATMENT", 181, 203], ["inadequate ovarian suppression", "PROBLEM", 217, 247], ["ovarian", "ANATOMY", 103, 110], ["inadequate ovarian suppression", "OBSERVATION", 217, 247]]], ["In addition, the administration of an LHRH agonist can be performed at home, if resources allow it.Early breast cancer (EBC)\u2022 For adjuvant bisphosphonates, oral formulations can be preferred during this pandemic.", [["breast cancer", "ANATOMY", 105, 118], ["EBC", "ANATOMY", 120, 123], ["oral", "ANATOMY", 156, 160], ["breast cancer", "DISEASE", 105, 118], ["bisphosphonates", "CHEMICAL", 139, 154], ["LHRH", "SIMPLE_CHEMICAL", 38, 42], ["breast cancer", "CANCER", 105, 118], ["EBC", "CANCER", 120, 123], ["bisphosphonates", "SIMPLE_CHEMICAL", 139, 154], ["oral", "ORGANISM_SUBDIVISION", 156, 160], ["an LHRH agonist", "TREATMENT", 35, 50], ["Early breast cancer", "PROBLEM", 99, 118], ["adjuvant bisphosphonates", "TREATMENT", 130, 154], ["oral formulations", "TREATMENT", 156, 173], ["breast", "ANATOMY", 105, 111], ["cancer", "OBSERVATION", 112, 118]]], ["Possible delay of administration or moving the administration earlier, when resources are still available may also be considered, in particular considering that the interval of administration of i.v. formulations is every 6 months.Advanced breast cancer (ABC)Advanced/metastatic breast cancer is an incurable disease, with a median survival of about 3 years, varying according to the breast cancer subtype.", [["breast cancer", "ANATOMY", 240, 253], ["ABC", "ANATOMY", 255, 258], ["metastatic breast cancer", "ANATOMY", 268, 292], ["breast cancer", "ANATOMY", 384, 397], ["breast cancer", "DISEASE", 240, 253], ["breast cancer", "DISEASE", 279, 292], ["breast cancer", "DISEASE", 384, 397], ["breast cancer", "CANCER", 240, 253], ["ABC", "CANCER", 255, 258], ["breast cancer", "CANCER", 279, 292], ["breast cancer", "CANCER", 384, 397], ["administration of i.v. formulations", "TREATMENT", 177, 212], ["Advanced breast cancer", "PROBLEM", 231, 253], ["Advanced/metastatic breast cancer", "PROBLEM", 259, 292], ["an incurable disease", "PROBLEM", 296, 316], ["the breast cancer subtype", "PROBLEM", 380, 405], ["breast", "ANATOMY", 240, 246], ["cancer", "OBSERVATION", 247, 253], ["metastatic", "OBSERVATION_MODIFIER", 268, 278], ["breast", "ANATOMY", 279, 285], ["cancer", "OBSERVATION", 286, 292], ["incurable", "OBSERVATION_MODIFIER", 299, 308], ["disease", "OBSERVATION", 309, 316], ["breast", "ANATOMY", 384, 390], ["cancer", "OBSERVATION", 391, 397]]], ["In addition, metastatic disease carries in itself some level of immunosuppression.", [["metastatic disease", "PROBLEM", 13, 31], ["immunosuppression", "TREATMENT", 64, 81], ["metastatic", "OBSERVATION", 13, 23], ["immunosuppression", "OBSERVATION", 64, 81]]], ["It is therefore essential that all ABC patients remain under adequate treatment, according to high quality international guidelines 33 , and close surveillance during the COVID-19 pandemic.Advanced breast cancer (ABC)Notwithstanding these facts, some measures may be taken to decrease the risk of complications and allow for adequate treatment of these patients. \u2022 The addition of an mTOR inhibitor or a Pi3KCA inhibitor to endocrine therapy must also take into account their immunosuppressive effect and the risk of pneumonitis/interstitial lung disease and other serious side effects, as well as the lack of survival benefit seen so far from the use of these agents.", [["breast cancer", "ANATOMY", 198, 211], ["endocrine", "ANATOMY", 424, 433], ["interstitial lung", "ANATOMY", 529, 546], ["breast cancer", "DISEASE", 198, 211], ["pneumonitis", "DISEASE", 517, 528], ["interstitial lung disease", "DISEASE", 529, 554], ["ABC", "ORGANISM", 35, 38], ["patients", "ORGANISM", 39, 47], ["breast cancer", "CANCER", 198, 211], ["patients", "ORGANISM", 353, 361], ["mTOR", "GENE_OR_GENE_PRODUCT", 384, 388], ["Pi3KCA", "GENE_OR_GENE_PRODUCT", 404, 410], ["lung", "ORGAN", 542, 546], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 353, 361], ["adequate treatment", "TREATMENT", 61, 79], ["close surveillance", "TEST", 141, 159], ["the COVID", "TEST", 167, 176], ["pandemic", "PROBLEM", 180, 188], ["Advanced breast cancer", "PROBLEM", 189, 211], ["complications", "PROBLEM", 297, 310], ["an mTOR inhibitor", "TREATMENT", 381, 398], ["a Pi3KCA inhibitor", "TREATMENT", 402, 420], ["endocrine therapy", "TREATMENT", 424, 441], ["pneumonitis", "PROBLEM", 517, 528], ["interstitial lung disease", "PROBLEM", 529, 554], ["other serious side effects", "PROBLEM", 559, 585], ["these agents", "TREATMENT", 655, 667], ["breast", "ANATOMY", 198, 204], ["cancer", "OBSERVATION", 205, 211], ["complications", "OBSERVATION", 297, 310], ["pneumonitis", "OBSERVATION", 517, 528], ["interstitial", "ANATOMY_MODIFIER", 529, 541], ["lung", "ANATOMY", 542, 546], ["disease", "OBSERVATION", 547, 554]]], ["Decision should be made on a case-by-case basis, considering the burden of metastatic disease, the pace of disease progression, the possibility of using these agents later in the course of the disease, and the availability of other therapeutic options.Advanced breast cancer (ABC)\u2022 When utilizing chemotherapy, preference should be given to oral agents and agents with lower risk of immunosuppression, such as capecitabine, including for triple negative or HER2+ ABC.", [["breast cancer", "ANATOMY", 261, 274], ["oral", "ANATOMY", 341, 345], ["breast cancer", "DISEASE", 261, 274], ["capecitabine", "CHEMICAL", 410, 422], ["capecitabine", "CHEMICAL", 410, 422], ["breast cancer", "CANCER", 261, 274], ["ABC", "CANCER", 276, 279], ["oral", "ORGANISM_SUBDIVISION", 341, 345], ["capecitabine", "SIMPLE_CHEMICAL", 410, 422], ["HER2", "GENE_OR_GENE_PRODUCT", 457, 461], ["HER2", "PROTEIN", 457, 461], ["ABC", "PROTEIN", 463, 466], ["metastatic disease", "PROBLEM", 75, 93], ["disease progression", "PROBLEM", 107, 126], ["these agents", "TREATMENT", 153, 165], ["the disease", "PROBLEM", 189, 200], ["other therapeutic options", "TREATMENT", 226, 251], ["Advanced breast cancer", "PROBLEM", 252, 274], ["chemotherapy", "TREATMENT", 297, 309], ["oral agents", "TREATMENT", 341, 352], ["agents", "TREATMENT", 357, 363], ["immunosuppression", "TREATMENT", 383, 400], ["capecitabine", "TREATMENT", 410, 422], ["metastatic", "OBSERVATION", 75, 85], ["breast", "ANATOMY", 261, 267], ["cancer", "OBSERVATION", 268, 274], ["immunosuppression", "OBSERVATION", 383, 400]]], ["Vinorelbine can be used in its oral formulation and a dose reduction can be considered to avoid haematological toxicity.Advanced breast cancer (ABC)\u2022 In cases where the use of i.v. agents and/or agents with higher risk of immunosuppression is needed, preference should be given to liposomal formulations of anthracyclines and 3-weekly regimens of taxanes or platinum compounds.", [["oral", "ANATOMY", 31, 35], ["haematological", "ANATOMY", 96, 110], ["breast cancer", "ANATOMY", 129, 142], ["liposomal", "ANATOMY", 281, 290], ["Vinorelbine", "CHEMICAL", 0, 11], ["toxicity", "DISEASE", 111, 119], ["breast cancer", "DISEASE", 129, 142], ["anthracyclines", "CHEMICAL", 307, 321], ["taxanes", "CHEMICAL", 347, 354], ["platinum", "CHEMICAL", 358, 366], ["Vinorelbine", "CHEMICAL", 0, 11], ["anthracyclines", "CHEMICAL", 307, 321], ["taxanes", "CHEMICAL", 347, 354], ["platinum", "CHEMICAL", 358, 366], ["Vinorelbine", "SIMPLE_CHEMICAL", 0, 11], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["breast cancer", "CANCER", 129, 142], ["ABC", "CANCER", 144, 147], ["anthracyclines", "SIMPLE_CHEMICAL", 307, 321], ["taxanes", "SIMPLE_CHEMICAL", 347, 354], ["platinum compounds", "SIMPLE_CHEMICAL", 358, 376], ["Vinorelbine", "TREATMENT", 0, 11], ["its oral formulation", "TREATMENT", 27, 47], ["a dose reduction", "TREATMENT", 52, 68], ["haematological toxicity", "PROBLEM", 96, 119], ["Advanced breast cancer", "PROBLEM", 120, 142], ["i.v. agents", "TREATMENT", 176, 187], ["agents", "TREATMENT", 195, 201], ["immunosuppression", "TREATMENT", 222, 239], ["liposomal formulations", "TREATMENT", 281, 303], ["anthracyclines", "TREATMENT", 307, 321], ["taxanes", "TREATMENT", 347, 354], ["platinum compounds", "TREATMENT", 358, 376], ["breast", "ANATOMY", 129, 135], ["cancer", "OBSERVATION", 136, 142], ["immunosuppression", "OBSERVATION", 222, 239]]], ["Once again, the number of visits should be balanced with the substantially better tolerability of weekly paclitaxel when compared to 3-weekly docetaxel, in particular for older and/or less fit patients.", [["paclitaxel", "CHEMICAL", 105, 115], ["docetaxel", "CHEMICAL", 142, 151], ["paclitaxel", "CHEMICAL", 105, 115], ["docetaxel", "CHEMICAL", 142, 151], ["paclitaxel", "SIMPLE_CHEMICAL", 105, 115], ["docetaxel", "SIMPLE_CHEMICAL", 142, 151], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["weekly paclitaxel", "TREATMENT", 98, 115], ["docetaxel", "TREATMENT", 142, 151]]], ["Use of prophylactic hematopoietic growth factors should also be considered.Advanced breast cancer (ABC)\u2022 For HER2+ ABC, the use of anti-HER2 agents is highly recommended, as per guidelines, in view of the substantial survival benefit and the absence of data suggesting any detrimental effect of their use during this pandemic.Advanced breast cancer (ABC)\u2022 The use of bone modulating agents should be discussed on a case-by-cases basis, depending on the burden of bone disease and the presence/absence of symptoms.", [["hematopoietic", "ANATOMY", 20, 33], ["breast cancer", "ANATOMY", 84, 97], ["breast cancer", "ANATOMY", 335, 348], ["bone", "ANATOMY", 367, 371], ["bone", "ANATOMY", 463, 467], ["breast cancer", "DISEASE", 84, 97], ["breast cancer", "DISEASE", 335, 348], ["bone disease", "DISEASE", 463, 475], ["breast cancer", "CANCER", 84, 97], ["ABC", "CANCER", 99, 102], ["HER2", "GENE_OR_GENE_PRODUCT", 109, 113], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 131, 140], ["breast cancer", "CANCER", 335, 348], ["ABC", "CANCER", 350, 353], ["bone", "TISSUE", 367, 371], ["bone", "TISSUE", 463, 467], ["prophylactic hematopoietic growth factors", "PROTEIN", 7, 48], ["HER2", "PROTEIN", 109, 113], ["prophylactic hematopoietic growth factors", "TREATMENT", 7, 48], ["Advanced breast cancer", "PROBLEM", 75, 97], ["ABC", "PROBLEM", 115, 118], ["anti-HER2 agents", "TREATMENT", 131, 147], ["Advanced breast cancer", "PROBLEM", 326, 348], ["bone modulating agents", "TREATMENT", 367, 389], ["bone disease", "PROBLEM", 463, 475], ["symptoms", "PROBLEM", 504, 512], ["breast", "ANATOMY", 84, 90], ["cancer", "OBSERVATION", 91, 97], ["breast", "ANATOMY", 335, 341], ["cancer", "OBSERVATION", 342, 348], ["bone", "ANATOMY", 367, 371], ["bone", "ANATOMY", 463, 467], ["disease", "OBSERVATION", 468, 475]]], ["In many circumstances, it is possible to increase the interval of administration of i.v. bisphosphonates, limiting the number of visits to the hospital while maintaining a good control of bone metastases.", [["bone metastases", "ANATOMY", 188, 203], ["bisphosphonates", "CHEMICAL", 89, 104], ["bone metastases", "DISEASE", 188, 203], ["bisphosphonates", "CHEMICAL", 89, 104], ["bisphosphonates", "SIMPLE_CHEMICAL", 89, 104], ["bone", "ORGAN", 188, 192], ["i.v. bisphosphonates", "TREATMENT", 84, 104], ["bone metastases", "PROBLEM", 188, 203], ["bone", "ANATOMY", 188, 192], ["metastases", "OBSERVATION", 193, 203]]], ["Furthermore, the administration of s.c. denosumabAdvanced breast cancer (ABC)can be performed at home, if resources allow it.The Psychological Management of Cancer Patients during the COVID-19 outbreakThe To deal with the increased risk of distress and psychological disorders and the obligation to adhere to social isolation, telemedicine has been used also by psychologists and psychiatrists to guarantee psychological individual and group support for patients while limiting visits to the cancer center.", [["breast cancer", "ANATOMY", 58, 71], ["Cancer", "ANATOMY", 157, 163], ["cancer", "ANATOMY", 492, 498], ["breast cancer", "DISEASE", 58, 71], ["Cancer", "DISEASE", 157, 163], ["distress and psychological disorders", "DISEASE", 240, 276], ["cancer", "DISEASE", 492, 498], ["breast cancer", "CANCER", 58, 71], ["ABC", "CANCER", 73, 76], ["Cancer", "CANCER", 157, 163], ["Patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 454, 462], ["cancer", "CANCER", 492, 498], ["Patients", "SPECIES", 164, 172], ["patients", "SPECIES", 454, 462], ["s.c. denosumabAdvanced breast cancer", "PROBLEM", 35, 71], ["Cancer", "PROBLEM", 157, 163], ["distress", "PROBLEM", 240, 248], ["psychological disorders", "PROBLEM", 253, 276], ["social isolation", "TREATMENT", 309, 325], ["telemedicine", "TREATMENT", 327, 339], ["group support", "TREATMENT", 436, 449], ["breast", "ANATOMY", 58, 64], ["cancer", "OBSERVATION", 65, 71], ["Cancer", "OBSERVATION", 157, 163]]], ["In order to propose the adequate support to patients, psychological status and associated contributing factors should be monitored at different time points of the care pathway.", [["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52]]], ["Hospital Anxiety and Depression Scale (HADS) is an easy to use questionnaire and has a good accuracy in assessing anxiety and depression in cancer patients 39 .The Psychological Management of Cancer Patients during the COVID-19 outbreakFurthermore, even in presence of low levels of depression and anxiety it will be crucial to identify critical levels of intolerance of uncertainty and feelings of loneliness in order to implement interventions to decrease the risk of further distress and psychopathological complications.ConclusionsIn the context of the COVID-19 pandemic, we recommended that routine breast screening be suspended, and that patients with early and advanced breast cancer be treated as outpatients as much as possible at the nearest medical center.", [["cancer", "ANATOMY", 140, 146], ["Cancer", "ANATOMY", 192, 198], ["breast", "ANATOMY", 604, 610], ["breast cancer", "ANATOMY", 677, 690], ["Anxiety and Depression", "DISEASE", 9, 31], ["anxiety", "DISEASE", 114, 121], ["depression", "DISEASE", 126, 136], ["cancer", "DISEASE", 140, 146], ["Cancer", "DISEASE", 192, 198], ["depression", "DISEASE", 283, 293], ["anxiety", "DISEASE", 298, 305], ["loneliness", "DISEASE", 399, 409], ["breast cancer", "DISEASE", 677, 690], ["cancer", "CANCER", 140, 146], ["patients", "ORGANISM", 147, 155], ["Cancer", "CANCER", 192, 198], ["Patients", "ORGANISM", 199, 207], ["breast", "ORGANISM_SUBDIVISION", 604, 610], ["patients", "ORGANISM", 644, 652], ["breast cancer", "CANCER", 677, 690], ["patients", "SPECIES", 147, 155], ["Patients", "SPECIES", 199, 207], ["patients", "SPECIES", 644, 652], ["Hospital Anxiety", "PROBLEM", 0, 16], ["Depression Scale (HADS)", "PROBLEM", 21, 44], ["anxiety", "PROBLEM", 114, 121], ["depression in cancer", "PROBLEM", 126, 146], ["Cancer", "PROBLEM", 192, 198], ["the COVID", "TEST", 215, 224], ["depression", "PROBLEM", 283, 293], ["anxiety", "PROBLEM", 298, 305], ["interventions", "TREATMENT", 432, 445], ["further distress", "PROBLEM", 470, 486], ["psychopathological complications", "PROBLEM", 491, 523], ["the COVID", "TEST", 553, 562], ["routine breast screening", "TEST", 596, 620], ["advanced breast cancer", "PROBLEM", 668, 690], ["Cancer", "OBSERVATION", 192, 198], ["low levels", "OBSERVATION_MODIFIER", 269, 279], ["breast", "ANATOMY", 677, 683], ["cancer", "OBSERVATION", 684, 690]]], ["Exams and appointments of patients on follow-up or under adjuvant endocrine therapy should either be postponed or managed through telemedicine.", [["endocrine", "ANATOMY", 66, 75], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["Exams", "TEST", 0, 5], ["adjuvant endocrine therapy", "TREATMENT", 57, 83]]], ["All treatment decisions should be taken in the context of a multidisciplinary tumour board, which may take place virtually.", [["tumour", "ANATOMY", 78, 84], ["tumour", "DISEASE", 78, 84], ["tumour", "CANCER", 78, 84], ["a multidisciplinary tumour board", "TREATMENT", 58, 90]]], ["All treatment decision-making should balance risk and benefits of treatment in the context of the specific pandemic level, on a case by case discussion, always including patients'Conclusionspreferences.", [["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["treatment", "TREATMENT", 66, 75]]], ["Localised outbreaks, which start to merge becoming indistinct.", [["Localised outbreaks", "PROBLEM", 0, 19], ["outbreaks", "OBSERVATION", 10, 19], ["indistinct", "OBSERVATION", 51, 61]]], ["In this scenario, there is sustained human-to-human transmission in the country (more than two generations of cases outside of sporadic clusters with known epidemiological links) and an increasing pressure on healthcare systems.", [["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 46, 51], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["an increasing pressure on healthcare systems", "PROBLEM", 183, 227], ["increasing", "OBSERVATION_MODIFIER", 186, 196], ["pressure", "OBSERVATION_MODIFIER", 197, 205]]], ["The objective at this stage is to mitigate the impact of the outbreak by decreasing the burden on healthcare systems and protect populations at risk of severe disease.Scenarios to describe progression of COVID-19 outbreaks -according to ECDCMultiple introductions but limited local transmission in the country.", [["COVID", "DISEASE", 204, 209], ["healthcare systems", "TREATMENT", 98, 116], ["severe disease", "PROBLEM", 152, 166], ["COVID", "TEST", 204, 209], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["disease", "OBSERVATION", 159, 166]]], ["Despite the introductions there is no apparent sustained transmission (only second generation cases observed or transmission within sporadic contained clusters with known epidemiological links).", [["apparent sustained transmission", "PROBLEM", 38, 69], ["no apparent", "UNCERTAINTY", 35, 46]]], ["In this situation, the objective is containment by blocking transmission opportunities, through early detection of imported and locally-transmitted COVID-19 cases in order to try to avoid or at least delay the spread of infection and theassociated burden on healthcare systemsScenarios to describe progression of COVID-19 outbreaks -according to ECDCIncreasing number of introductions and of more widespread reports of localised human-to-human transmission in the country.", [["infection", "DISEASE", 220, 229], ["COVID", "DISEASE", 313, 318], ["human-to-human transmission", "DISEASE", 429, 456], ["human", "ORGANISM", 429, 434], ["human", "ORGANISM", 438, 443], ["human", "SPECIES", 429, 434], ["human", "SPECIES", 438, 443], ["human", "SPECIES", 429, 434], ["human", "SPECIES", 438, 443], ["infection", "PROBLEM", 220, 229], ["theassociated burden on healthcare systems", "PROBLEM", 234, 276], ["COVID", "TEST", 313, 318], ["infection", "OBSERVATION", 220, 229]]], ["In this situation, the objective remains to contain where practicable and otherwise slow down the transmission of the infection.", [["infection", "DISEASE", 118, 127], ["the infection", "PROBLEM", 114, 127], ["infection", "OBSERVATION", 118, 127]]], ["This will increase the time available for development, production and distribution of PPE and effective therapeutic options, and would play a crucial role in reducing the burden on the healthcare system.European center disease control scenarios description https://www.ecdc.europa.eu/en/publications-data/rapid-riskassessment-coronavirus-disease-2019-covid-19-pandemicWidespread sustained transmission where healthcare systems are overburdened due to a large demand for emergency healthcare services, a strained ICU capacity, overworked healthcare workers and reduced staff availability due to illness, lack of PPE and lack of diagnostic testing capacity.", [["illness", "DISEASE", 594, 601], ["PPE", "PROBLEM", 86, 89], ["illness", "PROBLEM", 594, 601], ["PPE", "PROBLEM", 611, 614], ["diagnostic testing capacity", "TEST", 627, 654], ["disease", "OBSERVATION", 219, 226]]], ["The objective at this stage is still to mitigate the impact of the outbreak, decrease the burden on healthcare services, protect populations at risk of severe disease and reduce excess mortality.", [["healthcare services", "TREATMENT", 100, 119], ["severe disease", "PROBLEM", 152, 166], ["reduce excess mortality", "PROBLEM", 171, 194], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["disease", "OBSERVATION", 159, 166], ["excess mortality", "OBSERVATION", 178, 194]]], ["Localised outbreaks, which start to merge becoming indistinct.", [["Localised outbreaks", "PROBLEM", 0, 19], ["outbreaks", "OBSERVATION", 10, 19], ["indistinct", "OBSERVATION", 51, 61]]], ["In this scenario, there is sustained human-to-human transmission in the country (more than two generations of cases outside of sporadic clusters with known epidemiological links) and an increasing pressure on healthcare systems.", [["human", "ORGANISM", 37, 42], ["human", "ORGANISM", 46, 51], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 46, 51], ["an increasing pressure on healthcare systems", "PROBLEM", 183, 227], ["increasing", "OBSERVATION_MODIFIER", 186, 196], ["pressure", "OBSERVATION_MODIFIER", 197, 205]]], ["The objective at this stage is to mitigate the impact of the outbreak by decreasing the burden on healthcare systems and protect populations at risk of severe disease.Scenarios to describe progression of COVID-19 outbreaks -according to ECDCMultiple introductions but limited local transmission in the country.", [["COVID", "DISEASE", 204, 209], ["healthcare systems", "TREATMENT", 98, 116], ["severe disease", "PROBLEM", 152, 166], ["COVID", "TEST", 204, 209], ["severe", "OBSERVATION_MODIFIER", 152, 158], ["disease", "OBSERVATION", 159, 166]]], ["Despite the introductions there is no apparent sustained transmission (only second generation cases observed or transmission within sporadic contained clusters with known epidemiological links).", [["apparent sustained transmission", "PROBLEM", 38, 69], ["no apparent", "UNCERTAINTY", 35, 46]]], ["In this situation, the objective is containment by blocking transmission opportunities, through early detection of imported and locally-transmitted COVID-19 cases in order to try to avoid or at least delay the spread of infection and theassociated burden on healthcare systemsScenarios to describe progression of COVID-19 outbreaks -according to ECDCIncreasing number of introductions and of more widespread reports of localised human-to-human transmission in the country.", [["infection", "DISEASE", 220, 229], ["COVID", "DISEASE", 313, 318], ["human-to-human transmission", "DISEASE", 429, 456], ["human", "ORGANISM", 429, 434], ["human", "ORGANISM", 438, 443], ["human", "SPECIES", 429, 434], ["human", "SPECIES", 438, 443], ["human", "SPECIES", 429, 434], ["human", "SPECIES", 438, 443], ["infection", "PROBLEM", 220, 229], ["theassociated burden on healthcare systems", "PROBLEM", 234, 276], ["COVID", "TEST", 313, 318], ["infection", "OBSERVATION", 220, 229]]], ["In this situation, the objective remains to contain where practicable and otherwise slow down the transmission of the infection.", [["infection", "DISEASE", 118, 127], ["the infection", "PROBLEM", 114, 127], ["infection", "OBSERVATION", 118, 127]]], ["This will increase the time available for development, production and distribution of PPE and effective therapeutic options, and would play a crucial role in reducing the burden on the healthcare system.Scenarios to describe progression of COVID-19 outbreaks -according to ECDCWidespread sustained transmission where healthcare systems are overburdened due to a large demand for emergency healthcare services, a strained ICU capacity, overworked healthcare workers and reduced staff availability due to illness, lack of PPE and lack of", [["COVID", "DISEASE", 240, 245], ["illness", "DISEASE", 503, 510], ["PPE", "PROBLEM", 86, 89], ["COVID", "TEST", 240, 245], ["illness", "PROBLEM", 503, 510], ["PPE", "PROBLEM", 520, 523]]]], "PMC7411245": [["INTRODUCTIONCoronavirus disease 2019 (COVID-19) is a recently-discovered infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that has quickly become a global pandemic.", [["INTRODUCTIONCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["infectious disease", "DISEASE", 73, 91], ["acute respiratory syndrome coronavirus", "DISEASE", 113, 151], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 106, 153], ["SARS-CoV-2", "ORGANISM", 155, 165], ["CoV-2", "SPECIES", 160, 165], ["INTRODUCTIONCoronavirus disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 106, 151], ["SARS-CoV-2) virus", "SPECIES", 155, 172], ["INTRODUCTIONCoronavirus disease", "PROBLEM", 0, 31], ["infectious disease", "PROBLEM", 73, 91], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 102, 151], ["SARS", "PROBLEM", 155, 159], ["virus", "PROBLEM", 167, 172], ["a global pandemic", "PROBLEM", 197, 214], ["infectious", "OBSERVATION", 73, 83], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["respiratory syndrome", "OBSERVATION", 119, 139], ["global", "OBSERVATION_MODIFIER", 199, 205], ["pandemic", "OBSERVATION", 206, 214]]], ["As of the writing of this report, more than 3 million cases and nearly 250 000 deaths have been documented.", [["deaths", "DISEASE", 79, 85]]], ["However, the epidemiology of the disease is still being studied, and much more information is required to establish adequate measures for its prevention and control, especially among patients vulnerable to severe disease (pneumonia) or death [1].INTRODUCTIONSeveral studies have demonstrated higher frequencies of severe cases and mortality among COVID-19 patients with underlying comorbidities, such as diabetes, high blood pressure (HBP), obesity, and cardiovascular disease (CVD), relative to patients without comorbidities [2,3].", [["blood", "ANATOMY", 419, 424], ["cardiovascular", "ANATOMY", 454, 468], ["pneumonia", "DISEASE", 222, 231], ["death", "DISEASE", 236, 241], ["diabetes", "DISEASE", 404, 412], ["high blood pressure", "DISEASE", 414, 433], ["obesity", "DISEASE", 441, 448], ["cardiovascular disease", "DISEASE", 454, 476], ["CVD", "DISEASE", 478, 481], ["patients", "ORGANISM", 183, 191], ["patients", "ORGANISM", 356, 364], ["blood", "ORGANISM_SUBSTANCE", 419, 424], ["patients", "ORGANISM", 496, 504], ["patients", "SPECIES", 183, 191], ["patients", "SPECIES", 356, 364], ["patients", "SPECIES", 496, 504], ["the disease", "PROBLEM", 29, 40], ["severe disease (pneumonia)", "PROBLEM", 206, 232], ["death", "PROBLEM", 236, 241], ["INTRODUCTIONSeveral studies", "TEST", 246, 273], ["severe cases", "PROBLEM", 314, 326], ["underlying comorbidities", "PROBLEM", 370, 394], ["diabetes", "PROBLEM", 404, 412], ["high blood pressure (HBP)", "PROBLEM", 414, 439], ["obesity", "PROBLEM", 441, 448], ["cardiovascular disease (CVD)", "PROBLEM", 454, 482], ["comorbidities", "PROBLEM", 513, 526], ["disease", "OBSERVATION", 33, 40], ["severe", "OBSERVATION_MODIFIER", 206, 212], ["disease", "OBSERVATION", 213, 220], ["pneumonia", "OBSERVATION", 222, 231], ["higher frequencies", "OBSERVATION_MODIFIER", 292, 310], ["severe", "OBSERVATION_MODIFIER", 314, 320], ["obesity", "OBSERVATION", 441, 448], ["cardiovascular", "ANATOMY", 454, 468], ["disease", "OBSERVATION", 469, 476]]], ["Although the causal mechanisms by which chronic conditions increase the risk of COVID-19 severity and mortality are still being studied, it has been postulated that patients with HBP and diabetes have an increased susceptibility of severe SARS-CoV-2 infection [4,5].", [["HBP", "DISEASE", 179, 182], ["diabetes", "DISEASE", 187, 195], ["SARS-CoV-2 infection", "DISEASE", 239, 259], ["patients", "ORGANISM", 165, 173], ["CoV-2", "ORGANISM", 244, 249], ["patients", "SPECIES", 165, 173], ["chronic conditions", "PROBLEM", 40, 58], ["COVID", "TEST", 80, 85], ["mortality", "PROBLEM", 102, 111], ["HBP", "PROBLEM", 179, 182], ["diabetes", "PROBLEM", 187, 195], ["an increased susceptibility of severe SARS", "PROBLEM", 201, 243], ["CoV-2 infection", "PROBLEM", 244, 259], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["increased", "OBSERVATION_MODIFIER", 204, 213], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["SARS", "OBSERVATION", 239, 243]]], ["It has also been proposed that SARS-CoV-2 infection may cause or worsen endotheliitis, which can further affect the condition of people with previous endothelial dysfunction, such as those with obesity, diabetes, HBP, and other CVDs [5].", [["endothelial", "ANATOMY", 150, 161], ["infection", "DISEASE", 42, 51], ["endotheliitis", "DISEASE", 72, 85], ["endothelial dysfunction", "DISEASE", 150, 173], ["obesity", "DISEASE", 194, 201], ["diabetes", "DISEASE", 203, 211], ["HBP", "DISEASE", 213, 216], ["CVDs", "DISEASE", 228, 232], ["SARS-CoV-2", "ORGANISM", 31, 41], ["people", "ORGANISM", 129, 135], ["endothelial", "CELL", 150, 161], ["people", "SPECIES", 129, 135], ["SARS", "PROBLEM", 31, 35], ["CoV-2 infection", "PROBLEM", 36, 51], ["worsen endotheliitis", "PROBLEM", 65, 85], ["previous endothelial dysfunction", "PROBLEM", 141, 173], ["obesity", "PROBLEM", 194, 201], ["diabetes", "PROBLEM", 203, 211], ["HBP", "PROBLEM", 213, 216], ["other CVDs", "PROBLEM", 222, 232], ["endothelial dysfunction", "OBSERVATION", 150, 173]]], ["This raises the question of how multimorbidity\u2014the presence of 2 or more chronic comorbidities\u2014may influence disease severity and mortality in patients with SARS-CoV-2 infection.INTRODUCTIONMexico has one of the highest COVID-19 mortality rates among Latin American countries.", [["SARS-CoV-2 infection", "DISEASE", 157, 177], ["patients", "ORGANISM", 143, 151], ["SARS-CoV-2", "ORGANISM", 157, 167], ["patients", "SPECIES", 143, 151], ["SARS-CoV-2", "SPECIES", 157, 167], ["more chronic comorbidities\u2014may influence disease severity", "PROBLEM", 68, 125], ["SARS", "PROBLEM", 157, 161], ["CoV", "PROBLEM", 162, 165], ["2 infection", "PROBLEM", 166, 177], ["INTRODUCTIONMexico", "TREATMENT", 178, 196], ["the highest COVID", "TREATMENT", 208, 225], ["raises the question of", "UNCERTAINTY", 5, 27], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["infection", "OBSERVATION", 168, 177]]], ["As of May 18, 2020, more than 20 000 confirmed cases and 2154 deaths attributed to COVID-19 had been reported in Mexico [1].", [["deaths", "DISEASE", 62, 68], ["COVID-19", "CHEMICAL", 83, 91], ["COVID-19", "DNA", 83, 91], ["COVID", "TEST", 83, 88]]], ["The potential associations of multimorbidity with disease severity and mortality in COVID-19 patients have received special attention in Mexico, as it is one of the Latin American countries with the highest prevalence of chronic conditions; 19.0-25.5% of Mexican adults have HBP, 10.0% have diabetes, and 28.0% are obese [6,7].", [["multimorbidity", "DISEASE", 30, 44], ["HBP", "DISEASE", 275, 278], ["diabetes", "DISEASE", 291, 299], ["patients", "ORGANISM", 93, 101], ["adults", "ORGANISM", 263, 269], ["patients", "SPECIES", 93, 101], ["multimorbidity", "PROBLEM", 30, 44], ["disease severity", "PROBLEM", 50, 66], ["COVID", "TEST", 84, 89], ["chronic conditions", "PROBLEM", 221, 239], ["HBP", "TEST", 275, 278], ["diabetes", "PROBLEM", 291, 299], ["obese", "PROBLEM", 315, 320], ["multimorbidity", "OBSERVATION", 30, 44], ["chronic", "OBSERVATION_MODIFIER", 221, 228]]], ["To date, only 1 peer-reviewed study, conducted in China, has reported a higher combined risk of admission to intensive care, intubation, or death in patients with multimorbidity compared to those without multimorbidity [8].", [["death", "DISEASE", 140, 145], ["multimorbidity", "DISEASE", 163, 177], ["multimorbidity", "DISEASE", 204, 218], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["intensive care", "TREATMENT", 109, 123], ["intubation", "TREATMENT", 125, 135], ["death", "PROBLEM", 140, 145], ["multimorbidity", "PROBLEM", 163, 177]]], ["However, this association has not been studied in Latin America, and pneumonia and death have not been considered as separate outcomes.INTRODUCTIONThe epidemiological surveillance system of the Secretar\u00eda de Salud de M\u00e9xico collects information regarding the characteristics and comorbidities of diagnosed COVID-19 cases, as well as their clinical course and outcomes.", [["pneumonia", "DISEASE", 69, 78], ["death", "DISEASE", 83, 88], ["COVID", "DISEASE", 306, 311], ["pneumonia", "PROBLEM", 69, 78], ["death", "PROBLEM", 83, 88], ["COVID", "TEST", 306, 311], ["pneumonia", "OBSERVATION", 69, 78]]], ["In this study, we aimed to identify the chronic conditions and multimorbidity patterns present among COVID-19 patients and to examine their associations with pneumonia and death.", [["pneumonia", "DISEASE", 158, 167], ["death", "DISEASE", 172, 177], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["this study", "TEST", 3, 13], ["the chronic conditions", "PROBLEM", 36, 58], ["multimorbidity patterns", "PROBLEM", 63, 86], ["pneumonia", "PROBLEM", 158, 167], ["death", "PROBLEM", 172, 177], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["pneumonia", "OBSERVATION", 158, 167]]], ["Our results could help facilitate better understanding and decision-making regarding the identification of groups at relatively high risk of severe illness and death due to COVID-19 and the implementation of preventative measures affecting these groups.Study Design and Data Source ::: METHODSA cross-sectional study was performed to analyze the publicly available data of patients with COVID-19 diagnosed via reverse transcription-polymerase chain reaction (RT-PCR).", [["illness", "DISEASE", 148, 155], ["death", "DISEASE", 160, 165], ["patients", "ORGANISM", 373, 381], ["patients", "SPECIES", 373, 381], ["severe illness", "PROBLEM", 141, 155], ["death", "PROBLEM", 160, 165], ["COVID", "TEST", 173, 178], ["preventative measures", "TREATMENT", 208, 229], ["METHODSA cross-sectional study", "TEST", 286, 316], ["COVID", "TEST", 387, 392], ["reverse transcription", "TEST", 410, 431], ["polymerase chain reaction", "PROBLEM", 432, 457], ["RT-PCR", "TEST", 459, 465], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["illness", "OBSERVATION", 148, 155]]], ["Socio-demographic and medical data (regarding date of disease onset, disease duration, epidemiological profile, presence of chronic conditions, molecular diagnostic test result, and vital status), were collected by physicians using an epidemiological COVID-19 case report form in suspected COVID-19 patients.", [["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 299, 307], ["disease onset", "PROBLEM", 54, 67], ["disease duration", "PROBLEM", 69, 85], ["chronic conditions", "PROBLEM", 124, 142], ["molecular diagnostic test", "TEST", 144, 169]]], ["These data were systematized using an epidemiological surveillance system and are available at https://www.gob.mx/salud/documentos/datos-abiertos-152127.Study Variables ::: METHODSThe dependent variables were pneumonia and death in patients with COVID-19.", [["pneumonia", "DISEASE", 209, 218], ["death", "DISEASE", 223, 228], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["an epidemiological surveillance system", "TEST", 35, 73], ["METHODSThe dependent variables", "PROBLEM", 173, 203], ["pneumonia", "PROBLEM", 209, 218], ["death", "PROBLEM", 223, 228], ["COVID", "TEST", 246, 251], ["pneumonia", "OBSERVATION", 209, 218]]], ["Eight comorbidities were included as independent variables: HBP, diabetes, obesity, asthma, immunosuppression, other CVDs, chronic obstructive pulmonary disease (COPD), and chronic kidney disease.", [["pulmonary", "ANATOMY", 143, 152], ["kidney", "ANATOMY", 181, 187], ["diabetes", "DISEASE", 65, 73], ["obesity", "DISEASE", 75, 82], ["asthma", "DISEASE", 84, 90], ["immunosuppression", "DISEASE", 92, 109], ["CVDs", "DISEASE", 117, 121], ["chronic obstructive pulmonary disease", "DISEASE", 123, 160], ["COPD", "DISEASE", 162, 166], ["chronic kidney disease", "DISEASE", 173, 195], ["pulmonary", "ORGAN", 143, 152], ["kidney", "ORGAN", 181, 187], ["Eight comorbidities", "PROBLEM", 0, 19], ["HBP", "PROBLEM", 60, 63], ["diabetes", "PROBLEM", 65, 73], ["obesity", "PROBLEM", 75, 82], ["asthma", "PROBLEM", 84, 90], ["immunosuppression", "TREATMENT", 92, 109], ["other CVDs", "PROBLEM", 111, 121], ["chronic obstructive pulmonary disease", "PROBLEM", 123, 160], ["COPD)", "PROBLEM", 162, 167], ["chronic kidney disease", "PROBLEM", 173, 195], ["diabetes", "OBSERVATION", 65, 73], ["obesity", "OBSERVATION", 75, 82], ["asthma", "OBSERVATION", 84, 90], ["chronic", "OBSERVATION_MODIFIER", 123, 130], ["obstructive", "OBSERVATION_MODIFIER", 131, 142], ["pulmonary", "ANATOMY", 143, 152], ["disease", "OBSERVATION", 153, 160], ["COPD", "OBSERVATION", 162, 166], ["chronic", "OBSERVATION_MODIFIER", 173, 180], ["kidney", "ANATOMY", 181, 187], ["disease", "OBSERVATION", 188, 195]]], ["The chronic conditions included in the analysis corresponded to the conditions reported as associated with COVID-19 in the literature [9-15] and the availability of the relevant information in the patient data.", [["patient", "ORGANISM", 197, 204], ["patient", "SPECIES", 197, 204], ["The chronic conditions", "PROBLEM", 0, 22], ["the analysis", "TEST", 35, 47], ["COVID", "TEST", 107, 112], ["chronic", "OBSERVATION_MODIFIER", 4, 11], ["conditions", "OBSERVATION", 12, 22]]], ["A simple count of the 8 comorbidities was used to classify participants into 4 categories: no comorbidity, 1 comorbidity, 2 comorbidities, or 3 or more comorbidities.", [["participants", "SPECIES", 59, 71], ["A simple count", "TEST", 0, 14], ["the 8 comorbidities", "PROBLEM", 18, 37], ["comorbidity", "PROBLEM", 94, 105], ["2 comorbidities", "PROBLEM", 122, 137], ["no", "UNCERTAINTY", 91, 93]]], ["Likewise, the 3 most frequent comorbidities (HBP, diabetes, and obesity) were classified into dyads.", [["diabetes", "DISEASE", 50, 58], ["obesity", "DISEASE", 64, 71], ["the 3 most frequent comorbidities", "PROBLEM", 10, 43], ["diabetes", "PROBLEM", 50, 58], ["obesity", "PROBLEM", 64, 71], ["diabetes", "OBSERVATION", 50, 58]]], ["The presence of \u22652 of the 8 reported comorbidities was considered to indicate multimorbidity.Statistical Analysis ::: METHODSThe variables of interest were presented as frequencies and percentages for the categorical variables and as means and standard deviations for the continuous variables.", [["multimorbidity", "DISEASE", 78, 92], ["the 8 reported comorbidities", "PROBLEM", 22, 50], ["multimorbidity", "PROBLEM", 78, 92], ["the categorical variables", "TEST", 201, 226], ["multimorbidity", "OBSERVATION", 78, 92]]], ["The frequencies of pneumonia and death were presented according to the characteristics and comorbidities evaluated and stratified by sex.", [["pneumonia", "DISEASE", 19, 28], ["death", "DISEASE", 33, 38], ["pneumonia", "PROBLEM", 19, 28], ["death", "PROBLEM", 33, 38], ["pneumonia", "OBSERVATION", 19, 28]]], ["Simple logistic regression models were applied to measure the associations of the independent variables with pneumonia and death in patients with COVID-19.", [["pneumonia", "DISEASE", 109, 118], ["death", "DISEASE", 123, 128], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["Simple logistic regression models", "TREATMENT", 0, 33], ["pneumonia", "PROBLEM", 109, 118], ["death", "PROBLEM", 123, 128], ["COVID", "TEST", 146, 151], ["pneumonia", "OBSERVATION", 109, 118]]], ["The chronic conditions that were found to be associated with pneumonia or death (p<0.05) in the simple logistic regression analysis were included in two adjusted logistic regression models.", [["pneumonia", "DISEASE", 61, 70], ["death", "DISEASE", 74, 79], ["The chronic conditions", "PROBLEM", 0, 22], ["pneumonia", "PROBLEM", 61, 70], ["death", "PROBLEM", 74, 79], ["chronic", "OBSERVATION_MODIFIER", 4, 11], ["conditions", "OBSERVATION", 12, 22], ["pneumonia", "OBSERVATION", 61, 70]]], ["The covariables included in the adjusted models were age (continuous), gender (men/women), and smoking status (yes/no).", [["men", "ORGANISM", 79, 82], ["women", "ORGANISM", 83, 88], ["men", "SPECIES", 79, 82], ["women", "SPECIES", 83, 88]]], ["The results were expressed as odds ratios (ORs) and adjusted odds ratios (aORs) with 95% confidence intervals (CIs) for both models.", [["CIs", "TEST", 111, 114]]], ["Based on the adjusted models, the marginal effects were estimated along with their 95% CI, and the probabilities of pneumonia and death according to the number of comorbidities for each year of age were graphed.Statistical Analysis ::: METHODSStatistical analysis was performed using Stata version 14 (StataCorp., College Station, TX, USA).", [["pneumonia", "DISEASE", 116, 125], ["death", "DISEASE", 130, 135], ["pneumonia", "PROBLEM", 116, 125], ["death", "PROBLEM", 130, 135], ["METHODSStatistical analysis", "TEST", 236, 263], ["Stata version", "TEST", 284, 297], ["marginal", "OBSERVATION_MODIFIER", 34, 42], ["pneumonia", "OBSERVATION", 116, 125]]], ["For all analyses, a p-value <0.05 was considered statistically significant.Ethics Statement ::: METHODSAs an analysis of secondary data, this study did not require the approval of an institutional ethics committee.", [["all analyses", "TEST", 4, 16], ["a p-value", "TEST", 18, 27], ["this study", "TEST", 137, 147]]], ["The data are publicly available on the platform of the Secretar\u00eda de Salud de M\u00e9xico under the Mexican open data policy intended to facilitate the access, use, reuse, and redistribution of information.RESULTSComplete data regarding the study variables were available for 51 053 patients with COVID-19, and these patients were included in the analysis.", [["patients", "ORGANISM", 278, 286], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 278, 286], ["patients", "SPECIES", 312, 320], ["the study variables", "TEST", 232, 251], ["COVID", "TEST", 292, 297], ["the analysis", "TEST", 338, 350]]], ["A total of 580 patients were excluded due to incomplete data.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["Of the included patients, 29 422 were men (57.6%).", [["patients", "ORGANISM", 16, 24], ["men", "ORGANISM", 38, 41], ["patients", "SPECIES", 16, 24], ["men", "SPECIES", 38, 41]]], ["The overall mean age was 46.6\u00b115.8 years (men, 47.1\u00b115.7 years; women, 45.8\u00b116.0 years).", [["men", "ORGANISM", 42, 45], ["women", "ORGANISM", 64, 69], ["men", "SPECIES", 42, 45], ["women", "SPECIES", 64, 69]]], ["The mean disease duration was 4.2\u00b13.3 days.", [["The mean disease duration", "PROBLEM", 0, 25], ["mean disease", "OBSERVATION", 4, 16]]], ["A total of 14 684 (28.8%) patients presented with pneumonia (men, 32.5%; women, 23.7%).RESULTSRegarding the presence of chronic conditions, 27 667 (54.2%) of the participants had no comorbidities, while 13 652 (26.7%) presented 1 chronic condition.", [["pneumonia", "DISEASE", 50, 59], ["patients", "ORGANISM", 26, 34], ["men", "ORGANISM", 61, 64], ["women", "ORGANISM", 73, 78], ["participants", "ORGANISM", 162, 174], ["patients", "SPECIES", 26, 34], ["men", "SPECIES", 61, 64], ["women", "SPECIES", 73, 78], ["participants", "SPECIES", 162, 174], ["pneumonia", "PROBLEM", 50, 59], ["chronic conditions", "PROBLEM", 120, 138], ["comorbidities", "PROBLEM", 182, 195], ["1 chronic condition", "PROBLEM", 228, 247], ["total", "OBSERVATION_MODIFIER", 2, 7], ["pneumonia", "OBSERVATION", 50, 59], ["chronic", "OBSERVATION_MODIFIER", 120, 127], ["conditions", "OBSERVATION", 128, 138], ["no", "UNCERTAINTY", 179, 181], ["chronic", "OBSERVATION_MODIFIER", 230, 237]]], ["Multimorbidity was present in 9734 (19.1%) of the patients, with the presence of 2 (n=6518, 12.8%) and 3 (n=2490, 4.9%) comorbidities being the most common.", [["Multimorbidity", "DISEASE", 0, 14], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["Multimorbidity", "TEST", 0, 14], ["comorbidities", "PROBLEM", 120, 133], ["most common", "OBSERVATION_MODIFIER", 144, 155]]], ["The largest number of simultaneous chronic conditions was 8 (14 patients) (Table 1).RESULTSThe results included 5233 (10.3%) deaths (men, 12.1%; women, 7.7%), with a mean time from disease onset to death of 10.6\u00b16.5 days (Table 1).", [["deaths", "DISEASE", 125, 131], ["death", "DISEASE", 198, 203], ["patients", "ORGANISM", 64, 72], ["men", "ORGANISM", 133, 136], ["women", "ORGANISM", 145, 150], ["patients", "SPECIES", 64, 72], ["men", "SPECIES", 133, 136], ["women", "SPECIES", 145, 150], ["simultaneous chronic conditions", "PROBLEM", 22, 53], ["death", "PROBLEM", 198, 203], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["simultaneous", "OBSERVATION_MODIFIER", 22, 34], ["chronic", "OBSERVATION_MODIFIER", 35, 42], ["conditions", "OBSERVATION", 43, 53], ["disease", "OBSERVATION", 181, 188]]], ["Regarding age group, pneumonia was reported in more than 50% of the people in the 65-74 (50.3%), 75-84 (53.7%), and 85 or older (51.4%) age groups, while the greatest frequencies of death were found in the 65- 74 (27.1%), 75-84 (29.1%), and 85 or older (31.3%) age groups (Table 2).", [["pneumonia", "DISEASE", 21, 30], ["death", "DISEASE", 182, 187], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["pneumonia", "PROBLEM", 21, 30], ["death", "TEST", 182, 187], ["pneumonia", "OBSERVATION", 21, 30]]], ["In the adjusted logistic regression model, across the entire study population, it was found that chronic conditions such as HBP, diabetes, obesity, immunosuppression, other CVDs, COPD, and chronic kidney disease were associated with an increased risk of pneumonia.", [["kidney", "ANATOMY", 197, 203], ["HBP", "DISEASE", 124, 127], ["diabetes", "DISEASE", 129, 137], ["obesity", "DISEASE", 139, 146], ["immunosuppression", "DISEASE", 148, 165], ["CVDs", "DISEASE", 173, 177], ["COPD", "DISEASE", 179, 183], ["chronic kidney disease", "DISEASE", 189, 211], ["pneumonia", "DISEASE", 254, 263], ["kidney", "ORGAN", 197, 203], ["chronic conditions", "PROBLEM", 97, 115], ["HBP", "PROBLEM", 124, 127], ["diabetes", "PROBLEM", 129, 137], ["obesity", "PROBLEM", 139, 146], ["immunosuppression", "TREATMENT", 148, 165], ["other CVDs", "PROBLEM", 167, 177], ["COPD", "PROBLEM", 179, 183], ["chronic kidney disease", "PROBLEM", 189, 211], ["pneumonia", "PROBLEM", 254, 263], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["diabetes", "OBSERVATION", 129, 137], ["obesity", "OBSERVATION", 139, 146], ["COPD", "OBSERVATION", 179, 183], ["chronic", "OBSERVATION_MODIFIER", 189, 196], ["kidney", "ANATOMY", 197, 203], ["disease", "OBSERVATION", 204, 211], ["increased", "OBSERVATION_MODIFIER", 236, 245], ["pneumonia", "OBSERVATION", 254, 263]]], ["In men, other CVDs and COPD were not found to be associated with pneumonia.", [["CVDs", "DISEASE", 14, 18], ["COPD", "DISEASE", 23, 27], ["pneumonia", "DISEASE", 65, 74], ["men", "ORGANISM", 3, 6], ["men", "SPECIES", 3, 6], ["other CVDs", "PROBLEM", 8, 18], ["COPD", "PROBLEM", 23, 27], ["pneumonia", "PROBLEM", 65, 74], ["COPD", "OBSERVATION", 23, 27], ["pneumonia", "OBSERVATION", 65, 74]]], ["Likewise, across the study population, chronic conditions such as HBP, diabetes, obesity, immunosuppression, other CVDs, COPD, and chronic kidney disease were associated with an increased probability of death (Table 3).RESULTSA significant incremental gradient was observed for the association between multimorbidity and pneumonia in the general population (p<0.001), with the presence of 1 (aOR, 1.68; 95% CI, 1.60 to 1.77), 2 (aOR, 2.07; 95% CI, 1.95 to 2.20), and 3 or more chronic conditions (aOR, 2.40; 95% CI, 2.22 to 2.60) associated with a progressively increasing probability of this outcome.", [["kidney", "ANATOMY", 139, 145], ["HBP", "DISEASE", 66, 69], ["diabetes", "DISEASE", 71, 79], ["obesity", "DISEASE", 81, 88], ["immunosuppression", "DISEASE", 90, 107], ["CVDs", "DISEASE", 115, 119], ["COPD", "DISEASE", 121, 125], ["chronic kidney disease", "DISEASE", 131, 153], ["death", "DISEASE", 203, 208], ["multimorbidity", "DISEASE", 302, 316], ["pneumonia", "DISEASE", 321, 330], ["kidney", "ORGAN", 139, 145], ["chronic conditions", "PROBLEM", 39, 57], ["HBP", "PROBLEM", 66, 69], ["diabetes", "PROBLEM", 71, 79], ["obesity", "PROBLEM", 81, 88], ["immunosuppression", "TREATMENT", 90, 107], ["other CVDs", "PROBLEM", 109, 119], ["COPD", "PROBLEM", 121, 125], ["chronic kidney disease", "PROBLEM", 131, 153], ["death", "PROBLEM", 203, 208], ["significant incremental gradient", "PROBLEM", 228, 260], ["multimorbidity", "PROBLEM", 302, 316], ["pneumonia", "PROBLEM", 321, 330], ["aOR", "TEST", 392, 395], ["CI", "TEST", 407, 409], ["aOR", "TEST", 429, 432], ["CI", "TEST", 444, 446], ["more chronic conditions", "PROBLEM", 472, 495], ["aOR", "TEST", 497, 500], ["CI", "TEST", 512, 514], ["chronic", "OBSERVATION_MODIFIER", 39, 46], ["diabetes", "OBSERVATION", 71, 79], ["obesity", "OBSERVATION", 81, 88], ["COPD", "OBSERVATION", 121, 125], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["kidney", "ANATOMY", 139, 145], ["disease", "OBSERVATION", 146, 153], ["increased", "OBSERVATION_MODIFIER", 178, 187], ["significant", "OBSERVATION_MODIFIER", 228, 239], ["incremental", "OBSERVATION_MODIFIER", 240, 251], ["gradient", "OBSERVATION", 252, 260], ["pneumonia", "OBSERVATION", 321, 330], ["chronic", "OBSERVATION_MODIFIER", 477, 484], ["progressively", "OBSERVATION_MODIFIER", 548, 561], ["increasing", "OBSERVATION_MODIFIER", 562, 572]]], ["Likewise, across the study population, a significant incremental gradient (p<0.001) was found for the relationship between multimorbidity and death, in which the presence of 1 (aOR, 1.89; 95% CI, 1.75 to 2.04), 2 (aOR, 2.51; 95% CI, 2.30 to 2.73), and 3 or more chronic conditions (aOR, 3.49; 95% CI, 3.15 to 3.86) were associated with an increased probability of death among the patients.", [["multimorbidity", "DISEASE", 123, 137], ["death", "DISEASE", 142, 147], ["death", "DISEASE", 364, 369], ["patients", "ORGANISM", 380, 388], ["patients", "SPECIES", 380, 388], ["the study population", "TEST", 17, 37], ["a significant incremental gradient", "PROBLEM", 39, 73], ["multimorbidity", "PROBLEM", 123, 137], ["death", "PROBLEM", 142, 147], ["aOR", "TEST", 177, 180], ["CI", "TEST", 192, 194], ["aOR", "TEST", 214, 217], ["CI", "TEST", 229, 231], ["more chronic conditions", "PROBLEM", 257, 280], ["aOR", "TEST", 282, 285], ["CI", "TEST", 297, 299], ["an increased probability of death", "PROBLEM", 336, 369], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["incremental", "OBSERVATION_MODIFIER", 53, 64], ["gradient", "OBSERVATION_MODIFIER", 65, 73], ["chronic", "OBSERVATION_MODIFIER", 262, 269], ["increased", "OBSERVATION_MODIFIER", 339, 348]]], ["These gradients demonstrating higher probabilities of pneumonia and death in patients with more chronic conditions were also present in both men and women and were statistically significant (Table 4).RESULTSFigure 1 shows the marginal effects of age and number of comorbidities on the probabilities of pneumonia and death.", [["pneumonia", "DISEASE", 54, 63], ["death", "DISEASE", 68, 73], ["pneumonia", "DISEASE", 302, 311], ["death", "DISEASE", 316, 321], ["patients", "ORGANISM", 77, 85], ["men", "ORGANISM", 141, 144], ["women", "ORGANISM", 149, 154], ["patients", "SPECIES", 77, 85], ["men", "SPECIES", 141, 144], ["women", "SPECIES", 149, 154], ["pneumonia", "PROBLEM", 54, 63], ["death", "PROBLEM", 68, 73], ["more chronic conditions", "PROBLEM", 91, 114], ["comorbidities", "PROBLEM", 264, 277], ["pneumonia", "PROBLEM", 302, 311], ["death", "PROBLEM", 316, 321], ["gradients", "OBSERVATION_MODIFIER", 6, 15], ["higher", "OBSERVATION_MODIFIER", 30, 36], ["pneumonia", "OBSERVATION", 54, 63], ["significant", "OBSERVATION_MODIFIER", 178, 189], ["marginal", "OBSERVATION_MODIFIER", 226, 234], ["comorbidities", "OBSERVATION", 264, 277], ["pneumonia", "OBSERVATION", 302, 311]]], ["The probabilities of both pneumonia and death increased with the number of comorbidities and age.DISCUSSIONIn this study, we sought to identify patterns of chronic conditions and multimorbidity and to evaluate their associations with pneumonia and death in Mexican patients with COVID-19.", [["pneumonia", "DISEASE", 26, 35], ["death", "DISEASE", 40, 45], ["pneumonia", "DISEASE", 234, 243], ["death", "DISEASE", 248, 253], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273], ["both pneumonia", "PROBLEM", 21, 35], ["death", "PROBLEM", 40, 45], ["this study", "TEST", 110, 120], ["chronic conditions", "PROBLEM", 156, 174], ["multimorbidity", "PROBLEM", 179, 193], ["pneumonia", "PROBLEM", 234, 243], ["death", "PROBLEM", 248, 253], ["COVID", "TEST", 279, 284], ["both", "OBSERVATION_MODIFIER", 21, 25], ["pneumonia", "OBSERVATION", 26, 35], ["death", "OBSERVATION_MODIFIER", 40, 45], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["chronic", "OBSERVATION_MODIFIER", 156, 163], ["pneumonia", "OBSERVATION", 234, 243]]], ["Chronic conditions such as HBP, diabetes, obesity, other CVDs, and chronic kidney disease were found to increase the likelihood of pneumonia.", [["kidney", "ANATOMY", 75, 81], ["HBP", "DISEASE", 27, 30], ["diabetes", "DISEASE", 32, 40], ["obesity", "DISEASE", 42, 49], ["CVDs", "DISEASE", 57, 61], ["chronic kidney disease", "DISEASE", 67, 89], ["pneumonia", "DISEASE", 131, 140], ["kidney", "ORGAN", 75, 81], ["Chronic conditions", "PROBLEM", 0, 18], ["HBP", "PROBLEM", 27, 30], ["diabetes", "PROBLEM", 32, 40], ["obesity", "PROBLEM", 42, 49], ["other CVDs", "PROBLEM", 51, 61], ["chronic kidney disease", "PROBLEM", 67, 89], ["pneumonia", "PROBLEM", 131, 140], ["diabetes", "OBSERVATION", 32, 40], ["obesity", "OBSERVATION", 42, 49], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["kidney", "ANATOMY", 75, 81], ["disease", "OBSERVATION", 82, 89], ["pneumonia", "OBSERVATION", 131, 140]]], ["Likewise, HBP, diabetes, obesity, immunosuppression, COPD, and chronic kidney disease increased the probability of death in patients with COVID-19.", [["kidney", "ANATOMY", 71, 77], ["diabetes", "DISEASE", 15, 23], ["obesity", "DISEASE", 25, 32], ["immunosuppression", "DISEASE", 34, 51], ["COPD", "DISEASE", 53, 57], ["chronic kidney disease", "DISEASE", 63, 85], ["death", "DISEASE", 115, 120], ["COVID-19", "CHEMICAL", 138, 146], ["kidney", "ORGAN", 71, 77], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["HBP", "PROBLEM", 10, 13], ["diabetes", "PROBLEM", 15, 23], ["obesity", "PROBLEM", 25, 32], ["immunosuppression", "TREATMENT", 34, 51], ["COPD", "PROBLEM", 53, 57], ["chronic kidney disease", "PROBLEM", 63, 85], ["death", "PROBLEM", 115, 120], ["COVID", "TEST", 138, 143], ["diabetes", "OBSERVATION", 15, 23], ["obesity", "OBSERVATION", 25, 32], ["immunosuppression", "OBSERVATION", 34, 51], ["COPD", "OBSERVATION", 53, 57], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["kidney", "ANATOMY", 71, 77], ["disease", "OBSERVATION", 78, 85]]], ["Regarding multimorbidity, a greater number of chronic conditions was found to be associated with an increased probability of death or pneumonia among the study sample.DISCUSSIONIn the present study, an association was found between chronic conditions and pneumonia in patients with COVID-19.", [["death", "DISEASE", 125, 130], ["pneumonia", "DISEASE", 134, 143], ["pneumonia", "DISEASE", 255, 264], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["multimorbidity", "PROBLEM", 10, 24], ["chronic conditions", "PROBLEM", 46, 64], ["death", "PROBLEM", 125, 130], ["pneumonia", "PROBLEM", 134, 143], ["the study sample", "TEST", 150, 166], ["the present study", "TEST", 180, 197], ["chronic conditions", "PROBLEM", 232, 250], ["pneumonia", "PROBLEM", 255, 264], ["COVID", "TEST", 282, 287], ["greater", "OBSERVATION_MODIFIER", 28, 35], ["number", "OBSERVATION_MODIFIER", 36, 42], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["conditions", "OBSERVATION", 54, 64], ["increased", "OBSERVATION_MODIFIER", 100, 109], ["pneumonia", "OBSERVATION", 134, 143], ["chronic", "OBSERVATION_MODIFIER", 232, 239], ["conditions", "OBSERVATION", 240, 250], ["pneumonia", "OBSERVATION", 255, 264]]], ["An early report from Wuhan, China, noted that about half of a sample of patients who were hospitalized for SARS-CoV-2 pneumonia had an additional medical condition.", [["SARS", "DISEASE", 107, 111], ["pneumonia", "DISEASE", 118, 127], ["patients", "ORGANISM", 72, 80], ["SARS-CoV-2", "ORGANISM", 107, 117], ["patients", "SPECIES", 72, 80], ["CoV-", "SPECIES", 112, 116], ["SARS", "PROBLEM", 107, 111], ["CoV", "PROBLEM", 112, 115], ["pneumonia", "PROBLEM", 118, 127], ["pneumonia", "OBSERVATION", 118, 127]]], ["The most common comorbidities were HBP, diabetes, CVDs, and malignancies, which (except for malignancies) coincide with the most frequent conditions found in the Mexican population with COVID-19.", [["malignancies", "ANATOMY", 60, 72], ["malignancies", "ANATOMY", 92, 104], ["HBP", "DISEASE", 35, 38], ["diabetes", "DISEASE", 40, 48], ["CVDs", "DISEASE", 50, 54], ["malignancies", "DISEASE", 60, 72], ["malignancies", "DISEASE", 92, 104], ["malignancies", "CANCER", 60, 72], ["malignancies", "CANCER", 92, 104], ["HBP", "PROBLEM", 35, 38], ["diabetes", "PROBLEM", 40, 48], ["CVDs", "PROBLEM", 50, 54], ["malignancies", "PROBLEM", 60, 72], ["malignancies", "PROBLEM", 92, 104], ["the most frequent conditions", "PROBLEM", 120, 148], ["COVID", "TEST", 186, 191], ["diabetes", "OBSERVATION", 40, 48], ["malignancies", "OBSERVATION", 60, 72]]], ["Likewise, in the study from Wuhan, these conditions were associated with the presence of pneumonia [2].", [["pneumonia", "DISEASE", 89, 98], ["the study", "TEST", 13, 22], ["pneumonia", "PROBLEM", 89, 98], ["pneumonia", "OBSERVATION", 89, 98]]], ["Furthermore, the Centers for Disease Control and Prevention in the United States reported that people with serious medical conditions such as asthma (moderate to severe), COPD, diabetes, CVDs, kidney diseases, severe obesity, immunosuppression, and liver diseases have a greater probability of developing severe forms of COVID-19, including pneumonia [15].", [["kidney", "ANATOMY", 193, 199], ["liver", "ANATOMY", 249, 254], ["asthma", "DISEASE", 142, 148], ["COPD", "DISEASE", 171, 175], ["diabetes", "DISEASE", 177, 185], ["CVDs", "DISEASE", 187, 191], ["kidney diseases", "DISEASE", 193, 208], ["obesity", "DISEASE", 217, 224], ["immunosuppression", "DISEASE", 226, 243], ["liver diseases", "DISEASE", 249, 263], ["COVID", "DISEASE", 321, 326], ["pneumonia", "DISEASE", 341, 350], ["people", "ORGANISM", 95, 101], ["kidney", "ORGAN", 193, 199], ["liver", "ORGAN", 249, 254], ["people", "SPECIES", 95, 101], ["Disease Control", "TREATMENT", 29, 44], ["serious medical conditions", "PROBLEM", 107, 133], ["asthma (moderate to severe)", "PROBLEM", 142, 169], ["COPD", "PROBLEM", 171, 175], ["diabetes", "PROBLEM", 177, 185], ["CVDs", "PROBLEM", 187, 191], ["kidney diseases", "PROBLEM", 193, 208], ["severe obesity", "PROBLEM", 210, 224], ["immunosuppression", "TREATMENT", 226, 243], ["liver diseases", "PROBLEM", 249, 263], ["COVID", "TEST", 321, 326], ["pneumonia", "PROBLEM", 341, 350], ["moderate", "OBSERVATION_MODIFIER", 150, 158], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["COPD", "OBSERVATION", 171, 175], ["diabetes", "OBSERVATION", 177, 185], ["kidney", "ANATOMY", 193, 199], ["diseases", "OBSERVATION", 200, 208], ["severe", "OBSERVATION_MODIFIER", 210, 216], ["obesity", "OBSERVATION", 217, 224], ["immunosuppression", "OBSERVATION", 226, 243], ["liver", "ANATOMY", 249, 254], ["diseases", "OBSERVATION", 255, 263], ["greater", "OBSERVATION_MODIFIER", 271, 278], ["severe", "OBSERVATION_MODIFIER", 305, 311], ["pneumonia", "OBSERVATION", 341, 350]]], ["It has been postulated that the development and severity of pneumonia may be influenced by the use of antihypertensive medication, commonly prescribed to patients with HBP and diabetes.", [["pneumonia", "DISEASE", 60, 69], ["diabetes", "DISEASE", 176, 184], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 154, 162], ["pneumonia", "PROBLEM", 60, 69], ["antihypertensive medication", "TREATMENT", 102, 129], ["HBP", "PROBLEM", 168, 171], ["diabetes", "PROBLEM", 176, 184], ["severity", "OBSERVATION_MODIFIER", 48, 56], ["pneumonia", "OBSERVATION", 60, 69], ["diabetes", "OBSERVATION", 176, 184]]], ["These medications may lead to elevated lung tissue concentrations of angiotensin-converting enzyme 2, which acts as the receptor for the entry of SARS-CoV-2 [16,17].", [["lung tissue", "ANATOMY", 39, 50], ["angiotensin", "CHEMICAL", 69, 80], ["lung tissue", "TISSUE", 39, 50], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 69, 100], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 146, 156], ["angiotensin-converting enzyme 2", "PROTEIN", 69, 100], ["These medications", "TREATMENT", 0, 17], ["elevated lung tissue concentrations", "PROBLEM", 30, 65], ["angiotensin-converting enzyme", "TREATMENT", 69, 98], ["CoV", "TEST", 151, 154], ["lung", "ANATOMY", 39, 43], ["tissue", "OBSERVATION", 44, 50]]], ["However, other authors have reported that elevated angiotensinconverting enzyme 2 levels are not associated with an increased risk of pneumonia [18].", [["pneumonia", "DISEASE", 134, 143], ["angiotensinconverting enzyme 2", "GENE_OR_GENE_PRODUCT", 51, 81], ["angiotensinconverting enzyme 2", "PROTEIN", 51, 81], ["elevated angiotensinconverting enzyme 2 levels", "PROBLEM", 42, 88], ["pneumonia", "PROBLEM", 134, 143], ["not associated with", "UNCERTAINTY", 93, 112], ["increased", "OBSERVATION_MODIFIER", 116, 125], ["pneumonia", "OBSERVATION", 134, 143]]], ["This suggests the need for further study of the influence of chronic conditions on the development of COVID-19.DISCUSSIONRegarding multimorbidity and pneumonia in patients with COVID-19, the probability of developing pneumonia was found to increase as the number of chronic conditions increased.", [["multimorbidity", "DISEASE", 131, 145], ["pneumonia", "DISEASE", 150, 159], ["pneumonia", "DISEASE", 217, 226], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["further study", "TEST", 27, 40], ["chronic conditions", "PROBLEM", 61, 79], ["COVID", "TEST", 102, 107], ["multimorbidity", "PROBLEM", 131, 145], ["pneumonia", "PROBLEM", 150, 159], ["COVID", "TEST", 177, 182], ["developing pneumonia", "PROBLEM", 206, 226], ["chronic conditions", "PROBLEM", 266, 284], ["chronic", "OBSERVATION_MODIFIER", 61, 68], ["pneumonia", "OBSERVATION", 150, 159], ["pneumonia", "OBSERVATION", 217, 226], ["increase", "OBSERVATION_MODIFIER", 240, 248], ["chronic", "OBSERVATION_MODIFIER", 266, 273], ["conditions", "OBSERVATION", 274, 284], ["increased", "OBSERVATION_MODIFIER", 285, 294]]], ["COVID-19 patients with comorbidities have been reported to exhibit a worse response to treatment than patients without comorbidities [19].", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 102, 110], ["comorbidities", "PROBLEM", 23, 36], ["treatment", "TREATMENT", 87, 96], ["comorbidities", "PROBLEM", 119, 132]]], ["HBP and respiratory and CVDs are associated with a relatively severe presentation of COVID-19, including the development of pneumonia [20-22].", [["respiratory and CVDs", "DISEASE", 8, 28], ["pneumonia", "DISEASE", 124, 133], ["HBP", "SIMPLE_CHEMICAL", 0, 3], ["HBP", "TEST", 0, 3], ["respiratory and CVDs", "PROBLEM", 8, 28], ["COVID", "TEST", 85, 90], ["pneumonia", "PROBLEM", 124, 133], ["respiratory", "ANATOMY", 8, 19], ["CVDs", "OBSERVATION", 24, 28], ["relatively", "OBSERVATION_MODIFIER", 51, 61], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["pneumonia", "OBSERVATION", 124, 133]]], ["Likewise, greater patient age is associated with the development of pneumonia and the severe presentation of COVID-19 [23].", [["pneumonia", "DISEASE", 68, 77], ["COVID-19", "CHEMICAL", 109, 117], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["pneumonia", "PROBLEM", 68, 77], ["COVID", "TEST", 109, 114], ["greater", "OBSERVATION_MODIFIER", 10, 17], ["pneumonia", "OBSERVATION", 68, 77], ["severe", "OBSERVATION_MODIFIER", 86, 92]]], ["The presence of multimorbidity among adults (particularly older adults) impacts the physical and mental health of this group, particularly in lowincome and middle-income countries [24].", [["multimorbidity", "DISEASE", 16, 30], ["multimorbidity", "OBSERVATION", 16, 30]]], ["This affects the response capacity to treatment in these patients.DISCUSSIONAn association was found between the presence of chronic conditions and death in patients with COVID-19.", [["death", "DISEASE", 148, 153], ["COVID-19", "CHEMICAL", 171, 179], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 157, 165], ["chronic conditions", "PROBLEM", 125, 143], ["death", "PROBLEM", 148, 153], ["COVID", "TEST", 171, 176], ["response capacity", "OBSERVATION", 17, 34], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["conditions", "OBSERVATION", 133, 143]]], ["In China, a higher frequency of COVID-19 infection and a greater lethality of the disease have been reported among patients with HBP [4,13,20,24].", [["infection", "DISEASE", 41, 50], ["COVID-19", "GENE_OR_GENE_PRODUCT", 32, 40], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["COVID-19", "SPECIES", 32, 40], ["COVID-19 infection", "PROBLEM", 32, 50], ["a greater lethality of the disease", "PROBLEM", 55, 89], ["HBP", "TEST", 129, 132], ["infection", "OBSERVATION", 41, 50], ["disease", "OBSERVATION", 82, 89]]], ["Diabetes has also been described as one of the most common chronic conditions in patients with COVID-19, especially among those in the intensive care unit or with severe forms of the disease [12,19,25].", [["Diabetes", "DISEASE", 0, 8], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["Diabetes", "PROBLEM", 0, 8], ["COVID", "TEST", 95, 100], ["the disease", "PROBLEM", 179, 190], ["most common", "OBSERVATION_MODIFIER", 47, 58], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["conditions", "OBSERVATION", 67, 77], ["disease", "OBSERVATION", 183, 190]]], ["Obesity is another chronic condition associated with increased mortality risk due to challenges in the management of obese patients in relation to positioning, mobilization, and intubation [26,27].", [["Obesity", "DISEASE", 0, 7], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["Obesity", "PROBLEM", 0, 7], ["another chronic condition", "PROBLEM", 11, 36], ["increased mortality risk", "PROBLEM", 53, 77], ["obese patients", "PROBLEM", 117, 131], ["mobilization", "TREATMENT", 160, 172], ["intubation", "TREATMENT", 178, 188], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["mortality", "OBSERVATION", 63, 72], ["obese", "OBSERVATION", 117, 122]]], ["Regarding immunosuppression, the host immunological response to SARSCoV-2 infection and its relationship with the pathophysiology and prognosis of the disease is still under study [28,29].", [["infection", "DISEASE", 74, 83], ["SARSCoV-2", "ORGANISM", 64, 73], ["immunosuppression", "TREATMENT", 10, 27], ["SARSCoV-2 infection", "PROBLEM", 64, 83], ["the disease", "PROBLEM", 147, 158], ["disease", "OBSERVATION", 151, 158]]], ["It has been reported that patients with COPD have an increased risk of developing severe forms of illness, possibly due to alterations in the inflammatory response, immunological and microbiome imbalances, and the use of corticosteroids, among other factors [30].", [["COPD", "DISEASE", 40, 44], ["illness", "DISEASE", 98, 105], ["corticosteroids", "CHEMICAL", 221, 236], ["patients", "ORGANISM", 26, 34], ["corticosteroids", "SIMPLE_CHEMICAL", 221, 236], ["patients", "SPECIES", 26, 34], ["COPD", "PROBLEM", 40, 44], ["illness", "PROBLEM", 98, 105], ["the inflammatory response", "PROBLEM", 138, 163], ["microbiome imbalances", "PROBLEM", 183, 204], ["corticosteroids", "TREATMENT", 221, 236], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["illness", "OBSERVATION", 98, 105], ["possibly due to", "UNCERTAINTY", 107, 122], ["inflammatory", "OBSERVATION_MODIFIER", 142, 154]]], ["Chronic kidney disease has also been described as a chronic condition associated with a greater risk of severe manifestation of COVID-19 and death [8,31,32].DISCUSSIONWith respect to the relationship between multimorbidity and death in patients with COVID-19, an incrementally higher probability of death was observed among patients with more chronic conditions.", [["kidney", "ANATOMY", 8, 14], ["Chronic kidney disease", "DISEASE", 0, 22], ["COVID", "DISEASE", 128, 133], ["death", "DISEASE", 141, 146], ["multimorbidity", "DISEASE", 208, 222], ["death", "DISEASE", 227, 232], ["death", "DISEASE", 299, 304], ["kidney", "ORGAN", 8, 14], ["patients", "ORGANISM", 236, 244], ["patients", "ORGANISM", 324, 332], ["patients", "SPECIES", 236, 244], ["patients", "SPECIES", 324, 332], ["Chronic kidney disease", "PROBLEM", 0, 22], ["a chronic condition", "PROBLEM", 50, 69], ["COVID", "TEST", 128, 133], ["death", "PROBLEM", 141, 146], ["multimorbidity", "PROBLEM", 208, 222], ["death", "PROBLEM", 227, 232], ["COVID", "TEST", 250, 255], ["death", "PROBLEM", 299, 304], ["more chronic conditions", "PROBLEM", 338, 361], ["kidney", "ANATOMY", 8, 14], ["disease", "OBSERVATION", 15, 22], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["condition", "OBSERVATION", 60, 69], ["severe", "OBSERVATION_MODIFIER", 104, 110]]], ["The prevalence of multimorbidity increases with age [33].", [["multimorbidity", "DISEASE", 18, 32], ["multimorbidity", "PROBLEM", 18, 32], ["multimorbidity", "OBSERVATION_MODIFIER", 18, 32], ["increases", "OBSERVATION_MODIFIER", 33, 42]]], ["In addition, it has been reported that older adults who have 2 or more comorbidities have a higher mortality rate than adults who do not [33,34].", [["adults", "ORGANISM", 45, 51]]], ["The case series on COVID-19 published to date describe greater disease severity and a higher risk of death among older patients, particularly the most elderly [11,14].", [["death", "DISEASE", 101, 106], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["COVID", "TEST", 19, 24], ["greater disease severity", "PROBLEM", 55, 79], ["death", "PROBLEM", 101, 106]]], ["In Mexico, the presence of multimorbidity in adults has been described as a predictor of quality of life and all-cause mortality [35].", [["multimorbidity", "DISEASE", 27, 41], ["adults", "ORGANISM", 45, 51], ["multimorbidity", "PROBLEM", 27, 41], ["multimorbidity", "OBSERVATION", 27, 41]]], ["Mexico has a significant burden of disease due to chronic diseases; in 2016, 80% of deaths were attributable to chronic conditions [6].", [["chronic diseases", "DISEASE", 50, 66], ["deaths", "DISEASE", 84, 90], ["a significant burden of disease", "PROBLEM", 11, 42], ["chronic diseases", "PROBLEM", 50, 66], ["chronic conditions", "PROBLEM", 112, 130], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["burden", "OBSERVATION_MODIFIER", 25, 31], ["disease", "OBSERVATION", 35, 42], ["chronic", "OBSERVATION_MODIFIER", 50, 57], ["diseases", "OBSERVATION", 58, 66], ["chronic", "OBSERVATION_MODIFIER", 112, 119]]], ["This high rate of deaths due to chronic diseases corresponds to the high prevalence of chronic conditions in the Mexican population, among which 25.5% of individuals have HBP [7], and 28% of adults are obese [6].", [["deaths", "DISEASE", 18, 24], ["chronic diseases", "DISEASE", 32, 48], ["individuals", "ORGANISM", 154, 165], ["adults", "ORGANISM", 191, 197], ["chronic diseases", "PROBLEM", 32, 48], ["chronic conditions", "PROBLEM", 87, 105], ["HBP", "TEST", 171, 174], ["obese", "PROBLEM", 202, 207], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["diseases", "OBSERVATION", 40, 48], ["high prevalence", "OBSERVATION_MODIFIER", 68, 83], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["conditions", "OBSERVATION", 95, 105], ["obese", "OBSERVATION", 202, 207]]], ["Given that multimorbidity can increase the risk of death due to COVID-19, in countries like Mexico, which have a high burden of disease due to these conditions, it is necessary to develop strategies to mitigate the spread of this disease in these population subgroups to decrease the impact of COVID-19 on health systems.DISCUSSIONThis study was not without limitations.", [["multimorbidity", "DISEASE", 11, 25], ["death", "DISEASE", 51, 56], ["multimorbidity", "PROBLEM", 11, 25], ["death", "PROBLEM", 51, 56], ["COVID", "TEST", 64, 69], ["a high burden of disease", "PROBLEM", 111, 135], ["these conditions", "PROBLEM", 143, 159], ["this disease", "PROBLEM", 225, 237], ["COVID", "TEST", 294, 299], ["DISCUSSIONThis study", "TEST", 321, 341], ["not without", "UNCERTAINTY", 346, 357]]], ["The data analyzed were secondary in nature, and the accuracy of the data therefore, cannot be guaranteed.", [["The data", "TEST", 0, 8], ["the data", "TEST", 64, 72]]], ["Additionally, the cases analyzed included only patients diagnosed with COVID-19 via RT-PCR, and thus, false-negative results of the RT-PCR test would not have been included in the analysis.", [["patients", "ORGANISM", 47, 55], ["COVID-19", "DNA", 71, 79], ["patients", "SPECIES", 47, 55], ["COVID", "TEST", 71, 76], ["RT-PCR", "TEST", 84, 90], ["the RT-PCR test", "TEST", 128, 143], ["the analysis", "TEST", 176, 188]]], ["In addition, bias may have been introduced insofar as the process of obtaining and handling of the sample influenced the results of the diagnostic test.", [["the diagnostic test", "TEST", 132, 151]]], ["Another possible source of bias stems from the fact that patients with asymptomatic or mildly symptomatic COVID-19 who did not seek medical attention would not have been included among the cases analyzed.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["bias stems", "PROBLEM", 27, 37], ["mildly symptomatic COVID", "PROBLEM", 87, 111], ["possible", "UNCERTAINTY", 8, 16], ["bias stems", "OBSERVATION", 27, 37], ["mildly", "OBSERVATION_MODIFIER", 87, 93]]], ["Despite the limitations inherent to the information source, the use of a large dataset that includes all COVID-19 cases identified with molecular diagnostic tests and collected officially by the government of Mexico is useful for the initial study of the relationship between multimorbidity and COVID-19, bearing in mind the high burden of disease due to chronic conditions in Mexico.DISCUSSIONIn conclusion, several chronic conditions are associated with the development of pneumonia and death in Mexican patients with COVID-19.", [["multimorbidity", "DISEASE", 276, 290], ["pneumonia", "DISEASE", 475, 484], ["death", "DISEASE", 489, 494], ["patients", "ORGANISM", 506, 514], ["patients", "SPECIES", 506, 514], ["molecular diagnostic tests", "TEST", 136, 162], ["the initial study", "TEST", 230, 247], ["multimorbidity", "TEST", 276, 290], ["COVID", "TEST", 295, 300], ["the high burden of disease", "PROBLEM", 321, 347], ["chronic conditions", "PROBLEM", 355, 373], ["several chronic conditions", "PROBLEM", 409, 435], ["pneumonia", "PROBLEM", 475, 484], ["death", "PROBLEM", 489, 494], ["COVID", "TEST", 520, 525], ["high", "OBSERVATION_MODIFIER", 325, 329], ["disease", "OBSERVATION", 340, 347], ["chronic", "OBSERVATION_MODIFIER", 355, 362], ["conditions", "OBSERVATION", 363, 373], ["chronic", "OBSERVATION_MODIFIER", 417, 424], ["pneumonia", "OBSERVATION", 475, 484]]], ["Additionally, an increase in the number of simultaneous chronic conditions was found to be associated with increased risk of pneumonia and death among these patients.", [["pneumonia", "DISEASE", 125, 134], ["death", "DISEASE", 139, 144], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["simultaneous chronic conditions", "PROBLEM", 43, 74], ["pneumonia", "PROBLEM", 125, 134], ["death", "PROBLEM", 139, 144], ["increase", "OBSERVATION_MODIFIER", 17, 25], ["number", "OBSERVATION_MODIFIER", 33, 39], ["simultaneous", "OBSERVATION_MODIFIER", 43, 55], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["conditions", "OBSERVATION", 64, 74], ["pneumonia", "OBSERVATION", 125, 134]]], ["These findings may be useful in the effort by decisionmakers to develop strategies to prevent COVID-19 in vulnerable subgroups, such as people with comorbidities.", [["people", "ORGANISM", 136, 142], ["people", "SPECIES", 136, 142], ["COVID", "TEST", 94, 99], ["comorbidities", "PROBLEM", 148, 161], ["may be", "UNCERTAINTY", 15, 21]]], ["According to reports from different sources, patients with chronic conditions have a greater risk of COVID-19 than patients without such conditions.", [["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 115, 123], ["chronic conditions", "PROBLEM", 59, 77], ["COVID", "TEST", 101, 106], ["such conditions", "PROBLEM", 132, 147]]], ["Hence, additional research is necessary to understand and deepen the study of the pathophysiological processes that determine this association, and this research is particularly important due to the high burden of chronic disease in various Latin American countries, including Mexico.", [["chronic disease", "DISEASE", 214, 229], ["the study", "TEST", 65, 74], ["chronic disease", "PROBLEM", 214, 229], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["disease", "OBSERVATION", 222, 229]]]]}